<SEC-DOCUMENT>0001178913-23-000772.txt : 20230228
<SEC-HEADER>0001178913-23-000772.hdr.sgml : 20230228
<ACCEPTANCE-DATETIME>20230228070104
ACCESSION NUMBER:		0001178913-23-000772
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		76
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230228
DATE AS OF CHANGE:		20230228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COMPUGEN LTD
		CENTRAL INDEX KEY:			0001119774
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30902
		FILM NUMBER:		23678307

	BUSINESS ADDRESS:	
		STREET 1:		26 HAROKMIM STREET
		STREET 2:		BUILDING D
		CITY:			HOLON
		STATE:			L3
		ZIP:			5885849
		BUSINESS PHONE:		011-972-3-765-8585

	MAIL ADDRESS:	
		STREET 1:		26 HAROKMIM STREET
		STREET 2:		BUILDING D
		CITY:			HOLON
		STATE:			L3
		ZIP:			5885849
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>zk2329266.htm
<DESCRIPTION>20-F
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--INTEGIX by Ez-XBRL--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:cgen="http://cgen.com/20221231"  ><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/><title>COMPUGEN LTD - 1119774 - 2023</title></head><body><div style="font-size: 10pt;"><div style="font-size: 10pt;">
        <div style="display:none">
        <ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" contextRef="C_20220101to20221231"  id="FFact_0000000000684" >false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="C_20220101to20221231"  id="FFact_0000000000685" >0001119774</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="C_20220101to20221231"  id="FFact_0000000000686" >FY</ix:nonNumeric><ix:nonFraction name="cgen:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"  id="Fxbrl_20230214102832182" unitRef="usd"  xsi:nil="true"></ix:nonFraction></ix:hidden>
<ix:references>
        <link:schemaRef xlink:type="simple" xlink:href="cgen-20221231.xsd"/>
        </ix:references><ix:resources><xbrli:context id="C_20220101to20221231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200101to20201231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20130801to20130805"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2013-08-01</xbrli:startDate>
        <xbrli:endDate>2013-08-05</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20130805"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2013-08-05</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211130"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-11-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapIncomeTaxAuthorityAxis_usgaapDomesticCountryMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20201231_usgaapIncomeTaxAuthorityAxis_usgaapInternalRevenueServiceIRSMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20201201to20201218"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2020-12-01</xbrli:startDate>
        <xbrli:endDate>2020-12-18</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210901to20210929"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-09-01</xbrli:startDate>
        <xbrli:endDate>2021-09-29</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200101to20201231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200101to20201231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221101to20221111"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-11-01</xbrli:startDate>
        <xbrli:endDate>2022-11-11</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200101to20201231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_srtStatementScenarioAxis_cgenMasterClinicalAgreementOneMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_srtStatementScenarioAxis_cgenMasterClinicalAgreementOneMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_srtStatementScenarioAxis_cgenMasterClinicalAgreementTwoMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_srtStatementScenarioAxis_cgenMasterClinicalAgreementTwoMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200101to20201231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200101to20201231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20201231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20191231"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20230101to20230131_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_usgaapTypeOfArrangementAxis_cgenSalesAgreementWithSVBSecuritiesLLCMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SalesAgreementWithSVBSecuritiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-01-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20191231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20191231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20191231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_cgenSegmentReportingGeographicAreaAxis_srtEuropeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_cgenSegmentReportingGeographicAreaAxis_srtEuropeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_cgenSegmentReportingGeographicAreaAxis_countryIL"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:IL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_cgenSegmentReportingGeographicAreaAxis_countryIL"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:IL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_cgenSegmentReportingGeographicAreaAxis_countryUS"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_cgenSegmentReportingGeographicAreaAxis_countryUS"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_srtMajorCustomersAxis_cgenCustomerOneMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cgen:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_srtMajorCustomersAxis_cgenCustomerOneMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cgen:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200101to20201231_cgenSegmentReportingGeographicAreaAxis_srtEuropeMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200101to20201231_srtMajorCustomersAxis_cgenCustomerOneMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cgen:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20181010_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2018-10-10</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20181001to20181010_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2018-10-10</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211130_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-11-30</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211102to20211130_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-11-02</xbrli:startDate>
        <xbrli:endDate>2021-11-30</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200301to20200316_srtStatementScenarioAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2020-03-01</xbrli:startDate>
        <xbrli:endDate>2020-03-16</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200316_srtStatementScenarioAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-03-16</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200316_srtStatementScenarioAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember_usgaapAwardTypeAxis_cgenUnderwritersMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:UnderwritersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-03-16</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200401to20200414_srtStatementScenarioAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember_usgaapAwardTypeAxis_cgenUnderwritersMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:UnderwritersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-04-14</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_srtStatementScenarioAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapPlanNameAxis_cgenTwoThousandAndTwoThousandTenOptionsPlanMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgen:TwoThousandAndTwoThousandTenOptionsPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapPlanNameAxis_cgenTwoThousandAndTwoThousandTenOptionsPlanMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgen:TwoThousandAndTwoThousandTenOptionsPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_srtTitleOfIndividualAxis_srtDirectorMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_srtTitleOfIndividualAxis_srtDirectorMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20201231_srtTitleOfIndividualAxis_srtDirectorMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200101to20201231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200101to20201231_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200101to20201231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_usgaapAwardTypeAxis_usgaapWarrantMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20201231_usgaapAwardTypeAxis_usgaapWarrantMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_usgaapAwardTypeAxis_usgaapWarrantMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_usgaapAwardTypeAxis_usgaapWarrantMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20221231_usgaapAwardTypeAxis_usgaapWarrantMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_srtStatementScenarioAxis_cgenCollaborativeArrangementsMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:CollaborativeArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_srtStatementScenarioAxis_cgenCollaborativeArrangementsTwoMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:CollaborativeArrangementsTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember_srtRangeAxis_srtMinimumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember_srtRangeAxis_srtMaximumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20210101to20211231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20200101to20201231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20211231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:May2012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:context id="C_20220101to20221231_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember_srtRangeAxis_srtMinimumMember"><xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001119774</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:May2012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
        </xbrli:period></xbrli:context><xbrli:unit id="Item"><xbrli:measure>cgen:Item</xbrli:measure></xbrli:unit>
<xbrli:unit id="NIS_Per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:ILS</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_per_share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
</ix:resources></ix:header></div><div>
  <div>
    <div style="width:100%;clear:both">
      <hr style="border-top:3pt solid #000000;width:100%;margin-left:0pt;text-align:left" />
      <hr style="border-top:0.75pt solid #000000;width:100%;margin-left:0pt;text-align:left" />
    </div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt">&#160;</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">UNITED STATES</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:14pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">SECURITIES AND EXCHANGE COMMISSION</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">WASHINGTON, D.C. 20549</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:14pt;text-align:center;margin-top:12pt;margin-bottom:0pt"><span style="font-weight:bold">FORM </span><span style="font-weight:bold"><ix:nonNumeric id="FFact_0000000000001" name="dei:DocumentType" contextRef="C_20220101to20221231">20-F</ix:nonNumeric></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-20pt;padding-left:20pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonNumeric id="FFact_0000000000002" name="dei:DocumentRegistrationStatement" contextRef="C_20220101to20221231" format="ixt:fixed-false">&#9744;</ix:nonNumeric></span><span style="padding-left:16pt">&#160;</span><span style="font-weight:bold;padding-left:11.25pt">REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF </span><span style="font-weight:bold">1934</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:12pt;margin-bottom:0pt"><span style="font-weight:bold">OR</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonNumeric id="FFact_0000000000003" name="dei:DocumentAnnualReport" contextRef="C_20220101to20221231" format="ixt:fixed-true">&#9746;</ix:nonNumeric></span><span style="padding-left:16pt">&#160;</span><span style="font-weight:bold;padding-left:10pt">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:12pt;margin-bottom:0pt"><span style="font-weight:bold">For the fiscal year ended </span><span style="font-weight:bold"><span style="font-weight:bold"><span style="font-weight:bold"><ix:nonNumeric id="FFact_0000000000006" name="dei:DocumentPeriodEndDate" contextRef="C_20220101to20221231" format="ixt:date-monthname-day-year-en"><ix:nonNumeric id="FFact_0000000000004" name="dei:CurrentFiscalYearEndDate" contextRef="C_20220101to20221231" format="ixt:date-monthname-day-en">December 31</ix:nonNumeric>, <ix:nonNumeric id="FFact_0000000000005" name="dei:DocumentFiscalYearFocus" contextRef="C_20220101to20221231">2022</ix:nonNumeric></ix:nonNumeric></span></span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:12pt;margin-bottom:0pt"><span style="font-weight:bold">OR</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonNumeric id="FFact_0000000000007" name="dei:DocumentTransitionReport" contextRef="C_20220101to20221231" format="ixt:fixed-false">&#9744;</ix:nonNumeric></span><span style="padding-left:16pt">&#160;</span><span style="font-weight:bold;padding-left:11.25pt">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:12pt;margin-bottom:0pt"><span style="font-weight:bold">OR</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-20pt;padding-left:20pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonNumeric id="FFact_0000000000008" name="dei:DocumentShellCompanyReport" contextRef="C_20220101to20221231" format="ixt:fixed-false">&#9744;</ix:nonNumeric></span><span style="padding-left:16pt">&#160;</span><span style="font-weight:bold;padding-left:11.25pt">SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF </span><span style="font-weight:bold">1934</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-bottom:0pt;margin-left:10pt"><span style="padding-left:20pt">&#160; &#160;Date of event requiring this shell company report ____________</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:12pt;margin-bottom:0pt"><span style="font-weight:bold">For the transition period from ____________ to ____________</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:12pt;margin-bottom:0pt">Commission file number: <span style="font-weight:bold"><ix:nonNumeric id="FFact_0000000000009" name="dei:EntityFileNumber" contextRef="C_20220101to20221231">000-30902</ix:nonNumeric></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0px;margin-bottom:0pt">_________________________________________________</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:16pt;text-align:center;margin-top:12pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonNumeric id="FFact_0000000000010" name="dei:EntityRegistrantName" contextRef="C_20220101to20221231">Compugen Ltd</ix:nonNumeric></span><span style="font-weight:bold">.</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0px">(Exact name of Registrant as specified in its charter)</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0px;margin-bottom:0pt">____________________________________</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:12pt;margin-bottom:0pt">(Translation of Registrant&#8217;s name into English)</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0px;margin-bottom:0pt">___________________________________________________________</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:12pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonNumeric id="Fxbrl_20230214183311741" name="dei:EntityIncorporationStateCountryCode" contextRef="C_20220101to20221231" format="ixt-sec:edgarprovcountryen">Israel</ix:nonNumeric></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt">(Jurisdiction of incorporation or organization)</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:12pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonNumeric id="FFact_0000000000012" name="dei:EntityAddressAddressLine1" contextRef="C_20220101to20221231">Azrieli Center</ix:nonNumeric></span><span style="font-weight:bold">, </span><span style="font-weight:bold"><ix:nonNumeric id="FFact_0000000000013" name="dei:EntityAddressAddressLine2" contextRef="C_20220101to20221231">26 Harokmim Street</ix:nonNumeric></span><span style="font-weight:bold">, </span><span style="font-weight:bold"><ix:nonNumeric id="FFact_0000000000014" name="dei:EntityAddressAddressLine3" contextRef="C_20220101to20221231">Building D</ix:nonNumeric></span><span style="font-weight:bold">, </span><span style="font-weight:bold"><ix:nonNumeric id="FFact_0000000000015" name="dei:EntityAddressCityOrTown" contextRef="C_20220101to20221231">Holon</ix:nonNumeric></span><span style="font-weight:bold">&#160;</span><span style="font-weight:bold"><ix:nonNumeric id="FFact_0000000000016" name="dei:EntityAddressPostalZipCode" contextRef="C_20220101to20221231">5885849</ix:nonNumeric></span><span style="font-weight:bold">&#160;</span><span style="font-weight:bold"><ix:nonNumeric id="FFact_0000000000017" name="dei:EntityAddressCountry" contextRef="C_20220101to20221231" format="ixt-sec:countrynameen">Israel</ix:nonNumeric></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt">(Address of principal executive offices)</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0px;margin-bottom:0pt">________________________________________________</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:12pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonNumeric id="FFact_0000000000018" name="dei:ContactPersonnelName" contextRef="C_20220101to20221231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">Alberto Sessa</ix:nonNumeric></span><span style="font-weight:bold">, Chief Financial Officer</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Phone: +</span><span style="font-weight:bold"><ix:nonNumeric id="FFact_0000000000019" name="dei:CityAreaCode" contextRef="C_20220101to20221231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">972</ix:nonNumeric></span><span style="font-weight:bold">&#8212;</span><span style="font-weight:bold"><ix:nonNumeric id="FFact_0000000000020" name="dei:LocalPhoneNumber" contextRef="C_20220101to20221231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">3-765-8585</ix:nonNumeric></span><span style="font-weight:bold">, Fax: +</span><span style="font-weight:bold"><ix:nonNumeric id="FFact_0000000000021" name="dei:ContactPersonnelFaxNumber" contextRef="C_20220101to20221231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">972-3-765-8555</ix:nonNumeric></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold"><ix:nonNumeric id="FFact_0000000000022" name="dei:EntityAddressAddressLine1" contextRef="C_20220101to20221231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">Azrieli Center</ix:nonNumeric></span><span style="font-weight:bold">, </span><span style="font-weight:bold"><ix:nonNumeric id="FFact_0000000000023" name="dei:EntityAddressAddressLine2" contextRef="C_20220101to20221231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">26 Harokmim Street</ix:nonNumeric></span><span style="font-weight:bold">, </span><span style="font-weight:bold"><ix:nonNumeric id="FFact_0000000000024" name="dei:EntityAddressAddressLine3" contextRef="C_20220101to20221231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">Building D</ix:nonNumeric></span><span style="font-weight:bold">, </span><span style="font-weight:bold"><ix:nonNumeric id="FFact_0000000000025" name="dei:EntityAddressCityOrTown" contextRef="C_20220101to20221231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">Holon</ix:nonNumeric></span><span style="font-weight:bold">&#160;</span><span style="font-weight:bold"><ix:nonNumeric id="FFact_0000000000026" name="dei:EntityAddressPostalZipCode" contextRef="C_20220101to20221231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">5885849</ix:nonNumeric></span><span style="font-weight:bold">&#160;</span><span style="font-weight:bold"><ix:nonNumeric id="FFact_0000000000027" name="dei:EntityAddressCountry" contextRef="C_20220101to20221231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember" format="ixt-sec:countrynameen">Israel</ix:nonNumeric></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt">(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:12pt;margin-bottom:0pt">________________________________________________</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:12pt;margin-bottom:0pt"><span style="font-weight:bold">Securities registered or to be registered pursuant to Section 12(b) of the Act.</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0px;margin-bottom:0pt">&#160;</p>
    <div>
      <table cellpadding="0" style="width:100%" width="100%">

          <tr>
            <td style="vertical-align:bottom;width:33%">
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Title of each class</span></p>
            </td>
            <td style="vertical-align:bottom;width:33%">
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Trading Symbol(s)</span></p>
            </td>
            <td style="vertical-align:bottom;width:34%">
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Name of each exchange on which registered</span></p>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:top;width:33%">
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="FFact_0000000000028" name="dei:Security12bTitle" contextRef="C_20220101to20221231">Ordinary shares, par value NIS 0.01 per share</ix:nonNumeric></p>
            </td>
            <td style="vertical-align:top;width:33%">
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="FFact_0000000000029" name="dei:TradingSymbol" contextRef="C_20220101to20221231">CGEN</ix:nonNumeric></p>
            </td>
            <td style="vertical-align:top;width:34%">
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt">The <ix:nonNumeric id="FFact_0000000000030" name="dei:SecurityExchangeName" contextRef="C_20220101to20221231" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric> Stock Market LLC</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt">(The Nasdaq Global Market)</p>
            </td>
          </tr>

      </table>
    </div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:12pt;margin-bottom:0pt"><span style="font-weight:bold">Securities registered or to be registered pursuant to Section 12(g) of the Act.</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:12pt;margin-bottom:0pt">None</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0px;margin-bottom:0pt">(Title of Class)</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:12pt;margin-bottom:0pt"><span style="font-weight:bold">Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act.</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:12pt;margin-bottom:0pt">None</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0px;margin-bottom:10pt">(Title of Class)</p>
    <div>
      <hr style="border-top:1.5pt solid #000000;page-break-after:always" />
    </div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-bottom:0pt">&#160;</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0px;margin-bottom:0pt">Indicate the number of outstanding shares of each of the issuer&#8217;s classes of capital or common stock as of the close of the period covered by the annual report: <span style="font-weight:bold"><ix:nonFraction id="FFact_0000000000031" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_20221231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">86,624,643</ix:nonFraction></span><span style="font-weight:bold"> Ordinary Shares</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-bottom:0pt">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:12pt;margin-bottom:0pt">&#9744; Yes&#8195;&#8194;&#9746; <ix:nonNumeric id="FFact_0000000000032" name="dei:EntityWellKnownSeasonedIssuer" contextRef="C_20220101to20221231">No</ix:nonNumeric></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt">If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:12pt;margin-bottom:0pt">&#9744; Yes&#8195;&#8194;&#9746; <ix:nonNumeric id="FFact_0000000000033" name="dei:EntityVoluntaryFilers" contextRef="C_20220101to20221231">No</ix:nonNumeric></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:12pt;margin-bottom:0pt">&#9746; <ix:nonNumeric id="FFact_0000000000034" name="dei:EntityCurrentReportingStatus" contextRef="C_20220101to20221231">Yes</ix:nonNumeric>&#8195;&#8194;&#9744; No</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:12pt;margin-bottom:0pt">&#9746; <ix:nonNumeric id="FFact_0000000000035" name="dei:EntityInteractiveDataCurrent" contextRef="C_20220101to20221231">Yes</ix:nonNumeric>&#8195;&#8194;&#9744; No</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:10pt">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or an emerging growth company. See definition of &#8220;accelerated filer&#8221; &#8220;large accelerated filer&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>
    <div>
      <table cellpadding="0" style="border-spacing:0;margin:auto" width="100%">

          <tr>
            <td style="width:25%;vertical-align:top">
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt">Large accelerated filer &#9744;</p>
            </td>
            <td style="width:25%;vertical-align:top">
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="FFact_0000000000036" name="dei:EntityFilerCategory" contextRef="C_20220101to20221231" format="ixt-sec:entityfilercategoryen">Accelerated filer</ix:nonNumeric> &#9746;</p>
            </td>
            <td style="width:25%;vertical-align:top">
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt">Non-accelerated filer &#9744;</p>
            </td>
            <td style="width:25%;vertical-align:top">
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt">Emerging growth company &#9744;</p>
            </td>
          </tr>

      </table>
    </div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards&#8224; provided pursuant to Section 13(a) of the Exchange Act <ix:nonNumeric id="FFact_0000000000037" name="dei:EntityEmergingGrowthCompany" contextRef="C_20220101to20221231" format="ixt:fixed-false">&#9744;</ix:nonNumeric></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt">&#8224; The term &#8220;new or revised financial accounting standard&#8221; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <ix:nonNumeric id="FFact_0000000000038" name="dei:IcfrAuditorAttestationFlag" contextRef="C_20220101to20221231" format="ixt:fixed-true">&#9746;</ix:nonNumeric></p>
    <div style="text-align:left;margin-top:10pt;margin-bottom:0pt"><span style="font-size:13.3333px;color:rgb(0, 0, 0);font-style:normal;line-height:1.25;font-family:Times New Roman, serif;font-weight:normal">If securities are registered pursuant to Section 12(b) of the Act indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statement.&#160;<span style="font-weight:normal"><span style="color:#000000">&#9744;</span></span></span>
      <p style="margin:0pt"><span style="color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-size:13.3333px">&#160;</span></p>
    </div>
    <div style="text-align:left;margin-top:0px"><span style="font-size:13.3333px;color:rgb(0, 0, 0);font-style:normal;line-height:1.25;font-family:Times New Roman, serif;font-weight:normal">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).&#160;<span style="font-weight:normal"><span style="color:#000000">&#9744;</span></span></span></div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-bottom:0pt">Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
    <div>
      <table cellpadding="0" style="width:100%" width="100%">

          <tr>
            <td style="vertical-align:top;width:18.87%">
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="FFact_0000000000039" name="dei:DocumentAccountingStandard" contextRef="C_20220101to20221231">U.S. GAAP</ix:nonNumeric> &#9746;</p>
            </td>
            <td style="vertical-align:top;width:57.23%">
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt">International Financial Reporting Standards as issued</p>
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt">by the International Accounting Standards Board &#9744;</p>
            </td>
            <td style="vertical-align:top;width:23.39%">
              <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt">Other &#9744;</p>
            </td>
          </tr>

      </table>
    </div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt">If &#8220;Other&#8221; has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:12pt;margin-bottom:0pt">Item 17 &#9744;&#8195; Item 18 &#9744;</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt">If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:12pt;margin-bottom:0pt">&#9744; Yes&#8195;&#8194;<ix:nonNumeric id="FFact_0000000000040" name="dei:EntityShellCompany" contextRef="C_20220101to20221231" format="ixt:fixed-false">&#9746;</ix:nonNumeric> No</p>
    <div>
      <div style="width:100%;clear:both">&#160;</div>
      <hr style="border-top:1.5pt solid #000000;page-break-after:always" />
    </div>
    <div>
      <!-- Field: Include-Text; File: PF\body.htm; Date: 2023%2D02%2D27T19:38:47; Size: 0x0012FD15; Options: XMLPreprocess -->


<p style="margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman,Times,serif"> </span></p>

<div><br />

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold"><span style="text-decoration: underline">TABLE
OF CONTENTS</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-indent: -72pt; margin-left: 72pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><a href="#CAUTIONARYSTATEMENT">CAUTIONARY
STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</a></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<table cellspacing="0" cellpadding="0" border="0" id="z407b5cc30b5f4543be0bd4e48612accd" style="font: 10pt Times New Roman, Times, serif; color: #000000; width: 100%">
  <tr>
    <td rowspan="1" style="width: 8%">
        <div style="text-align: left; text-indent: -72pt; margin-left: 72pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><a href="#PARTI.">PART
        I.</a></div> </td>
    <td rowspan="1" style="width: 87%"><br /> </td>
    <td rowspan="1" style="width: 5%; text-align: right"><br /> </td> </tr>
  <tr>
    <td style="width: 8%">
        <div><a href="#ITEM1.">ITEM 1.</a></div> </td>
    <td style="width: 87%">
        <div>
        <div style="font-variant: small-caps"><a href="#ITEM1.">IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</a></div> </div> </td>
    <td style="width: 5%; text-align: right">1<br /> </td> </tr>
  <tr>
    <td style="width: 8%">
        <div><a href="#ITEM2.">ITEM 2.</a></div> </td>
    <td style="width: 87%">
        <div>
        <div style="font-variant: small-caps"><a href="#ITEM2.">OFFER STATISTICS AND EXPECTED TIMETABLE</a></div> </div> </td>
    <td style="width: 5%">
        <div style="text-align: right">1</div> </td> </tr>
  <tr>
    <td style="width: 8%">
        <div><a href="#ITEM3.">ITEM 3.</a></div> </td>
    <td style="width: 87%">
        <div>
        <div style="font-variant: small-caps"><a href="#ITEM3.">KEY INFORMATION</a></div> </div> </td>
    <td style="width: 5%">
        <div style="text-align: right">&#160;1</div> </td> </tr>
  <tr>
    <td style="width: 8%">
        <div><a href="#ITEM4.">ITEM 4.</a></div> </td>
    <td style="width: 87%">
        <div>
        <div style="font-variant: small-caps"><a href="#ITEM4.">INFORMATION ON THE COMPANY</a></div> </div> </td>
    <td style="width: 5%">
        <div style="text-align: right">47</div> </td> </tr>
  <tr>
    <td style="width: 8%">
        <div><a href="#ITEM4A.">ITEM 4A.</a></div> </td>
    <td style="width: 87%">
        <div>
        <div style="font-variant: small-caps"><a href="#ITEM4A.">UNRESOLVED STAFF COMMENTS</a></div> </div> </td>
    <td style="width: 5%">
        <div style="text-align: right">65</div> </td> </tr>
  <tr>
    <td style="width: 8%">
        <div><a href="#ITEM5.">ITEM 5.</a></div> </td>
    <td style="width: 87%">
        <div>
        <div style="font-variant: small-caps"><a href="#ITEM5.">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</a></div> </div> </td>
    <td style="width: 5%">
        <div style="text-align: right">65</div> </td> </tr>
  <tr>
    <td style="width: 8%">
        <div><a href="#ITEM6.">ITEM 6.</a></div> </td>
    <td style="width: 87%">
        <div>
        <div style="font-variant: small-caps"><a href="#ITEM6.">DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</a></div> </div> </td>
    <td style="width: 5%">
        <div style="text-align: right">&#160;76</div> </td> </tr>
  <tr>
    <td style="width: 8%">
        <div><a href="#ITEM7.">ITEM 7.</a></div> </td>
    <td style="width: 87%">
        <div>
        <div style="font-variant: small-caps"><a href="#ITEM7.">MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</a></div> </div> </td>
    <td style="width: 5%">
        <div style="text-align: right">&#160;98</div> </td> </tr>
  <tr>
    <td style="width: 8%"><a href="#ITEM8">ITEM 8.</a></td>
    <td style="width: 87%">
        <div>
        <div style="font-variant: small-caps"><a href="#ITEM8">FINANCIAL INFORMATION</a></div> </div> </td>
    <td style="width: 5%">
        <div style="text-align: right">&#160;99</div> </td> </tr>
  <tr>
    <td style="width: 8%">
        <div><a href="#ITEM9.">ITEM 9.</a></div> </td>
    <td style="width: 87%">
        <div>
        <div style="font-variant: small-caps"><a href="#ITEM9.">THE OFFER AND LISTING</a></div> </div> </td>
    <td style="width: 5%">
        <div style="text-align: right">&#160;100</div> </td> </tr>
  <tr>
    <td style="width: 8%">
        <div><a href="#ITEM10.">ITEM 10.</a></div> </td>
    <td style="width: 87%">
        <div>
        <div style="font-variant: small-caps"><a href="#ITEM10.">ADDITIONAL INFORMATION</a></div> </div> </td>
    <td style="width: 5%">
        <div style="text-align: right">&#160;100</div> </td> </tr>
  <tr>
    <td style="width: 8%">
        <div><a href="#ITEM11.">ITEM 11.</a></div> </td>
    <td style="width: 87%">
        <div>
        <div style="font-variant: small-caps"><a href="#ITEM11.">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></div> </div> </td>
    <td style="width: 5%">
        <div style="text-align: right">108 <br /> </div> </td> </tr>
  <tr>
    <td style="width: 8%">
        <div><a href="#ITEM12.">ITEM 12.</a></div> </td>
    <td style="width: 87%">
        <div>
        <div style="font-variant: small-caps"><a href="#ITEM12.">DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</a></div> </div> </td>
    <td style="width: 5%">
        <div style="text-align: right">109</div> </td> </tr>
  <tr>
    <td style="width: 8%">
        <div>
        <div style="text-align: justify; text-indent: -72pt; margin-right: 4.2pt; margin-left: 72pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><a href="#PARTII">PART
        II.</a></div> </div> </td>
    <td style="width: 87%"><br /> </td>
    <td style="width: 5%"><br /> </td> </tr>
  <tr>
    <td style="width: 8%">
        <div><a href="#ITEM13.">ITEM 13.</a></div> </td>
    <td style="width: 87%">
        <div>
        <div style="font-variant: small-caps"><a href="#ITEM13.">DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</a></div> </div> </td>
    <td style="width: 5%">
        <div style="text-align: right">109</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%"><a href="#ITEM14.">ITEM 14.</a></td>
    <td rowspan="1" style="width: 87%">
        <div style="font-variant: small-caps"><a href="#ITEM14.">MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</a></div>
        </td>
    <td rowspan="1" style="width: 5%; text-align: right">&#160;109</td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%"><a href="#ITEM15.">ITEM 15.</a></td>
    <td rowspan="1" style="width: 87%">
        <div style="font-variant: small-caps"><a href="#ITEM15.">CONTROLS AND PROCEDURES</a></div> </td>
    <td rowspan="1" style="width: 5%; text-align: right">&#160;109</td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%"><a href="#TEM16">ITEM 16.</a></td>
    <td rowspan="1" style="width: 87%">
        <div style="font-variant: small-caps"><a href="#TEM16">RESERVED</a></div> </td>
    <td rowspan="1" style="width: 5%; text-align: right">&#160;109</td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%"><a href="#ITEM16A">ITEM 16A.</a></td>
    <td rowspan="1" style="width: 87%">
        <div style="font-variant: small-caps"><a href="#ITEM16A">AUDIT COMMITTEE FINANCIAL EXPERT</a></div> </td>
    <td rowspan="1" style="width: 5%; text-align: right">&#160;110</td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%"><a href="#ITEM16B.">ITEM 16B.</a></td>
    <td rowspan="1" style="width: 87%">
        <div style="font-variant: small-caps"><a href="#ITEM16B.">CODE OF ETHICS</a></div> </td>
    <td rowspan="1" style="width: 5%; text-align: right">&#160;110</td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%"><a href="#ITEM16C.">ITEM 16C.</a></td>
    <td rowspan="1" style="width: 87%">
        <div style="font-variant: small-caps"><a href="#ITEM16C.">PRINCIPAL ACCOUNTANT FEES AND SERVICES</a></div> </td>
    <td rowspan="1" style="width: 5%; text-align: right">&#160;110</td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%"><a href="#ITEM16D.">ITEM 16D.</a></td>
    <td rowspan="1" style="width: 87%">
        <div style="font-variant: small-caps"><a href="#ITEM16D.">EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</a></div> </td>
    <td rowspan="1" style="width: 5%; text-align: right">&#160;111</td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%"><a href="#ITEM16E.">ITEM 16E.</a></td>
    <td rowspan="1" style="width: 87%">
        <div style="font-variant: small-caps"><a href="#ITEM16E.">PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</a></div>
        </td>
    <td rowspan="1" style="width: 5%; text-align: right">&#160;111</td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%"><a href="#ITEM16F.">ITEM 16F.</a></td>
    <td rowspan="1" style="width: 87%">
        <div style="font-variant: small-caps"><a href="#ITEM16F.">CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT</a></div> </td>
    <td rowspan="1" style="width: 5%; text-align: right">&#160;111</td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%"><a href="#ITEM16G.">ITEM 16G.</a></td>
    <td rowspan="1" style="width: 87%">
        <div style="font-variant: small-caps"><a href="#ITEM16G.">CORPORATE GOVERNANCE</a></div> </td>
    <td rowspan="1" style="width: 5%; text-align: right">&#160;111</td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%"><a href="#ITEM16H.">ITEM 16H.</a></td>
    <td rowspan="1" style="width: 87%">
        <div style="font-variant: small-caps"><a href="#ITEM16H.">MINE SAFETY DISCLOSURE</a></div> </td>
    <td rowspan="1" style="width: 5%; text-align: right">&#160;111</td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%"><a href="#ITEM16I">ITEM 16I.</a></td>
    <td rowspan="1" style="width: 87%">
        <div style="font-variant: small-caps"><a href="#ITEM16I">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</a></div>
        </td>
    <td rowspan="1" style="width: 5%; text-align: right">&#160;112</td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%">
        <div style="text-align: justify; text-indent: -72pt; margin-right: 4.2pt; margin-left: 72pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><a href="#PARTIII">PART
        III</a></div> </td>
    <td rowspan="1" style="width: 87%"><br /> </td>
    <td rowspan="1" style="width: 5%; text-align: right"><br /> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%"><a href="#ITEM17.">ITEM 17.</a></td>
    <td rowspan="1" style="width: 87%">
        <div style="font-variant: small-caps"><a href="#ITEM17.">FINANCIAL STATEMENTS</a></div> </td>
    <td rowspan="1" style="width: 5%; text-align: right">&#160;112</td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%"><a href="#ITEM18">ITEM 18.</a></td>
    <td rowspan="1" style="width: 87%">
        <div style="font-variant: small-caps"><a href="#ITEM18">FINANCIAL STATEMENTS</a></div> </td>
    <td rowspan="1" style="width: 5%; text-align: right">&#160;112</td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%"><a href="#ITEM19.">ITEM 19.</a></td>
    <td rowspan="1" style="width: 87%">
        <div style="font-variant: small-caps"><a href="#ITEM19.">EXHIBITS</a></div> </td>
    <td rowspan="1" style="width: 5%; text-align: right">113<br /> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"> <br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">(i)</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>
<!--PROfilePageNumberReset%LCR%2%(%)%-->

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">CERTAIN DEFINED TERMS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">All references in this Annual Report on
Form 20-F to &#8220;Compugen,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; or similar references
refer to Compugen Ltd. and our wholly owned subsidiary Compugen USA, Inc., except where the context otherwise requires or as otherwise
indicated.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;&#8209;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We have prepared our consolidated financial
statements in United States dollars and in accordance with generally accepted accounting principles in the United States, or U.S. GAAP.
All references herein to &#8220;dollars&#8221; or &#8220;$&#8221; are to United States dollars, and all references to &#8220;Shekels&#8221;
or &#8220;NIS&#8221; are to New Israeli Shekels.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">(ii)</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>
<!--PROfilePageNumberReset%LCR%3%(%)%-->

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold"><span id="CAUTIONARYSTATEMENT"><!--Anchor--></span>CAUTIONARY
STATEMENT REGARDING</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">FORWARD-LOOKING STATEMENTS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">This Annual Report on Form 20-F, or the
Annual Report, includes &#8220;forward-looking statements&#8221; within the meaning of the Securities Act of 1933, as amended, the Securities
Exchange Act of 1934, as amended, or the Exchange Act, and the safe-harbor provisions of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements are based on our current beliefs, expectations and assumptions. Forward-looking statements can
be identified by the use of terminology such as &#8220;will,&#8221; &#8220;may,&#8221; &#8220;assume,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221;
&#8220;could,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;believe,&#8221;
&#8220;suggest,&#8221; and &#8220;intend,&#8221; and similar expressions that are intended to identify forward-looking statements, although
not all forward-looking statements contain these identifying words. These forward-looking statements involve known and unknown risks and
uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance
or achievements expressed or implied by such forward-looking statements. Factors that could cause our actual results to differ materially
from those projected in the forward-looking statements include, without limitation, the risk factors set forth under &#8220;Item 3. Key
Information - D. Risk Factors,&#8221; the information about us set forth under &#8220;Item 4. Information on the Company&#8221; and information
related to our financial condition under &#8220;Item 5. Operating and Financial Review and Prospects.&#8221; Any forward-looking statements
represent our views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. We do
not assume any obligation to update any forward-looking statements unless required by law.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">(iii)</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>
<!--PROfilePageNumberReset%Num%1%%%-->

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold"><span id="PARTI."><!--Anchor--></span>PART
I.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">ITEM 1.<span id="ITEM1."><!--Anchor--></span></span><span style="font-family: Times New Roman,Times,serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<span style="font-weight: bold">IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</span></span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Not applicable.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">ITEM 2.</span><span style="font-family: Times New Roman,Times,serif"><span id="ITEM2."><!--Anchor--></span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<span style="font-weight: bold">OFFER STATISTICS AND EXPECTED TIMETABLE</span></span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Not applicable.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">ITEM 3.</span><span style="font-family: Times New Roman,Times,serif"><span id="ITEM3."><!--Anchor--></span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<span style="font-weight: bold">KEY INFORMATION</span></span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">A. [RESERVED]</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">B. CAPITALIZATION AND
INDEBTEDNESS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Not applicable.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">C.
REASONS FOR THE OFFER AND USE OF PROCEEDS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Not applicable.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">D. RISK FACTORS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times, serif"><span style="font-family: Times New Roman,Times,serif; font-style: italic">An
investment in our ordinary shares involves a high degree of risk and many factors could affect our results, financial condition, cash
flows and results of operations. You should carefully consider the following risk factors, as well as the other information in this Annual
Report. If we do not, or cannot, successfully address the risks to which we are subject, we could experience a material adverse effect
on our business, results of operations and financial condition, which could include the need to limit or even discontinue our business
operations, and accordingly our share price may decline, and you could lose all or part of your investment. We can give no assurance that
we will successfully address any of these risks. The principal risks we face are described below</span><span style="font-family: Times New Roman,Times,serif">.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Summary Risk Factors
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">Our business is subject
to a number of risks of which you should be aware of before making an investment decision. These risks are discussed more fully under
the caption &#8220;Item 3. Key Information - D. Risk Factors&#8221; section of this Annual Report. These risks include, but are not limited
to, the following:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zaae38ee34af34676a866f5cf0cc6fc94" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>We have a history of losses and we expect to incur future losses and may never achieve or sustain profitability. </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb51878e6db1441d4bc7950281c223d22" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>We may need to raise additional funds in the future, and if we are unable to raise such additional funds, we may need to limit, curtail
        or cease operations. To the extent any such funding is based on the sale of equity, our existing shareholders would experience dilution
        of their shareholdings.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zaa7d6447978c4d1f983ce41780bc8697" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>We cannot provide assurance that our business model will succeed in generating substantial revenues. </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z0a2744c73cd94a0a8d9e1e0c95f8cfc3" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>In the near term, we are highly dependent on the success of COM701 and of COM902. We may not be able to advance our internal clinical
        stage programs through clinical development or manufacturing or successfully partner or commercialize them, or obtain marketing approval,
        either alone or with a collaborator, or may experience significant delays in doing so.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9bdd8f25d8124bf7b55c373c76961fca" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Clinical trials of any product candidates that we, or any current or future collaborators may conduct, may fail to satisfactorily
        demonstrate safety and/or efficacy, and we, or any collaborator, may incur additional costs or experience delays in completing, or ultimately
        be unable to complete the development and commercialization of these product candidates.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9918d4c619094535b7ccb1fc463e6baf" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Clinical development involves a lengthy and expensive process, with an uncertain outcome. We may encounter substantial delays or
        even an inability to begin clinical trials for any specific product or may not be able to conduct or complete our trials on the timelines
        we expect.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd1367398882e408596d40db44d461cf6" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>From time to time we publicly disclose preliminary data from our ongoing clinical trials. As more patient data become available the
        data and the interpretation of the data may change.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zfc28dedca0fa4ac1b8e1b9f411400d96" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>We rely and expect to continue to rely on third parties to conduct our clinical trials. These third parties may not successfully
        or professionally carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, and we may experience
        significant delays in the conduct of our clinical trials as well as significant increased expenditures.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">1</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<table cellspacing="0" cellpadding="0" id="z6bef6593784e490d8e741c50427496b5" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Serious adverse events or undesirable side effects or lack of efficacy, may emerge in clinical trials conducted by other companies
        running clinical trials investigating the same target as us, which could adversely affect our development programs or our capability to
        enroll patients or partner the program for further development and commercialization.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z88badb06c6ef42db85b46e5f319b7f6e" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>We are subject to certain manufacturing risks, any of which could either result in additional costs or delays in completing, or ultimately
        make us unable to complete, the development and commercialization of our product candidates.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze4969c9fe2d249ff802e702d490c6b5b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Our current and future relationships, and/or the relationships of our collaborators through which we may market, sell, and distribute
        our products, with healthcare professionals, physicians and other parties in the United States and elsewhere may be subject, directly
        or indirectly, to applicable anti-kickback, fraud and abuse, false claims, physician payment transparency, health information and general
        privacy and security and other healthcare laws and regulations, which could expose us to adverse consequences.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd052d5f8fee14a988f94b850435aa749" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>There are risks that are inherent in the development and commercialization of new therapeutic products.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z74948759bb254617998190b24ecbef75" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>We have limited experience in the development of therapeutic product candidates, and we may be unable to implement our business strategy.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z41107dd84d1741a9a5074774d790a4fa" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Our approach to the discovery of therapeutic products is based on our predictive computational discovery capabilities that are not
        yet fully proven clinically, and we do not know whether we will be able to discover and develop additional potential product candidates
        or products of commercial value.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zbf494538566141cfb3dfd0c29c1c72a9" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>We are focusing our discovery and therapeutic development activities on therapeutic product candidates for uses in immuno-oncology.
        Our current candidates may fail, and we may fail to continue to discover and develop therapeutic product candidates of industry interest
        in this field.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zdfac116ac793440a93259135e3310772" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>We depend significantly on third parties to carry out the research, development and commercialization of our therapeutic product
        candidates. If we are unable to maintain our existing agreements or to enter into additional agreements with such third parties, including
        collaborators, in the future, our business will likely be materially harmed.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6135ce6003b549d79aacc577cb7d32c6" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Our dependence on collaboration agreements with third parties presents number of risks.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zcb3ee97d61214659b5b3d979c7a0c1f3" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>We operate in a highly competitive and rapidly changing industry which may result in others discovering, developing or commercializing
        competing products ahead of us or more successfully than we do.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za92d4fa015d04e45bd46d002a7be4c98" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Given our level of managerial, operational, financial and other resources, our current activities and future growth may be limited.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6fb618313d1346e886c7bc56f6e8212e" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>We may be unable to safeguard the integrity, security and confidentiality of our data or third parties&#8217; data.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z0a6be067dcec40e5aaf4dcf02c8ef739" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Our information technology systems, or those of our cloud providers, contract research organizations, or&#160; CROs, or other contractors
        or consultants, may fail or suffer security breaches, which could result in a material disruption of our pipeline and our business, as
        well as to regulatory investigations or actions; litigation; fines and penalties; reputational harm; loss of revenue and other adverse
        consequences.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zef5ec415af234f16b22f155ad6284990" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Our business and operations would suffer if our information technology systems or infrastructure or data, or our vendors&#8217; or
        partners&#8217;, are or were compromised.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6ee432e283aa419586973509d49e0b15" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>We are subject to stringent and changing obligations related to data privacy and security. Failure or perceived failure to comply
        with current or future obligations could lead to government enforcement actions (which could include civil or criminal penalties), private
        litigation, and/or adverse publicity and could negatively affect our operating results and business.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9ecca2f964ea4f4cb2e6e71ce3747393" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability
        to prevent our competitors from commercializing similar or identical product candidates would be adversely affected.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">2</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<table cellspacing="0" cellpadding="0" id="z89cbac93aaf74819afc49b84031d5c8f" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>In the future, we may need to obtain additional licenses of third-party technology or other rights that may not be available to us
        or are available only on commercially unreasonable terms, and which may cause us to operate our business in a more costly or otherwise
        adverse manner that was not anticipated.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zdcf95f30dd4442b5a1730dcfc6a35e92" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>We, or potential collaborators and licensees, may infringe third-party rights and may become involved in litigation, which may materially
        harm our business.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8948cfad9d3e4df2bfde9839a12a794b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time
        consuming and unsuccessful. </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd49119407c694d8bb785dd4c1a0de763" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>Conditions in the Middle East and in Israel may adversely affect our operations. </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z05329bfd14ef445686beee638899a1a6" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Our results of operations may be adversely affected by the exchange rate fluctuations between the dollar and the New Israeli Shekel.
        </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5f6d6a3b46f74014bab276fff52349e0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>We may not be able to meet the continued listing standards of The Nasdaq Stock Market LLC, or Nasdaq, which require a minimum closing
        bid price of $1.00 per share, which could result in our delisting and negatively impact the price of our ordinary shares and our ability
        to access the capital markets.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za38821d10b2643dab6097c06f9f6e275" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Future sales of our ordinary shares or securities convertible or exchangeable for our ordinary shares may depress our share price.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za7f4ae8f982a4b1d916d3969571f1f4f" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>If we sell ordinary shares in future financings, shareholders may experience immediate dilution and, as a result, our share price
        may decline. </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z37de8aa11b854e3baa7da9ad7109064f" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Our share price and trading volume have been volatile and may be volatile in the future and that could limit investors&#8217; ability
        to sell our shares at a profit and could limit our ability to successfully raise funds.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2e566092e1ac4d81843c47490971f1ed" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>If we are a passive foreign investment company, or PFIC, our U.S. shareholders may be subject to adverse U.S. federal income tax
        consequences.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Risks Related to our Business, Financial Results
and Financing Needs</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">We
have a history of losses and we expect to incur future losses and may never achieve or sustain profitability.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times, serif"><span style="font-family: Times New Roman,Times,serif">As
of December 31, 2022, we had an accumulated deficit of approximately $455.8 million and had incurred net losses of approximately $33.7
million in 2022, approximately $34.2 million in 2021 and approximately $29.7 million in 2020, in large part due to the expenditures associated
with our ongoing research and development and limited revenues received to date. In addition, we expect to continue to incur net losses
in the future due to our anticipated costs and expenses, primarily associated with our preclinical and clinical activities. We previously
entered into three pipeline program-based partnership agreements under which we have received to date a total amount of $90.7 million,
including a $32.0 million investment. Currently we have only one clinical collaboration agreement in effect, and we cannot be certain
that we will receive additional revenues under this agreement or that we will enter into additional arrangements for our programs or with
respect to our predictive computational discovery capabilities, or that such additional arrangements, if any, will provide sufficient
revenues to achieve profitability. </span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">We
may need to raise additional funds in the future, and if we are unable to raise such additional funds, we may need to limit, curtail or
cease operations. To the extent any such funding is based on the sale of equity, our existing shareholders would experience dilution of
their shareholdings.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times, serif"><span style="font-family: Times New Roman,Times,serif">Based
on our current plans we believe that our existing cash and cash equivalents and short-term bank deposits will be sufficient to fund operations
at least through the end of 2024, without considering the possible receipt of any additional funds, such as proceeds from existing or
additional licensing and/or collaborative agreements, or from financings. However, if we increase our cash expenditures beyond our current
plans, our cash balances may be sufficient for a shorter period of time. We cannot predict with any degree of certainty when, or even
if, we will generate significant revenues or achieve profitability at all, and therefore may need additional funds to continue financing
our operations. In 2020, we received net proceeds of approximately $74 million from a public offering and approximately $34 million from
warrants and option exercises. In 2021, we received a $20 million investment from our former partner, Bristol Myers Squibb Company, or
Bristol Myers Squibb. In addition to these equity fund raisings, in 2021 and 2022 we received milestone payments from our partners of
$8 million (of which $2 million was recognized as revenues in 2020) and $7.5 million, respectively. We may seek additional capital due
to strategic considerations even if we believe we have sufficient funds for our current and future operating plans. </span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">3</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Additional funds, including proceeds from
license or collaborative agreements, or from other financings, may not be available to us on acceptable terms, or at all. For example,
the termination of our collaboration with Bayer Pharma AG, or Bayer, decreases our potential to receive additional funds from existing
collaborative agreements. In addition, the terms of any financing may adversely affect the holdings or the rights of our existing shareholders.
For example, if we raise additional funds by issuing equity securities, our existing shareholders will experience dilution of their shareholdings.
Debt financing, if available, may involve restrictive covenants that could limit our flexibility in conducting future business activities.
If we are unable to obtain funding on a timely basis, we may be required to significantly curtail one or more of our research or development
programs or otherwise reduce our operations. We also could be required to seek funds through arrangements with partners or other investors
that may require us to enter into arrangements on terms that would otherwise not be acceptable to us. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times, serif"><span style="font-family: Times New Roman,Times,serif">Our
therapeutic programs have reached more costly stages of research and development, including preclinical and clinical drug development.
If we are not able to secure the funding or the capabilities required for such activities, we may be required to abandon, postpone, or
attempt to license out certain therapeutic product candidates at an earlier than anticipated stage, which may adversely affect us. Any
failure to raise funds as and when needed would materially harm our business, financial condition and results of operations, and result
in the inability to have some or all of such therapeutic product candidates developed to fit potential commercialization and have a negative
impact on our ability to pursue our business strategy.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">We
cannot provide assurance that our business model will succeed in generating substantial revenues.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times, serif"><span style="font-family: Times New Roman,Times,serif">Our
business model is primarily based on expected future revenues in various forms, including upfront fees, research funding, in-kind funding,
milestone payments, license fees, royalties on product sales and other revenue sharing payments from commercialization of products by
third parties, pursuant to various forms of collaborations for our novel targets and related drug product candidates at various stages
of research and development. Our primary focus in immuno-oncology utilizes our predictive computational discovery capabilities to identify
novel drug targets and develop potentially first-in-class therapeutics in the field of cancer immunotherapy. Drug target candidates discovered
by our predictive computational discovery capabilities undergo initial target validation studies and, in selected cases, are advanced
to the discovery and development of the therapeutic product candidate. Such drug target candidates and their related therapeutic product
candidates may serve as the basis for licensing and other forms of third-party collaborations. Following the termination of the Bristol
Myers Squibb and the Bayer collaborations, we currently have only one collaboration in effect with AstraZeneca plc, or&#160;AstraZeneca,
which was entered into at an early research and development stage and therefore has an inherently high risk of failure. The termination
of the collaboration agreements may have varying impacts on our financial position and, specifically, our ability to generate revenue.
For example, while the termination of our agreement with Bristol Myers Squibb has different effects on our operations, this termination
caused us to lose free access to PD-1 immune checkpoint inhibitor, which has an adverse impact on our expenditure thereby requiring us
to purchase PD-1 inhibitor for our clinical studies. The termination of the collaboration agreement with Bayer also has different effects
on our operations, but it mainly extinguished our potential to achieve future revenues from such collaboration and may adversely affect
the validation potential of our predictive computational discovery capabilities.&#160;The inability to derive adequate revenues, or at
all, from our business model would materially harm our business, financial condition and results of operations and could result in the
need to limit or even discontinue our business operations.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">The
widespread outbreak of an illness or any other communicable disease, or any other public health crisis, such as the COVID-19 pandemic,
and the governmental and societal responses thereto, may negatively impact the global economy and may also adversely affect our business
and results of operations. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Over two years after the World Health Organization
declared the novel coronavirus, or COVID-19, a pandemic, and after the enactment of governmental responses thereto, COVID-19 continues
to impact worldwide economic activity and financial markets, including a continued rapid increase in inflation rates. Variants of COVID-19
have caused and may continue to cause waves of increased infections. As a result of measures imposed by the governments in affected regions,
many commercial activities, businesses and schools have been affected by quarantines and other measures intended to contain the pandemic
and subsequent variants of the COVID-19 virus. The extent to which the COVID-19 pandemic ultimately impacts our business will depend on
future developments, which are highly uncertain and cannot be predicted, such as the duration of the outbreak, including current and subsequent
variants of COVID-19, travel restrictions and social distancing in Israel, the United States and other countries, business closures or
business disruptions, and the effectiveness of actions taken in Israel, the United States and other countries to contain and treat the
disease and to address its impact, including on financial markets or otherwise. These measures have impacted, and may further impact,
our suppliers and other business partners from conducting business activities as usual (including, without limitation, the availability
and pricing of materials, manufacturing and delivery efforts, clinical trials and other aspects that may affect our business) for an unknown
period of time. In addition, we, our suppliers and other business partners may experience significant impairments of business activities
due to operational shutdowns or suspensions that may be requested or mandated by national or local governmental authorities or self-imposed
by us, our suppliers or other business partners. For example, the availability of non-human primates has been severely affected and the
cost of such animals has heavily increased, and both the availability and pricing are uncertain. If measures, such as those listed above,
are taken again or additional measures are required in the event that the measures already taken prove to be insufficient or ineffective
to slow the spread of COVID-19 or other global or regional health pandemics or epidemics, we may face new and/or increasing concerns that
may affect our ability to conduct our business effectively, including, but not limited to, adverse effect on employees&#8217; health,
a slowdown and stoppage of work, slowdown or stoppage of our clinical trials and other activities which are essential and critical for
maintaining on-going business activities. Even if the measures taken, or that will be taken, prove themselves to be useful, we, our suppliers
and other business partners may recover at different rates, which may also affect our business activities.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">4</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">These effects could materially and adversely
affect our business, financial condition, results of operations and growth prospects. In addition, to the extent the evolving effects
of the COVID-19 pandemic or such other global or regional event adversely affect our business, financial condition, results of operations
and growth prospects, they may also have the effect of heightening many of the other risks and uncertainties described elsewhere in this
&#8220;Risk Factors&#8221; section.&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We have taken precautionary measures, and
may take additional measures, intended to minimize the risks of the COVID-19 pandemic to our employees and operations. The extent of the
impact of the COVID-19 pandemic or any other global or regional event on our operational and financial performance, including our ability
to execute our business strategies in the expected time frame or at all, will depend on future developments.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">We
have a limited operating history with respect to the partnering and commercialization aspects of our business model upon which investors
can base an investment decision or upon which to predict future revenues.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Our ability to generate revenues from partnerships
for our novel drug targets and related therapeutic product candidates at various stages of research and development has been limited to
date. Since we began focusing our discovery capabilities on therapeutic pipeline establishment in 2010, we have entered into three partnership
agreements with respect to our pipeline programs under which we have received to date a total amount of $90.7 million, of which $32 million
in the form of an investment. Currently, only our partnership with AstraZeneca is in effect. We recognized revenue of $7.5 million in
2022, $6.0 million in 2021 and $2.0 million in 2020 from our partnerships. There can be no guarantee that we will achieve the same level
of revenue in the future.&#160; </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We cannot be certain that our focus on discovery,
research and drug development in the field of immuno-oncology, along with advancing selected programs to later drug development and clinical
stages partially or fully at our own expense, will generate a stable or significant revenue stream. Moreover, we have very limited experience
with respect to the collaborative arrangements and financial terms that may be available for our candidates at their various R&amp;D stages.
Additionally, financial terms for agreements by other companies, to the degree disclosed, vary greatly. The inability to derive adequate
revenues within our field of focus and for our specific drug targets or product candidates would materially harm our business, financial
condition and results of operations and could result in the need to limit or even discontinue our business operations. Moreover, our operating
history with respect to the partnering and commercialization aspects of our model provides a limited basis to assess our ability to generate
significant fees, research revenues, milestone payments, royalties or other revenue sharing payments from the licensing, development and
anticipated future commercialization of our programs based on our existing and future novel drug targets and related therapeutic products
and any future product candidates. </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">5</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman, serif; font-style: italic; font-weight: bold"><span style="font-family: Times New Roman,Times,serif">Our
failure to establish and maintain effective internal control over financial reporting could result in material misstatements in our financial
statements or a failure to meet our reporting obligations. This may cause investors to lose confidence in our reported financial information,
which could result in the trading price of our shares to decline.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Our management is responsible for establishing
and maintaining adequate internal control over financial reporting, as such term is defined in Rule&#160;13a-15(f) of the Exchange Act.
Under the supervision and with the participation of our management, including the Chief Executive Officer and the Chief Financial Officer,
we carried out an evaluation of the effectiveness of our internal control over financial reporting as of December&#160;31, 2022, using
the criteria established in &#8220;Internal Control - Integrated Framework&#8221; issued by the Committee of Sponsoring Organizations
of the Treadway Commission (2013 framework) (the COSO criteria). Based on our assessment under that framework and the criteria established
therein, our management concluded that the Company&#8217;s internal control over financial reporting was effective as of December 31,
2022, in providing reasonable assurance regarding the reliability of the Company&#8217;s financial reporting.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">However, if we conclude in the future that
our internal controls over financial reporting are not effective, we may fail to meet our future reporting obligations on a timely basis,
our financial statements may contain material misstatements, our operating results may be negatively impacted, and we may be subject to
litigation and regulatory actions, causing investor perceptions to be adversely affected and potentially resulting in a decline in the
market price of our shares. Even if we conclude that our internal controls over financial reporting are adequate, any internal control
or procedure, no matter how well designed and operated, can only provide reasonable assurance of achieving desired control objectives
and cannot prevent all mistakes or intentional misconduct or fraud.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Risks Related to Development, Manufacturing,
Clinical Trials and Government Regulation</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">In
the near term, we are highly dependent on the success of COM701 and of COM902. We may not be able to advance our internal clinical stage
programs through clinical development or manufacturing or successfully partner or commercialize them, or obtain marketing approval, either
alone or with a collaborator, or may experience significant delays in doing so.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">We
currently have no products approved for sale and are investing a significant portion of our efforts and financial resources in the clinical
development of COM701 and of COM902. Our prospects are substantially dependent on our ability, or that of any existing and future partners,
to manufacture, develop, obtain marketing approval for and successfully commercialize COM701 and COM902 as a stand alone or in combination
with other drugs. We have reported favorable safety and toxicity profile and preliminary signals of antitumor activity in our ongoing
Phase 1 trial with COM701 monotherapy, COM701 combination with nivolumab, and in the triplet combination of COM701, nivolumab and BMS-986207
(anti-TIGIT antibody). We have reported preliminary signals of antitumor activity from our Phase 1 dose escalation monotherapy trial of
COM902 with a best response of stable disease. These preliminary clinical results may not predict the final results of the on-going clinical
trials or future clinical trials or otherwise be sufficient to attract a partner or support a future drug approval. Many companies in
the pharmaceutical, biopharmaceutical and biotechnology industries have suffered significant setbacks or failures in clinical trials after
achieving positive results, and we cannot be certain that we will not face similar setbacks or failures.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times, serif"><span style="font-family: Times New Roman,Times,serif">Our
pipeline currently consists of three clinical stage programs, which are at early stage of clinical development. Two, COM701 and COM902
are being developed internally and the third, rilvegostomig (previously known as AZD2936) is being developed by our collaborator, AstraZeneca.
Our pipeline also consists of additional future product candidates in early research and preclinical stage, the most advanced of which
is COM503, and require substantial development and investment.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">If we are able to advance our clinical programs,
we will need to expand our personnel and operational capabilities to support these activities. We may also need to raise additional capital
in such event. In part because of our limited infrastructure and limited experience in conducting clinical trials as a company and in
regulatory interactions, we cannot be certain that our clinical trials will be completed on time, that our planned clinical trials will
be initiated on time, if at all, that our planned development programs and development path forward would be acceptable to the U.S. Food
and Drug Administration, or FDA, or other comparable foreign regulatory authorities, or that, even if approval is obtained, such investigational
products can be successfully commercialized.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">6</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The success of COM701 and COM902 is dependent
upon several factors, including the following:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z80dfc5546b964577acc930a68fb0fb3d" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>the successful clinical trial design (and implementation thereof) and results;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div>&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">our ability to fund clinical trials designed to obtain regulatory approval and to become commercially successful;</div>
        </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div>&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">our ability to design trials required to allow for a path for registration or obtain regulatory approval;</div>
        </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div>&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">the success of trials designed to allow for a path for registration/approval by regulatory authorities;
        </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div>&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">our selected regulatory strategy; </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div>&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">our timely initiation, enrollment and completion of clinical trials;</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div>&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">demographics, past therapy and other criteria of patients enrolled, even if they meet the inclusion/exclusion
        enrollment criteria; </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div>&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">a safety, tolerability and efficacy profile, alone or in combination with other approved or investigational
        products, that is satisfactory to the FDA or comparable foreign regulatory authorities;</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div>&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">selection of drug dosing;</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div>&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">selection of indications; </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div>&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">selection of drug(s) for combinations; </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div>&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">access to drugs required for combination studies or approval;</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div>&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">successful identification of biomarkers, including for patient selection; </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div>&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">timely receipt of marketing approvals from applicable regulatory authorities;</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div>&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">the performance of our current and future collaborators, if any;</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div>&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">the extent of any required post-marketing approval commitments to applicable regulatory authorities;</div>
        </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div>&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">establishment and monitoring of manufacturing arrangements and processes with third-party service providers
        and clinical manufacturing organizations for manufacturing drug substance and drug product;</div> </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div>&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">establishment and monitoring of arrangements with third-party suppliers of raw materials and service for
        fill-finish, packaging and labeling;</div> </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div>&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">stability of our drug substance and drug products; </div> </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div>&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">supply of our drugs in sufficient quantities and quality for our clinical trials; </div> </div> </div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">

<div>&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">establishment of arrangements with third-party manufacturers and processes monitoring to obtain commercial
        quality drug product that is appropriately packaged for sale;</div> </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div>&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">adequate ongoing availability of raw materials and drug product for clinical development and any commercial
        sales;</div> </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div>&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">protection of our rights in our intellectual property portfolio;</div> </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div>&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">successful launch of commercial sales following any marketing approval;</div> </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div>&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">a continued acceptable safety profile following any marketing approval; and</div> </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div>&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">commercial acceptance by patients, the medical community and third-party payors.</div> </div> </div> </td>
        </tr>
  </table>

<div style="line-height: 1.25">

<div>&#160;</div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div>
</div> </div> </div> </div> </div> </div> </div> </div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Many of these factors are beyond our control,
including clinical development by us and our competitors, the regulatory submission and review process, potential threats to our intellectual
property rights and the manufacturing, marketing and sales efforts of any current and future third party. If we are unable to develop,
receive marketing approval for and successfully commercialize COM701 and/or COM902, on our own or with any collaborator, or experience
delays as a result of any of these factors or otherwise, our business could be substantially harmed.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">We
depend on enrollment of patients in our clinical trials in order to continue development of our product candidates.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times, serif"><span style="font-family: Times New Roman,Times,serif">We
are currently winding down of all of our combination clinical trials of COM701 in collaboration with Bristol Myers Squibb in patients
with advanced malignancies and we do not have any patient on our Phase 1 combination trial of COM902 with COM701. We expect to start enrolling
patients to clinical trial of COM701 in combination with COM902 and pembrolizumab in patients with metastatic microsatellite stable colorectal
cancer in the first quarter of 2023 and expect to start enrolling patients to clinical trials of COM701 in combination with COM902 and
pembrolizumab in patients with platinum resistant ovarian cancer in the second quarter of 2023. Our anticipated time to data in these
trials is subject to our ability to enroll a sufficient number of eligible patients that will need to be enrolled for observing clinical
activity, if at all. There can be no assurance that we will complete enrollment or have data from the trials when we anticipate or at
all and there is no guarantee that replacing pembrolizumab with nivolumab and COM902 with BMS-986207 in our new combination trials will
not cause other adverse effect that will not allow us, among others, to complete such clinical trials. The timely completion of clinical
trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients that are
in line with our inclusions and exclusion criteria and our ability to monitor these patients as required.</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">7</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We may experience difficulties in patient
enrollment in our clinical trials for a variety of reasons. Patient enrollment is affected by many factors including the size and nature
of the patient population, the eligibility criteria for the trial, the design of the clinical trial, the size of the patient population
required for analysis of the trial&#8217;s primary endpoints, the proximity of patients to clinical trial sites, our ability to recruit
clinical trial investigators with the appropriate competencies and experience, the number of enrolling clinical sites, our ability to
obtain and maintain patient consents, the risk that patients enrolled in clinical trials will drop out of the trials before completion
or even before any/sufficient imaging assessment, and competing clinical trials (including other clinical trials that we are conducting
or will conduct in the future) and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the drug being
studied in relation to other available therapies, or competing drugs against the same target as well as any new drugs that may be approved
for the indications we are investigating.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Many pharmaceutical companies are conducting
clinical trials in patients with the disease indications that COM701, COM902 and our future potential drug products may target. Additionally,
other pharmaceutical companies are already clinically investigating their own therapeutic candidates against PVRIG, the target of COM701,
or against TIGIT, the target of COM902, which may hamper the enrollment of patients in our trials for COM701 or COM902. For example, in
case of COM701, GSK plc, or GSK, is conducting a First-Time-in-Human study for GSK4381562 (formerly SRF813), and Junshi Biosciences announced
in April 2022 FDA IND approval for JS009, and Hengrui is conducting a Phase 1 study with SHR-2002, a PVRIG/TIGIT bi specific. These programs
are PVRIG targeting antibodies. In the case of COM902, there are a significant number of anti-TIGIT antibodies that are currently in clinical
trials such as tiragolumab by Roche, vibostolimab by Merck, ociperlimab by Beigene, domvanalimab and AB308 by Arcus, BMS-986207 by Bristol
Myers Squibb, GSK4428859A by GSK, and others (some of which are in a more advanced clinical stage than COM902). As a result, we must compete
with them for clinical sites, clinicians&#8217; interest and the limited number of patients who fulfill the stringent requirements for
participation in clinical trials in general. Also, patient enrollment may be limited due to changes in the regulatory landscape in the
indications of interest to us. Our clinical trials may be delayed or terminated due to the inability to enroll enough patients. The delay
or inability to meet planned patient enrollment may result in increased costs and delay or termination of our trials, which could have
a harmful effect on our ability to develop products.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Clinical
trials of any product candidates that we, or any current or future collaborators may conduct, may fail to satisfactorily demonstrate safety
and/or efficacy, and we, or any collaborator, may incur additional costs or experience delays in completing, or ultimately be unable to
complete the development and commercialization of these product candidates.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We, and any current or future collaborators,
are not permitted to commercialize, market, promote or sell any therapeutic product candidate in any jurisdiction without obtaining marketing
approval from the relevant regulatory authority, such as the FDA in case of the United States. We, and any collaborators, must complete
clinical trials to demonstrate the safety and efficacy of our therapeutic product candidates in humans before we will be able to obtain
these approvals.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Clinical testing is expensive, is difficult
to design and implement, can take many years to complete and is inherently uncertain as to outcome. We cannot guarantee that any clinical
trials will be conducted as planned or completed on schedule, if at all. The clinical development of our therapeutic product candidates
is susceptible to the risk of failure inherent at any stage of product development, including failure to demonstrate efficacy in a clinical
trial or across population of patients, choosing the incorrect patient population or indication, the occurrence of adverse events that
are severe or medically or commercially unacceptable, failure to comply with protocols or applicable regulatory requirements and determination
by the FDA that a therapeutic product candidate may not continue development or is not approvable. The outcome of preclinical studies
and early clinical trials may not predict the success of later clinical trials and interim results of a clinical trial do not necessarily
predict final results. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in
advanced clinical trials due to lack of efficacy or unacceptable safety profiles, notwithstanding promising results in earlier trials.
Despite the preliminary safety and anti-tumor activity results reported from our ongoing Phase 1 trial for COM701 and COM902 so far, we
do not know whether the clinical trials we or our partners may conduct will demonstrate adequate efficacy and safety to result in the
further advancement of clinical development or regulatory approval to market of COM701 and/or COM902, or any other of our product candidates
when they reach the clinic, in any particular jurisdiction or jurisdictions. It is also possible that, even if one or more of our therapeutic
product candidates has a beneficial effect, that effect will not be detected during clinical evaluation as a result of one or more of
a variety of factors, including the size, duration, design, measurements, conduct or analysis of our clinical trials, patient monitoring,
the dosing we choose and other factors.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">8</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Any inability to successfully complete preclinical
and clinical development could result in additional costs to us, or any collaborators and impair our ability to generate revenues from
product sales, development, regulatory and commercialization milestones and royalties. Moreover, if we, or any collaborators, are required
to conduct additional clinical trials or repeat clinical trials or other testing of our product candidates beyond the trials and testing
that we or they contemplate, if we, or they, are unable to successfully complete clinical trials of our product candidates or other testing,
or the results of these trials or tests are unfavorable, uncertain or are only modestly favorable, or there are unacceptable safety concerns
associated with our product candidates, we, or any collaborators, may:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div>&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">cease the development of the product candidates; </div> </div> </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div>

<div>&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">incur additional unplanned costs;</div> </div> </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div>

<div>&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">not obtain approval to proceed to next development phase; </div> </div> </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div>

<div>&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">be delayed in obtaining marketing approval for our product candidates;</div> </div> </div> </div> </td>
        </tr>
  </table>

<div style="line-height: 1.25">

<div>

<div>&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">not obtain marketing approval at all;</div> </div> </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div>

<div>&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">obtain approval for indications or patient populations that are not as broad as intended or desired;</div>
        </div> </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div>

<div>&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">obtain approval with labeling that includes significant use or distribution restrictions or significant
        safety warnings, including boxed warnings;</div> </div> </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div>

<div>&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">be subject to additional post-marketing testing or other requirements; or</div> </div> </div> </div> </td>
        </tr>
  </table>

<div style="line-height: 1.25">

<div>

<div>&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">be required to remove the product from the market after obtaining marketing approval.</div> </div> </div>
        </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div>&#160;<br /> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div> </div>
</div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Our failure to successfully initiate and
complete clinical trials of our product candidates and to demonstrate the efficacy and safety necessary to obtain regulatory approval
to market any of our product candidates would significantly harm our business, could further result in significant harm to our financial
position and results of operations and could result in the need to limit or even discontinue our business operations.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Clinical
development involves a lengthy and expensive process, with an uncertain outcome. We may encounter substantial delays or even an inability
to begin clinical trials for any specific product or may not be able to conduct or complete our trials on the timelines we expect.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Obtaining marketing approval
from regulatory authorities for the sale of any therapeutic product requires substantial preclinical development and then extensive human
clinical trials to demonstrate the safety and efficacy of such product candidates. It is impossible to predict when or if any of our programs
or those of our collaborators based on our target discoveries will yield products that will be approved for human testing, or, if such
testing is proven sufficiently safe and effective to receive regulatory approval for marketing. Preclinical and clinical testing is expensive,
time consuming, and subject to uncertainty and will require significant additional financial and management resources. As a company, we
have limited experience in conducting clinical trials and have never progressed a product candidate through to regulatory approval. In
part because of this lack of experience, our clinical trials may require more time and incur greater costs than we anticipate. We cannot
guarantee that any of our therapeutic drug candidates from our pipeline will be advanced into clinical trials or that our clinical trials
will be conducted as planned or completed on schedule, if at all. The outcome of preclinical testing and early clinical trials may not
be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results.
Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed
their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to continue to achieve
such successes at later stages of the clinical studies or to obtain marketing approval for such products.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">9</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We submitted to the FDA
an Investigational New Drug application, or IND, for COM701, which was cleared by the FDA in June 2018 and an IND for COM902, which was
cleared by the FDA in October 2019. However, there can be no assurance that we will submit additional INDs, nor if submitted, the actual
timing for such submission (including amendments), nor that such submissions will be accepted by the FDA allowing clinical trials to begin
or continue. There can be no assurance that clinical trials will begin at any predicted date or will be completed on schedule, if at all.
Moreover, even if these clinical trials begin, issues may arise that could result in the suspension of or termination of such clinical
trials. A failure of one or more clinical trials can occur at any stage of testing. Events that may prevent successful or timely completion
of clinical development include:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z149284ff8ec547c798bd56a8c328b2d4" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>inability to generate sufficient preclinical, toxicology, or other scientific data to support the initiation of clinical trials;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb0aa0f26a8a2411880757232c2a317a0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>lack of authorization from regulators or institutional review boards, or IRBs, or ethics committees to allow us or our investigators
        to amend a clinical trial or commence a clinical trial or conduct a clinical trial at a prospective trial site or continue such clinical
        trial;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z02b455f99d634b8dab0e76bd50033d30" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>delays in sufficiently developing, characterizing, or controlling a manufacturing process suitable for clinical trials;</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z23c4b6a6f38f47c4a3499ac4a3e727bb" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>inability to generate sufficient quantities or quality of our drug substance or drug product to support the initiation or continuation
        of clinical trials;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zea274dc6db334896a609d207151a947c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>delays in reaching a consensus with collaborators or regulatory agencies on trial design or trial amendment;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3c58d3d17cde409cb8083562f5caff81" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>delays in reaching agreement on acceptable terms with prospective CROs, and clinical trial sites, the terms of which can be subject
        to extensive negotiation and may vary significantly among different CROs and clinical trial sites;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf77efde94a324b17a461caa27f136c79" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>imposition of a temporary or permanent clinical hold by the FDA, or a similar delay imposed by foreign regulatory agencies for a
        number of reasons, including after review of an IND, other application or amendment; (i) as a result of a new safety finding that presents
        unreasonable risk to clinical trial participants; (ii) a negative finding from an inspection of our clinical trial operations or trial
        sites; (iii) developments on trials conducted by competitors for related technology that raises FDA concerns about risk to patients of
        the technology broadly; or (iv) if FDA finds that the investigational protocol or plan is clearly deficient to meet its stated objectives;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze3370bb978714b438ec5bef8b790c372" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>clinical trials of any product candidates may fail to show safety or efficacy, produce negative or inconclusive results and we may
        decide, or regulators may require us, to conduct additional preclinical studies or clinical trials or we may decide to abandon product
        development programs;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z086fc066cba4459d9d0f46da881d31e8" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>difficulty collaborating with patient groups and investigators;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3164d2eb04364b58bd879d36c42519e0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>failure by our CROs, other third parties, or us to adhere to clinical trial and related regulatory requirements;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2ca6d2e7101b4a18b694725aaabd930c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>failure to perform in accordance with the FDA&#8217;s Good Clinical Practice, or GCP, requirements, or similar applicable regulatory
        guidelines in other countries;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z078e6a9099f045ae8e401e3460e39b7c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>failure to perform in accordance with the FDA&#8217;s Good Manufacturing Practice, or GMP, requirements, or similar applicable regulatory
        guidelines in other countries;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zec3490c357784b3d9e62449cc43dac1c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>the number of patients required for clinical trials of any product candidates may be larger than we anticipate or can financially
        support, enrollment in these clinical trials may be slower than we anticipate, or participants may drop out of these clinical trials or
        fail to return for post-treatment follow-up at a higher rate than we anticipate;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8d87814e45c144068443d3bca1ac77da" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>delays in having patients complete their participation in a trial or return for post-treatment follow-up;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb15cabab69b1467eb0003b49d4cb1da4" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits;</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">10</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<table cellspacing="0" cellpadding="0" id="zff5c0d1758bd429b9e02053756d665e6" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z563f7009f178474eba51bd5c348d9381" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div style="font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">changes in the standard of care
        or in the regulatory landscape on which a clinical development plan was based, which may require new or additional trials;</span></div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z68febd4d2fd54381b57a1784c78b8628" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>the cost of clinical trials of our product candidates being greater than we anticipate;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z311bc746872d49d6afc4a1ce3277435a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>clinical trials of our product candidates producing negative or inconclusive results, or early results that will not be repeated
        in larger or future cohorts, which may result in our deciding, or regulators requiring us, to conduct additional clinical trials or abandon
        product development programs;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9682b0fe4672474594ab732c919857b3" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>choosing the wrong dosing regimen and/or the wrong drug combination;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9f93d66a5d4845f999d3ff63759e1078" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>delays or failure to secure supply agreements with suitable reagent suppliers, or any failures by suppliers to meet our quantity
        or quality requirements for necessary reagents; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z66c69722f2d549ee9605d1b6aece6b69" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>delays in manufacturing, testing, releasing, validating, or importing/exporting sufficient stable quantities of our product candidates
        for use in clinical trials or the inability to do any of the foregoing.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Our product development and other costs
will increase if we experience delays in clinical trials (including termination thereof) or in obtaining marketing approvals. We do not
know whether any of our preclinical studies or clinical trials will begin as planned, and once begun whether will need to be restructured
or will be completed on schedule, or at all. Significant preclinical or clinical trial delays also may allow our competitors to bring
products to market before we do, potentially impairing our ability to be first-in-class or successfully commercialize our product candidates
and harming our potential market share and business and results of operations. Any delays in our preclinical or clinical development programs
may harm our business, financial condition and prospects significantly.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">From
time to time we publicly disclose preliminary data from our ongoing clinical trials. As more patient data become available the data and
the interpretation of the data may change.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">From time to time, we publish preliminary
or interim investigator assessed data from our ongoing clinical trials. Preliminary data remain subject to audit confirmation and verification
procedures that may result in the final data being materially different from the preliminary data we previously published. Preliminary
data are also subject to the risk that one or more of the clinical outcomes may materially change as time goes by and cutoff date changes,
patient enrollment continues and with further patient monitoring where more patient data become available. As a result, preliminary data
should be viewed with caution until clinical trial completion where the final data are available. Material adverse changes in the final
data could significantly harm our business prospects and eventually harm our financial condition and results of operations.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">We
rely and expect to continue to rely on third parties to conduct our clinical trials. These third parties may not successfully or professionally
carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, and we may experience significant
delays in the conduct of our clinical trials as well as significant increased expenditures.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We do not have the ability to independently
conduct clinical trials. We rely and will continue to rely on medical institutions, clinical investigators, contract manufacturing research
organizations, contract laboratories, outsourced preclinical and clinical service providers and other third parties, such as CROs and
advisors, to conduct or otherwise support our clinical trials. We rely heavily and will continue to rely heavily on these parties for
execution of clinical trials for COM701 and COM902 and any other future product candidates we may take to the clinic, and we control only
certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our internal clinical trials is conducted
in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on these third
parties, including our CROs, will not relieve us of our regulatory responsibilities. For any violations of laws and regulations during
the conduct of our clinical trials, we could be subject to untitled and warning letters or enforcement action that may include civil penalties
up to and including criminal prosecution.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We believe that our financial results and
the commercial prospects for COM701, COM902, and any other future therapeutic product candidates we may take to the clinic, would be harmed,
our costs could materially increase and our ability to generate revenue could be significantly adversely impacted, if our clinical investigators,
CROs or other third parties providing us services fail to successfully carry out their contractual duties or obligations diligently and
in a professional manner or fail to meet their expected deadlines.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">11</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Serious
adverse events or undesirable side effects or lack of efficacy, may emerge in clinical trials conducted by other companies running clinical
trials investigating the same target as us, which could adversely affect our development programs or our capability to enroll patients
or partner the program for further development and commercialization.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">We
initiated a Phase 1 clinical trial for COM902, which targets TIGIT, in March 2020. There are additional companies that have a program
targeting TIGIT in clinical trials, such as GSK, Merck, Roche, Bristol Myers Squibb, BeiGene, and Arcus. We have no control over their
clinical trials or development programs, and lack of or insufficient efficacy such as recently reported for Roche&#8217;s TIGIT targeting
antibody tiragolumab in SCLC and NSCLC, adverse events or undesirable side effects experienced by subjects in their clinical trials could
affect our development and regulatory path of COM902 or the enthusiasm of clinicians recruiting patients for our clinical trials for COM902
or any other service provider or harm its potential to be partnered for further development and commercialization and generate revenues
for the Company.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Furthermore, any negative
results that may be reported in clinical trials of other programs targeting TIGIT may make it difficult or impossible to recruit and retain
subjects in our clinical trials of COM902. Delays in patient enrollment may result in increased costs or may affect the timing or outcome
of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development
of COM902. Failures in planned subject enrollment or retention may result in increased costs or program delays and could render further
development impossible.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">The
same risk applies to COM701 since other anti-PVRIG antibodies such as GSK&#8217;s GSK4381562 (formerly SRF813), Junshi&#8217;s JS009,
and Hengrui&#8217;s PVRIG/TIGIT bi-specific, SHR-2002, entered the clinic.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">We
are subject to certain manufacturing risks, any of which could either result in additional costs or delays in completing, or ultimately
make us unable to complete, the development and commercialization of our product candidates.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The process of manufacturing biologics,
in addition to the shipment and storage thereof, is susceptible to product loss or unavailability due to contamination, degradation, instability,
equipment failure, lack of critical reagents or disposables, improper installation or operation of equipment, vendor or operator error
leading to process deviations or any other factor. Even minor deviations from normal manufacturing processes could result in reduced production
yields, product defects and other supply disruptions up to supply termination. If microbial, viral or other contaminations are discovered
in our products or in the manufacturing facilities in which our products are made, the products may need to be manufactured again and/or
such manufacturing facilities may need to be closed for an extended time to investigate and remediate the contamination. In addition,
the product manufactured may be determined at later stage to be insufficiently stable or qualified as a therapeutic agent, even following
treatment.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We have not contracted with alternate suppliers
to support us in the event we experience any problems with our current manufacturers. If we are unable to arrange for alternative third-party
manufacturing sources or are unable to reserve another manufacturing slot with our current manufacturers or are unable to do so on commercially
reasonable terms or in a timely manner, or are unable to provide backup drug, we may incur additional costs or be delayed in the development
or delivery of our current and future product candidates, and even fail to supply drug to patients on study treatment on time or at all,
each event of which can cause us material harm.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">It may be difficult to
manufacture therapeutic products addressing our drug target candidates.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Our therapeutic pipeline
is focused mainly on monoclonal antibodies, or mAbs, generated against our discovered targets. These types of therapeutics can be difficult
to manufacture in the quantity and quality needed for preclinical, clinical and commercial use. The production of mAbs must be conducted
pursuant to a well-controlled and reproducible process and the resulting product testing must conform to defined quality standards. Should
it prove to be difficult to manufacture or repeat manufacturing, of any therapeutics addressing our drug candidates in sufficient quantities
or commercial scale, meeting the required quality standards or in an economical manner to conduct clinical trials and to commercialize
any approved therapeutic candidate, our business, financial condition and results of operations would be materially harmed. </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">12</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">We
or any of our collaborators, or third-party manufacturers, may fail to comply with regulatory and legal requirements, and we or they could
be subject to enforcement or other regulatory actions.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif">If we or any of our collaborators
or third-party manufacturers with whom we work or with whom we may enter into agreements in the future fail to comply with applicable
federal, state or foreign laws or regulations, or other legal obligations we or they could be subject to enforcement or other regulatory
actions. These actions may include:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z35710432567f4dd79f40cc087be09335" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>warning letters; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">clinical trial holds;</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div> </div>

<table cellspacing="0" cellpadding="0" id="zbd2a182f01d844028c081a4f2f4ef74c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>recalls, product seizures or medical product safety alerts; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z62739a29f818460d84b521344b59512d" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>data lock or order to destroy or not use personal data;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z493626759fd94e54a1a556635bfcd106" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>restrictions on, or prohibitions against, marketing such products; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z97dcc55991a341eea96b9bd9847a5e6e" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>restrictions on importation of such products; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9d27ab6afff6403e8ca15ab8fff915b7" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>suspension of review or refusal to accept or approve new or pending applications; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3b9787c8bb564c7aba0efe1970ab6a68" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>withdrawal of product approvals; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z26bdca7a6f2647f88b5559393d5eb5dd" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>injunctions; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z267b1b9187614e3ba478d47c1502f2d5" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>civil and criminal penalties and fines; or </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd2ed6fd33ec34137b952788b2e2ba079" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>debarment or other exclusions from government programs. </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">If we or our collaborators become subject
to such enforcement actions, these enforcement actions could affect the ability to successfully develop, market and sell therapeutic products
based on our discoveries and could significantly harm our financial status and/or reputation and lead to reduced acceptance of such products
by the market.&#160;In addition, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement
or imprisonment.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">We
may require companion or complimentary diagnostics and/or biomarkers for our clinical trials, or a portion of our clinical trials, and
may be required to have such in order to obtain marketing approval or commercialization of our therapeutic programs. Failure to successfully
discover, develop, validate and obtain regulatory clearance or approval for such tests could harm our patients&#8217; selection strategy
and may harm our clinical outcome.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Companion or complimentary diagnostics are
subject to regulation by the FDA and comparable foreign regulatory authorities and may require separate regulatory authorization prior
to commercialization. We may require for our clinical trials or for certain portions of our clinical programs, companion diagnostics and/or
biomarkers to correctly identify the right patients for the appropriate indications. We rely on access to patient tumor and blood samples
for analysis of protein, DNA, and RNA biomarkers. We may rely on third parties for the tumor and blood samples&#8217; handling, processing,
and analysis, discovery, development, and validation of these potential biomarker candidates, biomarkers and/or companion diagnostics,
as well as the application for and receipt of any required regulatory authorization. If we, or the third parties we engage for this purpose,
are unable to successfully discover, validate and/or develop the required companion diagnostics and/or biomarkers for our clinical programs,
or develop with altered specifications, or experience delays in doing so, the development of our clinical candidates may be adversely
affected and this can harm our patient selection and our clinical outcome, as well as obtaining marketing authorization for these product
candidates.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Our
current and future relationships, and/or the relationships of our collaborators through which we may market, sell, and distribute our
products, with healthcare professionals, physicians and other parties in the United States and elsewhere may be subject, directly or indirectly,
to applicable anti-kickback, fraud and abuse, false claims, physician payment transparency, health information and general privacy and
security and other healthcare laws and regulations, which could expose us to adverse consequences.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Our current and future business operations,
and our or our collaborators&#8217; business and financial arrangements and relationships with healthcare providers, physicians and other
parties through which we or our collaborators may market, sell and distribute our products, once approved, may be subject to extensive
U.S. federal, U.S. state and foreign healthcare fraud and abuse, transparency, health information and general data privacy and security
laws. For example, U.S. federal civil and criminal laws and regulations prohibit, among other things: knowingly and willfully soliciting,
receiving, offering or providing remuneration, directly or indirectly, to induce or reward either the referral of an individual, or the
furnishing, recommending or arranging for a good or service, for which payment may be made under a federal healthcare program, such as
the Medicare and Medicaid programs; knowingly presenting or causing to be presented, a false or fraudulent claim for payment by a federal
healthcare program; and knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program
(including a private payor), or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially
false statement in connection with the delivery of, or payment for, healthcare benefits, items or services. Many U.S. states and foreign
countries have analogous prohibitions that may be broader in scope and apply regardless of payor. In addition, we may be subject to U.S.
federal, U.S. state and foreign laws that require us to report information related to certain payments and other transfers of value to
certain health care professionals, as well as ownership and investment interests in our company held by those health care professionals
and their immediate family members, and health information and general security and privacy laws that restrict our practices with respect
to the use and storage of certain health information and other data.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">13</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Efforts to ensure that our current and future
business arrangements with third parties comply with applicable healthcare laws and regulations may involve substantial costs. If we or
our collaborators are found to be in violation of any of these laws, we or our collaborators could be subject to significant civil, criminal
and administrative penalties, including damages, fines, disgorgement, imprisonment, exclusion from participation in government healthcare
programs, additional integrity oversight and reporting obligations, contractual damages, reputational harm and the curtailment or restructuring
of our operations, any of which, whether enforced against us or our collaborators, could significantly harm our business and our royalties
from any of our products, once approved, that we license to such collaborators.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Risks Related to our
Discovery and Development Activities </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">There
are risks that are inherent in the development and commercialization of new therapeutic products.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We and our collaborators face a number of
risks of failure that are inherent in the lengthy and costly process of developing and commercializing new therapeutic products. These
risks, which typically result in very high failure rates even for successful biopharmaceutical companies, include, among others, the possibility
that:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zdecb0db3f3614c2198584827b310fc0f" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our new target candidates will prove to be inappropriate for treatment of cancer;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z50b7b77522fe4979b6f13d586101969a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our new target candidates will prove to be inappropriate targets for therapeutic product candidates; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z46cd5601b66b4eeb8e0f2eabb06fc801" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our new target candidates will prove to be inappropriate targets for immunotherapy;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">we will not succeed in selecting the appropriate tumor type, indication or patient population for the therapeutic
        product candidate; </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">we will not succeed in choosing the appropriate mAb for these targets, or the appropriate mAb lead or the
        appropriate mAb isotype; </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">we will not succeed in identifying or developing a biomarker or companion diagnostic for our therapeutic
        product candidates; </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div> </div> </div> </div>

<table cellspacing="0" cellpadding="0" id="z6096074a25b74d1c84ebbf7a93d30a06" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>we will not succeed in choosing the appropriate drug modality for these targets; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze2dcf63fd9034808984bc21221125319" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our therapeutic product candidates will fail to progress to preclinical studies or clinical trials;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9134920790a440f190ec650743da3e24" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our therapeutic product candidates will be found to be therapeutically ineffective;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">we will not choose or have access to the right drug combination for our therapeutic product candidates;
        </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">we will not select or find the appropriate dosing regimen; </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div> </div> </div>

<table cellspacing="0" cellpadding="0" id="zdcad62fd070a4c1fa7cdd2e9578466b7" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our therapeutic product candidates will be found to be toxic or to have other unacceptable side effects or negative consequences;
        </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z0c62c5fb25ed40dd8ca48c997b09af11" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our therapeutic product candidates will be inferior, or not show added value, compared to competing products or the standard of care;
        </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z28a5086afccd494080767807f2f09465" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our early-stage development efforts may provoke competition by others; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">14</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<table cellspacing="0" cellpadding="0" id="z88c1f2abec5a47fb98ebb6575213f6ab" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our products covered by our collaborations may face internal competition from our partners&#8217; internal pipeline;</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za6a3b6a98bdd499281d7b37b4fb399d9" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>we or our collaborators will fail to receive required regulatory approvals; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb43946278ed443e780e0c1439af73f6e" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>we or our collaborators will fail to manufacture our therapeutic product candidates in the quantity or quality needed for preclinical
        studies or clinical trials on a large or commercial scale, on time or in a cost-effective manner or with the drug stability required;
        </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3bef74b212fb46f79d5416b857d2c9f0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>the discovery of drug targets and the discovery, development or commercialization of our therapeutic product candidates will infringe
        third-party intellectual property rights; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z425096625c1c46918d67e8369da09b03" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>the development, marketing or sale of our therapeutic product candidates will fail because of our inability or failure to protect
        or maintain our own intellectual property rights; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z0c2d9685d4fc44e19136e6c8d47b1add" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>once a product is commercially available, there will be little or no demand for it for a number of possible reasons, including lack
        of acceptance by the medical community or by patients, lack of or insufficient coverage and payment by third-party payors, inefficient
        or insufficient marketing and sales activities or as a result of there being more attractive, less risky or less expensive, products available
        for the same use; and </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">the product will be withdrawn from the market, or sales limited due to side effects observed in clinical
        practice.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">If one or more of these risks or any similar
risks should materialize, our business, financial condition and results of operations may be materially harmed.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">We
have limited experience in the development of therapeutic product candidates, and we may be unable to implement our business strategy.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Our experience in the development of therapeutic
product candidates is limited. Therefore, we may encounter unforeseen expenses, difficulties, complications, delays and other known or
unknown factors in achieving our business objectives. To successfully develop and commercialize therapeutic products, we must either access
such expertise via collaborations, consultants or service providers, and/or enhance and improve our internal expertise and capabilities.
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times, serif"><span style="font-family: Times New Roman,Times,serif">If
we are not able to attract, retain and motivate necessary personnel or third party service providers or collaborators to accomplish our
business objectives or fail to have available, at the appropriate times, the required experience and expertise for the further development
and commercialization of our therapeutic product candidates, we may be unsuccessful in these activities, or these activities may be significantly
delayed and as a result we may be unable to implement our business strategy and our business would be materially harmed.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Our
computational target discovery activities are primarily focused on the discovery of new drug target candidates and our therapeutic pipeline
is based on our discovered targets.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">While
we believe that our drug target programs represent a compelling and unique opportunity to generate potentially first-in-class therapeutics
in the field of cancer immunotherapy, they require significant investment in the research and validation of the drug target candidate
and in the discovery and development of the respective therapeutic product candidate and bear high risk. Our predictive computational
discovery capabilities are a source for the development of potential first-in-class therapeutics in the field of cancer immunotherapy,
but the inherent lack of sufficient published scientific and clinical data to support the potential of these new drug targets candidates
to serve as therapeutic opportunities, increases the risk of failure. Although we have built the target identification, validation and
drug discovery infrastructure and capabilities that we believe are required to scientifically validate our new drug targets and to later
translate them into therapeutic antibody development programs, we cannot be assured that our investment in such new discoveries will result
in validated drug targets that will enable the development of effective cancer immunotherapies, nor that we will realize success in product
development or our ability to partner and commercialize such opportunities and generate revenues.</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">15</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Our
approach to the discovery of therapeutic products is based on our predictive computational discovery capabilities that are not yet fully
proven clinically, and we do not know whether we will be able to discover and develop additional potential product candidates or products
of commercial value.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times, serif"><span style="font-family: Times New Roman,Times,serif">Our
method of identifying novel drug targets is based on our predictive computational discovery capabilities and involves first identifying
unmet needs in the field of cancer immunotherapy, where we believe our predictive computational discovery capabilities would be relevant
or could be modified to be relevant. We focus on the discovery of drug targets that could serve as the basis for the development of possible
treatments for patients non-responsive, refractory or relapsing to existing cancer immunotherapies. In this field, we apply our predictive
computational target discovery capabilities, or develop new capabilities, to identify novel drug targets for addressing such unmet patient
need. </span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times, serif"><span style="font-family: Times New Roman,Times,serif">While
we believe that applying our predictive computational discovery capabilities to identify new drug targets may potentially enable the development
of potentially first-in-class therapeutics in the field of cancer immunotherapy, our capabilities are yet not fully proven clinically
and our efforts may not result in the discovery and development of therapeutic products, or commercially viable or successful therapeutic
products. Although our approach has resulted in the discovery of several new drug targets and their related potential first-in-class therapeutic
product candidates in the field of cancer immunotherapy, they are in early stages of research and development or in clinical stage, with
COM701 having entered the clinic in 2018, COM902 which entered the clinic in March 2020 and rilvegostomigwhich entered the clinic in the
fourth quarter of 2021. Our approach may not result in time savings, higher success rates or reduced costs, or clinically meaningful programs
and if not, we may not attract collaborators or develop new drugs as quickly or cost effectively or at all and therefore we may not be
able to partner and commercialize our products as expected. </span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">We
are focusing our discovery and therapeutic development activities on therapeutic product candidates for uses in immuno-oncology. Our current
candidates may fail, and we may fail to continue to discover and develop therapeutic product candidates of industry interest in this field.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The focus of our discovery and therapeutic
development activities is on mAb therapeutics in the field of immuno-oncology for treatment of cancer. As a result, we are not undertaking
internal discovery and development activities in other therapeutic areas or for other drug modalities, and presently we only pursue activities
in our area of focus. If our current candidates fail, or if we fail to continue to discover and develop therapeutic product candidates
of clinical value and medical interest in this field, or if we are unable to discover drug targets for mAb therapeutics, or if other modalities
would be more successful in treating cancer patients, our business will likely be materially harmed. With respect to cancer immunotherapies,
although there have been positive clinical results reported by others resulting in some products gaining approval by the FDA, there can
be no assurance that our therapeutic product candidates or our earlier stage immuno-oncology target candidates in our pipeline, will provide
similar clinical advantages or interest, that no long term adverse effects will be seen, or that other classes of targets or other products
will not be discovered and developed with comparable or superior attributes or clinical activity. In the event of any of these occurrences,
the actual and/or perceived value of a substantial portion of our pipeline would likely be reduced in which case our business may be materially
harmed. To date, we have signed three partnership agreements involving our product candidates, with only one of them with AstraZeneca
still in effect. There is no assurance that we will be able to enter into additional collaborations or agreements on reasonable terms,
if at all. In addition, if we fail to continue to discover and validate drug targets or develop product candidates of industry interest
in our field of focus, our business will likely be materially harmed. There are many risks associated with our decision to focus on immuno-oncology
that include, among others:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8587f6c2f9664245b1b4195163ea303b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>not being able to discover new drug targets in this field; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;

<table cellspacing="0" cellpadding="0" id="z8587f6c2f9664245b1b4195123ea303b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">our full scope of target discovery capabilities may not be adequate; </div> </div> </td> </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z83c8c09695314d23ba0a234afa93bee2" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>not having chosen the right therapeutic area; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze84eb0d9866d49f1a407e9a73febf034" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>having chosen a therapeutic area with a very high degree of competition;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2b379d6dcc084563a59161f7bec0546e" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>industry interest in this area or in specific classes/families of drug targets within this area of focus would decrease over time;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8062e2940c97408b8a97e83c910ef071" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>having chosen a therapeutic area of great biological complexity and with very high failure rates in product development; </div> </td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb78b615f1a4b445c81803e26b890cf5b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>not choosing the appropriate drug modality; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zfb3deadd1afd45fe97d787985244aa16" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>having insufficient knowledge, expertise, personnel or capabilities in our chosen therapeutic area to identify the right unmet medical
        needs, or drug targets, or to timely, properly and efficiently validate the targets and/or select the appropriate mAb for further development
        as therapeutic product candidates, or to timely, properly or efficiently further them in development; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z2febd58ec44447e4afa49dc71adf639d" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>the inherent risk of high program failure rate throughout therapeutic development. </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">16</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In each case, our failure could be due to
lack of experience and expertise, delays in our internal research programs or applying the wrong criteria or experimental systems and
procedures, or selecting an inappropriate drug modality, or unanticipated scientific, safety, activity or efficacy issues with our selected
drug targets or product candidates, with the possible result that none of our product candidates result in licensed or marketable products.
If any of these risks should materialize, our business, financial condition and results of operations would be materially harmed.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">We
may focus our efforts and resources on a particular target or therapeutic candidate or indication and fail to focus our efforts on targets
or therapeutic candidates or indications that may be more successful.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Due to our limited resources
and experience and due to the early stage of our discoveries, we prioritize our research programs and focus to programs that, we believe,
based on limited and preliminary amount of data, seem to have the highest potential. As a result, we might focus our limited resources
on the wrong target or therapeutic candidates or focus our candidates on the wrong therapeutic indication and delay in pursuing or fail
to pursue candidates that might be later proven (or never proven) as more successful.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Risks Related to Our Dependence on Third Parties</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">We
depend significantly on third parties to carry out the research, development and commercialization of our therapeutic product candidates.
If we are unable to maintain our existing agreements or to enter into additional agreements with such third parties, including collaborators,
in the future, our business will likely be materially harmed.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Our primary strategy
for the development and commercialization of products based on our drug target and therapeutic product candidates depends on third parties
to carry out and/or finance, the research, development and commercialization of such products, principally by pharmaceutical and biotechnology
companies and other healthcare related organizations and CROs, either on their own or in collaboration with us. To date, we have entered
into three partnership agreements with respect to our drug target candidates, only one of which, with AstraZeneca, is still in effect.
We cannot be sure that the partnership agreement with AstraZeneca will result in the successful development or commercialization of any
product. Further, we cannot provide assurance that we will succeed in identifying additional suitable parties or entering into any other
additional agreements on satisfactory terms or at all for the discovery, research, development and/or commercialization of our drug target
or therapeutic product candidates. If we are unable to identify such additional suitable parties or enter into new agreements on satisfactory
terms, or at all, our business will likely be materially harmed.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">We
rely and expect to continue to rely completely on third parties to manufacture and supply our preclinical and clinical drug supplies.
Our business could be harmed if those third parties fail to provide us with sufficient quantities of drug product or fail to do so at
acceptable quality and quantity levels, prices or timelines.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">We
do not currently have, nor do we plan to acquire, the infrastructure or capability internally to manufacture our preclinical and clinical
drug supplies for use in the conduct of pre-clinical testing and our clinical trials, and we lack the resources and the capability to
manufacture any of our product candidates on a clinical or commercial scale. In order to develop products, apply for regulatory approvals
and commercialize our products, we will need to develop, contract for, or otherwise arrange for access to the necessary manufacturing
capabilities. We rely and expect to continue to rely on contract manufacturing organizations, or CMOs, and other third-party contractors
to manufacture formulations and produce larger scale amounts and/or commercial-scale of drug substance and drug products required for
any clinical trials that we initiate and other related services. Such third parties may not be able to deliver in a timely manner, or
at all, or may fail to comply with the FDA&#8217;s current Good Manufacturing Practice, or cGMP, to manufacture our drugs in the required
quality or quantity. We have entered into manufacturing and supply agreements with third parties for the manufacturing and respective
analytics of each of COM701 and COM902, for which we have ongoing Phase 1 clinical trials. In addition, in October 2018 we entered into
a master clinical trial collaboration agreement, as amended from time to time, or the MCTC, with Bristol Myers Squibb, to evaluate combinations
of COM701 with Bristol Myers Squibb&#8217;s PD-1 immune checkpoint inhibitor Opdivo&#174; and its investigational antibody targeting TIGIT
known as BMS-986207. Pursuant to the MCTC, which is now terminated, Bristol Myers Squibb provided us at no cost Opdivo&#174; and BMS-986207.Accordingly,
if any of these third parties breach, terminate or otherwise are unable to fulfill their obligations under the agreements for drug supply,
we would need to identify an appropriately qualified alternative source, which could be time consuming, and we may not be able to do so
without incurring material delays and costs in the development of our products, including COM701 and COM902.</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">17</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The manufacturing process for any products
based on our technologies that we or our partners may develop is subject to the FDA regulation and foreign regulatory authority approval
process, and we will need to contract with manufacturers who can meet cGMP requirements and foreign regulatory authority requirements
on an ongoing basis. In addition, if we receive the necessary regulatory approval for any therapeutic drug candidate, we also expect to
rely on third parties, to produce materials required for late-stage pivotal clinical trial(s) and commercial supply. We may experience
difficulty in obtaining adequate manufacturing capacity for our needs, adequate and sufficient material as well as difficulties and challenges
in technology transfer from one manufacturer to the other, as needed. If we are unable to obtain or maintain adequate manufacturing sources
for these product candidates, or to do so on commercially reasonable terms and adequate timeline, quality and quantity, we may not be
able to successfully develop and commercialize our products.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">To the extent that we enter into manufacturing
or supply arrangements with third parties, we will depend on these third parties to perform their obligations in a timely manner and consistent
with regulatory requirements, including those related to quality control and quality assurance. We are also dependent upon these third
parties with respect to critical reagents supply, supplies required for our manufacturing and quality control, packaging, labelling, storage
and others. The failure of a third-party manufacturer or supplier to perform its obligations as expected could adversely affect our business
in a number of ways, including:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z1c02a77cfc514c56b8b5138d9871be15" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>we may not be able to initiate or continue preclinical and clinical trials of products that are under development;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze9a42e1220224157938f4768b1393f2b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>we may experience significant disruption and delay to our clinical supply chain;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3241003313014b7cbc48a5d26a77af41" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>we may experience significant adverse effect if we are unable to transfer the manufacturing process to a different third-party manufacturer
        in a timely and efficient manner;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf197b618d67f48fb8b511ea734e1fb99" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>we may need to repeat clinical trials or stop our clinical trials;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z76aa7687200f4618b1279e6b99d4d033" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>we may be delayed in submitting regulatory applications, or receiving regulatory approvals, for our product candidates;</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3aeabb55cf8c43168dd11309d564f296" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>we may lose the cooperation of our collaborators;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb4e95e26e21346369968245cb394ce08" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>we may be required to cease distribution or recall some or all batches of our products; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z608cd1ef2a4d465fb69b26d889721a79" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 12.1pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>ultimately, we may not be able to meet commercial demands for our products, if approved.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">If a third-party manufacturer or supplier
with whom we contract fails to perform its obligations, we may be forced to manufacture or otherwise obtain the materials ourselves, for
which we do not currently and may not in the future have the capabilities or resources, or identify and qualify a different third-party
manufacturer, which we may not be able to do timely or on reasonable terms, if at all. In some cases, the technical skills or processes
required to manufacture our product may be unique to the original manufacturer and we may have difficulty transferring such skills or
processes to a back-up or alternate manufacturer or supplier, or we may be unable to transfer such skills or processes at all. In addition,
if we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities
and procedures that comply with quality standards and with all applicable regulations and guidelines. We will also be required to demonstrate
that the newly manufactured material is similar to the previously manufactured material, or we may need to repeat clinical trials with
the newly manufactured material. The delays associated with the verification of a new manufacturer could negatively affect our ability
to develop product candidates or commercialize approved products in a timely manner or within budget. Furthermore, a manufacturer may
possess technology related to the manufacture of our product candidate that such manufacturer owns independently, which would increase
our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third-party manufacture
our products.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">18</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Our
dependence on collaboration agreements with third parties presents number of risks.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The risks that we face
in connection with our existing collaboration and other business alliances as well as those that we may enter into in the future include,
among others, the following:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z821087b5640e4266a10c9c1246f7bf0c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>we may be unable to reach mutually agreeable terms and conditions with respect to potential new collaborations; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z654ad1d1ac1045c88b31ceee6f7f24c3" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>we or our current and/or future collaborators may be unable to comply or fully comply with the obligations under collaboration agreements
        to which we are (or will become) a party, and as a result, we may not generate royalties or milestone payments from such agreements, and
        our ability to enter into additional agreements may be harmed; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z795d4dccb50c4c4f8c520da267318765" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our obligations under existing or future collaboration agreements may harm our ability to enter into additional collaboration agreements;
        </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf5ee26a717c44c0980f06d2e27f0bbd4" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>collaborators generally have significant discretion in electing whether to pursue any of the planned activities and the manner in
        which it will be done, including the amount and nature of the resources to be devoted to the development and commercialization of our
        product candidates; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9bc5756a29574e528e63af80fac5de7b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>collaborators generally have significant discretion in terminating the collaborations for scientific, clinical, business or other
        reasons; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf843d445eb0f4b4b9c4d9b6f87228030" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>if our current and/or future collaborators breach or terminate an agreement with us, the development and commercialization of our
        therapeutic product candidates could be adversely affected because at such time we may not have sufficient financial or other resources
        or capabilities or access to the other partner&#8217;s data and drug(s) to successfully develop and commercialize these therapeutics on
        our own or find other partners or enforce our rights under breached or terminated agreement; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze0c48e33f151450682b0c65f600c7000" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our current and/or future collaborators may fail to design and implement or analyze appropriate preclinical and/or clinical trials;
        </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb2f66f08c79c4f2b87b2f6cba2838a27" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our current and/or future collaborators may not have access to the drug combination treatment required for an effective treatment;
        </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z86c95ac397154bbb8e5b995fc3aa9eab" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our current and/or future collaborators may not be able to identify biomarkers that may be required for further product development
        or approval; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3253197f9b0e4e3da8e64deefb9ae7b3" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our current and/or future collaborators may require us changing or adopting the trial design to fit their business priorities, standards
        and other objectives; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5f20236a4680437abdf7086bcfca5f59" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our current and/or future collaborators may fail to manufacture our therapeutic product candidates needed for either clinical trials
        or for commercial purposes on a sufficiently large scale, in the required quality and/or in a cost-effective manner; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zde11b429818d4a728eca27f9ece78dd7" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our current and/or future collaborators may fail to develop and market products based on our discoveries due to various development
        hurdles or regulatory restrictions; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zbe8206bacd4c4df390359bf01dce4a60" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our current and/or future collaborators may fail to develop and market products based on our discoveries prior to the successful
        marketing of competing products by others or prior to expiry of the patents protecting such products; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zcb05878b29bb451e83636e800d415b68" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>changes in a collaborator&#8217;s business strategy may negatively affect its willingness or ability to complete its obligations
        under its arrangement or to continue with its collaboration with us; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zda74323b370a4279bcbe9c934498afd8" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our current and/or future collaborators may terminate the program or the agreement and then compete against us in the development
        or commercialization of similar therapeutics;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf8faedc2759249afaf4736fbd72a7517" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our current and/or future collaborators may terminate the program or the agreement due to the competitive threat we may present to
        them with similar products;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6fd9912113534fffb818f0b3fc3d6d9b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>ownership of the intellectual property generated under or incorporated in our current and/or future collaborations may be disputed;
        </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z148f13e0dbf4464f85b9b480edb3dcbc" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our ownership of rights in any intellectual property or products that may result from our current and/or future collaborations may
        depend on additional investment of resources that we may not be able or willing to make; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z88dafb8b5eb34b7aa40d1c010343b15f" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>current and/or future collaborators may pursue alternative products or technologies, by internally developing them or by preferring
        those of our competitors; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8050b7a364c44e38ba62586511da4ac7" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>disagreements between us and our current and/or future collaborators may lead to delays in, or termination of, the collaboration;
        </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z329e75bd3b6a46f2b9660861a3c7186a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our current and/or future collaborators may fail to develop or commercialize successfully any products based on our novel drug targets
        or therapeutic product candidates to which they have obtained rights from us; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">19</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<table cellspacing="0" cellpadding="0" id="z9b250140d5504d8fad56cec995206cb6" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>we or our current and/or future collaborators may not choose the right drug combinations for our therapeutic product;</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z019926b38e88461d8ace02ccdd1e8922" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our current and/or future collaborations may face internal competition by their internal pipelines;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb42cfa2d87a644d6befdce7567ba9864" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>prospective collaborators may hesitate to pursue collaborations on novel target candidates that lack robust validation to serve as
        a basis for the development of therapeutics; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5971664ba9cd4650939547eae1ef58d7" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our current and/or future collaborators may be acquired by, acquire, or merge with, another company, and the resulting entity may
        have different priorities or competitive products to the collaboration product being developed previously by these collaborators. </div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">If any of these risks should materialize, our business, financial
condition and results of operations may be materially harmed.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Our
existing partnership agreement with AstraZeneca is subject to many risks. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">In
March 2018, we entered into an exclusive license agreement with MedImmune Limited, the global biologics research and development arm of
AstraZeneca, which is currently part of AstraZeneca. Under the terms of the license agreement, we provided an exclusive license to AstraZeneca
to use our monospecific antibodies that bind to TIGIT, including COM902, for the development of bi-specific and multi-specific antibody
products, excluding such bi-specific and multi-specific antibodies that also bind to PVRIG, PVRL2 and/or TIGIT. In connection with such
license agreement, AstraZeneca developed rilvegostomig, a novel TIGIT/PD-1 bi-specific antibody with a TIGIT component that is derived
from our COM902. Subject to termination rights for material breach, bankruptcy or by us for patent challenge by AstraZeneca, the term
of the license agreement continues until the expiration of the last royalty term in the territory as further specified in the license
agreement. In addition, AstraZeneca may terminate the agreement for convenience upon prior written notice.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">If significant adverse unforeseen events
occur in this collaboration or it is terminated, particularly prior to our signing additional collaboration agreements, our business and
financial condition may be materially harmed.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Our
reliance on third parties for the performance of key activities heightens the risks faced by our business. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We outsource many of our activities and
many key functions to third parties, including major preclinical activities, drug development activities, manufacturing operations, research,
validation, discovery and others. We do not control the third parties to whom we outsourced these functions and have limited internal
expertise to appropriately manage their activities. However, we are dependent on them to undertake activities and provide services, results,
our product candidates or materials, including the production of certain biological reagents, which may be significant to us. If these
third parties fail to properly or timely perform these activities or provide us with incorrect or incomplete services or results or fail
to produce and/or provide certain materials, tests or analysis, this could lead to significant delays in the program or even program failure,
along with significant additional costs and damage. In addition, should any of these third parties fail to comply with the applicable
laws and regulations and/or research and development or manufacturing accepted standards in the course of their performance of services
for us, there is a risk that we could be held responsible for such violations of law as well. Any such failures by third parties could
have a material adverse effect on our business, financial condition or results of operations. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Moreover, we do not always independently
verify the results obtained by such third parties and in some cases, rely upon the data provided by the third-party. If we fail to identify
and obtain accurate and quality data, services and/or technologies from such third parties, or if the contractual demands of such third
parties become unreasonable and we are not able to reach satisfactory agreements with such third parties, we may lose our investment in
these services, fail to receive the expected benefits from our discoveries, and our validation and development capabilities, clinical
trials or other activities or our final products, may be significantly harmed, delayed or terminated.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">We
may need to obtain third-party drugs for combination with our clinical programs that may not be available to us or are available only
on commercially unreasonable terms or may not serve us as well as other drugs. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We&#160;may&#160;need to obtain certain
drugs from third&#160;parties&#160;to&#160;further&#160;develop&#160;our drug candidates to work in combinations with other drugs for
selected indications in order to commercialize&#160;our&#160;drug candidates. If we fail to obtain these drugs or license thereof, our
drug candidates may not be sufficiently efficient, and we may not be able to pursue them through development, registration and commercialization.
Furthermore, if we pursue clinical trials with third parties to&#160;further&#160;develop&#160;our drug candidates to work in combinations
with such other drugs for selected indications and those third parties&#8217; drugs have not received regulatory approval for an indication
of interest to us, such clinical trial may not provide us a path for registration and therefore may not serve us best as other drug(s)
in the relevant indication. </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">20</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Risks
Related to Competition and Commercialization</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Our
business model is challenging to implement and to date has not yielded significant revenues.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Our discovery and development capabilities
are designed to identify and develop novel products addressing a specific unmet need and enter into collaborations with partners with
respect to such novel products. Our objective is that under these collaborations, we will have the right to receive various forms of revenues
from such products or product candidates. To date, we have entered into three partnership agreements with respect to our pipeline programs,
only one of which, with AstraZeneca, is currently in effect. There can be no assurance that our current or any future agreements for novel
targets based on our discoveries and associated product candidates will be successful and thus provide significant revenues to us, nor
can there be any assurance that we will be able to enter into additional future agreements. If we are unable to succeed in securing additional
license agreements or other collaboration arrangements related to our discoveries and product candidates, our business may be materially
harmed.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Currently we have an ongoing collaboration
with AstraZeneca, pursuant to which rilvegostomig, a novel anti-PD-1/TIGIT bispecific antibody with a TIGIT component that is derived
from our COM902 program, entered into a Phase 2 clinical trial in the fourth quarter of 2022. In addition, we have two clinical programs
fully owned by us, COM701 and COM902, and a pre-clinical program, COM503, all of which are available for partnering arrangements.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">There can be no assurance that we will be
able to establish collaborations for COM701 or additional collaborations COM902 or for our early-stage programs in the target discovery,
research, validation and preclinical stage. Failure to enter into collaborations, may materially harm our business. The research and validation
data generated to date for our early-stage pipeline and the clinical data generated to date for COM701 and COM902 may not be sufficient
to attract interest from prospective collaborators and we may fail to generate data suitable to draw interest with potential partners.
Furthermore, our drug target candidates or therapeutic product candidates may not fit their corporate or clinical strategy. These companies
may require more data, including their independent testing of our early-stage therapeutic product candidate, before considering a collaboration.
We are therefore dependent on the potential fit of our programs with individual pharmaceutical company strategies and there can be no
assurance that we will be able to identify additional partners interested in our programs at their current stages. This may adversely
affect our ability to enter into additional agreements for the research, development, license or other form of collaborative arrangement
of our therapeutic product candidates, and as a result may harm our business.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times, serif"><span style="font-family: Times New Roman,Times,serif">Additionally,
we may not be able to demonstrate efficacy or safety, prove our scientific or preclinical hypothesis or obtain approval for and commercialize
our products as monotherapy treatments. We may be required to combine our product candidates with other products to provide sufficient
data for approval by FDA and other regulatory authorities, in all or in specific indications (which may require our dependency on third-party
drugs). As part of our business strategy, we are looking to establish clinical collaborations with pharmaceutical and biotechnology companies
to specifically test the hypothesis that there may be greater effects when combining our products with other products. In October 2018,
we entered into the MCTC, with Bristol Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol Myers
Squibb&#8217;s PD-1 immune checkpoint inhibitor Opdivo<sup style="font-family: Times New Roman, serif; vertical-align: text-top; line-height: 1; font-size: smaller">&#174;</sup>
and thereafter amended such agreement to further evaluate the safety, tolerability and antitumor activity of COM701 in combination with
Opdivo<sup style="font-family: Times New Roman, serif; vertical-align: text-top; line-height: 1; font-size: smaller">&#174;</sup> and
with and Bristol Myers Squibb&#8217;s investigational antibody targeting TIGIT known as BMS-986207. On August 3, 2022, we entered into
a letter agreement with Bristol Myers Squibb pursuant to which the MCTC between the parties was terminated as of such date. See &#8220;Business
Strategy and Partnerships - Bristol Myers Squibb Collaboration&#8221; below. There can be no assurance that we will be able to establish
additional clinical collaborations or to maintain our existing collaboration. Failure to enter into clinical collaborations to pursue
drug combinations may materially harm our business. These potential combination products may include both marketed as well as investigational
products, and as such, adverse events resulting from combining the products or investigational agents are unknown and could be severe,
including resulting in death of the patient due to these unknown toxicities. Furthermore, using our therapeutic product candidates as
part of combinations therapy may result in a situation under which our therapeutic product candidates will be entitled to only a fraction
of the anticipated product revenues. </span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">21</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">We
operate in a highly competitive and rapidly changing industry which may result in others discovering, developing or commercializing competing
products ahead of us or more successfully than we do.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">The
biotechnology and biopharmaceutical industries are highly competitive, subject to consolidation, characterized by rapid and significant
technological advancements, and have a strong emphasis on proprietary products. Our success is highly dependent upon our ability to identify,
develop and obtain regulatory approval for therapeutic products based on our discovered novel drug targets. In doing so, we face and will
continue to face intense competition from a variety of businesses, including large, fully integrated, well-established pharmaceutical
companies, specialty pharmaceutical and biopharmaceutical companies, academic institutions, government agencies and other private and
public companies and research institutions.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Many of the companies against which we are
competing or against which we may compete in the future have significantly greater resources and expertise in research and development,
manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved drugs than we do.
These competitors and others may develop competing products targeting the same mechanisms, the same drug targets and pathways as our products,
or the same therapeutic indications and they can leverage their resources or use different approaches than we do to receive marketing
approval before our products. Additionally, these third parties compete with us in recruiting and retaining qualified scientific, drug
development and management personnel and advisors, establishing clinical trial sites and patient enrollment for clinical trials, as well
as in acquiring technologies complementary to, or necessary for, our programs. Mergers and acquisitions in the biopharmaceutical industry
could result in even more resources being concentrated among a small number of our competitors or change in potential acquirers&#8217;
preferences. In addition, increased industry interest and deals in the anti-TIGIT and anti-PVRIG field may further enhance the competition
for our clinical stage assets COM902 and COM701 and may include companies with significantly greater resources and capabilities than we
have. For example, in January 2022 Coherus exercised its option to Junshi Biosciences&#8217; TIGIT-targeted antibody JS006 and initiated
phase 1 clinical trials, in December 2021 Novartis signed an option, collaboration and license agreement with Beigene for its TIGIT inhibitor
ociperlimab, in November 2021 Gilead and Taiho each exercised its option to Arcus&#8217; anti-TIGIT antibodies domvanalimab and AB308
each pursuant to its respective territorial rights, in June 2021 GSK and iTeos Therapeutics entered into an agreement to co-develop and
co-commercialize iTeos&#8217; anti-TIGIT antibody EOS-448, and in December 2020 GSK licensed worldwide development and commercial rights
to Surface Oncology&#8217;s preclinical program SRF813 (now GSK4381562), an antibody targeting PVRIG which has received FDA IND clearance
in December 2021 and initiated phase I studies.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Competition may further increase as a result
of advances in the commercial applicability of technologies similar to our predictive computational discovery capabilities and greater
availability of capital for investment in these industries. Over the last several years, there has been an increase in the interest of
pharmaceutical companies, the healthcare community and the investment community in applying computational methodologies, mostly Artificial
Intelligence (AI) and Machine Learning (ML) algorithms, to the field of data-driven drug discovery/healthcare. This interest may be seen
in the increase in the number of companies within the pharmaceutical and biotech industries which focus on this area, including by way
of establishing internal AI and/or ML capabilities or receiving investments or entering into partnerships or acquisitions in furtherance
thereof. Our competitors may succeed in discovering targets and therefore also develop products that are competitive to ours.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In addition, there is a trend towards consolidation
in the pharmaceutical, diagnostic and biotechnology industry, which may result in the remaining companies having greater financial resources
and discovery and technological capabilities, thus intensifying competition in our industry. In addition, it is possible that because
of adverse or volatile capital market conditions, companies may be willing to enter into mergers and acquisition transactions or other
sale of asset transactions on terms more favorable to acquirer and thereby further intensify competition. This trend may also result in
fewer potential collaborators or licensees for our therapeutic product candidates. Also, if a consolidating company is already doing business
with our competitors, we may lose existing or potential licensees or collaborators as a result of such consolidation. In addition, if
a consolidating company is already doing business with us, we may lose the interest of the consolidating parties in our discovery capabilities
or individual discoveries or product candidates as a result of a modified strategy, new priorities, competition and revised capabilities
or portfolio of such consolidated entity. This trend may adversely affect our ability to enter into agreements for the development and
commercialization of our therapeutic product candidates or to keep current collaboration in place or on-track and as a result may harm
our business.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">22</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Established biopharmaceutical companies
may invest heavily to accelerate discovery and development of novel drug targets or therapeutic products or to in-license novel drug targets
or therapeutic products that could make our product candidates less competitive. In addition, any new product that competes with an approved
product must demonstrate compelling advantages in efficacy, compliance regimen, tolerability and safety in order to overcome price competition
and to be commercially successful. Accordingly, our competitors may succeed in obtaining patent protection, discovering, developing, receiving
FDA approval for or commercializing drugs before we do, which would have an adverse impact on our business and results of operations.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Potential
collaborators, including major pharmaceutical companies, might be hesitant to pursue target validation and preclinical and clinical development
programs based on novel targets lacking robust experimental validation results particularly those discovered through a computational discovery
approach.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times, serif"><span style="font-family: Times New Roman,Times,serif">There
is a need for new drug targets generating new treatment options for patients who are non-responsive or refractory to current immunotherapies.
Our business model includes selectively entering into collaborations for novel targets and related therapeutic product candidates at various
stages of research and development under various revenue-sharing arrangements. Entering into collaborations with product candidates and
targets at an early validation stage or drug discovery stage is significantly more challenging than identifying partnerships for later-stage
products that would have a more complete data package to support its clinical and business potential. In addition, although we have demonstrated
success in validating our predictive computational discovery capabilities with product candidates in human clinical trials, major pharmaceutical
companies may be hesitant to enter into early-stage collaborations based on newly discovered targets, more so if discovered by computer
prediction and has no or limited published scientific support, as opposed to drug targets backed with human clinical trial data, or product
candidates with significant published experimental validation. Therefore, we cannot assure that our business model to enter into commercialization
arrangements for our early-stage novel targets and product candidates will be successful.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times, serif; font-style: italic"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">The
agreement cycle for potential collaborations is complex and long to implement and, if we are not able to establish collaborations on commercially
reasonable terms, we may expend substantial funds and management resources with no assurance of success</span><span style="font-family: Times New Roman,Times,serif">.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In general, each potential license agreement
or other form of collaboration we may enter into will require negotiating with our potential collaborator, a large number of scientific,
legal and business terms and conditions that can vary significantly in each instance due to the specific drug target or therapeutic product
candidate or candidates involved, the potential market opportunity, the potential collaborator&#8217;s licensing, development and business
operations and strategy, and competition in the partnering and business development space. The accommodation of these requirements mandates
a thorough consideration of both the scientific and business aspects of each transaction. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Whether we reach a definitive agreement
for new collaborations will depend, among other things, upon our assessment of the collaborator&#8217;s resources, capabilities and expertise,
the terms and conditions of the proposed collaboration, the proposed collaborator&#8217;s evaluation of our business, drug targets and
therapeutic product candidates, and the competition in the business development space. We may not be successful in our efforts to establish
a collaboration or other alternative arrangements for future product candidates because they may be deemed to be at too early of a stage
of development for collaborative effort and third parties may not view them as having the requisite potential to demonstrate safety and
efficacy or may find any other development hurdles and challenges as a limiting factor. If we are unable to do so, we will need to expend
substantial funds and substantial key personnel time and effort into these business development activities with no assurance of successfully
entering into agreements with potential collaborators and this could harm our business.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">We
rely on our predictive computational discovery capabilities to identify drug targets. Our competitive position could be materially harmed
if our competitors develop capabilities similar to ours and identify and develop rival drug targets and product candidates.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times, serif"><span style="font-family: Times New Roman,Times,serif">We
rely on know-how and other proprietary computational processes and tools to maintain our competitive computational discovery position.
We consider know-how to be our primary intellectual property with respect to our predictive computational discovery capabilities. Know-how
can be difficult to protect and enforce. In particular, we anticipate that with respect to our capabilities, this know-how may over time
be disseminated within the industry through independent development and the movement of skilled personnel.</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">23</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We cannot rule out that our competitors
may have or obtain the knowledge necessary to identify and develop therapeutic products based on novel drug targets that could compete
with the drug targets we identify. Our competitors may have significantly greater experience in artificial intelligence, computer sciences,
algorithmic tool development and alike to identify targets and greater experience in using translational science to develop product candidates
and may also have significantly greater financial, product development, scientific, technical and human resources than we do to discover
novel drug targets and develop product candidates. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We may not be able to prohibit our competitors
from using methods to identify and develop product candidates, including such methods that are the same as or similar to our own. Since
our competitors develop products that compete with COM701 or COM902 or any future product candidates we develop, our ability to develop
and commercialize these product candidates may diminish substantially, which could have a material adverse effect on our business prospects,
financial condition, and results of operations.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">The
biotechnology and pharmaceutical industries are highly competitive, and we may be unable to compete effectively.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The biotechnology and pharmaceutical industries
in general, and the immuno-oncology field in particular, are highly competitive. Numerous entities in the United States, Europe and elsewhere
compete with our efforts to discover, validate, develop and partner with licensees and/or collaborators to commercialize drug target and
therapeutic products candidates. Clinical trial failures of novel agents in the immuno-oncology field may adversely impact our ability
to sign early-stage collaborations, and as a result we may be required to advance our programs into clinical development and show clinical
proof of concept before we may attract potential collaborators. Our competitors include pharmaceutical and biotechnology companies, academic
and research institutions and governmental and other publicly funded agencies. We face, for COM701 and COM902, and expect to continue
to face for our future therapeutic product candidates, competition from these entities to the extent they develop products that have a
function similar or identical to or competing with the function of our therapeutic product candidates in the field of immuno-oncology
that may attract our potential collaborators or that may reach the market sooner. We also face, and expect to continue to face, competition
from entities that seek to develop technologies that enable the discovery of novel targets and therapeutic agents in the field of immuno-oncology.
These competitors include traditional pharmaceutical and biotechnology companies and additionally, an increasing number of new entities
looking to apply computer science, bioinformatics, AI or ML technologies to the field of target discovery. Many of our competitors have
one or more of the following:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6b1c86f6e2c84cf79e906b4f9349d466" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>much greater financial, technical and human resources than we have at every stage of the discovery, development, manufacture and
        commercialization process; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z60a25a7ea26f4ed38fa6703e469fbd77" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>more extensive experience in computational discovery, preclinical testing, conducting clinical trials, obtaining regulatory approvals,
        and in manufacturing and marketing therapeutics; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc96c2fbb0d5d4429b12faf0ccc0154fa" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>more extensive experience in oncology and immuno-oncology and in the fields of mAb therapeutics; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">accessibility to enhanced technologies that may result in better products; </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div> </div>

<table cellspacing="0" cellpadding="0" id="zf3462e397083499fbab6f4e591f58c8d" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>access to and experience in the development of therapeutic modalities that are competitive to mAb therapeutics;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zfe86a7115d6745e09606b291d3da8131" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>more extensive experience in oncology and immuno-oncology and in the field of target discovery;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z14ae6146d24a4551b725d3648621cc4d" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>more extensive experience in the research and development of biological or genetic markers to determine response of or responders
        to therapeutic agents or for patient selection;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zf0f99d4ffcb647cc9b53a1e9f687e1a0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>greater accessibility to data and proprietary data from patients;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z225a452d98b8457d9736b80465ae8210" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>access to internally developed, proprietary technologies for the discovery, research, development, or manufacturing of therapeutic
        agents; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zbf344b9fa54245548fec4f1499dca4e0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>greater resources and means to compete with us on target discovery and as well as in acquiring or generating technologies complementary
        to, or necessary for, our programs as well as in recruiting and retaining qualified scientific and management personnel and establishing
        clinical trial sites;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">24</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<table cellspacing="0" cellpadding="0" id="zfdb4e550b9734cb4b7150a508c4fdd01" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>products that have been approved or are in late stages of development and in many cases, PD-1 or PDL-1 inhibitors that are serving
        or will be serving as the backbone of cancer immunotherapy; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z44db66db0a4f4709ae0a840a0567f5c7" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>reduced reliance on collaborations or partnerships with third parties in order to further develop and commercialize competitive therapeutic
        products; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za9b2b3dab67448679b47e0ea5dbc7ce5" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>collaborative arrangements in our target markets with leading companies and research institutions. </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Since we are a small company with limited
human and financial resources, we are not able to work with a large number of collaborators in parallel and/or advance a large number
of drug target or therapeutic product candidates in parallel. Our competitors may develop or commercialize products with significant advantages
over any therapeutic products we, our collaborators or third-party licensees may develop. They may also obtain patents and other intellectual
property rights before us, or broader than ours, and thereby prevent us from pursuing the development and commercialization of our discoveries.
They may also develop products faster than us and therefore limit our market share. Our competitors may therefore be more successful in
developing and/or commercializing products than we, our collaborators, or third-party licensees are, which could adversely affect our
competitive position and business. If we are unable to compete successfully against existing or potential competitors, our financial results
and business may be materially harmed.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Healthcare
policy is volatile and changes in healthcare policy could increase our expenses, decrease our revenues and impact sales of, and reimbursement
for, our products.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times, serif"><span style="font-family: Times New Roman,Times,serif">Our
ability to commercialize our future therapeutic product candidates successfully, alone or with collaborators, will depend in part on the
extent to which coverage and reimbursement for these product candidates will be available from government health programs, such as Medicare
and Medicaid in the United States, private health insurers and other third-party payors. At present, significant changes in healthcare
policy, in particular the continuing efforts of the U.S. and other governments, insurance companies, managed care organizations and other
payors to contain or reduce health care costs are being discussed, considered and proposed.&#160;Drug prices in particular are under significant
scrutiny and continue to be subject to intense political and societal pressures, which we anticipate will continue and escalate on a global
basis.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times, serif"><span style="font-family: Times New Roman,Times,serif">For
example, in the United States, there have been several initiatives implemented to achieve these aims. The Patient Protection and Affordable
Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, and collectively, the ACA, represents the biggest
regulatory overhaul to the health care system in decades and substantially changes the way health care is financed by both governmental
and private insurers. Since its enactment, there have been&#160; congressional, judicial, and executive&#160; challenges to the ACA, which
have resulted in delays in the implementation of, and action taken to repeal or replace, certain aspects of the ACA For example, on June
17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because
the &#8220;individual mandate&#8221; was repealed by Congress. In addition, there have been a number of health reform initiatives by the
Biden administration that have impacted the ACA. On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or the
IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces
through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly
lowering the beneficiary maximum out-of-pocket cost through a newly established manufacturer discount program. It is possible that the
ACA will be subject to judicial or congressional challenges or additional health reform measures of the Biden administration will impact
the ACA and our business.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In addition, the IRA, among other things,
(i) directs the Secretary of HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare
Part B and Medicare Part D, and subjects drug manufacturers to civil monetary penalties and a potential excise tax by offering a price
that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law, and (ii) imposes rebates under Medicare
Part B and Medicare Part D to penalize price increases that outpace inflation. The IRA permits HHS to implement many of these provisions
through guidance, as opposed to regulation, for the initial years. These provisions will take effect progressively starting in fiscal
year 2023, although they may be subject to legal challenges. It is currently unclear how the IRA will be implemented but is likely to
have a significant impact on the pharmaceutical industry. Further, the Biden administration released an additional executive order on
October 14, 2022, directing HHS to submit a report within 90 days on how the Center for Medicare and Medicaid Innovation can be further
leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries. At the state level, legislatures have increasingly
passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient
reimbursement constraints, discounts, and restrictions on certain product access. In some cases, such legislation and regulations have
been designed to encourage importation from other countries and bulk purchasing.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">25</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We expect that the ACA, the IRA, and any
other healthcare reform measures that may be adopted in the future may result in additional reductions in Medicare and other healthcare
funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for
any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments
from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate
revenue, attain profitability or commercialize our product candidates, if approved.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">The
commercial success of our products depends on the availability and sufficiency of third-party payor coverage and reimbursement.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Market acceptance of drug products is dependent
on the extent to which coverage and reimbursement is available from third-party payors. Significant uncertainty exists as to the coverage
and reimbursement status of any products for which we may obtain regulatory approval. Coverage decisions may not favor new products when
more established or lower cost therapeutic alternatives are already available. Even if we obtain coverage for a given product, the associated
reimbursement rate may not be adequate to cover our costs, including research, development, intellectual property, manufacture, sale and
distribution expenses, or may require co-payments that patients find unacceptably high. Patients are unlikely to use our products unless
reimbursement is adequate to cover all or a significant portion of the cost of our products.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Coverage and reimbursement policies for
products can differ significantly from payor to payor as there is no uniform policy of coverage and reimbursement for products among third-party
payors in the United States. There may be significant delays in obtaining coverage and reimbursement as the process of determining coverage
and reimbursement is often time consuming and costly which will require us to provide scientific and clinical support for the use of our
products to each payor separately, with no assurance that coverage or adequate reimbursement will be obtained. It is difficult to predict
at this time what government authorities and third-party payors will decide with respect to coverage and reimbursement for our drug products.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Additionally, we or our collaborators may
develop companion diagnostic tests for use with our product candidates. We, or our collaborators, will be required to obtain coverage
and reimbursement for these tests separate and apart from the coverage and reimbursement we seek for our product candidates, once approved.
While we have not yet developed any companion diagnostic test for our product candidates, if we or our collaborators do, there is significant
uncertainty regarding our ability to obtain coverage and adequate reimbursement for the same reasons applicable to our product candidates.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Risks
Related to our Operations and Other Risks Related to our Business</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Given
our level of managerial, operational, financial and other resources, our current activities and future growth may be limited.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">We
manage our operations, including clinical trials and preclinical development activities of our therapeutic candidates with a limited workforce
and by using third parties to provide us services that we do not possess in-house. Our personnel, systems and facilities currently in
place may not be adequate to support our current activities or future growth.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">If we are unable to maintain or expand our
managerial, operational, financial and other resources to the extent required to manage our development and commercialization activities,
our business may be materially adversely affected.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times, serif; font-style: italic; font-weight: bold"><span style="font-family: Times New Roman,Times,serif">We
may be unable to hire or retain key personnel or sufficiently qualified management, clinical and scientific personnel. </span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Our business is highly dependent upon the
continued services of our senior management and key scientific and clinical personnel. While members of our senior management and other
key personnel have entered into employment or consulting agreements and non-competition and non-disclosure agreements, they can terminate
their employment agreements with us at any time without cause. We cannot be sure that these key personnel and others will not leave us
or compete with us, which could harm our business activities and operations. </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">26</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">It can also be difficult for us to find
employees with appropriate experience for our business, which difficulty is further heightened when seeking experienced personnel in Israel.
We require a multidisciplinary approach and some of our researchers require an understanding in both exact and biological sciences. In
addition, we require experience in drug and clinical development and immuno-oncology, for which there is significant competition for highly
qualified personnel in these fields. As a result, we may face higher than average employee turnover or challenges in hiring due to such
competition. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The competition for qualified personnel
in the pharmaceutical and biotech industry is intense. The loss of service of any of our key personnel could harm our business. Due to
our limited resources, we may not be able to effectively retain our existing key personnel or attract and recruit additional qualified
key personnel.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">We
may be unable to safeguard the integrity, security and confidentiality of our data or third parties&#8217; data.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times, serif"><span style="font-family: Times New Roman,Times,serif">We,
and the third parties upon whom we rely, process, collect, receive, store, process, generate, use, transfer, disclose, make accessible,
protect, secure, dispose of, transmit, and share (collectively, processing) proprietary, confidential, and sensitive data, including personal
data (such as health-related data), intellectual property, trade secrets and other sensitive data the Company may process (collectively,
sensitive information). We have implemented and maintain physical and software security measures to preserve and protect our computers
and communication, hardware and software systems as well as our data and third parties&#8217; data. However, these methods may not fully
protect us against fire, storm, flood, power loss, earthquakes, telecommunications failures, physical or software break-ins or similar
events. In addition, these measures may not be sufficient to prevent unauthorized access, use or publication of proprietary data. This
could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure
of, or access to our sensitive or proprietary information or our information technology systems, or those of the third parties upon whom
we rely. In addition, a party, including an employee or a contractor, who obtains unauthorized access to our proprietary data or breaches
a confidentiality agreement with us could publish or transfer large portions or all of our proprietary data, which could be used to undermine
our competitive advantage or market position. </span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Our
information technology systems, or those of our cloud providers, CROs or other contractors or consultants, may fail or suffer security
breaches, which could result in a material disruption of our pipeline and our business, as well as to regulatory investigations or actions;
litigation; fines and penalties; reputational harm; loss of revenue and other adverse consequences.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times, &apos;Times New Roman&apos;, serif"><span style="color: #000000">Our business is increasingly
dependent on critical, complex and interdependent information technology systems to support business processes as well as internal and
external communications. Despite the implementation of security measures, our information technology systems, cloud based computers and
those of our CROs and other contractors and consultants are vulnerable to damage. </span><span style="font-family: Times New Roman, serif; color: #000000">Cyber-attacks,
malicious internet-based activity, online and offline fraud, and other similar activities threaten the confidentiality, integrity, and
availability of our sensitive information and information technology systems, and those of the third parties upon which we rely. Such
threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources, including traditional
computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; organized criminal threat actors, personnel (such as through
theft or misuse), sophisticated nation states, and nation-state-supported actors.</span><span style="color: #000000"> Some actors now
engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons
and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we or the third parties
upon which we rely may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially
disrupt our systems and operations. While, to our knowledge, we have not experienced any such system failure, accident or security breach
to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption to our programs
and could materially harm our operations and even cause our business to cease. For example, the loss of clinical trial data from the clinical
trials of our therapeutic product candidate could result in delays in our regulatory approval efforts and significantly increase our costs
to recover or reproduce the data. In addition, our systems are potentially vulnerable to data security breaches, whether by employees
or others, which may expose sensitive data to unauthorized persons. Although we have invested in measures to reduce these risks, we cannot
assure you that these measures will be successful in preventing compromise and/or disruption of our information technology systems and
related data. While we are taking different measures as aforesaid, software such as those used by us can contain errors, defects, security
vulnerabilities or software bugs that are difficult to detect and correct, and </span><span style="font-family: Times New Roman, serif">in
a penetration test performed by our security vendor, there were critical vulnerabilities identified related to certain internal network
operations that we </span><span style="color: #000000">are actively working to remedy and mitigate any effects they may have on our business,
though, even if we are able to obtain a patch or other fix to address such vulnerabilities, such fix may be difficult to implement or
otherwise be delayed or become ineffective during the passage of time. To the extent that any disruption or security breach results in
a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur
liability and the further development of our therapeutic candidates could be delayed.</span></div>

<div style="line-height: 1.25">&#160;</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">27</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times, serif"><span style="font-family: Times New Roman,Times,serif">The
reliability and continuous availability of our information technology is critical to our success.&#160; However, software such as those
used by us can contain errors, defects, security vulnerabilities or software bugs that are difficult to detect and correct, particularly
when such vulnerabilities are first introduced or when new versions or enhancements are released. Additionally, even if we are able to
obtain a patch or other fix to address such vulnerabilities, such fix may be difficult to implement or otherwise be delayed. For example,
in connection with a penetration test performed by our security vendor, there were critical vulnerabilities identified related to certain
internal network operations. We are actively working to remedy the vulnerabilities and mitigate any effects they may have on our business.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Our
business and operations would suffer if our information technology systems or infrastructure or data, or our vendors&#8217; or partners&#8217;,
are or were compromised. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We, our vendors and our partners collect,
store, use, transmit, disclose, or otherwise process, or Process, proprietary, confidential, and sensitive data, including personal data
of our employees, clinical trial patients, and others, intellectual property and trade secrets. We rely on third-party service providers
and technologies to operate critical business systems to process sensitive information in a variety of contexts, including, without limitation,
cloud-based infrastructure, data center facilities, encryption and authentication technology, employee email, and other functions. We
also rely on third-party service providers to provide other services necessary to operate our business, including our CROs. Our ability
to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information
security measures in place. We, our vendors and our partners rely on information technology systems, including those provided by third-party
service providers, to keep financial records, capture laboratory data, maintain clinical trial data and corporate records, communicate
with staff and external parties and operate other critical functions. Our ability to monitor our vendors&#8217; and partners&#8217; information
security practices is limited, and these third parties may not have adequate information security measures in place. Our information technology
systems, and those of our vendors&#8217; and partners&#8217;, are vulnerable to a variety of evolving threats from various sources, including
traditional computer hackers, personnel (such as through theft or misuse), threat actors, sophisticated nation states, and nation-state-supported
actors. These threats include but are not limited to social-engineering attacks, malicious code (such as viruses), malware, denial-of-service
attacks, ransomware attacks, supply-chain attacks, server malfunctions, software or hardware failures, or other disruptive events including
but not limited to natural disasters. Remote work has become more common and has increased risks to our information technology systems
and data, as more of our employees utilize network connections, computers and devices outside our premises or network, including working
at home, while in transit and in public locations. If we or our vendors or partners were to suffer a security breach or other interruption,
we could experience unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure
of, or access to our data or data held by us or our vendors and partners (including personally identifiable information or personal data).
Although we have implemented security measures designed to protect against security breaches and other incidents and maintain offsite
back-ups of our data, such measures may fail. Security breaches, vulnerabilities, and other inappropriate access can be difficult to detect
because such threats and techniques change frequently and are often sophisticated in nature. If we or our vendors and partners experience
(or are perceived to have experienced) a security breach or other incident or disruption, we may experience adverse consequences, including
but not limited to, government enforcement actions (e.g., investigations, fines, penalties, audits, and inspections), federal, state and/or
foreign data breach notification obligations, additional reporting requirements and/or oversight, restrictions on processing data (including
clinical trial data), litigation, indemnification obligations, loss of data (including clinical trial data) or damage to the integrity
of that data, negative publicity, reputational harm, monetary fund diversions, interruptions in our operations, financial loss, and other
similar harms. Such attended consequences may interrupt our clinical trials, reduce demand for our product candidates, and delay or negatively
impact the development and commercialization of our product candidates and ability to grow and operate our business. We may expend significant
resources or modify our business activities (including our clinical trial activities) to try to protect against security incidents.If
our third-party service providers experience a security incident or other interruption, we could experience adverse consequences. While
we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us,
any award may be insufficient to cover our damages, or we may be unable to recover such award. Furthermore, our contracts may not contain
limitations of liability, and even where they do, there can be no assurances that limitations of liability in our contracts are sufficient
to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance
coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices,
that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.
Moreover, failure to maintain effective internal accounting controls related to data security in general could impact our ability to produce
timely and accurate financial statements and could subject us to regulatory scrutiny. </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">28</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">We
are subject to stringent and changing obligations related to data privacy and security. Failure or perceived failure to comply with current
or future obligations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation,
and/or adverse publicity and could negatively affect our operating results and business.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">We,
our vendors and our partners collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose
of, transmit, and share (collectively, processing) proprietary, confidential, and sensitive data, including personal data, data we collect
about trial participants in connection with clinical trials, sensitive third-party data, trade secrets, intellectual property, and other
sensitive data. We and our vendors and partners may be subject to numerous data privacy and security obligations, such as various federal,
state, local and foreign data laws, regulations, guidance, industry standards, external and internal privacy and security policies, contracts,
and other obligations that govern the processing of personal data by us and on our behalf. In the United States, numerous federal and
state laws and regulations, including federal health information privacy laws, state data breach notification laws, state health information
privacy laws and federal and state consumer protection laws, that govern the collection, use, disclosure and protection of health-related
and other personal data apply to our operations or the operations of our collaborators. For example, the federal Health Insurance Portability
and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH,
imposes specific requirements relating to the privacy, security, and transmission of individually identifiable health information. The
Controlling the Assault of Non-Solicited Pornography and Marketing Act of 2003 (&#8220;CAN-SPAM&#8221;) imposes specific requirements
on our correspondence with subscribers for email communication. Additionally, laws in all 50 states require businesses to provide notice
to parties whose personally identifiable information has been disclosed as a result of a data breach. The laws are not consistent, and
compliance in the event of a widespread data breach is costly. Furthermore, California enacted the California Consumer Privacy Act, or
the CCPA, which provides for civil penalties for violations, as well as a private right of action for data breaches. The California Privacy
Rights Act, or the CPRA, which took effect in most material respects on January 1, 2023, significantly modifies the CCPA, potentially
resulting in further uncertainty as the California Privacy Protection Agency is still working to promulgate final rules. The CCPA, as
amended requires businesses to provide specific disclosures in privacy notices and honor requests of California residents to exercise
certain privacy rights. The CCPA provides for civil penalties of up to $7,500 per violation and allows private litigants affected by certain
data breaches to recover significant statutory damages. Although the CCPA exempts some data processed in the context of clinical trials,
the CCPA increases compliance costs and potential liability with respect to other personal data we maintain about California residents.
Other states, such as Virginia and Colorado, have also passed comprehensive privacy laws, and similar laws are being considered in several
other states, as well as at the federal and local levels. While these states, like the CCPA, also exempt some data processed in the context
of clinical trials, these developments further complicate compliance efforts, and increase legal risk and compliance costs for us and
the third parties upon whom we rely. An increasing number of foreign data protection laws may also apply to health-related and other personal
data obtained from individuals outside of the United States. For example, the European Union&#8217;s General Data Protection Regulation,
or EU GDPR introduced new data protection requirements in the EU, as well as potential fines for noncompliant companies of up to the greater
of &#8364;20 million or 4% of annual global revenue. In addition, we are also subject to the Israeli Privacy Protection Law&#160;5741-1981&#160;and
the regulations promulgated thereunder, or the PPL, including the Israeli Privacy Protection Regulations (Data Security) 2017, imposing
obligations with respect to the manner personal data is processed, maintained, transferred, disclosed, accessed and secured, as well as
the guidelines of the Israeli Privacy Protection Authority. In this respect, the PPL may require us to adjust certain data protection
and data security practices, information security measures, certain organizational procedures, applicable positions and other technical
and organizational security measures. Failure to comply with the PPL and with guidelines issued by the Israeli Privacy Protection Authority,
may expose us to administrative fines, civil claims (including class&#160;actions) and in certain cases criminal liability. Furthermore,
many jurisdictions have enacted data localization laws and cross-border personal data transfer laws, which could make it more difficult
to transfer information across jurisdictions (such as transferring or receiving personal data that originates in the European Economic
Area). Existing mechanisms that may facilitate cross-border personal data transfers may change or be invalidated. For example, absent
appropriate safeguards or other circumstances, the EU GDPR regulates transfers of personal data subject to the EU GDPR to third countries
that have not been found to provide adequate protection to such personal data, including the United States, and the efficacy and longevity
of current transfer mechanisms between the EU and the United States remains uncertain. In addition, the United Kingdom similarly restricts
transfers of personal data outside of those jurisdictions to countries such as the United States that do not provide an adequate level
of personal data protection. If we cannot implement a valid compliance mechanism for cross-border data transfers, we could experience
material adverse effects. Our obligations related to privacy and security are quickly changing in an increasingly stringent fashion, creating
some uncertainty as to the effective future legal framework. Additionally, these obligations may be subject to differing applications
and interpretations, which may be inconsistent or in conflict among jurisdictions. Preparing for and complying with these obligations
requires us to devote significant resources (including, without limitation, financial and time-related resources). These obligations may
necessitate changes to our practices and to those of any third parties that process personal data on our behalf. In addition, these obligations
may require us to change our business model. Compliance with privacy and security obligations could require us to take on more onerous
obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate
in certain jurisdictions. Failure or perceived failure by us or our collaborators to comply with U.S. and foreign data privacy or security
obligations could result in government enforcement actions (which could include civil or criminal penalties), private litigation, bans
on processing personal data, and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical
trial subjects about whom we or our potential collaborators obtain information, as well as the providers who share this information with
us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#8217; privacy rights,
failed to comply with privacy or security obligations or breached our contractual obligations, even if we are not found liable, could
be expensive and time consuming to defend, could result in adverse publicity and could have a material adverse effect on our business,
financial condition, results of operations and prospects.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">29</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">If
a successful liability claim or other claim for damages or series of claims is brought against us for uninsured liabilities or in excess
of insured liabilities, we could be forced to pay substantial damage awards. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The use of any of our therapeutic product
candidates in clinical trials might expose us to liability. We have obtained clinical trial insurance coverage in amounts that we believe
are reasonable and customary in our industry based on the size and design of our clinical trials. However, there can be no assurance that
such insurance coverage will fully protect us against some or all of the claims to which we might become subject. We might not be able
to maintain adequate insurance coverage at a reasonable cost or in sufficient amounts or scope to protect us against potential losses.
In the event a claim is brought against us, we might be required to pay legal and other expenses to defend the claim, as well as uncovered
damages awards resulting from a claim brought successfully against us. Furthermore, whether or not we are ultimately successful in defending
any such claims, we might be required to direct financial and managerial resources to such defense and adverse publicity could result,
all of which could harm our business.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">If
we fail to comply with laws regulating the protection of the environment and health and human safety, our business could be adversely
affected.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Our research and development activities
involve the use of hazardous materials and chemicals, and we maintain quantities of microbial agents, various flammable and toxic chemicals
in our facilities. Although we believe our safety and other procedures for storing, handling and disposing these materials in our facilities
comply with applicable governmental and local regulations and guidelines, the risk to our employees or others of accidental contamination
or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which may exceed
our financial resources and may seriously harm our business. We are also subject to numerous environmental, health and workplace safety
laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of biohazardous
materials. We may be subject to liability and may be required to comply with new or existing laws and regulations regulating pharmaceuticals
or be subject to substantial fines or penalties if we violate any of these laws or regulations.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">30</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Risks Related to Intellectual
Property. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">If
the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent
our competitors from commercializing similar or identical product candidates would be adversely affected.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We have applied for patents covering proteins,
therapeutic and diagnostic product candidates and their method of use, and the success of our business depends, to a large extent, on
our ability to obtain and maintain such patents and any additional patents covering our future product candidates. We design our patent
strategy to fit the business competitive landscape and continual legislative changes. In addition, we periodically analyze and examine
our patent portfolio to align it with our pipeline strategy and business needs. We have issued patents and pending patent applications
that are related to our product candidates in the U.S., Europe, and other territories. We plan to continue to apply for patent protection
for our therapeutic and diagnostic inventions, but we cannot be sure that any of our patent applications will be accepted, or that they
will be accepted to the extent that we seek or that they will not be challenged. Additionally, we file for patent protection in selected
countries and not in all countries of the world. Therefore, we are exposed to competition in those countries in which we have no patent
protection. Also, due to our early-stage pipeline and various business considerations, we may be required to seek patent protection at
a very early-stage. This may cause us to file with insufficient supportive data, possibly making it difficult to obtain patents in jurisdictions
that do not accept post filing evidence to support the claims, and thus enabling others to compete with us. This may also cause issuance
of a patent at an earlier stage creating a shorter commercialization period under patent protection, possibly enabling others to compete
with us. Delays in filing patents may preclude us from obtaining protection on some or all of our product candidates due to others filing
ahead of us. Patent applications filed before us, but yet unpublished, may cause us to spend significant resources in areas that due to
these previously filed patents or applications we are not able to obtain patent protection or are only able to obtain a narrower scope
of protection than contemplated.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Because the patent position of biopharmaceutical
companies involves complex legal and factual questions, we cannot predict the validity, scope or enforceability of patents with certainty.
The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability and our patents may be subject to
a third party pre issuance submission of prior art to the patent authorities or become involved in opposition, derivation, revocation,
reexamination, post-grant and <span style="font-style: italic">inter partes</span> review, or other similar proceedings challenging our
patent rights in the United States and other jurisdictions which may result in such patents being narrowed, invalidated, or held unenforceable,
and thus could limit our ability to stop competitors from marketing related products or limit the length of the term of patent protection
that we may have for our product candidates. Such proceedings also may result in substantial cost and require our pending patent applications,
and those we may file in the future may not result in patents being issued. Furthermore, even if our patents do issue, and even if they
are unchallenged, our patents may not adequately protect all our intellectual property or prevent others from designing their products
in a way to avoid being covered by our claims. If the breadth or strength of protection provided by the patents we hold is threatened,
this could dissuade companies from collaborating with us to develop and could threaten our ability to commercialize product candidates
and expose us to unexpected competition that could have a material adverse impact on our business. For example, in October 2020, two parties,
one being GSK (following an assignment), filed oppositions in the European Patent Office, or EPO, requesting revocation of our granted
European patent relating to anti-PVRIG antibodies. Following our response, a preliminary non-binding opinion of the European opposition
division was received in October 2022, with a summons to attend oral proceedings in July 2023. The opposition division preliminary non-binding
opinion accepts some of our arguments filed in our response in March 2021 and acknowledges that the formal requirements of the priority
claim of the patent that is the subject matter of the opposition are being successfully met. Nevertheless, the preliminary non-binding
opinion states that the requirements of novelty and inventive step for the said patent are not met, mainly because the oppositions division
believes that our priority documents do not contain sufficient data that plausibly link anti-PVRIG antibodies to activation of T cells
and/or NK cells, and to the treatment of cancer. Based on similar considerations the division considers the claimed subject-matter insufficiently
disclosed in the patent.&#160;We plan to timely respond the preliminary non-binding opinion. In January 2023, another opposition was filed
by GSK, requesting revocation of our granted European patent relating to method of screening for inhibitors of the binding association
of PVRIG polypeptide with PVRL2. We plan to timely respond to this opposition.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Furthermore, changes in either the patent
laws or interpretation of the patent laws in the United States or other jurisdictions could weaken our ability to obtain new patents or
to enforce our existing patents and patents that we might obtain in the future and increase the uncertainties and costs surrounding the
prosecution of patent applications, and the enforcement or defense of our issued patents. Such changes could diminish the value of our
patents and applications, thereby impairing our ability to protect our product candidates, and could have a material adverse effect on
our business, financial condition, results of operations and prospects. For example, the U.S. Supreme Court has ruled on several patent
cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent
owners in certain situations. In October 2017, in <span style="font-style: italic">Amgen v. Sanofi</span>, the Federal Circuit overturned
the &#8220;newly characterized antigen&#8221; test, which permitted patentees to claim a genus of antibodies by describing the structure
of a corresponding antigen, on the grounds that it failed to satisfy the requirements found in Section 112 of the Patent Act, 35 U.S.C.
&#167; 112. In doing so, the Federal Circuit called into question the validity of numerous existing patents. In November 2022, the Supreme
Court granted certiorari in <span style="font-style: italic">Amgen v. Sanofi</span>, agreeing to review the Federal Circuit&#8217;s &#8220;full
scope of the claimed embodiments&#8221; test for enablement. Nonetheless, in the current IP environment in the U.S., we may not be able
to obtain or defend broad patent protection on our antibody inventions.</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif"> <br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Moreover, because of the extensive time
required for development, testing and regulatory review of a potential product, it is possible that, before any particular product candidate
can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby reducing
any advantage of the patent protection.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">31</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The process of obtaining patents for inventions
that cover our products is uncertain for a number of reasons, including but not limited to:</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze6d07e865b654fe39f123573fe7999f1" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>the patenting of inventions involves complex legal issues relating to intellectual property laws, prosecution and enforcement of
        patent claims across a number or patent jurisdictions, many of which have not yet been settled;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z50e90875d3d945c99947612def60826c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>legislative and judicial changes, or changes in the examination guidelines of governmental patent offices may negatively affect our
        ability to obtain patent claims to certain biological molecules- and/or use of certain therapeutic targets;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za6f0716318b544a9b21341409b072d58" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>if we are not the first to file a patent application on one of our inventions, we may not be able to obtain a patent on our invention,
        and may not be able to protect one or more of our therapeutic product candidates;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zcd6a42210b9a497aa8fcf10f05394edb" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>competition from other biotechnology and pharmaceutical companies who have already sought patent protection relating to proteins
        and protein based products, as well as therapeutic antibodies or other modulators specifically binding these proteins, and their utility
        based discoveries that we may intend to develop and commercialize; such prior patents may negatively affect our ability to obtain patent
        claims on antibodies or certain proteins or other biologic modulators, or may hinder our ability to obtain sufficiently broad patent claims
        for our inventions, and/or may limit our freedom to operate;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb33471865c0a47c592e6429ae22e6317" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>publication of data on gene products or proteins by non-commercial and commercial entities may hinder our ability to obtain sufficiently
        broad patent claims for our inventions;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z75e441bc5713453cb9b2fba5d851d39a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>even if we succeed in obtaining patent protection, such protection may not be sufficient to prevent third parties from circumventing
        our patent claims;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3993629a852f423e869ce5856a1fa0f8" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>even if we succeed in obtaining patent protection, we may face freedom to operate issues;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z4cfba70bd05d4984962491e252982578" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>even if we succeed in obtaining patent claims protecting our inventions and product candidates, our patents could be subject to challenge
        and litigation by our competitors, and may be partially or wholly invalidated as a result of such legal/judicial challenges and in connection
        with such challenges;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z933440e69a6c49baa2cfb4919c3ad323" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>significant costs that may need to be incurred in registering and filing patents;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z33dfbba54de943febe7108c23b18d35f" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>insufficient data to support our claims and/or may support others in strengthening their patents;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc8206c64e79044f19c467dac58aafb53" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>seeking patent protection at an early stage may prevent us from providing comprehensive data supporting the patent claims and may
        prevent allowance of certain patent claims or limit the scope of patent claim coverage;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z96ee7da95bd44abda3eaafd88db33092" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>we may not be able to supply sufficient data to support our claims, within the legally prescribed time following our initial filing
        in order to support our patent claims and this may harm our ability to get appropriate patent protection or protection at all;</div> </td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zba150277e23e457388bc2ff43bf65fc8" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our claims may be too broad and not have sufficient enablement, in which case such claims might be rejected by patent offices or
        invalidated in court; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze13f7ea8f3eb4cc3810577283ba2d01d" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>we might fail to demonstrate a unique technical feature for our antibodies as compared to existing prior art, in which case our claims
        might be rejected by the respective patent office, requiring superiority over prior art.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">If we do not succeed in obtaining patent
protection for our inventions (should it be discoveries, drug targets candidates and product candidates) to the fullest extent for which
we seek protection, or if we fail to select the best inventions to seek such protection, our business and financial results could be materially
harmed.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">32</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">We
may not be able to protect our intellectual property rights throughout the world.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Patents are of national or regional effect,
and filing, prosecuting and defending patents on all of our investigational products throughout the world would be extremely expensive.
Thus, we may not be able to prevent third parties from practicing or from selling or importing products made using our inventions in all
countries. Further, the legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of
patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing
of competing products in violation of our proprietary rights generally. In addition, certain countries have compulsory licensing laws
under which a patent owner may be compelled to grant licenses to third parties. In those countries, we and our licensors may have limited
remedies if patents are infringed or if we or our licensors are compelled to grant a license to a third party, which could materially
diminish the value of those patents. This could limit our potential revenues. Accordingly, our efforts to enforce our intellectual property
rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop
or license.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">The
existence of third-party intellectual property rights may prevent us from developing our discoveries or require us to expend financial
and other resources to be able to continue to do so.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In selecting a drug target
or a therapeutic product candidate for development, we take into account, among other considerations, the existence of third-party intellectual
property rights that may hinder our right to develop and commercialize that product candidate. To our knowledge, third parties, including
our competitors, have been filing patent applications covering an increasing portion of the human proteome or antibodies directed thereto.
As a result of the existence of third-party intellectual property rights, we may be further required to:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5ab75c6b5cc44a35a8df99f4646a4308" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>forgo the research, development and commercialization of certain drug target candidates and product candidates that we discover,
        notwithstanding their promising scientific and commercial merits; or </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z32832a77b8044f599bd767ef90499b59" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>invest substantial management and financial resources to either challenge or in-license such third-party intellectual property, and
        we cannot be sure that we will succeed in doing so on commercially reasonable terms, if at all. </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We do not always have
available to us, in a timely manner, information of the existence of third-party intellectual property rights related to our own discoveries.
The content of U.S. and other patent applications remains unavailable to the public for a period of approximately 18 months from the filing
date and therefore we cannot be certain that we were the first to file any patent application related to our product candidate. In some
instances, the content of U.S. patent applications remains unavailable to the public until the patents are issued. Moreover, when patents
ultimately are issued, the claims may be substantially different from those that were originally published and may vary from country to
country. Furthermore, there may be issued patents or pending patent applications that we are aware of, but that we think are irrelevant
to our therapeutic product candidates, but which may ultimately be found to be infringed by the manufacture, sale, or use of such product
candidates. As a result, we can never be certain that programs that we commence will be free of third-party intellectual property rights.
If we become aware of the existence of third-party intellectual property rights only after we have commenced a particular program, we
may have to forgo such project after having invested substantial resources in it or, to the extent such third-party right has not expired,
obtain a license which may involve substantial financial resources.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">33</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">In
the future, we may need to obtain additional licenses of third-party technology or other rights that may not be available to us or are
available only on commercially unreasonable terms, and which may cause us to operate our business in a more costly or otherwise adverse
manner that was not anticipated.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We may be required to
license technology or other rights from third parties to further develop or commercialize our investigational products. Should we be required
to obtain licenses to any third-party technology, such licenses may not be available to us on commercially reasonable terms, or at all.
The inability to obtain any third-party license required to develop or commercialize any of our products could cause us to abandon any
related efforts, which could seriously harm our business and operations.<span style="font-weight: bold; font-style: italic">&#160;</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">We,
or potential collaborators and licensees, may infringe third-party rights and may become involved in litigation, which may materially
harm our business.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif">If a third-party accuses
us, our collaborator or a potential collaborator and licensee of infringing its intellectual property rights or if a third-party commences
litigation against us, our collaborator or a potential collaborator and licensee for the infringement of patent or other intellectual
property rights, we may incur significant costs in obtaining a license or defending such action, whether or not we ultimately prevail.
We are aware of U.S. and foreign issued patents and pending patent applications controlled by third parties that may relate to the areas
in which we are developing therapeutic products. Because all issued patents are entitled to a presumption of validity in many countries,
including the United States and many European countries, issued patents held by others with claims related to products, may limit our
freedom to operate unless and until these patents expire or are declared invalid or unenforceable in a court of applicable jurisdiction,
if we do not obtain a license or other right to practice the claimed inventions. Typically, patent litigation in the pharmaceutical and
biotechnology industry is expensive and prolonged. Some claimants may have substantially greater resources than we do and may be able
to sustain the costs of complex intellectual property litigation to a greater degree and for longer periods of time than we could. Costs
that we may incur in defending third-party infringement actions would also result in the diversion of management&#8217;s and technical
personnel&#8217;s time. In addition, parties making claims against us may be able to obtain injunctive or other equitable relief that
could prevent us or our collaborators and licensees from further developing our discoveries or commercializing our products. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In the event of a successful
claim of infringement against us or a potential collaborator and licensee, we may be required to pay damages, including treble damages
and attorney&#8217;s fees if we are found to be willfully infringing a third-party&#8217;s patent, or obtain one or more licenses from
the prevailing third-party (if not obtained prior to such litigation), which may not be available to us on commercially reasonable terms,
if at all. Even if we were able to obtain a license, the rights may be nonexclusive, which would give our competitors access to the same
intellectual property. If we are not able to obtain such a license or not able to obtain such a license at a reasonable cost, we could
be prevented from commercializing a product until the relevant patents expired, or we could be forced to redesign our products, or to
cease some aspect of our business operations, and we could encounter delays in product introductions and loss of substantial resources
while we attempt to develop alternative products. Defense of any lawsuit or failure to obtain any such license could prevent us or our
partners from commercializing available products and could cause us to incur substantial expenditures and would divert management&#8217;s
attention from our core business.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">We
may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming
and unsuccessful. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Competitors may infringe,
misappropriate or otherwise violate our patents, trademarks, copyrights or other intellectual property, or those of our licensors. To
counter infringement, misappropriation, unauthorized use or other violations, we may be required to file legal claims, which can be expensive
and time consuming and divert the time and attention of our management and scientific personnel. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We may not be able to
prevent, alone or with our licensees or any future licensees, infringement, misappropriation or other violations of our intellectual property
rights, particularly in countries where the laws may not protect those rights as fully as in the United States. Any claims we assert against
perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents. In addition,
in a patent infringement or opposition proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable,
in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. In this respect, in
October 2020, two parties, one being GSK (following an assignment), filed oppositions in the EPO requesting revocation of our granted
European patent relating to anti-PVRIG antibodies that expires in 2036 as further described above, and in January 2023, another opposition
was filed by GSK, requesting revocation of our granted European patent relating to method of screening for inhibitors of the binding association
of PVRIG polypeptide with PVRL2. There is also a risk that, even if the validity of such patents is upheld, the court will construe the
patent&#8217;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the
grounds that our patents do not cover the invention. An adverse outcome in a litigation or proceeding involving our patents could limit
our ability to assert our patents against those parties or other competitors and may curtail or preclude our ability to exclude third
parties from making and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business
position, business prospects and financial condition. Similarly, if we assert trademark infringement claims, a court may determine that
the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior
rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">34</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In any infringement,
misappropriation or other intellectual property litigation, any award of monetary damages we receive may not be commercially valuable.
Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award
only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required
in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by
disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings
or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on our share
price. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement
claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such
litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result
of the proceedings.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Increased
progress in our scientific and technological environment may reduce our chances of obtaining a patent.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In order to obtain a patent to protect one
of our therapeutic product candidates, we must show that the underlying invention (that is, the product candidate itself or its use) is
inventive. As an increasing amount of scientific knowledge is becoming available regarding genes, proteins, biological mechanisms, and
the relevance of the genes and proteins to various clinical indications, the bar is increasingly raised to show sufficient inventiveness,
as inventiveness is judged against all publicly available information available prior to filing of the patent application (the exact date
may vary by country or due to other circumstances). As an increasing amount of scientific knowledge is becoming available for various
proteins and their potential use as drug targets, with time we may be limited or may not be able to obtain patents for our product candidates
due to the increased information published in this area. Our own published patent applications and other publications also serve as prior
art against our new inventions and patent applications and may prevent us from obtaining new patents.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">We may become subject
to claims for remuneration or royalties for assigned service invention rights by our employees, which could result in litigation and adversely
affect our business.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We enter into assignment of invention agreements
with our employees pursuant to which such individuals agree to assign to us all rights to any inventions created in the scope of their
employment or engagement with us. A significant portion of our intellectual property has been developed by our employees in the course
of their employment for us. Under the Israeli Patent Law, 5727-1967, or the Patent Law, inventions conceived by an employee due to and
during his or her employment with a company are regarded as &#8220;service inventions&#8221;, which belong to the employer, unless the
employee and employer have entered into a specific agreement stating otherwise, except if the employer waived the service invention within
six months of receipt of a notice by the employee regarding the creation of the service invention (in accordance with provisions of the
Patent Law). The Patent Law also provides that if there is no agreement with respect to whether the employee is entitled to remuneration
for his or her service invention, to what extent and under what conditions, such entitlement and terms shall be determined by the Israeli
Compensation and Royalties Committee, or the Committee, a body constituted under the Patent Law. Decisions by the Committee and Israeli
courts have created some uncertainty in this area. Although our employees have agreed to assign to us service invention rights and have
waived any rights for additional compensation for such service inventions, we may still face claims demanding remuneration in consideration
for assigned service inventions. As a consequence of such claims, we could be required to pay additional remuneration or royalties to
our current and/or former employees, or be forced to litigate such claims, which could negatively affect our business.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">35</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Obtaining
and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements
imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The USPTO and various foreign patent agencies
require compliance with a number of procedural, documentary, fee payment and other provisions to maintain patent applications and issued
patents. Noncompliance with these requirements can result in abandonment or lapse of a patent or patent application, resulting in partial
or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier
than would otherwise have been the case.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif; font-style: italic; font-weight: bold"><span style="font-family: Times New Roman,Times,serif">We
may be subject to claims that we or our employees or consultants have infringed, misappropriated or otherwise violated the intellectual
property of a third-party, or claiming ownership of what we regard as our own intellectual property.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">We
may be subject to claims that we or our employees or consultants have inadvertently or otherwise used or disclosed confidential information
of former employers, competitors or other third-parties. We may be further subject to ownership disputes in the future arising, for example,
from conflicting obligations of consultants or others who are involved in developing our product candidates, resulting, among others,
in disputes regarding ownership interest in our patents or other intellectual property. Although we have implemented reasonable measures
to ensure that our employees and consultants do not use the intellectual property of others in their work for us, we may become subject
to claims that we caused an employee or consultant to breach, among others, the terms of his or her non-competition, or that we or these
individuals have, inadvertently or otherwise, used or disclosed the alleged proprietary information of a former employer, competitor or
other third-party.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">While we may litigate to defend ourselves
against these claims, even if we are successful, litigation could result in substantial costs and could distract the attention of our
management. If our defenses to these claims fail, in addition to requiring us to pay monetary damages, a court could deprive our rights
in such technologies or features that are essential to our investigational products, if such technologies or features are found to incorporate
or be derived from the proprietary information of third-parties and prohibit us from using them. Moreover, any such litigation may adversely
affect our ability to form strategic alliances, engage with scientific advisors or hire employees or consultants.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In addition, while we typically require
our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning
such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual
property. To the extent that we fail to obtain such assignments, or such assignments do not contain a self-executing assignment of intellectual
property rights, or such assignments are breached, we may be forced to bring claims against third parties, or defend claims they may bring
against us, to determine the ownership of what we regard as our intellectual property. If we fail in prosecuting or defending any such
claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Such intellectual property rights could
be awarded to a third-party, and we could be required to obtain a license from such third-party to commercialize our technology or products.
Such a license may not be available on commercially reasonable terms or at all. Even if we are successful in prosecuting or defending
against such claims, litigation could result in substantial costs and be a distraction to our management and scientific personnel.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif; font-style: italic; font-weight: bold"><span style="font-family: Times New Roman,Times,serif">We
may become subject to claims challenging the inventorship or ownership of our patents.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We may be subject to claims that former
employees, collaborators or other third parties have an interest in our patents as co-inventor. The failure to name the proper inventors
on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting
views regarding the contributions of different individuals, the effects of foreign laws where foreign nationals are involved in the development
of the subject matter of the patent, conflicting obligations of third parties involved or as a result of questions regarding co-ownership
of potential joint inventions. Litigation may be necessary to resolve claims challenging inventorship and/or ownership. If we fail in
defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive
ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even
if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management
and other employees.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Patent terms may be inadequate
to protect our competitive position on our product candidates for an adequate amount of time.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Patents have a limited lifespan. In the
United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S.
non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited.
Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive
products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new
product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result,
our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar
or identical to ours.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">36</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Intellectual
property rights do not necessarily address all potential threats to our business.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Once granted, patents may remain open to
opposition (as specified above generally and with respect to us specifically), interference, re-examination, post-grant review, <span style="font-style: italic">inter
partes</span> review, nullification or derivation action in court or before patent offices or similar proceedings for a given period after
allowance or grant, during which time third parties can raise objections against such grant. In the course of such proceedings, which
may continue for a protracted period of time, the patent owner may be compelled to limit the scope of the allowed or granted claims thus
attacked or may lose the allowed or granted claims altogether. In addition, the degree of future protection afforded by our intellectual
property rights is uncertain because even granted intellectual property rights have limitations and may not adequately protect our business.
The following examples are illustrative:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z1b0d1d30186a4c49850c7a537c614962" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>issued patents that we may own or that we license may be held invalid or unenforceable, as a result of legal challenges; </div> </td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zae592a6eb82044c08aba6e380a1834e7" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div style="font-family: Times New Roman,serif"><span style="font-family: Times New Roman,Times,serif">others may be able to make products
        that are similar to our products but that are not covered by the claims of our patent rights&#894;</span></div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div>&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div style="font-family: Times New Roman,serif">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">we or our licensors or any future strategic partners might not
        have been the first to file patent applications on the inventions covered by the issued patent or pending patent application that we own
        or have exclusively licensed&#894;</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div>&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div style="font-family: Times New Roman,serif">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">others may independently develop similar or alternative technologies
        without infringing our intellectual property rights&#894;</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div>&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div style="font-family: Times New Roman,serif">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">it is possible that our pending patent applications will not
        lead to issued patents&#894;</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div>&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div style="font-family: Times New Roman,serif">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">issued patents that we may own or that we license may not provide
        us with any competitive advantage; </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div>&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div style="font-family: Times New Roman,serif">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">our competitors might conduct research and development activities
        in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products
        for sale in our major commercial markets&#894;</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div>&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div style="font-family: Times New Roman,serif">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">third parties performing manufacturing or testing for us using
        our product candidates or technologies could use the intellectual property of others without obtaining a proper license;</div> </div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">

<div>&#160;</div>

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div style="font-family: Times New Roman,serif">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">we may not develop additional proprietary technologies that are
        patentable&#894; and</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div> </div> </div> </div> </div> </div> </div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div style="font-family: Times New Roman,serif">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">the patents of others may have an adverse effect on our business.</div> </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Should any of these events occur, they could
have a material adverse effect on our business, financial condition, results of operations and prospects.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif; font-style: italic; font-weight: bold"><span style="font-family: Times New Roman,Times,serif">We
may rely on trade secret and proprietary know-how which can be difficult to trace and enforce.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In addition to seeking patent protection
for some of our technology and investigational products, we also rely on trade secrets, including unpatented know-how, technology and
other proprietary information, to maintain our competitive position. Trade secrets and know-how can be difficult to protect. Any disclosure,
either intentional or unintentional, by our employees or third-party consultants and vendors that we engage to perform research, clinical
trials or manufacturing activities, or misappropriation by third parties (such as through a security breach) of our trade secrets or proprietary
information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in
our market.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We require our employees to enter into written
employment agreements containing provisions of confidentiality and obligations to assign to us any inventions generated in the course
of their employment. We further seek to protect our potential trade secrets and proprietary know-how by entering into non-disclosure and
confidentiality agreements with any third parties who are given access to them, including our collaborators, contract manufacturers, consultants,
advisors and other third parties. With our consultants, contractors, and collaborators, these agreements typically include invention assignment
obligations. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information or assign
our inventions to third parties, which may be difficult to trace, and we may not be able to obtain adequate remedies for such breaches.
Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the
outcome is unpredictable.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">37</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">If we are unable to adequately protect our
proprietary know-how and trade secrets, competitors may be able to develop technologies and resulting discoveries and inventions that
are identical, similar to or better than our own discoveries and inventions, which could materially harm our business, financial condition
and results of operations. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary
rights, and failure to maintain trade secret protection could adversely affect our competitive business position. In addition, others
may independently discover or develop our trade secrets and proprietary information, and the existence of&#160;our own trade secrets affords
no protection against such independent discovery.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Risks Related to Operations
in Israel </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Conditions in the Middle
East and in Israel may adversely affect our operations. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Our headquarters and research and development
facilities are located in Israel. Accordingly, we are directly influenced by the political, economic and military conditions affecting
Israel. Specifically, we could be adversely affected by:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div style="font-family: Times New Roman,serif">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">hostilities involving Israel;</div> </div> </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div>&#160;</div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div style="font-family: Times New Roman,serif">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">a full or partial mobilization of the reserve forces of the Israeli army;</div> </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div>&#160;</div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div style="font-family: Times New Roman,serif">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">the interruption or curtailment of trade between Israel and its present trading partners; and </div> </div>
        </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">

<div>&#160;</div>

<div style="line-height: 1.25">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div style="font-family: Times New Roman,serif">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25">a downturn in the economic, political, social or financial condition in Israel.</div> </div> </div> </div>
        </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div> </div> </div> </div> </div> </div> </div> </div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Since its establishment in 1948, Israel
has been subject to a number of armed conflicts that have taken place between it and its Middle Eastern neighbors. While Israel has entered
into peace agreements with both Egypt and Jordan and has entered into several normalization agreements in 2020 with the United Arab Emirates,
Bahrain, Sudan and Morocco, Israel has no peace or arrangements with any other neighboring or Arab country. Further, all efforts to improve
Israel&#8217;s relationship with the Palestinians have failed to result in a permanent peaceful solution, and there have been numerous
periods of hostility as well as civil insurrection of Palestinians in the West Bank and the Gaza Strip in recent years. Israel is further
engaged, from time to time, in armed conflicts with Hamas (a militia group and political party controlling the Gaza Strip), which in some
occasions resulted in missiles being fired from the Gaza Strip against civilian targets in various parts of Israel, including areas in
which our employees are located, and negatively affected business conditions in Israel. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Also, relations between Israel and Iran
continue to be hostile, due to the fact that Iran is perceived by Israel as sponsor of Hamas and Hezbollah (a&#160;Shia&#160;Islamist&#160;political
party and&#160;militant&#160;group based in&#160;Lebanon), while maintaining a military presence in Syria and Lebanon, and with regard
to Iran&#8217;s nuclear program. In addition, the normalization agreements that Israel has entered into with some Arab countries in the
Middle East may affect the geo-political condition in the Middle East in general, and the relations between Israel and Iran in particular.
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">All of the above raise a concern as to the
stability in the region which may affect the political and security situation in Israel and therefore could adversely affect our business,
financial condition and results of operations. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Furthermore, certain countries, primarily
in the Middle East but also in Malaysia and Indonesia, as well as certain companies and organizations in different parts of the world,
continue to participate in a boycott of Israeli brands and others doing business with Israel and Israeli companies. The boycott, restrictive
laws, policies or practices directed towards Israel or Israeli businesses could, individually or in the aggregate, have a material adverse
effect on our business in the future. In addition, should the BDS Movement, the movement for boycotting, divesting and sanctioning Israel
and Israeli institutions (including universities) and products become increasingly influential in the United States and Europe, this may
also adversely affect our business and financial condition. Further deterioration of Israel&#8217;s relationship with the Palestinians
or countries in the Middle East could expand the disruption of international trading activities in Israel, may materially and negatively
affect our business conditions, could harm our results of operation and adversely affect the share price of our Company. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Our business may also be disturbed by the
obligation of personnel to perform military service. Our employees who are Israeli citizens are generally subject to a periodic obligation
to perform reserve military service, until they reach the age of 40 (or older, for reservists with certain occupations), but during military
conflicts, these employees may be called to active duty for longer periods of time. In response to the increase in violence and terrorist
activity in the past years, there have been periods of significant call-ups for military reservists and it is possible that there will
be further military reserve duty call-ups in the future. In case of further regional instability such employees who may include one or
more of our key employees, may be absent for extended periods of time which may materially adversely affect our business.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">38</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In addition, recent political and civil
actions in Israel during the months of January and February 2023, resulting from, among other things, proposed changes to certain Israeli
constitutional legislation, may have an adverse effect on the Israeli social, economic and political landscape and in turn, on us. However,
it is difficult to predict at this time what the effect of such actions will be, if any.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We can give no assurance that the political,
economic and security situation in Israel will not have a material adverse impact on our business in the future.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Furthermore, our Company&#8217;s insurance
does not cover any loss arising of events related to the security situation in the Middle East. While the Israeli government generally
covers the reinstatement value of direct damages caused by acts of war or terror attacks, we cannot be certain that such coverage will
be maintained or that it will sufficiently cover our damages.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Our
results of operations may be adversely affected by the exchange rate fluctuations between the dollar and the New Israeli Shekel.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We hold most of our cash, cash equivalents
and short-term and long-term bank deposits in dollars but incur a significant portion of our expenses, principally salaries and related
personnel expenses and administrative expenses for our Israeli based operations, in NIS. As a result, we are exposed to exchange rate
fluctuations between the dollar and the NIS, which may have a material adverse effect on our financial condition. For example, if the
NIS significantly devaluates against the dollar due to conditions in the Middle East and/or in Israel or otherwise, then the dollar cost
of our operations in Israel would increase and our results of operations would be adversely affected.&#160;In 2022 the dollar appreciated
against the NIS by 13.2% while in 2021 and 2020, the dollar depreciated against the NIS by 3.3% and by 7.0%, respectively. As a result
of these fluctuations, our NIS denominated expenses were affected.&#160; &#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">The
dollar cost of our operations in Israel will increase to the extent increases in the rate of inflation in Israel are not offset by a devaluation
of the NIS in relation to the dollar, which would harm our results of operations.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Inflation in Israel,
which increased significantly during 2022 and was 5.3%, has affected us by increasing the costs of materials and labor needed to operate
our business and could continue to adversely affect us in future periods. Additionally, since a considerable portion of our expenses such
as employees&#8217; salaries are linked to an extent to the rate of inflation in Israel, the dollar cost of our operations is influenced
by the extent to which any increase in the rate of inflation in Israel is or is not offset by the devaluation of the NIS in relation to
the dollar. As a result, we are exposed to the risk that the NIS, after adjustment for inflation in Israel, will appreciate in relation
to the dollar. In that event, the dollar cost of our operations in Israel will increase and our dollar-measured results of operations
will be adversely affected. We cannot predict whether the NIS will appreciate against the dollar or vice versa in the future. Any increase
in the rate of inflation in Israel, unless the increase is offset on a timely basis by a devaluation of the NIS in relation to the dollar,
will increase labor and other costs, which will increase the dollar cost of our operations in Israel and harm our results of operations.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">We
may not be entitled to certain Israeli tax benefits.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In the future, we may be entitled to benefit
from certain Israeli government programs and enjoy certain tax benefits, particularly tax exemptions, resulting from the &#8216;Benefiting
Enterprise&#8217; status, or Benefiting Enterprise, granted to us under the Israel Law for Encouragement of Capital Investments, 1959,
or the Investment Law. The availability of these tax benefits, however, is subject to us meeting certain conditions under the Investment
Law, including making specified investments in fixed assets and equipment. The tax benefits that we anticipate receiving under the &#8220;Benefiting
Enterprise&#8221; program may not be continued in the future at their current levels or at all. To date, we have not actually received
any such tax benefits because we have not yet generated any taxable income.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">39</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">It
may be difficult to enforce a U.S. judgment against us, or our officers and directors or to assert U.S. Securities law claims in Israel.
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We are incorporated under the laws of the
State of Israel. Service of process upon our directors and officers, the majority of whom reside outside the United States, may be difficult
to obtain within the United States. Furthermore, because the majority of our assets and investments, and a majority of our directors and
officers are located outside the United States, any judgment obtained in the United States against us or any of them may not be collectible
within the United States. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Furthermore, it may be difficult for an
investor, or any other person or entity, to assert U.S. securities law claims in original actions instituted in Israel. Israeli courts
may refuse to hear a claim based on an alleged violation of U.S. securities laws reasoning that Israel is not the most appropriate forum
to bring such a claim. In addition, even if an Israeli court agrees to hear such a claim, it is not certain whether Israeli law or U.S.
law will be applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proven as a fact
by expert witnesses, which can be a time consuming and costly process. Certain matters of procedure will also be governed by Israeli law.
There is little binding case law in Israel that addresses the matters described above.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Provisions
of Israeli law may delay, prevent or make undesirable an acquisition of all or a significant portion of our shares or assets. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Israeli corporate law regulates mergers
and acquisitions and requires that a tender offer be affected when certain thresholds of percentage ownership of voting power in a company
are exceeded (subject to certain conditions), which may have the effect of delaying, preventing or making more difficult a merger with,
or acquisition of, us. See &#8220;Item 10. Additional Information &#8211; B. Memorandum and Articles of Association.&#8221; Further, Israeli
tax considerations may make potential transactions undesirable to us or to some of our shareholders whose country of residence does not
have a tax treaty with Israel granting tax relief to such shareholders from Israeli tax. With respect to mergers, Israeli tax law allows
for tax deferral in certain circumstances but makes the deferral contingent on the fulfillment of numerous conditions, including a holding
period of two years from the date of the transaction during which certain sales and dispositions of shares of the participating companies
are restricted. Moreover, with respect to certain share swap transactions, the tax deferral is limited in time, and when such time expires,
the tax becomes payable even if no actual disposition of the shares has occurred. See &#8220;Item 10. Additional Information &#8211; E.
Taxation &#8211; Israeli Taxation.&#8221; </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In addition, in accordance with the Restrictive
Trade Practices Law, 1988 and under the Israeli Law for the Encouragement of Industrial Research and Development of 1984 and regulations
promulgated thereunder, together, the R&amp;D Law, approvals regarding a change in control (such as a merger or similar transaction) may
be required in certain circumstances. For more information regarding such required approvals please see &#8220;Item 5. Operating and Financial
Review and Prospects- C. Research and Development, Patents and Licenses &#8211; The Israel Innovation Authority.&#8221; In addition, as
a corporation incorporated under the laws of the State of Israel, we are subject to the Israeli Economic Competition Law, 1988 and the
regulations promulgated thereunder (formerly known as the Israeli Antitrust Law, 1988), under which we may be required in certain circumstances
to obtain the approval of the Israel Competition Authority (formerly known as the Israel Antitrust Authority) in order to consummate a
merger or a sale of all or substantially all of our assets. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif">These provisions of Israeli
law could have the effect of delaying or preventing a change in control and may make it more difficult for a third-party to acquire us,
even if doing so would be beneficial to our shareholders and may limit the price that investors may be willing to pay in the future for
our ordinary shares. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">We
received grants from the IIA that may expose us to payment of royalties and restrict the transfer of know-how that we develop. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">We
have received governmental grants from the Israeli Innovation Authority, or the IIA, for the financing of a portion of our research and
development expenditures. Even following full repayment of any IIA grants, and unless agreed otherwise by the applicable authority of
the IIA, we must nevertheless continue to comply with the requirements of the R&amp;D Law with respect to technologies which were financed
by such grants, or the Financed Know-How, including an obligation for repayment of such grants from sales of products (and related services)
based on the Financed Know-How, if and when such sales occur. In addition to the obligation to pay royalties to the IIA, the R&amp;D Law
requires that products which incorporate Financed Know-How be manufactured in Israel and prohibits the transfer of the Financed Know-How
and any right derived therefrom to third parties, unless otherwise approved in advance by the IIA; Such prior approval may be given by
the IIA subject to payment of increased royalties. Failure to comply with the requirements under the R&amp;D Law may subject us to financial
sanctions, to mandatory repayment of grants received by us (together with interest and penalties), as well as expose us to criminal proceedings.
Although such restrictions do not apply to the export from Israel of Company&#8217;s products developed with such Financed Know-How, they
may prevent us from engaging in transactions involving the sale, outsource or transfer of such Financed Know-How or of manufacturing activities
with respect to any product or technology based on Financed Know-How, outside of Israel, which might otherwise be beneficial to us. Furthermore,
the consideration available to our shareholders in a transaction involving the transfer outside of Israel of Financed Know-How (such as
a merger or similar transaction) may be reduced by any amounts that we are required to pay to the IIA. Moreover, the government of Israel
may from time to time audit sales of products which it claims incorporate Financed Know-How and this may lead to royalties being payable
on additional products, and may subject such products to the restrictions and obligations specified hereunder.&#160;For more information
regarding such restrictions please see &#8220;Item 5. Operating and Financial Review and Prospects- C. Research and Development, Patents
and Licenses &#8211; The Israel Innovation Authority.&#8221;</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">40</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Being
a foreign private issuer exempts us from certain SEC requirements and Nasdaq rules, which may result in less protection that is afforded
to investors under rules applicable to domestic issuers. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We are a &#8220;foreign private issuer&#8221;
within the meaning of rules promulgated by the SEC. As such, we are exempt from certain provisions under the Exchange Act,<span style="font-weight: bold">&#160;</span>applicable
to U.S. public companies, including:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zdb54331e9b124453a9d0b50f20eaef88" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form 10-Q and current reports on Form
        8-K; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze6ed226117ca482f8f76753f90da1bed" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered
        under the Exchange Act, including extensive disclosure of compensation paid or payable to certain of our highly compensated executives
        as well as disclosure of the compensation determination process; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5821629754cb4890b7068152aa4c7919" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>the provisions of Regulation FD aimed at preventing issuers from making selective disclosures of material information; and </div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zea867bcb180049c78997b96d0e8fbf01" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and establishing
        insider liability for profits realized from any &#8220;short-swing&#8221; trading transaction (a purchase and sale, or sale and purchase,
        of the issuer&#8217;s equity securities within less than six months). </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In addition, we may follow
home country corporate governance practices and law instead of those rules and practices otherwise required by Nasdaq for domestic issuers.
For instance, we have relied on the foreign private issuer exemption with respect to shareholder approval requirements for equity-based
incentive plans for our employees. For the list of specific exemptions that we chose to adopt, please see &#8220;Item 16G &#8211; Corporate
Governance.&#8221; </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Following our home country
corporate governance practices as opposed to the requirements that would otherwise apply to a U.S. company listed on Nasdaq may provide
less protection to investors than is afforded to investors under the Nasdaq Listing Rules applicable to domestic issuers. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">We
may lose our status as a foreign private issuer, which would increase our compliance costs and could negatively impact our operations
results.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We may lose our foreign
private issuer status if (a) a majority of our outstanding voting securities are either directly or indirectly owned of record by residents
of the United States and (b)(i) a majority of our executive officers or directors are U.S. citizens or residents, (ii) more than 50% of
our assets are located in the United States or (iii) our business is administered principally in the United States. If we will not be
a foreign private issuer, we will be required to file periodic reports and registration statements on U.S. domestic issuer forms with
the SEC, which are more extensive than the forms available to a foreign private issuer. We would also be required to follow U.S. proxy
disclosure requirements, including the requirement to disclose, under U.S. law, more detailed information about the compensation of our
senior executive officers on an individual basis. We may also be required to modify certain of our policies to comply with accepted governance
practices associated with U.S. domestic issuers. Such conversion and modifications will involve increased costs. In addition, we would
lose our ability to rely upon exemptions from certain corporate governance requirements on U.S. stock exchanges that are available to
foreign private issuers, as described in the previous risk factor above.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Our
shareholders rights and responsibilities are governed by Israeli law which differs in some material respects from the rights and responsibilities
of shareholders of U.S. companies.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Because we are incorporated under Israeli
law, the rights and responsibilities of our shareholders are governed by our Articles of Association, as amended from time to time, or
Articles, and Israeli law. These rights and responsibilities differ in some respects from the rights and responsibilities of shareholders
in U.S.-based corporations. In particular, a shareholder of an Israeli company has a duty to act in good faith and in a customary manner
in exercising its rights and performing its obligations towards the company and other shareholders and to refrain from abusing its power
in the company, including, among other things, in voting at the general meeting of shareholders on certain matters, such as an amendment
to a company&#8217;s articles of association, an increase of a company&#8217;s authorized share capital, a merger of a company and approval
of interested party transactions that require shareholder approval. A shareholder also has a general duty to refrain from discriminating
against other shareholders. In addition, a controlling shareholder or a shareholder who knows that it possesses the power to determine
the outcome of a shareholders&#8217; vote or to appoint or prevent the appointment of an office holder in a company or has another power
with respect to a company, has a duty to act in fairness towards such company. Israeli law does not define the substance of this duty
of fairness and there is limited case law available to assist us in understanding the nature of this duty or the implications of these
provisions. These provisions may be interpreted to impose additional obligations and liabilities on our shareholders that are not typically
imposed on shareholders of U.S. corporations. </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">41</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Risks Related to our Ordinary Shares </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">We
may not be able to meet the continued listing standards of Nasdaq, which require a minimum closing bid price of $1.00 per share, which
could result in our delisting and negatively impact the price of our ordinary shares and our ability to access the capital markets.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Our ordinary shares are listed on The Nasdaq
Global Market.&#160;The Nasdaq Stock Market LLC, or the Nasdaq, provides various continued listing requirements that a company must meet
in order for its shares to continue trading on the exchange. Among these requirements is the requirement that our shares trade at a minimum
bid price of $1.00 per share.&#160;On October 31, 2022, we received a written notice from the Listing Qualifications Department of Nasdaq,
notifying us that our ordinary shares failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as
required by Nasdaq Listing Rule 5450(a)(1), or the Minimum Bid Price Requirement.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Pursuant to Nasdaq Listing Rule 5810(c)(3)(A),
we have a compliance period of 180 calendar days from the date of the notification letter from Nasdaq, or until May 1, 2023, to regain
compliance with the Minimum Bid Price Requirement. If at any time before May 1, 2023, the closing bid price of our ordinary shares is
at least $1.00 for a minimum of 10 consecutive business days, we will be deemed to have regained compliance with the Minimum Bid Price
Requirement, following which, Nasdaq will provide a written confirmation of compliance and the matter will be closed. In the event that
we do not regain compliance by May 1, 2023, we may transfer the listing and trading of our ordinary shares to The Nasdaq Capital Market,
provided that we meet the applicable standards for initial listing of our ordinary shares on the Nasdaq Capital Market (other than the
Minimum Bid Price Requirement) and may be eligible for an additional 180 calendar day grace period by providing a written notice of our
intention to cure the deficiency during this second compliance period by effecting a reverse share split, if necessary. If we do not regain
compliance with the Minimum Bid Price Requirement by May 1, 2023, and we are ineligible for an additional grace period, Nasdaq will provide
written notice that the ordinary shares are subject to delisting from The Nasdaq Global Market. In that event, we may appeal the determination
to a Nasdaq hearings panel.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">There is no assurance that our share price
will trade&#160;at or above a minimum bid price of $1.00 per share and if we fail to meet minimum listing requirements,&#160;there can
be no assurance that we will be able to regain compliance with the Minimum Bid Price Requirement or will otherwise be in compliance with
other Nasdaq listing criteria. Any such delisting could adversely affect our ability to obtain financing for the continuation of our operations
and could result in the loss of confidence by investors, collaborators and employees.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Future
sales of our ordinary shares or securities convertible or exchangeable for our ordinary shares may depress our share price.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">If our existing shareholders or holders
of our options or warrants sell, or indicate an intention to sell, substantial amounts of our ordinary shares in the public market, the
trading price of our ordinary shares could decline. The perception in the market that these sales may occur could also cause the trading
price of our ordinary shares to decline. As of December 31, 2022, we had a total of 86,624,643<span style="font-weight: bold">&#160;</span>ordinary
shares outstanding.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">42</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Based on the number of shares subject to
awards under our 2010 Share Incentive Plan, as amended, or 2010 Plan, and our 2021 Employee Share Purchase Plan, or ESPP, as of December
31, 2022, 10,400,192 ordinary shares that are either subject to outstanding options or reserved for future issuance under our 2010 Plan
and ESPP were eligible for sale in the public market, subject to, in the case of shares issued to directors, executive officers and other
affiliates, the volume limitations under Rule 144 under the Securities Act. In addition, as of December 31, 2022, we had 297,469 warrants
outstanding exercisable into 297,469 ordinary shares. If these additional ordinary shares are sold, or if it is perceived that they will
be sold, in the public market, the trading price of our ordinary shares could decline.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In addition, our directors, executive officers
and other affiliates may establish, and certain executive officers and directors have established, programmed selling plans under Rule
10b5-1 of the Exchange Act, for the purpose of effecting sales of our ordinary shares. Any sales of securities by these shareholders,
or the perception that those sales may occur, including the entry into such programmed selling plans, could have a material adverse effect
on the trading price of our ordinary shares.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">If
we sell ordinary shares in future financings, shareholders may experience immediate dilution and, as a result, our share price may decline.
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In order to raise additional capital, we
may at any time offer additional ordinary shares or other securities convertible into or exchangeable for our ordinary shares at prices
that may not be the same as the price paid for our ordinary shares by our shareholders. The price per share at which we sell additional
ordinary shares, or securities convertible or exchangeable into ordinary shares, in future transactions may be higher or lower than the
price per share paid by our existing shareholders. If we issue ordinary shares or securities convertible into ordinary shares, our shareholders
will experience additional dilution and, as a result, our share price may decline.<span style="font-weight: bold; font-style: italic">&#160;</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In addition, as opportunities present themselves,
we may enter into financing or similar arrangements in the future, including the issuance of debt securities or ordinary shares with or
without additional securities convertible or exchangeable into ordinary shares. Whether or not we issue additional shares at a discount,
any issuance of ordinary shares will, and any issuance of other equity securities or of options, warrants or other rights to purchase
ordinary shares may, result in additional dilution of the percentage ownership of our shareholders and could cause our share price to
decline. New investors could also gain rights, preference and privileges senior to those of our shareholders, which could cause the price
of our ordinary shares to decline. Debt securities may also contain covenants that restrict our operational flexibility or impose liens
or other restrictions on our assets, which could also cause the price of our ordinary shares to decline.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Our
share price and trading volume have been volatile and may be volatile in the future and that could limit investors&#8217; ability to sell
our shares at a profit and could limit our ability to successfully raise funds. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">During the 2022 calendar year, our closing
share price on Nasdaq ranged from a low of $0.58 to a high of $4.64 and trading volume was volatile. The volatile price of our shares
and periodic volatile trading volume may make it difficult for investors to predict the value of their investment, to sell shares at a
profit at any given time, or to plan purchases and sales in advance. A variety of factors may affect the market price of our ordinary
shares including:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6b4ff69217554e70a3a48a4c5369a851" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>global or regional macroeconomic developments; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z83789302b384495294946d181f9ba27e" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>the spread, and resulting actions, of COVID-19 or other global or regional health pandemics or epidemics; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8c468d63e80b48c8889edeb4ebbf63d6" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>clinical data disclosed by us or our competitors; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z316a0087b3184495bcfe014674163c20" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>massive sell of our shares by a large shareholder; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb4e2880918f54b8cad1708401edc0912" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our success (or lack thereof) in entering into collaboration agreements and achieving certain research and developmental milestones
        thereunder; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z29b245a3c7e34223b5365735fa41a0e3" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our need to raise additional capital and our success or failure in doing so; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9f35113aa259496d9536208724a0138a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our ability (or lack thereof) to disclose key discoveries or developments due to competitive concerns or need to secure our intellectual
        property position;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze7e7f05269eb47e09a4cdd12bb2154d5" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>achievement or denial of regulatory approvals by us or our competitors; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze71fdc59557e4cf0bf6acb42c0fb3181" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>announcements of technological innovations or new commercial products by our competitors; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">43</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; text-indent: -13pt; margin-left: 26pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: Times New Roman,Times,serif">
<br /> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">trends in share price of companies in our field or industry; </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">announcement of corporate transactions, merger and acquisition activities or other similar events by companies
        in our field or industry;</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25">changes and developments effecting our field or industry; </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div> </div> </div> </div>

<table cellspacing="0" cellpadding="0" id="z05afe50b31814118804a08ee03199d58" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>developments concerning material proprietary rights, including material patents; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zeb5394e1ce12433fb3d120e9235d29ee" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>developments concerning our existing or new collaborations; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z970485dd776c4ff49b2553f11435276e" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>regulatory developments in the United States, Israel and other countries; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9616d07d65bd4cf88a172095db66e74c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>changes in the structure of healthcare payment systems;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z10366b0d8d9942198cfec486b8af6907" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>delay or failure by us or our partners in initiating, completing or analyzing preclinical or clinical trials or the unsatisfactory
        design or results of such trials; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5862954712834dce9237863c879844ae" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>period to period fluctuations in our results of operations; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zbebd235ac4d046c0b228fea2c36971a8" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>changes in estimates by securities analysts; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc19d4126d3484b4ca0849d5170aeae4c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>changes in senior management or the board of directors or changes in the size or structure of the company; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z4380e6082dcd4112a0603c3d2e029c07" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our ability (or lack thereof) to disclose the commercial terms of, or progress under, our collaborations; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z630de89877134d7794caa41d1ac78c2e" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>our ability (or lack thereof) to show and accurately predict revenues; and </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zde983637097c44f4892a0d68533de016" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>transactions with respect to our ordinary shares by insiders or institutional investors. </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We are not able to control many of these
factors, and we believe that period-to-period comparisons of our financial results will not necessarily be indicative of our future performance.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In addition, the stock
market in general, and the market for biotechnology companies in particular, have experienced extreme price and volume fluctuations that
may be unrelated or disproportionate to the operating performance of individual companies. These broad market and industry factors may
seriously harm the market price of our ordinary shares, regardless of our operating performance.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Furthermore, the market
prices of equity securities of companies that have a significant presence in Israel may also be affected by the changing security situation
in the Middle East and particularly in Israel. As a result, these companies may experience volatility in their stock prices and/or difficulties
in raising additional financing required to effectively operate and grow their businesses. Thus, market and industry-wide fluctuations
and political, economic and military conditions in the Middle East, but also in the US may adversely affect the trading price of our ordinary
shares, regardless of our actual operating performance.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif">As a result of the volatility
of our share price, we could be subject to securities litigation, which could result in substantial costs and divert management&#8217;s
attention and company resources from our business.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Because
we do not intend to declare cash dividends on our ordinary shares in the foreseeable future, shareholders must rely on appreciation of
the value of our ordinary shares for any return on their investment and may not receive any funds without selling their ordinary shares.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We have never declared
or paid cash dividends on our ordinary shares and do not anticipate declaring or paying any cash dividends in the foreseeable future.
In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, we expect that only appreciation
of the price of our ordinary shares, if any, could provide a return to investors for the foreseeable future. In addition, because we do
not intend to declare cash dividends on our ordinary shares in the foreseeable future, if our shareholders want to receive funds in respect
of our ordinary shares, they must sell their ordinary shares to do so.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Our ordinary shares are
traded on more than one market and this may result in price variations.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In addition to being traded on The Nasdaq
Global Market, our ordinary shares are also traded on the Tel Aviv Stock Exchange, or TASE. Trading in our ordinary shares on these markets
take place in different currencies (dollars on Nasdaq and NIS on the TASE), and at different times (resulting from different time zones,
trading days and public holidays in the United States and Israel). The trading prices of our ordinary shares on these two markets may
differ due to these and other factors. Any decrease in the price of our ordinary shares on one market could cause a decrease in the trading
price of our ordinary shares on the other market.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">44</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif; font-style: italic; font-weight: bold"><span style="font-family: Times New Roman,Times,serif">If
we are a passive foreign investment company, or PFIC, our U.S. shareholders may be subject to adverse U.S. federal income tax consequences.
</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif">For U.S. federal income
tax purposes, we generally will be classified as a PFIC for any taxable year in which, after the application of certain look-through rules
with respect to our subsidiaries, either: (i) 75% or more of our gross income is passive income or (ii) at least 50% of the average value
(determined on the basis of a weighted quarterly average) of our total assets for the taxable year produce or are held for the production
of passive income. For purposes of these tests, passive income includes, among other things, dividends, interest, and gains from the sale
or exchange of investment property and certain rents or royalties (excluding rents and royalties that are received from unrelated parties
in connection with the active conduct of a trade or business). Assets that produce or are held for the production of passive income may
include cash, even if held as working capital or raised in a public offering, marketable securities, and other assets that may produce
passive income. Generally, in determining whether a non-U.S. corporation is a PFIC, a non-U.S. corporation that directly or indirectly
owns at least 25% by value of the shares of another corporation is treated as holding and receiving directly its proportionate share of
assets and income of such corporation.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">Based
on our analysis of our estimated income, estimated assets, activities and market capitalization, we believe that we were a PFIC for the
taxable year ended December 31, 2022. However, the determination of whether or not we are a PFIC is a fact-intensive determination made
on an annual basis and because the applicable law is subject to varying interpretations, we cannot provide any assurance regarding our
PFIC status and our U.S. counsel expresses no opinion with respect to our PFIC status for any taxable year. If we are classified as a
PFIC for any taxable year during which a U.S. shareholder holds our ordinary shares, U.S. investors could be subject to adverse tax consequences
regardless of whether we continue to qualify as a PFIC, including the treatment of gains realized on the sale of our ordinary shares as
ordinary income, rather than as capital gain, the loss of the preferential rate applicable to dividends received on our ordinary shares
by individuals who are U.S. holders (as defined in &#8220;Item 10. Additional Information &#8211; E. Taxation &#8211; Certain Material
U.S. Federal Income Tax Considerations to U.S. Holders&#8221;), the addition of interest charges on certain taxes treated as deferred
taxes, and additional reporting requirements. A U.S. shareholder of a PFIC generally may mitigate these adverse U.S. federal income tax
consequences by making a &#8220;qualified electing fund&#8221; election, or QEF, or, in some circumstances, a &#8220;mark to market&#8221;
election. We may provide the information necessary for U.S. holders to make QEF elections if we were treated as a PFIC for any taxable
year, although, there is no assurance that we will do so. There is no assurance that we will have timely knowledge of our status as a
PFIC in the future. Accordingly, U.S. holders may be unable to make a timely QEF election with respect to our ordinary shares.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">For
further discussion of the PFIC rules and the adverse U.S. federal income tax consequences in the event we are classified as a PFIC, as
well as certain elections that may be available to U.S. holders, see &#8220;Item 10. Additional Information &#8211; E. Taxation &#8211;
Certain Material U.S. Federal Income Tax Considerations to U.S. Holders &#8211; Passive Foreign Investment Company Rules&#8221;.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">If
we are a controlled foreign corporation, there could be materially adverse U.S. federal income tax consequences to certain U.S. Holders
of our ordinary shares.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Each &#8220;Ten Percent
Shareholder&#8221; (as defined below) in a non-U.S. corporation that is classified as a controlled foreign corporation, or a &#8220;CFC&#8221;,
for U.S. federal income tax purposes generally is required to include in income for U.S. federal tax purposes such Ten Percent Shareholder&#8217;s
pro rata share of the CFC&#8217;s &#8220;Subpart F income&#8221; (as defined below), &#8220;global intangible low taxed income,&#8221;
and investment of earnings in U.S. property, regardless of whether we make any distributions. Subpart F income generally includes dividends,
interest, rents, royalties, gains from the sale of securities and income from certain transactions with related parties. In addition,
a Ten Percent Shareholder that realizes gain from the sale or exchange of shares in a CFC may be required to classify a portion of such
gain as dividend income rather than capital gain. An individual that is a Ten Percent Shareholder with respect to a CFC generally would
not be allowed certain tax deductions or foreign tax credits that would be allowed to a Ten Percent Shareholder that is a U.S. corporation.
We cannot provide any assurance that we will assist investors in determining whether we or any of our future non-U.S. subsidiaries are
treated as a CFC or furnish to any U.S. holder the information required to comply with the reporting and tax-paying obligations discussed
above. Failure to comply with these reporting obligations may subject a Ten Percent Shareholder to significant monetary penalties and
may prevent the statute of limitations with respect to such Ten Percent Shareholder&#8217;s U.S. federal income tax return for the year
for which reporting was due from starting.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">45</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif">A non-U.S. corporation
generally will be classified as a CFC for U.S. federal income tax purposes if Ten Percent Shareholders own, directly or indirectly, more
than 50% of either the total combined voting power of all classes of stock of such corporation entitled to vote or of the total value
of the stock of such corporation. A &#8220;Ten Percent Shareholder&#8221; is a United States person (as defined by the Internal Revenue
Code of 1986, as amended, or, the Code) who owns (directly or indirectly) 10% or more of the total combined voting power of all classes
of stock entitled to vote or 10% or more of the total value of all classes of stock of such corporation.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The determination of
CFC status is complex and includes attribution rules, the application of which is not entirely certain. In addition, changes to the attribution
rules relating to the determination of CFC status may make it difficult to determine our CFC status for any taxable year. Because our
group includes at least one U.S. subsidiary (Compugen USA, Inc.), those changes to the attribution rules may cause any non-U.S. subsidiaries
that we form or acquire in the future to be treated as controlled foreign corporations.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">Each
U.S. holder (as defined in Item 10. Additional Information &#8211; E. Taxation &#8211; Certain Material U.S. Federal Income Tax Considerations
to U.S. Holders&#8221;) should consult its own tax advisors with respect to the potential adverse U.S. tax consequences of becoming a
Ten Percent Shareholder in a CFC. If we are classified as both a CFC and a PFIC (as defined above), we generally will not be treated as
a PFIC with respect to those U.S. holders that meet the definition of a Ten Percent Shareholder during the period in which we are a CFC.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Shareholder activism can
negatively affect our business.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times, serif"><span style="font-family: Times New Roman,Times,serif">In
recent years, shareholder activists have become involved in numerous public companies. Shareholder activists could propose to involve
themselves in the governance, strategic direction and operations of a company. We encountered such activism prior to our 2017 annual general
shareholders&#8217; meeting, when we received a formal request from an individual private shareholder, holding approximately 1.3% of the
Company&#8217;s voting rights at that time, to add to the agenda of the meeting the proposed appointment of two new director candidates,
both of whom were not recommended by management. This proposal was rejected by the shareholders at the meeting.&#160;Shareholder activism,
including potential proxy contests, divert our management&#8217;s and board of directors&#8217; attention and resources from our business,
could give rise to perceived uncertainties as to our future direction and could result in the loss of potential business opportunities
and make it more difficult to attract and retain qualified personnel for positions in both management and on the board level and to raise
funds. If nominees advanced by activist shareholders are elected or appointed to our board of directors with a specific agenda, it may
adversely affect our ability to effectively and timely implement our strategic plans or to realize long-term value from our assets. Also,
we may be required to incur significant expenses including legal fees related to activist shareholder matters. Further, our share price
could be subject to significant fluctuations or otherwise be adversely affected by the events, risks and uncertainties of any shareholder
activism.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">General
Risks </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Unfavorable global or
domestic political or economic conditions could adversely affect our business, financial condition or results of operations.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The global economy continues
to experience significant volatility, and the economic environment may continue to be, or become, less favorable than that of past years.
Higher costs for goods and services, inflation, deflation, the imposition of tariffs or other measures that create barriers to or increase
the costs associated with international trade, overall economic slowdown or recession and other economic factors in Israel, the U.S. or
in any other markets in which we operate could adversely affect our operations and operating results. Among other matters, the continued
risk of a debt default by one or more European countries, related financial restructuring efforts in Europe, and/or evolving deficit and
spending reduction programs instituted by the U.S. and other governments could negatively impact the global economy and/or pharmaceutical
industry.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In addition, recent political
and civil actions in Israel during the month of January and February 2023, resulting from, among other things, proposed changes to certain
Israeli constitutional legislation, may have an adverse effect on the Israeli social, economic and political landscape and in turn, on
us. However, it is difficult to predict at this time what the effect of such actions will be, if any. Furthermore, although to date we
have not been directly impacted by the current military conflict between Russia and Ukraine, this conflict, or any expansion thereof,
could disrupt or otherwise adversely impact our operations and those of third parties upon which we rely. Related sanctions, export controls
or other actions have been or may in the future be initiated by nations including the United States, the European Union or Russia (e.g.,
potential cyberattacks, disruption of energy flows, etc.), which could adversely affect our business and/or our supply chain, our CROs,
CMOs and other third parties with whom we conduct business. Any of the foregoing could harm our business and we cannot anticipate all
of the ways in which the current economic climate and financial market conditions could adversely impact our business.&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">46</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Environmental, social
and governance matters may impact our business and reputation.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In addition to the importance
of their financial performance, companies are being increasingly judged by their performance on a variety of environmental, social and
governance, or ESG, matters, which are considered to contribute to the long-term sustainability of companies&#8217; performance.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif">A variety of organizations
measure the performance of companies on such ESG topics, and the results of these assessments are widely publicized. In addition, investment
in funds that specialize in companies that perform well in such assessments are increasingly popular, and major institutional investors
have publicly emphasized the importance of such ESG measures to their investment decisions. Topics taken into account in such assessments
include, among others, the company&#8217;s efforts and impacts on&#160;climate&#160;change&#160;and human rights, ethics and compliance
with law, and the role of the company&#8217;s board of directors in supervising various sustainability issues. In addition to the topics
typically considered in such assessments, in the healthcare industry, issues of the public&#8217;s ability to access a company&#8217;s
medicines are of particular importance.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In light of investors&#8217;
increased focus on ESG matters, there can be no certainty that we will manage such issues successfully, or that we will successfully meet
society&#8217;s expectations as to our proper role. Any failure or perceived failure by us in this regard could have a material adverse
effect on our reputation and on our business, share price, financial condition, or results of operations, including the sustainability
of our business over time.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Climate&#160;change,
or legal or regulatory measures to address&#160;climate&#160;change, may negatively affect us.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Climate&#160;change resulting
from increased concentrations of carbon dioxide and other greenhouse gases in the atmosphere could present risks to our operations. For
example, we have significant operations in California, where serious drought has made water less available and more costly and has increased
the risk of wildfires. Changes in&#160;climate&#160;patterns leading to extreme heat waves or unusual cold weather at some of our locations
can lead to increased energy usage and costs, or otherwise adversely impact our facilities and operations and disrupt our supply chains
and distribution systems. Concern over&#160;climate&#160;change can also result in new or additional legal or regulatory requirements
designed to reduce greenhouse gas emissions or mitigate the effects of&#160;climate&#160;change on the environment. Any such new or additional
legal or regulatory requirements may increase the costs associated with, or disrupt, sourcing, manufacturing and distribution of our products,
which may adversely affect our business and financial results. In addition, any failure to adequately address stakeholder expectations
with respect to ESG matters may result in the loss of business, adverse reputational impacts, diluted market valuations and challenges
in attracting and retaining customers and talented employees. In addition, our adoption of certain standards or mandated compliance to
certain requirements could necessitate additional investments that could impact our cash position and expected cash runway.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">ITEM 4.<span id="ITEM4."><!--Anchor--></span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
INFORMATION ON THE COMPANY</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25"><span style="font-family: Times New Roman,Times,serif">A. HISTORY AND DEVELOPMENT OF THE COMPANY</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">History</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Our legal and commercial name is Compugen
Ltd. We were incorporated on February 10, 1993, as an Israeli corporation and operate under the Israeli Companies Law, 5759-1999, as amended
together with all regulations promulgated thereunder, or the Companies Law. Our principal offices are located at 26 Harokmim Street, Holon
5885849, Israel, and our telephone number is +972-3-765-8585. Our web address is <span style="font-style: italic">www.cgen.com</span>.
Information contained on our website does not constitute a part of this Annual Report. The SEC maintains an internet site, http://www.sec.gov
that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.
Neither such internet addresses are a part of this Annual Report.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times, serif"><span style="font-family: Times New Roman,Times,serif">Our
agent for service of process in the United States is Compugen USA, Inc., our wholly owned U.S. subsidiary located at 225 Bush Street,
Suite 348, San Francisco, CA 94104, which was incorporated in Delaware in March 1997 and is qualified to do business in California. This
subsidiary did not have any significant operations from 2008 to March 2012.</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">47</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Principal Capital Expenditures </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In the years ended December 31, 2022, 2021
and 2020, our capital expenditures were $0.4 million, $0.4 million and $0.1 million, respectively. As of December 31, 2022, we had no
significant commitments for capital expenditures.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">B. BUSINESS OVERVIEW</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Summary</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">

<div style="line-height: 1.25"><span style="color: #000000">We are a clinical-stage therapeutic discovery and development company utilizing
our broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop
therapeutics in the field of cancer immunotherapy. Our innovative immuno-oncology pipeline consists of three clinical stage programs,
targeting immune checkpoints we discovered computationally by COM701, COM902 and </span><span style="font-family: Times, &apos;Times New Roman&apos;, serif; color: #000000">rilvegostomig</span><span style="color: #000000">.
Our lead product candidates, COM701, a potential first-in-class anti-PVRIG antibody, and COM902, a potential best-in-class therapeutic
anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in
combination of dual (PVRIG/PD-1, PVRIG/TIGIT) and triple (PVRIG/PD-1/TIGIT) blockade. Based on the data from the Phase 1 trials and as
part of our corporate focus on two specific tumor types for the further clinical evaluation of COM701 and COM902, we intend to initiate
two clinical trials evaluating the triple combination treatment of COM701, COM902 and pembrolizumab, one in metastatic microsatellite
stable colorectal cancer patients and one in platinum resistant ovarian cancer patients. We plan to dose first patient to these trials
in the first quarter of 2023 and in the second quarter of 2023, respectively. As part of Phase 1 clinical trials for our lead product
candidates, COM701, we evaluated COM701 as a monotherapy and under clinical collaboration with Bristol Myers Squibb Company in combination
with nivolumab &#177; Bristol Myers Squibb investigational anti-TIGIT, BMS-986207. Following the termination of our collaboration with
Bristol Myers Squibb Company, these combination studies are being wound down while the monitoring of patients on study treatment is ongoing.
</span><span style="font-family: Times, &apos;Times New Roman&apos;, serif; color: #000000">Rilvegostomig,</span>&#160;<span style="color: #000000">a
novel anti PD-1/TIGIT bispecific antibody with a TIGIT-specific component that is derived from our COM902 antibody, is being developed
by AstraZeneca pursuant to an exclusive license agreement between us and AstraZeneca and is in Phase 2 clinical trial in patients with
advanced or metastatic non-small cell lung cancer and locally advanced or metastatic gastric cancer. Our therapeutic pipeline of early-stage
immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance. Our most advanced early-stage
program, COM503, is a potential first-in-class high affinity antibody, which blocks the interaction between IL-18 binding protein and
IL-18, thereby releasing the natural IL-18 into the tumor microenvironment to inhibit cancer growth. COM503 is being advanced into IND
enabling studies and we plan to file an IND in 2024. Our business model is to selectively enter into collaborations for our novel targets
and drug product candidates at various stages of research and development under various revenue-sharing arrangements. Integrating cutting
edge computational capabilities with ground-breaking immuno-oncology research and drug development expertise is our differentiator and
has enabled the advancement of three drug targets from computer prediction through successful preclinical studies to the clinic and as
a result, we believe that we are uniquely positioned to discover and develop potential new, first-in-class treatment options for cancer
patients.</span></div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Our
Strategy</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif">We aim to transform patient lives
by developing first-in-class therapeutics in the field of cancer immunotherapy based on our computational target discovery capabilities.
Our pipeline strategy for the development of potentially first-in-class cancer immunotherapies is differentiated in the competitive landscape
of immuno-oncology in the following manner:</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" id="z2e87d1068a104ca5a22e29858e75dc3c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>We discover novel drug targets and biological pathways with the potential to address the unmet need of patients non-responsive to
        current cancer immunotherapies;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" id="z3254ecf650da469e99dc8a0b8b6bbb65" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>We integrate our cutting-edge computational capabilities with our ground-breaking immuno-oncology research and drug development expertise
        to inform our target discovery and drug development process; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">48</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<table cellspacing="0" cellpadding="0" id="zebfb4d816ce7469cabfd8d42eae441f7" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>We identify drug combinations and design biomarker strategy for potential future patient selection.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We believe this uniquely positions us in
the discovery and the development of first-in-class drugs for cancer immunotherapy.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">In our clinical therapeutic pipeline, our most advanced programs
are:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" id="z472c5aeaec064331a6c29e4306f2ac61" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div style="color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">COM701
        </span><span style="font-family: Times New Roman,Times,serif">is our lead immuno-oncology pipeline program. COM701 is a humanized antibody
        that binds with high affinity to PVRIG, a novel immune checkpoint target candidate discovered by us that blocks the interaction with its
        ligand, PVRL2. Our data suggests that the PVRIG pathway is parallel and complementary to TIGIT, an immune checkpoint discovered computationally
        by us in 2009. These two pathways intersect with DNAM-1, a costimulatory receptor on T cells and NK cells. The PD-1 pathway also intersects
        with DNAM-1. In certain tumors, the blockade of both TIGIT and PVRIG may be required to stimulate an antitumor immune response, with or
        without additional PD-1 pathway blockade. Phase 1 trials for COM701 were initiated in September 2018.</span></div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" id="z97b2b56b120a47db8f0b06051e2e1490" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div style="color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">COM902</span><span style="font-family: Times New Roman,Times,serif">
        is a high affinity, fully human antibody developed by us, targeting TIGIT, an immune checkpoint. COM902 blocks the interaction of TIGIT
        with PVR, its ligand. Our preclinical data suggests that in certain tumor indications the blockage of both TIGIT and PVRIG, two coinhibitory
        arms of the DNAM-1 axis, may be required to stimulate an anti-tumor immune response with or without the blockade of the PD-1 pathway.
        Phase 1 trials for COM902 were initiated in March 2020.</span></div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" id="zaf46e66083ce401aa70c09082536b51d" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify">
        <div style="font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Rilvegostomig</span><span style="font-family: Times New Roman,Times,serif">&#160;is
        a novel PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from COM902 and is being developed by AstraZeneca pursuant
        to an exclusive license agreement with AstraZeneca. AstraZeneca initiated its Phase 2 trial in patients with advanced or metastatic non-small
        cell lung cancer in September 2022. In February 2023, AstraZeneca announced that it plans to initiate a Phase 3 trial for rilvegostomig
        and that expanded Phase 2 for rilvegostomig is in development.</span></div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">In
addition to our clinical therapeutic pipeline, bapotulimab, an antibody targeting ILDR2, licensed to Bayer, under a research and discovery
collaboration and license agreement has been evaluated in Phase 1 clinical trials in na&#239;ve head and neck squamous cell carcinoma
patients. This research and discovery collaboration and license agreement expired on February 27, 2023, and we are currently in the process
of obtaining certain rights from Bayer to allow us to continue the development and commercialization of bapotulimab, should we choose
to do so.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Research Focus - Immuno-Oncology</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Our research and development efforts focus
on identifying novel drug targets and developing first-in-class therapeutics in the field of cancer immunotherapy.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Cancer immunotherapies represents a significant
commercial market. Global cancer immunotherapy revenues of $87 billion were reported for 2020 and sales of therapies targeting immune
checkpoints registered approximately $31 to 37 billion worldwide in 2021. Industry analysts estimate that the cancer immunotherapy market
has a significant growth potential and annual sales&#8217; projections of some of $144 billion by 2025 with immune checkpoints accounting
for approximately $63 billion.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The immune system is naturally programmed
to seek out and destroy abnormal cells. Cancer is believed to thrive, in part, because of a number of cellular mechanisms that aid in
the evasion of immune response. Such mechanisms of immune system evasion include masking or reducing the expression of tumor antigens
to avoid detection, recruiting T-cell suppressor cells or expressing inhibitory molecules that suppress immune activation, inducing conditions
in the tumor microenvironment that promote tumor cell proliferation and survival, and a number of other factors. Immuno-oncology therapies
that overcome immune suppression by stimulating responses directed to cancer cells are emerging as a powerful means of counteracting the
cellular mechanisms that enable the growth and spread of tumors. Immuno-oncology agents are expanding as a potential path to durable and
long-lasting responses in certain patients.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Our discovery strategy is focused on the
discovery of new drug targets involved in mechanisms of immune resistance and which may consequently provide new cancer immunotherapies
for enhancing anti-tumor immune responses in cancer patients.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">49</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">While immunotherapy revolutionized the landscape
for oncology treatments by providing a new treatment option leading to lasting benefits for some patients; the response rates to immunotherapy
vary greatly across different cancer indications, averaging approximately 15% to 30% overall thereby leaving a significant unmet medical
need for many patients that may be addressed by the discovery of new biological pathways that could serve for the development of new cancer
immunotherapies.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Therapeutic Pipeline</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7f58cbd8115a4f61aa87616e707f95ae" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="font-style: italic; font-weight: bold">COM701 - a therapeutic antibody targeting PVRIG</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="margin-left: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">Pathway expression and
preclinical data</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">COM701 is a potentially
first-in-class humanized antibody that binds with high affinity to PVRIG, a novel immune checkpoint target candidate discovered by Compugen,
blocking the interaction with its ligand, PVRL2. Blockade of PVRIG by COM701 has demonstrated potent, reproducible enhancement of T cell
activation, consistent with the desired mechanism of action of activating T cells in the tumor microenvironment to generate anti-tumor
immune responses.&#160; In addition, COM701 combined with anti-PD-1 antibodies has demonstrated synergistic effects in enhancing human
T cell stimulation and inhibiting tumor growth in murine models, supporting the suggested intersection of the PVRIG and PD-1 inhibitory
pathways and the potential of these combinations to further enhance immune response against tumors.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">PVRIG and TIGIT constitute
parallel immune checkpoint pathways that interact with DNAM-1, a costimulatory molecule on T cells and NK cells. While PVRIG and TIGIT
are complementary and part of the same biological axis,&#160;our research&#160;shows that they are in fact distinct. PVRIG and TIGIT bind
to different ligands (PVRL2 and PVR, respectively), they are expressed on different immune cell types and their ligands have different
expression patterns.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Furthermore, our data
show that similar to TIGIT, PVRIG is expressed in stem-like memory T cells (TSCM) and PVRL2 is expressed in both dendritic cells and tertiary
lymphoid structures, as well as in PD-L1low&#160;less inflamed tumors. TSCM&#160;cells, dendritic cells and tertiary lymphoid structures
have all been shown to be important in clinical response to checkpoint inhibitors. Preclinical data for COM701 suggest that PVRIG may
be a dominant checkpoint pathway in diverse patient populations with tumors that express elevated PVRL2, the ligand of PVRIG, as compared
to expression of PVR, the ligand of TIGIT. This includes patients with breast, endometrial, and ovarian cancers. In addition, expression
studies showed that PVRIG, TIGIT, and their respective ligands, are expressed in a broad variety of tumor types, such as those noted above,
as well as lung, kidney, colorectal and head &amp; neck cancers. In these tumors the blockade of both TIGIT and PVRIG may be required
to stimulate an anti-tumor immune response, with or without additional PD-1 pathway blockade. COM701 is in a Phase 1 clinical trial in
patients with advanced solid tumors, to evaluate in combination therapy with PD-1 inhibitor &#177; TIGIT inhibitor.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">Clinical
Development - Bristol Myers Squibb Collaboration</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In October 2018, we entered
into the MCTC with Bristol Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol Myers Squibb&#8217;s
PD-1 immune checkpoint inhibitor Opdivo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#174;</sup> (nivolumab).
In February 2020, the MCTC was amended to include a Phase 1/2 clinical trial, sponsored by Compugen, to evaluate the safety, tolerability
and antitumor activity of COM701 in combination with Opdivo&#174; (nivolumab), and Bristol Myers Squibb&#8217;s investigational antibody
targeting TIGIT known as BMS-986207, in patients with advanced solid tumors. In February 2021, the MCTC was further amended to include
an expansion of the Phase 1 combination trial designed to evaluate the dual combination of COM701 and Opdivo&#174; in patients with advanced
solid tumors and in November 2021 the MCTC was amended again to, among other things, establish a joint steering committee (alongside the
existing joint development committee which acts at an operational level) to facilitate strategic oversight and guidance for the programs
run under the collaboration.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">On August 3, 2022, in
efforts to adapt to challenging market conditions, we took a strategic decision to focus on prioritized indications and to wind down our
broad Phase 1 cohort expansion program and therefore entered into a letter agreement with Bristol Myers Squibb pursuant to which the MCTC
between the parties was terminated as of such date. In connection with such termination, the parties agreed to use reasonable efforts
to wind down activities under the CTCA with respect to the dual combination study of COM701 with Opdivo&#174; and the triple combination
study of COM701 with Opdivo&#174; and Bristol Myers Squibb&#8217;s investigational anti-TIGIT antibody BMS- 986207 and to create a sub-team
of the parties to oversee such wind-down activities. See &#8220;Business Strategy and Partnerships - Bristol Myers Squibb Collaboration&#8221;
below. Until the conclusion of the wind down of the combination studies with Bristol Myers Squibb, Bristol Myers Squibb continues to supply
at no cost Opdivo&#174; for the dual combination trial and supplies both Opdivo&#174; and its investigational antibody targeting TIGIT
known as BMS-986207 at no cost, for the triple combination trial.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">50</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">COM701
Clinical Programs</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In September 2018, we
dosed our first patient in the Phase 1 clinical trial of COM701.</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"> <br /> </div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Phase
1 Arm A</span><span style="font-family: Times New Roman,Times,serif"> of the trial evaluated the safety and tolerability and preliminary
antitumor activity of COM701 monotherapy. We completed the enrollment to both the dose escalation and expansion cohorts.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The patient population
enrolled in the dose escalation was all comers and included patients who have failed prior therapies including other checkpoint inhibitors
and have no other available approved therapies.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Phase
1 Arm B</span><span style="font-family: Times New Roman,Times,serif"> of the trial evaluates the safety and tolerability and preliminary
antitumor activity of COM701 in combination with a PD-1 inhibitor. A patient population with similar eligibility criteria as enrolled
for the dose escalation cohorts in Arm A was enrolled for this part of the trial and enrollment was completed during 2020.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In June 2021, we announced
that the first patient in the combination expansion cohort of this Phase 1 Arm B clinical has been dosed.&#160;The indications for the
combination therapy expansion cohort, ovarian, breast, endometrial and colorectal cancers were selected based on preclinical biomarker
assessments and based on emerging clinical data from the dose-escalation cohorts of the trial.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Following the completion
of enrollment of few cohorts in the study and data disclosure from this completed cohorts, we are currently winding down this study and
do not plan to further enroll additional patients.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="text-decoration: underline">Data
disclosed from this arm in 2022:</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In November 2022, at
the 37<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">th</sup> Annual Meeting of the Society for Immunotherapy
of Cancer (SITC), we presented preliminary data in a poster titled &#8220;PVRIG, a novel T cell checkpoint, is preferentially expressed
in TLS on stem-like memory T cells, potentially inhibiting their expansion&#8221;. Key findings from the poster included:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5f4e8d1a7c6b4e71a3ae5a01b8435608" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>COM701 in combination with nivolumab induced preliminary anti-tumor activity and TME immune-modulation in patients with MSS-CRC typically
        not responsive to approved checkpoint inhibitors</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z9136aea5de1241f69cace07b83e494ae" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>PVRIG has a unique dominant expression on early differentiated T like stem cells (Tscm) and its ligand, PVRL2, is expressed on dendritic
        cells (DCs)</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z65674101848b4c149867ab4538c54bc9" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Spatial transcriptomic analysis showed that Tscm and DCs preferentially localize to Tertiary Lymphoid Structures (TLS) regions while
        exhausted T cells localize to the tumor</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z6fa2bcd88b6840d485ec228dd7b565b3" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>PVRIG is dominantly expressed on CD8+ T cells in TLS region</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="zdad9376a7fbd4042bd125537afce75fb" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>PVRIG blockade may enhance Tscm activation by DCs in lymph-nodes and TLS, a mechanism which potentially could lead to increased T
        cell expansion and infiltration into cold tumors</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In November 2022, at
the 37<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">th</sup> Annual Meeting of the Society for Immunotherapy
of Cancer (SITC), we presented preliminary data in a poster titled &#8220;COM701 plus nivolumab demonstrates preliminary antitumor activity
and immune modulation of tumor microenvironment in patients with metastatic MSS-CRC and liver metastases&#8221;. Key findings from the
poster, with a data cut-off date of June 17, 2022, included:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zb0f9324828734a2e99670262c8f7f1c1" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>COM701+ nivolumab combination is well tolerated with a favorable safety profile</div> </td> </tr>
  </table>

<div> <br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">51</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<table cellspacing="0" cellpadding="0" id="z089f0851ad11458f87fc82a9436afd1b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>ORR 2/22 (9%) higher than ORR (1-2%) reported for standard of care - regorafenib or TAS-102</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z84a523554b5e43d3a2905cf70a1aa201" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Encouraging preliminary antitumor activity in the subset of MSS-CRC patients with liver metastases, ORR 2/17 (12%), compared to 0%
        ORR historically for other immunotherapies in a U.S. patient population&#160;</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="zf817942b35b843e0b51f89826e9290b6" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Translational data demonstrated potent TME immune activation, in the majority of patients based on 13 paired biopsies, most notable
        in responders and consistent with COM701 mechanism of action. Such modulation is not typical of checkpoint inhibitors in cold indications</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In December 2022,
at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO), we presented preliminary data from poster&#160;&#8220;COM701 in
combination with nivolumab demonstrates preliminary antitumor activity in patients with platinum resistant epithelial ovarian cancer&#8221;.
Key findings from the poster, with a data cut-off date of November 23, 2022,&#160;included:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zec16e11e0e1340ea83d5d8ff5a127fa7" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>In 20 patients who had exhausted all standard therapies, with a median number of 6 prior therapies, the dual combination demonstrated:</div>
        </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z8405efeddb9740fb95bda51fb721c18e" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 54pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Encouraging overall response rate of 10%, with 2 partial responses and 1 ongoing at the data cut-off date</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z1c0d0f991eaa48db9c0cd75427adebec" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 54pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Disease control rate of 45% (2 confirmed partial responses, 7 stable disease)</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z55b094d15756442f9db4c3b615b5602c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 54pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Translational assessment of peripheral blood, showed a pharmacodynamic activation of the immune system</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z487b959086f04eb1885ffb86d07ad9b9" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 54pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>One patient with a partial response supported by increased infiltration of CD8 cells into the tumor microenvironment, had high grade
        serous adenocarcinoma, 7 prior lines of treatment including best response of progressive disease on the combination of nivolumab and lucitanib
        (an investigational agent)</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z2fcc9a9606644cafb9d9fa4fc53c05f2" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 54pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Most frequent treatment related adverse events grade 1/2, no grade 4/5 adverse events</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z4c0c0a784a194d1489514d25093f34a6" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>65% of the patients had high-grade serous adenocarcinoma, including the two responders</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; margin-left: 35.45pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In December 2022,
at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO), we presented preliminary data from poster&#160;&#8220;COM701 &#177;
Nivolumab &#8211; preliminary results of antitumor activity from a phase 1 trial in patients with metastatic NSCLC who have received prior
PD-1/PD-L1 inhibitor&#8221;. Key findings from the poster, with a data cut-off date of November 23, 2022,&#160;showed that COM701 &#177;
nivolumab demonstrates preliminary encouraging signal of antitumor activity in a heavily pretreated population of patients with NSCLC
with prior ICI treatment. Most of the patients 4/7 [57%] received &#8805;2 prior lines of immune checkpoint inhibitors, all 4 patients
with SD, with 2/4 [50%] with SD &#8805;6 months median overall survival (median of 4 prior lines of therapy including multiple ICI in
57% of patients): COM701 + nivolumab (10 months), COM701 monotherapy (9.5 months). Historical data with LungMAP2: post ICI NSCLC data
- 1 prior line of ICI in metastatic setting, median overall survival 14.5 months (80% CI: 13.9 to 16.1) for ramucirumab + pembrolizumab
vs standard of care of 11.6 months (80% CI 9.9 to 13.0).</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Phase
1/2 </span><span style="font-family: Times New Roman,Times,serif">trial was designed to evaluate the safety, tolerability and antitumor
activity of COM701 in combination with Opdivo&#174;&#160;and BMS-986207. The trial was designed to evaluate a safe and tolerable dose
of the combination during dose escalation and antitumor activity in selected tumor types in the expansion cohorts (ovarian cancer, endometrial
cancer, head and neck and a biomarker-driven arm of tumor types with high expression of PVRL2).&#160;Dose levels for Opdivo&#174;&#160;and
BMS-986207 combinations have already been determined through prior testing by Bristol Myers Squibb, allowing for dose escalation of COM701
with fixed doses of Opdivo&#174;&#160;and BMS&#8209;986207.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In July 2021 we dosed
the first patient in this trial. Following the completion of enrollment of the ovarian cohort in the study and its respective data disclosure
we are currently winding down this study and do not plan to further enroll additional patients.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">52</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="text-decoration: underline">Data
disclosed from this trial in 2022:</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In December 2022, at
the European Society of Medical Oncology Immuno-Oncology (ESMO-IO), we presented data from poster:&#160;&#8220;Triple blockade of the
DNAM-axis with COM701 + BMS-986207 + nivolumab demonstrates preliminary antitumor activity in patients with platinum resistant OVCA.&#8221;
Key findings from the poster, with a data cut-off date of November 23, 2022,&#160;included:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3aa433ff28364e918cc94450a688a864" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>In 20 patients who had exhausted all standard therapies, with a median number of 4 prior therapies, the triple combination demonstrated:</div>
        </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z4ba2034669574325b21d90b1e47a3e38" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 54pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Encouraging overall response rate of 20%, with 4 confirmed partial responses, out of which 3 are responding for at least 9 months.
        All 4 responders are still on study treatment at the data cut-off date, therefore median duration of response has not been reached</div>
        </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z59a62b30c5284964996b0f2ccbcf7c67" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 54pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Disease control rate of 45% (4 confirmed partial responses, 5 stable disease)</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z3c2770d12e4342a39a2cf9bfb60b446f" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 54pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Low pre-treatment PD-L1 expression in 2 of the responders (CPS &lt;1 and 3), analysis of the other responders is still ongoing</div>
        </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z50f7cfbff90e44049ec1a1a8a60aa34e" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 54pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Translational assessment of peripheral blood, including profiling of cytokines and circulating immune cells, showed a pharmacodynamic
        activation of the immune system</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z47ee24a746ec40788b4f0b327174daaa" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 54pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Most frequent treatment related adverse events grade 1/2, no grade 4/5 treatment related adverse events</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z25c26a5e8fbb41cebc78449302b6bf0e" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 35.45pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 14.2pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>55% of the patients had high-grade serous adenocarcinoma, including three of the responders</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Phase
1 Combination of COM902 with COM701 </span><span style="font-family: Times New Roman,Times,serif">&#8211; For details please see information
below under the header &#8220;COM902 - a therapeutic antibody targeting TIGIT<span style="font-style: italic">&#8221;.</span></span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z20927790b67e492ea173de209be1c0b4" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="font-style: italic; font-weight: bold">COM902 - a therapeutic antibody targeting TIGIT</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">Pathway
expression and preclinical data</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">COM902, a high affinity,
fully human and a potentially best-in-class antibody targeting TIGIT, an immune checkpoint is developed by us. COM902 was shown to have
superior binding affinity to T cells with similar and or greater in vitro function compared to several clinical anti-TIGIT antibodies.
COM902 is a mouse-cross reactive Ab and inhibited tumor growth and increased survival when combined with anti-PVRIG or anti-PD-L1 antibodies
in in-vivo studies. Preclinical data demonstrated that TIGIT inhibition, either alone or in combination with other checkpoint inhibitors,
can enhance T&#160;cell activation and increase anti-tumor immune responses. In pre-clinical studies, parallel inhibition of TIGIT and
PVRIG, two coinhibitory arms of the DNAM-1 axis, resulted in synergistic effects on effector T&#160;cell function and tumor growth inhibition
in various model systems that can be further increased with the addition of PD-1 blockade. Based on preclinical data these combinations
may be clinically important for enhancing anti-tumor immune response and expanding the patient population responsive to checkpoint inhibition.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We discovered TIGIT in
2009 with our immune checkpoint computational discovery capabilities through which PVRIG was also discovered. The TIGIT discovery was
published by us in October 2009 in the Proceedings of the National Academy of Sciences (PNAS).</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Expression studies show
that PVRIG and TIGIT, and their respective ligands, are expressed in a broad variety of tumor types, such as breast, endometrial, ovarian,
lung, kidney, and head &amp; neck cancers. These results indicate that within the same tumor indications there are variations with respect
to the possible dominance of the two pathways, and that in patient populations where the two pathways are operative, the blockade of both
TIGIT and PVRIG may be required to sufficiently stimulate an anti-tumor immune response.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">Clinical
Development</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In March 2020, we dosed
our first patient in the Phase 1 clinical trial of COM902.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">53</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">COM902
Clinical Programs</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Phase
1 Monotherapy </span><span style="font-family: Times New Roman,Times,serif">trial evaluated the safety and tolerability of COM902 in patients
with advanced malignancies through sequential dose escalations. The patient population enrolled to the dose escalation cohort is all comers
and included patients who have failed prior therapies including other checkpoint inhibitors and have no other available approved therapies.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We completed the monotherapy
dose escalation trial, and enrolled patients to the expansion cohort.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Phase
1 Combination of COM902 with COM701 </span><span style="font-family: Times New Roman,Times,serif">was designed to assess the safety, tolerability
and preliminary antitumor activity of COM902 in combination with COM701 in patients with advanced malignancies during dose escalation
and in selected tumor types in the expansion cohorts (colorectal cancer, non-small cell lung cancer and head and neck). Enrollment to
these cohorts was terminated in conjunction with the winding down of the studies under collaboration with Bristol Myers Squibb and the
decision to focus on two tumor types for further studies. We amended the study protocol to include patients with metastatic CRC (MSS)
and platinum resistant ovarian cancer. These patients with MSS-CRC and platinum resistant ovarian cancer will receive study treatment
with COM902 + COM701 + pembrolizumab.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z07af647847554217a9d543f7abdead30" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top">
        <div style="font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-weight: bold; font-style: italic">Rilvegostomig
        - a therapeutic PD-1/TIGIT bi-specific antibody with a TIGIT component that is derived from our COM902</span></div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">Rilvegostomig
is a novel PD-1/TIGIT bi-specific antibody with a TIGIT component that is derived from our COM902 being developed by AstraZeneca pursuant
to an exclusive license between us and AstraZeneca.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">In
March 2018, we entered into an exclusive license agreement with AstraZeneca, pursuant to which, we granted to AstraZeneca an exclusive
license to use our monospecific antibodies that bind to TIGIT, including COM902, for the development of bi-specific and multi-specific
antibody products, excluding such bi-specific and multi-specific antibodies that also bind to PVRIG, PVRL2 and/or TIGIT.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">Rilvegostomig
is currently being evaluated by AstraZeneca in a Phase 2 trial in patients with advanced or metastatic non-small cell lung cancer and
in Phase 2 in patients with Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In February 2023, AstraZeneca
announced that it plans to initiate a Phase 3 trial for rilvegostomig and that expanded Phase 2 for rilvegostomig is in development.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8bb819a761d64d64a4d28347b76edd0c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="font-style: italic; font-weight: bold">Bapotulimab (formerly known as BAY1905254) &#8211; a therapeutic antibody targeting
        CGEN-15001T/ILDR2</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">Bapotulimab (formerly
known as BAY1905254, an antibody to ILDR2 (formerly CGEN-15001T), a novel immune checkpoint target discovered by Compugen, was developed
with Bayer pursuant to a research and discovery collaboration and license agreement signed in August 2013. See &#8220;Business Strategy
and Partnerships - Bayer Collaboration&#8221; below. Studies testing the immune function of ILDR2 demonstrated inhibitory effects on T
cells consistent with it being an immune checkpoint ligand. ILDR2 appears to have a unique mechanism of action relative to other immune
checkpoints currently being targeted in clinical testing. ILDR2 is expressed in lymph nodes, suggesting that bapotulimab&#160;exerts its
effects on immune cell priming rather than on directly enhancing immune cell killing effects in the tumor microenvironment.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In April 2018, Bayer
disclosed bapotulimab&#160;(formerly known as BAY1905254) a human/monkey/mouse cross-reactive antibody blocking the immunosuppressive
activity of ILDR2. Bapotulimab has exhibited anti-tumor activity as a monotherapy in various mouse models and was also shown to have additive
anti-tumor effects in combination with other cancer therapy approaches, indicating the possibility for multiple combination uses in cancer
immunotherapy.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">Under
the collaboration agreement, bapotulimab&#160;was previously evaluated by Bayer in a Phase 1 expansion trial in combination with Keytruda,
in head and neck cancer that has returned or is discovered to be metastatic and is expressing PDL1 to evaluate the combination treatment.</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">54</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">On November 29, 2022,
Bayer notified us that it has resolved to terminate, effective as of February 27, 2023, our 2013 research and development collaboration
and license agreement.&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-left: 36pt; line-height: 1.25; font-family: Times New Roman,Times,serif">In accordance with the
terms of said agreement, we are currently in the process of obtaining certain rights from Bayer to allow us to continue the development
and commercialization of bapotulimab, should we choose to do so.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Biomarker Driven Strategy</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">We
recognize that one of the major limitations of current immunotherapy approaches is the lack of tools to help predict patient responses.
Through the use of informed biomarker driven strategies, based on the new biological pathways we discover, we aim to identify biomarkers
that can help us predict which patients are most likely to respond to our novel therapies. This long-term approach also seeks to improve
the probability of success of our clinical studies.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We are using three approaches in our biomarker
strategy. We are computationally analyzing omics data to identify tumor indications in which the pathway of our target is elevated. This
analysis is thereafter being validated experimentally, and the validated data is used for indication selection for our clinical trials.
We used this approach for COM701 to select the tumor types for inclusion in our cohort expansion studies. Such antitumor activity further
supports our biomarker-informed approach and predictive discovery capabilities.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The second part of our biomarker strategy
is the identification of potential biomarkers for future patient selection. In this approach, being used for our COM701 program as a stand-alone
and in combination, we are using various cutting-edge technologies and methodologies on both biopsies, liquid biopsies, and blood samples.
The different technologies include immunohistochemistry, transcriptomic, genomic and proteomic analysis. Data generated by these technologies
also inform us on the suggested mechanism of action of COM701. In the immunohistochemistry analysis, we are currently evaluating the correlation
between the expression of PDL-1 and the PVRIG pathway with clinical response.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Thirdly, we have a pharmacodynamic biomarker
approach where we measure immune modulation induced by COM701 and combinations in peripheral and tumor patient samples obtained before
and during treatment. In this analysis we measure both protein and sequence analytics, such as cytokine analysis, immune phenotyping,
proteomic changes, transcriptomics analysis, and TCR clonality. This again serves for the identification of potential biomarkers and also
inform us on the suggested mechanism of action of COM701.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Early-Stage Pipeline</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Immuno-oncology represents a paradigm shift
in the treatment of cancer, and biological drugs blocking immune checkpoint targets have already resulted in long-term patient survival
in certain cancer types. Despite their potential, current checkpoint inhibitors are limited to a few targets and are only effective in
certain patients and in certain cancers. We believe that the identification of new drug targets and new biological pathways has the potential
to broaden the reach of cancer immunotherapies to more types of cancers and many more patients.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; font-family: Times New Roman, serif">Our early-stage programs were discovered using our discovery capabilities
and consists of drug targets with the potential to address various mechanisms of immune resistance and consequently may provide new cancer
immunotherapies for patients non-responsive to current cancer therapies.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Our most advanced early-stage program, COM503,
is a potential first-in-class, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, thereby releasing
the natural IL-18 into the tumor microenvironment to inhibit cancer growth. We are currently advancing COM503 into IND enabling studies
and plan to file an IND in 2024.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Our Predictive Computational Discovery Approach</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">Our
target discovery is a predictive, proprietary computational process that we initiate based on a clinical need. The unmet clinical need
and the therapeutic strategy dictate the target discovery approach, the appropriate tools and most relevant data to be employed. We have
developed predictive drug target discovery capabilities that leverage the power of computational modeling, guided by our scientific expertise
and extensive public and proprietary datasets, to identify novel drug targets and new biological pathways towards the development of new
cancer immunotherapy treatments. Our multi-omics data analysis is designed to identify first-in-class drug target candidates, which are
generally difficult to identify using traditional experimental approaches.&#160;We believe that our computational approach integrated
with robust experimental validation is a key differentiator from others employing computational discovery approaches.</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">55</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="line-height: 1.25; color: #000000; font-family: Times New Roman, serif">Our broadly applicable predictive drug target discovery
capabilities employ a suite of cloud-based computational solutions and purpose-built algorithms to sort through both public and proprietary
datasets encompassing genomics, single cell and spatial transcriptomics, proteomics and machine learning based analysis of IHC images.
From these massive datasets, our platforms analyze characteristics, such as gene structure, protein domains, predicted cellular localization,
expression pattern, as well as other characteristics to identify potential druggable targets and predict their biological functions. Over
the past decade, we have continued to refine our analysis by incorporating new public and in-house experimental data.</div>

<div style="line-height: 1.25">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We have demonstrated the applicability of
our discovery approach in computationally identifying multiple in-silico targets, including&#160;PVRIG,&#160;TIGIT&#160;and&#160;ILDR2,
the first two now serve as the targets for therapeutic antibodies currently being evaluated in the clinic by us and others. The antibodies
designed to block these targets have all been evaluated in Phase 1 clinical trials by us (COM701 and COM902) or by our partners (bapotulimab
and rilvegostomig).</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Business Strategy and Partnerships</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times, serif"><span style="font-family: Times New Roman,Times,serif">Our
business strategy includes entering into various forms of revenue-sharing collaborations with pharmaceutical or biotechnology partners
for our novel drug targets and product candidates at various stages of research and development. Such collaborations or other types of
partnering arrangements might include one or more of our therapeutic pipeline programs. Through these collaborations we seek to create,
further develop and commercialize our therapeutic product candidates. Additionally, our discovery capabilities designed to feed our internal
pipeline may allow for research and discovery collaborations aimed at harnessing our capabilities towards a potential partner&#8217;s
pipeline needs. Potential revenue sources in line with this business model could include upfront fees, research funding, in-kind funding,
milestones payments, license fees, royalties and other revenue sharing payments. We may also seek co-development arrangements pursuant
to which we would further advance partnered programs under any such partnership in order to retain higher share from future sales revenues.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">AstraZeneca
License</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In March 2018, we entered into an exclusive
license agreement with AstraZeneca, to enable the development of bi-specific and multi-specific immuno-oncology antibody products.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Under the terms of the license agreement,
we granted an exclusive license to AstraZeneca to use our monospecific antibodies that bind to TIGIT, including COM902, for the development
of bi-specific and multi-specific antibody products, excluding such bi-specific and multi-specific antibodies that also bind to PVRIG,
PVRL2 and/or TIGIT. AstraZeneca has the right to create multiple products under this license and will be solely responsible for all research,
development and commercial activities under the agreement. In connection with such license agreement, AstraZeneca developed rilvegostomig,
a novel PD-/TIGIT bi-specific antibody with a TIGIT component that is derived from our COM902 and entered the clinic in September 2021
and moved to Phase 2 in November 2022. We received a $10&#160;million upfront payment and are eligible to receive up to $200 million in
development, regulatory and commercial milestones for the first product as well as tiered royalties on future product sales, out of which
we accrued $2 million in 2020 as a preclinical milestone, $6 million in 2021 as a clinical milestone (triggered by the dosing of the first
patient in a Phase 1/2 trial evaluating rilvegostomig) and an additional $7.5 million as a clinical milestone (triggered by the dosing
of the first patient in its ARTEMIDE Phase 2 trial evaluating rilvegostomig). If additional products are developed, additional milestones
and royalties would be due to us for each product. We retained all other rights to our entire pipeline of programs as monotherapies and
in combination with other products.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In February 2023, AstraZeneca announced
that it plans to initiate a Phase 3 trial for rilvegostomig and that expanded Phase 2 for rilvegostomig is in development.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">56</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Subject to termination rights for material
breach, bankruptcy or by us for patent challenge by AstraZeneca, the term of the license agreement continues until the expiration of the
last Royalty Term in the Territory, each as defined in the license agreement. In addition, AstraZeneca may terminate the agreement for
convenience upon prior written notice.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Bayer Collaboration</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">On August 5, 2013, we entered into a collaboration
with Bayer, or the Bayer Collaboration, for the research, development, and commercialization of antibody-based therapeutics against two
novel Compugen-discovered immune checkpoint regulators, CGEN 15001T/ILDR2 and CGEN 15022.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Under the terms of the Bayer Collaboration,
we received an upfront payment of $10 million, and, following the return of the CGEN 15022 program to us, we were eligible to receive
an aggregate of over $250 million in potential milestone payments for bapotulimab&#160;(formerly known as BAY1905254) (an antibody against
CGEN 15001T/ILDR2), not including aggregate milestone payments of approximately $23 million received to date. Additionally, we are eligible
to receive mid-to-high single digit royalties on global net sales of any approved products under the collaboration. </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times, serif"><span style="font-family: Times New Roman,Times,serif">In
2014, we achieved the first and second preclinical milestones and in 2015 we achieved the third preclinical milestone with respect to
bapotulimab. Pursuant to the terms of the Bayer Collaboration, this program was transferred to Bayer&#8217;s full control for further
preclinical and clinical development activities, and worldwide commercialization under milestone and royalty bearing licenses from us.
In September 2018, the program achieved the fourth milestone, following the dosing of the first patient in the Phase 1 clinical trial
of bapotulimab.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">On November 29, 2022, Bayer notified us
that it has resolved to terminate, effective as of February 27, 2023, our 2013 research and development collaboration and license agreement.&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In accordance with the terms of said agreement,
we are currently in the process of obtaining certain rights from Bayer to allow us to continue the development and commercialization of
bapotulimab, should we choose to do so.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Bristol
Myers Squibb Collaboration</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">On October 10, 2018, we entered into the
MCTC with Bristol Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol Myers Squibb&#8217;s PD-1
immune checkpoint inhibitor Opdivo&#174; (nivolumab), in patients with advanced solid tumors.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The collaboration was also designed to address
potential future combinations, including trials to investigate combined inhibition of checkpoint mechanisms. The parties agreed that Bristol
Myers Squibb and Compugen will each supply the other company with its own compound for the other party&#8217;s study, and otherwise each
party will be responsible for all costs associated with the study that it is conducting. Any combination trial performed under this agreement
is referred to as a Combined Therapy Study.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Pursuant to the terms of MCTC, as amended
from time to time, we conducted triple combination clinical trials to evaluate the safety, tolerability and antitumor activity of COM701
in combination with Opdivo&#174; (nivolumab), and Bristol Myers Squibb&#8217;s investigational antibody targeting TIGIT known as BMS-986207,
in patients with advanced solid tumors, and dual combination clinical trials to evaluate the dual combination of COM701 and Opdivo&#174;
in patients with advanced solid tumors. In all these clinical trials we were responsible for and sponsored all the clinical trials and
Bristol Myers Squibb provided us with Opdivo&#174; and BMS-986207 at no cost to us.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The MCTC provided Bristol Myers Squibb a
right to negotiate a license for commercialization and further provided Bristol Myers Squibb with certain exclusivity rights.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In conjunction with the signing of the MCTC
in October 2018, Bristol Myers Squibb made a $12&#160;million investment in us and in conjunction with the signing one of the amendments
to the MCTC in November 2021, Bristol Myers Squibb made additional $20 million investment in us. In both investments, the share price
paid by Bristol Myers Squibb represented a 33% premium over the closing price of our ordinary shares on the last trading day immediately
prior to the execution of the applicable securities purchase agreement. In these two investments, we issued to Bristol Myers Squibb 4,757,058
ordinary shares aggregately.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">On August 3, 2022, in an effort to adapt
to challenging market conditions, we took a strategic decision to focus on prioritized indications and to wind down our broad Phase 1
cohort expansion program and therefore entered into a letter agreement with Bristol Myers Squibb pursuant to which the MCTC between the
parties was terminated as of such date and all ongoing clinical trials at the time of the termination entered into a winding down process.
Please see &#8220;Item 5. Operating and Financial Review and Prospects Finance - B. Liquidity and Capital Resources.&#8221;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">57</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Main
Academic Collaboration</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We also advance our pipeline through academic
collaborations with leading researchers and key opinion leaders in the field of immuno-oncology. Our current main academic collaboration
is with Johns Hopkins University, School of Medicine.&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The collaboration focuses on the evaluation
of novel T cell and myeloid checkpoint targets identified by us for the potential treatment of cancer. The scope of the collaboration
includes identifying differentiating features of our novel targets relative to known immuno-oncology targets, and the therapeutic potential
of drugs modulating the activity of those novel drug targets. Research is conducted under the leadership of Drew Pardoll, M.D., Ph.D.,
Abeloff Professor of Oncology, Medicine, Pathology, and Molecular Biology and Genetics at Johns Hopkins University, School of Medicine,
and Director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy and Co-Director of the Cancer Immunology Program at the Sidney
Kimmel Comprehensive Cancer Center, Johns Hopkins, and Chairman of our Scientific Advisory Board.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In May 2021, we announced an expansion to
our research collaboration with Johns Hopkins University to include studies investigating the biology of a specific novel myeloid target
that was computationally-discovered by us, with initial studies demonstrating the potential of this target to serve as a novel myeloid
immunomodulator, with significant tumor growth inhibition observed upon genetic deletion in&#160;in-vivo&#160;studies.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The research program is expected to explore
the biological function and mechanism of this novel target, which is expressed on myeloid cells and macrophages in various cancers. The
expanded research plan is intended to further evaluate and validate the role of the target in various tumors.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Competition</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The biotechnology and pharmaceutical industries
are highly competitive and characterized by the rapid evolution of new technologies and the adoption of new therapies. Additionally, the
oncology therapeutic space, and in particular the immuno-oncology or cancer immunotherapy subsector, represents the therapeutic area with,
what we believe to be one of the highest industry focus and investment. In addition, in recent years, computational approaches and systems
are being integrated into multiple life science aspects, including the formation of new companies focusing on computational drug target
discovery. Our competitors include biotechnology and pharmaceutical companies both small and large, the research and discovery groups
within pharmaceutical companies, computational discovery and development companies, academic and research institutions, newly founded
companies and governmental and other publicly funded agencies.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times, serif"><span style="font-family: Times New Roman,Times,serif">Any
product candidates that we successfully develop will compete with currently approved therapies and new therapies that may become available
in the future. We face, and expect to continue to face, ongoing competition from entities that discover novel targets and develop novel
products, and that have therapeutic product candidates or products that address the same drug targets or act by similar, or possibly identical,
mechanism of action (MOA) as well as by different mechanisms but address the same drug target or unmet clinical need. Our potential competitors
are also comprised of companies that discover and develop monoclonal antibody therapies and/or therapeutic proteins to novel targets,
and/or cell therapies for oncology diseases. Specifically, in the field of immune checkpoints and myeloid drug targets for cancer immunotherapy,
there are several leading pharmaceutical and biotechnology companies as well as smaller biotechnology companies and academic institutions
that are developing cancer immunotherapies to enhance immune response towards tumors, some of which may be based on the same targets we
have discovered. For example, there are a significant number of anti-TIGIT antibodies that are currently in advanced clinical studies
such as tiragolumab by Roche, vibostolumab by Merck, ociperlimab by Beigene, domvanalimab and AB308 by Arcus, BMS-986207 by Bristol Myers
Squibb, GSK4428859A by GSK, and others at earlier stages in development. In addition, GSK is developing the PVRIG targeting antibody GSK4381562
(formerly SRF813), Junshi Biosciences lists an anti-PVRIG antibody (JS009) and a TIGIT/PVRIG bispecific (JS209) in its pipeline and Hengrui
is conducting a Phase 1 clinical trial with SHR-2002, a PVRIG/TIGIT bi specific. If approved, such cancer immunotherapy products would
compete with our product candidates for commercialization or approved products in the respective fields. If in development stage, such
cancer immunotherapy products would compete with our product candidates for entering into strategic partnerships with pharmaceutical and
biotechnology companies which form the basis of our business model.</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">58</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Our discovery program depends, in large
part, on our computational discovery capabilities in integration with our immune-oncology experimental capabilities and drug development
capabilities as well as our proprietary data to make inventions and establish intellectual property rights in our drug target candidates
and product candidates. There are additional companies exploring computational approaches and systems for drug target discovery and number
of other means by which such inventions and intellectual property can be generated. We believe that our computational capabilities, and
specifically our IO predictive computational discovery capabilities, provide us with a competitive advantage in predicting new protein
functions and linking proteins to specific diseases, and as a result, predicting new immune-oncology drug targets. We believe that this
advantage is made possible by building an integrated immune-oncology platform for predictive discovery based on the integration of scientific
understanding and predictive models as well as our unique team of multidisciplinary research scientists, who have vast experience in computational
discovery, including developing and handling advance data science approaches, and who over time discovered three drug targets that entered
clinical studies and have generated&#160; peer reviewed publications&#160; in scientific journals.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Many of our potential competitors, either
alone or with their collaborative partners, have substantially greater financial, technical and human resources than we do and significantly
greater experience in computational approaches and the discovery, development and manufacturing of therapeutics, obtaining FDA and other
regulatory approvals, and commercialization of products. Accordingly, our competitors may be more successful than we may be in identifying
new drug targets and product candidates, protecting them with patent applications, developing them, accelerating their development process,
obtaining FDA and other regulatory<span style="font-size: 10.5pt">&#160;</span>approvals and achieving widespread market acceptance. We
anticipate that we will face intense and increasing competition as advanced technologies or new therapy modalities become available.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Intellectual Property Rights </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times, serif"><span style="font-family: Times New Roman,Times,serif">Our
intellectual property assets are our principal assets. These assets include the intellectual property rights subsisting in our proprietary
know-how and trade secrets underlying our predictive biology capabilities and discovery capabilities, our patents and patent applications,
particularly with respect to our discovered proteins, therapeutic and diagnostic product candidates. We seek to vigorously protect our
rights and interests in our intellectual property. We expect that our commercial success will depend on, among other things, our ability
to obtain commercially valuable patents, especially for our therapeutic and diagnostic product candidates, maintain the confidentiality
of our proprietary know-how and trade secrets, and otherwise protect our intellectual property. We design our patent strategy to fit the
business competitive landscape and continual legislative changes. In addition, we periodically analyze and examine our patent portfolio
to align it with our pipeline strategy and business needs. We seek patent protection for certain promising inventions that relate to our
therapeutic and diagnostic product candidates. As of February 1, 2023, we had a total of 52 issued and allowed patents, of which 14 are
U.S. patents, 8 are European patents and additional 30 patents in other territories. Our issued and allowed patents expire between 2028
and 2037. As of February 1, 2023, we had over 168 pending patent applications that have been filed in the United States, Europe and in
other territories as well as pending patent applications that have been filed under the Patent Cooperation Treaty for which we have not
yet designated the countries of filing. The patents issued in the U.S. and Europe for COM701 and COM902 were issued between 2017 and 2022
and should expire no earlier than 2036. These patents include issued claims directed to, among others, the composition of these product
candidates and/or methods of using the same to treat cancer by activating T cells and/or NK cells, and/or combinations of our product
candidates with other checkpoint inhibitors. Our general policy is to continue patent filings and maintenance for our therapeutic and
diagnostic product candidates, only with respect to candidates or programs that are being actively pursued internally or with partners,
or that we believe to have future commercial value. We routinely abandon patent applications and may choose to abandon maintenance of
patents supporting candidates or programs that do not meet these criteria.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We also seek protection for our proprietary
know-how and trade secrets that are not protectable or protected by patents, by way of safeguarding them against unauthorized disclosure.
This is done through the extensive use of confidentiality agreements and assignment agreements with our employees, consultants and third
parties as well as by technological means. We use license agreements both to access third-party technologies and to grant licenses to
third parties to exploit our intellectual property rights.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In October 2020, two parties, one being
GSK (following an assignment), filed oppositions in the European Patent Office, or EPO, requesting revocation of our granted European
patent relating to anti-PVRIG antibodies, that expires in 2036. We responded to this opposition in March 2021.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">59</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Following our response, a preliminary non-binding
opinion of the European opposition division was received in October 2022, with a summons to attend oral proceedings in July 2023. The
opposition division preliminary non-binding opinion accepts some of our arguments filed in our response in March 2021 and acknowledges
that the formal requirements of the priority claim of the patent that is the subject matter of the opposition are being successfully met.
Nevertheless, the preliminary non-binding opinion states that the requirements of novelty and inventive step for the said patent are not
met, mainly because the oppositions division believes that our priority documents do not contain sufficient data that plausibly link anti-PVRIG
antibodies to activation of T cells and/or NK cells, and to the treatment of cancer. Based on similar considerations the division considers
the claimed subject-matter insufficiently disclosed in the patent.&#160;In January 2023, another opposition was filed by GSK, requesting
revocation of our granted European patent relating to method of screening for inhibitors of the binding association of PVRIG polypeptide
with PVRL2. We plan to timely respond to this opposition.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Manufacturing </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">We
currently rely on contract manufacturers or our collaborative partners to produce and control materials, drug substances and drug products
required for the research and development activities. We do not currently own or operate manufacturing facilities for the production of
clinical or commercial quantities of our therapeutic drug candidates. We do not have, and we do not currently plan to acquire or develop
the facilities or capabilities to manufacture bulk drug substance or filled drug product for use in human clinical trials. We rely on
CMOs, advisors and third-party contractors to generate formulations and produce small scale and larger scale amounts of GLP, cGMP clinical
and commercial drug substance and the drug product required for our clinical trials for the foreseeable future. We also contract with
CMOs and third-party contractors for the labeling, packaging, storage and distribution of investigational drug products.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We entered into agreements with certain
CMOs for the manufacturing and respective analytics of COM701, COM902 and COM503. Our manufacturing strategy is currently structured to
support the current clinical development of COM701 and COM902 and to support the current preclinical development and future clinical development
of COM503. Although we believe the general manufacturing strategy developed for the United States will be applicable in other geographies,
specific strategies for other geographies will be developed as part of our clinical and commercial plans for such other geographies. See
&#8220;Item 3. Key Information - D. Risk Factors - Risks Related to Our Dependence on Third Parties - We rely and expect to continue to
rely completely on third parties to manufacture and supply our preclinical and clinical drug supplies. Our business could be harmed if
those third parties fail to provide us with sufficient quantities of drug product or fail to do so at acceptable quality and quantity
levels, prices or timelines.&#8221;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Government Regulation</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Regulation of Therapeutic
Product Candidates </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In the United States, the FDA regulates
pharmaceutical and biologic products under the Federal Food, Drug, and Cosmetic Act, or FDCA, the<span style="font-size: 10.5pt">&#160;</span>Public
Health Service Act, other statutes and regulations and implementing regulations. We anticipate that our product candidates will be regulated
as biologics. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state and local statutes
and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable United States
requirements at any time during the product development process, approval process or after approval, may subject an applicant to administrative
or judicial sanctions. The process required by the FDA before a biologic may be marketed in the United States generally involves the following:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z554c667162ea4172bcd216a23857570f" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>completion of preclinical laboratory tests and animal studies in compliance with the FDA&#8217;s GLP or other applicable regulations;
        </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z04b8a50fa79e48caa313127acfc988cf" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>submission to the FDA of an IND, which must become effective before human clinical trials may begin; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6fcafeb7ed974dcaad5c10106e1f8eec" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>performance of adequate and well-controlled human clinical trials in accordance with GCPs to establish the safety and efficacy of
        the product for its intended use; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z8516e408010c4662b1007c78fec2fbbc" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>submission of annual reports to regulatory authorities; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z322291b4fe0a4e19a34639dd0728900d" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>submission to the FDA of a biologics license application, or BLA; </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">60</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<table cellspacing="0" cellpadding="0" id="z8970879cfd9248ba89631a9fa4740fcd" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug or biologic is produced
        to assess compliance with current Good Manufacturing Practice, or cGMP, to assure that the facilities, methods and controls are adequate
        to preserve the product&#8217;s identity, strength, quality and purity; and </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za01a9725d419430583675e96ac8ea1d8" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>FDA review and approval of the BLA. </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Once a pharmaceutical candidate is identified
for development it enters the preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry, toxicity
and formulation, as well as animal studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing
information and analytical data, among other information, to the FDA as part of the IND. The sponsor will also include a clinical protocol
detailing, among other things, the objectives of the first phase of the clinical trial, the parameters to be used in monitoring safety,
and the effectiveness criteria to be evaluated, if the first phase lends itself to an efficacy evaluation. The IND automatically becomes
effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, places the clinical trial on a clinical hold.
In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Clinical holds
also may be imposed by the FDA at any time before or during a clinical trial due to, among other things, safety concerns or non-compliance
with applicable requirements.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times, serif"><span style="font-family: Times New Roman,Times,serif">All
clinical trials must be conducted under the supervision of one or more qualified investigators in accordance with GCPs. An IRB at each
institution participating in the clinical trial must review and approve the study plan for any clinical trial before it commences at that
institution. An IRB considers, among other things, whether the risks to individuals participating in the trials are minimized and are
reasonable in relation to anticipated benefits. The IRB also reviews the information regarding the trial, participant recruiting materials
and the informed consent form that must be provided to each trial subject or his or her legal representative before participating in the
trial. In addition, the IRB will monitor the trial until completed.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Each new clinical protocol must be submitted
to the FDA, and to the IRBs. Protocols detail, among other things, the objectives of the study, dosing procedures, subject selection and
exclusion criteria, and the parameters to be used to monitor subject safety and determine efficacy.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Human clinical trials are typically conducted
in three sequential phases that may overlap or be combined:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25"><span style="font-style: italic">Phase 1: </span>The product candidate is initially introduced into healthy
        human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion. In the case of<span style="font-style: italic">&#160;</span>some
        products, usually for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer
        to healthy volunteers, the initial human testing may be conducted in patients. </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25"><span style="font-style: italic">Phase 2: </span>Involves studies in a limited patient population to identify
        possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific<span style="font-style: italic">&#160;</span>targeted
        diseases and to determine dosage tolerance and optimal dosage. </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>
        <div style="line-height: 1.25"><span style="font-style: italic">Phase 3: </span>Involves studies undertaken to further evaluate dosage,
        clinical efficacy and safety in an expanded patient population at geographically dispersed clinical trial sites.<span style="font-style: italic">&#160;</span>These
        studies are intended to establish the overall risk-benefit ratio of the product and provide an adequate basis for product labeling and
        approval. </div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div> </div> </div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times, serif"><span style="font-family: Times New Roman,Times,serif">Progress
reports detailing the results of the clinical trials must be submitted at least annually to the FDA and safety reports for serious and
unexpected adverse events must be submitted to the FDA and the investigators more frequently. The FDA or the sponsor may suspend or terminate
a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable
health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being
conducted in accordance with the applicable regulations or IRB requirements or if the drug has been associated with unexpected serious
harm to patients.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Concurrent with clinical trials, companies
usually complete additional nonclinical studies and must also finalize a process for manufacturing the product in commercial quantities
in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product
within required specifications and, among other things, the manufacturer must develop methods for testing the identity, strength, quality
and purity of the product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to
demonstrate that the product does not undergo unacceptable deterioration over its shelf life.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">61</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">United States Review and Approval Processes</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The results of product development, nonclinical
studies and clinical trials, along with descriptions of the manufacturing process, analytical tests, proposed labeling, and other relevant
information are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The FDA initially
reviews all BLAs submitted to ensure that they are sufficiently complete for substantive review before it accepts them for filing. The
FDA may request additional information rather than accept a BLA for filing. Once the submission is accepted for filing, the FDA begins
an in-depth substantive review. The FDA may refer the BLA to an advisory committee for review, evaluation and recommendation as to whether
the application should be approved and under what conditions. The FDA is not bound by the recommendation of an advisory committee.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The review process is lengthy, and the FDA
may issue a complete response letter rather than approve a BLA if the applicable regulatory criteria are not satisfied or may require
the submission of additional clinical or other data and information. Even if such data and information are submitted, the FDA may ultimately
decide that the BLA does not satisfy the criteria for approval.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">If a product receives regulatory approval,
the approval will be limited to specific diseases and dosages or the approved indications for use may otherwise be limited, which could
restrict the commercial value of the product. In addition, the FDA may require a company to conduct post-approval testing and clinical
trials, to further assess a product&#8217;s safety and effectiveness after BLA approval and may require testing and surveillance programs
to monitor the safety of approved products which have been commercialized including Risk Evaluation and Mitigation Strategy (REMS) programs
to ensure that the benefits of a product outweigh its risks.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">Post-approval Requirements</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Approved biologics are subject to extensive
and continuing regulation by the FDA, including, among other things, cGMP compliance, record-keeping requirements, reporting of adverse
experiences, providing the FDA with updated safety and efficacy information, and complying with FDA promotion and advertising requirements.
After an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements is not maintained or if serious
problems occur after the product reaches the market. Biologics may be promoted for use only for the approved indication or indications
and in accordance with the provisions of the approved label. The FDA and other federal and state agencies actively enforce the laws and
regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be
subject to criminal and civil penalties.<span style="font-style: italic">&#160;</span>However, physicians may, in their independent medical
judgment, prescribe legally available products for off-label uses. The FDA does not regulate the behavior of physicians in their choice
of treatments, but the FDA does restrict manufacturer&#8217;s communications on the subject of off-label use of their products.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">Other Healthcare Laws </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Our current and future business operations,
including, among other things, our clinical research activities and our business and financial arrangements and relationships with healthcare
providers, physicians and other parties through which we may market, sell and distribute our products, once approved, may be subject to
extensive U.S. federal, U.S. state and foreign healthcare fraud and abuse, transparency, and data privacy and security laws. For example,
U.S. federal civil and criminal laws and regulations prohibit, among other things: knowingly and willfully soliciting, receiving, offering
or providing remuneration, directly or indirectly, to induce or reward either the referral of an individual, or the furnishing, recommending
or arranging for a good or service, for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid
programs; knowingly presenting or causing to be presented, a false or fraudulent claim for payment by a federal healthcare program; and
knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program (including a private payor),
or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection
with the delivery of, or payment for, healthcare benefits, items or services. Many U.S. states and foreign countries have analogous prohibitions
that may be broader in scope and apply regardless of payor. In addition, we may be subject to U.S. federal, U.S. state and foreign laws
that require us to report information related to certain payments and other transfers of value to certain health care professionals, as
well as ownership and investment interests in our company held by those health care professionals and their immediate family members,
and data security and privacy laws that restrict our practices with respect to the use and storage of certain data.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">62</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">Efforts
to ensure that our current and future business arrangements with third parties comply with applicable healthcare laws and regulations
may involve substantial costs. If we are found to be in violation of any of these laws, we could be subject to significant civil, criminal
and administrative penalties, including damages, fines, disgorgement, imprisonment, exclusion from participation in government healthcare
programs, additional integrity oversight and reporting obligations, contractual damages, reputational harm and the curtailment or restructuring
of our operations.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">Healthcare Policy and Reform</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times, serif"><span style="font-family: Times New Roman,Times,serif">Our
ability to commercialize our future therapeutic product candidates successfully, alone or with collaborators, will depend in part on the
extent to which coverage and reimbursement for these product candidates will be available from government health programs, such as Medicare
and Medicaid in the United States, private health insurers and other third-party payors. At present, significant changes in healthcare
policy, in particular the continuing efforts of the U.S. and other governments, insurance companies, managed care organizations and other
payors to contain or reduce health care costs are being discussed, considered and proposed.&#160;Drug prices in particular are under significant
scrutiny and continue to be subject to intense political and societal pressures, which we anticipate will continue and escalate on a global
basis.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">For
example, in the United States, there have been several initiatives implemented to achieve these aims. The Patient Protection and Affordable
Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, collectively, the ACA, substantially changed the
way healthcare is financed by both governmental and private insurers and significantly affects the pharmaceutical industry. With regard
to biopharmaceutical products, the ACA has, among other things, expanded and increased industry rebates for products covered under Medicaid
programs and changed the coverage requirements under the Medicare Part D program. There have been congressional, judicial, and executive
branch challenges to&#160; the ACA, which has resulted in delays in the implementation of, and action taken to repeal or replace, certain
aspects of the ACA. For example, on June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the
Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. In addition,
there have been a number of health reform initiatives by the Biden administration that have impacted the ACA. On August 16, 2022, President
Biden signed the Inflation Reduction Act of 2022, or the IRA, into law, which among other things, extends enhanced subsidies for individuals
purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221;
under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost through a newly
established manufacturer discount program. It is possible that the ACA will be subject to judicial or congressional challenges in the
future. It is unclear how other such challenges and any additional healthcare reform measures of the Biden administration will impact
the ACA and the pharmaceutical industry.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In addition, other legislative changes have
been proposed and adopted since the ACA was enacted. The Budget Control Act of 2011, triggered automatic reduction to several government
programs, including reductions to Medicare payments to providers, which went into effect in April 2013 and will remain in effect until
2031, unless additional congressional action is taken. Under current legislation, the actual reduction in Medicare payments will vary
from 1% in 2022 to up to 4% in the final fiscal year of this sequester.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Additionally, there has been increasing
legislative and enforcement interest in the United States with respect to drug pricing practices. Specifically, there have been several
recent U.S. congressional inquiries, presidential executive orders and legislation designed to, among other things, bring more transparency
to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient
programs and reform government program reimbursement methodologies for drugs. For example, in July 2021, the Biden administration released
an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs.
In response to Biden&#8217;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices
that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to
advance these principles. In addition, the IRA, among other things, (i) directs the Secretary of HHS to negotiate the price of certain
high-expenditure, single-source drugs and biologics covered under Medicare Part B and Medicare Part D, and subjects drug manufacturers
to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the negotiated &#8220;maximum
fair price&#8221; under the law, and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace
inflation. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years.
These provisions will take effect progressively starting in fiscal year 2023, although they may be subject to legal challenges. It is
currently unclear how the IRA will be implemented but is likely to have a significant impact on the pharmaceutical industry. Further,
the Biden administration released an additional executive order on October 14, 2022, directing HHS to submit a report within 90 days on
how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for lowering drug costs for Medicare and
Medicaid beneficiaries.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">63</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We cannot predict what healthcare reform
initiatives may be adopted in the future. However, we anticipate that Congress, state legislatures, and third-party payors may continue
to review and assess alternative healthcare delivery and payment systems and may in the future propose and adopt legislation or policy
changes or implementations effecting additional fundamental changes in the healthcare delivery system. We also expect ongoing legislative
and regulatory initiatives to increase pressure on drug pricing.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">Coverage and Reimbursement</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Market acceptance of products is dependent
on the extent to which coverage and reimbursement is available from third-party payors. Significant uncertainty exists as to the coverage
and reimbursement status of any products for which we may obtain regulatory approval. Coverage decisions may not favor new products when
more established or lower cost therapeutic alternatives are already available. Even if we obtain coverage for a given product, the associated
reimbursement rate may not be adequate to cover our costs, including research, development, intellectual property, manufacture, sale and
distribution expenses, or may require co-payments that patients find unacceptably high. Coverage and reimbursement policies for products
can differ significantly from payor to payor as there is no uniform policy of coverage and reimbursement for products among third party
payors in the United States. Additionally, we, or our collaborators, may develop companion diagnostic tests for use with our product candidates,
once approved. We, or our collaborators, will be required to obtain coverage and reimbursement for these tests separate and apart from
the coverage and reimbursement we seek for our product candidates, once approved.&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">Non-U.S. Regulations</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In addition to regulations in the United
States, biologics are subject to a variety of foreign laws and regulations governing clinical trials and commercial sales and distribution
before they may be sold outside the United States. Whether or not we obtain FDA approval for a product, we must obtain the necessary approvals
from comparable regulatory authorities of foreign countries before we can commence clinical trials or marketing of the product in those
countries. The approval process varies from country to country and the time may be longer or shorter than that required for FDA approval.
In some countries, we will also have to get pricing approval.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Environmental Regulation</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Some of our research and development activities
involve the controlled use of biologic and chemical materials, a small amount of which could be considered to be hazardous. We are subject
to laws and regulations in the U.S., European Union and Israel governing the use, storage, handling and disposal of all these materials
and resulting waste products. We store relatively small amounts of biologic and chemical materials. To our knowledge, we substantially
comply with these laws and regulations. However, the risk of accidental contamination or injury from these materials cannot be entirely
eliminated. In the event of an accident, we could be held liable for any resulting damages, and any liability could exceed our resources.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Regulation of Use of Human
Tissue</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We need to access and use various human
or non-human tissue samples for the purpose of research, development and or validation of some of our product candidates. Our access and
use of these samples are subject to government regulation, in the United States, Israel and elsewhere and may become subject to further
regulation. The use of clinical data associated with human tissue samples is also heavily regulated in the United States, Israel and elsewhere<span style="font-size: 10.5pt">.
</span>United States and other governmental agencies may also impose restrictions on the use of data derived from human or other tissue
samples.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Regulations Concerning
the Use of Animals in Research</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We also are subject to various laws and
regulations regarding laboratory practices and the use of animals in our research. In the United States, the FDA regulations describe
good laboratory practices, or GLPs, for various types of nonclinical laboratory studies that support or are intended to support applications
for research or marketing permits for products regulated by the FDA, including INDs. Nonclinical animal studies conducted by us or third
parties on our behalf may be subject to the U.S. Animal Welfare Act, the U.S. Public Health Service Policy on Humane Animal Care and Use<span style="font-size: 10.5pt">,
</span>U.S. Department of Agriculture regulations for certain animal species or applicable laws and regulations of other countries where
we or third parties on our behalf conduct these studies. In Israel, the Council on Animal Experimentation has regulatory and enforcement
powers, including the ability to suspend, change or withdraw approvals, among other powers. To our knowledge, we and the third-party service
providers we work with, as applicable, substantially comply with these regulatory requirements.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">64</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Regulation of Products
Developed with the Support of Research and Development Grants</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">For a discussion of regulations governing
products developed with research and development grants from the Government of Israel, see &#8220;Item 5. Operating and Financial Review
and Prospects - C. - Research and Development, Patents and Licenses - The Israel Innovation Authority.&#8221;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">C.
ORGANIZATIONAL STRUCTURE</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We were incorporated under the laws of the
State of Israel on February 10, 1993, as Compugen Ltd., which is both our legal and commercial name. Compugen USA, Inc., our wholly owned
subsidiary, was incorporated in Delaware in March 1997 and is qualified to do business in California.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">D.
PROPERTY, PLANTS AND EQUIPMENT</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In December 2015, we moved to new facilities
in Holon, Israel where we leased an aggregate of approximately 35,250 square feet of office, biology laboratory facilities and warehouse.
Following the exercise of our first option, we lease 30,140 square feet under that lease that expires on March 14, 2026 (with an option
to extend the lease for additional five-year period). In addition, Compugen USA, Inc. currently leases approximately 400 square feet of
office space in San Francisco, California, under a lease that expires on October 31, 2025.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">To our knowledge, there are no environmental
issues that affect our use of the properties that we lease.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">ITEM 4A.</span><span style="font-family: Times New Roman,Times,serif"><span id="ITEM4A."><!--Anchor--></span>&#160;&#160;&#160;&#160;&#160;&#160;
<span style="font-weight: bold">UNRESOLVED STAFF COMMENTS</span></span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">None</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">ITEM 5.</span><span style="font-family: Times New Roman,Times,serif"><span id="ITEM5."><!--Anchor--></span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<span style="font-weight: bold">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</span></span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-style: italic">The
following discussion of our operating and financial review and prospects should be read in conjunction with our consolidated financial
statements and related notes, prepared in accordance with U.S. GAAP as of December 31, 2022, and with any other financial data included
elsewhere in this Annual Report</span><span style="font-family: Times New Roman,Times,serif">.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Background</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif">

<div style="line-height: 1.25"><span style="color: #000000">We are a clinical-stage therapeutic discovery and development company utilizing
our broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop
therapeutics in the field of cancer immunotherapy. Our innovative immuno-oncology pipeline consists of three clinical stage programs,
targeting immune checkpoints we discovered computationally by COM701, COM902 and </span><span style="font-family: Times, &apos;Times New Roman&apos;, serif; color: #000000">rilvegostomig</span><span style="color: #000000">.
Our lead product candidates, COM701, a potential first-in-class anti-PVRIG antibody, and COM902, a potential best-in-class therapeutic
anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in
combination of dual (PVRIG/PD-1, PVRIG/TIGIT) and triple (PVRIG/PD-1/TIGIT) blockade. Based on the data from the Phase 1 trials and as
part of our corporate focus on two specific tumor types for the further clinical evaluation of COM701 and COM902, we intend to initiate
two clinical trials evaluating the triple combination treatment of COM701, COM902 and pembrolizumab, one in metastatic microsatellite
stable colorectal cancer patients and one in platinum resistant ovarian cancer patients. We plan to dose first patient to these trials
in the first quarter of 2023 and in the second quarter of 2023, respectively. As part of Phase 1 clinical trials for our lead product
candidates, COM701, we evaluated COM701 as a monotherapy and under clinical collaboration with Bristol Myers Squibb Company in combination
with nivolumab &#177; Bristol Myers Squibb investigational anti-TIGIT, BMS-986207. Following the termination of our collaboration with
Bristol Myers Squibb Company, these combination studies are being wound down while the monitoring of patients on study treatment is ongoing.
</span><span style="font-family: Times, &apos;Times New Roman&apos;, serif; color: #000000">Rilvegostomig,</span>&#160;<span style="color: #000000">a
novel anti PD-1/TIGIT bispecific antibody with a TIGIT-specific component that is derived from our COM902 antibody, is being developed
by AstraZeneca pursuant to an exclusive license agreement between us and AstraZeneca and is in Phase 2 clinical trial in patients with
advanced or metastatic non-small cell lung cancer and locally advanced or metastatic gastric cancer. Our therapeutic pipeline of early-stage
immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance. Our most advanced early-stage
program, COM503, is a potential first-in-class high affinity antibody, which blocks the interaction between IL-18 binding protein and
IL-18, thereby releasing the natural IL-18 into the tumor microenvironment to inhibit cancer growth. COM503 is being advanced into IND
enabling studies and we plan to file an IND in 2024. Our business model is to selectively enter into collaborations for our novel targets
and drug product candidates at various stages of research and development under various revenue-sharing arrangements. Integrating cutting
edge computational capabilities with ground-breaking immuno-oncology research and drug development expertise is our differentiator and
has enabled the advancement of three drug targets from computer prediction through successful preclinical studies to the clinic and as
a result, we believe that we are uniquely positioned to discover and develop potential new, first-in-class treatment options for cancer
patients.</span></div>

<div style="line-height: 1.25">&#160;</div> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">65</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">A. OPERATING RESULTS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Overview</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Since our inception, we have incurred significant
losses and, as of December 31, 2022, we had an accumulated deficit of $455.8 million. We expect to continue to incur net losses for the
foreseeable future.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">While
our predictive computational discovery capabilities have potentially broad applicability and is not limited to a certain indication or
therapeutic field, we focus our predictive computational discovery efforts on the discovery of novel drug targets and new biological pathways
towards the development of new therapeutic antibodies for cancer, a significant unmet medical need for cancer patients. We have discovered
three new targets through computational prediction with three different product candidates being clinically evaluated, supporting the
power and validity of our computational capabilities.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">In
2013 we entered into our first collaboration based on novel targets identified by us. Under the Bayer Collaboration, we jointly worked
with Bayer on the preclinical development of bapotulimab. Over the years, we have significantly increased our research activities in the
field of immuno-oncology to identify novel drug targets and develop first-in-class therapeutics in the field of cancer immunotherapy.
In 2018, we entered into two agreements with leading pharmaceutical companies, an MCTC with Bristol Myers Squibb in connection with our
lead immuno-oncology program, COM701, and an exclusive license agreement with AstraZeneca for the development of bi-specific and multi-specific
antibody products derived from our COM902. We also engage in collaborations with a leading academic research center in the United States
to advance our research and development efforts.&#160;We incurred net losses of approximately $29.7 million in 2020, approximately $34.2
million in 2021 and approximately $33.7 million in 2022. We expect to continue to incur net losses for the foreseeable future due in part
to the costs and expenses associated with our research, development and discovery activities. While we currently have only one collaboration
with AstraZeneca, our business model primarily involves establishing collaborations for our novel targets and therapeutic product candidates
at various stages of research and development providing us with potential milestone payments and royalties on product sales or other forms
of revenue sharing payments.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Our research and development expenses are
expected to continue to be our major operating expense in 2023, expected to account for approximately 75% of our expected total 2023 operating
expenses. Our research and development expenditures have always comprised a significant portion of our total cash expenditures, and they
are expected to remain in 2023 at similar level compared to 2022.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We believe that we have sufficient cash
and cash equivalents and short-term bank deposits in order to sustain our operations at least through the end of 2024, based on our current
plans. For a detailed description of our cash and cash equivalents position, see &#8220;Item 5. Operating and Financial Review and Prospects
- B. Liquidity and Capital Resources.&#8221;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Years
Ended December 31, 2022 and 2021</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-style: italic">Revenues.</span><span style="font-family: Times New Roman,Times,serif">
Revenues for the year ended December 31, 2022, were $7.5 million, compared with $6.0 million in the comparable period of 2021. The revenues
for 2022 and 2021 reflect clinical milestones from the license agreement with AstraZeneca.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-style: italic">Cost
of Revenues. </span><span style="font-family: Times New Roman,Times,serif">During the year ended December 31, 2022, the Company had approximately
$1.0 million in cost of revenues compared with approximately $0.7 million cost of revenues in the comparable period of 2021. Cost of revenues
for the years ended December 31, 2022 and 2021, represents milestone and royalty payments in connection with our revenues.</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">66</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-style: italic">Research
and Development Expenses. </span><span style="font-family: Times New Roman,Times,serif">Research and development expenses during 2022
increased by 7% and totaled approximately $30.6 million compared with approximately $28.7 million in the comparable period of 2021. The
increase is mainly due to higher expenses associated with our preclinical and CMC activities, offset by higher Bristol Myers Squibb participation
in R&amp;D expenses. Research and development expenses, as a percentage of total operating expenses, were 73% in 2022 compared to 71%
in 2021.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-style: italic">Marketing
and Business Development Expenses</span><span style="font-family: Times New Roman,Times,serif">. Marketing and business development expenses
increased by 11% and totaled in approximately $0.9 million in 2022 compared with approximately $0.8 million in the comparable period of
2021. Marketing and business development expenses, as a percentage of total operating expenses, were 2% in 2022 and 2021.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-style: italic">General
and Administrative Expenses. </span><span style="font-family: Times New Roman,Times,serif">General and administrative expenses during
2022 decreased by 5% and totaled approximately $10.3 million in 2022 compared with approximately $10.9 million in the comparable period
of 2021. The decrease during 2022 was attributed mostly to decrease in D&amp;O insurance premium costs (that effected our industry) and
non-cash stock option related expenses. General and administrative expenses, as a percentage of total operating expenses, were 25% in
2022 compared to 27% 2021.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-style: italic">Financial
Income (loss), Net. </span><span style="font-family: Times New Roman,Times,serif">Financial and other income increased to approximately
$1.7 million in 2022 from approximately $0.9 million in the comparable period of 2021. The increase is attributed mainly to increased
interest income due to higher interest rates in the market offset by lower level of cash and deposits balances.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-style: italic">Taxes
on Income. </span><span style="font-family: Times New Roman,Times,serif">Taxes on income were approximately $0.1 million in 2022. The
taxes on income represent state income taxes of our U.S. subsidiary.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Years
Ended December 31, 2021 and 2020</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-style: italic">Revenues.</span><span style="font-family: Times New Roman,Times,serif">
Revenues for the year ended December 31, 2021, were $6.0 million, compared with $2.0 million in the comparable period of 2020. The revenues
for 2021 reflect a $6.0 million clinical milestone from the license agreement with AstraZeneca.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-style: italic">Cost
of Revenues. </span><span style="font-family: Times New Roman,Times,serif">During the year ended December 31, 2021, the Company had approximately
$0.7 million in cost of revenues compared with approximately $0.1 million cost of revenues in the comparable period of 2020. Cost of revenues
for the year ended December 31, 2021, represents milestone and royalty payments in connection with our revenues.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-style: italic">Research
and Development Expenses. </span><span style="font-family: Times New Roman,Times,serif">Research and development expenses during 2021increased
by 26% and totaled approximately $28.7 million compared with approximately $22.8 million in the comparable period of 2020. The increase
is mainly due to higher expenses associated with our various clinical studies, preclinical and CMC activities and headcount related to
our U.S.-based clinical team. Research and development expenses, as a percentage of total operating expenses, were 71% in 2021 compared
to 68% in 2020.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-style: italic">Marketing
and Business Development Expenses</span><span style="font-family: Times New Roman,Times,serif">. Marketing and business development expenses
were approximately $0.8 million in 2021 compared with approximately $0.9 million in the comparable period of 2020. Marketing and business
development expenses, as a percentage of total operating expenses, were 2% in 2021 compared to 3% in 2020.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-style: italic">General
and Administrative Expenses. </span><span style="font-family: Times New Roman,Times,serif">General and administrative expenses during
2021 increased by 11% and totaled approximately $10.9 million in 2021 compared with approximately $9.8 million in the comparable period
of 2020. The increase during 2021 was attributed mostly to increased D&amp;O insurance premium costs (that effected our industry) and
non-cash stock option related expenses. General and administrative expenses, as a percentage of total operating expenses, were 27% in
2021 compared to 29% 2020.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-style: italic">Financial
Income (loss), Net. </span><span style="font-family: Times New Roman,Times,serif">Financial and other income decreased to approximately
$0.9 million in 2021 from approximately $1.8 million in 2020. The decrease is attributed mainly to decreased interest income due to lower
interest rates in the market and lower level of cash and deposits balances.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Governmental
Policies that Materially Affected or Could Materially Affect Our Operations</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Our income tax obligations consist of those
of Compugen Ltd. in Israel and of Compugen USA, Inc. in its taxing jurisdictions.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">67</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The corporate tax rate in Israel was 23%
in 2022, 2021 and 2020.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">In
the future, if and when we generate taxable income, our effective tax rate may be influenced by, among others: (a) the split of taxable
income between the various tax jurisdictions; (b) the availability of tax loss carry forwards and the extent to which valuation allowance
has been recorded against deferred tax assets; (c) the portion of our income which is entitled to tax benefits pursuant to the Investment
Law; (d) the changes in the exchange rate of the dollar to the NIS and (e) the Company&#8217;s election to submit its tax returns for
2014 and onwards on a dollar basis, which may not be accepted by the Israeli Tax Authority. We may benefit from certain government programs
and tax legislation, particularly as a result of the Benefiting Enterprise status that resulted from our eligibility for tax benefits
under the Investment Law. To be eligible for these benefits, we need to meet certain conditions. Should we fail to meet such conditions,
these benefits could be cancelled, and we might be required to refund the amount of the benefits previously received, if any, in whole
or in part, together with interest and linkage differences to the Israeli CPI, or other monetary penalty. We also benefit from a Government
of Israel program under which we received grants from the IIA. For more information, please see &#8220;Item 5 Operating and Financial
Review and Prospects - C. Research and Development, Patents and Licenses - The Israel Innovation Authority.&#8221; There can be no assurance
that these programs and tax legislation will continue in the future or that the available benefits will not be reduced.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The termination or curtailment of these
programs or the loss or reduction of benefits under the Investment Law could have a material adverse effect on our business, financial
condition and results of operations.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Currently we have one Benefiting Enterprise
program under the Investment Law. The tax benefits period with respect to this program has not yet begun as we have not yet generated
any taxable income. These benefits should result in income recognized by us being tax exempt or taxed at a lower rate for a specified
period of time after we begin to report taxable income and exhaust any net operating loss carry-forward. However, these benefits may not
be applied to reduce the U.S. federal tax rate for any income that our U.S. subsidiary may generate.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In April 2005, substantive amendments to
the Investment Law came into effect. Under these amendments, eligible investment programs of the type in which we participated prior to
the amendment were eligible to qualify for substantially similar benefits as a &#8216;Benefiting Enterprise&#8217;, subject to meeting
certain criteria. This replaced the previous terminology of &#8216;Approved Enterprise&#8217;, which required pre-approval from the Investment
Center of the Ministry of the Economy of the State of Israel. As a result of these amendments, tax-exempt income generated from Benefiting
Enterprises under the provisions of the amended law will, if distributed upon liquidation or if paid to a shareholder for the purchase
of his or her shares, be deemed distributed as a dividend and will subject the Company to the applicable corporate tax that would otherwise
have been payable on such income. Therefore, a company may be required to record deferred tax liability with respect to such tax-exempt
income, which would have an adverse effect on its results of operations.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Additional amendments to the Investment
Law became effective in January 2011 and were further amended in August 2013, or the 2011 Amendment. Under the 2011 Amendment, income
derived by &#8216;Preferred Companies&#8217; from &#8216;Preferred Enterprises&#8217; (both as defined in the 2011 Amendment) would be
subject to a uniform rate of corporate tax for an unlimited period as opposed to the incentives prior to the 2011 Amendment that were
limited to income from Approved or Benefiting Enterprises during their benefits period. According to the 2011 Amendment, the uniform tax
rate on such income, referred to as &#8216;Preferred Income&#8217;, would be 10% in areas in Israel that are designated as Development
Zone A and 15% elsewhere in Israel during 2011-2012, 7% and 12.5%, respectively, in 2013, and 9% and 16%, respectively, thereafter. Income
derived by a Preferred Company from a &#8216;Special Preferred Enterprise&#8217; (as defined in the Investment Law) would enjoy further
reduced tax rates for a period of ten years of 5% in Development Zone A and 8% elsewhere. As of January 1, 2014, dividends distributed
from Preferred Income would subject the recipient to a 20% tax (or lower, if so provided under an applicable tax treaty), which would
generally be withheld by the distributing company, provided however that dividends distributed from &#8216;Preferred Income&#8217; from
one Israeli corporation to another, would not be subject to tax<span style="font-size: 7pt">. </span>Under the transitional provisions
of the 2011 Amendment, companies may elect to irrevocably implement the 2011 Amendment with respect to their existing Approved and Benefiting
Enterprises while waiving benefits provided under the legislation prior to the 2011 Amendment or keep implementing the legislation prior
to the 2011 Amendment. Should a company elect to implement the 2011 Amendment with respect to its existing Benefiting Enterprises prior
to June 30, 2015 dividends distributed from taxable income derived from Benefiting Enterprises to another Israeli company would not be
subject to tax. While a company may incur additional tax liability in the event of distribution of dividends from tax exempt income generated
from its Benefiting Enterprise, as previously described, no additional tax liability will be incurred by a company in the event of distribution
of dividends from Preferred Income. We have not elected to implement the 2011 Amendment and we do not currently have any Preferred Enterprises.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">68</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In December 2016, the Economic Efficiency
Law (Legislative Amendments for Applying the Economic Policy for the 2017 and 2018 Budget Years), 2016 which includes Amendment 73 to
the Law, or Amendment 73, was published. According to Amendment 73, a Preferred Enterprise located in development area A will be subject,
under certain conditions, to a tax rate of 7.5% instead of 9% effective from January 1, 2017, and thereafter (the tax rate applicable
to preferred enterprises located in other areas remains at 16%). Amendment 73 also prescribes special tax tracks for Technological Enterprises,
which are subject to regulations issued by the Minister of Finance on May 16, 2017.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The new tax tracks under the Amendment are
as follows:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Technological Preferred Enterprise - an
enterprise for which total consolidated revenues of its parent company and all subsidiaries are less than NIS 10 billion. A Technological
Preferred Enterprise, as defined in the Law, which is located in the center of Israel will be subject to tax at a rate of 12% on profits
deriving from intellectual property (in development area A - a tax rate of 7.5%).</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Special Technological Preferred Enterprise
- an enterprise for which total consolidated revenues of its parent company and all subsidiaries exceed NIS 10 billion. Such enterprise
will be subject to tax at a rate of 6% on profits deriving from intellectual property, regardless of the enterprise&#8217;s geographical
location.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Any dividends distributed to &#8220;foreign
companies&#8221;, as defined in the Law, deriving from income from the Technological Enterprises will be subject, under certain conditions,
to tax at a rate of 4%.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">As of December 31, 2022, our net operating
loss carry-forward for Israeli tax purposes amounted to approximately $398.1 million. Under Israeli law, these net operating losses may
generally be carried forward indefinitely and offset against certain future taxable income.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">As of December 31, 2022, the net operating
loss carry-forward of our U.S. subsidiary for federal income tax purposes amounted to approximately $0.7 million.<span style="font-style: italic">&#160;</span>These
losses may be carried forward indefinitely, but the deductibility of such federal net operating losses may be limited.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Use of our U.S. net operating losses may
be subject to substantial annual limitation due to the &#8220;change in ownership&#8221; provisions of the Code and similar state provisions.
The annual limitation may result in the expiration of net operating losses before utilization.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">For a description of Israel government policies
that affect our research and development expenses, and the financing of our research and development, see &#8220;Item 5. Operating and
Financial Review and Prospects - C. Research and Development, Patents and Licenses - The Israel Innovation Authority.&#8221;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">B.
LIQUIDITY AND CAPITAL RESOURCES</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Public
Offering of Ordinary Shares</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">Registered Direct Offering</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">On June 14, 2018, we entered into a definitive
securities purchase agreement with certain institutional investors and a placement agency agreement with JMP Securities LLC, in connection
with a registered direct offering which resulted in the issuance of 5,316,457 of our ordinary shares at a purchase price of $3.95 per
share. In connection with the issuance of the ordinary shares, we also issued warrants to purchase up to approximately 4.3 million additional
ordinary shares. The warrants have an exercise price of $4.74 per share and have a term of five years from the date of issuance. Gross
proceeds from the sale of the ordinary shares were approximately $21 million, before deducting placement agent discounts and commissions
and offering expenses paid by us.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">During 2020, the Company issued and sold
3,866,139 ordinary shares underlying 3,866,139 warrants (with proceeds of approximately $18.3 million). During 2021, the Company issued
and sold 89,557 ordinary shares underlying 89,557 warrants (with proceeds of approximately $0.4 million). As of December 31, 2022, 297,469
warrants remained outstanding.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">Public Offering</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">On March 11, 2020, we entered into an underwriting
agreement with SVB Securities LLC (previously known as SVB Leerink LLC) and Stifel,&#160;Nicolaus &amp; Company, Incorporated, as representatives
of the several underwriters named therein, for the issuance and sale in a public offering of 8,333,334 of our ordinary shares at a price
to the public of $9.00 per share. In addition, we granted the underwriters a 30-day option to purchase up to 1,250,000 additional ordinary
shares at the public offering price, less the underwriting discounts and commissions.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">69</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In this underwritten public offering we
issued a total of 8,816,339 ordinary shares (including the shares issued upon exercise of the underwriters&#8217; option) at said $9.00
price per share. Gross proceeds from the sale of the ordinary shares were approximately $79 million, before deducting underwriting discounts
and commissions and offering expenses paid by us.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">Sales Agreement with
SVB Securities LLC</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">On January 31, 2023, we entered into a Sales
Agreement, or the Sales Agreement with SVB Securities LLC, or SVB, as sales agent, pursuant to which we may offer and sell, from time
to time through SVB, our ordinary shares. The offer and sale of our ordinary shares, if any, will be made pursuant to the our shelf registration
statement on Form F-3, as supplemented by the prospectus supplement filed on January 31, 2023. Pursuant to the said prospectus supplement,
we may offer and sell up to $50 million of our ordinary shares.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We are not obligated to make any sales under
the Sales Agreement and no assurance can be given that we will sell any ordinary shares under the Sales Agreement, or, if we do, as to
the price or number of ordinary shares that we will sell, or the dates on which any such sales will take place.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">As of February 27, 2023, the Company has
not sold any ordinary shares through the Sales Agreement.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Shelf
Registration Statement</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">On
July 30, 2020, we filed a shelf registration statement on Form F-3 with the SEC under which we may offer and sell from time to time in
one or more offerings, our ordinary shares, debt securities, rights, warrants and units having an aggregate offering price of up to $350
million. Under this Form F-3 we also registered up to 749,104&#160;ordinary shares underlying the warrants issued in our registered direct
offering in June 2018. This registration statement was declared effective by the SEC on August 7, 2020.&#160; Although we believe that
we have sufficient cash and cash equivalents and short-term bank deposits in order to sustain our operations at least through the end
of 2024, based on our current plans, we may seek additional capital or strategic considerations. <span style="font-weight: bold; font-style: italic">Securities
Purchase Agreement</span></span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">Bristol Myers Squibb
Securities Purchase Agreement</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">On November 10, 2021, the Company and Bristol
Myers Squibb entered into a securities purchase agreement pursuant to which Bristol Myers Squibb made a $20 million investment in Compugen
comprised of the purchase of 2,332,815 ordinary shares of Compugen at $8.57333 per share, which represented a 33% premium over the closing
price of our ordinary shares on the last trading day immediately prior to the execution of this agreement. This investment is in addition
to Bristol Myers Squibb&#8217;s $12 million investment (at $4.95 per share, which represented a 33% premium over the average closing price
on the last 20 Nasdaq trading days prior to signing) that took place in October 2018.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">License
Agreement</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic">AstraZeneca License
Agreement</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">On
March 30, 2018, the Company and AstraZeneca, entered into an exclusive license agreement to enable the development of bi-specific and
multi-specific immuno-oncology antibody products&#160;based on the Company&#8217;s monospecific antibodies that bind to TIGIT, including
COM902, pursuant to which the Company received an upfront payment of $10 million and is eligible to receive up to $200 million in development,
regulatory and commercial milestones for the first product as well as tiered royalties on future product sales, out of which we accrued
$2 million in 2020 as a preclinical milestone, $6 million in 2021 as a clinical milestone (triggered by the dosing of the first patient
in a Phase 1/2 trial evaluating rilvegostomig) and additional $7.5 million as a clinical milestone (triggered by the dosing of the first
patient in its ARTEMIDE Phase 2 trial evaluating rilvegostomig). If additional products are developed, additional milestones and royalties
would be due to us for each product. </span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Capital
Resources</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In 2022, our primary sources of cash were:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z48587b60826444ae994283b67c6814bc" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>cash at hand; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z98afd15ad39641e088078ac38a7f9f06" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>proceeds from AstraZeneca in connection with its 2022 milestone payment.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: -34pt; margin-left: 34pt; line-height: 1.25; font-family: Times New Roman,Times,serif">We
used these funds primarily to finance our business operations.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">70</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We expect that our sources of cash for 2023
will include cash held in our bank accounts. Additional sources of cash may include proceeds generated from agreements with collaborators
and other third parties with respect to our novel targets and therapeutic drug candidates and proceeds from issuance of ordinary shares
as a result of exercise of options, warrants and shares pursuant to our employee share purchase plan and/or from financing transactions.
In addition, if we choose to do so, we may generate proceeds from sales of our shares pursuant to the Sales Agreement.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Net
Cash Used in Operating Activities</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">Net
cash used in operating activities was approximately $28.3 million in 2020, approximately $22.8 million in 2021 and approximately $34.5
million in 2022. Increase in net cash used in 2022 compared to 2021 is mainly due to $5 million Bristol Myers Squibb participation in
R&amp;D expenses in 2021 and an increase in operating expenses, mainly expenses associated with our Phase 1 studies, preclinical activities
and headcount related expenses.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Net
Cash Provided by (used in) Investing Activities</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">Net
cash used by investing activities was approximately $82.2 million in 2020, compared with net cash provided in investing activities of
approximately $6.6 million in 2021 and $37.1 million in 2022. Changes in net cash during the years are affected by the level of cash in
the Company over the years which are deposited or withdrawn from bank deposits based on the cash needs to fund our operating activities.
During 2022 cash provided by investing activities was higher than prior year as a result of higher operating expenses and no fund raising
compared to $20 million investment by Bristol Myers Squibb in 2021.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif; font-style: italic"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Net
Cash Provided by Financing Activitie</span><span style="font-family: Times New Roman,Times,serif">s</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">Net
cash provided by financing activities was approximately $108.5 million in 2020, approximately $16.8 million in 2021 and approximately
$0.4 million in 2022. The principal source of cash provided by financing activities in 2022 was proceeds received from stock-based awards
exercises. The principal source of cash provided by financing activities in 2021 were the Bristol Myers Squibb investment and proceeds
received from stock-based awards exercises.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Net
Liquidity</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Liquidity refers to the liquid financial
assets available to fund our business operations and pay for near-term obligations. These liquid financial assets mostly consist of cash
and cash equivalents as well as short-term bank deposits. As of December 31, 2022, we had cash and cash equivalents and short-term bank
deposits of approximately $83.3 million compared to approximately $117.0 million on December 31, 2021. We believe that our existing cash
and cash equivalents, and short-term bank deposits will be sufficient to fund our operations over the next 12 months. We believe we will
meet longer-term expected future cash requirements at least through the end of 2024. We believe that our working capital is sufficient
for our present requirements.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The table below summarizes our contractual
obligations as of December 31, 2022 and should be read together with the accompanying comments that follow.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6555e624800344b8b3bccde6e493f415" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="18" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="line-height: 1.25"> </span></div>
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Payments due by period</div>
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">(US$ in thousands)</div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="line-height: 1.25"> </span></div> </div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="line-height: 1.25"> </span></div>
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Total</div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="line-height: 1.25"> </span></div> </div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="line-height: 1.25"> </span></div>
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Less than 1 year</div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="line-height: 1.25"> </span></div> </div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="line-height: 1.25"> </span></div>
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">1-3 years</div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="line-height: 1.25"> </span></div> </div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="line-height: 1.25"> </span></div>
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">3-5 years</div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="line-height: 1.25"> </span></div> </div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="line-height: 1.25"> </span></div>
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">More than 5 years</div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="line-height: 1.25"> </span></div> </div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 40%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Operating Lease Obligations<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup></div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">2,091</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">699</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">1,278</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">114</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 40%">
        <div style="line-height: 1.25">Accrued Severance Pay, net<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(2)</sup></div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">471</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">-</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">471</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 40%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Total</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">2,562</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">699</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">1,278</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">114</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">471</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: -14.15pt; margin-left: 28.35pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup>&#160;
Consists of operating leases for our facilities and for motor vehicles. Includes the first five-year option period of the lease of the
Israeli facility. The first option was exercised during 2020.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: -14.15pt; margin-left: 28.35pt; line-height: 1.25; font-family: Times New Roman,Times,serif"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(2)</sup>&#160;
Severance pay obligations to our Israeli employees. For more information please see &#8220;Item 6. Directors, Senior Management and Employees
&#8211; D. Employees.&#8221;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">71</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The above table does not include royalties
that we may be required to pay to the IIA. For more information, see &#8220;Item 5. Operating and Financial Review and Prospects - C.
Research and Development, Patents and Licenses.&#8221;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The above table also does not include contingent
contractual obligations or commitments that may enter into effect in the future, such as contractual undertakings to pay royalties subject
to certain conditions occurring.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Although we have sufficient cash and cash
equivalents and short-term bank deposits that we believe will enable us to fund our operations through at least the end of 2024, our ability
to fund our capital needs depends on our ongoing ability to generate cash from existing and future collaborations and from our ability
to raise additional funds.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">C.
RESEARCH AND DEVELOPMENT, PATENTS AND LICENSES</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We invest heavily in research and development.
Research and development expenses were our major operating expenses representing approximately 70% of total operating expenses in 2022,
2021 and 2020. Our research and development expenses, net, were approximately $30.6 million in 2022, compared to approximately $28.7 million
in 2021 and approximately $22.8 million in 2020. As of December 31, 2022, 46 of our employees were engaged in research and development
on a full-time basis. This represents approximately 70% of our entire work force at that time.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We focus our efforts on the development
of our discovery capabilities and related technologies, and the discovery and validation of our drug targets and the preclinical and clinical
development of the respective therapeutic product. Our pipeline programs continuously evaluate our computationally predicted drug target
candidates and are advancing selected drug target programs into preclinical and clinical development of therapeutic products. We expect
that in 2023 our research and development expenses will continue to be our major operating expense.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We believe that our future success will
depend, in large part, on our ability to discover promising drug target candidates and therapeutic product candidates and to successfully
advance the research and development of certain of our product candidates under our internal pipeline towards preclinical and clinical
studies and to successfully enter into revenue-sharing partnering agreements with pharmaceutical companies with respect to our product
candidates at the various development stages. In addition, we expect to continue to expand our discovery infrastructure and capabilities
which provide us with the underlying engine for the discovery of promising drug targets for our therapeutic pipeline.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Research and Development
Grants</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We have participated in programs offered
by the IIA that support research and development activities. See Note 7b to our 2022 consolidated financial statement. We have not applied
for additional grants from the IIA for research and technological development since 2012.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">The
Israel Innovation Authority</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The government of Israel encourages research
and development projects in Israel through the IIA, pursuant to and subject to the provisions of the R&amp;D Law. Under the R&amp;D Law,
research and development projects which are approved by the Research Committee of the IIA are eligible for grants, in exchange for payment
of royalties from revenues generated by the products developed within the framework of such approved project and subject to compliance
with certain requirements and restrictions under the R&amp;D Law as detailed below, which must generally continue to be complied with
even following full repayment of all IIA grants.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We received grants from the IIA for several
projects and may receive additional grants in the future. Under the terms of the grants received, we are required to pay royalties ranging
between 3% to 5% of the revenues we generate from our products which incorporate Financed Know-How, or IIA Products, until 100% of the
dollar value of the grant is repaid (plus LIBOR interest applicable to grants received on or after January 1, 1999). As of December 31,
2022, we received grants from the IIA in the principal amount of approximately $7.3 million. Therefore, our contingent obligation for
royalties, net of royalties already paid or accrued in the sum of approximately $2.0 million, along with the accumulated LIBOR interest
to date of approximately $4.3 million, totaled to approximately $9.6 million as of December 31, 2022.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In addition, the Company participated in
four MAGNET Consortium programs - Drugs and Diagnostic Kits, or DAAT Consortium, Tevel Biotechnology Consortium, Pharmalogica Consortium
and Rimonim Consortium &#8211; for which it received from the IIA a total amount of approximately $2.1 million, and in two MAGNETON programs,
for which it received from the IIA approximately $0.5 million. These grants do not bear any royalty obligations, but as the R&amp;D Law
applies to these programs, the restrictions on transfer of know-how or manufacturing outside of Israel, as detailed below, do apply. The
R&amp;D Law requires that the manufacture of IIA Products will be carried out in Israel, unless the IIA provides its approval to the contrary.
This approval may be subject to various conditions, including the repayment of increased royalties equal to up to 300% of the total grant
amount plus applicable interest and an increase of 1% in the royalty rate, depending on the extent of the manufacturing that is to be
conducted outside of Israel. The R&amp;D Law also provides that Financed Know-How and any right derived therefrom may not be transferred
to third parties, unless such transfer was approved in accordance with the R&amp;D Law. The Research Committee operating under the IIA
may approve the transfer of Financed Know-How between Israeli entities, provided that the transferee undertakes all the obligations in
connection with the grant as prescribed under the R&amp;D Law. In certain cases, the research committee may also approve a transfer of
the Financed Know-How outside of Israel, in both cases, subject to the receipt of certain payments calculated according to a formula set
forth in the R&amp;D Law. In the case of transfer outside of Israel, a payment of up to 600% of the total amount of grants plus applicable
interest; and in the case the R&amp;D activity related to the know-how remains in Israel, a payment of up to 300% of such total amount.
These approvals are not required for the sale or export of any products resulting from such R&amp;D activity or based on such Financed
Know-How. In addition, the government of Israel may from time to time audit sales of products which it claims incorporate Financed Know-How
and this may lead to royalties being payable on additional products, and may subject such products to the restrictions and obligations
specified hereunder. Failure to comply with the requirements under the R&amp;D Law may subject us to financial sanctions, to mandatory
repayment of grants received by us (together with interest and penalties), as well as expose us to criminal proceedings.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">72</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">At the end of 2021, the publication of the
LIBOR ceased, and alternative interests were applied throughout the worldwide economy, including the SOFR interest. As of the date of
this Annual Report, the IIA has not yet published the alternative interest that will be applied on the grants that the Company received
from the IIA. While the effect that the replacement of the LIBOR interest will have on the Company remains uncertain as of the date of
this Annual Report, the Company assesses that such change will not have a material effect on its operations and financial condition in
light of the common interests in the market.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times, serif"><span style="font-family: Times New Roman,Times,serif">For
a discussion regarding the effects of the grants we received from the IIA on our business, see &#8220;Item 3. Key Information &#8211;
D. Risk Factors - Risks Related to Operations in Israel -<span style="font-weight: bold">&#160;</span>We received grants from the IIA
that may expose us to payment of royalties and restrict the transfer of know-how that we develop.&#8221;</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">D.
TREND INFORMATION</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We are a clinical development stage company
and it is not possible for us to predict with any degree of accuracy the outcome of our research and development efforts. As such, it
is not possible for us to predict with any degree of accuracy any significant trends, uncertainties, demands, commitments or events that
are reasonably likely to have a material effect on our net loss, liquidity or capital resources, or that would cause financial information
to not necessarily be indicative of future operating results or financial condition. However, subject to such limitation, we did identify
certain trends that may have an effect on us, some of which are as specified below, and as covered in the risk factors set forth under
&#8220;Item 3. Key Information - D. Risk Factors&#8221;.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Access
to Additional Funds</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Should we need to secure additional sources
of liquidity, we believe that we could finance our needs through the issuance of equity securities, including through our Sales Agreement
with SVB, debt securities or other arrangements. However, we cannot guarantee that we will be able to obtain financing through the issuance
of any of the above arrangements on reasonable terms. The COVID-19 pandemic, including the variants to COVID-19 and government actions
implemented as a result thereof, together with the ongoing Russia and Ukraine conflict and other global economic factors, have caused
a negative impact on the outlook for the global economy and created significant volatility and disruption of financial markets. In addition,
many countries across the globe, including the United States and Israel, are seeing an increase in inflation. An extended period of economic
disruption, including a continued market downfall, could materially affect our ability to secure additional funds and could further materially
affect our business, strategy, results of operations and financial condition.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">With the exception of the resulting economic
impact of the Russia and Ukraine conflict, our operations and business to date have not been impacted. However, should this conflict persist
or expand to include additional countries or regions, or should the downfall in the market continue, we could be impacted. We will continue
to assess global and regional conflicts and any impact they may have on our ability to access additional funds. <br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">73</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Unfavorable Global or
Domestic Political or Economic Conditions </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; margin-right: 1pt; line-height: 1.25; font-family: Times New Roman,Times,serif">The global economy continues
to experience significant volatility, and the economic environment may continue to be, or become, less favorable than that of past years.
Higher costs for goods and services, inflation, deflation, the imposition of tariffs or other measures that create barriers to or increase
the costs associated with international trade, overall economic slowdown or recession and other economic factors in Israel, the U.S. or
in any other markets in which we operate could adversely affect our operations and operating results and can result in increased operations
costs. In addition, recent political and civil actions in Israel during the month of January and February 2023, resulting from, among
other things, proposed changes to certain Israeli constitutional legislation, may have an adverse effect on the Israeli social, economic
and political landscape and in turn, on us, and may cause, among other things, to major devaluation in the NIS.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Exchange
Rate</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">A significant portion of our expenses is
denominated in currencies other than the dollar. The Company is therefore subject to non-U.S. currency risks and non-U.S. exchange exposure,
especially the NIS. Exchange rates can be volatile and a substantial change of foreign currencies against the dollar could increase or
reduce the Company&#8217;s expenses and net loss and impact the comparability of results from period to period. The appreciation (devaluation)
of the dollar against the NIS was 13.2%, (3.3%) and (7.0%) in 2022, 2021 and 2020, respectively. For example, for the year ended December
31, 2021, assuming a 10% devaluation of the dollar against the NIS, we would have experienced an increase in our net loss of approximately
$1.4 million, while assuming a 10% appreciation of the dollar against the NIS, we would experience a decrease in our net loss of approximately
$1.1 million. For more information regarding exchange rate risk please see &#8220;Item 11. Quantitative And Qualitative Disclosures About
Market Risk &#8211; Interest Rate Risk.&#8221;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Interest
rate</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">A significant portion of our cash and cash
equivalents is invested in bank deposits and bear interest. The Company&#8217;s financial income is therefore subject to interest rate
risk. Interest rates can be volatile, and a substantial change in interest rates could increase or reduce the Company&#8217;s financial
income and net loss. In addition to the impact on our cash and cash equivalents, rising interest rates, or the perception thereof, may
have wide economic impacts, including an adverse impact on capital markets, the price of our shares and on supplies that we require to
conduct our different operations. For more information regarding interest rate risk please see &#8220;Item 11. Quantitative And Qualitative
Disclosures About Market Risk &#8211; Interest Rate Risk.&#8221;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Trend
Towards Biologics</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times, serif"><span style="font-family: Times New Roman,Times,serif">Biologics
(monoclonal and bispecific antibodies, ADCs, enzymes and pegylated proteins) represent one of the fastest growing segments in the drug
industry, making up 29% of FDA approved drugs in 2022. The growth of this class has driven a large number of companies to invest in new
technologies (e.g., bi-specific monoclonal antibodies, multi-specific antibodies, antibody fragments) and new approaches to fully exploit
the potential of this class. In addition, the striking efficacy and recent approval ofcell therapies for the treatment of cancer, such
as CAR-T therapies, has also captured much attention in the pharma industry. The availability of such new technologies and approaches
to address drug targets may increase the differentiation and attractiveness of our novel therapeutic candidates. </span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">E.
CRITICAL ACCOUNTING ESTIMATES</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The preparation of our consolidated financial
statements and other financial information appearing in this Annual Report requires our management to make estimates and judgments that
affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities.
We evaluate on an on-going basis these estimates, mainly related to share-based payments, deferred participation in research and development
expenses, revenue recognition, and research and development expenses.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We base our estimates on our experience
and on various assumptions that we believe are reasonable under the circumstances. The results of our estimates form the basis for our
management&#8217;s judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual
results may differ from these estimates under different assumptions or conditions.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">74</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Share
Based Payments</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">We
account for stock-based compensation in accordance with ASC 718, &#8220;Compensation - Stock Compensation&#8221;, or ASC 718, which requires
companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. We account for
forfeitures as they occur. The value of the pro-rata portion of the award, assuming no forfeiture, is recognized in our consolidated statement
of comprehensive loss as an expense over the requisite service periods. Upon forfeiture the expense is adjusted so that expense is recognized
for the portion of the award that actually vested.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We selected the Black-Scholes-Merthon option
pricing model as the most appropriate method for estimating the fair value of our share-based awards. The resulting cost of an equity
incentive award is recognized as an expense over the requisite service period of the award, which is usually the vesting period. We recognize
compensation expense over the vesting period using the straight-line method and classify these amounts in the consolidated financial statements
based on the department to which the related employee reports.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">This model evaluates the options as if there
is a single exercise point, and thus considers expected option life (expected term). The input factored in this model is constant for
the entire expected life of the option.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The determination of the grant date fair
value is affected by estimates and assumptions regarding a number of complex and subjective variables, including the expected term of
the options, the expected volatility of our share price over the expected term, risk-free interest rates and expected dividends. The computation
of expected volatility is based on historical volatility of our shares. The risk-free interest rate assumption is the implied yield currently
available on United States treasury zero-coupon issues with a remaining term equal to the expected life term of the options. We determined
the expected life of the options based on historical experience, representing the period of time that options granted are expected to
be outstanding.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Share-based compensation expense recognized
under ASC 718 was approximately $4.3 million, $4.3 million and $2.8 million for the years ended December 31, 2022, 2021 and 2020, respectively.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Revenue Recognition</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Our revenues are generated mainly from collaborative
and license agreements. In the agreements, revenues are typically derived mainly from upfront payment and contingent payments related
to milestone achievements.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The Company recognizes revenue in accordance
with ASC 606 - &#8220;Revenue from Contracts with Customers&#8221;.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">As such, the Company analyzes its collaborative
and license agreements to assess whether they are within the scope of ASC 606. In determining the appropriate amount of revenue to be
recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following five steps: (i) identification
of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination
of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition
of revenue when, or as, we satisfy a performance obligation.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The consideration promised in a contract
with a customer may include fixed amounts, variable amounts, or both. Variable consideration will only be included in the transaction
price when it is not considered constrained. We use assumptions to determine the standalone selling price of each performance obligation
identified in the contract. We then allocate the total transaction price to each performance obligation based on the estimated standalone
selling prices of each performance obligation. We recognize as revenue the amount of the transaction price that is allocated to the respective
performance obligation when the performance obligation is satisfied.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">After contract inception, the transaction
price is reassessed at every period end and updated for changes such as resolution of uncertain events. Any change in the transaction
price is allocated to the performance obligations on the same basis as at contract inception.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">In
December 2020 the program under the exclusive license agreement with AstraZeneca achieved a preclinical milestone and in September 2021
and in November 2022 such program achieved clinical milestones and in connection with such milestones, we recognized revenues in an amount
of $2 million, $6 million and $7.5 million, in the years 2020, 2021 and 2022, respectively, in accordance with the criteria prescribed
under ASC 606. See Note 2j to our 2022 consolidated financial statements.</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">75</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Research and Development
Expenses</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Research and development costs are charged
to the statement of comprehensive loss as incurred.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">The
Company accrues costs for pre-clinical and clinical trial activities based upon estimates of the services received and related expenses
incurred that have yet to be invoiced by the contract research organizations or other pre-clinical or clinical trial vendors that perform
the activities. In certain circumstances, the Company is required to make nonrefundable advance payments to vendors for goods or services
that will be received in the future for use in research and development activities. In such circumstances, the nonrefundable advance payments
are deferred and capitalized, even when there is no alternative future use for the research and development, until related goods or services
are provided.&#160;Payments made in advance of the performance of the related services are recorded as prepaid expenses until the services
are rendered.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The portion of the Bristol Myers Squibb
$12.0 million investment in 2018 over the fair market value of the shares issued in the amount of approximately $4.1 million and the portion
of the Bristol Myers Squibb $20.0 million investment in 2021 over the fair market value of the shares issued in the amount of $5.0 million
were considered as deferred participation of Bristol Myers Squibb in research and development expenses which is amortized over the period
of the clinical trial based on the progress in the research and development, in accordance with ASC 808 &#8220;Collaborative Arrangements&#8221;,
see Note 1f and Note 8b to our 2022 consolidated financial statements.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Amortization of participation in research
and development expenses for the years ended December 31, 2022, 2021 and 2020 were approximately $6.0 million, $1.3 million and $0.8 million,
respectively.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Recent Accounting Pronouncements</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">See Note 2s to our 2022 consolidated financial
statement.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">ITEM 6.</span><span style="font-family: Times New Roman,Times,serif"><span id="ITEM6."><!--Anchor--></span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<span style="font-weight: bold">DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</span></span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">A.
DIRECTORS AND SENIOR MANAGEMENT</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The following table sets forth information
with respect to Compugen&#8217;s directors and senior management as of February 9, 2023:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9c9f9d29518f4c629aa1020086dc00b5" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 40%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Name</div> </div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top; padding-bottom: 2px">&#160;</td>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 10%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Age</div> </div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top; padding-bottom: 2px">&#160;</td>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; width: 48%; vertical-align: top">
        <div style="line-height: 1.25">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Positions</div> </div>
        </td> </tr>
  <tr>
    <td style="width: 40%; vertical-align: middle; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25">Paul Sekhri<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(3)</sup></div>
        </td>
    <td colspan="1" style="width: 1%; vertical-align: middle; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="width: 10%; vertical-align: middle; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25">64</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: middle; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="width: 48%; vertical-align: middle; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Chairman of the Board of Directors (Chairman of the Nomination and Corporate Governance Committee)</div>
        </td> </tr>
  <tr>
    <td style="width: 40%; vertical-align: middle; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">Anat Cohen-Dayag, Ph.D.</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: middle; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 10%; vertical-align: middle; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">56</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: middle; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 48%; vertical-align: middle; font-family: Times New Roman,Times,serif">
        <div style="margin-right: 2.55pt; line-height: 1.25">President and Chief Executive Officer, Director</div> </td> </tr>
  <tr>
    <td style="width: 40%; vertical-align: middle; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Mathias Hukkelhoven, Ph.D.</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: middle; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="width: 10%; vertical-align: middle; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25">69</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: middle; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="width: 48%; vertical-align: middle; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="margin-right: 2.55pt; line-height: 1.25">Director</div> </td> </tr>
  <tr>
    <td style="width: 40%; vertical-align: middle; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">Gilead Halevy<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(2)</sup></div>
        </td>
    <td colspan="1" style="width: 1%; vertical-align: middle; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 10%; vertical-align: middle; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">56</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: middle; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 48%; vertical-align: middle; font-family: Times New Roman,Times,serif">
        <div style="margin-right: 2.55pt; line-height: 1.25">Director (Chairman of the Audit Committee)</div> </td> </tr>
  <tr>
    <td style="width: 40%; vertical-align: middle; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25">Kinneret Livnat Savitzky, Ph.D.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)(3)</sup></div>
        </td>
    <td colspan="1" style="width: 1%; vertical-align: middle; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="width: 10%; vertical-align: middle; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25">55</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: middle; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="width: 48%; vertical-align: middle; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Director</div> </td> </tr>
  <tr>
    <td style="width: 40%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">Eran Perry<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)(2)</sup></div>
        </td>
    <td colspan="1" style="width: 1%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 10%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">52</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 48%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Director</div> </td> </tr>
  <tr>
    <td style="width: 40%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25">Sanford (Sandy) Zweifach<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)(2)(3)</sup></div>
        </td>
    <td colspan="1" style="width: 1%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="width: 10%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25">66</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="width: 48%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Director (Chairman of the Compensation Committee)</div> </td> </tr>
  <tr>
    <td style="width: 40%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">Alberto Sessa</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 10%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">60</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 48%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Chief Financial Officer</div> </td> </tr>
  <tr>
    <td style="width: 40%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Henry Adewoye, MD</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="width: 10%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25">58</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="width: 48%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Senior Vice President and Chief Medical Officer</div> </td> </tr>
  <tr>
    <td style="width: 40%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Oliver Froescheis, Ph.D.<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(4)</sup></div>
        </td>
    <td colspan="1" style="width: 1%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 10%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">57</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 48%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Senior Vice President, Corporate and Business Development</div> </td> </tr>
  <tr>
    <td style="width: 40%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25">Zurit Levine, Ph.D.</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="width: 10%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25">55</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="width: 48%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Senior Vice President, Technology Innovation</div> </td> </tr>
  <tr>
    <td style="width: 40%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">Yaron Turpaz, Ph.D.</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 10%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">52</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 48%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Senior Vice President and Senior Advisor, Computational Discovery</div> </td> </tr>
  <tr>
    <td style="width: 40%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25">Eran Ophir, Ph.D.</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="width: 10%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25">45</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">&#160;</td>
    <td style="width: 48%; vertical-align: top; font-family: Times New Roman,Times,serif; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Senior Vice President, Research and Drug Discovery</div> </td> </tr>
  <tr>
    <td style="width: 40%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">Pierre Ferre, Ph.D.</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 10%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">46</div> </td>
    <td colspan="1" style="width: 1%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td style="width: 48%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Vice President, Preclinical Development</div> </td> </tr>
  </table>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">____________________</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="font: 9pt Times New Roman,Times,serif; width: 18pt; vertical-align: top">(1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="font-size: 9pt">
        <div style="line-height: 1.25">Member of our Compensation Committee</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="font: 9pt Times New Roman,Times,serif; width: 18pt; vertical-align: top">(2)</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="font-size: 9pt">
        <div style="line-height: 1.25">Member of our Audit Committee</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="font: 9pt Times New Roman,Times,serif; width: 18pt; vertical-align: top">(3)</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="font-size: 9pt">
        <div style="line-height: 1.25">Member of our Nomination and Corporate Governance Committee</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;

<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="font: 9pt Times New Roman,Times,serif; width: 18pt; vertical-align: top">(4)</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="font-size: 9pt">
        <div>Dr. Oliver Froescheis retired from his position on February 10, 2023.</div> </div> </td> </tr>
  </table>

<div style="line-height: 1.25">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman, Times, serif; color: #000000; font-weight: normal; font-style: normal">76</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div> </div> </div> </div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Paul
Sekhri </span><span style="font-family: Times New Roman,Times,serif">joined Compugen&#8217;s Board of Directors as its Chairman in October
2017. Mr. Sekhri serves as the President and Chief Executive Officer of vTv Therapeutics Inc. Prior to joining vTv Therapeutics Inc.,
from January 2019 until April 2022, Mr. Sekhri served as the President and CEO of eGenesis, Inc. since January 2019. Prior to joining
eGenesis, Inc., Mr. Sekhri served as President and CEO of Lycera Corp. from February 2015 through December 2018. From April 2014 through
January 2015, Mr. Sekhri served as Senior Vice President, Integrated Care for Sanofi. From May 2013 through March 2014, Mr. Sekhri served
as Group Executive Vice President, Global Business Development and Chief Strategy Officer for Teva Pharmaceutical Industries Ltd. Prior
to joining Teva, Mr. Sekhri spent five years as Operating Partner and Head of the Biotechnology Operating Group at TPG Biotech, the life
sciences venture capital arm of TPG Capital. From 2004 to 2009, Mr. Sekhri was Founder, President, and Chief Executive Officer of Cerimon
Pharmaceuticals, Inc. Prior to founding Cerimon, Mr. Sekhri was President and Chief Business Officer of ARIAD Pharmaceuticals, Inc. Previously,
Mr. Sekhri spent four years at Novartis, as Senior Vice President, and Head of Global Search and Evaluation, Business Development and
Licensing for Novartis Pharma AG. Mr. Sekhri also developed the Disease Area Strategy for Novartis, identifying those specific therapeutic
areas upon which the company would focus. Mr. Sekhri&#8217;s first role at Novartis was as Global Head, Early Commercial Development.
Mr. Sekhri completed graduate work in Neuroscience at the University of Maryland School of Medicine, where he also received his BS in
Zoology. Mr. Sekhri is currently a member of the Board of Directors of vTv Therapeutics Inc., eGenesis, Inc., Veeva Systems Inc., Ipsen
S.A., Oryn Therapeutics, LLC, Axcella Health Inc. and Spring Discovery</span><span style="font-family: Times New Roman,Times,serif; font-size: 11pt">&#160;</span><span style="font-family: Times New Roman,Times,serif">and
Chairman of the Board of Directors of Pharming N.V. and of Longboard Pharmaceuticals, Inc. Additionally, Mr. Sekhri is the Chairman of
the Board of the Young Concert Artists (YCA), and a member of Boards of The Metropolitan Opera. Mr. Sekhri is also an active member of
the Patrons Council of Carnegie Hall, where he established the Life Sciences Council of Carnegie Hall.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Anat
Cohen-Dayag, Ph.D. </span><span style="font-family: Times New Roman,Times,serif">joined Compugen&#8217;s Board of Directors in February
2014. Dr. Anat Cohen-Dayag has over 25 years of experience in the biotech industry, both in R&amp;D and executive leadership roles. Anat
joined Compugen in 2002, and has held various senior managerial positions, including VP R&amp;D, before being appointed President and
CEO in 2010. Under her leadership, Compugen transformed from a service provider in the field of computational biology to a therapeutic
discovery and development company advancing an innovative immuno-oncology pipeline originating from the company&#8217;s computational
discovery platforms. Anat joined Gamida Cell&#8217;s Board of Directors in January 2022, and she is also a member of the Board of Directors
of Pyxis Ltd. Prior to Compugen, Anat was the Head of R&amp;D and was a member of the executive management team of Mindsense Biosystems
Ltd. Anat holds a B.Sc. in Biology from Ben-Gurion University, and an M.Sc. in Chemical Immunology and a Ph.D. in Cellular Biology, both
from the Weizmann Institute of Science.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Dr.
Mathias (Math) Hukkelhoven </span><span style="font-family: Times New Roman,Times,serif">joined Compugen&#8217;s Board of Directors in
March 2022. Dr. Hukkelhoven has a wealth of experience in global regulatory affairs and drug development, evidenced by his contribution
to more than 50 NCEs and hundreds of new indications and line extensions over his career to date. Dr. Hukkelhoven has participated in
activities that have shaped health authority interactions for the industry, including serving as chairperson of the Regulatory Affairs
Coordinating Committee at PhRMA, and recently as a PhRMA negotiator for the PDUFA VII negotiations with the FDA. Since his retirement
from Bristol Myers Squibb in July 2021, Math has been a consultant for several biotech companies, R&amp;D Strategy Advisor for LianBio
and Senior Advisor for McKinsey and on July 1, 2022 he joined the Board of Directors of Centessa Pharmaceuticals plc. Math joined Bristol
Myers Squibb in March 2010 as the Senior Vice President, Global Regulatory, Safety &amp; Biometrics and was also responsible for the R&amp;D
group in BMS China and the Clinical Pharmacology and Pharmacometrics group. As such, he had responsibility for a large part of the global
Bristol Myers Squibb development organization. Since the acquisition of Celgene by Bristol Myers Squibb, he was responsible for Global
Regulatory and Safety Sciences at Bristol Myers Squibb. He was accountable for setting regulatory strategy and driving execution of global
regulatory and pharmacovigilance plans for Bristol Myers Squibb. He led the regulatory and development efforts across the product development
and commercialization process to ensure optimal regulatory strategy and interactions at each step of the process &#8211; research and
development, manufacturing, and commercialization. Prior to joining Bristol Myers Squibb, Math held the role of Chairman Portfolio Stewardship
Board at Novartis Pharmaceuticals. From 2001 to 2009, he was the Senior Vice President, Global Head Drug Regulatory Affairs at Novartis.
Math received&#160;his B.S. and Ph.D. honors degrees in Biology and Biochemistry from the University of Nijmegen, the Netherlands.</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">77</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Gilead
Halevy </span><span style="font-family: Times New Roman,Times,serif">joined Compugen&#8217;s Board of Directors in June 2018. Mr. Halevy
serves as a general partner of Kedma Capital Partners, a leading Israeli private equity fund, of which he is also a founding member, since
2006. Prior to establishing Kedma, Mr. Halevy served as a Director at Giza Venture Capital from 2001 to 2006, where he led investments
in communication and information technology companies and directed Giza&#8217;s European business activities. From 1998 to 2001, Mr. Halevy
practiced law at White &amp; Case LLP. Mr. Halevy was also a founding member of the White &amp; Case Israel practice group during that
time. Mr. Halevy currently serves as chairman of board of directors of Carmel Wineries; Continuity Software Ltd., Zriha Hlavin Industries
Ltd. and a director of S. AL Holdings. Mr. Halevy holds a B.A. in Humanities (multidisciplinary program for exceptional students) and
an LL.B. (Magna Cum Laude) both from the Hebrew University of Jerusalem.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Dr.
Kinneret Livnat Savitzky </span><span style="font-family: Times New Roman,Times,serif">joined Compugen&#8217;s Board of Directors in June
2018. Dr. Livnat Savitzky currently serves as a managing partner at Team8 and Director at Team8 Health, Partner 1 GP Ltd. Dr. Livnat Savitzky
also serves on the boards of the following biotechnology or healthcare companies: Ramot (TTO of Tel-Aviv University), Nutritional Growth
Solutions Ltd., DreaMed Diabetes Ltd., and Biomica Ltd. Between 2017 and 2021 she served as the CEO of FutuRx Ltd., an Israeli biotechnology
accelerator established by OrbiMed Israel Partners, Johnson &amp; Johnson Innovation, Takeda Ventures Inc., and LEAPS, the venture arm
of Bayer. From 2010 to 2016, Dr. Livnat Savitzky served as CEO of BioLineRX Ltd., a Nasdaq-listed drug development company focused on
oncology and immunology. During her tenure, BioLineRX signed a strategic collaboration with Novartis as well as licensing agreements with
Merck (MSD), Genentech and others. Prior to being appointed CEO of BioLineRX, Dr. Livnat Savitzky held various R&amp;D management positions
at BioLineRX and Compugen. Dr. Livnat Savitzky holds a B.Sc. in Biology from The Hebrew University of Jerusalem, and an M.S.c and Ph.D.
with distinction in Human Genetics from Tel Aviv University.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Eran
Perry </span><span style="font-family: Times New Roman,Times,serif">joined Compugen&#8217;s Board of Directors in July 2019. Eran Perry
brings to Compugen over 20 years of diverse experience across various segments of the healthcare industry as an entrepreneur and venture
capital investor as well as in general management and strategy. In 2018, Mr.&#160;Perry co-founded MII Fund &amp; Labs, a dermatology-focused
venture capital fund where he also serves as Managing Director and Chairman of the Investment Committee. Mr. Perry is also the co-founder
and board member of several pharmaceutical companies including Musli Thyropeutics, ICD Pharma, Seanergy Dermatology, Follicle Pharma and
Upstream Bio. Mr. Perry also serves on the board of directors of MyBiotics Pharma and Noon Aesthetics. From 2006 to 2016, he served as
Managing Director and Partner of Israel Healthcare Ventures (IHCV) and represented IHCV in numerous portfolio companies. Prior to IHCV,
Mr. Perry was a consultant in McKinsey &amp; Company, serving clients worldwide in the pharmaceutical industry, among others. Prior to
that, he was a member of the Global Marketing group at Novartis Oncology.&#160;Before moving to the private sector, Mr.&#160;Perry served
in the Israeli Ministry of Justice. Mr. Perry holds an MBA from Columbia University, and an LL.B. in Law and a B.Sc. in Mathematics and
Computer Science, both from Tel Aviv University.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Sanford
(Sandy) Zweifach </span><span style="font-family: Times New Roman,Times,serif">joined Compugen&#8217;s Board of Directors in June 2018.
Mr. Zweifach is the Founder of Nuvelution Pharma, Inc. and since 2015 through 2019 was the Chief Executive Officer of Nuvelution Pharma,
Inc. From 2010 to 2015, Mr. Zweifach served as CEO of Ascendancy Healthcare, Inc., which he also founded. He has also been a Partner at
Reedland Capital Partners, a boutique investment bank, from 2005 to 2010, where he headed its life sciences M&amp;A and advisory efforts.
From 2003 to 2005, he was CEO of Pathways Diagnostics, a biomarker development company. Mr. Zweifach was a Managing Director/CFO of Bay
City Capital, a venture capital/merchant banking firm, specializing in the biotech and the life science industry, where he was responsible
for oversight of the firm&#8217;s finance department, as well as President of the firm&#8217;s M&amp;A and financing division. Prior to
this, he was President and CFO of Epoch Biosciences, which was acquired by Nanogen in 2004. Currently Mr. Zweifach serves as an Executive
Chairman of the Board of Directors of Kaerus Bioscience, Chairman of the Board of Directors of Carisma Therapeutics, Inc., Acting President
and Chair of the Business Advisory Board of IMIDomics, S.L. and as a member of the Board of Directors of Essa Pharma, Inc. Earlier in
his career, Mr. Zweifach was a Certified Public Accountant (US) for Coopers &amp; Lybrand and held various investment banking positions
focusing on biotech. He received his B.A. in Biology from UC San Diego and an M.S. in Human Physiology from UC Davis.</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">78</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Alberto
Sessa</span><span style="font-family: Times New Roman,Times,serif"> joined Compugen in November 2022 as Chief Financial Officer. Alberto
brings more than 30 years of industry experience to Compugen by serving in public and private companies. Throughout his career he has
gained vast experience in leading financing, investor relations, M&amp;A, and business development transactions. He most recently served
as acting CFO at several startup companies in the high-tech industry. Prior to this, as CFO at Nasdaq and TASE listed Allot, he was instrumental
in helping turn around the company to reach a path of sustained growth. Previously, Alberto spent seven years as Worldwide Group CFO at
Nasdaq listed Amdocs with responsibility for the global financial business activities. Alberto holds a Master of Business Administration
and bachelor&#8217;s in economics and statistics from the Hebrew University of Jerusalem.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Dr.
Henry Adewoye </span><span style="font-family: Times New Roman,Times,serif">joined Compugen in March 2018 as Chief Medical Officer, bringing
to Compugen over 20 years of extensive experience in leading multiple clinical trials in Oncology and Hematology in both the biopharmaceutical
industry and academia. Before Compugen, Dr. Adewoye was with Gilead Sciences Inc., as Clinical Director in Oncology Clinical Research
and was on the Oncology Leadership Team. He most recently served as Project Team and Clinical Lead for Idelalisib (first-in-class PI3K
delta inhibitor approved for the treatment of relapsed CLL, FL/SLL) and Andecaliximab (MMP9 mAb inhibitor). Previously, he was Clinical
Research Medical Director in Oncology at Amgen Inc. Dr. Adewoye was the Global Medical Monitor for the initial registrational trial of
the bi-specific antibody blinatumomab (Blincyto&#174;) and several Phase 2 and 3 studies evaluating VEGF inhibitors (Motesanib, Trebananib)
in patients with solid tumors. Dr. Adewoye completed his fellowship in Hematology/Oncology at Boston Medical Center and completed his
residency in Internal Medicine at Meharry Medical College. Dr. Adewoye received his medical degree at the University of Jos, Nigeria and
Fellowship training in Hematology and Laboratory medicine at the University College Hospital Ibadan, Nigeria. Dr. Adewoye has initial
board certifications by the American Board of Internal Medicine in Medical Oncology, Hematology and Internal Medicine.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Oliver
Froescheis, Ph.D.</span><span style="font-family: Times New Roman,Times,serif"> joined Compugen in January 2020 as Senior Vice President,
Corporate and Business Development. Dr. Froescheis has over 20 years of experience in the pharmaceutical industry where he held positions
in research, project management, marketing and business development. Dr. Froescheis joined Compugen from Roche, where he spent the last
12 years in the Partnering organization, initially serving as Global Due Diligence Director for in-licensing and M&amp;A projects, then
acting as Director of Business Development &amp; Licensing, responsible for oncology/immuno-oncology partnering projects and most recently
leading R&amp;D out-licensing across therapeutic areas. Dr. Froescheis holds a Diploma in Chemistry and a Ph.D. in Analytical Chemistry,
both from the University of Ulm, Germany.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Zurit
Levine, Ph.D. </span><span style="font-family: Times New Roman,Times,serif">was appointed as Senior Vice President, Technology Innovation
in 2018, responsible for leading and advancing the Company&#8217;s computational innovation towards new discovery fields and areas. In
this capacity, Dr. Levine is also responsible for the Company&#8217;s IP strategy and portfolio. Dr. Levine joined Compugen in 1999 and
has held several positions in Compugen&#8217;s Research &amp; Development department. In 2004, she was appointed Director of Therapeutic
Selection &amp; Validation, which position she held until 2007 when she was appointed Director of Therapeutic Discovery. In 2009, she
was appointed Executive Director of Research &amp; Development. From January 2010 to August 2011, she held the position of Vice President,
Research and Development. In August 2011 she was appointed Vice President, Research and Discovery. Dr. Levine holds a B.Sc. in Biology,
a M.Sc. in Biochemistry and a Ph.D. in Biochemistry, all from the Tel Aviv University, Israel.</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">79</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Yaron
Turpaz, Ph.D.</span><span style="font-family: Times New Roman,Times,serif"> joined Compugen in November 2019 as Senior Vice President
and Senior Advisor, Computational Discovery. Dr. Turpaz has over 15 years of experience in the fields of research and development informatics,
data sciences and technology in the biotech and pharma space with hands-on experience using cloud based high throughput computational,
machine learning and genomics platforms for drug discovery and development applications in precision medicine. In his extensive pharma
and biotech career, he held senior R&amp;D Informatics roles at Human Longevity, AstraZeneca, Eli Lilly, Global Gene Corp. and Affymetrix.
Dr. Turpaz continues to serve as Chief Information Officer and Senior Advisor at Engine Biosciences. Dr. Turpaz received a B.Sc. in Biology
from Tel Aviv University, a Ph.D. in Bioengineering from the University of Illinois and an MBA from the University of Chicago, Booth School
of Business. He also held an Adjunct Assistant Professor position at the <span style="font-size: 9pt">Centre</span> for Quantitative Medicine
of Duke-National University of Singapore, Graduate Medical School.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Eran
Ophir, Ph.D.</span><span style="font-family: Times New Roman,Times,serif"> joined Compugen in 2015 and was appointed Vice President of
Research and Drug Discovery in March 2020 and became a Senior Vice President, of Research and Drug Discovery in March 2022. In his role,
Dr. Ophir is responsible for Compugen&#8217;s research and drug discovery activities, overseeing the research into the biology of Compugen&#8217;s
computationally discovered targets and therapeutic lead antibody identification and selection. Dr. Ophir brings significant expertise
in immunology and immuno-oncology from his research work at the Weizmann Institute of Science and the Ludwig Institute for Cancer Research
in Lausanne, Switzerland. Dr. Ophir joined Compugen&#8217;s immuno-oncology group as a senior scientist and has since held various positions
in the Research and Development department, with increasing responsibilities. Dr. Ophir received a B.Sc. in Bioinformatics from Tel Aviv
University and a Ph.D. in Biology from the Weizmann Institute of Science.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-weight: bold">Pierre
Ferre, Ph.D.</span><span style="font-family: Times New Roman,Times,serif"> joined Compugen in April 2021 as Vice President Preclinical
Development. Dr. Ferre has two decades of experience in all aspects of clinical and non-clinical drug development in oncology and immuno-oncology.
Dr. Ferre joined Compugen from Pierre Fabre Pharmaceuticals, France, where he spent most of his career in multiple positions, lastly as
Director of Oncology Programs in which he led the development strategy of a portfolio of R&amp;D programs in oncology from initiation
and discovery, through preclinical and clinical development. Previously, at Pierre Fabre Oncology R&amp;D, he acted as Director, Pharmacokinetics/Pharmacodynamics,
overseeing also translational, biomarker-related activities. Before that Dr. Ferre was in charge of oncology preclinical pharmacokinetics.
Dr. Ferre is a Doctor in Veterinary Medicine, holds a PhD in biology from Toulouse INP (Institut National Polytechnique), and a MSc from
Aix-Marseille University and Paris INA-PG (Institut National Agronomique) for his research work conducted in experimental pathophysiology
and toxicology.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Arrangements Involving
Directors and Senior Management</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">There are no arrangements or understandings
of which we are aware relating to the election of our directors or the appointment of executive officers in our Company. In addition,
there are no family relationships among any of the individuals listed in this Item 6.A.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">B.
COMPENSATION</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Aggregate Executive Compensation</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">During 2022, the aggregate compensation
paid or accrued by us to all persons listed in Item 6.A above (Directors and Senior Management), as well as one director (Dr. Jean-Pierre
Bizzari) and one member of Senior Management (Mr. Ari Krashin) who ceased to serve before the end of 2022, was approximately $6.0 million.
This amount includes approximately $0.6 million set aside or accrued to provide pension, severance, retirement or similar benefits, but
excludes expenses (including business travel, professional and business association dues and expenses) reimbursed to our executives and
other fringe benefits commonly reimbursed or paid by companies in Israel.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">During
2022, we granted to our Directors and Senior Management listed in Item 6.A a total of 907,500 options to purchase ordinary shares. These
options are exercisable at an average exercise price of $2.67 per share, and generally expire ten years after their respective dates of
grant. As of December 31, 2022, there were a total of 4,312,624 outstanding options to purchase ordinary shares that were held by our
Directors and Senior Management listed in Item 6.A.</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">80</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Individual Compensation
of Covered Office Holders</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25">The table below outlines the compensation granted to our five most highly compensated
Office Holders (as such term is defined in the Companies Law - see below under &#8220;Approvals Required for Office Holders Terms of Employment&#8221;)
with respect to the year ended December&#160;31, 2022. All amounts reported in the table reflect the cost to the Company, as recognized
in our financial statements for the year ended December&#160;31, 2022. We refer to the five individuals for whom disclosure is provided
herein as our &#8220;Covered Office Holders&#8221;.<br /> <br /> </div> </div>

<table cellspacing="0" cellpadding="3" border="0" id="ze4e5bb55a2f6423597e0a35328d75d13" class="cfttable" style="font: 10pt Times New Roman,Times,serif; text-align: left; color: rgb(0, 0, 0); width: 100%">
  <tr>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-weight: bold; text-align: left">Information Regarding the Covered Office Holders</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; padding-bottom: 2px; text-align: center">&#160;</td>
    <td colspan="14" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25"><span style="line-height: 1.25"> </span></div>
        <div style="line-height: 1.25; font-weight: bold">Compensation for Services<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(2)</sup></div>
        </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-weight: bold; text-align: left">Name and Principal Position<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup></div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; padding-bottom: 2px; text-align: center"><br /> </td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-weight: bold">Base Salary ($)</div> </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; text-align: center; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; padding-bottom: 2px; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-weight: bold">Benefits and </div>
        <div style="line-height: 1.25; font-weight: bold">Perquisites ($)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(3)</sup></div>
        </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; text-align: center; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; padding-bottom: 2px; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-weight: bold">Stock-Based </div>
        <div style="line-height: 1.25; font-weight: bold">Compensation ($)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(4)</sup></div>
        </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; text-align: center; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; padding-bottom: 2px; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25; font-weight: bold">Total ($)</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 52%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Dr. Anat Cohen-Dayag</div>
        <div style="line-height: 1.25">President &amp; Chief Executive Officer</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">479,073</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">317,446</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">567,035</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">1,363,554</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 52%">
        <div style="line-height: 1.25">Dr. Henry Adewoye</div>
        <div style="line-height: 1.25">Senior Vice President and Chief Medical Officer</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">420,833</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">184,458</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">306,884</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">912,175</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 52%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Dr. Oliver Froescheis<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(5)</sup></div>
        <div style="line-height: 1.25">Senior Vice President, Corporate and Business Development</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">382,500</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">560</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">263,290</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">646,350</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 52%">
        <div style="line-height: 1.25">Dr. Pierre Ferre</div>
        <div style="line-height: 1.25">Vice President, Preclinical Development</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">205,441</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">209,659</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">108,945</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">524,045</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%">&#160;</td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 52%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Dr. Zurit Levine</div>
        <div style="line-height: 1.25">Senior VP, Technology Innovations</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">205,381</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">140,316</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">178,097</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">523,794</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  </table>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z4adb3527add049f684e42c4b8e8ec6c0" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>All Covered Office Holders listed in the table were full-time officers of the Company during their term of service in 2022.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z1ccf7bf46b174c068f3248d1986ec58e" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">2)</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Cash compensation amounts denominated in currencies other than the dollar were converted into dollars at an exchange rate of NIS
        3.3596= $1.00, which reflects the average conversion rate for 2022, or the Representative Rate.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9909b07114924ebd9129ff6bd10b3065" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">3)</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Amounts reported in this column include benefits and perquisites, including those mandated by applicable law. Such benefits and perquisites
        may include, to the extent applicable to the respective Covered Office Holder, bonuses, payments, contributions and/or allocations for
        savings funds, pension, severance, vacation, car or car allowance, medical insurances and benefits, risk insurance (e.g., life, disability,
        accident), phone, convalescence pay, payments for social security, tax gross-up payments and other benefits and perquisites consistent
        with the Company&#8217;s policies.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z1eb384fd57e845e2bc3d3a44a44a6816" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">4)</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Amounts reported in this column represent the expense recorded in our financial statements for the year ended December 31, 2022,
        with respect to options to purchase our ordinary shares granted to our Covered Office Holders. Assumptions and key variables used in the
        calculation of such amounts are discussed in Note 2m to our 2022 consolidated financial statements set forth elsewhere in this report.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc72011e2389d43bea9a26c65e9290cd5" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="font: 11pt Times New Roman,Times,serif; width: 18pt; vertical-align: top">5)</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Dr. Oliver Froescheis retired from his position on February 10, 2023.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">81</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Compensation Policy</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Under the Companies Law we are required
to adopt a compensation policy, which sets forth company&#8217;s policy regarding the terms of office and employment of office holders,
including compensation, equity awards, severance and other benefits, exemption from liability and indemnification. Such compensation policy
should take into account, among other things, the provision of proper incentives to directors and officers, management of risks by the
company, the officer&#8217;s contribution to achieving corporate objectives and increasing profits, and the function of the officer or
director.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Our compensation policy, or the Compensation
Policy, is designed to balance between the importance of incentivizing office holders to reach personal targets and the need to assure
that the overall compensation meets our Company&#8217;s long-term strategic performance and financial objectives. The Compensation Policy
provides our compensation committee and our board of directors with adequate measures and flexibility to tailor each of our office holder&#8217;s
compensation package based, among other matters, on geography, tasks, role, seniority and capability. Moreover, the Compensation Policy
is intended to motivate our office holders to achieve ongoing targeted results in addition to high-level business performance in the long
term, without encouraging excessive risk taking. The Company draws upon a pool of talent that is highly sought after by large and established
global pharmaceutical and biotechnology companies, as well as by other development-stage life science companies which operate both within
and outside of the Company&#8217;s geographic areas. The Company believes that it therefore must offer compensation terms, both to its
executives and to its directors that are competitive with the compensation standards that exist in the companies with whom it competes
for such talents.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In accordance with the Companies Law, an
Israeli public company&#8217;s compensation policy and any amendments thereto must be approved by the board of directors, after considering
the recommendations of the compensation committee, and by a special majority of our shareholders, or a Special Majority<span style="font-size: 11pt">,
</span>which should include (i) at least a majority of the shareholders who are not controlling shareholders and who do not have a personal
interest in the matter, present and voting (abstentions are disregarded), or (ii) the non-controlling shareholders and shareholders who
do not have a personal interest in the matter who were present and voted against the matter hold two percent or less of the voting power
of the company<span style="font-size: 11pt">.</span> The compensation policy must be reviewed from time to time by the board and must
be re-approved or amended by the board of directors and the shareholders no less than every three years. If the compensation policy is
not approved by the shareholders, the compensation committee and the board of directors may nonetheless approve the policy, following
further discussion of the matter and for detailed reasons.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Our Compensation Policy for office holders
was originally approved by our shareholders in September 2013, with the most recent amendment adopted at the 2020 Annual General Meeting
of Shareholders.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Approvals Required for
Office Holders Terms of Employment</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">The
term &#8220;Office Holder&#8221; as defined in the Companies Law includes a director, the chief executive officer, chief business manager,
deputy chief executive officer, vice chief executive officer, any other person fulfilling or assuming any of the foregoing positions without
regard to such person&#8217;s title, and any manager who is directly subordinated to the chief executive officer. In addition to each
person listed in the table under &#8220;Item 6. Directors, Senior Management and Employees - A. Directors and Senior Management&#8221;,
two other individuals have been Office Holders as of December 31, 2022.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8220;Terms of Office and Employment&#8221;
means the terms of office and employment of our Office Holders, including exemption and release of the Office Holder from liability for
breach of his or her duty of care to the Company, an undertaking to indemnify the Office Holder, post factum indemnification or insurance;
any grant, payment, remuneration, compensation, or other benefit provided in connection with termination of service and any benefit, other
payment or undertaking to provide any payment as aforesaid.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-style: italic">Compensation
for Office Holders subordinated to the Chief Executive Officer.</span><span style="font-family: Times New Roman,Times,serif"> The terms
of office and employment of Office Holders (other than directors and the chief executive officer) require the approval of the compensation
committee and the board of directors, provided such terms are in accordance with the company&#8217;s compensation policy. Shareholder
approval is also required if the compensation of such officer is not in accordance with such policy. However, in special circumstances
the compensation committee and then the board of directors may nonetheless approve such compensation even if such compensation was not
approved by the shareholders, following a further discussion and for detailed reasoning.</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">82</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-style: italic">Compensation
for Office Holders who are Directors or Chief Executive Officers.</span><span style="font-family: Times New Roman,Times,serif"> The Terms
of Office and Employment of directors, other than directors who serve as chief executive officers and/or who possess a controlling interest
in a company or who are external directors (to the extent applicable), require the approval of the compensation committee, board of directors
and shareholders by a simple majority, as long as it complies with the compensation policy. With respect to our president and chief executive
officer, who is also a director, or with respect to any chief executive officer who is not a director (to the extent applicable in the
future), further approval of the shareholders by the Special Majority is required. However: (A) under certain circumstances, and to the
extent that the proposed Terms of Office and Employment are in compliance with the compensation policy, a company may be exempt from receiving
shareholder approval with respect to the Terms of Office and Employment of a candidate for the position of chief executive officer (provided
that the candidate is not a director) (i) provided that the company&#8217;s compensation committee and board of directors approved such
terms and that such terms: (a) are not more beneficial than the terms of the former chief executive officer, or are essentially the same
in their effect; (b) are in line with the compensation policy; and (c) are brought for shareholder approval at the next general meeting
of shareholders; and (B) a company&#8217;s compensation committee and board of directors are permitted to approve Terms of Office and
Employment of a director, without convening a general meeting of shareholders, provided that such terms are only beneficial to the Company
or that such terms are in compliance with the terms set forth in the Israeli Companies Regulations (Rules Regarding Compensation and Expenses
of External Directors), 2000, or the Compensation Regulations. To the extent applicable, external directors are entitled to Terms of Office
and Employment as set forth in the Compensation Regulations, as supplemented by the Israeli Companies Regulations (Alleviation for Public
Companies whose shares are Traded on the Stock Exchange Outside of Israel), 2000, or the Alleviation Regulations. In addition, the Israel
Securities Authority may issue from time to time bulletins or staff position statements relating to, among other things, compensation
payable to external directors. Since our board of directors determined to opt out of the requirement to elect and have external directors
and composition criteria of the audit committee and compensation committee under the Companies Law pursuant to the relief available under
the Alleviation Regulations, as further detailed in this Item below under &#8220;Board Practices - External Directors and Independent
Directors Under the Companies Law&#8221;, we are not subject to such bulletins or staff position statements.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-style: italic">Variable
Compensation and Annual Cash Bonuses of Office Holders</span><span style="font-family: Times New Roman,Times,serif">. The Companies Law
requires that all variable compensation of directors and chief executive officers be based on measurable criteria, with the exception
of a non-substantial portion of up to 3 monthly salaries, which should take into consideration the applicable Office Holder&#8217;s contribution
to the company. With respect to Office Holders who are not directors or chief executive officers, the Companies Law allows that 100% of
the variable compensation be based on non-measurable criteria. Our Compensation Policy allows for a non-substantial portion of up to 20%
of the bonus objectives for each year to be based on non-measurable criteria, provided, however, that with respect to (i) our Office Holders
who are not directors nor our chief executive officer, our compensation committee and board of directors may increase the portion of targets
based on non-measurable criteria above the rate of 20%, up to 50% and with respect to our chief executive officer, our compensation committee
and board of directors may increase the portion of targets based on non-measurable criteria for up to three (3) monthly base salaries.
Further, the annual cash bonus of each of our Office Holders who is not a director is determined according to a formula that is consistent
with the Compensation Policy and that links the bonus payment score to measurable and qualitative objectives relating to both the Company&#8217;s
performance and to the performance by each such Office Holder of his responsibilities. In the case of our Office Holders, other than the
chief executive officer, assuming that the bonus terms conform to the Compensation Policy, the annual bonus objectives and subsequent
payment scores are determined by the compensation committee and board of directors, while the bonus terms for our chief executive officer
generally require the additional approval by our shareholders. For each fiscal year, our board of directors determines the maximum target
bonus for each of our Office Holders, including our chief executive officer.</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">83</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Compensation Paid to
our Non-Executive Directors (other than Mr. Paul Sekhri)</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">On
August 6, 2018, our shareholders approved, following previous resolutions made by our audit committee (then sitting as a compensation
committee) and the board of directors, and consistent with our Compensation Policy, to compensate each of our non-executive directors
whether currently in office or appointed in the future, excluding the Chairman of the Board (each a &#8220;non-executive director&#8221;)
as follows:</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic"><span style="text-decoration: underline">Cash
Fee</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; margin-left: 7.1pt; line-height: 1.25; font-family: Times New Roman,Times,serif">(i) an annual fee of
$45,000; and</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; margin-left: 9pt; line-height: 1.25; font-family: Times New Roman,Times,serif">(ii) an additional annual
amount to be paid to non-executive directors for service as members on each of the Company&#8217;s committees, as follows:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" id="za644a9cf8b5248a7a4429175458b76b3" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 22.5pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">(a)</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Audit Committee - $2,500 for a member, or $5,000 for the chairperson;</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="ze5d6860485f74908967336158c7a6031" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 22.5pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">(b)</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Compensation Committee - $2,000 for a member, or $4,000 for the chairperson; and</div> </td> </tr>
  </table>

<table cellspacing="0" cellpadding="0" id="z4a53c3bb3d8b48a3b122c0178a81a909" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 22.5pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">(c)</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Nomination and Governance Committee - $1,000 for a member, or $3,000 for the chairperson.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">No additional compensation shall be paid
for attendance at a board or committee meeting.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">VAT is added to the above compensation in
accordance with applicable law.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic"><span style="text-decoration: underline">Equity</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In addition to the cash compensation detailed
above, each non-executive director is entitled to a yearly grant of options to purchase the Company&#8217;s ordinary shares, so that in
the first year of service as a director, each non-executive director shall be entitled to a one-time grant of 35,000 options, or Initial
Option Grant, and, in addition, to a yearly grant of 10,000 options in each of the following years of service, or the Annual Option Grant,
as detailed below.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The grant date of each Initial Option Grant
is the date of appointment for service as director, whether initially appointed by the Board or by the general meeting of shareholders,
with an exercise price equal to the closing price of the Company&#8217;s ordinary shares on the Nasdaq on the last trading day prior to
the date of their initial appointment to serve on the Board. The grant date of each Annual Option Grant shall be such date in each year
on which the Board approves the annual option grants to other management Office Holders (provided that the service as director continues
at the time of each grant), with an exercise price equal to the closing price of the Company&#8217;s ordinary shares on the Nasdaq on
the last trading day prior to such Board approval.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Both the Initial and the Annual Option Grants
are subject (other than as described herein) to the terms and conditions of the 2010 Plan, or any other equity-based incentive plan the
Company may adopt in the future and pursuant to which these equity awards would be granted. All such grants vest over a four-year period
as follows: twenty five percent (25%) of the options granted vest on the first day of the quarter one calendar year immediately following
the quarter in which the options were granted; and an additional 6.25% of the options granted vest each quarter thereafter, for the next
36 months.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Notwithstanding the terms of the relevant
plan, all options granted to non-executive directors become fully vested immediately upon the completion of one or more of the following
events, whether by way of a consolidation, merger or reorganization of the Company or otherwise: (a) a sale of all or substantially all
of Company&#8217;s issued share capital or assets to any other company, entity, person or a group of persons, or (b) the acquisition of
more than 50% of the Company&#8217;s equity or voting power by any shareholder or group of shareholders. Further, notwithstanding the
terms of the relevant plan, all options granted which shall be vested as of the date of final termination of office as a non-executive
director of the Company may be exercised within one year following such termination of office. To the extent legally available and applicable,
such options will be granted to the non-executive directors through a trustee under Section 102 of the Israel Income Tax Ordinance [New
Version], 5721-1961, or the Tax Ordinance, under the capital gains route.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">At
the Company&#8217;s Annual General Meeting of Shareholders for 2020, held on September 16, 2020, or the 2020 AGM, our shareholders approved,
following previous resolutions made by our compensation committee and the board of directors, and consistent with our Compensation Policy,
that instead of an Annual Option Grant, the compensation committee and the board may issue to all non-executive directors RSUs or other
equity awards which are not options, or Other Equity,&#160;in which case the Annual Option Grant of 10,000 options shall be&#160;adjusted
to 5,000 units of Other Equity awards, provided, that with respect to an annual equity grant that combines both types of equity awards
(</span><span style="font-family: Times New Roman,Times,serif; font-style: italic">i.e.</span><span style="font-family: Times New Roman,Times,serif">,
options and Other Equity), such grant shall be adjusted, on a&#160;pro rata&#160;basis, to give effect to the relative portion of each
type of equity awarded (for illustration purposes, if the compensation committee and board approve the grant of 4,000 RSUs to the non-executive
directors, the relevant&#160;annual equity grant will be comprised of a total of 6,000 units, out of which 4,000 will be RSUs and 2,000
will be options).</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">The
provisions relating to vesting, acceleration and exercise period applicable to options, as specified above, shall apply to Other Equity
that may be granted,&#160;<span style="font-style: italic">mutatis mutandis</span>.</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">84</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Compensation to the Company&#8217;s
Chairman of the Board of Directors, a Non-Executive Director</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">On
October 19, 2017, our shareholders approved, following previous resolutions made by our audit committee (then sitting as a compensation
committee) and the board of directors, and consistent with our Compensation Policy, the following compensation for our non-executive Chairman
of the Board, Mr. Paul Sekhri:</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-style: italic">Cash
Fees: </span><span style="font-family: Times New Roman,Times,serif">An annual cash fee in the amount of $150,000. No meeting fees will
be paid in addition to such annual cash fee.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-style: italic">Grant
of Options to Purchase Ordinary Shares:</span><span style="font-family: Times New Roman,Times,serif"> In connection with his appointment
as the Chairman of the Board, we issued to Mr. Sekhri an initial grant of options to purchase 500,000 ordinary shares. These options were
issued pursuant to the terms and conditions applicable to options granted under the Company&#8217;s 2010 Option Plan. Such grant vested
over a four-year period as follows: twenty five percent (25%) vested on the first day of the quarter one calendar year immediately following
the quarter in which the options were granted; and an additional 6.25% vested each quarter thereafter for the next 36 months. These options
will expire ten years after the grant date, unless they expire earlier in accordance with the terms of the Company&#8217;s 2010 Option
Plan. The acceleration provisions applicable to options granted to other non-executive directors also apply to the options granted to
Mr. Sekhri and all options granted which shall be vested as of the date of final termination of office as a director of the Company may
be exercised within one year following such termination date.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">At the 2020 AGM, our shareholders approved,
following previous resolutions made by our compensation committee and the board of directors, and consistent with our Compensation Policy,
that Mr. Sekhri, in his role as the non-executive chairman of the Board, shall be entitled to an annual option grant of 10,000 options
to purchase Ordinary Shares each year, or Chairman&#8217;s Annual Option Grant, starting from 2020 and for each of the following years
of service, similar to the terms of the Annual Option Grant to the other non-executive directors as specified above.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">As approved for the other non-executive
directors, instead of Chairman&#8217;s Annual Option Grant, the compensation committee and the board may issue to Mr. Sekhri Other Equity,&#160;in
which case the Chairman&#8217;s Annual Option Grant of 10,000 options shall be&#160;adjusted to 5,000 units of Other Equity awards, provided,
that with respect to an annual equity grant that combines both types of equity awards, such grant shall be adjusted, on a&#160;pro rata&#160;basis,
to give effect to the relative portion of each type of equity awarded as specified above with respect to other non-executive directors.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">The
provisions relating to vesting, acceleration and exercise period applicable to the options, as specified above, shall apply to Other Equity
that may be granted as set forth above,&#160;</span><span style="font-family: Times New Roman,Times,serif; font-style: italic">mutatis
mutandis</span><span style="font-family: Times New Roman,Times,serif">.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Compensation to our President
and Chief Executive Officer</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">Pursuant
to Dr. Anat Cohen-Dayag&#8217;s employment agreement (and in accordance with the approval of her updated compensation terms at the 2020
AGM), as the chief executive officer of the Company she is entitled to a gross monthly salary of NIS 134,125 (approximately $39,920 according
to the Representative Rate). Dr. Cohen-Dayag is also entitled to certain benefits and perquisites customary in Israel, including those
mandated by applicable law. In addition, Dr. Anat Cohen-Dayag is eligible for an annual grant of equity-based compensation and to an annual
cash bonus based upon achievement of objectives determined by the Company, both subject to receipt of all approvals required by applicable
law and to the terms of our Compensation Policy.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">At
the 2020 AGM, our shareholders approved that Dr. Cohen-Dayag shall be eligible to receive an annual cash bonus of up to nine monthly salaries
for each of the calendar years 2021, 2022 and 2023, without the need for further shareholder approval, subject to meeting the specific
performance criteria determined by the compensation committee and board with respect to each such year, in accordance with the objectives
and terms thereof and the continuous employment of Dr. Cohen-Dayag as the Company&#8217;s chief executive officer through the last day
of the calendar year with respect to which the annual cash bonus is proposed to be paid. Additionally, at the 2020 AGM, our shareholders
approved an annual equity grant plan for Dr. Cohen-Dayag for each of the calendar years 2021, 2022 and 2023, according to which Dr. Cohen-Dayag
shall be granted options to purchase up to 150,000 Ordinary Shares, or Equity Framework, in each of these years, as shall be determined
by the compensation committee and board of directors with respect to each such year. In order to align such grants (including the exercise
price and vesting period) with the annual grant of options to other executive Office Holders (for whom shareholder approval is not required),
our shareholders resolved that the annual grant to Dr. Cohen-Dayag will be made on such date in 2021, 2022 and 2023 on which the board
of directors approves the respective year&#8217;s annual option grants to management Office Holders in such year.</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">85</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The compensation committee and the board
of directors may nevertheless determine that as part of an annual equity grant, they wish to issue&#160;Dr. Cohen-Dayag Other Equity.
For the purpose of demining the applicability of the Equity Framework to Other Equity, Other Equity shall be given a &#8220;double weight&#8221;
relative to options, so that each unit of Other Equity will be equal to two (2) option units. For illustration purposes, if the compensation
committee and board of directors approve an annual equity grant to Dr. Cohen-Dayag of 40,000 options and 30,000 RSUs, then for the purpose
of determining whether such grant is within the Equity Framework, the 30,000 RSUs will be given a weight of 60,000 units and the 40,000
options will be counted as 40,000 units, comprising an aggregate of 100,000 units which is within the Equity Framework. In any event,
at least 30% of the value of any annual equity grant to Dr. Cohen-Dayag shall be based on either (i) options granted with fair market
value exercise price; or (ii) Other Equity which vesting is based on both time and performance criteria, as shall be determined by the
compensation committee and board of directors.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The options granted in each respective year
shall be subject to the terms and conditions applicable to options granted under the 2010 Plan (or any other option plan adopted by the
Company). Each annual option grant will vest over a four-year period as follows: twenty five percent (25%) will vest on the last day of
the quarter one calendar year from the date of grant; and an additional 6.25% will vest each quarter thereafter for the next 36 months.
These options will have an exercise price equal to the closing price of the Company&#8217;s ordinary shares on Nasdaq on the last trading
day prior to the approval of each year&#8217;s grant by the board of directors. These options will expire ten years after the grant date,
unless they expire earlier in accordance with the terms of the 2010 Plan or the terms of the option agreement to be entered into between
the Company and Dr. Cohen-Dayag. If applicable, the options will be granted through a trustee under Section 102 of the Tax Ordinance and,
in accordance with the Company&#8217;s previous election in this regard, be subject to the capital gains route for tax purposes.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">All vested options and Other Equity (to
the extent applicable) granted to Dr. Cohen-Dayag under the Equity Framework shall have a one-year exercise period following the termination
of her employment as the Company&#8217;s chief executive officer, other than in the event of termination for &#8220;cause&#8221; (as defined
in her employment agreement as shall be in effect from time to time). In addition to the foregoing, and not as part of the Equity Framework,
Dr. Anat Cohen-Dayag will be entitled to participate in the ESPP or any other employee share purchase plan(s) that may be adopted by the
Company from time to time until the end of 2023, as long as the fair market value of the benefit provided to her under such employee share
purchase plan(s) (determined by the Company at the beginning of the respective offering period) in any given twelve (12) month period
does not exceed ten percent (10%) of her annual base salary.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In 2022 Dr. Cohen-Dayag was granted with
150,000 options, with an exercise price of $3.24, pursuant to the terms of the CEO&#8217;s three-year equity framework approved by our
shareholders in 2020. As of December 31, 2022, Dr. Cohen-Dayag held options to purchase a total of 1,240,000 ordinary shares. Out of these
outstanding options: (i) options to purchase 889,375 ordinary shares, with a weighted average exercise price of $6.18 per share, were
exercisable as of December 31, 2022; and (ii) options to purchase 350,625 ordinary shares, with a weighted average exercise price of $6.60
per share, had not vested as of December 31, 2022. Of the unvested options on December 31, 2022, options to purchase 163,125 ordinary
shares are expected to vest during 2023, options to purchase 112,500 ordinary shares are expected to vest during 2024 and options to purchase
the remaining 75,000 ordinary shares are expected to vest during the period between March 31, 2025, and March 31, 2026. These unvested
options were granted under the Company&#8217;s 2010 Plan. For additional information on Dr. Cohen-Dayag&#8217;s holdings see &#8220;Item
6. Directors, Senior Management and Employee - E. Share Ownership - Share Ownership by Directors and Other Executive Officers.&#8221;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Dr. Cohen-Dayag&#8217;s employment agreement
may generally be terminated by either party by providing six (6) months advance written notice, provided that in the event of termination
by the Company for &#8220;justifiable cause&#8221; (as such term is defined in her employment agreement as shall be in effect from time
to time) the Company may terminate Dr. Cohen-Dayag&#8217;s employment without advance notice and that Dr. Cohen-Dayag may resign with
advance notice of only two (2) months in the event of resignation for &#8220;good reason&#8221; (as such term is defined in her employment
agreement as shall be in effect from time to time). Upon termination, Dr. Anat Cohen-Dayag will be entitled to receive certain payments
associated with termination.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In the event that Dr. Cohen-Dayag&#8217;s
employment is: (a) terminated by the Company, other than for &#8220;justifiable cause&#8221;; or (b) terminated by Dr. Cohen-Dayag for
&#8220;good reason&#8221; (hereinafter, (a) and (b) shall be referred to together as &#8220;Dismissal&#8221;), Dr. Cohen-Dayag will also
be entitled to an additional one-time payment equal to six (6) monthly salaries, or the Termination Payment, and upon Dismissal within
one year following certain &#8220;change of control&#8221; events (as defined in her employment agreement as shall be in effect from time
to time), Dr. Cohen-Dayag will be entitled to a special termination payment (in addition to the Termination Payment) in an amount equal
to six (6) monthly salaries.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">86</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In addition, upon Dismissal, or in the event
of a &#8220;change of control&#8221;, all outstanding unvested options granted to Dr. Cohen-Dayag as of such time will be accelerated
and become immediately exercisable as of the effective date of such Dismissal or change of control. Upon Dismissal, Dr. Cohen-Dayag will
also be entitled to exercise all outstanding vested options (including those options vested as a result of such accelerated vesting) for
a period of one (1) year from the date of such Dismissal, provided that such period does not extend beyond ten (10) years from the date
of grant. Upon an event of change of control, following which Dr. Cohen-Dayag&#8217;s employment is, within 12 months of the closing of
such an event: (a) terminated by the Company, other than for &#8220;justifiable cause&#8221;; or (b) terminated by Dr. Cohen-Dayag for
any reason, Dr. Cohen-Dayag will be entitled to exercise all outstanding vested options (including those vested as a result of such accelerated
vesting) for a period of one (1) year from the date of termination of her employment, provided that such period does not extend beyond
ten (10) years from the date of grant.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Dr. Cohen-Dayag is not entitled to any compensation
(including in connection with her role as a director) in addition to that being paid to her as the chief executive officer of the Company.
However, in the event of termination of Dr. Cohen-Dayag employment agreement, she will be entitled to receive such compensation to the
extent and for as long as she will serve as a non-executive director of the Company.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Insurance, Indemnification
and Exemption</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-style: italic">Our
Office Holder&#8217;s Insurance</span><span style="font-family: Times New Roman,Times,serif">. Our Articles provide that, subject to the
provisions of the Companies Law, we may enter into contracts to insure the liabilities of our Office Holders for any liabilities or expenses
incurred by or imposed upon them as a result of any act (or omission) carried out by them as our Office Holders, including with respect
to any of the following:</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z929ff1c67e2446e6a15647ecdb1ca4a9" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>a breach of duty of care to us or to another person;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z64a1de80f0b143f3a2520169529f1b7f" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>a breach of duty of loyalty to us, provided that the Office Holder acted in good faith and had reasonable grounds to assume that
        such act would not prejudice our interests;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z0140c181c4cf4ae0ae8e3ac7a42ab7fe" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>monetary liabilities or obligations imposed upon him or her in favor of another person;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="za39600fb4849426e8adb1e8293dc0465" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>A payment which the Office Holder is obligated to make to an injured party as set forth in Section 52(54)(a)(1)(a) of the Israel
        Securities Law, 5728-1968, or the Securities Law, and expenses that the Office Holder incurred in connection with a proceeding under Chapters
        H&#8217;3, H&#8217;4 or I&#8217;1 of the Securities Law, including reasonable litigation expenses, including attorney&#8217;s fees, or
        in connection with Article D of Chapter Four of Part Nine of the Companies Law; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z5f96480aacfb435bafcd21ea7d76fc53" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Expenses incurred by the Office Holder in connection with a proceeding under Chapter G&#8217;1, of the Israel Restrictive Trade Practices
        Law, 5748-1988, or Restrictive Trade Law, including reasonable litigation expenses, including attorney&#8217;s fees.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Under the Companies Law, exemption and indemnification
of, and procurement of insurance coverage for, our Office Holders, must be approved by our compensation committee and our board of directors
and, with respect to an Office Holder who is the CEO or a director, also by our shareholders. However, according to regulations promulgated
under the Companies Law, shareholders and board of directors approvals for the procurement of such insurance are not required if the insurance
policy is approved by our compensation committee and: (i) the terms of such policy are within the framework for insurance coverage as
approved by our shareholders and set forth in our Compensation Policy; (ii) the premium paid under the insurance policy is at fair market
value; and (iii) the insurance policy does not and may not have a substantial effect on the Company&#8217;s profitability, assets or obligations.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In accordance with our Compensation Policy,
approved by our shareholders at the 2020 AGM,&#160;we are currently entitled to hold directors&#8217; and officers&#8217; liability insurance
policy for the benefit of our Office Holders with insurance coverage of up to $100 million and with such annual premium reflecting market&#160;terms&#160;and
not having a substantial effect on our profitability, assets or obligations.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">87</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-style: italic">Our
Office Holders&#8217; Indemnification.</span><span style="font: italic 11pt Times New Roman,Times,serif">&#160;</span><span style="font-family: Times New Roman,Times,serif">Our
Articles provide that, subject to the provisions of the Companies Law, we may indemnify any of our Office Holders for all liabilities
and expenses incurred by them arising from or as a result of any act (or omission) carried out by them as Office Holders of the Company,
including as follows:</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z29e9df5b7f5448aa8b59e7af6ba2a9f4" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>For any monetary liabilities or obligations imposed on our Office Holder in favor of another person pursuant to a court judgment,
        including a compromise judgment or an arbitrator&#8217;s decision approved by a court;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zec05e677e49e4957acdb3b0188ce01f6" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>For any payments which our Office Holder is obligated to make to an injured party as set forth in Section 52(54)(a)(1)(a) of the
        Securities Law and expenses the Office Holder incurred in connection with a proceeding under Chapters H&#8217;3, H&#8217;4 or I&#8217;1
        of the Securities Law, including reasonable litigation expenses, including attorney&#8217;s fees, or in connection with Article D of Chapter
        Four of Part Nine of the Companies Law;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc3fdcf744b39436a9818813f90135ce7" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>For reasonable litigation expenses, including attorney&#8217;s fees, incurred by the Office Holder in consequence of an investigation
        or proceeding instituted against the Office Holder by an authority that is authorized to conduct such investigation or proceeding, and
        which was concluded without filing of an indictment against the Office Holder and without imposing on the Office Holder a financial obligation
        in lieu of criminal proceedings, or which was concluded without filing of an indictment against the Office Holder but with imposing on
        such Office Holder a financial obligation in lieu of criminal proceedings in respect of an offense that does not require proof of criminal
        intent or in connection with a financial sanction; For the purposes hereof: (i) &#8220;a proceeding that concluded without filing an indictment
        in a matter in respect of which an investigation was conducted&#8221;; and (ii) &#8220;financial obligation in lieu of a criminal proceeding&#8221;,
        shall have the meanings specified in Section 260(a)(1A) of the Companies Law;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z09a03aa25c18442f8e16f725fc2af90d" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>For reasonable litigation expenses, including attorney&#8217;s fees, incurred by the Office Holder or which the Office Holder is
        ordered to pay by a court, in a proceeding filed against the Office Holder by the Company or on its behalf or by another person, or in
        a criminal action of which the Office Holder is acquitted, or in a criminal action in which the Office Holder is convicted of an offense
        that does not require proof of criminal intent;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7fd4ebb6e3bb4f7eb3aed5523473eb72" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>For expenses incurred by our Office Holder in connection with a proceeding under Chapter G&#8217;1, of the Restrictive Trade Law,
        including reasonable litigation expenses, including attorney&#8217;s fees; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z05df676d0b5c4aa2895e2aac8c202c38" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>For any other liability, obligation or expense indemnifiable or which our Officer Holders may from time to time be indemnifiable
        by law.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The Company may undertake to indemnify an
office holder as mentioned above: (a) prospectively, provided that with respect of the first act (financial liability) the undertaking
is limited to events which in the opinion of the board of directors are foreseeable in light of the Company&#8217;s actual operations
when the undertaking to indemnify is given, and to an amount or criteria set by the board of directors as reasonable under the circumstances,
and further provided that such events and amount or criteria are set forth in the undertaking to indemnify, and (b) retroactively.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Indemnification letters, covering indemnification
of those liabilities discussed above, were granted to each of our present Office Holders and were amended at the Company&#8217;s Annual
General Meeting of Shareholders for 2021, held on September 2, 2021, or the 2021 AGM. The indemnification letters, as amended, seek to
indemnify our Office Holders to the fullest extent permitted under the Companies Law, subject to the specific limitations specified therein.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-style: italic">Our
Office Holder&#8217;s Exemption</span><span style="font: italic 11pt Times New Roman,Times,serif">. </span><span style="font-family: Times New Roman,Times,serif">Our
Articles provide that, subject to the provisions of the Companies Law, we may exempt and release our Office Holders, including in advance,
from all or part of such Office Holder&#8217;s liability for monetary or other damages due to a breach of their duty of care to the Company.
Our directors are released and exempt from all liability as aforesaid to the fullest extent permitted by law with respect to any such
breach, which has been or may be committed.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-style: italic">Limitations
on Insurance, Indemnification and Exemption</span><span style="font: italic 11pt Times New Roman,Times,serif">.</span><span style="font-family: Times New Roman,Times,serif; font-size: 11pt">&#160;</span><span style="font-family: Times New Roman,Times,serif">The
Companies Law provides that a company may not insure, exempt or indemnify an Office Holder for any breach of his or her liability arising
from any of the following:</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zade3d6faf73c4599806f9cd8f1486d2e" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>a breach by the Office Holder of his or her duty of loyalty, except that the company may enter into an insurance contract or indemnify
        an Office Holder if the Office Holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the company;</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z7263423bea384fbbb7ac0dd74cf1eef2" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>a breach by the Office Holder of his or her duty of care if such breach was intentional or reckless, but unless such breach was solely
        negligent;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">88</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<table cellspacing="0" cellpadding="0" id="z1c27bd79949447398c76b2c9a2c21155" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>any act or omission done with the intent to derive an illegal personal benefit; or</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zcef2dbaebcc84349be3082518bedc22b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>any fine, civil fine, financial sanction or monetary settlement in lieu of criminal proceedings imposed on such Office Holder.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Administrative Enforcement</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The Israeli Securities Law includes an administrative
enforcement procedure that may be used by the Israeli Securities Authority, to enhance the efficacy of enforcement in the securities market
in Israel. Pursuant to the Companies Law and the Israeli Securities Law, the Israeli Securities Authority is authorized to impose administrative
sanctions, including monetary fines, against companies like ours and their officers and directors for certain violations of the Israeli
Securities Law or the Companies Law. Furthermore, the Israeli Securities Law requires that the CEO of a company supervise and take all
reasonable measures to prevent the company or any of its employees from breaching the Israeli Securities Law. The CEO is presumed to have
fulfilled such supervisory duty if the company adopts internal enforcement procedures designed to prevent such breaches, appoints a representative
to supervise the implementation of such procedures and takes measures to correct the breach and prevent its reoccurrence.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Under the Israeli Securities Law, a company
cannot obtain insurance against or indemnify a third-party (including its officers and/or employees) for any administrative procedure
and/or monetary fine (other than for payment of damages to an injured party). The Israeli Securities Law permits insurance and/or indemnification
for expenses related to an administrative procedure, such as reasonable legal fees, provided that it is permitted under the company&#8217;s
articles of association.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We have adopted and implemented an internal
enforcement plan to reduce our exposure to potential breaches of sections in the Companies Law and the Israeli Securities Law, applicable
to us. Our Articles and letters of indemnification permit, among others, insurance and/or indemnification as contemplated under the Israeli
Securities Law (see &#8220;<span style="font-style: italic">Insurance, Indemnification and Exemption&#8221;</span> above).</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">C.
BOARD PRACTICES</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We are incorporated in Israel, and, therefore,
are generally subject to various corporate governance practices under Israeli law such as with respect to external directors, independent
directors, audit committee, compensation committee, an internal auditor and approvals of interested party transactions. These matters
are in addition to the requirements of The Nasdaq Global Market and other relevant provisions of U.S. securities laws applicable to us.
Under the Nasdaq Listing Rules, a foreign private issuer may generally follow its home country practices for corporate governance in lieu
of the comparable Nasdaq Global Market requirements, except for certain matters such as composition and responsibilities of the audit
committee and the SEC-mandated standards for the independence of its members. We currently comply with all the above-mentioned requirements.
See &#8220;Item 3. Key Information - D. Risk Factors - Risks related to operations in Israel - Being a foreign private issuer exempts
us from certain SEC requirements and Nasdaq rules, which may result in less protection that is afforded to investors under rules applicable
to domestic issuers&#8221;. For information regarding home country practices followed by us see &#8220;Item 16G - Corporate Governance&#8221;.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Board of Directors</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">Our
Articles provide that we may have no less than five nor more than fourteen directors. Currently our board of directors consists of seven
members. Our directors are elected at the annual general meeting for a term of approximately one year, ending at the annual general meeting
immediately following the annual general meeting at which they were elected or upon earlier termination in circumstanced referred to under
the Companies Law or our Articles. Our directors may further be appointed by the board of director and in this case shall hold office
until the end of the immediately following annual general meeting or upon earlier termination in circumstanced referred to under the Companies
Law or our Articles.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">None of our directors is party to a service
contract with us that provides for any severance or similar benefits upon termination of his or her service, other than our president
and chief executive officer, Dr. Anat Cohen-Dayag, with whom we entered into an employment agreement. For additional information on the
employment agreement entered into with Dr. Cohen-Dayag, please see &#8220;Item 6 - Directors, Senior Management and Employees - B. Compensation
- Compensation to our President and Chief Executive Officer.&#8221;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">89</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Board of Directors Diversity</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">The table below provides certain information regarding the diversity
of our board of directors.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="2" border="0" id="ze15bcf4c7c3b46aeba52e81232c4d115" style="font: 10pt Times New Roman,Times,serif; width: 100%; text-align: left; color: rgb(0, 0, 0)">
  <tr>
    <td colspan="5" style="border-top: rgb(0, 0, 0) 2px solid; width: 100%; vertical-align: top; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25">Board Diversity Matrix as of February 15, 2023</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25">Total Number of Directors</div> </td>
    <td colspan="4" style="border-top: rgb(0, 0, 0) 2px solid; width: 64.18%; vertical-align: top; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25">7</div> </td> </tr>
  <tr>
    <td style="border-top: #000000 2px solid; background-color: #AAAAAA; border-left: #000000 2px solid; vertical-align: top; width: 35.82%; font-family: Times New Roman, Times, serif">&#160;</td>
    <td style="border-top: #000000 2px solid; background-color: #AAAAAA; border-left: #000000 2px solid; vertical-align: top; width: 16.04%; font-family: Times New Roman, Times, serif">
        <div style="text-align: center; line-height: 1.25">Female</div> </td>
    <td style="border-top: #000000 2px solid; background-color: #AAAAAA; border-left: #000000 2px solid; vertical-align: top; width: 16.04%; font-family: Times New Roman, Times, serif">
        <div style="text-align: center; line-height: 1.25">Male</div> </td>
    <td style="border-top: #000000 2px solid; background-color: #AAAAAA; border-left: #000000 2px solid; vertical-align: top; width: 16.04%; font-family: Times New Roman, Times, serif">
        <div style="text-align: center; line-height: 1.25">Non-Binary</div> </td>
    <td style="border-top: #000000 2px solid; background-color: #AAAAAA; border-left: #000000 2px solid; border-right-style: solid; border-right-width: 2px; vertical-align: top; width: 16.04%; font-family: Times New Roman, Times, serif">
        <div style="text-align: center; line-height: 1.25">Did Not Disclose Gender</div> </td> </tr>
  <tr>
    <td style="border-top: #000000 2px solid; background-color: #AAAAAA; border-left: #000000 2px solid; vertical-align: top; width: 35.82%; font-family: Times New Roman, Times, serif">
        <div style="line-height: 1.25">Part I: Gender Identity</div> </td>
    <td colspan="4" style="border-top: #000000 2px solid; background-color: #AAAAAA; border-left: #000000 2px solid; border-right-style: solid; border-right-width: 2px; vertical-align: top; width: 64.18%; font-family: Times New Roman, Times, serif">&#160;</td>
        </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25">Directors</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25">2</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25">4<br /> </div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25">1<br /> </div> </td> </tr>
  <tr>
    <td style="border-top: #000000 2px solid; background-color: #AAAAAA; border-left: #000000 2px solid; vertical-align: top; width: 35.82%; font-family: Times New Roman, Times, serif">
        <div style="line-height: 1.25">Part II: Demographic Background</div> </td>
    <td colspan="4" style="border-top: #000000 2px solid; background-color: #AAAAAA; border-left: #000000 2px solid; border-right-style: solid; border-right-width: 2px; vertical-align: top; width: 64.18%; font-family: Times New Roman, Times, serif">&#160;</td>
        </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25">African American or Black</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
        </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25">Alaskan Native or Native American</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
        </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25">Asian</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
        </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25">Hispanic or Latinx</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
        </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25">Native Hawaiian or Pacific Islander</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
        </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25">White</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25">2</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25">3<br /> </div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
        </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25">Two or More Races or Ethnicities</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25">1</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 16.04%; vertical-align: top; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
        </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 35.82%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25">LGBTQ+</div> </td>
    <td colspan="4" style="border-top: rgb(0, 0, 0) 2px solid; width: 64.18%; vertical-align: top; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25">1</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 35.82%; vertical-align: top; border-bottom: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25">Did Not Disclose Demographic Background</div> </td>
    <td colspan="4" style="border: rgb(0, 0, 0) 2px solid; width: 64.18%; vertical-align: top">
        <div style="text-align: center; line-height: 1.25">1<br /> </div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Directors Under the Companies
Law - General</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">A nominee for service as a director in a
public company may not be elected without submitting a declaration to the company, prior to his or her election, specifying that he or
she has the requisite qualifications to serve as a director, an external director or an independent director, as applicable, and the ability
to devote the appropriate time to performing his or her duties as such.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">A director, including an external director
or an independent director, who ceases to meet the statutory requirements to serve as a director, external director or independent director,
as applicable, must notify the company to that effect immediately and his or her service as a director will expire upon submission of
such notice.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">External Directors and
Independent Directors Under the Companies Law</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">Under
the Companies Law, Israeli public companies are generally required to have on their board of directors at least two external directors
meeting certain independence criteria, provided under Israeli law. In accordance with the Alleviation Regulations, we, as an Israeli public
company with no controlling shareholder (within the meaning of the Companies Law), whose shares are listed on The Nasdaq Global Market,
may exempt ourselves from the requirement of having external directors on our board of directors and related requirements concerning the
composition of the audit and compensation committees of the board of directors, provided that we continue to comply with the U.S. securities
laws and Nasdaq Listing Rules applicable to U.S. domestic issuers regarding the independence of the board of directors and the composition
of the audit and compensation committee. On June 7, 2018, our board of directors determined to opt out of the requirement to elect and
have external directors and composition criteria of the audit committee and compensation committee under the Companies Law pursuant to
the relief available under the Alleviation Regulations, since at that time (and since that time) we have not had a controlling shareholder
and as we have been complying with the Nasdaq majority board independence requirement, and with the Nasdaq and SEC audit and compensation
committee composition requirements, or the Opt Out Criteria. In accordance with this decision, we currently have no external directors
on our board of directors.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The term controlling shareholder, as used
in the Companies Law for purposes of all matters related to external directors and for certain other purposes, means a shareholder that
has the ability to direct the activities of the company, other than by virtue of being an Office Holder. For purposes of all matters related
to external directors, a shareholder is presumed to be a controlling shareholder if the shareholder holds 50% or more of the voting rights
in the company or has the right to appoint the majority of the directors of the company or its chief executive officer.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">90</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Under the Companies Law, an &#8216;independent
director&#8217; is either an external director or a director appointed or classified as such who meets the same non-affiliation criteria
as an external director, as determined by the company&#8217;s audit committee, and who has not served as a director of the company for
more than nine consecutive years. For these purposes, ceasing to serve as a director for a period of two years or less would not be deemed
to sever the consecutive nature of such director&#8217;s service. However, as our shares are listed on The Nasdaq Global Market, pursuant
to the Alleviation Regulations, we may also classify directors who qualify as independent directors under the relevant non-Israeli rules,
as &#8216;independent directors&#8217; under the Companies Law. In addition, the Alleviation Regulations provide that &#8216;independent
directors&#8217; may be elected for additional terms that do not exceed three years each, beyond the 9 consecutive years, provided that,
if the director is being re-elected for an additional term or terms beyond the 9 consecutive years, the audit committee and board of directors
must determine that, in light of the director&#8217;s expertise and special contribution to the board of directors and its committees,
the re-election for an additional term is to the company&#8217;s benefit and the director must be re-elected by the required majority
of shareholders and subject to the terms specified in the Companies Law. Each of our directors, other than Dr. Anat Cohen-Dayag, who also
serves as our chief executive officer, meets the &#8216;independent directors&#8217; criteria under the Companies Law.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Independent
Directors Under the Nasdaq Listing Rules</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In addition to the requirements of the Companies
Law as described above, since our shares are listed on The Nasdaq Global Market, pursuant to the Nasdaq Listing Rules, a majority of our
directors must be independent (as defined under the Nasdaq Listing Rules). We comply with such Nasdaq independence requirement, as each
of our directors, other than Dr. Anat Cohen-Dayag, who also serves as our president and chief executive officer, has been determined by
our board of directors to meet the Nasdaq independence requirements.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Financial
and Accounting Expertise Under the Companies Law</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">Pursuant
to the Companies Law, the board of directors of a publicly traded company is required to make a determination as to the minimum number
of directors who must have financial and accounting expertise according to criteria set forth under the Companies Law and regulations
promulgated there under and based, among other things, on the type of company, its size, the volume and complexity of the company&#8217;s
activities and the number of directors. Our board of directors has determined that the minimum number of directors with financial and
accounting expertise is one. Currently, each of Mr. Gilead Halevy, Mr. Eran Perry and Mr. Sanford (Sandy) Zweifach qualifies as such.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Board Committees</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Audit
Committee</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">The
Companies Law requires public companies such as ours to appoint an audit committee, the responsibilities of which include, among other
things: (i) identifying flaws in the management of the company&#8217;s business, among other things, in consultation with the company&#8217;s
internal auditor or external auditor, and making recommendations to the board of directors as to how to correct them, (ii) reviewing and
considering certain related party transactions and certain actions involving conflicts of interest (as well as deciding whether certain
actions specified in the Companies Law are considered material or non-material and whether certain transactions are considered exceptional
or ordinary), (iii) establishing procedures to be followed with respect to related party transactions with a &#8220;controlling shareholder&#8221;
(where such are not extraordinary transactions), which may include, where applicable, the establishment of a competitive process for such
transaction, under the supervision of the audit committee, or individual, or other committee or body selected by the audit committee,
in accordance with criteria determined by the audit committee, (iv) determining procedures for approving certain related party transactions
with a &#8220;controlling shareholder&#8221;, which were determined by the audit committee not to be extraordinary transactions, but which
were also determined by the audit committee not to be negligible transactions, (v) reviewing the internal auditor&#8217;s work program
performance, examining the company&#8217;s internal control structure and processes and determining whether the internal auditor has the
requisite tools and resources required to perform his or her role, (vi) examining the external auditor&#8217;s scope of work as well as
the external auditor&#8217;s fees and providing its recommendations to the appropriate corporate organ, (vii) overseeing the accounting
and financial reporting processes of the Company, and (viii) providing arrangements regarding employee complaints with respect to flaws
in the management of the Company&#8217;s business.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Under the Nasdaq Listing Rules, we are required
to maintain an audit committee that operates under a formal written charter and has certain responsibilities and authority, including
being directly responsible for the appointment, compensation, retention and oversight of the work of our external auditor. However, under
Israeli law and our Articles, the appointment of external auditor requires the approval of the shareholders and their compensation requires
the approval of our board of directors. In addition, as described above, pursuant to the Companies Law, the audit committee is required
to examine the external auditor&#8217;s scope of work as well as the external auditor&#8217;s fees and to provide its recommendations
with respect thereto to the appropriate corporate organ. Accordingly, the appointment of our external auditor is approved by our shareholders
at the audit committee&#8217;s recommendation and its compensation for audit and non-audit services is approved by the board of directors
following the audit committee&#8217;s recommendation.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">91</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We have adopted a charter for the audit
committee, which sets forth the purpose and responsibilities of such committee.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In carrying out its duties, the audit committee
meets with management at least once in each fiscal quarter at which time, among other things, it reviews, and either approves or disapproves,
the financial results of the Company for the immediately preceding fiscal quarter and conveys its conclusions in this regard to the board
of directors. The audit committee also generally monitors the services provided by the Company&#8217;s external auditor to ensure their
independence and reviews all audit and non-audit services provided by them. The Company&#8217;s external and internal auditors also report
regularly to the audit committee and the audit committee discusses with our external auditor the quality, not just the acceptability,
of the accounting principles, the reasonableness of significant judgments and the clarity of disclosures in our financial statements,
as and when it deems it appropriate to do so.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Under the Nasdaq Listing Rules, the audit
committee is required to consist of at least three independent directors, each of whom is financially literate and at least one of whom
has accounting or related financial management expertise.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">We
have an audit committee consisting of three directors, Mr. Gilead Halevy,</span><span style="font-family: Times New Roman,Times,serif; font-weight: bold">&#160;</span><span style="font-family: Times New Roman,Times,serif">who</span><span style="font-family: Times New Roman,Times,serif; font-weight: bold">&#160;</span><span style="font-family: Times New Roman,Times,serif">serves
as the chairman of our audit committee, Mr. Eran Perry and Mr. Sanford (Sandy) Zweifach, all of whom are financially literate under the
applicable rules and regulations of the SEC and Nasdaq Listing Rules and each of whom is an audit committee financial expert, as defined
by the SEC rules, and has the requisite financial experience required under the Nasdaq Listing Rules. Additionally, each of the members
of the audit committee is &#8220;independent&#8221; as such term is defined in Rule 10A-3(b)(1) under the Exchange Act, which is different
from the general test for independence of board and committee members under the Nasdaq Listing Rules.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The audit committee composition requirements
referred to under Section 115 of the Companies Law are not applicable to the Company as our board of directors, as part of its decision
to opt out of the requirement to elect external directors pursuant to the relief available under the Alleviation Regulations, also adopted
relief from such composition requirements on the basis that the Company complies, and will continue to comply, with the U.S. Securities
Law and Nasdaq Listing Rules described above.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Compensation
Committee</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The Companies Law generally provides that
public companies such as the Company must appoint a compensation committee, the responsibilities of which include, among others: (i) reviewing
and making recommendations to the board of directors with respect to our Compensation Policy and with respect to any updates which may
be required thereto from time to time, (ii) reviewing the implementation of the Compensation Policy by the Company, (iii) reviewing and
considering arrangements with respect to the Terms of Office and Employment of Office Holders, (iv) exempting, under certain circumstances,
a transaction relating to the Terms of Office and Employment of Office Holders from the requirement of approval of the shareholders, and
(v) overseeing, subject to applicable law, the administration of the Company&#8217;s various compensation plans and arrangements, including,
incentive compensation and equity based plans. Under the Companies Law, the compensation committee may need to seek the approval of the
board of directors and the shareholders for certain compensation-related decisions, (see &#8220;Item 6 - Directors, Senior Management
and Employees - B. Compensation - Approvals Required for Office Holders Terms of Employment&#8221;).</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We have adopted a charter for the compensation
committee, which sets forth the purpose and responsibilities of such committee.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Under the Nasdaq Listing Rules, we are required
to maintain a compensation committee consisting of at least two independent directors (as defined under the Nasdaq Listing Rules). Each
compensation committee member must also be deemed by our board of directors to meet the enhanced independence requirements for members
of the compensation committee under the Nasdaq Listing Rules, which requires, among other things, that our board of directors considers
the source of each such committee member&#8217;s compensation in considering whether he or she is independent.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">92</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The compensation committee composition requirements
referred to under Section 118A of the Companies Law are not applicable to the Company as our board of directors, as part of its decision
to opt out of the requirement to elect external directors pursuant to the relief available under the Alleviation Regulations, also adopted
relief from such composition requirements on the basis that the Company complies, and will continue to comply, with the Nasdaq majority
board independence requirement and with US Securities Law and Nasdaq Listing Rules concerning the composition of the compensation committee.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We have a compensation committee consisting
of three directors, Mr. Sanford (Sandy) Zweifach, who serves as the chairman of our compensation committee, Dr. Kinneret Livnat Savitzky
and Eran Perry.&#160;Each member of our compensation committee is an &#8216;independent director&#8217; in accordance with the Nasdaq
listing standards.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Nomination
and Corporate Governance Committee</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The Nasdaq Listing Rules require that director
nominees be selected or recommended for the board&#8217;s selection either by a nomination committee composed solely of independent directors,
or by a majority of independent directors, in a vote in which only independent directors participate, subject to certain exceptions. Mr.
Paul Sekhri, who serves as the chairman of our nomination and corporate governance committee, Dr. Kinneret Livnat Savitzky and Mr. Sanford
(Sandy) Zweifach, each an independent director, are the members of our nomination and corporate governance committee, which, among other
responsibilities, recommends director nominees for our board&#8217;s approval.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Internal Auditor</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Under the Companies Law, the board of directors
must appoint an internal auditor, recommended by the audit committee. The role of the internal auditor is to examine, among other matters,
whether the company&#8217;s actions comply with the law and orderly business procedures. Under the Companies Law, an interested party
or an Office Holder of a company, or a relative of an interested party or of an Office Holder of a company, as well as the company&#8217;s
external auditor or any one on behalf of the external auditor may not serve as a company&#8217;s internal auditor. The internal auditor&#8217;s
tenure cannot be terminated without his or her consent, nor can he or she be suspended from such position unless the board of directors
has so resolved after hearing the opinion of the audit committee and after providing the internal auditor with the opportunity to present
his or her position to the board of directors and to the audit committee. An interested party is defined in the Companies Law as a holder
of 5% or more of the company&#8217;s outstanding shares or voting rights, any person or entity who has the right to designate one or more
directors or the chief executive officer of the company or any person who serves as a director or as a chief executive officer of the
company.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Ms. Sharon Cohen of Brightman, Almagor,
Zohar &amp; Co., a member firm of Deloitte Touche Tohmatsu, has served as our internal auditor since 2019 (replacing a different partner
at Brightman Almagor Zohar &amp; Co., a member firm of Deloitte Touche Tohmatsu). Ms. Sharon Cohen is not an employee, affiliate or Office
Holder of the Company, or affiliated with the Company&#8217;s external auditor.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Fiduciary Duties and
Approval of Related Party Transactions Under Israeli Law</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Fiduciary
Duties of Office Holders</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The Companies Law codifies the fiduciary
duties that Office Holders owe to a company. All persons listed in the table under &#8220;Item 6. Directors, Senior Management and Employees
- A. Directors and Senior Management&#8221; are Office Holders. In addition to those persons listed in the table under Item 6.A, there
were two additional individuals who were Office Holders of the Company as of December 31, 2022.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">An Office Holder&#8217;s fiduciary duties
consist of a duty of care and a duty of loyalty. The duty of care requires an Office Holder to act with the standard of skills with which
a reasonable Office Holder in the same position would have acted under the same circumstances. The duty of care includes a duty to use
reasonable means to obtain:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z3e519f76c33946dc808cb09d8fad92ba" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>information regarding the business advisability of a given action brought for the Office Holder&#8217;s approval or performed by
        the Office Holder by virtue of his or her position; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z9fab3ea772ee4aae9c7155bdf0dde542" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>all other information of importance pertaining to the aforesaid actions.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">93</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The duty of loyalty requires an Office Holder
to act in good faith and for the benefit of the company and includes the duty to:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="ze68f0135c0574795ad29106f55b9f517" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>refrain from any act involving a conflict of interest between the fulfillment of his or her position in the company and the fulfillment
        of any other position or his or her personal affairs;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd5d7f20cb41241d3b12c8e51645b0bb3" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>refrain from any act that is competitive with the business of the company;</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zc40c4196791b4a6399bf865837a0e0bf" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>refrain from exploiting any business opportunity of the company with the aim of obtaining a personal gain for himself or herself
        or for others; and</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z542b0bd35c0543a8837c52eda2440d25" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 13pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 13pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>disclose to the company all relevant information and provide it with all documents relating to the company&#8217;s affairs which
        the Office Holder obtained due to his or her position in the company.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Disclosure
of Personal Interests of Office Holders and Approval of Certain Transactions</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">The
Companies Law requires that an Office Holder promptly discloses to the company any personal interest that the Office Holder may have,
and all related material information known to him or her, in connection with any existing or proposed transaction by the company. In addition,
if the transaction is an extraordinary transaction, as defined under Israeli law, the Office Holder must also disclose any personal interest
held by the Office Holder&#8217;s spouse, siblings, parents, grandparents, descendants, spouse&#8217;s descendants and the spouses of
any of the foregoing, or a Relative. In addition, the Office Holder must also disclose any interest held by any corporation in which the
Office Holder: (i) holds at least 5% of the company&#8217;s outstanding share capital or voting rights; (ii) is a director or general
manager; or (iii) has the right to appoint at least one director or the general manager. An extraordinary transaction is defined as a
transaction which is either not in the ordinary course of business, not on market terms, or likely to have a material impact on the company&#8217;s
profitability, assets or liabilities.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Under the Companies Law, unless the articles
of association of a company provide otherwise, a transaction in which an Office Holder has a personal interest and which is not an extraordinary
transaction, requires board approval, after the Office Holder complies with the above disclosure requirement and provided the transaction
is not adverse to the company&#8217;s interest. Our Articles do not provide for a different method of approval. Furthermore, if the transaction
is an extraordinary transaction, then, in addition to any approval stipulated by the articles of association, it also must be approved
by the company&#8217;s audit committee and then by the board of directors, and, under certain circumstances, by the shareholders of the
company.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">A person with a personal interest in any
matter may not generally be present at any audit committee, compensation committee or board of directors meeting where such matter is
being considered, and if he or she is a member of the committee or a director, he or she may not generally vote on such matter at the
applicable meeting.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Disclosure of Personal
Interest of Controlling Shareholders and Approval of certain Transactions</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The Companies Law extends the disclosure
requirements applicable to an Office Holder to a &#8216;controlling shareholder&#8217; in a public company. For this purpose, a &#8216;controlling
shareholder&#8217; is a shareholder who has the ability to direct the activities of a company, including a shareholder or a group of shareholders
who together own 25% or more of the voting rights if no other shareholder holds more than 50% of the voting rights.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Extraordinary transactions of a public company
with a controlling shareholder or in which a controlling shareholder has a personal interest, as well as any engagement by a public company
of a controlling shareholder or of such controlling shareholder&#8217;s Relative, directly or indirectly, with respect to the provision
of services to the company, and, if such person is also an Office Holder of such company, with respect to such person&#8217;s Terms of
Office and Employment as an Office Holder, and if such person is an employee of the company but not an Office Holder, with respect to
such person&#8217;s employment by the company, generally require the approval of each of the audit committee (or with respect to Terms
of Office and Employment, the compensation committee), the board of directors and the shareholders of the company, in that order. The
shareholder approval must fulfill one of the following requirements: (i) it received the positive vote of at least a majority of the voting
rights in the company who are present and voting in the meeting and held by shareholders who do not have a personal interest in the transaction;
(abstentions are disregarded) or (ii) the voting rights held by shareholders who have no personal interest in the transaction and who
have voted against the transaction, do not exceed two percent of the voting rights in the company.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">94</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Any extraordinary transactions with a controlling
shareholder or in which a controlling shareholder has a personal interest with a term of more than three years generally need to be brought
for re-approval in accordance with the above procedure every three years, unless the audit committee determines that the duration of the
transaction is reasonable given the circumstances related thereto and has been approved by the shareholders for such longer duration.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Pursuant to regulations promulgated under
the Companies Law, certain transactions with a controlling shareholder or his or her Relative, or with directors, that would otherwise
require approval of a company&#8217;s shareholders may be exempt from shareholder approval upon certain determinations of the audit committee
or the compensation committee and board of directors.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">For information concerning the direct and
indirect personal interests of certain of our Office Holders and principal shareholders in certain transactions with us, see &#8220;Item
7. Major Shareholders and Related Party Transactions - B. Related Party Transactions.&#8221;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Shareholders
Duties</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Pursuant to the Companies Law, a shareholder
has a duty to: (i) act in good faith in fulfilling his obligations towards the company and the other shareholders; and (ii) refrain from
abusing his or her power with respect to the company, including, when voting at a general meeting with respect to the following matters:
(a) an amendment to the company&#8217;s articles of association; (b) an increase of the company&#8217;s authorized share capital; (c)
a merger; or (d) approval of interested party transactions that require shareholders&#8217; approval.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In addition, any controlling shareholder,
any shareholder who knows that it possesses power to determine the outcome of a shareholder vote and any shareholder who, pursuant to
the provisions of a company&#8217;s articles of association has the power to appoint or prevent the appointment of an office holder in
the company, is under a duty of fairness towards the company. The Companies Law does not describe the substance of such duty of fairness
but states that the remedies generally available upon a breach of contract will also apply in the event of a breach of the duty of fairness,
taking into account such shareholder&#8217;s position.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Approval
of Significant Private Placement</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Under the Companies Law, a significant private
placement of securities requires approval by the board of directors and the shareholders by a simple majority. A private placement is
considered a significant private placement if it results in a person becoming a controlling shareholder, or if all of the following conditions
are met: the securities issued amount to 20% or more of the company&#8217;s outstanding voting rights before the issuance; some or all
of the consideration is other than cash or listed securities or the transaction is not on market terms; and the transaction will increase
the relative holdings of a shareholder who holds 5% or more of the company&#8217;s outstanding share capital or voting rights or will
cause any person to become, as a result of the issuance, a holder of more than 5% of the company&#8217;s outstanding share capital or
voting rights.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">D.
EMPLOYEES</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The following table sets out the number
of our full-time employees engaged in specified activities, at the end of the fiscal years 2022, 2021 and 2020 (the numbers include employees
of our wholly owned U.S. subsidiary Compugen USA, Inc.):</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="2" border="0" id="z99bf736133ca42d1aae8b8a93227612b" style="font: 10pt Times New Roman,Times,serif; width: 100%; text-align: left; color: rgb(0, 0, 0)">
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 39.54%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">&#160;</td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 18.74%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25">December 31, 2022</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 20.94%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25">December 31, 2021</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 20.78%; vertical-align: top; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: center; line-height: 1.25">December 31, 2020</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 39.54%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255)">
        <div style="margin-right: 28.4pt; line-height: 1.25">Research &amp; Development</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 18.74%; vertical-align: bottom; border-left: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255)">
        <div style="text-align: right; margin-right: 2.85pt; margin-left: 2.85pt; line-height: 1.25">46</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 20.94%; vertical-align: bottom; border-left: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255)">
        <div style="text-align: right; margin-right: 2.85pt; margin-left: 2.85pt; line-height: 1.25">51</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 20.78%; vertical-align: bottom; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255)">
        <div style="text-align: right; margin-right: 2.85pt; margin-left: 2.85pt; line-height: 1.25">45</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 39.54%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25">Administration, Accounting and Operations</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 18.74%; vertical-align: bottom; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: right; margin-right: 2.85pt; margin-left: 2.85pt; line-height: 1.25">21</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 20.94%; vertical-align: bottom; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: right; margin-right: 2.85pt; margin-left: 2.85pt; line-height: 1.25">21</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 20.78%; vertical-align: bottom; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: right; margin-right: 2.85pt; margin-left: 2.85pt; line-height: 1.25">21</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 39.54%; vertical-align: top; border-left: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Marketing and Business Development</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 18.74%; vertical-align: bottom; border-left: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255)">
        <div style="text-align: right; margin-right: 2.85pt; margin-left: 2.85pt; line-height: 1.25">2</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 20.94%; vertical-align: bottom; border-left: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255)">
        <div style="text-align: right; margin-right: 2.85pt; margin-left: 2.85pt; line-height: 1.25">1</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 20.78%; vertical-align: bottom; border-right: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid; background-color: rgb(204, 238, 255)">
        <div style="text-align: right; margin-right: 2.85pt; margin-left: 2.85pt; line-height: 1.25">2</div> </td> </tr>
  <tr>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 39.54%; vertical-align: top; border-bottom: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="line-height: 1.25">Total</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 18.74%; vertical-align: top; border-bottom: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: right; margin-right: 2.85pt; line-height: 1.25">69</div> </td>
    <td style="border-top: rgb(0, 0, 0) 2px solid; width: 20.94%; vertical-align: top; border-bottom: rgb(0, 0, 0) 2px solid; border-left: rgb(0, 0, 0) 2px solid">
        <div style="text-align: right; margin-right: 2.85pt; line-height: 1.25">73</div> </td>
    <td style="border: rgb(0, 0, 0) 2px solid; width: 20.78%; vertical-align: top">
        <div style="text-align: right; margin-right: 2.85pt; line-height: 1.25">68</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">95</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In addition to the headquarters in Holon,
Israel, we maintain a subsidiary in South San Francisco, California. On December 31, 2020, 58 of our employees were located in Israel,
nine were located in the United States and 1 employee was located in Europe, on December 31, 2021, 58 of our employees were located in
Israel, 12 were located in the United States and 3 employees were located in Europe and on December 31, 2022, 57 of our employees were
located in Israel, 8 were located in the United States and 4 employees were located in Europe.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We consider our relations with our employees
to be satisfactory and we have not experienced a significant labor dispute or strike. We are not a party to any collective bargaining
agreement with respect to our Israeli employees. However, we are subject to certain labor related statutes and to certain provisions of
expansion orders the Israeli Minister of the Economy has given to collective bargaining agreements between the Histadrut (General Federation
of Labor in Israel) and the Coordinating Bureau of Economic Organizations and/or the Industrialists&#8217; Association, which are applicable
to our Israeli employees. These statutes and provisions and additional Israeli labor law provisions cover a wide range of subjects and
provide certain minimum employment standards, including the length of the workday and work week, minimum wages, travel expenses, contributions
to a pension fund, insurance for work-related accidents, determination of severance pay, annual and other vacations, sick pay and other
conditions of employment. We generally provide our employees with benefits and working conditions beyond the required minimum.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Our severance pay liability to our Israeli
employees, based upon the number of years of service and the latest monthly salary, is in the large part covered by regular deposits with
recognized pension funds, deposits with severance pay funds and purchases of insurance policies. Pursuant to Section 14 of the Israeli
Severance Pay Law 5723-1963, certain of our liabilities for employee severance rights upon termination are covered by regular contributions
to defined contribution plans, so that upon termination of employment of the relevant employees, we are only required to release the payments
made by us to such funds on account of severance and by doing so are deemed to have complied with all of our severance payment obligations
relating to the service of applicable employees with respect to the period during which the provisions of such section apply. For information
concerning our liability for severance pay, see Note 2m to our 2022 consolidated financial statements.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Our employees are not represented by a labor
union. We have written employment contracts (including signed offers of employment) with each of our employees.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">E.
SHARE OWNERSHIP</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Share Ownership by Directors
and Other Executive Officers</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">All
of the persons listed above under the caption &#8220;Directors and Senior Management&#8221; own ordinary shares of the Company and/or
options to purchase ordinary shares of the Company. Except as set forth in the table below, none of the directors or executive officers
beneficially owns ordinary shares and/or ordinary shares underlying options amounting to 1% or more of the outstanding ordinary shares.
The following table sets forth certain information as of February 9, 2023, regarding the beneficial ownership by our directors and senior
management. All numbers quoted in the table are inclusive of options to purchase shares that are exercisable within 60 days after February
9, 2023. The shares that may be issued under these options are deemed to be outstanding for the purpose of computing the percentage of
ownership of such individual or group but are not deemed to be outstanding for the purpose of computing the percentage of ownership of
the other individual or group shown in the table. The information in this table is based on 86,624,643 ordinary shares outstanding as
of February 9, 2023.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zd52ce542a8df4622b4d4d08bf5d5c6c7" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Beneficial Owner</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: center">
        <div style="line-height: 1.25; font-weight: bold">Amount </div>
        <div style="line-height: 1.25; font-weight: bold">Owned</div> </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; font-family: Times New Roman,Times,serif; text-align: center; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: center">
        <div style="line-height: 1.25; font-weight: bold">Percent of </div>
        <div style="line-height: 1.25; font-weight: bold">Class</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 76%; background-color: rgb(204, 238, 255)">
        <div style="text-align: justify; line-height: 1.25">Anat Cohen-Dayag<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup></div>
        </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">1,029,872</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">1.2</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">%</div> </td> </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%">
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">All directors and executive officers as
        a group (14 persons)<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(2)</sup></div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">2,996,117</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">3.3</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">%</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">___________________</sup></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z52d38115a0b94f558cb986323e0c27e6" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 22.5pt; vertical-align: top"><span style="font-family: Times New Roman,Times,serif"><sup style="color: rgb(0, 0, 0); vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup></span></td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Includes (i) 56,122 shares held by Dr. Cohen-Dayag, and (ii) 973,750 shares subject to options that are exercisable within 60 days
        after February 9, 2023, with a weighted average exercise price of $6.18 per share, and which expire between September 2023 and March 2032.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="z6fb7d0c150564c689ac39a1d431d556b" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 22.5pt; vertical-align: top; font-family: Times New Roman,Times,serif"><sup style="color: rgb(0, 0, 0); vertical-align: text-top; line-height: 1; font-size: smaller">(2)</sup></td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Includes (i) a total of 76,259 ordinary shares held by directors and executive officers, and (ii) a total of 2,919,858 shares subject
        to options that are beneficially owned by directors and executive officers that are exercisable within 60 days after February 9, 2023,
        with a weighted average exercise price of $5.43 per share and which expire between July 2023 and March 2032.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">96</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Share Incentive Plan
and Employee Share Purchase Plan</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We currently maintain one active share incentive
plan, which is our 2010 Share Incentive Plan, or the 2010 Plan. In addition to the discussion below, see Note 8 to our 2022 consolidated
financial statements.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Compugen
2010 Share Incentive Plan</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">On July 25, 2010, our board of directors
adopted the 2010 Plan which was also approved by our shareholders on May 12, 2011. In addition, the board of directors and shareholders
resolved that the options available for grants under the 2000 Option Plan, at such time, as well as any options that may return to such
pool in connection with terminated options, will be made available for future grants under the 2010 Plan. In May 2020 the board of directors
extended the term of the 2010 Plan by additional ten (10) years. Subject to applicable law, our board of directors may amend the 2010
Plan, provided that any action by our board of directors which will alter or impair the rights or obligations of an option holder requires
the prior consent of that option holder. Our board of directors last increased the number of shares available under the 2010 Plan in March
2022.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The compensation committee administers the
2010 Plan and has the authority to designate the terms of the options granted thereunder, including the identity of the grantees, exercise
prices, grant dates, vesting schedules and expiration dates, which may be no more than ten years after the grant date. According to the
2010 Plan, options may not be granted with an exercise price of less than the fair market value of our ordinary shares on the date of
grant, unless otherwise determined by our board of directors. The administration of the 2010 Plan by our compensation committee is subject
to applicable law, including with respect to the approval procedure of compensation to Office Holders required under the Companies Law
(for additional information on the approval procedure of compensation to Office Holders, see &#8220;Item 6. Directors, Senior Management
and Employees - B. Approvals Required for Office Holders Terms of Employment&#8221;).</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">If a grantee leaves his or her employment
or other relationship with us, or if his or her relationship with us is terminated without cause (and other than by reason of death or
disability, as defined in the 2010 Plan), the term of his or her unexercised options will generally expire in 90 days, unless determined
otherwise by our board of directors.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">As of December 31, 2022, options to purchase
8,157,749 ordinary shares at a weighted average exercise price of approximately $5.43 per share were outstanding (i.e., were granted but
not canceled, expired nor exercised) under the 2010 Plan and 1,918,297 ordinary shares remained available for future grant under the 2010
Plan. Options to purchase 4,319,106 ordinary shares under the 2010 Plan have previously been exercised through December 31, 2022, at a
weighted average exercise price of approximately $4.92. As of December 31, 2022, outstanding options granted by the Company pursuant to
the 2010 Plan expire between January 2023 and November 2032 (subject to terms of the plan).</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Compugen
2021 Employee Share Purchase Plan</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In November 2020, we adopted the Compugen
Ltd. 2021 Employee Share Purchase Plan, or ESPP.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The ESPP currently applies to our employees
and officers.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Pursuant to the ESPP, in each twelve (12)
months period, there are two offering periods, comprised of six (6) months each (except for the first offering period under the ESPP which
was for five (5) months only). Each eligible participant, has the right to contribute up to 15% of his or her monthly Compensation (as
defined in the ESPP), in order to buy ordinary shares from us at a price per share equal with respect to each offering period, to 85%
of the Fair Market Value of a share on the Entry Date or the Purchase Date (as such terms are defined in the ESPP), whichever is lower,
until changed by the committee of the board administering the ESPP prior to the commencement of the enrollment process for such offering
period. The maximum number of ordinary shares a Participant may purchase during any calendar year shall be that whole number of ordinary
shares determined by dividing $40,000 by the Purchase Price.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">97</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The maximum number of shares available for
issuance under the ESPP in the aggregate is 600,000.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">As of December 31, 2022 (following issuance
of shares in connection with offering periods already ended), there are 324,146 ordinary shares available for issuance under the ESPP.
Currently our ESPP is suspended, and we reserve the right to resume it at any time.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Taxation
of Equity Granted under our 2010 Plan and ESPP to Israeli Grantees</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Our board of directors elected the &#8220;Capital
Gains Track&#8221; (as defined in Section 102(b) (2) of the Tax Ordinance) for the grant of equity under the 2010 Plan and ESPP to Israeli
grantees who are eligible for grant under said Section 102 of the Tax Ordinance.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Pursuant to such election, and provided
such eligible grantees comply with all the requirements of the &#8220;Capital Gains Track&#8221;, gains derived by them, arising from
the sale of shares acquired pursuant to the ESPP or the exercise of options granted to them, will generally be subject to a flat capital
gains tax rate of 25%, although these gains, or part of them, will also be considered part of a grantee&#8217;s regular salary and subject
to such grantee&#8217;s regular tax rate applicable to such salary. As a result of the Company&#8217;s election in the &#8220;Capital
Gains Track&#8221; under Section 102, the Company is not allowed to claim as an expense for tax purposes in Israel the amounts credited
to the grantee as capital gains, although it is generally entitled to do so in respect of the salary income component (if any) of such
grant, if any, when the related tax is paid by the grantee as long as the grantee complies with all the requirements of the &#8220;Capital
Gains Track&#8221;.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">F.
DISCLOSURE OF A REGISTRANT&#8217;S ACTION TO RECOVER ERRONEOUSLY AWARDED COMPENSATION.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Not applicable.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">ITEM 7.<span id="ITEM7."><!--Anchor--></span>
MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">A.
MAJOR SHAREHOLDERS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">The
following table sets forth share ownership information as of February 15, 2023 (unless otherwise noted below) with respect to each person
who is known by us to be the beneficial owner of more than 5% of our outstanding ordinary shares. The information contained in the table
below has been obtained from the Company&#8217;s records or from information furnished by an individual or entity to the Company or disclosed
in public filings with the SEC. Except where otherwise indicated, and except pursuant to community property laws, we believe, based on
information furnished by such owners, that the beneficial owners of the ordinary shares listed below have sole investment and voting power
with respect to such shares. As of February 15, 2023, there were a total of 35 holders of record of our ordinary shares, of which 22 were
registered with addresses in the United States. Such United States holders were, as of such date, the holders of record of approximately
99 % of our outstanding ordinary shares.<span style="font-weight: bold">&#160;</span>Our ordinary shares are traded on the Nasdaq Global
Market in the United States and on the TASE in Israel. A significant portion of our shares are held in &#8220;street name&#8221;, therefore
we cannot determine who our shareholders are, their geographical location or how many shares a particular shareholder owns.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Total &#8220;Number of Ordinary Shares Beneficially
Owned&#8221; in the table below include shares that may be acquired by any of the below entities upon the exercise of options or warrants
known to us, that are either currently exercisable or will become exercisable within 60&#160;days of February 15, 2023.</div> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">The shareholders listed below do not have any different voting
rights from any of our other shareholders.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </div>

<table cellspacing="0" cellpadding="0" id="z3b7a909b5fcf4d05b5f14ee8dec01780" class="cfttable" style="font: 10pt Times New Roman, Times, serif; text-align: left; color: #000000; width: 100%">
  <tr>
    <td style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; font-family: Times New Roman,Times,serif; text-align: center">
        <div style="margin-right: 4.5pt; line-height: 1.25; font-weight: bold">Reporting Beneficial Owner</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Number of Ordinary Shares </div>
        <div style="text-align: center; line-height: 1.25; font-weight: bold">Beneficially Owned</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: top">
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Percent of Ordinary Shares
        </div>
        <div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Beneficially Owned<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup></div>
        </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; width: 76%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">Bristol-Myers
        Squibb Company<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(2)</sup>&#160;</span></div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">4,757,058</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">5.5</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">%</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" id="z9881492a85524ae0a57d7489d97beb17" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="font: 9pt Times New Roman,Times,serif; width: 18pt; vertical-align: top">(1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="font-size: 9pt">Based upon 86,624,643 ordinary shares issued and outstanding as of February 15, 2023.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" id="zd2df1b2134bd45ddb1c9d0b11a5f8a14" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="font: 9pt Times New Roman,Times,serif; width: 18pt; vertical-align: top">(2)</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div style="font-size: 9pt">Based upon information provided by the shareholder in its Form 13G filed with the SEC on November 19, 2021.
        With respect to the ordinary shares reported in its Schedule 13G, Bristol-Myers Squibb Company, indicated as having (i) sole voting power
        and dispositive power with respect to 4,757,058 ordinary shares, and (ii) no shared voting power nor shared dispositive power with respect
        to ordinary shares. Furthermore, in such filing BMS indicated aggregate beneficial ownership of 4,757,058 ordinary shares. The address
        of the principal business office of BMS is 430 East 29th&#160;Street, New York, NY 10016.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">98</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">B.
RELATED PARTY TRANSACTIONS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Other than as set forth below and transactions
related to compensation of our executive officers and directors as described under &#8220;Item 6. Directors, Senior Management and Employees
- B. Compensation,&#8221; since January 1, 2022, we have not entered into any material related party transaction.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div> </div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Indemnification and Exemption
Agreements</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25">

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Our Articles permit us to exculpate, indemnify
and insure our Office Holders to the fullest extent permitted by the Companies Law. Accordingly, we release our Office Holders from liability
and indemnify them to the fullest extent permitted by law and provide them with letters of indemnification and exemption and release for
this purpose, in the form most recently approved at our 2021 AGM. Under the letters of indemnification and exemption and release (i) our
undertaking to indemnify each Office Holder for monetary liabilities or obligations imposed by a court judgment (including a settlement
or an arbitrator&#8217;s award approved by a court) is limited to matters that result from or are connected to those events or circumstances
set forth therein, and (ii) the indemnification that we undertake towards all persons whom it resolved to indemnify for the matters and
circumstances described therein, jointly and in the aggregate, do not exceed the higher of the: (i) an amount equal to 25% of the Company&#8217;s
shareholders&#8217; equity, per the most recent financial statements (audited or reviewed) after the time that notice is provided to the
Company; or (y) $20 million.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<div style="text-align: justify; line-height: 1.25">Our Office Holders are also covered by directors&#8217; and officers&#8217; liability
insurance. For more information see &#8220;Item 6. Directors, Senior Management and Employees - B. Compensation - Insurance, Indemnification
and Exemption.&#8221;</div> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">C.
INTERESTS OF EXPERTS AND COUNSEL</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Not applicable.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">ITEM 8<span id="ITEM8"><!--Anchor--></span>.
FINANCIAL INFORMATION</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">A.
CONSOLIDATED STATEMENTS AND OTHER FINANCIAL INFORMATION</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Consolidated Financial
Statements</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Our consolidated financial statements are
included beginning on page F-1 of this Annual Report. See also &#8220;Item 18. Financial Statements.&#8221;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Legal
Proceedings</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Currently, we are not a party to any legal
or arbitration proceedings, including governmental proceedings, that are pending or known to be contemplated, that our management believes,
individually or in the aggregate, may have, or have had in the recent past, a significant effect on our financial position or profitability,
nor are we party to any material proceeding in which any director, member of our senior management or affiliate is a party adverse to
us or our subsidiary or has a material interest adverse to us or our subsidiary.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Dividend
Distribution Policy</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We have never paid any cash dividends on
our ordinary shares, and we do not intend to pay cash dividends on our ordinary shares in the foreseeable future. Our current policy is
to retain any earnings we have (if any) for use in our business.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In the event that we decide to pay a cash
dividend from income that is tax exempt under our Benefiting Enterprises program, we would be required to pay the applicable corporate
tax that would otherwise have been payable on such income which would be in addition to the tax payable by the dividend payee. See Note
9 to our 2022 consolidated financial statements and &#8220;Item 10. Additional Information - E. Taxation.&#8221;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">B. <span style="font-style: italic">SIGNIFICANT
CHANGES</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Not applicable.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">99</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">ITEM 9.<span id="ITEM9."><!--Anchor--></span>
THE OFFER AND LISTING</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">A.
OFFER AND LISTING DETAILS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">Our
ordinary shares were listed on The Nasdaq Global Market through June 16, 2009. On June 17, 2009, the listing of our ordinary shares was
transferred from The Nasdaq Global Market to The Nasdaq Capital Market, and on January 27, 2014, the listing of our ordinary shares transferred
back from The Nasdaq Capital Market to The Nasdaq Global Market. Our trading symbol on Nasdaq is CGEN. Our ordinary shares have been dually
listed on the Tel Aviv Stock Exchange since January 2002. Our trading symbol on each of The Nasdaq Global Market and the Tel Aviv Stock
Exchange is </span><span style="font-family: Times New Roman,Times,serif; font-size: 11.5pt">CGEN</span><span style="font-family: Times New Roman,Times,serif">.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">B.
PLAN OF DISTRIBUTION</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Not applicable</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">C.
MARKETS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Our ordinary shares are traded in the United
States on The Nasdaq Global Market and in Israel on the Tel Aviv Stock Exchange (TASE).</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">D.
SELLING SHAREHOLDERS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Not applicable</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">E.
DILUTION</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Not applicable</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">F.
EXPENSES OF THE ISSUE</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Not applicable</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">ITEM 10.<span id="ITEM10."><!--Anchor--></span>
ADDITIONAL INFORMATION</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">A.
SHARE CAPITAL</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Not applicable</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">B.
MEMORANDUM AND ARTICLES OF ASSOCIATION</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Copies of our Amended and Restated Articles
and our Amended and Restated Memorandum of Association, as in effect as of the date of this Annual Report, are attached as Exhibits 1.1
and 1.2, respectively, to this Annual Report. The information called for by this Item is set forth in Exhibit 2.1 to this Annual Report
and is incorporated by reference into this Annual Report.&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">C.
MATERIAL CONTRACTS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Please see &#8220;Item 4. Information on
the Company - B. Business Overview - Business Strategy and Partnerships - AstraZeneca License&#8221; and &#8220;Item 5. Operating and
Financial Review and Prospects Finance - B. Liquidity and Capital Resources&#8221; for a discussion of our material contracts.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">D.
EXCHANGE CONTROLS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">There are currently no exchange controls
in effect in Israel that restrict the repatriation by non-residents of Israel in non-Israeli currency of any dividends, if any are declared
and paid, and liquidation distributions or the Company&#8217;s ability to import and export capital, except that such restrictions may
exist with respect to citizens of countries which are in a state of war with Israel.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">E.
TAXATION</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The following is a brief summary of certain
material Israeli and U.S. federal tax consequences concerning the ownership and disposition of our ordinary shares by purchasers or holders
of our ordinary shares. Because parts of this discussion are based on new or existing tax or other legislation that has not been subject
to judicial or administrative interpretation, there can be no assurance that the views expressed herein will be accepted by the tax or
other authorities in question. The summary below does not address all of the tax consequences that may be relevant to all purchasers or
holders of our ordinary shares in light of each purchaser&#8217;s or holder&#8217;s particular circumstances and specific tax treatment.
For example, the summary below does not address the tax treatment of residents of Israel and traders in securities who are subject to
specific tax regimes. As individual circumstances may differ, holders of our ordinary shares should consult their own tax advisors as
to U.S., Israeli or other tax consequences of the purchase, ownership and disposition of our ordinary shares. This discussion is not intended,
nor should it be construed, as legal or professional tax advice and it is not exhaustive of all possible tax considerations. Each person
should consult his, her or its own tax or legal advisor.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">100</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Israeli Taxation</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Taxation
of Capital Gains Applicable to Non-Israeli Shareholders</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Israeli law generally imposes a capital
gains tax on the sale of securities of an Israeli resident company traded on the TASE, on an authorized stock exchange outside Israel
or on a regulated market (which includes a system through which securities are traded pursuant to rules prescribed by the competent authority
in the relevant jurisdiction), which includes Nasdaq, in or outside Israel, or a &#8220;Recognized Exchange&#8221; (which includes Nasdaq).
Pursuant to amendments to the Tax Ordinance, effective as of January 1, 2012, the capital gains tax rate applicable to individuals upon
the sale of such securities is such individual&#8217;s marginal tax rate but not more than 25%, or 30% with respect to an individual who
meets the definition of a &#8216;Substantial Shareholder&#8217; on the date of the sale of the securities or at any time during the 12
months preceding such date. A &#8216;Substantial Shareholder&#8217; is defined as a person who, either alone or together with any other
person, holds, directly or indirectly, at least 10% of any of the means of control of a company (which includes, among other things, the
right to receive profits of the company, voting rights, the right to receive the company&#8217;s liquidation proceeds and the right to
appoint a director).</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">With respect to corporate investors, capital
gain tax equal to the corporate tax rate (23% in 2023 and thereafter) will be imposed on the sale of our traded shares.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">However,
if our ordinary shares are traded on a Recognized Exchange gains on the sale of our ordinary shares held by non-Israeli tax resident investors
will generally be, subject to certain conditions, exempt from Israeli capital gains tax so long as the gains were not derived from a permanent
establishment that the non-Israeli tax resident investor maintains in Israel. Furthermore, non-Israeli &#8220;Body of Persons&#8221; (as
defined in the Ordinance, and includes corporate entities, partnerships, and other entities) corporations will not be entitled to such
exemption if Israeli residents, whether directly or indirectly, (i) holds more than 25% of the means of control in such non-Israeli corporation
or (ii) are the beneficiaries of or are entitled to 25% or more of the revenues or profits of such corporation.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Notwithstanding the foregoing, dealers in
securities in Israel are taxed at regular tax rates applicable to business income.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In addition, persons paying consideration
for shares, including purchasers of shares, Israeli securities dealers effecting a transaction, or a financial institution through which
securities being sold are held, are required, subject to any applicable exemptions and the demonstration by the selling shareholder of
its non-Israeli residency and other requirements, to withhold tax upon the sale of publicly traded securities at a rate of 25% for individuals
and at the corporate tax rate (23% in 2023 and thereafter) for corporations.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The sale of shares may also be exempt from
Israeli capital gain tax under the provisions of an applicable tax treaty. For example, the Convention Between the Government of the United
States and the Government of the State of Israel With Respect to Taxes of Income, as amended, or the U.S.-Israel Tax Treaty), exempts
U.S. residents for the purposes of the treaty (who are entitled to claim the benefits of the U.S.-Israel Tax Treaty) from Israeli capital
gain tax in connection with such sale, provided (i) the U.S. resident owned, directly or indirectly, less than 10% of the Israeli resident
company&#8217;s voting power at any time within the 12-month period preceding such sale; (ii) the seller, being an individual, is present
in Israel for a period or periods of less than 183 days during the taxable year; and (iii) the capital gain from the sale was not derived
through a permanent establishment of the U.S. resident in Israel. Under the U.S.-Israel Tax Treaty, U.S. residents for the purposes of
the treaty may be permitted to claim a credit for such taxes against U.S. federal income tax imposed on the sale, under the circumstances
and subject to the limitations specified in the U.S.-Israel Tax Treaty and U.S. tax legislation, as discussed below under &#8220;<span style="font-style: italic">Certain
Material U.S. Federal Income Tax Considerations to U.S. Holders &#8211; Distributions</span>.&#8221;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Income
Taxes on Dividend Distribution to Non-Israeli Shareholders</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In principle, non-Israeli residents (whether
individuals or corporations) are generally subject to Israeli income tax on the receipt of dividends paid by Israeli publicly traded companies
at the rate of 25% if the shares are registered with a nominee company (as such term is used in the Israeli Securities Law). If the shares
are not registered with a nominee company, the rate of 25% will apply to non-Israeli residents shareholders who are not considered Substantial
Shareholders, as defined above, and who were not considered Substantial Shareholders at any time during the 12 months preceding the date
of the distribution, and the rate of 30% will apply to dividends paid to Substantial Shareholders and to persons who were Substantial
Shareholders at any time during the 12 months preceding the date of the distribution. Notwithstanding the above, a lower tax rate may
be provided under an applicable tax treaty between Israel and the shareholder&#8217;s country of residence (subject to the receipt in
advance of a valid tax certificate from the Israel Tax Authority allowing for a reduced tax rate). The distribution of dividends to non-Israeli
residents (either individuals or corporations) from income derived from a company&#8217;s Approved Enterprises or Benefiting Enterprises
during the applicable benefits period or from Preferred Enterprises is subject to withholding tax at a rate of 20%, unless a lower tax
rate is provided under an applicable tax treaty (subject to the receipt in advance of a valid tax certificate from the Israel Tax Authority
allowing for a 20% withholding tax rate or a lower tax rate, provided by an applicable tax treaty).</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">101</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">A
non-resident of Israel who has received dividend income derived from or accrued in Israel, from which the full amount of tax was withheld,
is generally exempt from the duty to file tax returns in Israel in respect of such income, provided that: (i) such income was not derived
from a business conducted in Israel by the taxpayer; (ii) the taxpayer has no other taxable sources of income in Israel with respect to
which a tax return is required to be filed; and (iii) the taxpayer is not liable for Excess Tax (as described below).</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Residents of the United States generally
will have withholding tax in Israel deducted at source. They may be entitled to a credit or deduction for U.S. federal income tax purposes
for all or part of the amount of the taxes withheld, subject to detailed rules contained in U.S. tax legislation, as discussed below under
&#8220;<span style="font-style: italic">Certain Material U.S. Federal Income Tax Considerations to U.S. Holders &#8211; Distributions</span>.&#8221;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">U.S.
Israel Tax Treaty</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Under the U.S.-Israel Tax Treaty, the maximum
Israeli withholding tax rate on dividends paid to a holder of our ordinary shares who is a U.S. resident for the purposes of the U.S.-Israel
Tax Treaty, is generally 25%. The U.S.-Israel Tax Treaty provides that a 15% or a 12.5% Israeli dividend withholding tax will apply to
dividends paid to a U.S. corporation owning 10% or more of an Israeli company&#8217;s voting shares during, in general, the current and
preceding tax year of the Israeli company. The 15% rate applies to dividends distributed from income derived from an Approved Enterprise,
or a Benefiting Enterprise, in each case within the applicable period or, from a Preferred Enterprise, and the lower 12.5% rate applies
to dividends distributed from income derived from other sources. However, these provisions do not apply if the company has certain amounts
of passive income. The aforementioned rates under the U.S.-Israel Treaty will not apply if the dividend income was derived through a permanent
establishment of the U.S. resident in Israel.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Excess Tax</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Furthermore, an additional tax liability
at the rate of 3% is applicable on the annual taxable income, including, but not limited to, income derived from dividends, interest and
capital gains, of individuals who are subject to tax in Israel (whether such individual is an Israeli resident or non-Israeli resident)
exceeding a certain threshold (NIS 698,280 in 2023), which amount is linked to the Israeli consumer price index.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Estate and Gift Tax</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Israeli law currently does not impose estate
or gift taxes.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Certain Material U.S.
Federal Income Tax Considerations to U.S. Holders</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">General</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The following is a summary of certain material
U.S. federal income tax considerations generally applicable to the acquisition, ownership and disposition of our ordinary shares by U.S.
holders (as defined below) that hold our ordinary shares as &#8220;capital assets&#8221; (generally, property held for investment) under
the Code. For this purpose, a U.S. holder is, a holder who, for U.S. federal income tax purposes is a beneficial owner of ordinary shares
and who is: (a) a citizen or individual resident of the United States; (b) a corporation (or other entity taxable as a corporation for
U.S. federal income tax purposes) created or organized in or under the laws of the United States, any state thereof or the District of
Columbia; (c) an estate the income of which is subject to U.S. federal income tax regardless of its source; or (d) a trust that is subject
to the primary supervision of a court over its administration and one or more U.S. persons control all substantial decisions, or a trust
that has validly elected to be treated as a domestic trust under applicable Treasury Regulations. This summary does not address any tax
consequences to persons other than U.S. holders.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Except where noted, this summary deals only
with ordinary shares held as capital assets within the meaning of Section 1221 of the Code (generally, property held for investment).
The following summary does not address any tax consequences to certain types of U.S. holders that are subject to special treatment under
the U.S. federal income tax laws, such as banks, insurance companies, tax-exempt or governmental organizations, financial institutions,
broker-dealers, dealers in securities or currencies, traders in securities that elect to use the mark-to-market method of accounting for
their securities, S corporations, partnerships or other pass-through entities (or arrangements treated as a partnership) for U.S. federal
tax purposes, regulated investment companies, real estate investment trusts, expatriates, persons owning, directly, constructively or
by attribution, 10% or more, by voting power or value, of our ordinary shares, persons whose &#8220;functional currency&#8221; is not
the dollar, persons holding ordinary shares as part of a hedging, constructive sale or conversion, straddle, or other risk-reducing transaction,
certain former U.S. citizens or long term residents of the United States, corporations that accumulate income to avoid U.S. federal income
tax, persons that received an interest in our ordinary shares through the exercise of an option or otherwise in exchange for services,
or persons holding our ordinary shares in connection with a trade or business, permanent establishment or fixed base outside the United
States.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">102</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">This summary is a general summary and does
not address all aspects of U.S. federal income taxation that may be relevant to particular U.S. holders based on their particular investment
or tax circumstances.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">This summary relates only to U.S. federal
income taxes and does not address any other taxes, including but not limited to, state, local, or non-U.S. taxes and does not describe
all of the U.S. federal income tax consequences that may be relevant, including the special tax accounting rules under Section 451(b)
of the Code, the U.S. federal non-income tax considerations, including estate or gift tax considerations, the Medicare contribution tax
and the alternative minimum tax.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">If a partnership (including an entity or
arrangement classified as a partnership for U.S. federal income tax purposes) holds our ordinary shares, the tax treatment of a partner
(including a person classified as a partner for U.S. federal income tax purposes) will generally depend upon the status of the partner
and the activities of the partnership. A partner of a partnership holding our ordinary shares should consult its tax advisors.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The statements in this summary are based
on the current U.S. federal income tax laws as contained in the Code, Treasury Regulations, and relevant judicial decisions and administrative
guidance, all as of the date hereof, and such authorities may be replaced, revoked or modified, possibly with retroactive effect, so as
to result in U.S. federal income tax consequences different from those discussed below. The U.S. federal tax laws are subject to change,
and any such change may materially affect the U.S. federal income tax consequences of purchasing, owning, or disposing of our ordinary
shares. We cannot assure you that new laws, interpretations of law or court decisions, any of which may take effect retroactively, will
not cause any statement in this summary to be inaccurate. No ruling has been sought from the U.S. Internal Revenue Service, or IRS, or
opinions of counsel has been sought in connection with the matters discussed herein. There can be no assurance that the positions we take
on our tax returns will be accepted by the IRS.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">This summary is not a
substitute for careful tax planning. Investors are urged to consult their own tax advisors regarding the specific U.S. federal, state,
foreign and other tax consequences to them, in light of their own particular circumstances, of the purchase, ownership and disposition
of our ordinary shares and the effect of potential changes in applicable tax laws.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Passive
Foreign Investment Company Rules</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In general, a corporation organized outside
the United States will be classified as a passive foreign investment company, or PFIC, for U.S. federal income tax purposes for any taxable
year in which, after the application of certain look-through rules with respect to income and assets of its subsidiaries, either:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" id="zdab50952eccb432f91a02879a093d619" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>at least 75% of its gross income is passive income, or</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<table cellspacing="0" cellpadding="0" id="zecc35f966b994c4b83c3e8bae64e7b1c" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 18pt; font-family: Times New Roman,Times,serif"><br /> </td>
    <td style="width: 18pt; vertical-align: top; font-family: Times New Roman,Times,serif">&#8226;</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>at least 50% of the value (determined on the basis of a quarterly weighted average) of its total assets for the taxable year is attributable
        to assets that produce or are held for the production of passive income.</div> </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">For this purpose, passive income generally
includes, among other things, dividends, interest, royalties and rents (other than royalties and rents derived in the active conduct of
a trade or business and not derived from a related person). Assets that produce or are held for the production of passive income may include
cash (unless held in a non-interest bearing account for short term working capital needs), marketable securities and other assets that
may produce passive income. The 50% passive asset test described above is generally based on the fair market value of each asset, with
the value of goodwill and going concern value determined in large part by reference to the market value of our ordinary shares, which
may be volatile. Generally, in determining whether a non-U.S. corporation is a PFIC, a proportionate share of the income and assets of
each corporation in which it owns, directly or indirectly, at least a 25% interest (by value) is taken into account. Whether we are a
PFIC for any taxable year will depend on the composition of our income and the composition and value of our assets (which, may be determined
in large part by reference to the market price of the ordinary shares, which is likely to continue to fluctuate) in each year, and because
this is a factual determination made annually after the end of each taxable year, there can be no assurance that we will not be considered
a PFIC in any taxable year.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">103</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Based on the composition of our income,
and the composition and value of our assets, in 2022, we believe that we were a PFIC for the taxable year ended December 31, 2022. However,
the determination of whether or not we are a PFIC is a fact-intensive determination made on an annual basis and because the applicable
law is subject to varying interpretations we cannot provide any assurance regarding our PFIC status and our U.S. counsel expresses no
opinion with respect to our PFIC status for any taxable year. In particular, our status as a PFIC in current or any future tax year is
uncertain because, among other things, (i) we currently own a substantial amount of passive assets, including cash, (ii) we may not receive
milestone payments under any of our collaboration agreements, in which case, our income may be exclusively passive and (iii) the valuation
of our assets that generate non-passive income for PFIC purposes, including our intangible assets, is uncertain and may be determined
in substantial part by our market capitalization, which may vary substantially over time. Furthermore, there can be no assurance that
the IRS will agree with our conclusion or that the IRS would not successfully challenge our position. No ruling from the IRS concerning
our status as a PFIC has been obtained or is currently planned to be requested. Accordingly, we cannot provide any assurances regarding
our PFIC status for the current or future taxable years.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">If we are classified as a PFIC in any taxable
year during a U.S. holder&#8217;s holding period of our ordinary shares, such U.S. holder could be liable for additional taxes and interest
charges upon (1) a distribution paid during a taxable year that is greater than 125% of the average annual distributions paid in the three
preceding taxable years, or, if shorter, the U.S. holder&#8217;s holding period for the ordinary shares, and (2) any gain recognized on
a sale, exchange or other taxable disposition, including a pledge, of the ordinary shares, whether or not we continue to be a PFIC. In
these circumstances, the tax will be determined by allocating such distribution or gain ratably over the U.S. holder&#8217;s holding period
for the ordinary shares. The amount allocated to the current taxable year (i.e., the year in which the distribution occurs, or the gain
is recognized) and any year prior to the first taxable year in which we are a PFIC will be taxed as ordinary income earned in the current
taxable year. The amount allocated to other taxable years will be taxed at the highest marginal rates in effect for individuals or corporations,
as applicable, to ordinary income for each such taxable year, and an interest charge, generally applicable to underpayments of tax, will
be added to the tax. In addition, non-corporate U.S. Holders will not be eligible for reduced rates of taxation on any dividends received
from us, if we are a PFIC in the taxable year in which such dividends are paid or in the preceding taxable year.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">If we are a PFIC for any year during which
a U.S. holder holds the ordinary shares, we must generally continue to be treated as a PFIC by that holder for all succeeding years during
which the U.S. holder holds the ordinary shares, unless we cease to meet the requirements for PFIC status and the U.S. holder makes a
&#8220;deemed sale&#8221; election with respect to the ordinary shares. If such election is made, the U.S. holder will be deemed to have
sold the ordinary shares it holds at their fair market value on the last day of the last taxable year in which we qualified as a PFIC,
and any gain from such deemed sale would be subject to the consequences described above. After the deemed sale election, the U.S. holder&#8217;s
ordinary shares with respect to which the deemed sale election was made will not be treated as shares in a PFIC unless we subsequently
again become a PFIC.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">If a U.S. holder has made a qualified electing
fund, or QEF covering all taxable years during which the holder holds ordinary shares and in which we are a PFIC, distributions and gains
will not be taxed as described above. Instead, a U.S. holder that makes a QEF election is required for each taxable year to include in
income (i) the holder&#8217;s pro rata share of the PFIC&#8217;s ordinary earnings as ordinary income or (ii) the holder&#8217;s pro rata
share of the QEF net capital gain as capital gain, regardless of whether such earnings or gain have in fact been distributed, for each
taxable year that the entity is classified as a PFIC. If a U.S. holder makes a QEF election with respect to us, any distributions paid
by us out of our earnings and profits that were previously included in the U.S. holder&#8217;s income under the QEF election would not
be taxable to the holder. A U.S. holder will increase its tax basis in its ordinary shares by an amount equal to any income included under
the QEF election and will decrease its tax basis by any amount distributed on the ordinary shares that is not included in the holder&#8217;s
income. If a U.S. holder has made a QEF election with respect to its ordinary shares, any gain or loss recognized by the U.S. holder on
a sale or other disposition of such ordinary shares will constitute capital gain or loss. In addition, if a U.S. holder makes a timely
QEF election, our ordinary shares will not be considered shares in a PFIC in years in which we are not a PFIC, even if the U.S. holder
had held ordinary shares in prior years in which we were a PFIC.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">104</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">U.S. holders should consult their tax advisors
regarding making QEF elections in their particular circumstances. If a U.S. holder does not make and maintain a QEF election for the U.S.
holder&#8217;s entire holding period for our ordinary shares by making the election for the first year in which the U.S. holder owns our
ordinary shares, the U.S. holder will be subject to the adverse PFIC rules discussed above unless the U.S. holder can properly make a
&#8220;purging election&#8221; with respect to our ordinary shares in connection with the U.S. holder&#8217;s QEF election. A purging
election may require the U.S. holder to recognize taxable gain on the U.S. holder&#8217;s ordinary shares.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In order to comply with the requirements
of a QEF election, a U.S. holder must receive certain information from us. The QEF election is made on a shareholder-by-shareholder basis
and can be revoked only with the consent of the IRS. A shareholder makes a QEF election by attaching a completed IRS Form 8621, including
the information provided in the PFIC annual information statement, to a timely filed U.S. federal income tax return and by filing a copy
of the form with the IRS. We may provide the information necessary for U.S. holders to make QEF elections if we were treated as a PFIC
for any taxable year, although, there is no assurance that we will do so. There is no assurance that we will have timely knowledge of
our status as a PFIC in the future. Accordingly, U.S. holders may be unable to make a timely QEF election with respect to our ordinary
shares.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">U.S. holders should consult their tax advisors
to determine whether any of these above elections would be available and if so, what the consequences of the alternative treatments would
be in their particular circumstances.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The tax consequences that would apply if
we are a PFIC would also be different from those described above if a timely and valid &#8220;mark-to-market&#8221; election is made by
a U.S. holder for the ordinary shares held by such U.S. holder. An electing U.S. holder would generally take into account as ordinary
income or loss each year an amount equal to the difference between the U.S. holder&#8217;s adjusted tax basis in such ordinary shares
and their fair market value; however, losses would be allowed only to the extent of the excess of amounts previously included in income
over ordinary losses deducted in prior years as a result of the mark-to-market election. Any gain from a sale, exchange or other taxable
disposition of the ordinary shares in any taxable year in which we are a PFIC would be treated as ordinary income and any loss from such
sale, exchange or other taxable disposition would be treated first as ordinary loss (to the extent of any net mark-to-market gains previously
included in income) and thereafter as capital loss. The adjusted tax basis of a U.S. holder&#8217;s ordinary shares is increased by the
amount included in gross income under the mark-to-market regime, or is decreased by the amount of the deduction allowed under the regime.
If a U.S. holder makes a mark-to-market election it will be effective for the taxable year for which the election is made and all subsequent
taxable years unless the shares are no longer regularly traded on a qualified exchange or the IRS consents to the revocation of the election.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">A mark-to-market election is available to
a U.S. holder only for &#8220;marketable stock.&#8221; Generally, stock will be considered marketable stock if it is &#8220;regularly
traded&#8221; on a &#8220;qualified exchange&#8221; within the meaning of applicable Treasury Regulations. A class of stock is regularly
traded during any calendar year during which such class of stock is traded, other than in <span style="font-style: italic">de minimis</span>
quantities, on at least 15 days during each calendar quarter. The ordinary shares will be marketable stock as long as they remain listed
on a qualified exchange, such as Nasdaq, and are regularly traded. However, we can provide no assurances that our ordinary shares will
continue to be listed on a qualified exchange or will be regularly traded. A mark-to-market election will not apply to the ordinary shares
for any taxable year during which we are not a PFIC but will remain in effect with respect to any subsequent taxable year in which we
become a PFIC. U.S. holders are urged to consult their tax advisor about the availability of the mark-to-market election, and whether
making the election would be advisable in such holder&#8217;s particular circumstances.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">If we are a PFIC and, at any time, have
a non-U.S. subsidiary that is classified as a PFIC (a &#8220;lower-tier&#8221; PFIC), U.S. holders of our ordinary shares generally would
be deemed to own, and also would be subject to the PFIC rules with respect to, their indirect ownership interests in that lower-tier PFIC.
If we are a PFIC and a U.S. holder of our ordinary shares does not make a QEF election in respect of a lower-tier PFIC, the U.S. holder
could incur liability for the deferred tax and interest charge described above if either (1) we receive a distribution from, or dispose
of all or part of our interest in, the lower-tier PFIC or (2) the U.S. holder disposes of all or part of its ordinary shares. We may provide
the information necessary for U.S. holders to make QEF elections with respect to any lower-tier PFIC, although there is no assurance that
we will do so. A mark-to-market election under the PFIC rules with respect to our ordinary shares would not apply to a lower-tier PFIC,
and a U.S. holder would not be able to make such a mark-to-market election in respect of its indirect ownership interest in that lower-tier
PFIC. Consequently, U.S. holders of our ordinary shares could be subject to the PFIC rules with respect to income of the lower-tier PFIC
the value of which already had been taken into account indirectly via mark-to-market adjustments. U.S. holders are urged to consult their
own tax advisors regarding the issues raised by lower-tier PFICs.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">105</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Each U.S. holder who is a shareholder of
a PFIC must file an annual information report on IRS Form 8621 containing such information as the U.S. Treasury Department may require.
The failure to file IRS Form 8621 could result in the imposition of penalties and the extension of the statute of limitations with respect
to U.S. federal income tax.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">THE RULES DEALING WITH
PFICS AND WITH THE QEF AND MARK-TO-MARKET ELECTIONS ARE VERY COMPLEX AND ARE AFFECTED BY VARIOUS FACTORS IN ADDITION TO THOSE DESCRIBED
ABOVE, INCLUDING OUR OWNERSHIP OF ANY NON-U.S. SUBSIDIARIES. AS A RESULT, U.S. HOLDERS OF ORDINARY SHARES ARE STRONGLY ENCOURAGED TO CONSULT
THEIR TAX ADVISORS ABOUT THE PFIC RULES IN CONNECTION WITH THEIR PURCHASING, HOLDING OR DISPOSING OF ORDINARY SHARES.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-weight: bold; font-style: italic">U.S.
Federal Income Tax Consequences If We Are Not a PFIC</span><span style="font-family: Times New Roman,Times,serif">.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The description of the U.S. federal income
tax consequences of the receipt of distributions and the sale or other taxable exchange of our ordinary shares, described in the following
two sections &#8220;- <span style="font-style: italic">Distributions</span>&#8221; and &#8220;<span style="font-style: italic">- Disposition
of Ordinary Shares</span>,&#8221; apply only if we are not a PFIC in the relevant year and our ordinary shares are not subject to the
rules described above under &#8220;-<span style="font-style: italic">Passive Foreign Investment Company Rules</span>&#8221; because we
were a PFIC with respect to a U.S. holder and its ordinary shares in a prior year.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Distributions</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Subject to the discussion under &#8220;<span style="font-style: italic">-
Passive Foreign Investment Company Rules</span>&#8221; above, the gross amount of any distributions with respect to our ordinary shares
(including any amounts withheld to reflect Israeli withholding taxes) will be taxable as dividends, to the extent paid out of our current
or accumulated earnings and profits, as determined under U.S. federal income tax principles. Such income (including any withheld taxes)
will be includable in a U.S. holder&#8217;s gross income as ordinary income on the day actually or constructively received. Distributions
in excess of earnings and profits will be non-taxable to the U.S. holder to the extent of, and will be applied against and reduce (but
not below zero), the U.S. holder&#8217;s adjusted tax basis in the ordinary shares. Distributions in excess of earnings and profits and
such adjusted tax basis will generally be taxable to the U.S. holder as described below under &#8220;<span style="font-style: italic">-
Disposition of Ordinary Shares</span>.&#8221; However, since we do not calculate our earnings and profits under U.S. federal income tax
principles, it is expected that any distribution will be reported as a dividend, even if that distribution would otherwise be treated
as a non-taxable return of capital or as capital gain under the rules described above. The amount of any dividend paid by us will be treated
as foreign-source dividend income to U.S. holders, and the dividends received deduction will not be available to a U.S. holder that is
taxed as a corporation as a result.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">With respect to non-corporate U.S. holders,
certain dividends received from a &#8220;qualified foreign corporation&#8221; that is not a PFIC may be subject to reduced rates of taxation.
A qualified foreign corporation includes a foreign corporation that is eligible for the benefits of a comprehensive income tax treaty
with the United States which the United States Treasury Department determines to be satisfactory for these purposes and which includes
an exchange of information provision. The United States Treasury Department has determined that the US-Israel Tax Treaty meets these requirements.
A foreign corporation is also treated as a qualified foreign corporation with respect to dividends paid by that corporation on shares
that are readily tradable on an established securities market in the United States. As discussed under &#8220;- <span style="font-style: italic">Passive
Foreign Investment Company Rules</span>&#8221; above, there can be no assurance that our ordinary shares will be considered readily tradable
on an established securities market in any year. If we are a qualified foreign corporation, and we are not classified as a PFIC for the
taxable year in which a dividend is paid or in the preceding taxable year (as discussed above under &#8220;<span style="font-style: italic">-
Passive Foreign Investment Company Rules</span>&#8221;), dividend income will generally qualify as &#8220;qualified dividend income&#8221;
in the hands of individual U.S. holders, which is generally taxed at the lower applicable long term capital gains rates, provided certain
holding period and other requirements for treatment of such dividends as &#8220;qualified dividend income&#8221; are satisfied. U.S. holders
should consult their own tax advisors regarding the availability of the lower rate for dividends paid with respect to our ordinary shares.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">106</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Although, to the extent we pay dividends
in the future, we intend to pay dividends to U.S. holders in dollars, the amount of any dividend paid in Israeli currency will equal its
dollar value for U.S. federal income tax purposes, calculated by reference to the exchange rate in effect on the date the dividend is
received by the U.S. holder, regardless of whether the Israeli currency is converted into dollars. If the Israeli currency received as
a dividend are converted into United States dollars on the date they are received, the U.S. holder generally will not be required to recognize
foreign currency gain or loss in respect of the dividend income. If the Israeli currency is not converted into dollars on the date of
receipt, the U.S. holder will have a basis in the Israeli currency equal to its dollar value on the date of receipt. Any subsequent gain
or loss upon the conversion or other disposition of the Israeli currency will be treated as ordinary income or loss, and generally will,
for U.S. federal income tax purposes, be treated as income or loss from U.S. sources.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Certain U.S. holders generally may be eligible,
subject to a number of complex limitations, to claim Israeli taxes withheld from distributions and paid over to the Israeli taxing authorities
either as a deduction from gross income or as a credit against U.S. federal income tax liability. To the extent a refund of the tax withheld
is available to a U.S. holder under Israeli law or under the Treaty, the amount of tax withheld that is refundable will not be eligible
for credit against a U.S. holder&#8217;s United States federal income tax liability. The foreign tax credit is subject to numerous complex
limitations that must be determined and applied on an individual basis. U.S. holders should consult their own tax advisors regarding the
foreign tax credit rules.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Disposition
of Ordinary Shares</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In general, subject to the discussion under
&#8220;- <span style="font-style: italic">Passive Foreign Investment Company Rules</span>&#8221;, above, a U.S. holder will recognize
U.S.-source capital gain or loss upon a taxable disposition of an ordinary share equal to the difference between the sum of the fair market
value of any property and the amount of cash received in such disposition (including the amount of any foreign taxes withheld therefrom)
and the U.S. holder&#8217;s adjusted tax basis in such share. A U.S. holder&#8217;s adjusted tax basis generally will equal the U.S. holder&#8217;s
acquisition cost less any distributions treated as a return of capital as described under &#8220;- <span style="font-style: italic">Distributions</span>&#8221;
above. Such capital gain or loss will be long-term capital gain or loss if a U.S. holder&#8217;s holding period in the ordinary share
is more than one year at the time of the taxable disposition. Under current law, subject to certain exceptions (including but not limited
to those described under &#8220;<span style="font-style: italic">- Passive Foreign Investment Company Rules</span> &#8221; above), long-term
capital gain realized by a non-corporate U.S. holder generally will be eligible for reduced rates of tax. The deduction of capital losses
may be subject to limitation. Because gain from the sale or other taxable disposition of an ordinary share will generally be treated as
U.S.-source income and, subject to certain exceptions, Treasury Regulations generally preclude U.S. taxpayers from claiming a foreign
tax credit with respect to any non-U.S. tax imposed on gains from dispositions of shares held as capital assets unless the tax is creditable
under an applicable income tax treaty, your ability to claim a foreign tax credit with respect to Israeli tax imposed on any such sale
or other taxable disposition, if any, may be significantly limited. U.S. holders should consult their own tax advisors regarding the foreign
tax credit rules with respect to any foreign taxes withheld from a taxable disposition of ordinary shares, as well as regarding any foreign
currency gain or loss in connection with such a disposition.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Backup
Withholding and Information Reporting</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">In general, information reporting will apply
to dividends in respect of our ordinary shares and the proceeds from the sale or exchange of our ordinary shares that are paid to a U.S.
holder within the United States (and in certain cases, outside the United States), unless such holder is an exempt recipient. A backup
withholding tax generally applies to such payments if the U.S. holder fails to provide a taxpayer identification number and a duly executed
IRS Form W-9 or certification of other exempt status unless the U.S. holder otherwise establishes that it is exempt from such rules.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Any amounts withheld under the backup withholding
rules will be allowed as a refund or a credit against a U.S. holder&#8217;s U.S. federal income tax liability provided the required information
is furnished to the IRS in a timely manner.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Individuals who own &#8220;specified foreign
financial assets&#8221; with an aggregate value in excess of $50,000 may be required to file an information report on IRS Form 8938, &#8220;Statement
of Specified Foreign Financial Assets,&#8221; with respect to such assets with their tax returns. &#8220;Specified foreign financial assets&#8221;
include any financial accounts maintained by foreign financial institutions, as well as any of the following, but only if they are not
held in accounts maintained by financial institutions: (i) stocks and securities issued by non-U.S. persons; (ii) financial instruments
and contracts held for investment that have non-U.S. issuers or counterparties; and (iii) interests in foreign entities. U.S. holders
that are individuals are urged to consult their tax advisors regarding the application of these rules to their ownership of our ordinary
shares.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">107</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">F.
DIVIDENDS AND PAYING AGENTS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Not applicable.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">G.
STATEMENT BY EXPERTS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Not applicable.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">H.
DOCUMENTS ON DISPLAY</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif">We
are required to file reports and other information with the SEC under the Exchange Act, and the regulations thereunder applicable to foreign
private issuers. As a &#8220;foreign private issuer&#8221; we are exempt from the rules and regulations under the Securities Exchange
Act prescribing the furnishing and content of proxy statements, and our officers, directors and principal shareholders are exempt from
the reporting and &#8220;short-swing&#8221; profit recovery provisions contained in Section 16 of the Securities Exchange Act, with respect
to their purchase and sale of our shares. In addition, we are not required to file reports and financial statements with the SEC as frequently
or as promptly as U.S. companies whose securities are registered under the Securities Exchange Act. Nasdaq rules generally require that
companies send an annual report to shareholders prior to the annual general meeting, however we rely upon an exception under the Nasdaq
Listing Rules and follow the generally accepted business practice for companies in Israel. Specifically, we file annual reports on Form
20-F, which contain financial statements audited by an independent accounting firm, electronically with the SEC and post a copy on our
website. We also furnish to the SEC reports on Form 6-K containing unaudited financial information after the end of each of the first
three quarters.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">You may review a copy of our filings with
the SEC, including any exhibits and schedules, at the offices of the Israel Securities Authority at 22 Kanfei Nesharim St., Jerusalem,
Israel. As a foreign private issuer, we were only required to file through the SEC&#8217;s EDGAR system as of November 2002. Our periodic
filings are therefore available on the SEC&#8217;s Website <span style="font-style: italic">www.sec.gov</span> from that date. You may
read and copy any reports, statements or other information that we file with the SEC, through the SEC&#8217;s EDGAR system available on
the SEC&#8217;s website. These SEC filings are also available to the public on the Israel Securities Authority&#8217;s website at <span style="font-style: italic">www.isa.gov.il</span>
and from commercial document retrieval services.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Any statement in this Annual Report about
any of our contracts or other documents is not necessarily complete. If the contract or document is filed as an exhibit to this Annual
Report, the contract or document is deemed to modify the description contained in this Annual Report. We urge you to review the exhibits
themselves for a complete description of the contract or document.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">I.
SUBSIDIARY INFORMATION</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Not applicable.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">ITEM 11.<span id="ITEM11."><!--Anchor--></span>
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We are exposed to a variety of risks, including
changes in interest rates and foreign currency exchange risk and inflation.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Interest Rate Risk</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">As of December 31, 2022, we had approximately
$83.7 million in cash, cash equivalents, restricted cash and short-term bank deposits. We mostly invest our cash surplus in bank deposits.
Since these investments typically carry fixed interest rate, financial income over the holding period is not sensitive to changes in interest
rates. For more information, see Note 2 to our 2022 consolidated financial statements.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Foreign Currency Exchange
Risk and Inflation</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The cost of our Israel operations, as expressed
in dollars, is influenced by the extent to which any increase in the rate of inflation in Israel is not offset (or is offset on a lagging
basis) by a devaluation of the NIS in relation to the dollar. The inflation rate in Israel was 5.3%, 2.8% and (0.7%) in 2022, 2021 and
2020, respectively. The appreciation (devaluation) of the dollar against the NIS was 13.2%, (3.3%) and (7.0%) in 2022, 2021 and 2020,
respectively. For 2022, assuming a 10% devaluation of the dollar against the NIS, we would experience an increase in our net loss of approximately
$1.4 million, while assuming a 10% appreciation of the dollar against the NIS, we would experience a decrease in our net loss of approximately
$1.1 million. A significant portion of our expenditures is employee compensation related. Salaries for Israel-based employees are paid
in NIS and may be adjusted for changes in the Israeli consumer price index, or CPI, through salary increases or adjustments. These upward
adjustments increase salary expenses in dollar terms. The devaluation/appreciation of the NIS against the dollar decreases/increases employee
compensation expenditures as expressed in dollars proportionally. Some of our other NIS based expenses are either currently adjusted to
dollars or are adjusted to the CPI. We currently have no foreign currency derivative contracts to hedge against currency exchange risk
fluctuation but may consider entering into such contracts in the future. For more information, see Note 2 of our 2022 consolidated financial
statements.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">108</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">ITEM 12.<span id="ITEM12."><!--Anchor--></span>
DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Not applicable.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold"><span id="PARTII"><!--Anchor--></span>PART
II</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">ITEM 13.<span id="ITEM13."><!--Anchor--></span>
DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">None.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: -45pt; margin-left: 45pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">ITEM
14.<span id="ITEM14."><!--Anchor--></span> MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Not applicable.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">ITEM 15.<span id="ITEM15."><!--Anchor--></span>
CONTROLS AND PROCEDURES</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">A.
DISCLOSURE CONTROLS AND PROCEDURES</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Our disclosure controls and procedures are
designed to ensure that information required to be disclosed in the reports we are required to file is recorded, processed, summarized
and reported on a timely basis. Under the supervision of our chief executive officer (principal executive officer) and chief financial
officer (principal financial officer), we conducted an evaluation of the effectiveness of our disclosure controls and procedures, as such
term is defined under Rule 13a-15(f) and 15d-15(f) promulgated under the Exchange Act. Based on this evaluation, our chief executive officer
and chief financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by
this Annual Report.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">B.
MANAGEMENT&#8217;S ANNUAL REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Our management, with the involvement of
our board of directors and audit committee, is responsible for establishing and maintaining adequate internal control over financial reporting.
Our internal control over financial reporting (as defined in Rules 13a-15(e) and 15(d) - 15(e) of the Exchange Act) has been designed
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our consolidated financial statements
for external purposes in accordance with generally accepted accounting principles.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Under the supervision of our chief executive
officer (principal executive officer) and chief financial officer (principal financial officer), our management conducted an evaluation
of the effectiveness of our internal control over financial reporting, as such term is defined under Rules 13a-15(f) and 15d-15(f) promulgated
under the Exchange Act. In making this assessment, our management used the criteria established in Internal Control - Integrated Framework
issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on this evaluation, our chief executive officer
and chief financial officer have concluded that our internal control over financial reporting was effective as of the end of the period
covered by this Annual Report.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Notwithstanding the foregoing, all internal
control systems no matter how well designed have inherent limitations. Therefore, even those systems determined to be effective may not
prevent or detect misstatements and can provide only reasonable assurance with respect to financial statement preparation and presentation.
Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because
of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">109</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Kost Forer Gabbay &amp; Kasierer, a member
firm of Ernst &amp; Young Global, an independent registered public accounting firm in Israel,&#160;which has audited our financial statements
for the year ended December 31, 2022, that are included in this Annual Report, has issued an attestation report on our internal control
over financial reporting as of December&#160;31, 2022.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">C.
ATTESTATION REPORT OF THE REGISTERED PUBLIC ACCOUNTING FIRM</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The attestation report of Kost Forer Gabbay
&amp; Kasierer, a member firm of Ernst &amp; Young Global, an independent registered public accounting firm in Israel, on our internal
control over financial reporting as of December 31, 2022 is provided on page F-4, as included under Item 18 of this Annual Report and
is incorporated herein by reference.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">D.
CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Based on the evaluation conducted by our
management, with the participation of our chief executive officer and chief financial officer, pursuant to Rules 13a-15(f) and 15d-15(f)
promulgated under the Exchange Act, our management (including such officers) have concluded that, there were no changes in our internal
control over financial reporting that occurred during the period covered by this Annual Report that have materially affected, or are reasonably
likely to materially affect, our internal control over financial reporting.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">ITEM 16<span id="TEM16"><!--Anchor--></span>.
RESERVED</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">ITEM 16A<span id="ITEM16A"><!--Anchor--></span>.
AUDIT COMMITTEE FINANCIAL EXPERT</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Our board of directors has determined that
each of Mr. Gilead Halevy, Mr. Eran Perry and Mr. Sanford (Sandy) Zweifach, each of whom serves on our audit committee and who meets the
&#8220;independence&#8221; definition under the Nasdaq Listing Rules, qualifies as an &#8220;audit committee financial expert&#8221; as
defined in the instructions to this Item 16A of Form 20-F. See<span style="font-style: italic">&#160;</span>&#8220;Item 6.A &#8211; Directors,
Senior Management and Employees &#8211; Directors and Senior Management&#8221; for a summary of Mr. Gilead Halevy and Mr. Eran Perry&#8217;s
relevant professional experience.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">ITEM 16B.<span id="ITEM16B."><!--Anchor--></span>
CODE OF ETHICS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We have adopted a code of business conduct
that applies to all of our employees, officers and directors as well as a code of ethics for senior financial officers that applies to
our chief executive officer, chief financial officer, director of finance, controller, assistant controller and persons performing similar
functions at our subsidiary.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The code of ethics for senior financial
officers is available on our website, <span style="font-style: italic"><span style="text-decoration: underline">www.cgen.com</span></span>.
However, information contained on our website does not constitute a part of this Annual Report.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">We intend to post on our website all disclosures
that are required by the rules and regulations of the SEC or by the Nasdaq Listing Rules concerning any amendments to, or waivers from,
any provision of the code of business conduct or the code of ethics.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">ITEM 16C.<span id="ITEM16C."><!--Anchor--></span>
PRINCIPAL ACCOUNTANT FEES AND SERVICES</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The following table presents the fees billed
or accrued to us by our principal accountant for professional services rendered in the years ended December 31, 2022, and 2021:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" border="0" id="z8b12dc3dd2da49c794d1598e6d56cc8f" class="cfttable" style="font: 10pt Times New Roman, Times, serif; margin-left: auto; width: 70%; color: #000000; text-align: left; margin-right: auto">
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="line-height: 1.25"> </span></div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">2022</div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="line-height: 1.25"> </span></div> </div> </td>
    <td colspan="1" class="cftfncell" style="white-space: nowrap; text-align: center; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; padding-bottom: 2px; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: rgb(0, 0, 0) 2px solid; vertical-align: bottom; text-align: center">
        <div style="line-height: 1.25">
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="line-height: 1.25"> </span></div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">2021</div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="line-height: 1.25"> </span></div> </div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; vertical-align: bottom; padding-bottom: 2px">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 76%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Audit Fees</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">163,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">133,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 76%">
        <div style="line-height: 1.25">Audit Related Fees</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">10,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">25,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 76%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">Tax Fees</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">4,500</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25">4,500</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 76%">
        <div style="line-height: 1.25">All Other Fees</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">2,500</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">
        <div style="line-height: 1.25">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%">
        <div style="line-height: 1.25">2,500</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%">&#160;</td>
        </tr>
  <tr>
    <td style="vertical-align: bottom; vertical-align: top; font-family: Times New Roman,Times,serif; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">
        <div style="margin-right: 2.85pt; line-height: 1.25; font-weight: bold">Total</div> </td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold">180,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftguttercell" style="vertical-align: bottom; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
    <td colspan="1" class="cftcurrcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold">$</div> </td>
    <td colspan="1" class="cftnumcell" style="vertical-align: bottom; border-bottom: rgb(0, 0, 0) 4px double; font-family: Times New Roman,Times,serif; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255)">
        <div style="line-height: 1.25; font-weight: bold">165,000</div> </td>
    <td colspan="1" class="cftfncell" style="vertical-align: bottom; white-space: nowrap; font-family: Times New Roman,Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255)">&#160;</td>
        </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">110</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8220;Audit Fees&#8221; are fees for professional
services rendered by our principal accountant in connection with the integrated audit (including review of internal control over financial
reporting) of our consolidated annual financial statements and review of our unaudited interim financial statements;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8220;Audit Related Fees&#8221; are fees
for professional services rendered by our principal accountant in connection with the audit and other assignments, including consultancy
and consents with respect to registration statements filed with the SEC;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8220;Tax Fees&#8221; are fees for services
rendered by our principal accountant in connection with tax compliance, tax advice and tax planning which in years 2021 and 2020 were
consultancy relating to withholding tax on payments to foreign suppliers and annual Israeli tax reports; and</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">&#8220;All Other Fees&#8221; are fees for
other consulting services rendered by our principal accountant to us.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-style: italic; font-weight: bold">Pre-Approval
Policies for Non-Audit Services</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Our audit committee is in charge of a policy
and procedures for approval of audit and non-audit services rendered by our external auditor. This policy generally provides that we will
not engage our independent registered public accounting firm to render audit or non-audit services unless the service is specifically
approved in advance by our audit committee or the engagement is entered into pursuant to the pre-approval procedure described below. Annually,
our audit committee pre-approves specified types of services that are expected to be provided to us by our independent registered public
accounting firm during the next 12 months. Any such pre-approval is detailed as to the particular service or type of services to be provided
and is also generally subject to a maximum dollar amount. All of the fees listed in the table above were approved by our audit committee.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: -81pt; margin-left: 81pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">ITEM
16D.<span id="ITEM16D."><!--Anchor--></span> EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Not Applicable.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: -54pt; margin-left: 54pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">ITEM
16E.<span id="ITEM16E."><!--Anchor--></span> PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Not applicable.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">ITEM 16F.<span id="ITEM16F."><!--Anchor--></span>
CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANT</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Not applicable.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">ITEM 16G.<span id="ITEM16G."><!--Anchor--></span>
CORPORATE GOVERNANCE</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The Nasdaq Listing Rules require companies
with securities listed thereon to comply with its corporate governance standards. As a foreign private issuer whose shares are listed
on Nasdaq, we are permitted to follow certain home country corporate governance practices instead of those followed by U.S. companies
under the Nasdaq Listing Rules, including:</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-style: italic">Shareholder
Approval.</span><span style="font-family: Times New Roman,Times,serif"> Pursuant to Israeli law, we seek shareholder approval for all
corporate actions requiring such approval under the requirements of the Companies Law, which are different from the requirements for seeking
shareholder approval under Nasdaq Listing Rule 5635. We seek shareholder approval in specified situations, including upon issuance of
options to directors in their capacity as directors, as required by Israeli law.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-style: italic">Quorum
at an Adjourned General Meeting of Shareholders.</span><span style="font-family: Times New Roman,Times,serif"> Consistent with Israeli
law, generally, a quorum for an adjourned general meeting of shareholders of the Company is any two shareholders present in person, by
proxy, by proxy card or by electronic vote at such meeting. As such, the Israeli quorum requirements for an adjourned meeting are different
from the Nasdaq requirement that an issuer listed on Nasdaq have a quorum requirement that in no case be less than 33 1/3% of the outstanding
shares of the company&#8217;s common voting stock.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; color: #000000; font-family: Times New Roman, serif"><span style="font-family: Times New Roman,Times,serif; font-style: italic">Distribution
of Annual Reports</span><span style="font-family: Times New Roman,Times,serif">. We have chosen to follow our home country practice in
lieu of the requirements of Nasdaq Rule 5250(d)(1), relating to an issuer&#8217;s furnishing of its annual report to shareholders. Specifically,
we file annual reports on Form 20-F, which contain financial statements audited by an independent accounting firm, electronically with
the SEC and post a copy on our website.</span></div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">ITEM 16H.<span id="ITEM16H."><!--Anchor--></span>
MINE SAFETY DISCLOSURE</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Not applicable.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">111</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">ITEM 16I<span id="ITEM16I"><!--Anchor--></span>.
DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Notapplicable.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold"><span id="PARTIII"><!--Anchor--></span>PART
III</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">ITEM 17.<span id="ITEM17."><!--Anchor--></span>
FINANCIAL STATEMENTS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">See Item 18.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">ITEM 18<span id="ITEM18"><!--Anchor--></span>.
FINANCIAL STATEMENTS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Our consolidated financial statements and
related notes are included in this Annual Report beginning on page F-1.</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">112</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; text-indent: -72pt; margin-left: 72pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">ITEM
19.<span id="ITEM19."><!--Anchor--></span> EXHIBITS</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: center; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">Index to Exhibits</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<table cellspacing="0" cellpadding="0" border="0" id="zf0d0c0f28111422ea32071d539d2a210" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Exhibit </div>
        <div style="text-align: justify; line-height: 1.25; font-weight: bold">Number</div> </td>
    <td style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25; font-weight: bold">Description</div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: bottom; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891319002031/exhibit_99-4.htm">1.1</a></div>
        </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891319002031/exhibit_99-4.htm">Articles
        of Association of Compugen, as amended (incorporated by reference to Annex A3 of Exhibit 99.4 to Compugen&#8217;s report on Form 6-K filed
        with the SEC on August 5, 2019 (File No. 000-30902)).</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891319002031/exhibit_99-4.htm">1.2</a></div>
        </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891319002031/exhibit_99-4.htm">Memorandum
        of Association of Compugen, as amended (incorporated by reference to Annex A2 of Exhibit 99.4 to Compugen&#8217;s report on Form 6-K filed
        with the SEC on August 5, 2019 (File No. 000-30902)).</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891322000863/exhibit_2-1.htm">2.1</a></div>
        </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891322000863/exhibit_2-1.htm">Description
        of Securities (incorporated by reference to Exhibit 2.1 to Compugen&#8217;s Annual Report on Form 20-F/A for the year ended December 31,
        2021, filed with the SEC on February 28, 2022 (File No. 000-30902)).</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891320003355/exhibit_10-1.htm">4.1</a></div>
        </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891320003355/exhibit_10-1.htm">Compugen
        Ltd. 2021 Employee Share Purchase Plan (incorporated by reference to Exhibit 10.1 to Compugen&#8217;s Registration Statement on Form S-8
        filed with the SEC on December 12, 2020 (File No. 333-251263)).</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891320002176/exhibit_4-1.htm">4.2</a></div>
        </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891320002176/exhibit_4-1.htm">Compugen
        Ltd. 2010 Share Incentive Plan, as amended (incorporated by reference to Exhibit 4.1 to Compugen&#8217;s Registration Statement on Form
        S-8, filed with the SEC on July 30, 2020 (File No.333-240182)).</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891322000863/exhibit_4-3.htm">4.3#</a></div>
        </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891322000863/exhibit_4-3.htm">Research
        and Development Collaboration and License Agreement, dated August 5, 2013, by and between Compugen Ltd. and BayerPharma AG (&#8220;Bayer&#8221;)
        (incorporated by reference to Exhibit 4.3 to Compugen&#8217;s Annual Report on Form 20-F/A for the year ended December 31, 2021, filed
        with the SEC on February 28, 2022 (File No. 000-30902)).</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891322000863/exhibit_4-4.htm">4.4#</a></div>
        </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891322000863/exhibit_4-4.htm">First
        Amendment to the Research and Development Collaboration and License Agreement, by and between Compugen Ltd. and Bayer dated as of February
        5, 2014 (incorporated by reference to Exhibit 4.4 to Compugen&#8217;s Annual Report on Form 20-F/A for the year ended December 31, 2021,
        filed with the SEC on February 28, 2022 (File No. 000-30902)).</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891322000863/exhibit_4-5.htm">4.5#</a></div>
        </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891322000863/exhibit_4-5.htm">Second
        Amendment to the Research and Development Collaboration and License Agreement, by and between Compugen Ltd. and Bayer, dated as of July
        27, 2015 (incorporated by reference to Exhibit 4.5 to Compugen&#8217;s Annual Report on Form 20-F/A for the year ended December 31, 2021,
        filed with the SEC on February 28, 2022 (File No. 000-30902)).</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891322000863/exhibit_4-6.htm">4.6#</a></div>
        </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891322000863/exhibit_4-6.htm">Third
        Amendment to Research and Development Collaboration and License Agreement, by and between Compugen Ltd. and Bayer, dated as of April 17,
        2016 (incorporated by reference to Exhibit 4.6 to Compugen&#8217;s Annual Report on Form 20-F/A for the year ended December 31, 2021,
        filed with the SEC on February 28, 2022 (File No. 000-30902)).</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891322000863/exhibit_4-8.htm">4.7</a></div>
        </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891322000863/exhibit_4-8.htm">Amended
        and Restated Form of Indemnification Undertaking and Exemption and Release between Compugen Ltd. and its directors and office holders
        (incorporated by reference to Exhibit 4.8 to Compugen&#8217;s Annual Report on Form 20-F/A for the year ended December 31, 2021, filed
        with the SEC on February 28, 2022 (File No. 000-30902)).</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891315001448/exhibit_99-2.htm">4.8</a></div>
        </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891315001448/exhibit_99-2.htm">Office
        Lease Agreement (&#8220;Holon Lease&#8221;), dated March 2015, by and between Kanit Hashalom Investments Ltd. and Compugen Ltd. (incorporated
        by reference to Exhibit 99.2 to Compugen&#8217;s Form 6-K filed with the SEC on May 5, 2015 (File No. 000-30902)).</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891316004622/exhibit_4-10.htm">4.9</a></div>
        </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891316004622/exhibit_4-10.htm">Amendment
        to Holon Lease made and entered into on November 26, 2015, by and between Kanit Hashalom Investments Ltd. and Compugen Ltd. (incorporated
        by reference to Exhibit 4.10 to Compugen&#8217;s Annual Report on Form 20-F for the year ended December 31, 2015, filed with the SEC on
        March 7, 2016 (File No. 000-30902)).</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891321000791/exhibit_4-11.htm">4.10</a></div>
        </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891321000791/exhibit_4-11.htm">Addendum
        to Holon Lease made and entered into on October 14, 2020 by and between Kanit Hashalom Investments Ltd. and Compugen Ltd. (incorporated
        by reference to Exhibit 4.11 to Compugen&#8217;s Annual Report on Form 20-F for the year ended December 31, 2020, filed with the SEC on
        February 25, 2021 (File No. 000-30902))</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891318001533/exhibit_10-1.htm">4.11@</a></div>
        </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891318001533/exhibit_10-1.htm">License
        Agreement, between the Company and MedImmune Limited (&#8220;MedImmune&#8221;), entered into as of March 30, 2018 (incorporated by reference
        to Exhibit 10.1 to Compugen&#8217;s Form 6-K, filed with the SEC on May 9, 2018 (File No. 000-30902)).</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891318002228/exhibit_10-1.htm">4.12@</a></div>
        </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891318002228/exhibit_10-1.htm">Amendment
        No. 1 to the License Agreement, between the Company and MedImmune, dated May 9, 2018 (incorporated by reference to Exhibit 10.1 to Compugen&#8217;s
        Form 6-K, filed with the SEC on August 1, 2018 (File No. 000-30902)).</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891321000791/exhibit_4-14.htm">4.13</a></div>
        </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891321000791/exhibit_4-14.htm">Amendment
        No. 2 to the License Agreement, between the Company and MedImmune, dated September 16, 2020 (incorporated by reference to Exhibit 4.14
        to Compugen&#8217;s Annual Report on Form 20-F for the year ended December 31, 2020, filed with the SEC on February 25, 2021 (File No.
        000-30902)).</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891322000863/exhibit_4-15.htm">4.14#</a></div>
        </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891322000863/exhibit_4-15.htm">Amendment
        No. 3 to the License Agreement, between the Company and MedImmune, dated August 4, 2021 (incorporated by reference to Exhibit 4.15 to
        Compugen&#8217;s Annual Report on Form 20-F/A for the year ended December 31, 2021, filed with the SEC on February 28, 2022 (File No.
        000-30902)).</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891318001935/exhibit_4-1.htm">4.15</a></div>
        </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891318001935/exhibit_4-1.htm">Form
        of Warrant to Purchase Ordinary Shares (incorporated by reference to Exhibit 4.1 to Compugen&#8217;s Form 6-K, filed with the SEC on June
        19, 2018 (File No. 000-30902)).</a></div> </td> </tr>
  </table>

<div><br /> </div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">113</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<table cellspacing="0" cellpadding="0" border="0" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_8-1.htm">8.1*</a></div> </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_8-1.htm">Subsidiaries.</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_12-1.htm">12.1*</a></div> </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_12-1.htm">Certification by Principal Executive Officer pursuant to
        Rule 13a-14(a)/Rule 15d-14(a) under the Exchange Act and Section 302 of the Sarbanes-Oxley Act of 2002.</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_12-2.htm">12.2*</a></div> </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_12-2.htm">Certification by Principal Financial Officer pursuant to
        Rule 13a-14(a)/Rule 15d-14(a) under the Exchange Act and Section 302 of the Sarbanes-Oxley Act of 2002.</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_13-1.htm">13.1*</a></div> </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_13-1.htm">Certification by Principal Executive Officer and Principal
        Financial Officer pursuant to Rule 13a-14(b)/Rule 15d-14(b) under the Exchange Act and 18 U.S.C. Section 1350, as adopted pursuant to
        Section 906 of the Sarbanes-Oxley Act of 2002.</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_15-1.htm">15.1*</a></div> </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25"><a href="exhibit_15-1.htm">Consent of Kost Forer Gabbay &amp; Kasierer, a member firm
        of Ernst &amp; Young Global.</a></div> </td> </tr>
  <tr>
    <td rowspan="1" style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td>
    <td rowspan="1" style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">&#160;</td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">101*</div> </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="text-align: justify; line-height: 1.25">The following financial information from Compugen Ltd.&#8217;s Annual Report on Form
        20-F for the year ended December 31, 2022, formatted in Inline XBRL (eXtensible Business Reporting Language): (i) Consolidated Statements
        of Operations for the years ended December 31, 2022, 2021 and 2020; (ii) Consolidated Balance Sheets as of December 31, 2022 and 2021;
        (iii) Consolidated Statements of Changes in Shareholders&#8217; Equity for the years ended December 31, 2022, 2021 and 2020; (iv) Consolidated
        Statements of Cash Flows for the years ended December 31, 2022, 2021 and 2020; and (v) Notes to Consolidated Financial Statements.</div>
        </td> </tr>
  </table>

<div> <br /> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"> <hr style="border-style: none; height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto" /></div>
</div>

<table cellspacing="0" cellpadding="0" border="0" id="z596487ec7bc74e8d9d54b7263f8f2bc2" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">101.INS</div> </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Inline XBRL Instance Document</div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">101.SCH</div> </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Inline XBRL Taxonomy Extension Schema Document</div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">101.PRE</div> </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Inline XBRL Taxonomy Extension Presentation Linkbase Document</div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">101.CAL</div> </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Inline XBRL Taxonomy Calculation Linkbase Document</div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">101.LAB</div> </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Inline XBRL Taxonomy Label Linkbase Document</div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">101.DEF</div> </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Inline XBRL Taxonomy Extension Definition Linkbase Document</div> </td> </tr>
  <tr>
    <td style="width: 8%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">104</div> </td>
    <td style="width: 92%; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div style="line-height: 1.25">Cover Page Interactive Data File&#160;(Formatted as Inline XBRL and contained in Exhibit 101).</div> </td>
        </tr>
  </table>

<div> <br /> </div>

<div style="line-height: 1.25">

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"> <hr style="border-style: none; height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto" /></div>
</div>

<table cellspacing="0" cellpadding="0" id="z0b700c215e0440f6b46339a9ef60c32e" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top; font-family: Times New Roman,Times,serif">*</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Filed herewith.</div> </td> </tr>
  </table>

<div> <br /> </div>

<table cellspacing="0" cellpadding="0" id="z45ac409e07fa48529eb1586205321066" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top; font-family: Times New Roman,Times,serif">@</td>
    <td style="width: auto; vertical-align: top; font-family: Times New Roman,Times,serif">
        <div>Confidential treatment has been granted by the Securities and Exchange Commission as to certain portions.</div> </td> </tr>
  </table>

<div> <br /> </div>

<table cellspacing="0" cellpadding="0" id="zc54ebe2357a143c08873fe5c429fce5a" class="DSPFListTable" style="font: 10pt Times New Roman, Times, serif; width: 100%; text-align: left; color: #000000">
  <tr>
    <td style="width: 36pt; vertical-align: top; font-family: Times New Roman,Times,serif">#</td>
    <td style="width: auto; vertical-align: top; text-align: justify; font-family: Times New Roman,Times,serif">
        <div>Portions of this exhibit (indicated by asterisks therein) have been omitted as these portions are both not material and confidential.</div>
        </td> </tr>
  </table>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageNumberArea" style="text-align: center"><span class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal">114</span></div>

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: center; margin-right: 28.4pt; margin-left: 18pt; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">SIGNATURES</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">The registrant hereby certifies that it
meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report
on its behalf.</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif">

<table cellspacing="0" cellpadding="0" border="0" id="z32884021f47744578bdbd2b016de12ad" style="font: 10pt Times New Roman, Times, serif; color: #000000; width: 100%">
  <tr>
    <td style="width: 50%">
        <div>&#160;</div> </td>
    <td style="width: 50%">
        <div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif; font-weight: bold">COMPUGEN LTD.</div>
        <div style="line-height: 1.25; font-family: Times New Roman,Times,serif">&#160;</div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif"><span style="text-decoration: underline">Signature:
        /s/ Dr. Anat Cohen-Dayag</span></div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Name: Dr. Anat Cohen-Dayag</div>
        <div style="text-align: left; line-height: 1.25; font-family: Times New Roman,Times,serif">Title: President and Chief Executive Officer,
        Director</div>
        <div style="text-align: left; line-height: 1.25; font-family: Times New Roman,Times,serif"> <br /> </div>
        <div style="text-align: justify; line-height: 1.25; font-family: Times New Roman,Times,serif">Date: February 28, 2023</div> </div> </td>
        </tr>
  </table> </div>

<div style="line-height: 1.25; font-family: Times New Roman,Times,serif"><br /> </div>

<div style="text-align: center"><span class="BRPFPageNumber" style="font-family: Times New Roman,Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal">115</span></div>

<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt">

<div class="BRPFPageBreak" style="page-break-after: always"> <hr style="border-width: 0px; margin: 4px 0px; clear: both; width: 100%; height: 2px; color: #000000; background-color: #000000" /></div>
</div> </div>
<!-- Field: /Include-Text -->
<div style="width:100%;clear:both">&#160;</div>
    </div>
  </div>

  <p style="font:10pt Times New Roman, Times, serif;text-align:center;margin-top:11pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:9pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">CONSOLIDATED FINANCIAL STATEMENTS</span></span></span></p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:9pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">AS OF DECEMBER 31, 2022</span></span></span></p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:9pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">U.S. DOLLARS IN THOUSANDS</span></span></span></p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:11pt;margin-bottom:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">INDEX</span></span></span></p>
  <div>
    <table cellpadding="0" style="border-spacing:0;margin:auto" width="100%">

        <tr>
          <td style="width:90%;vertical-align:top">&#160;</td>
          <td style="width:10%;border-bottom:1.5pt solid #000000;vertical-align:top">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Page</span></span></span></p>
          </td>
        </tr>
        <tr>
          <td style="width:90%;vertical-align:top">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
          </td>
          <td style="width:10%;vertical-align:top">&#160;</td>
        </tr>


        <tr>
          <td style="width:90%;vertical-align:bottom">
            <div style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><a href="#report_integixAnchor"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Report of Independent Registered Public Accounting Firm</span></span></span></span></span></span></span></span></span></span></span></span></a></span></span></span></span></span></span></span></span></span></span></span></span> <span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-style:italic">(PCAOB ID: </span><span style="font-style:italic"><ix:nonNumeric id="FFact_0000000000042" name="dei:AuditorFirmId" contextRef="C_20220101to20221231">1281</ix:nonNumeric></span><span style="font-style:italic">)</span></span></span></div>
          </td>
          <td style="width:10%;vertical-align:bottom">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">F-2</span><span style="font-weight:bold">&#8201;-&#8201;F-4</span></span></span></p>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <table cellpadding="0" style="border-spacing:0;margin:auto" width="100%">

        <tr>
          <td style="width:90%;vertical-align:bottom">&#160;</td>
          <td style="width:10%;vertical-align:bottom">&#160;</td>
        </tr>
        <tr>
          <td style="width:90%;vertical-align:bottom">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><a href="#balancesheets_integixAnchor"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Consolidated Balance Sheets</span></span></span></span></span></span></span></span></span></span></span></span></a></span></span></span></span></span></span></span></span></span></span></span></span></p>
          </td>
          <td style="width:10%;vertical-align:bottom">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">F-5</span><span style="font-weight:bold">&#8201;-&#8201;F-6</span></span></span></p>
          </td>
        </tr>
        <tr>
          <td style="width:90%;vertical-align:bottom">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
          </td>
          <td style="width:10%;vertical-align:bottom">&#160;</td>
        </tr>
        <tr>
          <td style="width:90%;vertical-align:bottom">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><a href="#comprehensiveloss_integixAnchor"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Consolidated Statements of Comprehensive Loss</span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></a></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
          </td>
          <td style="width:10%;vertical-align:bottom">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">F-7</span></span></span></p>
          </td>
        </tr>
        <tr>
          <td style="width:90%;vertical-align:bottom">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
          </td>
          <td style="width:10%;vertical-align:bottom">&#160;</td>
        </tr>
        <tr>
          <td style="width:90%;vertical-align:bottom">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><a href="#shareholdersequity_integixAnchor"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Statements of Changes in Shareholders&#8217; Equity</span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></a></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
          </td>
          <td style="width:10%;vertical-align:bottom">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">F-8</span></span></span></p>
          </td>
        </tr>
        <tr>
          <td style="width:90%;vertical-align:bottom">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
          </td>
          <td style="width:10%;vertical-align:bottom">&#160;</td>
        </tr>
        <tr>
          <td style="width:90%;vertical-align:bottom">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><a href="#cashflows_integixAnchor"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Consolidated Statements of Cash Flows</span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></a></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></span></p>
          </td>
          <td style="width:10%;vertical-align:bottom">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">F-9</span><span style="font-weight:bold">&#8201;-&#8201;F-10</span></span></span></p>
          </td>
        </tr>
        <tr>
          <td style="width:90%;vertical-align:bottom">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
          </td>
          <td style="width:10%;vertical-align:bottom">&#160;</td>
        </tr>
        <tr>
          <td style="width:90%;vertical-align:bottom">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><a href="#financialstatements_integixAnchor"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Notes to Consolidated Financial Statements</span></span></span></span></span></span></span></span></span></span></span></span></a></span></span></span></span></span></span></span></span></span></span></span></span></p>
          </td>
          <td style="width:10%;vertical-align:bottom">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">F-11</span><span style="font-weight:bold">&#8201;-&#8201;F-38</span></span></span></p>
          </td>
        </tr>

    </table>
  </div>
  <div>
    <div style="width:100%;clear:both;margin-top:0pt;margin-bottom:0pt">&#160;</div>
    <div style="width:100%;clear:both;margin-top:0pt;margin-bottom:0pt;text-align:center">
      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="text-align:center;font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-style:normal;font-weight:400">-</span><span style="color:#000000;font-family:Times New Roman, Times, serif;font-size:13.3333px;font-style:normal;font-variant-ligatures:normal;text-align:center;white-space:normal;background-color:#ffffff;text-decoration-thickness:initial;text-decoration-style:initial;text-decoration-color:initial;font-weight:bold">&#160;</span><span style="text-align:center;font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-style:normal;font-weight:400">-</span><span style="color:#000000;font-family:Times New Roman, Times, serif;font-size:13.3333px;font-style:normal;font-variant-ligatures:normal;text-align:center;white-space:normal;background-color:#ffffff;text-decoration-thickness:initial;text-decoration-style:initial;text-decoration-color:initial;font-weight:bold">&#160;</span><span style="text-align:center;font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-style:normal;font-weight:400">-</span><span style="color:#000000;font-family:Times New Roman, Times, serif;font-size:13.3333px;font-style:normal;font-variant-ligatures:normal;text-align:center;white-space:normal;background-color:#ffffff;text-decoration-thickness:initial;text-decoration-style:initial;text-decoration-color:initial;font-weight:bold">&#160;</span><span style="text-align:center;font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-style:normal;font-weight:400">-</span><span style="color:#000000;font-family:Times New Roman, Times, serif;font-size:13.3333px;font-style:normal;font-variant-ligatures:normal;text-align:center;white-space:normal;background-color:#ffffff;text-decoration-thickness:initial;text-decoration-style:initial;text-decoration-color:initial;font-weight:bold">&#160;</span><span style="text-align:center;font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-style:normal;font-weight:400">-</span><span style="color:#000000;font-family:Times New Roman, Times, serif;font-size:13.3333px;font-style:normal;font-variant-ligatures:normal;text-align:center;white-space:normal;background-color:#ffffff;text-decoration-thickness:initial;text-decoration-style:initial;text-decoration-color:initial;font-weight:bold">&#160;</span><span style="text-align:center;font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-style:normal;font-weight:400">-</span><span style="color:#000000;font-family:Times New Roman, Times, serif;font-size:13.3333px;font-style:normal;font-variant-ligatures:normal;text-align:center;white-space:normal;background-color:#ffffff;text-decoration-thickness:initial;text-decoration-style:initial;text-decoration-color:initial;font-weight:bold">&#160;</span><span style="text-align:center;font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-style:normal;font-weight:400">-</span><span style="color:#000000;font-family:Times New Roman, Times, serif;font-size:13.3333px;font-style:normal;font-variant-ligatures:normal;text-align:center;white-space:normal;background-color:#ffffff;text-decoration-thickness:initial;text-decoration-style:initial;text-decoration-color:initial;font-weight:bold">&#160;</span><span style="text-align:center;font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-style:normal;font-weight:400">-</span><span style="color:#000000;font-family:Times New Roman, Times, serif;font-size:13.3333px;font-style:normal;font-variant-ligatures:normal;text-align:center;white-space:normal;background-color:#ffffff;text-decoration-thickness:initial;text-decoration-style:initial;text-decoration-color:initial;font-weight:bold">&#160;</span><span style="text-align:center;font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-style:normal;font-weight:400">-</span><span style="color:#000000;font-family:Times New Roman, Times, serif;font-size:13.3333px;font-style:normal;font-variant-ligatures:normal;text-align:center;white-space:normal;background-color:#ffffff;text-decoration-thickness:initial;text-decoration-style:initial;text-decoration-color:initial;font-weight:bold">&#160;</span><span style="text-align:center;font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-style:normal;font-weight:400">-</span><span style="color:#000000;font-family:Times New Roman, Times, serif;font-size:13.3333px;font-style:normal;font-variant-ligatures:normal;text-align:center;white-space:normal;background-color:#ffffff;text-decoration-thickness:initial;text-decoration-style:initial;text-decoration-color:initial;font-weight:bold">&#160;</span><span style="text-align:center;font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-style:normal;font-weight:400">-</span></p>
      <p style="margin:0pt">&#160;</p>
    </div>
    <hr style="border-top:1.5pt solid #000000;margin-top:0pt" />
    <div style="page-break-after:always">&#160;</div>
  </div>
  <div>
    <table cellpadding="0" style="width:100%" width="100%">

        <tr>
          <td style="vertical-align:middle;width:20%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#8201;</span></span><span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><img alt=" " src="cgen_img01.jpg" style="width:99px;height:114px" /></span></span></span></p>
          </td>
          <td style="vertical-align:middle;width:30%">
            <p style="font-family:Times New Roman, Times, serif;font-size:8pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Kost Forer Gabbay &#38; Kasierer</span></span></span></p>
            <p style="font-family:Times New Roman, Times, serif;font-size:8pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">144 Menachem Begin Road, Building A,</span></span></p>
            <p style="font-family:Times New Roman, Times, serif;font-size:8pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tel-Aviv 6492102, Israel</span></span></p>
          </td>
          <td style="vertical-align:middle;width:25%">
            <p style="font-family:Times New Roman, Times, serif;font-size:8pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tel: +972-3-6232525</span></span></p>
            <p style="font-family:Times New Roman, Times, serif;font-size:8pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fax: +972-3-5622555</span></span></p>
            <p style="font-family:Times New Roman, Times, serif;font-size:8pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ey.com</span></span></p>
          </td>
          <td style="vertical-align:top;width:25%">&#160;</td>
        </tr>

    </table>
  </div>
  <div style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:11pt;margin-bottom:0pt"><span id="report_integixAnchor"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></span></span></span></div>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:11pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">To the Shareholders and Board of Directors of</span></span></span></p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:11pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">COMPUGEN LTD.</span></span></span></p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Opinion on the Financial Statements</span></span></span></p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We have audited the accompanying consolidated balance sheets of Compugen Ltd. and its subsidiary (the &#8220;Company&#8220;) as of December 31, 2022 and 2021, the related consolidated statements of comprehensive loss, changes in shareholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2022, and related notes (collectively referred to as the &#8220;consolidated financial statements&#8220;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022, in conformity with U.S. generally accepted accounting principles.</span></span></p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 28, 2023, expressed an unqualified opinion thereon.</span></span></p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Basis for Opinion</span></span></span></p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></span></p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></span></p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:9pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Critical audit matter</span></span></span></p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></span></p>
  <p style="margin:0pt">&#160;</p>
  <div>
    <div>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:3pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F&#8201;-&#8201;2</span></span></p>
    </div>
    <hr style="border-top:1.5pt solid #000000;margin-top:0pt" />
    <div style="page-break-after:always">&#160;</div>
  </div>
  <div>
    <table cellpadding="0" style="border-spacing:0" width="100%">

        <tr>
          <td style="width:15%;vertical-align:top">&#160;</td>
          <td style="width:2%;vertical-align:top">&#160;</td>
          <td style="width:84%;vertical-align:top">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Accrued pre-clinical and clinical trial expenses</span></span></span></p>
          </td>
        </tr>


        <tr>
          <td style="width:15%;vertical-align:top">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:6pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Description of the matter</span></span></p>
          </td>
          <td style="width:2%;vertical-align:top">&#160;</td>
          <td style="width:84%;vertical-align:top">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:6pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As discussed in Note 2(k) to the consolidated financial statements, the Company records costs for pre-clinical and clinical trial activities based upon estimates of costs incurred through the balance sheet date that have yet to be invoiced by the contract research organizations and other vendors.</span></span></p>
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Auditing the Company&#8217;s accruals for pre-clinical and clinical trial activities is challenging due to the fact that information necessary to estimate the accruals for the services that have been received during the reporting period is accumulated from multiple sources such as Company&#8217;s personnel that oversee the pre-clinical and clinical trial activities, information from service providers and terms and conditions included in the contracts with the service providers. In addition, in certain circumstances, the determination of the nature and level of services that have been received during the reporting period requires judgment because the timing and pattern of vendor invoicing does not correspond to the level of services provided and there may be delays in invoicing from pre-clinical and clinical study sites and other vendors.</span></span></p>
          </td>
        </tr>
        <tr>
          <td style="width:15%;vertical-align:top">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:6pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">How we addressed the matter in our audit</span></span></p>
          </td>
          <td style="width:2%;vertical-align:top">&#160;</td>
          <td style="width:84%;vertical-align:top">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:6pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We obtained an understanding of, evaluated the design and tested the operating effectiveness of internal controls that addressed the identified risks related to the Company&#8217;s process for recording accrued pre-clinical and clinical trial expenses.</span></span></p>
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">To test the pre-clinical and clinical trial accruals, our audit procedures included, among others, reviewing a sample of agreements with the service providers to corroborate key terms and conditions and testing the accuracy and completeness of the underlying data used in the accrual computations. We also evaluated management&#8217;s estimates of the progress of a sample of pre-clinical and clinical trial activities by making direct inquiries of the Company&#8217;s personnel that oversee the pre-clinical and clinical trial activities and obtaining information directly from certain service providers which indicated the progress of pre-clinical and clinical trial completed through the balance sheet date and compared that to the Company&#8217;s accrual computations. To evaluate the completeness of the accruals, we also examined subsequent invoices from the service providers and cash disbursements to the service providers, to the extent such invoices were received, or payments were made prior to the date that the consolidated financial statements were issued.</span></span></p>
          </td>
        </tr>

    </table>
  </div>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:16pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">KOST FORER GABBAY &#38; KASIERER</span></span></p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A Member of Ernst &#38; Young Global</span></span></p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-bottom:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We have served as the Company&#8217;s auditor since 2002</span></span></p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tel-Aviv, Israel</span></span></p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">February 28, 2023</span></span></p>
  <p style="margin:0pt">&#160;</p>
  <div>
    <div style="width:100%;clear:both;margin-bottom:0pt">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:3pt"><span style="font-size:10pt;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">F&#8201;-&#8201;3</span></span></p>
    </div>
    <hr style="border-top:1.5pt solid #000000;margin-top:0pt" />
    <div style="page-break-after:always">&#160;</div>
  </div>
  <div>
    <table cellpadding="0" style="width:100%" width="100%">

        <tr>
          <td style="vertical-align:middle;width:20%">
            <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><img alt=" " src="cgen_img01.jpg" style="width:99px;height:114px" /></p>
          </td>
          <td style="vertical-align:middle;width:30%">
            <p style="font-family:Times New Roman, Times, serif;font-size:8pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Kost Forer Gabbay &#38; Kasierer</span></span></span></p>
            <p style="font-family:Times New Roman, Times, serif;font-size:8pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">144 Menachem Begin Road, Building A,</span></span></p>
            <p style="font-family:Times New Roman, Times, serif;font-size:8pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tel-Aviv 6492102, Israel</span></span></p>
          </td>
          <td style="vertical-align:middle;width:25%">
            <p style="font-family:Times New Roman, Times, serif;font-size:8pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Tel: +972-3-6232525</span></span></p>
            <p style="font-family:Times New Roman, Times, serif;font-size:8pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Fax: +972-3-5622555</span></span></p>
            <p style="font-family:Times New Roman, Times, serif;font-size:8pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">ey.com</span></span></p>
          </td>
          <td style="vertical-align:top;width:25%">&#160;</td>
        </tr>

    </table>
  </div>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:11pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></span></span></p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:11pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">To the Shareholders and Board of Directors of</span></span></span></p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:11pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">COMPUGEN LTD.</span></span></span></p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Opinion on Internal Control over Financial Reporting</span></span></span></p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We have audited Compugen Ltd. and its subsidiary&#8217;s internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Compugen Ltd. and its subsidiary (the &#8220;Company&#8220;) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on the COSO criteria.</span></span></p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2022 and 2021 and the related consolidated statements of comprehensive loss, changes in shareholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2022, and the related notes and our report dated February 28, 2023, expressed an unqualified opinion thereon.&#160;</span></span></p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Basis for Opinion</span></span></span></p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></span></p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></span></p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures, as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></span></p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">Definition and Limitations of Internal Control Over Financial Reporting</span></span></span></p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></span></p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></span></p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="FFact_0000000000043" name="dei:AuditorName" contextRef="C_20220101to20221231">KOST FORER GABBAY &#38; KASIERER</ix:nonNumeric></span></span></p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">A Member of Ernst &#38; Young Global</span></span></p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="FFact_0000000000044" name="dei:AuditorLocation" contextRef="C_20220101to20221231">Tel-Aviv, Israel</ix:nonNumeric></span></span></p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">February 28, 2023</span></span></p>
  <p style="margin:0pt">&#160;</p>
  <div>
    <div style="width:100%;clear:both">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:3pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F&#8201;-&#8201;4</span></span></p>
    </div>
    <hr style="border-top:1.5pt solid #000000;page-break-after:always;margin-top:0px" />
  </div>

  <p id="d1e668_anchor" style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:9pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0px;margin-bottom:0pt">&#160;</p>
  <div>
    <div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span id="balancesheets_integixAnchor"><span><span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>CONSOLIDATED BALANCE SHEETS</span></span></span></span></span></span></span></div>
        <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" />
      </div>
      <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>U.S. dollars in thousands</span></span></span></span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December 31,</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Note</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2021</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>ASSETS</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>CURRENT ASSETS:</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">
              <div style="margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Cash and cash equivalents</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>$</span></span></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="FFact_0000000000045" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,059</ix:nonFraction></span></span></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>$</span></span></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="FFact_0000000000046" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,801</ix:nonFraction></span></span></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Restricted cash</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000047" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">362</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000048" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">713</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">
              <div style="margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Short-term bank deposits</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;text-align:center" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000049" name="us-gaap:OtherShortTermInvestments" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">72,287</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000050" name="us-gaap:OtherShortTermInvestments" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">109,248</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64.66%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">
              <div style="margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Other accounts receivable and prepaid expenses</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">
              <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>3</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000053" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,417</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000054" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,460</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64.66%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:center;width:9.08%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64.66%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="margin-left:2.85pt;line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="text-decoration:underline">Total</span><span> current assets</span></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:center;width:9.08%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000055" name="us-gaap:AssetsCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">86,125</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000056" name="us-gaap:AssetsCurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">123,222</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64.66%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:center;width:9.08%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64.66%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>NON-CURRENT ASSETS:</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:center;width:9.08%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64.66%" valign="bottom">
              <div style="margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Long-term prepaid expenses</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:center;width:9.08%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000057" name="us-gaap:PrepaidExpenseNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,899</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000058" name="us-gaap:PrepaidExpenseNoncurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,911</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64.66%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Severance pay fund</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:center;width:9.08%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000059" name="cgen:SeverancePayFundNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,794</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000060" name="cgen:SeverancePayFundNoncurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,125</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64.66%" valign="bottom">
              <div style="margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Operating lease right of use asset</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%" valign="bottom">
              <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>4</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000061" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,826</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000062" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,247</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64.66%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Property and equipment, net</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>5</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000063" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,532</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000064" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,658</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64.66%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:center;width:9.08%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64.66%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="margin-left:2.85pt;line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="text-decoration:underline">Total</span><span> non- current assets</span></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000065" name="us-gaap:AssetsNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,051</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000066" name="us-gaap:AssetsNoncurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,941</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64.66%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64.66%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="margin-left:2.85pt;line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="text-decoration:underline">Total</span><span> assets</span></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>$</span></span></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="FFact_0000000000067" name="us-gaap:Assets" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,176</ix:nonFraction></span></span></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>$</span></span></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="FFact_0000000000068" name="us-gaap:Assets" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">132,163</ix:nonFraction></span></span></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The accompanying notes are an integral part of the consolidated financial statements.</span></span></span></span></div>
    </div>
  </div>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0px;margin-bottom:0pt">&#160;</p>
  <div>
    <div style="width:100%;clear:both">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:3pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F&#8201;-&#8201;5</span></span></p>
    </div>
    <hr style="border-top:1.5pt solid #000000;page-break-after:always;margin-top:0pt" />
  </div>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:10t;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0px;margin-bottom:0pt">&#160;</p>
  <div>
    <div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>CONSOLIDATED BALANCE SHEETS</span></span></span></span></div>
      </div>
      <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" />
      <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>U.S. dollars in thousands (except share and per share data)</span></span></span></span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>December 31,</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Note</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2022</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>2021</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="margin-left:17pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>LIABILITIES AND SHAREHOLDERS<span style="color:rgb(0, 0, 0)">&#8217;</span> EQUITY</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>CURRENT LIABILITIES:</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">
              <div style="margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Trade payables</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>$</span></span></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="FFact_0000000000069" name="us-gaap:AccountsPayableCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,773</ix:nonFraction></span></span></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>$</span></span></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="FFact_0000000000070" name="us-gaap:AccountsPayableCurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,621</ix:nonFraction></span></span></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Short-term deferred participation in R&#38;D expenses</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;text-align:center;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000071" name="cgen:ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">325</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000072" name="cgen:ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,629</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64.66%" valign="bottom">
              <div style="margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Current maturity of operating lease liability</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%" valign="bottom">
              <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>4</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000073" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">613</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000074" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">768</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64.66%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">
              <div style="margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Other accounts payable and accrued expenses</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">
              <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>6</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000075" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,208</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000076" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,078</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64.66%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:center;width:9.08%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64.66%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="margin-left:2.85pt;line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="text-decoration:underline">Total</span><span> current liabilities</span></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:center;width:9.08%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000077" name="us-gaap:LiabilitiesCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,919</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000078" name="us-gaap:LiabilitiesCurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,096</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64.66%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:center;width:9.08%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64.66%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>NON- CURRENT LIABILITIES:</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:center;width:9.08%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64.66%" valign="bottom">
              <div style="margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Long-term deferred participation in R&#38;D expenses</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:center;width:9.08%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000079" name="cgen:LongTermDeferredParticipationInResearchAndDevelopmentExpenses" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000080" name="cgen:LongTermDeferredParticipationInResearchAndDevelopmentExpenses" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,715</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64.66%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Long-term operating lease liability</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:center;width:9.08%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000081" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,312</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000082" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,982</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64.66%;padding-bottom:2px" valign="bottom">
              <div style="margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Accrued severance pay</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:center;width:9.08%;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000083" name="us-gaap:PostemploymentBenefitsLiabilityNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,265</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000084" name="us-gaap:PostemploymentBenefitsLiabilityNoncurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,677</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64.66%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:center;width:9.08%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64.66%;padding-bottom:2px" valign="bottom">
              <div style="margin-left:2.85pt;line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="text-decoration:underline">Total</span><span> non-current liabilities</span></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:center;width:9.08%;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000085" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,577</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000086" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,374</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64.66%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:center;width:9.08%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64.66%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>COMMITMENTS AND CONTINGENT LIABILITIES</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%" valign="bottom">
              <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>7</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230221100858646" name="us-gaap:CommitmentsAndContingencies" contextRef="C_20221231" unitRef="usd" xsi:nil="true"></ix:nonFraction></span></span></td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%" valign="bottom"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230221100903927" name="us-gaap:CommitmentsAndContingencies" contextRef="C_20211231" unitRef="usd" xsi:nil="true"></ix:nonFraction></span></span></td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64.66%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:center;width:9.08%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64.66%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>SHAREHOLDERS<span style="color:rgb(0, 0, 0)">&#8217;</span> EQUITY:</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%" valign="bottom">
              <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>8</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64.66%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Share capital:</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64.66%" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Ordinary shares of NIS <ix:nonFraction id="Fxbrl_20230214011115128" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20211231" unitRef="NIS_Per_Share" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230214011053357" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_20221231" unitRef="NIS_Per_Share" decimals="INF" format="ixt:num-dot-decimal">0.01</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction id="Fxbrl_s_20230214011030882" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20211231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230214011030883" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20221231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized at December 31, 2022 and 2021; <ix:nonFraction id="Fxbrl_20230214101530012" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20221231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_0000000000092" name="us-gaap:CommonStockSharesIssued" contextRef="C_20221231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">86,624,643</ix:nonFraction></ix:nonFraction> and <ix:nonFraction id="Fxbrl_20230214011437479" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20211231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="FFact_0000000000094" name="us-gaap:CommonStockSharesIssued" contextRef="C_20211231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">86,433,432</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2022 and 2021, respectively</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000095" name="us-gaap:CommonStockValue" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">240</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000096" name="us-gaap:CommonStockValue" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">239</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64.66%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Additional paid-in capital</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000097" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">533,213</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000098" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">528,533</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64.66%;padding-bottom:2px" valign="bottom">
              <div style="margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Accumulated deficit</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="FFact_0000000000099" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">455,773</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>(<ix:nonFraction id="FFact_0000000000100" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">422,079</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>)</span></span></span></span></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64.66%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64.66%;padding-bottom:2px" valign="bottom">
              <div style="margin-left:2.85pt;line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="text-decoration:underline">Total</span><span> shareholders<span style="color:rgb(0, 0, 0)">&#8217;</span> equity</span></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000101" name="us-gaap:StockholdersEquity" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">77,680</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><ix:nonFraction id="FFact_0000000000102" name="us-gaap:StockholdersEquity" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">106,693</ix:nonFraction></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64.66%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;width:64.66%;padding-bottom:4px" valign="bottom">
              <div style="margin-left:2.85pt;line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span style="text-decoration:underline">Total</span><span> liabilities and shareholders<span style="color:rgb(0, 0, 0)">&#8217;</span> equity</span></span></span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:4px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9.08%;padding-bottom:4px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.04%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:4px" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>$</span></span></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="FFact_0000000000103" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,176</ix:nonFraction></span></span></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:4px" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span>$</span></span></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9.08%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><ix:nonFraction id="FFact_0000000000104" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">132,163</ix:nonFraction></span></span></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.04%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The accompanying notes are an integral part of the consolidated financial statements.</span></span></span></span>
        <p style="margin:0pt">&#160;</p>
      </div>
    </div>
  </div>
  <div>
    <div style="width:100%;clear:both">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-bottom:3pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F&#8201;-&#8201;6</span></span></p>
    </div>
    <hr style="border-top:1.5pt solid #000000;page-break-after:always;margin-top:0pt" />
  </div>

  <div>
    <div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="text-align:justify;line-height:1.25;font-weight:bold">
          <div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></div>
        </div>
        <div style="text-align:justify;line-height:1.25;font-weight:bold">&#160;</div>
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span id="comprehensiveloss_integixAnchor"><span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS </span></span> </span></span>
          <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" />
        </div>
      </div>
      <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S. dollars in thousands (except share and per share data)</span></span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="10" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Note</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2020</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Revenue</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_0000000000105" name="us-gaap:Revenues" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,500</ix:nonFraction></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_0000000000106" name="us-gaap:Revenues" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,000</ix:nonFraction></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20230214012425376" name="us-gaap:Revenues" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,000</ix:nonFraction></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">
              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cost of revenue</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000108" name="us-gaap:CostOfRevenue" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">975</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000109" name="us-gaap:CostOfRevenue" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">680</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214012430928" name="us-gaap:CostOfRevenue" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">60</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">
              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gross profit</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000111" name="us-gaap:GrossProfit" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,525</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000112" name="us-gaap:GrossProfit" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,320</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214012436309" name="us-gaap:GrossProfit" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,940</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">
              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating expenses:</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">
              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development expenses, net</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230222115443735_Fact_0000000000117" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,648</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230222115443735_Fact_0000000000118" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,694</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230222115443735_Fact_0000000000119" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,760</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Marketing and business development expenses</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000117" name="us-gaap:BusinessDevelopment" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">932</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000118" name="us-gaap:BusinessDevelopment" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">842</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000119" name="us-gaap:BusinessDevelopment" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">871</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">
              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General and administrative expenses</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230222115622478_Fact_0000000000117" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,319</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230222115622478_Fact_0000000000118" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,858</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230222115622478_Fact_0000000000119" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,805</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;padding-bottom:2px" valign="bottom">
              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Total</span><span> operating expenses</span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230222115529913" name="us-gaap:OperatingExpenses" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,899</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000124" name="us-gaap:OperatingExpenses" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,394</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000125" name="us-gaap:OperatingExpenses" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,436</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">
              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating loss</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000126" name="us-gaap:OperatingIncomeLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">35,374</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000127" name="us-gaap:OperatingIncomeLoss" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">35,074</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000128" name="us-gaap:OperatingIncomeLoss" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">31,496</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255);text-align:center" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:46.17%;padding-bottom:2px" valign="bottom">
              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Financial and other income, net</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.44%;padding-bottom:2px" valign="bottom">
              <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">11</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.38%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000129" name="cgen:FinancialIncomeExpenseNet" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,738</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.38%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000130" name="cgen:FinancialIncomeExpenseNet" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">871</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.38%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000131" name="cgen:FinancialIncomeExpenseNet" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,798</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:46.17%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:center;width:10.44%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.38%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.38%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.38%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:46.17%" valign="bottom">
              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss before taxes on income</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:center;width:10.44%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.38%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000132" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">33,636</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.38%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000133" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">34,203</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.38%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000134" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">29,698</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:46.17%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Taxes on income</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.44%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.38%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214012403897" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">58</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.38%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214012406780" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.38%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000137" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:46.17%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:center;width:10.44%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.38%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.38%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.38%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:46.17%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:center;width:10.44%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.38%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000138" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">33,694</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.38%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000139" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">34,203</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.38%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000140" name="us-gaap:NetIncomeLoss" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">29,698</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:46.17%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:center;width:10.44%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.38%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.38%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.38%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:46.17%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic net loss per share</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.44%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.38%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(<ix:nonFraction id="FFact_0000000000141" name="us-gaap:EarningsPerShareBasic" contextRef="C_20220101to20221231" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal" sign="-">0.39</ix:nonFraction></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.38%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(<ix:nonFraction id="FFact_0000000000142" name="us-gaap:EarningsPerShareBasic" contextRef="C_20210101to20211231" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal" sign="-">0.41</ix:nonFraction></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.38%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(<ix:nonFraction id="FFact_0000000000143" name="us-gaap:EarningsPerShareBasic" contextRef="C_20200101to20201231" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal" sign="-">0.37</ix:nonFraction></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:46.17%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.44%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.38%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.38%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.38%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:46.17%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Diluted net loss per share</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.44%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.38%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(<ix:nonFraction id="FFact_0000000000144" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20220101to20221231" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal" sign="-">0.39</ix:nonFraction></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.38%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(<ix:nonFraction id="FFact_0000000000145" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20210101to20211231" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal" sign="-">0.41</ix:nonFraction></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.38%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(<ix:nonFraction id="FFact_0000000000146" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20200101to20201231" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal" sign="-">0.37</ix:nonFraction></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:46.17%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.44%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.38%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.38%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.38%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:46.17%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total comprehensive loss</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.44%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.38%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(<ix:nonFraction id="FFact_0000000000147" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">33,694</ix:nonFraction></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.38%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(<ix:nonFraction id="FFact_0000000000148" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">34,203</ix:nonFraction></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1.1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:10.38%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(<ix:nonFraction id="FFact_0000000000149" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">29,698</ix:nonFraction></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1.1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:46.17%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.44%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.38%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.38%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.38%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:46.17%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average number of ordinary shares used in computing basic net loss per share</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.44%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.38%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000150" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20220101to20221231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">86,555,628</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.38%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000151" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20210101to20211231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">84,203,971</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.38%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000152" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20200101to20201231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">79,591,187</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:46.17%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.44%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.38%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.38%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.38%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:46.17%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average number of ordinary shares used in computing diluted net loss per share</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.44%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.38%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000153" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20220101to20221231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">86,555,628</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.38%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000154" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20210101to20211231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">84,203,971</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:10.38%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000155" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_20200101to20201231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">79,591,187</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1.1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="line-height:1.25;font-family:Times New Roman, Times, serif;margin-bottom:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of the consolidated financial statements.</span></span></div>
    </div>
  </div>
  <div>
    <div style="width:100%;clear:both">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt">&#160;</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0px;margin-bottom:3pt">F - 7</p>
    </div>
    <hr style="border-top:1.5pt solid #000000;page-break-after:always;margin-top:0pt" />
  </div>

  <p id="d1e3423_anchor" style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:10pt;margin-bottom:0pt"><span style="font-weight:bold">CO</span><span><span style="font-weight:bold">MPUGEN LTD. AND ITS SUBSIDIARY</span></span></p>
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0px;margin-bottom:0pt">&#160;</p>
  <div>
    <div>
      <div style="line-height:1.25">
        <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt"><span id="shareholdersequity_integixAnchor"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY</span></span></span></span>
          <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" />
        </div>
      </div>
      <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S. dollars in thousands (except share data)</span></span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Ordinary shares</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;text-align:center">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Additional paid-in</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;text-align:center">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accumulated</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;text-align:center">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total shareholders<span style="color:rgb(0, 0, 0)">&#8217;</span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Number</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amount</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">capital</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">deficit</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;text-align:center;vertical-align:bottom;padding-bottom:2px;white-space:nowrap">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;text-align:center">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0);text-align:center">
              <div style="line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">equity</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of January 1, 2020</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000156" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20191231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">67,922,836</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000157" name="us-gaap:StockholdersEquity" contextRef="C_20191231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">187</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000158" name="us-gaap:StockholdersEquity" contextRef="C_20191231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">396,312</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000159" name="us-gaap:StockholdersEquity" contextRef="C_20191231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">358,178</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_0000000000160" name="us-gaap:StockholdersEquity" contextRef="C_20191231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,321</ix:nonFraction></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Options exercised</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000161" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">3,070,542</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000162" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000163" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,906</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000164" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,915</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants exercised</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214013524660" name="cgen:NumberOfWarrantsExercised" contextRef="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">3,866,139</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214013608017" name="cgen:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214013559422" name="cgen:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,314</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214013636006" name="cgen:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,325</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuance of shares, net</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000165" name="cgen:IssuanceOfSharesAndWarrantsNetShares" contextRef="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">8,816,339</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000166" name="cgen:IssuanceOfSharesAndWarrantsNetValue" contextRef="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000167" name="cgen:IssuanceOfSharesAndWarrantsNetValue" contextRef="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,123</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000168" name="cgen:IssuanceOfSharesAndWarrantsNetValue" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,147</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Stock-based compensation relating to options issued to employees, directors and non-employees</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000169" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" contextRef="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,772</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000170" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,772</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000171" name="us-gaap:NetIncomeLoss" contextRef="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">29,698</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000172" name="us-gaap:NetIncomeLoss" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">29,698</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of December 31, 2020</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000173" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">83,675,856</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000174" name="us-gaap:StockholdersEquity" contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">231</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000175" name="us-gaap:StockholdersEquity" contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">507,427</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000176" name="us-gaap:StockholdersEquity" contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">387,876</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000177" name="us-gaap:StockholdersEquity" contextRef="C_20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">119,782</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercise of options and ESPP shares</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214013709298" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">335,204</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214013718917" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214013728837" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,454</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214013739149" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,455</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants exercised</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000182" name="cgen:NumberOfWarrantsExercised" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">89,557</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<span style="-sec-ix-hidden:Fxbrl_20230214102832182">*</span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000184" name="cgen:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">425</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230221102251303" name="cgen:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">425</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Issuance of shares, net</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000186" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">2,332,815</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000187" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000188" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,951</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000189" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,958</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Stock-based compensation issued to employees, directors and non-employees</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000190" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,276</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000191" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,276</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">-</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000192" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">34,203</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000193" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">34,203</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of December 31, 2021</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000194" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">86,433,432</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000195" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">239</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000196" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">528,533</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000197" name="us-gaap:StockholdersEquity" contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">422,079</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000198" name="us-gaap:StockholdersEquity" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">106,693</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Exercise of options and ESPP shares</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000199" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">191,211</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000200" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000201" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">352</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000202" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">353</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Stock-based compensation issued to employees, directors and non-employees</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000211" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,328</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000212" name="cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,328</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000213" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">33,694</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000214" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">33,694</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:40%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Balance as of December 31, 2022</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000215" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">86,624,643</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000216" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">240</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000217" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">533,213</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000218" name="us-gaap:StockholdersEquity" contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">455,773</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_0000000000219" name="us-gaap:StockholdersEquity" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">77,680</ix:nonFraction></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(*) Representing amount lower than $1.</span></span></span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif;margin-bottom:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of the consolidated financial statements.</span></span>
        <p style="margin:0pt">&#160;</p>
      </div>
    </div>
  </div>
  <div>
    <div style="width:100%;clear:both">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0px;margin-bottom:3pt">F&#8201;-&#8201;8</p>
    </div>
    <hr style="border-top:1.5pt solid #000000;page-break-after:always;margin-top:0px" />
  </div>

  <div>
    <div>
      <div style="font-family:'Times New Roman',Times,serif">
        <div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></div>
      </div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
        <div style="text-align:justify;line-height:1.25;font-weight:bold">&#160;</div>
        <div style="text-align:justify;line-height:1.25;font-weight:bold"><span id="cashflows_integixAnchor"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></span></span>
          <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" />
        </div>
      </div>
      <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S. dollars in thousands</span></span></div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="10" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
              <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2020</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Cash flows from operating activities:</span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
            <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss</span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(<ix:nonFraction id="FFact_0000000000220" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">33,694</ix:nonFraction></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(<ix:nonFraction id="FFact_0000000000221" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">34,203</ix:nonFraction></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(<ix:nonFraction id="FFact_0000000000222" name="us-gaap:NetIncomeLoss" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">29,698</ix:nonFraction></span></span></span></div>
            </td>
            <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Adjustments required to reconcile net loss to net cash used in operating activities:</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Stock-based compensation</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000223" name="us-gaap:ShareBasedCompensation" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,328</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000224" name="us-gaap:ShareBasedCompensation" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,276</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000225" name="us-gaap:ShareBasedCompensation" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,772</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Depreciation</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000226" name="us-gaap:Depreciation" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">482</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000227" name="us-gaap:Depreciation" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">461</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000228" name="us-gaap:Depreciation" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">715</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Increase (decrease) in severance pay, net</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000229" name="cgen:SeverancePayNet" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">81</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230214015430934" name="cgen:SeverancePayNet" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">101</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000231" name="cgen:SeverancePayNet" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">184</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Loss (gain) from property and equipment sales and disposals</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000232" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000233" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000234" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease (increase) in interest receivables from short-term bank deposits</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230214015508662" name="cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">584</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000236" name="cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">469</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230214015458380" name="cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">532</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease (increase) in trade receivables</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000238" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000239" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,000</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230214015520285" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,000</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease (increase) in other accounts receivable and prepaid expenses</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000241" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3,043</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000242" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,802</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000243" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,613</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease (increase) in long-term prepaid expenses</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000244" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000245" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">31</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230214015551570" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,187</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease in operating lease right of use asset</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000247" name="cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">658</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000248" name="cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">525</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000249" name="cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">475</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Increase (decrease) in trade payables and other accounts payable and accrued expenses</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230214015610319" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,601</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000251" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,367</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000252" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,817</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Increase (decrease) in deferred participation in R&#38;D expenses</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230214015629815" name="cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">6,019</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000254" name="cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,708</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000255" name="cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">829</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;padding-bottom:2px" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:19.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Decrease in operating lease liability</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000256" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1,062</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000257" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">416</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000258" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">412</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;padding-bottom:2px" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net cash used in operating activities</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000259" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">34,506</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000260" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">22,750</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000261" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">28,320</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom">
              <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Cash flows from investing activities:</span></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds from maturity of short-term bank deposits</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000262" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">114,445</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000263" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">136,850</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000264" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">70,300</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Investment in short-term bank deposits</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000265" name="us-gaap:PaymentsToAcquireInvestments" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,900</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000266" name="us-gaap:PaymentsToAcquireInvestments" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">129,945</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000267" name="us-gaap:PaymentsToAcquireInvestments" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">152,350</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Purchase of property and equipment</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000268" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">477</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000269" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">292</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000270" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">166</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:64%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Costs of disposal of property and equipment</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230222115924752_Fact_0000000000268" name="us-gaap:PropertyPlantAndEquipmentDisposals" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230222115924752_Fact_0000000000269" name="us-gaap:PropertyPlantAndEquipmentDisposals" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230222115924752_Fact_0000000000270" name="us-gaap:PropertyPlantAndEquipmentDisposals" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:64%;padding-bottom:2px" valign="bottom">
              <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds from sale of property and equipment</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230222112447073" name="cgen:PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000272" name="cgen:PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">3</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000273" name="cgen:PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">44</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;padding-bottom:2px" valign="bottom">
              <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net cash provided by (used in) investing activities</span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000274" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,060</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000275" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,616</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230214015724492" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">82,172</ix:nonFraction></span></span></div>
            </td>
            <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
              <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
            </td>
          </tr>

      </table>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
      <div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif;margin-bottom:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of the consolidated financial statements.</span></span>
        <p style="margin:0pt">&#160;</p>
      </div>
    </div>
  </div>
  <div>
    <div style="width:100%;clear:both">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0px;margin-bottom:3px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F&#8201;-&#8201;9</span></span></p>
    </div>
    <hr style="border-top:1.5pt solid #000000;break-after:page;margin-top:0px" />
    <div style="text-align:right;margin-top:11pt"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></strong></div>
  </div>
  <div>
    <div>
      <div>
        <div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
            <div style="text-align:justify;line-height:1.25;font-weight:bold">&#160;</div>
            <div style="text-align:justify;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></span>
              <hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" />
            </div>
          </div>
          <div style="text-align:justify;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">U.S. dollars in thousands</span></span></div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;color:#000000;width:100%">

              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                <td colspan="10" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                  <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2020</span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Cash flows from financing activities:</span></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;background-color:rgb(204, 238, 255)" valign="bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds from issuance of ordinary shares, net</span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000277" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000278" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,958</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000279" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,147</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds from exercise of warrants</span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000280" name="us-gaap:ProceedsFromWarrantExercises" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000281" name="us-gaap:ProceedsFromWarrantExercises" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">425</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="Fxbrl_20230214015741861" name="us-gaap:ProceedsFromWarrantExercises" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,325</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Proceeds from exercise of stock-based awards</span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000283" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">353</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000284" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,455</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000285" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,991</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net cash provided by financing activities</span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000286" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">353</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000287" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,838</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000288" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">108,463</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;background-color:rgb(204, 238, 255)" valign="bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Increase (decrease) in cash, cash equivalents and restricted cash</span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000289" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,907</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000290" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">704</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230214015801453" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">2,029</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;padding-bottom:2px" valign="bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash, cash equivalents and restricted cash at the beginning of the year</span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000292" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,514</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000293" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,810</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000294" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20191231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,839</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;padding-bottom:4px" valign="bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash and cash equivalents and restricted cash at the end of the year</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_0000000000295" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,421</ix:nonFraction></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_0000000000296" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,514</ix:nonFraction></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_0000000000297" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,810</ix:nonFraction></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Supplemental disclosure of non-cash investing and financing activities:</span></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;padding-bottom:4px" valign="bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Purchase of property and equipment</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_0000000000298" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">117</ix:nonFraction></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_0000000000299" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">116</ix:nonFraction></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_0000000000300" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Right-of-use asset obtained in exchange for operating lease liability</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20230214015821971" name="cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">237</ix:nonFraction></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_0000000000305" name="cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(<ix:nonFraction id="Fxbrl_20230214015838501" name="cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">194</ix:nonFraction></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></div>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;background-color:rgb(204, 238, 255)" valign="bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Cash paid (received) during the year for:</span></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Interest payments received from short-term bank deposits and cash equivalents</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_0000000000307" name="cgen:InterestPaidReceivedNet" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">852</ix:nonFraction></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_0000000000308" name="cgen:InterestPaidReceivedNet" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,364</ix:nonFraction></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_0000000000309" name="cgen:InterestPaidReceivedNet" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,232</ix:nonFraction></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;background-color:rgb(204, 238, 255)" valign="bottom">
                  <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="text-decoration:underline">Reconciliation of cash, cash equivalents and restricted cash:</span></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;background-color:rgb(204, 238, 255)" valign="bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash and cash equivalents</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_0000000000310" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,059</ix:nonFraction></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_0000000000311" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,801</ix:nonFraction></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_0000000000312" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,143</ix:nonFraction></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;padding-bottom:2px" valign="bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Restricted cash</span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000313" name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">362</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000314" name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">713</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000315" name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="C_20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">667</ix:nonFraction></span></span></div>
                </td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;padding-bottom:4px" valign="bottom">
                  <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total cash, cash equivalents and restricted cash</span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_0000000000316" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,421</ix:nonFraction></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_0000000000317" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,514</ix:nonFraction></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
                <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                  <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_0000000000318" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="C_20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,810</ix:nonFraction></span></span></span></div>
                </td>
                <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
              </tr>

          </table>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif;margin-bottom:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The accompanying notes are an integral part of the consolidated financial statements.</span></span>
            <p style="margin:0pt">&#160;</p>
          </div>
        </div>
      </div>
    </div>
  </div>
  <div>
    <div style="width:100%;clear:both">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0px;margin-bottom:3pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">F&#8201;-&#8201;10</span></span></p>
    </div>
    <hr style="border-top:1.5pt solid #000000;page-break-after:always;margin-top:0px" />
  </div>

  <p id="d1e6494_anchor" style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:9pt;margin-bottom:0pt"><span style="font-weight:bold">COMPUGEN LTD. AND ITS SUBSIDIARY</span></p>
  <p style="margin:0pt">&#160;</p>
  <div style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span id="financialstatements_integixAnchor"><span style="font-weight:bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></span></div>
  <hr style="border-top:1.5pt solid #000000;width:100%;margin-left:0pt;text-align:left;margin-top:3pt;margin-bottom:0pt" />
  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:3pt;margin-bottom:10pt"><span style="font-weight:bold">U.S. dollars in thousands (except share and per share data)</span></p>
  <ix:nonNumeric id="FFact_0000000000331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="C_20220101to20221231" escape="true">
    <div>
      <div>
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 1: -</span><span>&#160;<span style="font-weight:bold">GENERAL</span></span></span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>a.</span></span></span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Compugen Ltd. (the &#8220;Company&#8221;) is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Compugen&#8217;s innovative immuno-oncology pipeline consists of three clinical stage programs, targeting immune checkpoints Compugen discovered computationally by COM701, COM902 and rilvegostomig. The Company&#8217;s lead product candidates, COM701, a potential first-in-class anti-PVRIG antibody, and COM902, a potential best-in-class therapeutic anti-TIGIT antibody are in Phase 1 clinical trials and have been evaluated, for the treatment of solid tumors as a monotherapy and in combination of dual (PVRIG/PD-1, PVRIG/TIGIT) and triple (PVRIG/PD-1/TIGIT) blockade. As part of Phase 1 clinical trials for the Company&#8217;s lead product candidates, COM701, the Company evaluated COM701 as a monotherapy and under clinical collaboration with Bristol Myers Squibb Company in combination with nivolumab &#177; Bristol Myers Squibb investigational anti-TIGIT, BMS-986207. Following the termination of the Company&#8217;s collaboration with Bristol Myers Squibb Company, these combination studies are being wound down while the monitoring of patients on study treatment is ongoing. Rilvegostomig, a novel anti PD-1/TIGIT bispecific antibody with a TIGIT specific component that is derived from Compugen&#8217;s COM902 antibody, is being developed by AstraZeneca pursuant to an exclusive license agreement between Compugen and AstraZeneca and is in Phase 2 clinical trial in patients with advanced or metastatic non-small cell lung and locally advanced or metastatic gastric cancer. Compugen&#8217;s therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance. The Company&#8217;s most advanced early-stage program, COM503, is a potential first-in-class, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, thereby releasing the natural IL-18 into the tumor microenvironment to inhibit cancer growth. COM503 is &#160;being advanced into IND enabling studies. Compugen&#8217;s business model is to selectively enter into collaborations for its novel targets and drug product candidates at various stages of research and development under various revenue-sharing arrangements. Integrating cutting edge computational capabilities with ground-breaking immuno-oncology research and drug development expertise is the Company&#8217;s differentiator and has enabled the advancement of three drug targets from computer prediction through successful preclinical studies to the clinic.</span></span></span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company is headquartered in Holon, Israel. Its clinical development activities are headed from its United States subsidiary, Compugen USA, Inc, located in San Francisco, CA.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has incurred losses in the amount of $<ix:nonFraction id="FFact_0000000000319" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">33,694</ix:nonFraction> during the year ended December 31, 2022, has an accumulated deficit of $<ix:nonFraction id="FFact_0000000000320" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">455,773</ix:nonFraction> as of December 31, 2022 and has an accumulated negative cash flow from operating activities in the amount of $<ix:nonFraction id="FFact_0000000000321" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">34,506</ix:nonFraction> for the year ended December 31, 2022. <span style="color:rgb(0, 0, 0)">The Company believes that its existing capital resources will be adequate to satisfy its expected liquidity requirements at the current level of yearly expenditures at least </span>twelve months from the reporting date<span style="color:rgb(0, 0, 0)">.</span></span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div><ix:exclude>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 11</span></span></span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:3pt;margin-bottom:10pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:4pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" /><p style="margin-top:4pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
          </div>
          <div style="margin-top:0pt;margin-bottom:0pt">
            <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 1: -</span><span>&#160;<span style="font-weight:bold">GENERAL (Cont.)</span></span></span></span></div>
          </div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        </ix:exclude></div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On August 5, 2013, the Company entered into a Research and Development Collaboration and License Agreement (<span style="color:rgb(0, 0, 0)">&#8220;</span>Bayer Agreement<span style="color:rgb(0, 0, 0)">&#8220;</span>) with Bayer Pharma AG (<span style="color:rgb(0, 0, 0)">&#8220;</span>Bayer<span style="color:rgb(0, 0, 0)">&#8220;</span>) for the research, development, and commercialization of antibody-based therapeutics against two novel, Compugen-discovered immune checkpoint regulators.</span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">&#160;</td>
            </tr>

        </table>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under the terms of the Bayer Agreement, the Company received an upfront payment of $<ix:nonFraction id="FFact_0000000000323" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="C_20130801to20130805" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction>, and,<span style="color:rgb(0, 0, 0)"> following the return of the CGEN 15022 program in 2017,</span> the Company is eligible to receive an aggregate amount of over $<ix:nonFraction id="FFact_0000000000324" name="cgen:ResearchAndDevelopmentArrangementPaymentsReceivable" contextRef="C_20130805" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">250,000</ix:nonFraction> in potential milestone payments for <span style="color:rgb(0, 0, 0)">Bapotulimab (formerly known as BAY1905254)</span>, not including aggregate milestone payments of $<ix:nonFraction id="FFact_0000000000325" name="cgen:ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" contextRef="C_20130805" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,200</ix:nonFraction> received to date. Additionally, the Company is eligible to receive mid to high single digit royalties on global net sales of any approved products under the collaboration.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant to the terms of Bayer Agreement, <span style="color:rgb(0, 0, 0)">Bapotulimab</span> program was transferred to Bayer&#8217;s full control for further preclinical and clinical development activities, and worldwide commercialization under milestone and royalty bearing license from Compugen.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On November 29, 2022, Bayer notified the Company that it has resolved to terminate, effective as of February 27, 2023, the Bayer Agreement.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:54pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:31.5pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Effective March 30, 2018, the Company entered into an exclusive license agreement with MedImmune Limited, the global biologics research and development arm of AstraZeneca (&#8220;AstraZeneca&#8221;) to enable the development of bi-specific and multi-specific immuno-oncology antibody products. Under the terms of the agreement, Compugen provided an exclusive license to AstraZeneca for the development of bi-specific and multi-specific antibody products derived from COM902. AstraZeneca has the right to create multiple products under this license and will be solely responsible for all research, development, and commercial activities under the agreement. Compugen received a $<ix:nonFraction id="FFact_0000000000326" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction> upfront payment, and received $<ix:nonFraction id="FFact_0000000000327" name="cgen:AccruedMilestonePayment" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,500</ix:nonFraction> milestone payments out of up to $<ix:nonFraction id="FFact_0000000000328" name="cgen:ResearchAndDevelopmentArrangementPaymentsReceivable" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">200,000</ix:nonFraction> it is eligible to receive in development, regulatory and commercial milestones for the first product in addition to tiered royalties on future product sales. If additional products are developed, additional milestones and royalties would be due to Compugen for each product.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:54pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:31.5pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement (the &#8220;Agreement&#8221;) with Bristol-Myers Squibb Company (&#8220;Bristol-Myers Squibb&#8221;) to evaluate the safety and tolerability of Compugen&#8217;s COM701 in combination with Bristol-Myers Squibbs&#8217; PD-1 immune checkpoint inhibitor Opdivo&#174; (nivolumab), in patients with advanced solid tumors.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="text-align:justify;margin-left:85.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div><ix:exclude>
          <div style="text-align:justify;line-height:1.25;font-family:Times New Roman, Times, serif">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 12</span></span></span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:3pt;margin-bottom:10pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:4pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" /><p style="margin-top:4pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
          </div>
          <div style="margin-top:0pt;margin-bottom:0pt">
            <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 1: -</span><span>&#160;<span style="font-weight:bold">GENERAL (Cont.)</span></span></span></span></div>
            <div>&#160;</div>
          </div>
          <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

              <tr>
                <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                <td style="width:28.35pt;vertical-align:top;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f.</span></span></td>
                <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                  <div style="color:rgb(0, 0, 0)"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(Cont.)</span></span></div>
                </td>
              </tr>
              <tr>
                <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
                <td style="width:28.35pt;vertical-align:top;color:rgb(0, 0, 0);font-family:'Times New Roman',Times,serif">&#160;</td>
                <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">&#160;</td>
              </tr>

          </table>
        </ix:exclude></div>
        <div style="text-align:justify;text-indent:0pt;margin-left:85.5pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Pursuant to the Agreement, Compugen was responsible for and sponsored the ongoing two-part Phase 1 trial, which included the evaluation of the combination of COM701 and Opdivo&#174;. The collaboration was also designed to address potential future combinations, including trials sponsored by Bristol-Myers Squibb to investigate combined inhibition of checkpoint mechanisms, such as PVRIG and TIGIT. Bristol-Myers Squibb and Compugen each supplied the other company with its own compound for the other party&#8217;s study, and otherwise each party was responsible for all costs associated with the study that it is conducting.</span><br /><br /><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In conjunction with the signing of the Agreement in October 2018, Bristol-Myers Squibb made a $<ix:nonFraction id="FFact_0000000000329" name="us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,000</ix:nonFraction> investment in Compugen, see Note 8b.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:85.5pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On February 14, 2020, the Agreement was amended to include a triple combination clinical trial to evaluate the safety, tolerability and antitumor activity of COM701 in combination with Opdivo&#174; (nivolumab), and Bristol-Myers Squibb&#8217;s investigational antibody targeting TIGIT known as BMS-986207, in patients with advanced solid tumors, instead of the planned expansion of the combined therapy study designed to evaluate the dual combination of COM701 and Opdivo&#174;.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:85.5pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant to the Agreement, as amended, the Company sponsored the two-part Phase 1/2 trial, which evaluates the triple combination of COM701, Opdivo&#174; and BMS-986207, in patients with advanced solid tumors where Bristol-Myers Squibb provided Opdivo&#174; and BMS-986207 at no cost to the Company.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;text-indent:-0.45pt;margin-left:85.5pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As part of the amended Agreement, it was agreed that the Company will complete the dose escalation arm of the dual combination of COM701 with Opdivo<sup style="vertical-align:text-top;line-height:1;font-size:smaller">&#174;</sup> under the ongoing Phase 1 study and will not continue the expansion cohorts of the dual combination. However, on February 19, 2021, the Agreement was further amended to include an expansion of the Phase 1 combination study designed to evaluate the dual combination of COM701 and Opdivo&#174; in patients with advanced solid tumors, where the Company is responsible for and sponsored the expansion cohort and Bristol Myers Squibb provided Opdivo&#174; at no cost to the Company for this study.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;text-indent:-0.45pt;margin-left:85.5pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On November 10, 2021, the Agreement was further amended to establish a joint steering committee (alongside the existing joint development committee which acts at an operational level) to facilitate strategic oversight and guidance for the programs run under the collaboration.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;text-indent:0pt;margin-left:85.5pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In conjunction with the signing of the amendment to the Agreement in November 2021, Bristol-Myers Squibb made a $<ix:nonFraction id="FFact_0000000000330" name="us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue" contextRef="C_20211130" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,000</ix:nonFraction> investment in Compugen, see Note 8b.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;text-indent:-0.45pt;margin-left:85.5pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On August 3, 2022, the Company and Bristol-Myers Squibb entered into a letter agreement pursuant to which the Agreement, as amended thereafter, was terminated as of such date.</span></span></div>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 13</span></span></span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:3pt;margin-bottom:10pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:4pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" /><p style="margin-top:4pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

  <ix:nonNumeric id="FFact_0000000000405" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_20220101to20221231" escape="true">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-weight:bold">NOTE 2: -&#160;</span><span style="font-weight:bold">SIGNIFICANT ACCOUNTING POLICIES</span></span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:56.7pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;).</span></span></p>
    <ix:nonNumeric id="FFact_0000000000332" name="us-gaap:UseOfEstimates" contextRef="C_20220101to20221231" escape="true">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">a.<span style="padding-left:22.06pt">Use of estimates:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company&#8217;s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</span></span></p>
    </ix:nonNumeric>
    <ix:nonNumeric id="FFact_0000000000333" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">b.<span style="padding-left:22.5pt">Financial statements in U.S. dollars:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The reporting and functional currency of the Company is the U.S. dollar, as the Company&#8217;s management believes that the U.S. dollar is the primary currency of the economic environment in which the Company and Compugen USA, Inc. have operated and expect to continue to operate in the foreseeable future.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts denominated in currencies other than the dollar are re-measured into dollars in accordance with ASC No. 830, &#8220;Foreign Currency Matters&#8221;. All transaction gains and losses from the re-measurement of monetary balance sheet items are reflected in the consolidated statement of comprehensive loss as financial income or expenses, as appropriate.</span></span></p>
    </ix:nonNumeric>
    <ix:nonNumeric id="FFact_0000000000334" name="us-gaap:ConsolidationPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">c.<span style="padding-left:22.06pt">Basis of consolidation:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The consolidated financial statements include the accounts of the Company and Compugen USA, Inc. Intercompany transactions and balances have been eliminated upon consolidation.</span></span></p>
    </ix:nonNumeric>
    <ix:nonNumeric id="FFact_0000000000335" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">d.<span style="padding-left:22.5pt">Cash equivalents:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition.</span></span></p>
    </ix:nonNumeric>
    <ix:nonNumeric id="FFact_0000000000336" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" contextRef="C_20220101to20221231" escape="true">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">e.<span style="padding-left:22.06pt">Restricted cash:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Restricted cash is held in interest bearing saving accounts which are used as a security for the Company&#8217;s Israeli facility leasehold&#160;and leased cars fueling bank guarantees and credit card security for Compugen USA, Inc.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
      <div><ix:exclude>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 14</span></span></span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:3pt;margin-bottom:10pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:4pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" /><p style="margin-top:4pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
        <p style="margin:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>NOTE 2: - SIGNIFICANT ACCOUNTING POLICIES (Cont.)</strong></span></span></p>
        <p style="margin:0pt">&#160;</p>
      </ix:exclude></div>
    </ix:nonNumeric>
    <ix:nonNumeric id="FFact_0000000000339" name="cgen:ShortTermBankDepositsPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">f.<span style="padding-left:22.17pt">Short-term bank deposits:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Bank deposits with maturities of more than three months but less than one year are included in short-term bank deposits. Such short-term bank deposits are stated at cost which approximates market values.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The short-term bank deposits as of December 31, 2022&#160;and 2021&#160;are in U.S. dollars and bear an annual weighted average interest rate of <ix:nonFraction id="FFact_0000000000337" name="cgen:ShortTermBankDepositsWeightedAverageRateForeign" contextRef="C_20220101to20221231" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.84</ix:nonFraction>% and <ix:nonFraction id="FFact_0000000000338" name="cgen:ShortTermBankDepositsWeightedAverageRateForeign" contextRef="C_20210101to20211231" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.77</ix:nonFraction>%, respectively.</span></span></p>
    </ix:nonNumeric>
    <ix:nonNumeric id="FFact_0000000000346" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">g.<span style="padding-left:22.5pt">Property and equipment, net:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates:</span></span></p>
      <div style="margin-left:85.05pt">
        <ix:nonNumeric id="Fxbrl_20230214021114712" name="cgen:ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock" contextRef="C_20220101to20221231" escape="true">
          <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

              <tr>
                <td style="vertical-align:bottom;width:50%">&#160;</td>
                <td style="vertical-align:bottom;width:2%">&#160;</td>
                <td style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom;width:48%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">%</span></span></strong></p>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:50%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
                </td>
                <td style="vertical-align:bottom;width:2%">&#160;</td>
                <td style="vertical-align:bottom;width:48%">&#160;</td>
              </tr>


              <tr style="background-color:#cceeff">
                <td style="vertical-align:bottom;width:50%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Computers, software and related equipment</span></span></p>
                </td>
                <td style="vertical-align:bottom;width:2%">&#160;</td>
                <td style="vertical-align:bottom;width:48%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="FFact_0000000000340" name="cgen:AnnualDepreciationRate" contextRef="C_20220101to20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">33</ix:nonFraction></span></span></p>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:50%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Laboratory equipment and office furniture</span></span></p>
                </td>
                <td style="vertical-align:bottom;width:2%">&#160;</td>
                <td style="vertical-align:bottom;width:48%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="FFact_0000000000341" name="cgen:AnnualDepreciationRate" contextRef="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">6</ix:nonFraction> - <ix:nonFraction id="FFact_0000000000342" name="cgen:AnnualDepreciationRate" contextRef="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">20</ix:nonFraction> (mainly <ix:nonFraction id="FFact_0000000000343" name="cgen:AnnualDepreciationRate" contextRef="C_20220101to20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">20</ix:nonFraction>)</span></span></p>
                </td>
              </tr>
              <tr style="background-color:#cceeff">
                <td style="vertical-align:bottom;width:50%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Leasehold improvements</span></span></p>
                </td>
                <td style="vertical-align:bottom;width:2%">&#160;</td>
                <td style="vertical-align:bottom;width:48%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonNumeric id="FFact_0000000000344" name="cgen:AnnualDepreciationRateDescription" contextRef="C_20220101to20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember">Shorter of the term of the lease or useful life</ix:nonNumeric></span></span></p>
                </td>
              </tr>

          </table>
        </ix:nonNumeric>
      </div>
    </ix:nonNumeric>
    <ix:nonNumeric id="FFact_0000000000347" name="us-gaap:PropertyPlantAndEquipmentImpairment" contextRef="C_20220101to20221231" escape="true">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">h.<span style="padding-left:22.5pt">Impairment of long-lived assets:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The long-lived assets of the Company and Compugen USA, Inc. are reviewed for impairment in accordance with ASC 360, &#8220;Property, Plant, and Equipment&#8221; whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset with the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the years 2022, 2021&#160;and 2020, no impairment losses have been identified.</span></span></p>
    </ix:nonNumeric>
    <div>
      <div>
        <div>
          <ix:nonNumeric id="Fxbrl_20230222132032545" name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">
            <div>
              <div>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">i.<span style="padding-left:22.72pt">Leases:</span></span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The Company accounts for its leases according to ASC 842 - Leases (&#8220;ASC 842&#8221;). The Company determines if an arrangement is a lease and the classification of that lease at inception based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of the asset. The Company elected to not recognize a lease liability and a right-of-use (&#8220;ROU&#8221;) asset for leases with a term of twelve months or less.</span></span></p>
                <p style="margin:0pt">&#160;</p>
                <div><ix:exclude>
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 15</span></span></span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:3pt;margin-bottom:10pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:4pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" /><p style="margin-top:4pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
                  <p style="margin-top:0pt;margin-bottom:0px;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-weight:bold">NOTE 2: -&#160;</span><span style="font-weight:bold">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span></span></span></p>
                  <p style="margin-top:11pt;margin-bottom:0pt;text-align:left;margin-left:76pt;text-indent:-20pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">i.<span style="padding-left:22.06pt">Leases&#160;</span>&#160;(Cont.):&#160;</span></span></p>
                  <p style="margin:0pt">&#160;</p>
                </ix:exclude></div>
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:85.05pt;text-align:justify">ROU assets and lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. ROU assets are initially measured at amounts, which represents the discounted present value of the lease payments over the lease, plus any initial direct costs incurred. The lease liability is initially measured based on the discounted present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. The implicit rate within the operating leases is generally not determinable, therefore the Company uses the Incremental Borrowing Rate (&#8220;IBR&#8221;) based on the information available at commencement date in determining the present value of lease payments. The Company&#8217;s IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located.</p>
                <p style="margin:0pt">&#160;</p>
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:85.05pt;text-align:justify">An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate the lease is considered unless it is reasonably certain that the Company will not exercise the option.</p>
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:85.05pt;text-align:justify">&#160;</p>
              </div>
            </div>
          </ix:nonNumeric>
        </div>
      </div>
    </div>
    <div>
      <div>
        <div>
          <div>
            <ix:nonNumeric id="Fxbrl_20230222132059448" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">
              <div>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:76pt;text-indent:-20pt">j.<span style="padding-left:23.06pt">Revenue recognition:</span></p>
                <p style="margin:0pt">&#160;</p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:85.05pt;text-align:justify">The Company generates revenues mainly from its collaborative and license agreements. The revenues are derived mainly from upfront license payments, research and development services and contingent payments related to milestone achievements.</p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The Company recognizes revenue in accordance with ASC 606 &#8211; &#8220;Revenue from Contracts with Customers&#8221;.</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">As such, the Company analyzes its contracts to assess whether they are within the scope of ASC 606. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps:</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">&#8226;</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:-12pt;text-indent:114pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-style:italic">Identification of the contract, or contracts, with a customer</span></span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">&#8226;</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:-12pt;margin-left:114pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-style:italic">Identification of the performance obligations in the contract</span>&#160;</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">&#8226;</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:-12pt;margin-left:114pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-style:italic">Determination of the transaction price</span>&#160;</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">&#8226;</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:-12pt;margin-left:114pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-style:italic">Allocation of the transaction price to the performance obligations in the contract</span>&#160;</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">&#8226;</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:-12pt;margin-left:114pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-style:italic">Recognition of revenue when, or as, the Company satisfies a performance obligation</span>&#160;</span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
                <div><ix:exclude>
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 16</span></span></span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:3pt;margin-bottom:10pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:4pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" /><p style="margin-top:4pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
                  <p style="margin-top:0pt;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-weight:bold">NOTE 2: -&#160;</span><span style="font-weight:bold">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span></span></span></p>
                  <p style="margin-top:11pt;margin-bottom:0pt;text-align:left;margin-left:76pt;text-indent:-20pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">j.<span style="padding-left:23.06pt">Revenue recognition (Cont.):</span></span></span></p>
                  <p style="margin-top:0pt;margin-bottom:0pt;text-align:left;margin-left:76pt;text-indent:-20pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
                </ix:exclude></div>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:85pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">At the contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></span></p>
                <p style="margin:0pt">&#160;</p>
                <div>
                  <div style="margin-left:85.05pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company entered into an exclusive license agreement with AstraZeneca. Under the terms of the agreement, Compugen provided AstraZeneca with an exclusive license to intellectual property ("IP&#8221;) rights of the Company for the development of bi-specific and multi-specific antibody products derived from COM902. Compugen received a $<ix:nonFraction id="FFact_0000000000348" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,000</ix:nonFraction> upfront nonrefundable payment and is eligible to receive up to $<ix:nonFraction id="FFact_0000000000349" name="cgen:ResearchAndDevelopmentArrangementPaymentsReceivable" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">200,000</ix:nonFraction> for development, regulatory and commercial milestones for the first product, of which $<ix:nonFraction id="FFact_0000000000350" name="cgen:AccruedMilestonePayment" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,500</ix:nonFraction> was received to date as well as tiered royalties on future product sales.</span></span></div>
                </div>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Under ASC 606, the Company determined the license to the IP to be a functional IP that has significant standalone functionality. The Company is not required to continue to support, develop or maintain the intellectual property transferred and will not undertake any activities to change the standalone functionality of the IP. Therefore, the license to the IP is a distinct performance obligation and as such revenue is recognized at the point in time that control of the license is transferred to the customer.</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Future milestone payments are considered variable consideration and are subject to the variable consideration constraint (i.e. will be recognized once concluded that it is &#8220;probable&#8221; that a significant reversal of the cumulative revenues recognized under the contract will not occur in future periods when the uncertainty related to the variable consideration is resolved). Therefore, as the milestone payments are not probable, revenue was not recognized in respect to such milestone payments prior to achievement of such milestone.</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Sales&#160;or usage-based royalties to be received in exchange for licenses of IP are recognized at the later of when (1) the subsequent sale or usage occurs or (2) the performance obligation to which some or all of the sales&#160;or usage-based royalty has been allocated is satisfied (in whole or in part). As royalties are payable based on future Commercial Sales, as defined in the agreement, which did not occur as of the financial statements date, the Company did not recognize any revenues from royalties.</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">On December 18, 2020 the first milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $&#160;<ix:nonFraction id="FFact_0000000000351" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="C_20201201to20201218" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,000</ix:nonFraction> in accordance with the criteria prescribed under ASC 606.</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">On September 29, 2021 the second milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $&#160;<ix:nonFraction id="FFact_0000000000352" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="C_20210901to20210929" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,000</ix:nonFraction> in accordance with the criteria prescribed under ASC 606.</span></span></p>
                <p style="margin:0pt">&#160;</p>
                <div><ix:exclude>
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 17</span></span></span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:3pt;margin-bottom:10pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:4pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" /><p style="margin-top:4pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong>NOTE 2: - SIGNIFICANT ACCOUNTING POLICIES (Cont.)</strong></p>
                  <p style="margin:0pt">&#160;</p>
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:76pt;text-indent:-20pt"><span style="font-family:Times New Roman, Times, serif;font-size:10pt">j.<span style="padding-left:23.06pt">Revenue recognition (Cont.):</span></span></p>
                  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:76pt;text-indent:-20pt">&#160;</p>
                </ix:exclude></div>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">On November 11, 2022, the third milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ <ix:nonFraction id="Fxbrl_20230214012742011" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="C_20221101to20221111" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,500</ix:nonFraction> in accordance with the criteria prescribed under ASC 606.</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">For additional information regarding revenues, please refer to Note 10 below.</span></span></p>
              </div>
            </ix:nonNumeric>
          </div>
        </div>
      </div>
    </div>
    <ix:nonNumeric id="FFact_0000000000354" name="cgen:CostOfSalesContractWithCustomerPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">k.<span style="padding-left:22.72pt">Cost of revenues:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Cost of revenues consist of certain royalties and milestones paid or accrued.</span></span></p>
    </ix:nonNumeric>
    <ix:nonNumeric id="FFact_0000000000363" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="C_20220101to20221231" escape="true">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">l.<span style="padding-left:24.5pt">Research and development expenses, net:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Research and development costs are charged to the statement of comprehensive loss as incurred and are presented net of the amount of any grants the Company receives for research and development in the period in which the grant was received.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">As part of the process of preparing the consolidated financial statements, the Company accrues costs for pre-clinical and clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the contract research organizations or other pre-clinical or clinical trial vendors that perform the activities. In certain circumstances, the Company is required to make nonrefundable advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the nonrefundable advance payments are deferred and capitalized, and amortized as the related goods or services are provided. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense.</span></span></p>
      <p style="margin:0pt">&#160;</p>
      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:85.05pt;text-align:justify">The portion of the Bristol-Myers Squibb $ <ix:nonFraction id="Fxbrl_20230221140432370" name="us-gaap:EquityMethodInvestmentAggregateCost" contextRef="C_20221231_srtStatementScenarioAxis_cgenMasterClinicalAgreementOneMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,000</ix:nonFraction> investment in 2018 over the fair market value of the shares issued in the amount of $ <ix:nonFraction id="Fxbrl_20230221140440887" name="cgen:DeferredParticipationOfBMSInRAndDExpenses" contextRef="C_20220101to20221231_srtStatementScenarioAxis_cgenMasterClinicalAgreementOneMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,121</ix:nonFraction> and the portion of the $ <ix:nonFraction id="Fxbrl_20230221140447657" name="us-gaap:EquityMethodInvestmentAggregateCost" contextRef="C_20221231_srtStatementScenarioAxis_cgenMasterClinicalAgreementTwoMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,000</ix:nonFraction> investment in 2021 over the fair market value of the shares issued in the amount of $ <ix:nonFraction id="Fxbrl_20230221140456655" name="cgen:DeferredParticipationOfBMSInRAndDExpenses" contextRef="C_20220101to20221231_srtStatementScenarioAxis_cgenMasterClinicalAgreementTwoMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,000</ix:nonFraction> were considered as deferred participation of Bristol-Myers Squibb in R&#38;D expenses which is amortized over the period of the clinical trial based on the progress in the R&#38;D, see Note 1f and Note 8b.</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Amortization of participation in R&#38;D expenses for the years ended December 31, 2022, 2021&#160;and 2020&#160;were $&#160;<ix:nonFraction id="FFact_0000000000360" name="us-gaap:AdjustmentForAmortization" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,019</ix:nonFraction>, $&#160;<ix:nonFraction id="FFact_0000000000361" name="us-gaap:AdjustmentForAmortization" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,291</ix:nonFraction> and $&#160;<ix:nonFraction id="FFact_0000000000362" name="us-gaap:AdjustmentForAmortization" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">829</ix:nonFraction>, respectively.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
    </ix:nonNumeric>
    <div><ix:exclude>
      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 18</span></span></span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:3pt;margin-bottom:10pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:4pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" /><p style="margin-top:4pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong>NOTE 2: - SIGNIFICANT ACCOUNTING POLICIES (Cont.)</strong></p>
      <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
    </ix:exclude></div>
    <ix:nonNumeric id="FFact_0000000000367" name="cgen:ServerancePayPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">m.<span style="padding-left:18.72pt">Severance pay:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The Company&#8217;s liability for severance pay for its Israeli employees is calculated pursuant to Israeli Severance Pay Law based on the most recent salary of the employees multiplied by the number of years of employment as of the balance sheet date, and is in large part covered by regular deposits with recognized pension funds, deposits with severance pay funds and purchases of insurance policies. The value of these deposits and policies is recorded as an asset in the Company&#8217;s balance sheet. Pursuant to Section 14 of the Israeli Severance Pay Law, for Israeli employees under this section, the Company&#8217;s contributions for severance pay have replaced its severance obligation. Upon contribution of the full amount of the employee&#8217;s monthly salary for each year of service, no additional calculations are conducted between the parties regarding the matter of severance pay and no additional payments are made by the Company to the employee.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Further, the related obligation and amounts deposited on behalf of the employee for such obligation are not stated on the balance sheet, as the Company is legally released from the obligation to employees once the deposit amounts have been paid.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Severance expenses for the years ended December 31, 2022, 2021&#160;and 2020&#160;amounted to approximately $&#160;<ix:nonFraction id="FFact_0000000000364" name="us-gaap:SeveranceCosts1" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">468</ix:nonFraction>, $&#160;<ix:nonFraction id="FFact_0000000000365" name="us-gaap:SeveranceCosts1" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">383</ix:nonFraction> and $&#160;<ix:nonFraction id="FFact_0000000000366" name="us-gaap:SeveranceCosts1" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">572</ix:nonFraction>, respectively.</span></span></p>
    </ix:nonNumeric>
    <ix:nonNumeric id="FFact_0000000000394" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="C_20220101to20221231" escape="true">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">n.<span style="padding-left:22.06pt">Stock-based compensation:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The Company accounts for stock-based compensation to employees and non-employees in accordance with ASC 718, &#8220;Compensation - Stock Compensation&#8221;, (&#8220;ASC 718&#8221;), which requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The Company accounts for forfeitures as they occur.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The Company recognizes compensation expenses for the value of its awards granted based on the straight-line method over the requisite service period of each of the awards.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The Company selected the Black-Scholes-Merton (&#8220;Black-Scholes&#8221;) option-pricing model as the most appropriate fair value method for its share-options awards and Employee Stock Purchase Plan (&#8220;ESPP&#8221;). The option-pricing model requires a number of assumptions, of which the most significant are the expected share price volatility and the expected option term. Expected volatility was calculated based on actual historical share price movements over a term that is equivalent to the expected term of granted options. The expected term of options granted is based on historical experience and represents the period of time that options granted are expected to be outstanding.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.</span></span></p>
      <p style="margin:0pt">&#160;</p>
      <div><ix:exclude>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 19</span></span></span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:3pt;margin-bottom:10pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:4pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" /><p style="margin-top:4pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
        <p style="margin:0pt"><span style="font-family:Times New Roman, Times, serif;font-size:10pt"><span style="font-weight:bold">NOTE 2: -&#160;</span><span style="font-weight:bold">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span></span></p>
        <p style="margin:0pt">&#160;</p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:76pt;text-indent:-20pt"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">n.<span style="padding-left:21.72pt">Stock-based compensation (Cont.):</span></span></p>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p>
      </ix:exclude></div>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The Company used the following assumptions for options granted to employees, directors and non-employees and ESPP:</span></span></p>
      <div style="margin-left:85.05pt">
        <ix:nonNumeric id="Fxbrl_20230214021045368" name="cgen:ScheduleOfWeightedAverageAssumptionsForGrantedOptions" contextRef="C_20220101to20221231" continuedAt="F20230214151604936" escape="true">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%">

              <tr>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="10" rowspan="1" style="vertical-align:bottom;border-bottom:1.5pt solid black">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-weight:bold">Year ended December 31,</span></span></span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:1.5pt solid black">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-weight:bold">2022</span></span></span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:1.5pt solid black">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-weight:bold">2021</span></span></span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:1.5pt solid black">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-weight:bold">2020</span></span></span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:49%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:14%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:14%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:14%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
              </tr>


              <tr style="background-color:rgb(204, 238, 255)">
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>Employee stock options</span></span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              </tr>
              <tr style="background-color:rgb(255, 255, 255)">
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
              </tr>
              <tr style="background-color:rgb(204, 238, 255)">
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Volatility</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20230222111557515" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">69.44</ix:nonFraction>%-<ix:nonFraction id="Fxbrl_20230222111657770" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">74.61</ix:nonFraction>%</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20230222111705802" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20210101to20211231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">66.02</ix:nonFraction>%-<ix:nonFraction id="Fxbrl_20230222111709770" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20210101to20211231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">69.05</ix:nonFraction>%</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20230222111716009" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20200101to20201231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">55.12</ix:nonFraction>%-<ix:nonFraction id="Fxbrl_20230222111720906" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20200101to20201231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">65.59</ix:nonFraction>%</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              </tr>
              <tr style="background-color:rgb(255, 255, 255)">
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Risk-free interest rate</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20230222111846385" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.54</ix:nonFraction>%-<ix:nonFraction id="Fxbrl_20230222111850185" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.39</ix:nonFraction>%</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20230222111857816" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20210101to20211231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.51</ix:nonFraction>%-<ix:nonFraction id="Fxbrl_20230222111901472" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20210101to20211231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.14</ix:nonFraction>%</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20230222111908255" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20200101to20201231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.26</ix:nonFraction>%-<ix:nonFraction id="Fxbrl_20230222111911818" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20200101to20201231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.64</ix:nonFraction>%</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
              </tr>
              <tr style="background-color:rgb(204, 238, 255)">
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Dividend yield</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="FFact_0000000000374" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20220101to20221231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction>%</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="FFact_0000000000375" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20210101to20211231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction>%</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="FFact_0000000000376" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20200101to20201231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction>%</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              </tr>
              <tr style="background-color:rgb(255, 255, 255)">
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Expected life (years)</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonNumeric id="Fxbrl_20230222111920863" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" format="ixt-sec:duryear">5.05</ix:nonNumeric>-<ix:nonNumeric id="Fxbrl_20230222111935802" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" format="ixt-sec:duryear">5.4</ix:nonNumeric></span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonNumeric id="Fxbrl_20230222111942937" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20210101to20211231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" format="ixt-sec:duryear">5.04</ix:nonNumeric>-<ix:nonNumeric id="Fxbrl_20230222111945746" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20210101to20211231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" format="ixt-sec:duryear">5.31</ix:nonNumeric></span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonNumeric id="Fxbrl_20230222111951712" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20200101to20201231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" format="ixt-sec:duryear">5.02</ix:nonNumeric>-<ix:nonNumeric id="Fxbrl_20230222111955217" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20200101to20201231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" format="ixt-sec:duryear">5.31</ix:nonNumeric></span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
              </tr>

          </table>
        </ix:nonNumeric>
      </div>
      <div style="margin-left:85.05pt">
        <div style="margin-top:10pt">
          <ix:continuation id="F20230214151604936">
            <div>
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%">

                  <tr>
                    <td style="vertical-align:bottom">&#160;</td>
                    <td style="vertical-align:bottom">&#160;</td>
                    <td colspan="10" rowspan="1" style="vertical-align:bottom;text-align:center;border-bottom:1.5pt solid black">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="line-height:110%">Year ended December 31,</span></span></span></strong></p>
                    </td>
                    <td style="vertical-align:bottom;text-align:center">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom">&#160;</td>
                    <td style="vertical-align:bottom">&#160;</td>
                    <td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center;border-bottom:1.5pt solid black">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span>2022</span></strong></span></span></p>
                    </td>
                    <td style="vertical-align:bottom;text-align:center">&#160;</td>
                    <td style="vertical-align:bottom;text-align:center">&#160;</td>
                    <td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center;border-bottom:1.5pt solid black">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span>2021</span></strong></span></span></p>
                    </td>
                    <td style="vertical-align:bottom;text-align:center">&#160;</td>
                    <td style="vertical-align:bottom;text-align:center">&#160;</td>
                    <td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center;border-bottom:1.5pt solid black">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span>2020</span></strong></span></span></p>
                    </td>
                    <td style="vertical-align:bottom;text-align:center">&#160;</td>
                  </tr>
                  <tr style="background-color:rgb(204, 238, 255)">
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>ESPP</span></span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                  </tr>
                  <tr style="background-color:rgb(255, 255, 255)">
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                  </tr>
                  <tr style="background-color:rgb(204, 238, 255)">
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Volatility</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="padding-left:0pt"><ix:nonFraction id="FFact_0000000000380" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">69.74</ix:nonFraction></span><span style="padding-left:0pt">%</span></span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20230214015505042" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20210101to20211231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">64.68</ix:nonFraction>%-<ix:nonFraction id="Fxbrl_20230214015511155" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20210101to20211231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">69.68</ix:nonFraction>%</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20230214015610374" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_20200101to20201231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:fixed-zero">-</ix:nonFraction></span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                  </tr>
                  <tr style="background-color:rgb(255, 255, 255)">
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Risk-free interest rate</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="FFact_0000000000384" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.63</ix:nonFraction>%</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20230214015516923" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20210101to20211231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.04</ix:nonFraction>%-<ix:nonFraction id="Fxbrl_20230214015523604" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20210101to20211231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.10</ix:nonFraction>%</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20230214015615908" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_20200101to20201231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:fixed-zero">-</ix:nonFraction></span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                  </tr>
                  <tr style="background-color:rgb(204, 238, 255)">
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Dividend yield</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="FFact_0000000000388" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction>%</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20230214015529421" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20210101to20211231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction>%</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonFraction id="Fxbrl_20230214015623237" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_20200101to20201231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:fixed-zero">-</ix:nonFraction></span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                  </tr>
                  <tr style="background-color:rgb(255, 255, 255)">
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Expected life (years)</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonNumeric id="FFact_0000000000391" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember" format="ixt-sec:duryear">0.50</ix:nonNumeric></span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><ix:nonNumeric id="Fxbrl_20230214015535420" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20210101to20211231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember" format="ixt-sec:duryear">0.42</ix:nonNumeric>-<ix:nonNumeric id="Fxbrl_20230214015542343" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_20210101to20211231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember" format="ixt-sec:duryear">0.50</ix:nonNumeric></span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">-</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                  </tr>

              </table>
            </div>
          </ix:continuation>
        </div>
      </div>
    </ix:nonNumeric>
    <ix:nonNumeric id="FFact_0000000000395" name="us-gaap:ConcentrationRiskCreditRisk" contextRef="C_20220101to20221231" escape="true">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">o.<span style="padding-left:21.5pt">Concentration of credit risks:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Financial instruments that potentially subject the Company and Compugen USA, Inc. to concentration of credit risk consist principally of cash and cash equivalents, restricted cash and short-term bank deposits.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Cash, cash equivalents, restricted cash and short-term bank deposits are invested in major banks in Israel. Generally, these deposits may be redeemed upon demand and bear minimal risk.</span></span></p>
    </ix:nonNumeric>
    <ix:nonNumeric id="FFact_0000000000399" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_20220101to20221231" escape="true">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">p.<span style="padding-left:22.5pt">Basic and diluted loss per share:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Basic loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260, &#8220;Earnings per Share&#8220;.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">All outstanding share options and warrants for the years ended December 31, 2022, 2021 and 2020 have been excluded from the calculation of the diluted net loss per share, because all such securities are anti-dilutive for all periods presented. As of December 31, 2022, 2021 and 2020 the average number of shares related to outstanding options and warrants excluded from the calculations of diluted net loss per share were <ix:nonFraction id="FFact_0000000000396" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20220101to20221231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapStockOptionMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">8,405,615</ix:nonFraction>, <ix:nonFraction id="FFact_0000000000397" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20210101to20211231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapStockOptionMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">6,758,300</ix:nonFraction> and <ix:nonFraction id="FFact_0000000000398" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_20200101to20201231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapStockOptionMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">7,150,648</ix:nonFraction>, respectively.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
      <div><ix:exclude>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 20</span></span></span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:3pt;margin-bottom:10pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:4pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" /><p style="margin-top:4pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-weight:bold">NOTE 2: -&#160;</span><span style="font-weight:bold">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span></span></span></p>
        <p style="margin-top:0pt;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
      </ix:exclude></div>
    </ix:nonNumeric>
    <ix:nonNumeric id="FFact_0000000000400" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">q.<span style="padding-left:22.5pt">Income taxes:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The Company accounts for income taxes in accordance with ASC No. 740, &#8220;Income Taxes&#8220;, (&#8220;ASC 740&#8220;) which prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2022 and 2021, a full valuation allowance was provided by the Company.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been recorded pursuant to ASC 740-10.</span></span></p>
    </ix:nonNumeric>
    <ix:nonNumeric id="FFact_0000000000401" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="C_20220101to20221231" escape="true">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">r.<span style="padding-left:23.5pt">Fair value of financial instruments:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The Company applies ASC 820, &#8220;Fair Value Measurements and Disclosures&#8221; (&#8220;ASC 820&#8221;), pursuant to which fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &#8220;exit price&#8221;) in an orderly transaction between market participants at the measurement date.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputting that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company.</span></span></p>
      <p style="margin:0pt">&#160;</p>
      <div><ix:exclude>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 21</span></span></span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:3pt;margin-bottom:10pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:4pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" /><p style="margin-top:4pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
        <p style="margin-top:0pt;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman, Times, serif;font-size:10pt"><span style="font-weight:bold">NOTE 2: -&#160;</span><span style="font-weight:bold">SIGNIFICANT ACCOUNTING POLICIES (Cont.)</span></span></p>
        <p style="margin-top:11pt;margin-bottom:0pt;text-align:left;margin-left:76pt;text-indent:-20pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman, Times, serif;font-size:10pt">r.<span style="padding-left:23.5pt">Fair value of financial instruments (Cont.):</span></span></p>
        <p style="margin-top:01pt;margin-bottom:0pt;text-align:left;margin-left:76pt;text-indent:-20pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
      </ix:exclude></div>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:85.05pt;margin-bottom:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The hierarchy is broken down into three levels based on the inputs as follows:</span></span></p>
      <table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%">

          <tr>
            <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:85.5pt">&#160;</td>
            <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:56.7pt">
              <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt">Level 1&#160; &#160;&#160;</span><span style="font-size:10pt">-</span></p>
            </td>
            <td style="font-family:Times New Roman, Times, serif;vertical-align:top;text-align:justify;width:auto"><span style="font-size:10pt"><span>Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can </span>access at the measurement date.</span></td>
          </tr>

      </table>
      <div style="margin-top:10pt">
        <table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%">

            <tr>
              <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:85.5pt">&#160;</td>
              <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:56.7pt">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt">Level 2&#160; &#160; -</span></p>
              </td>
              <td style="font-family:Times New Roman, Times, serif;vertical-align:top;text-align:justify;width:auto"><span style="font-size:10pt"><span>Valuations based on one or more quoted prices in markets that are not active or for which all </span>significant inputs are observable, either directly or indirectly.</span></td>
            </tr>
            <tr>
              <td style="width:85.5pt">&#160;</td>
              <td style="width:56.7pt">&#160;</td>
              <td style="text-align:justify;width:auto">&#160;</td>
            </tr>
            <tr>
              <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:85.5pt">&#160;</td>
              <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:56.7pt">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt">Level 3&#160; &#160; -</span></p>
              </td>
              <td style="font-family:Times New Roman, Times, serif;vertical-align:top;text-align:justify;width:auto"><span style="font-size:10pt"><span>Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</span></span></td>
            </tr>

        </table>
      </div>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The carrying amounts of cash and cash equivalents, restricted cash, short-term bank deposits, other accounts receivable and prepaid expenses, trade payable and other accounts payable and accrued expenses approximate their fair values due to the short-term maturities of such instruments.</span></span></p>
    </ix:nonNumeric>
    <ix:nonNumeric id="FFact_0000000000404" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_20220101to20221231" escape="true">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">s.<span style="padding-left:22.06pt">Recently issued and recently adopted Accounting Standards:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Although there are several other new accounting standards issued or proposed by the FASB, which the Company has adopted or will adopt, as applicable, the Company does not believe any of these accounting pronouncements has had or will have a material impact on its consolidated financial statements.</span></span></p>
    </ix:nonNumeric>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>
  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 22</span></span></span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:3pt;margin-bottom:10pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:4pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" /><p style="margin-top:4pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

  <ix:nonNumeric id="Fxbrl_20230222132226340" name="cgen:OtherAccountsReceivableAndPrepaidExpensesTextBlock" contextRef="C_20220101to20221231" escape="true">
    <div>
      <div>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 3: - OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES</span></span></span></p>
        <div>
          <div>
            <div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;<div style="margin-left:63pt">
                  <ix:nonNumeric id="Fxbrl_20230222132243765" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" contextRef="C_20220101to20221231" escape="true">
                    <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;float:left">

                        <tr>
                          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                          <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                            <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Prepaid expenses</span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000406" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,100</ix:nonFraction></span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_0000000000407" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,272</ix:nonFraction></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
                            <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Government authorities</span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000408" name="cgen:GovernmentAuthorities" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">85</ix:nonFraction></span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000409" name="cgen:GovernmentAuthorities" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">57</ix:nonFraction></span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">
                            <div style="text-indent:-4.25pt;margin-left:7.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000410" name="us-gaap:OtherAssetsCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">232</ix:nonFraction></span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000411" name="us-gaap:OtherAssetsCurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">131</ix:nonFraction></span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000412" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,417</ix:nonFraction></span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_0000000000413" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,460</ix:nonFraction></span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                        </tr>

                    </table>
                  </ix:nonNumeric>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
    </div>
  </ix:nonNumeric>

  <ix:nonNumeric id="FFact_0000000000441" name="us-gaap:LesseeOperatingLeasesTextBlock" contextRef="C_20220101to20221231" escape="true">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 4: - LEASES</span></span></span></p>
    <div>
      <div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company leases all its real estate, storage area and cars under various operating lease agreements that expire on various dates.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s operating leases have original lease periods expiring between 2021 and 2025. The offices in Israel lease include two options to renew, one of which was exercised in 2020. The Company does not assume renewals in its determination of the lease term unless the renewals are deemed to be reasonably certain.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In October 2020 the Company&#8217;s lease for its offices in Israel was amended. The amendment was not accounted for as a new lease. As a result of the amendment the operating lease right of use asset increased by $<ix:nonFraction id="FFact_0000000000416" name="cgen:IncreaseOperatingLeaseRightOfUseAsset" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction>, the operating lease liability decreased by $<ix:nonFraction id="FFact_0000000000417" name="cgen:DecreaseOperatingLeaseLiability" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">194</ix:nonFraction> and the Company recorded foreign currency exchange rate of $<ix:nonFraction id="FFact_0000000000418" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">237</ix:nonFraction>.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease payments included in the measurement of the lease liability comprise the following: the fixed non-cancelable lease payments and payments for optional renewal periods where it is reasonably certain the renewal period will be exercised.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under ASC 842, all leases, including non-cancelable operating leases, are now recognized on the balance sheet. The aggregated present value of lease payments is recorded as a long-term asset titled Operating lease right of use asset. The corresponding lease liabilities are split between current maturity of operating lease liability within current liabilities and long-term operating lease liability within long-term liabilities. The Company&#8217;s leases do not provide an implicit rate, therefore the Company uses its incremental borrowing rate based on information available on the commencement date in determining the present value of lease payments.</span></span></div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div><ix:exclude>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
            <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 23</span></span></span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:3pt;margin-bottom:10pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:4pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" /><p style="margin-top:4pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
          </div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">
            <div>
              <div style="text-align:justify;line-height:1.25;font-weight:bold">
                <div style="line-height:1.25">
                  <div style="line-height:1.25">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 4: - LEASES </span>(Cont.)</span></span></div>
                      <div style="line-height:1.25">&#160;</div>
                    </div>
                  </div>
                </div>
              </div>
            </div>
          </div>
        </ix:exclude></div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table represents the weighted-average remaining lease term and discount rate:</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="margin-left:56.7pt">
          <ix:nonNumeric id="Fxbrl_20230222013426728" name="cgen:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate" contextRef="C_20220101to20221231" escape="true">
            <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:90%">

                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average remaining lease term</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonNumeric id="FFact_0000000000421" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_20221231" format="ixt-sec:duryear">3.16</ix:nonNumeric></span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%" valign="bottom">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average discount (annual) rate</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000422" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_20221231" unitRef="Pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">5.52</ix:nonFraction>%</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25">&#160;</div>
                    </div>
                  </td>
                </tr>

            </table>
          </ix:nonNumeric>
        </div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating lease expenses were approximately $<ix:nonFraction id="FFact_0000000000424" name="us-gaap:OperatingLeasePayments" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">884</ix:nonFraction>, $<ix:nonFraction id="FFact_0000000000425" name="us-gaap:OperatingLeasePayments" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">956</ix:nonFraction> and $<ix:nonFraction id="FFact_0000000000426" name="us-gaap:OperatingLeasePayments" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">944</ix:nonFraction> in the years ended December 31, 2022, 2021 and 2020, respectively.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash paid for amounts included in the measurement of lease liabilities was approximately $<ix:nonFraction id="FFact_0000000000427" name="cgen:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">959</ix:nonFraction>, $<ix:nonFraction id="FFact_0000000000428" name="cgen:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">914</ix:nonFraction> and $<ix:nonFraction id="FFact_0000000000429" name="cgen:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">927</ix:nonFraction> in the years ended December 31, 2022, 2021 and 2020, respectively.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Maturities of operating lease liabilities were as follows:</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="margin-left:56.7pt">
          <ix:nonNumeric id="Fxbrl_20230222013609784" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="C_20220101to20221231" escape="true">
            <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:90%">

                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December 31,</span><span>&#160;<span style="font-weight:bold">2022</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_0000000000430" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">699</ix:nonFraction></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%" valign="bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000431" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">669</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000432" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">609</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%;padding-bottom:2px" valign="bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2026</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000433" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">114</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%" valign="bottom">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total operating lease payments</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000435" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,091</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less: imputed interest</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000436" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">166</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Present value of lease liabilities</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000437" name="us-gaap:OperatingLeaseLiability" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,925</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%" valign="bottom">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease liabilities, current</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000438" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">613</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease liabilities, non- current</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000439" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,312</ix:nonFraction></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Present value of lease liabilities</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20230214024012785" name="us-gaap:OperatingLeaseLiability" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,925</ix:nonFraction></span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                </tr>

            </table>
          </ix:nonNumeric>
        </div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The above annual minimum future rental commitments include the period covered by the first exercised option with respect to the leased facility of Compugen Ltd. through March 2026 and exclude the second option to extend the lease of the Company facility for additional five-year period following expiration of the current lease period.</span></span></div>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 24</span></span></span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:3pt;margin-bottom:10pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:4pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" /><p style="margin-top:4pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

  <ix:nonNumeric id="FFact_0000000000468" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="C_20220101to20221231" escape="true">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:10pt"><span style="font-weight:bold">NOTE 5: -&#160;</span><span style="font-weight:bold">PROPERTY AND EQUIPMENT, NET</span></p>
    <ix:nonNumeric id="FFact_0000000000460" name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="C_20220101to20221231" escape="true">
      <div style="margin-left:56.7pt">
        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="6" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">December 31,</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2022</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2021</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Cost:</p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Computers, software and related equipment</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000442" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,617</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000443" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,506</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Laboratory equipment and office furniture</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000444" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,831</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000445" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,674</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Leasehold improvements</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000446" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,314</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000447" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,321</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:76%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000448" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,762</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000449" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,501</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Accumulated depreciation:</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Computers, software and related equipment</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000450" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,435</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000451" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,351</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Laboratory equipment and office furniture</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000452" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,190</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000453" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,114</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Leasehold improvements</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000454" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,605</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000455" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,378</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000456" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,230</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000457" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,843</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Depreciated cost</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000458" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,532</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000459" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,658</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>
      </div>
    </ix:nonNumeric>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:56.7pt;margin-bottom:0pt">During 2022&#160;and 2021&#160;total cost of $&#160;<ix:nonFraction id="FFact_0000000000461" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">99</ix:nonFraction>&#160;and $&#160;<ix:nonFraction id="FFact_0000000000462" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">26</ix:nonFraction>, respectively and total accumulated depreciation of $&#160;<ix:nonFraction id="FFact_0000000000463" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">95</ix:nonFraction>&#160;and $&#160;<ix:nonFraction id="FFact_0000000000464" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">26</ix:nonFraction>, respectively were disposed from the consolidated balance sheets.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:56.7pt;margin-bottom:0pt">For the years ended December 31, 2022, 2021&#160;and 2020, depreciation expenses were approximately $&#160;<ix:nonFraction id="FFact_0000000000465" name="us-gaap:Depreciation" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">482</ix:nonFraction>, $&#160;<ix:nonFraction id="FFact_0000000000466" name="us-gaap:Depreciation" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">461</ix:nonFraction>&#160;and $&#160;<ix:nonFraction id="FFact_0000000000467" name="us-gaap:Depreciation" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">715</ix:nonFraction>, respectively.</p>
  </ix:nonNumeric>
  <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

  <ix:nonNumeric id="FFact_0000000000476" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" contextRef="C_20220101to20221231" escape="true">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:10pt"><span style="font-weight:bold">NOTE 6: - </span><strong>OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES</strong></p>
    <div>
      <div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="margin-left:54pt">
          <ix:nonNumeric id="Fxbrl_20230222132609363" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" contextRef="C_20220101to20221231" escape="true">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;float:left">

                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold">December 31,</div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold">2022</div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold">2021</div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25">Employees and related accruals</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-family:'Times New Roman',Times,serif">$</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-family:'Times New Roman',Times,serif"><ix:nonFraction id="FFact_0000000000469" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,812</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-family:'Times New Roman',Times,serif">$</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-family:'Times New Roman',Times,serif"><ix:nonFraction id="FFact_0000000000470" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,299</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px" valign="bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25">Accrued expenses</div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="FFact_0000000000471" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,396</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                    <div style="line-height:1.25"><ix:nonFraction id="FFact_0000000000472" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,779</ix:nonFraction></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-family:'Times New Roman',Times,serif">$</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-family:'Times New Roman',Times,serif"><ix:nonFraction id="FFact_0000000000473" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,208</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-family:'Times New Roman',Times,serif">$</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-family:'Times New Roman',Times,serif"><ix:nonFraction id="FFact_0000000000474" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,078</ix:nonFraction></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>

            </table>
          </ix:nonNumeric>
        </div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
  <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 25</span></span></span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:3pt;margin-bottom:10pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:4pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" /><p style="margin-top:4pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

  <ix:nonNumeric id="FFact_0000000000498" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_20220101to20221231" escape="true">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0px;margin-bottom:0pt"><span style="font-weight:bold">NOTE 7: -&#160;</span><span style="font-weight:bold">COMMITMENTS AND CONTINGENCIES</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt">a.<span style="padding-left:21.5pt">The Company provided bank guarantees in the amount of $&#160;</span><ix:nonFraction id="FFact_0000000000477" name="us-gaap:GuaranteeObligationsMaximumExposure" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">318</ix:nonFraction> related to its offices in Israel, leased cars fueling in Israel and credit card security for its U.S. subsidiary.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt">b.<span style="padding-left:21.5pt">Under the Office of the Israel Innovation Authority of the Israeli Ministry of Industry, Trade and Labor, formerly </span>known as the Office of the Chief Scientist, (the &#8220;IIA&#8221;), the Company is not obligated to repay any amounts received from the IIA if it does not generate any income from the results of the funded research program(s). If income is generated from a funded research program, the Company is committed to pay royalties at a rate of between <ix:nonFraction id="FFact_0000000000478" name="cgen:RoyaltyPercentageBasedOnFutureRevenues" contextRef="C_20220101to20221231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember_srtRangeAxis_srtMinimumMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">3</ix:nonFraction>% to <ix:nonFraction id="FFact_0000000000479" name="cgen:RoyaltyPercentageBasedOnFutureRevenues" contextRef="C_20220101to20221231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember_srtRangeAxis_srtMaximumMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction>% of future revenue arising from such research program(s), and up to a maximum of 100% of the amount received, linked to the U.S. dollar (for grants received under programs approved subsequent to January 1, 1999, the maximum to be repaid is <ix:nonFraction id="FFact_0000000000480" name="cgen:MaximumRoyaltyRepaidAsPercentageOfGrantReceived" contextRef="C_20220101to20221231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction>% plus interest at LIBOR). For the years ended December 31, 2022, 2021&#160;and 2020, the Company had an aggregate of paid or accrued royalties to the IIA, recorded as cost of revenue in the consolidated statements of comprehensive loss in the amount of $&#160;<ix:nonFraction id="FFact_0000000000481" name="us-gaap:RoyaltyExpense" contextRef="C_20220101to20221231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">225</ix:nonFraction>, $&#160;<ix:nonFraction id="FFact_0000000000482" name="us-gaap:RoyaltyExpense" contextRef="C_20210101to20211231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">180</ix:nonFraction> and $&#160;<ix:nonFraction id="FFact_0000000000483" name="us-gaap:RoyaltyExpense" contextRef="C_20200101to20201231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">60</ix:nonFraction>, respectively.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt">As of December 31, 2022, the Company&#8217;s aggregate contingent obligations for payments to IIA, based on royalty-bearing participation received or accrued, net of royalties paid or accrued, totaled approximately to $&#160;<ix:nonFraction id="FFact_0000000000484" name="cgen:RoyaltyContingentObligations" contextRef="C_20211231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,631</ix:nonFraction>.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt">c.<span style="padding-left:21.06pt">On June 25, 2012 the Company entered into an Antibodies Discovery Collaboration Agreement (the &#8220;Antibodies </span>Discovery Agreement&#8221;) with a U.S. antibody technology company (&#8220;mAb Technology Company&#8221;), providing an established source for fully human mAbs. Under the Antibodies Discovery Agreement, the mAb Technology Company will be entitled to certain royalties that could be eliminated, upon payment of certain one-time fees (all payments referred together as &#8220;Contingent Fees&#8221;). For the years ended December 31, 2022, 2021&#160;and 2020, the Company incurred such Contingent Fees in the amounts of $&#160;<ix:nonFraction id="FFact_0000000000485" name="cgen:ContingentFees" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">750</ix:nonFraction>, $&#160;<ix:nonFraction id="FFact_0000000000486" name="cgen:ContingentFees" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">500</ix:nonFraction> and $&#160;<ix:nonFraction id="FFact_0000000000487" name="cgen:ContingentFees" contextRef="C_20201231" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">500</ix:nonFraction>.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt">d.<span style="padding-left:21.5pt">On </span><ix:nonNumeric id="FFact_0000000000488" name="cgen:AgreementStartDate" contextRef="C_20220101to20221231_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember" format="ixt:date-monthname-day-year-en">May 9, 2012</ix:nonNumeric>, the Company entered into agreement (the &#8220;May 2012 Agreement&#8221;) with a U.S. Business Development Strategic Advisor (&#8220;Advisor&#8221;) for the purpose of entering into transactions with Pharma companies related to selected Pipeline Program Candidates.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt">Under the agreement the Advisor was entitled to <ix:nonFraction id="FFact_0000000000489" name="cgen:ParticipationRights" contextRef="C_20220101to20221231_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember_srtRangeAxis_srtMinimumMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">4</ix:nonFraction>% of the cash considerations that may be received under such transactions. <ix:nonNumeric id="FFact_0000000000490" name="cgen:AgreementTerminationDescription" contextRef="C_20220101to20221231_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember">In 2014, the May 2012 Agreement was terminated except for certain payments arising from the Bayer Agreement which survive termination until August 5, 2025.</ix:nonNumeric></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt">The Bayer Agreement was terminated effective February 27, 2023 and no further payments are expected under the May 2012 Agreement</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt">For the years ended December 31, 2022, 2021 and 2020, the Company has not paid and did not accrue payments under this agreement.&#160;</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
    <div><ix:exclude>
      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 26</span></span></span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:3pt;margin-bottom:10pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:4pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" /><p style="margin-top:4pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">NOTE 7: -&#160;</span><span style="font-weight:bold">COMMITMENTS AND CONTINGENCIES (Cont.)</span></p>
      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">&#160;</p>
    </ix:exclude></div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt">e.<span style="padding-left:21.06pt">Effective as of January 5, 2018, the Company entered into a Commercial License Agreement (CLA) with a European </span>cell line development company. Under the agreement the Company is required to pay an annual maintenance fee, certain amounts upon the occurrence of specified milestones events, and <ix:nonFraction id="FFact_0000000000491" name="cgen:RoyaltyPercentage" contextRef="C_20220101to20221231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction>% royalties on annual net sales with respect to each commercialized product manufactured using the company&#8217;s cell line. Royalties due under the CLA are creditable against the annual maintenance fee. In addition, the Company may at any time prior to the occurrence of a specific milestone event buy-out the royalty payment obligations in a single fixed amount. For the years ended December 31, 2022, 2021&#160;and 2020, the Company incurred in the research and development expenses in connection with such milestone payment in the amounts of $&#160;<ix:nonFraction id="FFact_0000000000492" name="cgen:ResearchAndDevelopmentExpensesMilestonePaymentWithConnection" contextRef="C_20220101to20221231" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">0</ix:nonFraction>, $&#160;<ix:nonFraction id="FFact_0000000000493" name="cgen:ResearchAndDevelopmentExpensesMilestonePaymentWithConnection" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">0</ix:nonFraction> and $&#160;<ix:nonFraction id="FFact_0000000000494" name="cgen:ResearchAndDevelopmentExpensesMilestonePaymentWithConnection" contextRef="C_20200101to20201231" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">52</ix:nonFraction>.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-27pt;margin-left:85pt;margin-bottom:0pt">f.<span style="padding-left:21.17pt">Effective as of October 28, 2020, the Company entered into a collaboration agreement with a U.S. antibody </span>discovery and optimization company for generation and optimization of therapeutic antibodies for the Company. Under the agreement the Company is required to pay service fees per services performed and certain amounts upon the occurrence of specified milestones events, and single-digit percent royalties on annual net sales with respect to each product sold that comprises or contains one or more antibodies so generated or optimized. The royalty rate is dependent upon the product type and any third-party contribution. For the years ended December 31, 2022, 2021&#160;and 2020, the Company incurred in the research and development expenses such milestone payment in the amounts of $&#160;<ix:nonFraction id="FFact_0000000000495" name="cgen:ResearchAndDevelopmentExpensesMilestonePayment" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">0</ix:nonFraction>, $&#160;<ix:nonFraction id="FFact_0000000000496" name="cgen:ResearchAndDevelopmentExpensesMilestonePayment" contextRef="C_20210101to20211231" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">250</ix:nonFraction> and $&#160;<ix:nonFraction id="FFact_0000000000497" name="cgen:ResearchAndDevelopmentExpensesMilestonePayment" contextRef="C_20200101to20201231" unitRef="usd" scale="0" decimals="0" format="ixt:num-dot-decimal">0</ix:nonFraction>.</p>
  </ix:nonNumeric>
  <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

  <ix:nonNumeric id="FFact_0000000000590" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" contextRef="C_20220101to20221231" escape="true">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">NOTE 8: -&#160;</span><span style="font-weight:bold">SHAREHOLDERS&#8217; EQUITY</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt">a.<span style="padding-left:21.06pt">Ordinary shares:</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt">The ordinary shares confer upon their holders the right to attend and vote at general meetings of the shareholders. Subject to the rights of holders of shares with limited or preferred rights which may be issued in the future, the ordinary shares of the Company confer upon the holders thereof equal rights to receive dividends, and to participate in the distribution of the assets of the Company upon its winding-up, in proportion to the amount paid up or credited as paid up on account of the nominal value of the shares held by them respectively and in respect of which such dividends are being paid or such distribution is being made, without regard to any premium paid in excess of the nominal value, if any.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt">b.<span style="padding-left:21.5pt">Issuance of shares:</span></p>
    <p style="margin:0pt">&#160;</p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:85.05pt">On June 14, 2018, the Company entered into securities purchase agreement with certain institutional investors and a placement agency agreement with JMP Securities LLC in connection with a registered direct offering (the &#8220;Offering&#8221;) of an aggregate of 5,316,457 ordinary shares (the &#8220;RD Shares&#8221;) of the Company at a purchase price of $ 3.95 per RD Share. In connection with the issuance of the RD Shares, the Company also issued warrants to purchase an aggregate of up to 4,253,165 additional ordinary shares. The Warrants are exercisable at a price of $ 4.74 per ordinary share and have a term of five years from the date of issuance. The Offering was made pursuant to the Company&#8217;s Registration Statement. Proceeds from the Offering were $ 19,767 (net of $ 1,233 issuance expenses).</p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:80pt">&#160;</p>
    <div><ix:exclude>
      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 27</span></span></span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:3pt;margin-bottom:10pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:4pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" /><p style="margin-top:4pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
      <p style="margin-top:0pt;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-weight:bold">NOTE 8: -&#160;</span><span style="font-weight:bold">SHAREHOLDERS&#8217; EQUITY (Cont.)</span></p>
      <p style="margin-top:11pt;margin-bottom:0pt;text-align:left;text-indent:-28pt;margin-left:85pt;font-size:10pt;font-family:Times New Roman, Times, serif">b.<span style="padding-left:21.06pt">Issuance of shares: (Cont.):</span></p>
      <p style="margin-top:0pt;margin-bottom:0pt;text-align:left;text-indent:60pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
    </ix:exclude></div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">During the years ended December 31, 2021 and 2020, warrants to purchase an aggregate of <ix:nonFraction id="Fxbrl_20230214033051318" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20201231_usgaapAwardTypeAxis_usgaapWarrantMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230214032847386" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_20211231_usgaapAwardTypeAxis_usgaapWarrantMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">3,955,696</ix:nonFraction></ix:nonFraction> ordinary shares were exercised with proceeds of approximately $ <ix:nonFraction id="Fxbrl_20230214033059280" name="us-gaap:ProceedsFromWarrantExercises" contextRef="C_20220101to20221231_usgaapAwardTypeAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230214032855904" name="us-gaap:ProceedsFromWarrantExercises" contextRef="C_20210101to20211231_usgaapAwardTypeAxis_usgaapWarrantMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,750</ix:nonFraction></ix:nonFraction> and as of December 31, 2022 and 2021, warrants to purchase up to <ix:nonFraction id="Fxbrl_20230214032904124" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_20221231_usgaapAwardTypeAxis_usgaapWarrantMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">297,469</ix:nonFraction> ordinary shares remain outstanding.&#160;</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt">On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement (the &#8220;Master Clinical Agreement&#8221;) with Bristol-Myers Squibb to evaluate the safety and tolerability of the Company&#8217;s COM701 in combination with Bristol-Myers Squibb&#8217;s PD-1 immune checkpoint inhibitor Opdivo&#174; (nivolumab), in patients with advanced solid tumors. In conjunction with the Master Clinical Agreement, Bristol-Myers Squibb made a $&#160;<ix:nonFraction id="FFact_0000000000516" name="us-gaap:EquityMethodInvestmentAggregateCost" contextRef="C_20181010_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,000</ix:nonFraction> equity investment in the Company.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt">Under the terms of the securities purchase agreement, Bristol-Myers Squibb purchased <ix:nonFraction id="FFact_0000000000517" name="cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock" contextRef="C_20181001to20181010_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,424,243</ix:nonFraction> ordinary shares of the Company at a purchase price of $&#160;<ix:nonFraction id="FFact_0000000000518" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_20181010_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">4.95</ix:nonFraction> per share. The share price represented a <ix:nonFraction id="FFact_0000000000519" name="cgen:PercentageOfClosingPrice" contextRef="C_20181001to20181010_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">33</ix:nonFraction>% premium over the average closing price of Compugen&#8217;s ordinary shares for twenty (20) Nasdaq trading days prior to the execution of the securities purchase agreement. The investment closed on October 12, 2018.</p>
    <p style="margin:0pt">&#160;</p>
    <div>
      <div style="margin-left:85.05pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The premium over the fair market value in the amount of $<ix:nonFraction id="Fxbrl_20230221120705140" name="cgen:DeferredParticipationOfBMSInRAndDExpenses" contextRef="C_20220101to20221231_srtStatementScenarioAxis_cgenCollaborativeArrangementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,121</ix:nonFraction> represents the relative fair value of deferred participation of Bristol-Myers Squibb in R&#38;D expenses (which are amortized over the period of the clinical trial, based on the progress in the R&#38;D) and $<ix:nonFraction id="Fxbrl_20230221120728895" name="cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock" contextRef="C_20220101to20221231_srtStatementScenarioAxis_cgenCollaborativeArrangementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,788</ix:nonFraction> (net of $<ix:nonFraction id="Fxbrl_20230221120826639" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20220101to20221231_srtStatementScenarioAxis_cgenCollaborativeArrangementsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">91</ix:nonFraction> issuance expenses) were considered equity investment.</span></span></div>
    </div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt">In conjunction with the signing of the amendment to the Master Clinical Agreement in November 2021, Bristol Myers Squibb made a $&#160;<ix:nonFraction id="FFact_0000000000523" name="us-gaap:EquityMethodInvestmentAggregateCost" contextRef="C_20211130_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,000</ix:nonFraction> investment in the Company, purchasing <ix:nonFraction id="FFact_0000000000524" name="cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock" contextRef="C_20211102to20211130_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,332,815</ix:nonFraction> ordinary shares of the Company at a purchase price of $&#160;<ix:nonFraction id="FFact_0000000000525" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_20211130_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">8.57333</ix:nonFraction> per share. The share price represented a <ix:nonFraction id="FFact_0000000000526" name="cgen:PercentageOfClosingPrice" contextRef="C_20211102to20211130_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">33</ix:nonFraction>% premium over the closing price of Company&#8217;s ordinary shares on the last Nasdaq trading day immediately prior to the execution of the securities purchase agreement.</p>
    <p style="margin:0pt">&#160;</p>
    <div>
      <div style="margin-left:85.05pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The premium over the fair market value in the amount of $<ix:nonFraction id="Fxbrl_20230221122449076" name="cgen:DeferredParticipationOfBMSInRAndDExpenses" contextRef="C_20220101to20221231_srtStatementScenarioAxis_cgenCollaborativeArrangementsTwoMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,000</ix:nonFraction> represents the relative fair value of deferred participation of Bristol-Myers Squibb in R&#38;D expenses (which are amortized over the period of the clinical trial, based on the progress in the R&#38;D) and $<ix:nonFraction id="Fxbrl_20230221122456788" name="cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock" contextRef="C_20220101to20221231_srtStatementScenarioAxis_cgenCollaborativeArrangementsTwoMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,958</ix:nonFraction> (net of $<ix:nonFraction id="Fxbrl_20230221122504540" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20220101to20221231_srtStatementScenarioAxis_cgenCollaborativeArrangementsTwoMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">42</ix:nonFraction> issuance expenses) were considered equity investment.</span></span></div>
      <div style="margin-left:85.05pt">&#160;</div>
    </div>
    <div><ix:exclude>
      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 28</span></span></span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:3pt;margin-bottom:10pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:4pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" /><p style="margin-top:4pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
      <p style="margin-top:0pt;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-weight:bold">NOTE 8: - </span><span style="font-weight:bold">SHAREHOLDERS&#8217; EQUITY (Cont.)</span></p>
      <p style="margin-top:11pt;margin-bottom:0pt;text-align:left;text-indent:-28pt;margin-left:85pt;font-size:10pt;font-family:Times New Roman, Times, serif">b.<span style="padding-left:21.06pt">Issuance of shares: (Cont.):</span></p>
      <p style="margin-top:0pt;margin-bottom:0pt;text-align:left;text-indent:60pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
    </ix:exclude></div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">In March 2020, the Company entered into an underwriting agreement with SVB Leerink LLC and Stifel, Nicolaus &#38; Company, Incorporated, as representatives of several underwriters relating to the issuance and sale in a public offering of <ix:nonFraction id="FFact_0000000000530" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20200301to20200316_srtStatementScenarioAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">8,333,334</ix:nonFraction> of the Company&#8217;s ordinary shares at a price to the public of $&#160;<ix:nonFraction id="FFact_0000000000531" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_20200316_srtStatementScenarioAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">9.00</ix:nonFraction> per share (and a price of $&#160;<ix:nonFraction id="FFact_0000000000532" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_20200316_srtStatementScenarioAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember_usgaapAwardTypeAxis_cgenUnderwritersMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">8.46</ix:nonFraction> per share to the underwriters). Such shares were issued on March 16, 2020. In addition, the Company granted the underwriters a 30-day option to purchase additional ordinary shares at the price set forth above. On April 14, 2020, the Company issued and sold, pursuant to that underwriting agreement additional <ix:nonFraction id="FFact_0000000000533" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20200401to20200414_srtStatementScenarioAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember_usgaapAwardTypeAxis_cgenUnderwritersMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">483,005</ix:nonFraction> ordinary shares pursuant to the underwriters&#8217; option specified above. The Company sold a total of <ix:nonFraction id="FFact_0000000000534" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_20220101to20221231_srtStatementScenarioAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">8,816,339</ix:nonFraction> ordinary shares in the offering with proceeds of $<ix:nonFraction id="FFact_0000000000535" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="C_20220101to20221231_srtStatementScenarioAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,147</ix:nonFraction> (net of $&#160;<ix:nonFraction id="FFact_0000000000536" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_20220101to20221231_srtStatementScenarioAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,200</ix:nonFraction> issuance expenses).</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt">c.<span style="padding-left:21.06pt">Share option plan:</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt">Under the Company&#8217;s 2010 Share Option Plan as amended (the &#8220;Plan&#8220;), options may be granted to employees, directors and non-employees of the Company and Compugen USA, Inc.</p>
    <p style="margin:0pt">&#160;</p>
    <p style="margin:0pt 0pt 0pt 85.05pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under the 2010 Share Option Plan the Company reserved for issuance up to an aggregate of <ix:nonFraction id="FFact_0000000000537" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_20221231_usgaapPlanNameAxis_cgenTwoThousandAndTwoThousandTenOptionsPlanMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">14,395,152</ix:nonFraction> ordinary shares. <span style="color:rgb(0, 0, 0)">The Company</span>&#8217;<span style="color:rgb(0, 0, 0)">s Board of Directors last amended the Plan in March 2022, to increase the number of shares available under the 2010 Plan.</span> As of December 31, 2022, an aggregate of <ix:nonFraction id="FFact_0000000000538" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_20221231_usgaapPlanNameAxis_cgenTwoThousandAndTwoThousandTenOptionsPlanMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">1,918,297</ix:nonFraction> options under the 2010 Share Option Plan of the Company were still available for future grants.</span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt">In general, options granted under the Plan vest over a <ix:nonNumeric id="FFact_0000000000539" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cgenTwoThousandAndTwoThousandTenOptionsPlanMember" format="ixt-sec:durwordsen">four-year</ix:nonNumeric> period and expire <ix:nonNumeric id="FFact_0000000000540" name="cgen:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" contextRef="C_20220101to20221231_usgaapPlanNameAxis_cgenTwoThousandAndTwoThousandTenOptionsPlanMember" format="ixt-sec:duryear">10</ix:nonNumeric> years from the date of grant and are granted at an exercise price of not less than the fair market value of the Company&#8217;s ordinary shares on the date of grant, unless otherwise determined by the Company&#8217;s board of directors. The exercise price of the options granted under the Plan may not be less than the nominal value of the shares into which such options are exercised and the expiration date may not be later than 10 years from the date of grant. If a grantee leaves his or her employment or other relationship with the Company, or if his or her relationship with the Company is terminated without cause (and other than by reason of death or disability, as defined in the Plan), the term of his or her unexercised options will generally expire in 90 days, unless determined otherwise by the Company.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt">Any options that are cancelled, forfeited or expired become available for future grants.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:80pt;margin-bottom:0pt">&#160;</p>
    <div><ix:exclude>
      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 29</span></span></span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:3pt;margin-bottom:10pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:4pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" /><p style="margin-top:4pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
      <p style="margin-top:0pt;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-weight:bold">NOTE 8: -&#160;</span><span style="font-weight:bold">SHAREHOLDERS&#8217; EQUITY (Cont.)</span></p>
      <p style="margin-top:11pt;margin-bottom:0pt;text-align:left;text-indent:-28pt;margin-left:85pt;font-size:10pt;font-family:Times New Roman, Times, serif">c.<span style="padding-left:21.06pt">Share option plan: (Cont.):</span></p>
      <p style="margin-top:0pt;margin-bottom:0pt;text-align:left;text-indent:60pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
    </ix:exclude></div>
    <ix:nonNumeric id="FFact_0000000000561" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" contextRef="C_20220101to20221231" escape="true">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:10pt">Transactions related to the grant of options to employees, directors and non-employees under the above Plan during the year ended December 31, 2022, were as follows:</p>
      <div style="margin-left:85.04pt">
        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Number of</span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">options</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Weighted</span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">average</span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">exercise </span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">price</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Weighted</span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">average</span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">remaining</span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">contractual </span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">life</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Aggregate</span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">intrinsic</span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">value</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">$</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Years</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">$</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:52%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Options outstanding at beginning of year</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000541" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20211231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">6,976,104</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000542" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20211231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">6.39</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="FFact_0000000000543" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="C_20210101to20211231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember" format="ixt-sec:duryear">6.69</ix:nonNumeric></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000544" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_20211231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,323</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:52%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Options granted</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000545" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">2,186,400</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000546" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">2.58</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:52%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Options exercised</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(<ix:nonFraction id="FFact_0000000000547" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">33,186</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">)</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000548" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">3.14</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:52%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Options forfeited</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(<ix:nonFraction id="FFact_0000000000549" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">778,069</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">)</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000550" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">6.42</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:baseline;width:52%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Options expired</p>
              </td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(<ix:nonFraction id="FFact_0000000000551" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">193,500</ix:nonFraction></p>
              </td>
              <td style="vertical-align:baseline;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:1pt">)</p>
              </td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000552" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">4.21</ix:nonFraction></p>
              </td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;width:9%">&#160;</td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;width:9%">&#160;</td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:52%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:52%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Options outstanding at end of year</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000553" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_20221231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">8,157,749</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000554" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_20221231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">5.43</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="FFact_0000000000555" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember" format="ixt-sec:duryear">6.32</ix:nonNumeric></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000556" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_20221231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:52%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:52%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Exercisable at end of year</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000557" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_20221231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">4,635,040</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000558" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="C_20221231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">5.68</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonNumeric id="FFact_0000000000559" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember" format="ixt-sec:duryear">4.52</ix:nonNumeric></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000560" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="C_20221231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>
      </div>
    </ix:nonNumeric>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt">Weighted average fair value of options granted to employees, directors and non-employees during the years 2022, 2021&#160;and 2020&#160;was $&#160;<ix:nonFraction id="FFact_0000000000562" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_20220101to20221231" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">1.51</ix:nonFraction>, $&#160;<ix:nonFraction id="FFact_0000000000563" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_20210101to20211231" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">3.81</ix:nonFraction> and $&#160;<ix:nonFraction id="FFact_0000000000564" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_20200101to20201231" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">7.15</ix:nonFraction> per share, respectively.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt">Aggregate intrinsic value of exercised options by employees, directors and non-employees during the years 2022, 2021 and 2020&#160;was $&#160;<ix:nonFraction id="FFact_0000000000565" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="C_20221231_srtTitleOfIndividualAxis_srtDirectorMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">19</ix:nonFraction>, $&#160;<ix:nonFraction id="FFact_0000000000566" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="C_20211231_srtTitleOfIndividualAxis_srtDirectorMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">759</ix:nonFraction>&#160;and $&#160;<ix:nonFraction id="FFact_0000000000567" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="C_20201231_srtTitleOfIndividualAxis_srtDirectorMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,610</ix:nonFraction>, respectively. The aggregate intrinsic value of the exercised options represents the total intrinsic value (the difference between the sale price of the Company&#8217;s share at the date of exercise, and the exercise price) multiplied by the number of options exercised.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt">The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the Company&#8217;s closing share price on the last trading day of calendar 2021 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on December 31, 2022. This amount is impacted by the changes in the fair market value of the Company&#8217;s shares.&#160;</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt">As of December 31, 2022, the total unrecognized estimated compensation cost related to non-vested share options granted prior to that date was $&#160;<ix:nonFraction id="FFact_0000000000568" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,715</ix:nonFraction> which is expected to be recognized over a weighted average period of approximately <ix:nonNumeric id="FFact_0000000000569" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_20220101to20221231" format="ixt-sec:duryear">2.47</ix:nonNumeric> years.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt">d.<span style="padding-left:21.5pt">Employee Stock Purchase Plan:</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt">The Company adopted an ESPP in November 2020, with the first offering period starting at January 1, 2021. In connection with its adoption, a total of <ix:nonFraction id="FFact_0000000000570" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_20221231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">600,000</ix:nonFraction> ordinary shares were reserved for issuance under this plan.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
    <div><ix:exclude>
      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 30</span></span></span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:3pt;margin-bottom:10pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:4pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" /><p style="margin-top:4pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
      <p style="margin-top:0pt;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-weight:bold">NOTE 8: -&#160;</span><span style="font-weight:bold">SHAREHOLDERS&#8217; EQUITY (Cont.)</span></p>
      <p style="margin-top:11pt;margin-bottom:0pt;text-align:left;text-indent:-28pt;margin-left:85pt;font-size:10pt;font-family:Times New Roman, Times, serif">d.<span style="padding-left:21.06pt">Employee Stock Purchase Plan: (Cont.):</span></p>
      <p style="margin-top:0pt;margin-bottom:0pt;text-align:left;text-indent:60pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
    </ix:exclude></div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">The ESPP is implemented through six-month offering periods (except for the first offering period that was <ix:nonNumeric id="FFact_0000000000571" name="us-gaap:InitialOfferingPeriod" contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">five months</ix:nonNumeric>). According to the ESPP, eligible employees and non-employees may use up to <ix:nonFraction id="FFact_0000000000572" name="cgen:PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares" contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">15</ix:nonFraction>% of their base salaries to purchase ordinary shares up to an aggregate limit of $&#160;<ix:nonFraction id="FFact_0000000000573" name="cgen:AggregateLimitOfOrdinarySharesPerCalendarYear" contextRef="C_20221231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal">40</ix:nonFraction> per participant for every calendar year. The price of an ordinary share purchased under the ESPP is equal to <ix:nonFraction id="FFact_0000000000574" name="cgen:PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering" contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">85</ix:nonFraction>% of the lower of the fair market value of the ordinary share on the first day of each offering period or on the last day of such period.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt">Since its adoption and through December 31, 2022, <ix:nonFraction id="FFact_0000000000575" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">275,854</ix:nonFraction> ordinary shares had been purchased under the ESPP and as of December 31, 2022, <ix:nonFraction id="FFact_0000000000576" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_20221231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">324,146</ix:nonFraction> ordinary shares were available for issuance under the ESPP.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt">In accordance with ASC No. 718, the ESPP is compensatory and, as such, results in recognition of compensation cost.</p>
    <p style="margin:0pt">&#160;</p>
    <div>
      <ix:nonNumeric id="FFact_0000000000589" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="C_20220101to20221231" escape="true">
        <div>
          <div>
            <p style="text-indent:-28pt;margin-left:85pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">e.<span style="padding-left:21.5pt;font-size:10pt;font-family:Times New Roman, Times, serif">The stock-based compensation expenses related to stock options and ESPP are included as follows in the expense categories:</span></p>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
            <div style="margin-left:85.05pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;float:left">

                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="10" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2020</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development expenses</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_0000000000577" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,158</ix:nonFraction></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_0000000000578" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,971</ix:nonFraction></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_0000000000579" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20200101to20201231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,123</ix:nonFraction></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Marketing and business development expenses</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000580" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">269</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000581" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">215</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000582" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20200101to20201231_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">172</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General and administrative expenses</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000583" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,901</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000584" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,090</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000585" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20200101to20201231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,477</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_0000000000586" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,328</ix:nonFraction></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_0000000000587" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,276</ix:nonFraction></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_0000000000588" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,772</ix:nonFraction></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>

              </table>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
            </div>
          </div>
        </div>
      </ix:nonNumeric>
    </div>
  </ix:nonNumeric>

  <ix:nonNumeric id="FFact_0000000000629" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="C_20220101to20221231" escape="true">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">NOTE 9: - </span><span style="font-weight:bold">INCOME TAXES</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt">a. <span style="padding-left:18.73pt">Israeli taxation:</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-28pt;margin-left:113pt;margin-bottom:0pt">1.<span style="padding-left:20.5pt">Tax rates applicable to the income of the Company.</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt">Taxable income of the Company is subject to a corporate tax rate of <ix:nonFraction id="Fxbrl_20230214114856319" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_20200101to20201231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230214114847978" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_20210101to20211231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="Fxbrl_20230214114839776" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_20220101to20221231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">23</ix:nonFraction></ix:nonFraction></ix:nonFraction>% in 2020, 2021&#160;and 2022.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-28pt;margin-left:113pt;margin-bottom:0pt">2.<span style="padding-left:20.5pt">Measurement of taxable income in US dollars:</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt">The Company has elected to measure its taxable income and file its tax return under the Israeli Income Tax Regulations (Principles Regarding the Management of Books of Account of Foreign Invested Companies and Certain Partnerships and the Determination of Their Taxable Income), 1986. Accordingly, results for tax purposes are measured in terms of earnings in dollars.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:100pt;margin-bottom:0pt">&#160;</p>
    <div><ix:exclude>
      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 31</span></span></span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:3pt;margin-bottom:10pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:4pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" /><p style="margin-top:4pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
      <p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-weight:bold">NOTE 9: -&#160;</span><span style="font-weight:bold">INCOME TAXES (Cont.)</span></p>
      <p style="margin-top:11pt;margin-bottom:0pt;text-align:left;text-indent:-28pt;margin-left:85pt;font-size:10pt;font-family:Times New Roman, Times, serif">a. <span style="padding-left:18.73pt">Israeli taxation (Cont.):</span></p>
      <p style="margin-top:0pt;margin-bottom:0pt;text-align:left;text-indent:60pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
    </ix:exclude></div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;text-indent:-28pt;margin-left:113pt;margin-bottom:0pt;text-align:justify">3.<span style="padding-left:20.5pt">Tax benefits under the Israeli Law for the Encouragement of Capital Investments, 1959 (the &#8220;Investment Law&#8221;):</span>&#8201;&#8201;</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt">On April 1, 2005, an amendment to the Investment Law came into effect (the &#8220;Amendment 60&#8221;) that significantly changed the provisions of the Investment Law. The Amendment 60 limits the scope of enterprises that may be approved by the Investment Center by setting criteria for the approval of a facility as a &#8220;Beneficiary Enterprise&#8221; including a provision generally requiring that at least <ix:nonFraction id="FFact_0000000000594" name="cgen:ReducedTaxRate" contextRef="C_20220101to20221231" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction>% of the Beneficiary Enterprise&#8217;s income will be derived from export.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt">Another condition for receiving the benefits under the alternative track in respect of expansion programs pursuant to Amendment 60 is a minimum qualifying investment. The Company was eligible under the terms of minimum qualifying investment and elected 2012 as its &#8220;year of election&#8221;.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt">Additionally, the Amendment 60 enacted major changes in the manner in which tax benefits are awarded under the Investment Law so that companies no longer require Investment Center approval in order to qualify for tax benefits. However, the Investment Law provides that terms and benefits included in any certificate of approval already granted will remain subject to the provisions of the Investment Law as they were on the date of such approval.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt">As of December 31, 2022, there was no taxable income attributable to the Beneficiary Enterprise.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt">In January 2011, another amendment to the Investment Law came into effect (&#8220;the 2011 Amendment&#8221;). According to the 2011 Amendment, the benefit tracks in the Investment Law were modified and a flat tax rate applies to the Company&#8217;s entire income subject to this amendment (the &#8220;Preferred Income&#8221;).</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt">Once an election is made, the Company&#8217;s income will be subject to the amended tax rate of 16% from 2015 and thereafter (or 9% for a preferred enterprise located in development area A).</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt">Commencing 2011 tax year, the Company can elect (without possibility of reversal) to apply the Amendment in a certain tax year and from that year and thereafter, it will be subject to the amended tax rates.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt">The Company does not currently intend to adopt the 2011 Amendment and intends to continue to comply with the Investment Law as in effect prior to enactment of the 2011 Amendment. Accordingly, the Company did not adjust its deferred tax balances as of December 31, 2022. The Company&#8217;s position may change in the future.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:113.4pt;margin-bottom:0pt">&#160;</p>
    <div><ix:exclude>
      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 32</span></span></span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:3pt;margin-bottom:10pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:4pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" /><p style="margin-top:4pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
      <p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-weight:bold">NOTE 9: -&#160;</span><span style="font-weight:bold">INCOME TAXES (Cont.)</span></p>
      <p style="margin-top:11pt;margin-bottom:0pt;text-align:left;text-indent:-28pt;margin-left:85pt;font-size:10pt;font-family:Times New Roman, Times, serif">a. <span style="padding-left:18.73pt">Israeli taxation (Cont.):</span></p>
      <p style="margin-top:0pt;margin-bottom:0pt;text-align:left;text-indent:60pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
    </ix:exclude></div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:113.4pt;margin-bottom:0pt">In December 2016, the Economic Efficiency Law (Legislative Amendments for Applying the Economic Policy for the 2016 and 2017 Budget Years), 2016, which includes Amendment 73 to the Law (the &#8220;Amendment 73&#8221;) was published. According to Amendment 73, a preferred enterprise located in development area A will be subject to a tax rate of 7.5% instead of 9% effective from January 1, 2016 and thereafter (the tax rate applicable to preferred enterprises located in other areas remains at 16%).</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt">Amendment 73 also prescribes special tax tracks for technological enterprises, which are subject to rules that were issued by the Minister of Finance in May 2017. The new tax tracks under the Amendment are as follows:</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt">Preferred Technological Enterprise (&#8220;PTE&#8221;) - an enterprise for which total consolidated revenues of its parent company and all subsidiaries are less than NIS 10 billion in a tax year. A PTE, as defined in the Law, which is located in the center of Israel will be subject to tax at a rate of 12% on profits deriving from intellectual property (in development area A - a tax rate of 7.5%).</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt">The above changes in the tax rates relating to PTE tax track were not taken into account in the computation of deferred taxes as of December 31, 2022 and 2021, since the Company estimates that it will not implement the PTE tax track.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-28pt;margin-left:113pt;margin-bottom:0pt">4.<span style="padding-left:20.5pt">Tax benefits under the law for the Encouragement of Industry (Taxes), 1969 (the &#8220;Encouragement Law&#8221;):</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt">The Encouragement Law provides several tax benefits for industrial companies. An industrial company is defined as a company resident in Israel, at least 90% of the income of which in a given tax year exclusive of income from specified Government loans, capital gains, interest and dividends, is derived from an industrial enterprise owned by it. An industrial enterprise is defined as an enterprise whose major activity in a given tax year is industrial production activity.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt">Management believes that the Company is currently qualified as an &#8220;industrial company&#8221; under the Encouragement Law and, as such, is entitled to tax benefits, including: (1) deduction of purchase of know-how and patents and/or right to use a patent over an eight-year period; (2) the right to elect, under specified conditions, to file a consolidated tax return with additional related Israeli industrial companies and an industrial holding company; (3) accelerated depreciation rates on equipment and buildings; and (4) expenses related to a public offering on the Tel-Aviv Stock exchange and on recognized stock markets outside of Israel, are deductible in equal amounts over three years.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;padding-left:100pt;margin-bottom:0pt">&#160;</p>
    <div><ix:exclude>
      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 33</span></span></span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:3pt;margin-bottom:10pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:4pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" /><p style="margin-top:4pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
      <p style="margin-top:0px;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-weight:bold">NOTE 9: -&#160;</span><span style="font-weight:bold">INCOME TAXES (Cont.)</span></p>
      <p style="margin-top:11pt;margin-bottom:0pt;text-align:left;text-indent:-28pt;margin-left:85pt;font-size:10pt;font-family:Times New Roman, Times, serif">a. <span style="padding-left:18.73pt">Israeli taxation (Cont.):</span></p>
      <p style="margin-top:0pt;margin-bottom:0pt;text-align:left;text-indent:60pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
    </ix:exclude></div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:113.4pt;margin-bottom:0pt">Eligibility for benefits under the Encouragement Law is not subject to receipt of prior approval from any Governmental authority. No assurance can be given that the Israeli tax authorities will agree that the Company qualifies, or, that the Company will continue to qualify as an industrial company or that the benefits described above will be available to the Company in the future.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-28pt;margin-left:113pt;margin-bottom:0pt">5.<span style="padding-left:20.5pt">Net operating losses carryforward and capital loss:</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt">As of December 31, 2022, Compugen Ltd. &#8217;s net operating losses carryforward for tax purposes in Israel amounted to approximately $&#160;<ix:nonFraction id="FFact_0000000000595" name="us-gaap:OperatingLossCarryforwards" contextRef="C_20221231_usgaapIncomeTaxAuthorityAxis_usgaapDomesticCountryMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">398,100</ix:nonFraction>. These net operating losses may be carried forward indefinitely and may be offset against future taxable income.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt">b.<span style="padding-left:20.73pt">Non-Israeli subsidiary, Compugen USA, Inc.:</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:85.5pt;margin-bottom:0pt">On December 22, 2017, the United States enacted the Tax Cuts and Jobs Act (the &#8220;U.S. Tax Reform&#8221; or &#8220;TCJA&#8221;); a comprehensive tax legislation that includes significant changes to the taxation of business entities. These changes include several key tax provisions that might impact the Company, among others: (i) a permanent reduction to the statutory federal corporate income tax rate from 35% to 21% effective for tax years beginning after December 31, 2017; (ii) a shift of the U.S. taxation of multinational corporations from a tax on worldwide income to a territorial system (along with certain new rules designed to prevent erosion of the U.S. income tax base - &#8220;BEAT&#8221;); (iii) establishing immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits; and (iv) providing a permanent deduction to corporations generating revenues from non-US markets (known as a deduction for foreign derived intangible income - &#8220;FDII&#8221;).</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:85.5pt;margin-bottom:0pt">As of December 31, 2022, Compugen USA, Inc. has net operating loss carryforwards for federal income tax purposes of approximately $ <ix:nonFraction id="FFact_0000000000597" name="cgen:NetOperatingLossCarryforwardExpired" contextRef="C_20201231_usgaapIncomeTaxAuthorityAxis_usgaapInternalRevenueServiceIRSMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">700</ix:nonFraction>. These losses may be carried forward indefinitely, but the deductibility of such federal NOLs may be limited. Utilization of the U.S. net operating losses may be subject to substantial annual limitation due to the &#8220;change in ownership&#8220; provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitation may result in the expiration of net operating losses before utilization.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:85.5pt;margin-bottom:0pt">Neither Israeli income taxes, foreign withholding taxes nor deferred income taxes were provided in relation to undistributed earnings of the Company&#8217;s foreign subsidiary. This is because the Company has the intent and ability to reinvest these earnings indefinitely in the foreign subsidiary and therefore those earnings are continually redeployed in those jurisdictions.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;padding-left:80pt;margin-bottom:0pt">&#160;</p>
    <div><ix:exclude>
      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 34</span></span></span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:3pt;margin-bottom:10pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:4pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" /><p style="margin-top:4pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
      <p style="margin-top:0pt;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-weight:bold">NOTE 9: - </span><span style="font-weight:bold">INCOME TAXES (Cont.)</span></p>
      <p style="margin-top:0pt;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
    </ix:exclude></div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:-28pt;margin-left:85pt;margin-bottom:11pt">c.<span style="padding-left:20.73pt">Loss (income) before taxes is comprised as follows:</span></p>
    <div style="margin-left:85.5pt">
      <ix:nonNumeric id="Fxbrl_20230214044607742" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" contextRef="C_20220101to20221231" escape="true">
        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="10" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Year ended December 31,</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2022</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2021</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2020</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:64%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Domestic (Israel)</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000600" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">34,096</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000601" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">34,619</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000602" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">30,010</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:baseline;width:64%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Foreign</p>
              </td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(<ix:nonFraction id="FFact_0000000000603" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">460</ix:nonFraction></p>
              </td>
              <td style="vertical-align:baseline;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:1.5pt">)</p>
              </td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(<ix:nonFraction id="FFact_0000000000604" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">416</ix:nonFraction></p>
              </td>
              <td style="vertical-align:baseline;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:1.5pt">)</p>
              </td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(<ix:nonFraction id="FFact_0000000000605" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">312</ix:nonFraction></p>
              </td>
              <td style="vertical-align:baseline;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:1.5pt">)</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:64%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:64%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000606" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">33,636</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000607" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">34,203</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000608" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">29,698</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>
      </ix:nonNumeric>
    </div>
    <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
    <div>
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif">d.</td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div>Taxes on income for the year ended December 31, 2022, represent state income taxes in the United States.</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt">e.<span style="padding-left:20.73pt">Deferred taxes:</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.5pt;margin-bottom:11pt">Deferred taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company and Compugen USA, Inc.&#8217;s deferred tax assets are comprised of operating loss carryforward and other temporary differences. Significant components of the Company and Compugen USA, Inc. deferred tax assets are as follows:</p>
    <div>
      <ix:nonNumeric id="Fxbrl_20230214044633836" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="C_20220101to20221231" escape="true">
        <div>
          <div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
            <div style="margin-left:85.5pt">
              <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;float:left;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%">

                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating loss carryforward</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_0000000000610" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">91,704</ix:nonFraction></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_0000000000611" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">86,068</ix:nonFraction></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000612" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,083</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000613" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,773</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrued social benefits and other</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000614" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,123</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000615" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,801</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Right of use assets</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000616" name="cgen:DeferredIncomeTaxRightOfUseAssets" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">415</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000617" name="cgen:DeferredIncomeTaxRightOfUseAssets" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">520</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease liabilities</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000618" name="cgen:DeferredIncomeTaxLeaseLiabilities" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">444</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000619" name="cgen:DeferredIncomeTaxLeaseLiabilities" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">636</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px" valign="bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property and equipment</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000620" name="cgen:DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000621" name="cgen:DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred tax asset before valuation allowance</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000622" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">106,941</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000623" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">98,760</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px" valign="bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Valuation allowance</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000624" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">106,941</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000625" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">98,760</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px" valign="bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net deferred tax asset</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20230214114648154" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="Fxbrl_20230214114719209" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:fixed-zero">-</ix:nonFraction></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>

              </table>
            </div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
          </div>
        </div>
      </ix:nonNumeric>
    </div>
    <div>
      <div style="margin-left:85.5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has provided full valuation allowances in respect of deferred tax assets resulting from operating loss carryforward and other temporary differences. Management currently believes that since the Company has a history of losses, it is more likely than not that the deferred tax regarding the operating loss carryforward and other temporary differences will not be realized in the foreseeable future.</span></span></div>
      <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
    </div>
    <div><ix:exclude>
      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 35</span></span></span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:3pt;margin-bottom:10pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:4pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" /><p style="margin-top:4pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
      <p style="margin-top:0pt;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-weight:bold">NOTE 9: - </span><span style="font-weight:bold">INCOME TAXES (Cont.)</span></p>
      <p style="margin-top:0pt;margin-bottom:0pt;text-align:left;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p>
    </ix:exclude></div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt">f.<span style="padding-left:22.73pt">Reconciliation of the theoretical tax expense (benefit) to the actual tax expense (benefit):</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:85.5pt;margin-bottom:0pt">The main reconciling items between the statutory tax rate of the Company and the effective tax rate are the non-recognition of tax benefits from accumulated net operating loss carryforward among the Company and Compugen USA, Inc. due to the uncertainty of the realization of such tax benefits.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt">g.<span style="padding-left:20.73pt">Tax assessments:</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11px;margin-left:85.5pt;margin-bottom:0px">The Company has tax assessments through 2017&#160;that are deemed to be final.</p>
  </ix:nonNumeric>
  <p style="margin:0pt">&#160;</p>

  <ix:nonNumeric id="Fxbrl_20230222123726446" name="us-gaap:SegmentReportingDisclosureTextBlock" contextRef="C_20220101to20221231" escape="true">
    <div>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">NOTE 10: -&#160;</span><span style="font-weight:bold">GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:56.7pt;margin-bottom:0pt">The Company&#8217;s business is currently comprised of <ix:nonFraction id="FFact_0000000000630" name="us-gaap:NumberOfOperatingSegments" contextRef="C_20220101to20221231" unitRef="Item" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> operating segment, the research, development and commercialization of therapeutic and product candidates. The nature of the products and services provided by the Company and the type of customers for these products and services are similar. Operations in Israel and the United States include research and development, clinical operations, marketing and business development. The Company follows ASC 280, <span style="color:black">&#8220;</span>Segment Reporting<span style="color:black">&#8220;</span>. Total revenues are attributed to geographic areas based on the location of the end customer.</p>
      <ix:nonNumeric id="FFact_0000000000643" name="us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" contextRef="C_20220101to20221231" escape="true">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:56.7pt;margin-bottom:11pt">The following represents the total revenue for the years ended December 31, 2022, 2021&#160;and 2020&#160;and long-lived assets as of December 31, 2022&#160;and 2021:</p>
        <div style="margin-left:56.7pt;margin-bottom:11pt">
          <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

              <tr>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="10" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Year ended December 31,</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2022</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2021</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2020</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>


              <tr style="background-color:#cceeff">
                <td style="vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Revenue from sales to customers:</p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>
              <tr style="background-color:#cceeff">
                <td style="vertical-align:bottom;width:64%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Europe</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
                </td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000631" name="us-gaap:Revenues" contextRef="C_20220101to20221231_cgenSegmentReportingGeographicAreaAxis_srtEuropeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,500</ix:nonFraction></p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
                </td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000632" name="us-gaap:Revenues" contextRef="C_20210101to20211231_cgenSegmentReportingGeographicAreaAxis_srtEuropeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,000</ix:nonFraction></p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
                </td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20230214023238881" name="us-gaap:Revenues" contextRef="C_20200101to20201231_cgenSegmentReportingGeographicAreaAxis_srtEuropeMember" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,000</ix:nonFraction></p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:9%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:9%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:9%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
              </tr>
              <tr style="background-color:#cceeff">
                <td style="vertical-align:bottom;width:64%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Total revenue</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
                </td>
                <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000634" name="us-gaap:Revenues" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,500</ix:nonFraction></p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
                </td>
                <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000635" name="us-gaap:Revenues" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,000</ix:nonFraction></p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
                </td>
                <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20230214023305010" name="us-gaap:Revenues" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,000</ix:nonFraction></p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
              </tr>

          </table>
        </div>
        <div style="margin-left:60pt;margin-bottom:0pt">
          <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

              <tr>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="6" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">December 31,</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2022</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2021</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>


              <tr style="background-color:#cceeff">
                <td style="vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Long-lived assets:</p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>
              <tr style="background-color:#cceeff">
                <td style="vertical-align:bottom;width:76%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Israel</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
                </td>
                <td style="vertical-align:bottom;width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000637" name="us-gaap:NoncurrentAssets" contextRef="C_20221231_cgenSegmentReportingGeographicAreaAxis_countryIL" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,239</ix:nonFraction></p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
                </td>
                <td style="vertical-align:bottom;width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000638" name="us-gaap:NoncurrentAssets" contextRef="C_20211231_cgenSegmentReportingGeographicAreaAxis_countryIL" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,787</ix:nonFraction></p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">United States</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000639" name="us-gaap:NoncurrentAssets" contextRef="C_20221231_cgenSegmentReportingGeographicAreaAxis_countryUS" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">119</ix:nonFraction></p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000640" name="us-gaap:NoncurrentAssets" contextRef="C_20211231_cgenSegmentReportingGeographicAreaAxis_countryUS" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">118</ix:nonFraction></p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
              </tr>
              <tr style="background-color:#cceeff">
                <td style="vertical-align:bottom;width:76%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:9%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:9%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Total long-lived assets</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
                </td>
                <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000641" name="us-gaap:NoncurrentAssets" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,358</ix:nonFraction></p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
                </td>
                <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000642" name="us-gaap:NoncurrentAssets" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,905</ix:nonFraction></p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
              </tr>

          </table>
        </div>
      </ix:nonNumeric>
      <p style="margin:0pt 0pt 0px">&#160;</p>
      <div><ix:exclude>
        <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 36</span></span></span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:3pt;margin-bottom:10pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:4pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" /><p style="margin-top:4pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">NOTE 10: - </span><span style="font-weight:bold">GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS</span><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span style="line-height:110%">&#160;(Cont.)</span></strong></span></span></p>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
      </ix:exclude></div>
      <ix:nonNumeric id="FFact_0000000000647" name="us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" contextRef="C_20220101to20221231" escape="true">
        <div style="margin-left:56.7pt;margin-top:0pt">
          <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

              <tr>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="8" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Year ended December 31,</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2022</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2021</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2020</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>


              <tr style="background-color:#cceeff">
                <td style="vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Sales to a single customer exceeding 10%:</p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>
              <tr style="background-color:#cceeff">
                <td style="vertical-align:bottom;width:62%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Customer A</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000644" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_20220101to20221231_srtMajorCustomersAxis_cgenCustomerOneMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></p>
                </td>
                <td style="vertical-align:bottom;width:2%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">%</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000645" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_20210101to20211231_srtMajorCustomersAxis_cgenCustomerOneMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></p>
                </td>
                <td style="vertical-align:bottom;width:2%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">%</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="Fxbrl_20230214023433284" name="us-gaap:ConcentrationRiskPercentage1" contextRef="C_20200101to20201231_srtMajorCustomersAxis_cgenCustomerOneMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember" unitRef="Pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></p>
                </td>
                <td style="vertical-align:bottom;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td>
              </tr>

          </table>
        </div>
      </ix:nonNumeric>
    </div>
  </ix:nonNumeric>
  <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

  <ix:nonNumeric id="FFact_0000000000665" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" contextRef="C_20220101to20221231" escape="true">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"><span style="font-weight:bold">NOTE 11: -&#160;</span><span style="font-weight:bold">FINANCIAL AND OTHER INCOME, NET</span></p>
    <ix:nonNumeric id="FFact_0000000000664" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" contextRef="C_20220101to20221231" escape="true">
      <div style="margin-left:56.7pt;margin-bottom:0pt">
        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="10" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Year ended December 31,</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2022</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2021</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2020</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:64%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Interest income</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000649" name="us-gaap:InvestmentIncomeInterest" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,437</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000650" name="us-gaap:InvestmentIncomeInterest" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">894</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000651" name="us-gaap:InvestmentIncomeInterest" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,765</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:64%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Bank fees and other finance expenses</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(<ix:nonFraction id="FFact_0000000000652" name="us-gaap:InterestAndDebtExpense" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">27</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">)</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(<ix:nonFraction id="FFact_0000000000653" name="us-gaap:InterestAndDebtExpense" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">)</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(<ix:nonFraction id="FFact_0000000000654" name="us-gaap:InterestAndDebtExpense" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">42</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">)</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:64%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Foreign currency transaction adjustments</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000655" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">340</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(<ix:nonFraction id="Fxbrl_20230214022140608" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">1</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000657" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">63</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
            </tr>
            <tr>
              <td style="vertical-align:baseline;width:64%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gain (loss) from sales and disposals of fixed assets</span></span></p>
              </td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="Fxbrl_20230214022153855" name="us-gaap:GainLossOnSaleOfOtherAssets" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">12</ix:nonFraction></span></span></p>
              </td>
              <td style="vertical-align:baseline;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000659" name="us-gaap:GainLossOnSaleOfOtherAssets" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></span></p>
              </td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000660" name="us-gaap:GainLossOnSaleOfOtherAssets" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></span></p>
              </td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:64%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:64%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Financial and other income, net</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000661" name="cgen:FinancialIncomeExpenseNet" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,738</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000662" name="cgen:FinancialIncomeExpenseNet" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">871</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><ix:nonFraction id="FFact_0000000000663" name="cgen:FinancialIncomeExpenseNet" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,798</ix:nonFraction></p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>
      </div>
    </ix:nonNumeric>
  </ix:nonNumeric>
  <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

  <ix:nonNumeric id="FFact_0000000000672" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="C_20220101to20221231" escape="true">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"><span style="font-weight:bold">NOTE 12: - </span><span style="font-weight:bold">RELATED PARTY BALANCES AND TRANSACTION</span></p>
    <ix:nonNumeric id="FFact_0000000000671" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" contextRef="C_20220101to20221231" escape="true">
      <div>
        <div>
          <div style="margin-left:56.7pt">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt">

                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Trade payables and accrued expenses</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_0000000000666" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="C_20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">83</ix:nonFraction></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_0000000000667" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="C_20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">94</ix:nonFraction></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                </tr>

            </table>
          </div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <div style="margin-left:56.7pt">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt">

                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="10" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2020</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amounts charged to:</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development expenses</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_0000000000668" name="us-gaap:CostsAndExpensesRelatedParty" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">194</ix:nonFraction></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_0000000000669" name="us-gaap:CostsAndExpensesRelatedParty" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">240</ix:nonFraction></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><ix:nonFraction id="FFact_0000000000670" name="us-gaap:CostsAndExpensesRelatedParty" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal">294</ix:nonFraction></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                </tr>

            </table>
            <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
          </div>
        </div>
      </div>
    </ix:nonNumeric>
    <div>
      <div style="margin-left:56.7pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the years ended December 31, 2022, 2021 and 2020 the Company received research and development services related with cancer studies in animal models, and breeding and maintenance of animals (mice) to support such studies. The transaction was at arm&#8217;s length.</span></span></div>
    </div>
  </ix:nonNumeric>
  <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
  <div style="margin-bottom:0pt">
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:10pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>F - 37</span></span></span></span></p><div style="page-break-after:always"><hr style="background:rgb(0, 0, 0);width:100%;border-top:2px solid black;margin-top:3pt;margin-bottom:10pt" /></div><div style="text-align:right"><div style="text-align:right;line-height:1.25;font-weight:bold;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span><span><span><span><span style="line-height:110%">COMPUGEN LTD. AND ITS SUBSIDIARY</span></span></span></span></span></strong></span></span><p style="margin:0pt">&#160;</p></div></div><div><p style="margin-top:0pt;margin-bottom:4pt;border:none;padding:0cm;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </strong></span></span></span></span></span></span></span></p><hr style="height:2px;color:#000000;background-color:#000000;text-align:center;margin-left:auto;margin-right:auto;border:none;text-align:center" /><p style="margin-top:4pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span><span><span><span style="line-height:110%"><strong><span><span style="line-height:110%">U.S. dollars in thousands (except share and per share data)</span></span></strong></span></span></span></span></span></span></span></p></div><p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
  </div>

  <ix:nonNumeric id="Fxbrl_20230222124735774" name="us-gaap:EarningsPerShareTextBlock" contextRef="C_20220101to20221231" escape="true">
    <div>
      <div>
        <div>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 13: - LOSSES PER SHARE</span></span></span></p>
        </div>
      </div>
      <div>
        <div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <ix:nonNumeric id="Fxbrl_20230222124750140" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="C_20220101to20221231" escape="true">
            <div style="text-align:justify;text-indent:-28.35pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table sets forth the computation of basic and diluted losses per share:</span></span></div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
            <div style="margin-left:56.7pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt">

                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="10" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2020</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Numerator:</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss for basic and diluted loss per share</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000673" name="us-gaap:NetIncomeLoss" contextRef="C_20220101to20221231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">33,694</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000674" name="us-gaap:NetIncomeLoss" contextRef="C_20210101to20211231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">34,203</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(<ix:nonFraction id="FFact_0000000000675" name="us-gaap:NetIncomeLoss" contextRef="C_20200101to20201231" unitRef="usd" scale="3" decimals="-3" format="ixt:num-dot-decimal" sign="-">29,698</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Denominator:</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average number of ordinary shares used in computing basic and diluted net loss per share</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000676" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20220101to20221231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">86,555,628</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000677" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20210101to20211231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">84,203,971</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><ix:nonFraction id="FFact_0000000000678" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_20200101to20201231" unitRef="Shares" decimals="INF" format="ixt:num-dot-decimal">79,591,187</ix:nonFraction></span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic and diluted loss per ordinary share</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(<ix:nonFraction id="Fxbrl_20230214135651704" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20220101to20221231" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="FFact_0000000000679" name="us-gaap:EarningsPerShareBasic" contextRef="C_20220101to20221231" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal" sign="-">0.39</ix:nonFraction></ix:nonFraction></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(<ix:nonFraction id="Fxbrl_20230214135713278" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20210101to20211231" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="FFact_0000000000680" name="us-gaap:EarningsPerShareBasic" contextRef="C_20210101to20211231" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal" sign="-">0.41</ix:nonFraction></ix:nonFraction></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(<ix:nonFraction id="Fxbrl_20230214135731057" name="us-gaap:EarningsPerShareDiluted" contextRef="C_20200101to20201231" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal" sign="-"><ix:nonFraction id="FFact_0000000000681" name="us-gaap:EarningsPerShareBasic" contextRef="C_20200101to20201231" unitRef="USD_per_share" decimals="INF" format="ixt:num-dot-decimal" sign="-">0.37</ix:nonFraction></ix:nonFraction></span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></div>
                    </td>
                  </tr>

              </table>
            </div>
          </ix:nonNumeric>
        </div>
      </div>
    </div>
  </ix:nonNumeric>
  <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>

  <ix:nonNumeric id="Fxbrl_20230214053733944" name="us-gaap:SubsequentEventsTextBlock" contextRef="C_20220101to20221231" escape="true">
    <div>
      <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>NOTE 14: -&#160;<span>Subsequent Events</span></strong></span></span></p>
      <p style="margin-top:11pt;margin-bottom:0pt;font-family:Times New Roman, Times, serif;margin-left:56.7pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>On January 31, 2023, the Company entered into a </span>Sales Agreement with SVB Securities LLC (&#8220;SVB&#8221;), as sales agent, pursuant to which the Company may offer and sell, from time to time through SVB, our ordinary shares. The offer and sale of our ordinary shares, if any, will be made pursuant to our shelf registration statement on Form F-3, as supplemented by the prospectus supplement filed on January 31, 2023. Pursuant to the said prospectus supplement, the Company may offer and sell up to $<ix:nonFraction id="Fxbrl_20230222014139521" name="cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock" contextRef="C_20230101to20230131_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_usgaapTypeOfArrangementAxis_cgenSalesAgreementWithSVBSecuritiesLLCMember" unitRef="usd" scale="6" decimals="-6" format="ixt:num-dot-decimal">50</ix:nonFraction> million of its ordinary shares.</span></span></span></p>
    </div>
  </ix:nonNumeric>
  <div>
    <div style="width:100%;clear:both">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:11pt"><span style="text-align:center;font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-style:normal;font-weight:400">-</span><span style="color:#000000;font-family:Times New Roman, Times, serif;font-size:13.3333px;font-style:normal;font-variant-ligatures:normal;text-align:center;white-space:normal;background-color:#ffffff;text-decoration-thickness:initial;text-decoration-style:initial;text-decoration-color:initial;font-weight:bold">&#160;</span><span style="text-align:center;font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-style:normal;font-weight:400">-</span><span style="color:#000000;font-family:Times New Roman, Times, serif;font-size:13.3333px;font-style:normal;font-variant-ligatures:normal;text-align:center;white-space:normal;background-color:#ffffff;text-decoration-thickness:initial;text-decoration-style:initial;text-decoration-color:initial;font-weight:bold">&#160;</span><span style="text-align:center;font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-style:normal;font-weight:400">-</span><span style="color:#000000;font-family:Times New Roman, Times, serif;font-size:13.3333px;font-style:normal;font-variant-ligatures:normal;text-align:center;white-space:normal;background-color:#ffffff;text-decoration-thickness:initial;text-decoration-style:initial;text-decoration-color:initial;font-weight:bold">&#160;</span><span style="text-align:center;font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-style:normal;font-weight:400">-</span><span style="color:#000000;font-family:Times New Roman, Times, serif;font-size:13.3333px;font-style:normal;font-variant-ligatures:normal;text-align:center;white-space:normal;background-color:#ffffff;text-decoration-thickness:initial;text-decoration-style:initial;text-decoration-color:initial;font-weight:bold">&#160;</span><span style="text-align:center;font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-style:normal;font-weight:400">-</span><span style="color:#000000;font-family:Times New Roman, Times, serif;font-size:13.3333px;font-style:normal;font-variant-ligatures:normal;text-align:center;white-space:normal;background-color:#ffffff;text-decoration-thickness:initial;text-decoration-style:initial;text-decoration-color:initial;font-weight:bold">&#160;</span><span style="text-align:center;font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-style:normal;font-weight:400">-</span><span style="color:#000000;font-family:Times New Roman, Times, serif;font-size:13.3333px;font-style:normal;font-variant-ligatures:normal;text-align:center;white-space:normal;background-color:#ffffff;text-decoration-thickness:initial;text-decoration-style:initial;text-decoration-color:initial;font-weight:bold">&#160;</span><span style="text-align:center;font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-style:normal;font-weight:400">-</span><span style="color:#000000;font-family:Times New Roman, Times, serif;font-size:13.3333px;font-style:normal;font-variant-ligatures:normal;text-align:center;white-space:normal;background-color:#ffffff;text-decoration-thickness:initial;text-decoration-style:initial;text-decoration-color:initial;font-weight:bold">&#160;</span><span style="text-align:center;font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-style:normal;font-weight:400">-</span><span style="color:#000000;font-family:Times New Roman, Times, serif;font-size:13.3333px;font-style:normal;font-variant-ligatures:normal;text-align:center;white-space:normal;background-color:#ffffff;text-decoration-thickness:initial;text-decoration-style:initial;text-decoration-color:initial;font-weight:bold">&#160;</span><span style="text-align:center;font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-style:normal;font-weight:400">-</span><span style="color:#000000;font-family:Times New Roman, Times, serif;font-size:13.3333px;font-style:normal;font-variant-ligatures:normal;text-align:center;white-space:normal;background-color:#ffffff;text-decoration-thickness:initial;text-decoration-style:initial;text-decoration-color:initial;font-weight:bold">&#160;</span><span style="text-align:center;font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-style:normal;font-weight:400">-</span><span style="color:#000000;font-family:Times New Roman, Times, serif;font-size:13.3333px;font-style:normal;font-variant-ligatures:normal;text-align:center;white-space:normal;background-color:#ffffff;text-decoration-thickness:initial;text-decoration-style:initial;text-decoration-color:initial;font-weight:bold">&#160;</span><span style="text-align:center;font-size:13.3333px;color:rgb(0, 0, 0);font-family:Times New Roman, Times, serif;font-style:normal;font-weight:400">-</span></p>
    </div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:11pt;margin-bottom:3pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">F&#8201;-&#8201;38</span></span></p>
    <div style="width:100%;clear:both;margin-top:0pt">
      <hr style="border-top:0.75pt solid #000000;width:100%;margin-left:0pt;text-align:left;margin-top:0pt" />
      <hr style="border-top:3pt solid #000000;width:100%;margin-left:0pt;text-align:left" />
    </div>
  </div>
</div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>exhibit_2-1.htm
<DESCRIPTION>EXHIBIT 2.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 23.1.1.5115
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><u>Exhibit 2.1</u></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">DESCRIPTION OF SECURITIES</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">The descriptions of the securities contained herein summarize the material terms and provisions of the ordinary shares of
      Compugen Ltd. (the &#8220;Company&#8221;), registered under Section 12 of the Securities Exchange Act of 1934.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">ORDINARY SHARES</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Our authorized share capital is NIS 2,000,000 divided into 200,000,000 ordinary shares, nominal (par) value NIS 0.01 per share.
      Subject to our amended and restated articles of association, or our Articles, fully paid ordinary shares of the Company confer on the holders thereof rights to attend and to vote at general meetings of the shareholders. Subject to the rights of
      holders of shares with limited or preferred rights which may be issued in the future, the ordinary shares of the Company confer upon the holders thereof equal rights to vote, to receive dividends and to participate in the distribution of the assets
      of the Company upon its winding-up, in proportion to the amount paid up or credited as paid up on account of the nominal value of the shares held by them respectively and in respect of which such dividends are being paid or such distribution is being
      made, without regard to any premium paid in excess of the nominal value, if any. All outstanding ordinary shares are validly issued and fully paid.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">The Nasdaq Global Market and the Tel Aviv Stock Exchange</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Our ordinary shares are listed on each of The Nasdaq Global Market and the Tel Aviv Stock Exchange&#160;under
      the symbol &#8220;CGEN&#8221;.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Rights Attached to Our Shares</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Subject to our Articles, fully paid ordinary shares confer on the holders thereof rights to attend and to vote at general
      meetings of the shareholders. Subject to the rights of holders of shares with limited or preferred rights which may be issued in the future, our ordinary shares confer upon the holders thereof equal rights to receive dividends and to participate in
      the distribution of our assets upon our winding-up, in proportion to the amount paid up or credited as paid up on account of the nominal value of the shares held by them respectively and in respect of which such dividends are being paid or such
      distribution is being made, without regard to any premium paid in excess of the nominal value, if any. No preferred shares are currently authorized. All outstanding ordinary shares are validly issued and fully paid.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-style: italic; font-weight: bold;">Voting Rights</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Subject to the provisions of our Articles, holders of ordinary shares have one vote for each ordinary share held by such
      shareholder of record, on all matters submitted to a vote of shareholders. Shareholders may vote in person, by proxy or by proxy card. Alternatively, shareholders who hold shares through members of the Tel Aviv Stock Exchange may vote electronically
      via the electronic voting system of the Israel Securities Authority, or Electronic Vote. These voting rights may be affected by the grant of any special voting rights to the holders of a class of shares with preferential rights that may be authorized
      in the future. As our ordinary shares do not have cumulative voting rights in the election of directors, the holders of the majority of the shares present and voting at a shareholders meeting have the power to elect all of our directors. In the event
      that we cease meeting the Opt Out Criteria (as defined in the annual report on Form 20-F to which this Exhibit 2.1 is attached), or if our board of directors shall decide to opt in the requirement to elect and have
        external directors and comply with the composition criteria of the audit committee and compensation committee under the Companies Law, the external directors will be elected by a special majority vote, as set forth under the Companies Law.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-style: italic; font-weight: bold;">Transfer of Shares</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Our ordinary shares which have been fully paid-up are transferable by submission of a proper instrument of transfer together
      with the certificate of the shares to be transferred and such other evidence of title, as our board of directors may require, unless such transfer is prohibited by another instrument or by applicable securities laws.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-style: italic; font-weight: bold;">Dividends</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Under the Companies Law, dividends may be distributed only out of profits available for dividends as determined by the Companies
      Law, provided that there is no reasonable concern that the distribution will prevent the Company from being able to meet its existing and anticipated obligations when they become due. If the company does not meet the profit requirement, a court may
      nevertheless allow the company to distribute a dividend, as long as the court is convinced that there is no reasonable concern that such distribution will prevent the company from being able to meet its existing and anticipated obligations when they
      become due. Pursuant to our Articles, no dividend shall be paid other than out of the profits of the Company. Generally, under the Companies Law, the decision to distribute dividends and the amount to be distributed is made by a company&#8217;s board of directors.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Our Articles provide that our board of directors, may, subject to the Companies Law, from time to time, declare and cause the
      Company to pay such dividends as may appear to the board of directors to be justified by the profits of our Company. Subject to the rights of the holders of shares with preferential, special or deferred rights that may be authorized in the future,
      our profits which shall be declared as dividends shall be distributed according to the proportion of the nominal (par) value paid up or credited as paid up on account of the shares held at the date so appointed by the Company and in respect of which
      such dividend is being paid, without regard to the premium paid in excess of the nominal (par) value, if any. The declaration of dividends does not require shareholders&#8217; approval.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">To date, we have not declared or distributed any dividend and we do not intend to pay cash dividends on our ordinary shares in
      the foreseeable future.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-style: italic; font-weight: bold;">Liquidation Rights</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">In the event of our winding up on liquidation or dissolution, subject to applicable law and after satisfaction of liabilities to
      creditors, our assets available for distribution among the shareholders shall be distributed to the holders of ordinary shares in proportion to the amount paid up or credited as paid up on account of the nominal value of the shares held by them
      respectively and in respect of which such distribution is being made, without regard to any premium paid in excess of the nominal value, if any. This liquidation right may be affected by the grant of limited or preferential rights as to liquidation
      to the holders of a class of shares that may be authorized in the future.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-style: italic; font-weight: bold;">Redemption Provisions</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">We may, subject to applicable law and to our Articles, issue redeemable shares and redeem the same upon such terms and
      conditions as determined by our board of directors.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-style: italic; font-weight: bold;">Limitation of Liability</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Under our Articles, the liability of each shareholder for the Company&#8217;s obligations is
      limited to the unpaid sum, if any, owing to the Company in consideration for the issuance of the shares held by such shareholder.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-style: italic; font-weight: bold;">Modification of Class Rights</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Our amended and restated Memorandum of Association, or Memorandum, provides that we may amend the Memorandum in order to
      increase, consolidate or divide or otherwise amend our share capital by a simple majority of the voting power present at a shareholders meeting as currently provided in our Articles or by such other majority as shall be set forth in our Articles from
      time to time.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Pursuant to our Articles, if at any time our share capital is divided into different classes of shares, the rights attached to
      any class, unless otherwise provided by our Articles, may be modified or abrogated by the Company, subject to the consent in writing of, or sanction of a resolution passed by, the holders of a majority of the issued shares of such class at a separate
      general meeting of the holders of the shares of such class.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Limitations on the Rights to Own Securities</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Our Articles and Israeli law do not restrict the ownership or voting of ordinary shares by non-residents or persons who are not
      citizens of Israel, though such ownership is prohibited under applicable law with respect to subjects of nations which are in a state of war with Israel.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Changes in Authorized Share Capital</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Our Articles enable us, among others, to increase or reduce our authorized share capital. Any such changes are subject to the
      provisions of the Companies Law and our Articles and must be approved by a resolution duly passed by a simple majority of our shareholders at a general meeting by voting on such change in capital.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Shareholders&#8217; Meetings and Resolutions</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Our Articles and the Companies Law provide that our annual general meeting shall be held once in every calendar year at such
      time (within a period of not more than fifteen months after the last preceding annual general meeting), and place determined by our board of directors. Our board of directors may, in its discretion, convene additional special shareholders meetings
      and, pursuant to the Companies Law, must convene a meeting upon the demand of: (a) two directors or one quarter of the directors in office; or (b) the holder or holders of (i) 5% or more of our issued share capital and one percent or more of our
      voting rights; or (ii) 5% or more of our voting rights. All demands for shareholders meetings must set forth the items to be considered at that meeting. If the board of directors does not convene a meeting upon a valid demand of any of the above,
      then the persons who made the demand, and in the case of shareholders, part of such demanding shareholders holding at least half of the voting rights of such demanding shareholders, may convene a meeting of the shareholders to be held within three
      months of the demand. Alternatively, upon petition by the individuals making the demand, a court may order that a meeting be convened.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">The chairman of the board of directors, or any other director or office holder of the Company which may be designated for this
      purpose by the board of directors, shall preside as chairman at each of our general meetings. If there is no such chairman, or if the appointed chairman is unwilling to take the chair, or if he shall have indicated in advance that he will not be
      attending, or if at any meeting such chairman is not present within thirty (30) minutes after the time fixed for holding the meeting, then those present at the meeting shall choose someone present to be chairman of the meeting. The office of chairman
      shall not, by itself, entitle the holder thereof to vote at any general meeting nor shall it entitle a second or casting vote.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">According to regulations promulgated pursuant to the Companies Law and governing the terms of notice and publication of
      shareholder meetings of public companies, or the General Meeting Regulations, holder(s) of one percent or more of the Company&#8217;s voting rights may propose any matter appropriate for deliberation at a shareholder
      meeting to be included on the agenda of a shareholder meeting, generally by submitting a proposal within seven days of publicizing the convening of a shareholder meeting, or within fourteen days, if the Company publishes at least 21 days prior to
      publicizing the proxy materials for a shareholder meeting, a preliminary notice stating its intention to convene such meeting, the agenda thereof, shareholder&#8217;s right to propose a matter to be included on the agenda of such meeting and company&#8217;s
      right not to examine such proposals received upon termination of 14 day period from the publication of such notice. Any such proposal must further comply with the information requirements under applicable law and our Articles, and in the event that
      such shareholders propose to appoint directors for service on the Company&#8217;s board of directors, the proposal must include information regarding the director candidates as well as certain declarations of the director candidates, as required pursuant
      to the General Meeting Regulations. The agenda for a shareholder meeting is determined by the board of directors and must include matters in respect of which the convening of a shareholder meeting was demanded and any matter requested to be included
      by holder(s) of one percent of the Company&#8217;s voting rights, as detailed above.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Pursuant to the Companies Law and the General Meeting Regulations shareholder meetings generally require prior notice of not
      less than 21 days, and not less than 35 days in certain cases. Pursuant to our Articles, we are not required to deliver or serve notice of a general meeting or of any adjournments thereof to any shareholder. However, subject to applicable law and
      stock exchange rules and regulations, we will publicize the convening of a general meeting in any manner reasonably determined by us, and any such publication shall be deemed duly made, given and delivered to all shareholders on the date on which it
      is first made, posted, filed or published in the manner so determined by us in our sole discretion.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">The function of the general meeting is to elect directors, receive and consider the profit and loss account, the balance sheet
      and the ordinary reports and accounts of the directors and auditors, appoint external auditor, approve certain interested party transactions requiring general meeting approval as provided in the Companies Law, approve
        the Company&#8217;s merger, exercise of the powers of the board of directors if the board of directors is unable to exercise its powers and the exercise of any of its powers is vital for our proper management, approve amendments of the Articles
      and transact any other business which under our Articles or applicable law may be transacted by the shareholders of the Company in a general meeting.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Pursuant to our Articles, the quorum required for a meeting of shareholders consists of at least two shareholders, present in
      person, by proxy, by proxy card or by Electronic Vote and holding shares conferring in the aggregate twenty-five percent (25%) or more of the voting power of the Company. If within half an hour from the time appointed for the meeting a quorum is not
      present, the meeting shall stand adjourned to the same day in the following week at the same time and place or to such other later day, time and place as the board of directors may determine and specify in the publication with respect to the Meeting.
      At the adjourned meeting, any number of participants will constitute a quorum present, in person, by proxy, by proxy card or by Electronic Vote; provided, however, that special general meeting which was convened by the Board upon the demand of
      shareholders or directors then in office, as detailed above, or directly by such shareholders or directors, in accordance the terms of the Companies Law, shall be cancelled.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Generally, under the Companies Law and our Articles, shareholder resolutions are deemed adopted if approved by the holders of a
      simple majority of the voting rights represented at the meeting, in person, by proxy, by proxy card or by Electronic Vote, and voting on the matter, unless a different majority is required by law or pursuant to our Articles such as a resolution for
      the voluntary winding up of our Company which requires the approval of holders of 75% of the voting power presented and voting at the meeting, or resolutions concerning certain related party transactions as set forth in Sections 267 and 270-275 of
      the Companies Law.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Change of Control</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-style: italic; font-weight: bold;">Merger</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Under the Companies Law, a merger is generally required to be approved by the shareholders and board of directors of each of the
      merging companies. If the share capital of the company that will not be the surviving company is divided into different classes of shares, the approval of each class is also required, unless determined otherwise by the court. Similarly, unless an
      Israeli court determines otherwise, a merger will not be approved if it is objected to by shareholders holding a majority of the voting rights participating and voting at the meeting (abstentions are disregarded), after excluding the shares held by
      the other party to the merger, by any person who holds 25% or more of the other party to the merger or by anyone on their behalf, including by the relatives of, or corporations controlled by, these persons. In approving a merger, the board of
      directors of both merging companies must determine that there is no reasonable concern that, as a result of the merger, the surviving company will not be able to satisfy its obligations to its creditors. Similarly, upon the request of a creditor of
      either party to the proposed merger, an Israeli court may prevent or delay the merger if it concludes that there exists a reasonable concern that, as a result of the merger, the surviving company will not be able to satisfy the obligations of the
      merging parties. A court may also issue other instructions for the protection of the creditors&#8217; rights in connection with a merger. Further, a merger may not be completed unless at least (i) 50 days have passed
      from the time that the requisite proposals for the approval of the merger were filed with the Israeli registrar of companies; and (ii) 30 days have passed since the merger was approved by the shareholders of each party.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-style: italic; font-weight: bold;">Special Tender Offer</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">The Companies Law provides that an acquisition of shares of an Israeli public company must be made by means of a special tender
      offer if as a result of the acquisition the purchaser would become a holder of 25% or more of the voting rights in the company. This rule does not apply if there is already another holder of 25% or more of the voting rights in the company. Similarly,
      the Companies Law provides that an acquisition of shares in a public company must be made by means of a special tender offer if as a result of the acquisition the purchaser would become a holder of more than 45% of the voting rights in the company,
      if there is no other shareholder of the company who holds more than 45% of the voting rights in the company. These requirements do not apply if the acquisition (i) occurs in the context of a private placement by the company that received shareholder
      approval for the purpose of allowing the purchaser to hold more than 25% of the voting rights in the company if there is no other holder of 25% or more of the voting rights in the company, or 45% of the voting rights
        in the company if there is no other holder of 45% or more of the voting rights in the company, as the case may be, (ii) was from a shareholder holding 25% or more of the voting rights in the company and resulted in the acquirer becoming a
      holder of 25% or more of the voting rights in the company, or (iii) was from a holder of more than 45% of the voting rights in the company and resulted in the acquirer becoming a holder of more than 45% of the voting rights in the company. A special
      tender offer may be consummated only if (i) at least 5% of the voting power attached to the company&#8217;s outstanding shares will be acquired by the offeror and (ii) the number of shares tendered in the offer exceeds
      the number of shares whose holders objected to the offer (excluding controlling shareholders, holders of 25% or more of the voting rights in the company and any person having a personal interest in the acceptance of the special tender offer).</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">In the event that a special tender offer is made, a company&#8217;s board of directors is
      required to express its opinion on the advisability of the offer, or shall abstain from expressing any opinion if it is unable to do so, provided that it gives the reasons for its abstention. An office holder in a target company who, in his or her
      capacity as an office holder, performs an action the purpose of which is to cause the failure of an existing or foreseeable special tender offer or is to impair the chances of its acceptance, is liable to the potential purchaser and shareholders for
      damages, unless such office holder acted in good faith and had reasonable grounds to believe he or she was acting for the benefit of the company. However, office holders of the target company may negotiate with the potential purchaser in order to
      improve the terms of the special tender offer and may further negotiate with third parties in order to obtain a competing offer. Shares purchased in contradiction to the tender offer rules under the Companies Law will have no rights and will become
      dormant shares.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">If a special tender offer is accepted, then shareholders who did not respond to or that had objected the offer may accept the
      offer within four days of the last day set for the acceptance of the offer. In the event that a special tender offer is accepted, then the purchaser or any person or entity controlling it or under common control with the purchaser or such controlling
      person or entity may not make a subsequent tender offer for the purchase of shares of the target company and may not enter into a merger with the target company for a period of one year from the date of the offer, unless the purchaser or such person
      or entity undertook to effect such an offer or merger in the initial special tender offer.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-style: italic; font-weight: bold;">Full Tender Offer</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Under the Companies Law, a person may not acquire shares in a public company if, after the acquisition, the acquirer will hold
      more than 90% of the shares or more than 90% of any class of shares of that company, unless a tender offer is made to purchase all of the shares or all of the shares of the particular class. The Companies Law also generally provides that as long as a
      shareholder in a public company holds more than 90% of the company&#8217;s shares or of a class of shares, that shareholder shall be precluded from purchasing any additional shares. In order for all of the shares that
      the purchaser offered to purchase be transferred to him by operation of law, one of the following needs to have occurred: (i) the shareholders who declined or do not respond to the tender offer hold less than 5% of the company&#8217;s outstanding share capital or of the relevant class of shares and the majority of offerees who do not have a personal interest in accepting the tender offer accepted the offer, or (ii) the shareholders who declined or do not respond
      to the tender offer hold less than 2% of the company&#8217;s outstanding share capital or of the relevant class of shares.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">A shareholder that had his or her shares so transferred, whether he or she accepted the tender offer or not, has the right,
      within six months from the date of acceptance of the tender offer, to petition the court to determine that the tender offer was for less than fair value and that the fair value should be paid as determined by the court. However, the purchaser may
      provide in its offer that shareholders who accept the tender offer will not be entitled to such rights.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">If the conditions set forth above are not met, the purchaser may not acquire additional shares of the company from shareholders
      who accepted the tender offer to the extent that following such acquisition, the purchaser would own more than 90% of the company&#8217;s issued and outstanding share capital. The above restrictions apply, in addition
      to the acquisition of shares, to the acquisition of voting power.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.1
<SEQUENCE>3
<FILENAME>exhibit_8-1.htm
<DESCRIPTION>EXHIBIT 8.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 23.1.1.5115
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><u>Exhibit 8.1</u></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">SUBSIDIARIES</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="zafb3b1b99bd24d65865329bfb39e297f">

          <tr>
            <td style="width: 50.00%;">
              <div>
                <div style="text-align: left; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;"><u>Subsidiary</u></font><font style="font-family: 'Times New Roman',Times,serif;"><br>
                  </font></div>
              </div>
            </td>
            <td style="width: 50.00%;">
              <div><font style="font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;"><u>Jurisdiction</u></font></font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 50.00%;" rowspan="1">
              <div style="text-align: left; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">Compugen USA, Inc.<br>
                </font></div>
            </td>
            <td style="width: 50.00%;" rowspan="1"><font style="font-family: 'Times New Roman',Times,serif;">Delaware</font></td>
          </tr>

      </table>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="line-height: 1.25;"><br>
      <font style="font-family: 'Times New Roman',Times,serif;"></font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>4
<FILENAME>exhibit_12-1.htm
<DESCRIPTION>EXHIBIT 12.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 23.1.1.5115
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><u>Exhibit 12.1</u></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">CERTIFICATION</font><font style="font-family: 'Times New Roman',Times,serif;">&#160;<font style="font-weight: bold;">PURSUANT TO</font></font></div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">RULE 13a-14(a)/RULE 15d-14(a) UNDER </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">THE EXCHANGE ACT AND SECTION 302</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">OF THE SARBANES-OXLEY ACT OF 2002</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">I, Dr. Anat Cohen-Dayag, certify that:</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 20-F of Compugen Ltd.;</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
          misleading with respect to the period covered by this report;</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for,
          the periods presented in this report;</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The company&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
          defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 28.4pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">a.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information
          relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 28.4pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">b.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable
          assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 28.4pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">c.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;evaluated the effectiveness of the company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and
          procedures, as of the end of the period covered by this report based on such evaluation; and</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 28.4pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">d.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;disclosed in this report any change in the company&#8217;s internal control over financial reporting that occurred during the period covered by the annual report that has materially
          affected, or is reasonably likely to materially affect, the company's internal control over financial reporting; and</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The company&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&#8217;s auditors and the audit committee of the company's board of directors (or
          persons performing the equivalent functions):</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 28.4pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">a.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the
          company's ability to record, process, summarize and report financial information; and</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 28.4pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">b.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal control over financial reporting.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Date: February 28, 2023</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><u>/s/ Dr. Anat Cohen-Dayag</u></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Title: President and Chief Executive Officer</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br>
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><br>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>5
<FILENAME>exhibit_12-2.htm
<DESCRIPTION>EXHIBIT 12.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 23.1.1.5115
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><u>Exhibit 12.2</u></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">CERTIFICATION PURSUANT TO</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">RULE 13a-14(a)/RULE 15d-14(a) UNDER THE EXCHANGE ACT </div>
    <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif; font-weight: bold;"><font style="font-family: 'Times New Roman',Times,serif;">AND SECTION 302</font></div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">OF THE SARBANES-OXLEY ACT OF 2002</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">I, Alberto Sessa, certify that:</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 20-F of Compugen Ltd.;</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
          misleading with respect to the period covered by this report;</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for,
          the periods presented in this report;</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The company&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
          defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 28.4pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">a.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information
          relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 28.4pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">b.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable
          assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 28.4pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">c.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;evaluated the effectiveness of the company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and
          procedures, as of the end of the period covered by this report based on such evaluation; and</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 28.4pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">d.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;disclosed in this report any change in the company&#8217;s internal control over financial reporting that occurred during the period covered by the annual report that has materially
          affected, or is reasonably likely to materially affect, the company's internal control over financial reporting; and</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The company&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&#8217;s auditors and the audit committee of the company's board of directors (or
          persons performing the equivalent functions):</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 30.7pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">a.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the
          company's ability to record, process, summarize and report financial information; and</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-right: 30.7pt; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">b.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal control over financial reporting.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Date: February 28, 2023</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><u>/s/ Alberto Sessa</u></div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Title: Chief Financial Officer</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>6
<FILENAME>exhibit_13-1.htm
<DESCRIPTION>EXHIBIT 13.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 23.1.1.5115
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><u>Exhibit 13.1</u></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">CERTIFICATION PURSUANT TO</div>
    <div style="text-align: center; line-height: 1.25; color: #000000; font-family: 'Times New Roman', serif;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">RULE 13a-14(b)/RULE
        15d-14(b)UNDER THE EXCHANGE ACT </font></div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">AND 18 U.S.C. SECTION 1350, </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">AS ADOPTED PURSUANT TO </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">SECTION 906</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">OF THE SARBANES-OXLEY ACT OF 2002</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">In connection with the annual report of Compugen Ltd. (the &#8220;Company&#8221;) on Form 20-F for the fiscal year ended December 31, 2021
      as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned officers of the Company, certify, pursuant to Rule 13a-14(b)/Rule 15d-14(b) under the Securities Exchange Act of 1934, as amended and 18
      U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to such officer&#8217;s knowledge:</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Sections 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><u>/s/ Dr. Anat Cohen-Dayag</u></div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">Title:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;President and Chief Executive Officer</font></div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">Date:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;February 28, 2023</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><u>/s/ Alberto Sessa</u></div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">Title:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Chief Financial Officer</font></div>
    <div style="line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;">Date:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;February 28, 2023</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>7
<FILENAME>exhibit_15-1.htm
<DESCRIPTION>EXHIBIT 15.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K Global
         Document created using Broadridge PROfile 23.1.1.5115
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><u>Exhibit 15.1</u></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Consent of Independent Registered Public Accounting Firm</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', serif;">
      <div style="text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">We consent to the incorporation by
          reference in the Registration Statement (Form S-8 Nos. 333-169239, 333-204869, 333-223937, 333-240182, 333-251263, 333-266508) pertaining to the Employee&#8217;s share option plans of Compugen Ltd. and Registration Statement (Form F-3 No. 333-240183) of our reports dated February 28, 2023, with respect to the consolidated financial statements of Compugen Ltd., and the effectiveness of internal control over financial
          reporting of Compugen Ltd., included in this Annual Report (Form 20-F) for the year ended December 31, 2022.</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 49.64%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">February 28, 2023</div>
          </td>
          <td style="width: 50.36%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">/s/ KOST FORER GABBAY &amp; KASIERER</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.64%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">Tel-Aviv, Israel</div>
          </td>
          <td style="width: 50.36%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">A Member Firm of Ernst &amp; Young Global</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>cgen-20221231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<schema xmlns:cgen="http://cgen.com/20221231" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" targetNamespace="http://cgen.com/20221231" elementFormDefault="qualified">
  <!-- INTEGIX by Ez-XBRL -->
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd"/>
  <import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd"/>
  <import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"/>
  <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd"/>
  <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://cgen.com/role/cgen-daei1" id="cgen-daei1">
        <link:definition>0001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
        <link:definition>0002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-cbsp" id="cgen-cbsp">
        <link:definition>0003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-csocl" id="cgen-csocl">
        <link:definition>0004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/StatementsOfChangesInShareholdersEquity" id="StatementsOfChangesInShareholdersEquity">
        <link:definition>0005 - Statement - STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
        <link:definition>0006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-g" id="cgen-g">
        <link:definition>0007 - Disclosure - GENERAL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-sap" id="cgen-sap">
        <link:definition>0008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-oarape" id="cgen-oarape">
        <link:definition>0009 - Disclosure - OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/Leases" id="Leases">
        <link:definition>0010 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-paen" id="cgen-paen">
        <link:definition>0011 - Disclosure - PROPERTY AND EQUIPMENT, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-oapaae" id="cgen-oapaae">
        <link:definition>0012 - Disclosure - OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-cac1" id="cgen-cac1">
        <link:definition>0013 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-se12" id="cgen-se12">
        <link:definition>0014 - Disclosure - SHAREHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-it" id="cgen-it">
        <link:definition>0015 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-giamc" id="cgen-giamc">
        <link:definition>0016 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-faoin" id="cgen-faoin">
        <link:definition>0017 - Disclosure - FINANCIAL AND OTHER INCOME, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-rpbat" id="cgen-rpbat">
        <link:definition>0018 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-lps" id="cgen-lps">
        <link:definition>0019 - Disclosure - LOSSES PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/SUBSEQUENTEVENTS" id="SUBSEQUENTEVENTS">
        <link:definition>0020 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-sapp" id="cgen-sapp">
        <link:definition>0021 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-sapt" id="cgen-sapt">
        <link:definition>0022 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-oarapet" id="cgen-oarapet">
        <link:definition>0023 - Disclosure - OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/LeasesTables" id="LeasesTables">
        <link:definition>0024 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-paent" id="cgen-paent">
        <link:definition>0025 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-oapaaet" id="cgen-oapaaet">
        <link:definition>0026 - Disclosure - OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-set1" id="cgen-set1">
        <link:definition>0027 - Disclosure - SHAREHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-itt" id="cgen-itt">
        <link:definition>0028 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-giamct" id="cgen-giamct">
        <link:definition>0029 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-faoint" id="cgen-faoint">
        <link:definition>0030 - Disclosure - FINANCIAL AND OTHER INCOME, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables" id="RelatedPartyBalancesAndTransactionsTables">
        <link:definition>0031 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-lpst" id="cgen-lpst">
        <link:definition>0032 - Disclosure - LOSSES PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-gd" id="cgen-gd">
        <link:definition>0033 - Disclosure - GENERAL (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-sapnd" id="cgen-sapnd">
        <link:definition>0034 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-sapsodrfpaed" id="cgen-sapsodrfpaed">
        <link:definition>0035 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Depreciation Rates for Property and Equipment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails" id="SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails">
        <link:definition>0036 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Weighted-Average Assumptions for Granted Options) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-oaraped" id="cgen-oaraped">
        <link:definition>0037 - Disclosure - OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/LEASESNarrative" id="LEASESNarrative">
        <link:definition>0038 - Disclosure - LEASES (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/LeasesScheduleOfWeighted-averageRemainingLeaseTermAndDiscountRateDetails" id="LeasesScheduleOfWeighted-averageRemainingLeaseTermAndDiscountRateDetails">
        <link:definition>0039 - Disclosure - LEASES (Schedule of Weighted-Average Remaining Lease Term and Discount Rate) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails" id="LeasesScheduleOfOperatingLeasesDetails">
        <link:definition>0040 - Disclosure - LEASES (Schedule of Operating Leases) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails" id="PROPERTYANDEQUIPMENTNETNarrativeDetails">
        <link:definition>0041 - Disclosure - PROPERTY AND EQUIPMENT, NET (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-paend" id="cgen-paend">
        <link:definition>0042 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-oapaaed" id="cgen-oapaaed">
        <link:definition>0043 - Disclosure - OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
        <link:definition>0044 - Disclosure - COMMITMENTS AND CONTINGENCIES (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-sesopnd" id="cgen-sesopnd">
        <link:definition>0045 - Disclosure - SHAREHOLDERS' EQUITY (Share Option Plans) (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails" id="ShareholdersEquityScheduleOfOptionActivityDetails">
        <link:definition>0046 - Disclosure - SHAREHOLDERS' EQUITY (Schedule Of Option Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/cgen-sesosced" id="cgen-sesosced">
        <link:definition>0047 - Disclosure - SHAREHOLDERS' EQUITY (Schedule Of Stock Compensation Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/IncomeTaxesNarrativeDetails" id="IncomeTaxesNarrativeDetails">
        <link:definition>0048 - Disclosure - INCOME TAXES (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/IncomeTaxesEncouragementOfCapitalInvestmentsNarrativeDetails" id="IncomeTaxesEncouragementOfCapitalInvestmentsNarrativeDetails">
        <link:definition>0049 - Disclosure - INCOME TAXES (Encouragement Of Capital Investments) (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails" id="IncomeTaxesScheduleOfLossBeforeTaxesDetails">
        <link:definition>0050 - Disclosure - INCOME TAXES (Schedule of Loss before Taxes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>0051 - Disclosure - INCOME TAXES (Schedule of Deferred Tax Assets and Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/GeographicInformationAndMajorCustomersDetails" id="GeographicInformationAndMajorCustomersDetails">
        <link:definition>0052 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails" id="FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails">
        <link:definition>0053 - Disclosure - FINANCIAL AND OTHER INCOME, NET (Schedule of Financial and Other Income, Net) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/RelatedPartyBalancesAndTransactionsDetails" id="RelatedPartyBalancesAndTransactionsDetails">
        <link:definition>0054 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails" id="LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails">
        <link:definition>0055 - Disclosure - LOSSES PER SHARE (Schedule of Computation of Basic and Diluted Losses Per Share) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cgen.com/role/SubsequentEventsNarrativeDetails" id="SubsequentEventsNarrativeDetails">
        <link:definition>0056 - Disclosure - Subsequent Events (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="cgen-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cgen-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cgen-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="cgen-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
    </appinfo>
  </annotation>
  <element name="AccruedMilestonePayment" id="cgen_AccruedMilestonePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AggregateLimitOfOrdinarySharesPerCalendarYear" id="cgen_AggregateLimitOfOrdinarySharesPerCalendarYear" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AgreementMember" id="cgen_AgreementMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AgreementOptionAdditionalNumberOfSharesIssuable" id="cgen_AgreementOptionAdditionalNumberOfSharesIssuable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AgreementStartDate" id="cgen_AgreementStartDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AgreementTerminationDescription" id="cgen_AgreementTerminationDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" id="cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AnnualDepreciationRate" id="cgen_AnnualDepreciationRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AnnualDepreciationRateDescription" id="cgen_AnnualDepreciationRateDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AtMarketOfferingProgramMember" id="cgen_AtMarketOfferingProgramMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" id="cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable" id="cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CollaborativeArrangementsMember" id="cgen_CollaborativeArrangementsMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CollaborativeArrangementsTwoMember" id="cgen_CollaborativeArrangementsTwoMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ContingentFees" id="cgen_ContingentFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CostOfSalesContractWithCustomerPolicyTextBlock" id="cgen_CostOfSalesContractWithCustomerPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CustomerOneMember" id="cgen_CustomerOneMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DecreaseOperatingLeaseLiability" id="cgen_DecreaseOperatingLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DeferredIncomeTaxLeaseLiabilities" id="cgen_DeferredIncomeTaxLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DeferredIncomeTaxRightOfUseAssets" id="cgen_DeferredIncomeTaxRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DeferredParticipationOfBMSInRAndDExpenses" id="cgen_DeferredParticipationOfBMSInRAndDExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" id="cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="DerivativeRelatedExpense" id="cgen_DerivativeRelatedExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear" id="cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmployeesAndDirectorsMember" id="cgen_EmployeesAndDirectorsMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmployeeStockPurchasePlanMember" id="cgen_EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ExtendLease" id="cgen_ExtendLease" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FinancialIncomeExpenseNet" id="cgen_FinancialIncomeExpenseNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="GovernmentAndOtherGrantsAxis" id="cgen_GovernmentAndOtherGrantsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="GovernmentAndOtherGrantsDomain" id="cgen_GovernmentAndOtherGrantsDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GovernmentAuthorities" id="cgen_GovernmentAuthorities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" id="cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" id="cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="IncreaseOperatingLeaseRightOfUseAsset" id="cgen_IncreaseOperatingLeaseRightOfUseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="InterestPaidReceivedNet" id="cgen_InterestPaidReceivedNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IssuanceOfSharesAndWarrantsNetShares" id="cgen_IssuanceOfSharesAndWarrantsNetShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="IssuanceOfSharesAndWarrantsNetValue" id="cgen_IssuanceOfSharesAndWarrantsNetValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="LaboratoryEquipmentAndOfficeFurnitureMember" id="cgen_LaboratoryEquipmentAndOfficeFurnitureMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LongTermDeferredParticipationInResearchAndDevelopmentExpenses" id="cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="MasterClinicalAgreementMember" id="cgen_MasterClinicalAgreementMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MasterClinicalAgreementOneMember" id="cgen_MasterClinicalAgreementOneMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MasterClinicalAgreementTwoMember" id="cgen_MasterClinicalAgreementTwoMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MaximumAuthorizedProceedsFromIssuanceOfCommonStock" id="cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="MaximumRoyaltyRepaidAsPercentageOfGrantReceived" id="cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="May2012AgreementMember" id="cgen_May2012AgreementMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract" id="cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NetOperatingLossCarryforwardExpired" id="cgen_NetOperatingLossCarryforwardExpired" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues" id="cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfWarrantsExercised" id="cgen_NumberOfWarrantsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" id="cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OtherAccountsReceivableAndPrepaidExpensesTextBlock" id="cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ParticipationRights" id="cgen_ParticipationRights" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities" id="cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="PercentageOfClosingPrice" id="cgen_PercentageOfClosingPrice" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfConsolidatedRevenuesOfCollaborator" id="cgen_PercentageOfConsolidatedRevenuesOfCollaborator" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering" id="cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares" id="cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PeriodSinceApprovalWasGranted" id="cgen_PeriodSinceApprovalWasGranted" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PeriodSinceEnterpriseBeganOperating" id="cgen_PeriodSinceEnterpriseBeganOperating" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ReceivablesOnAccountOfShares" id="cgen_ReceivablesOnAccountOfShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ReducedCorporateIncomeTaxRate" id="cgen_ReducedCorporateIncomeTaxRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ReducedTaxRate" id="cgen_ReducedTaxRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RegisteredDirectOfferingMember" id="cgen_RegisteredDirectOfferingMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ResearchAndDevelopmentArrangementPaymentsReceivable" id="cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" id="cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" id="cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ResearchAndDevelopmentExpensesMilestonePayment" id="cgen_ResearchAndDevelopmentExpensesMilestonePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ResearchAndDevelopmentExpensesMilestonePaymentWithConnection" id="cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ResearchAndDevelopmentGrantOneMember" id="cgen_ResearchAndDevelopmentGrantOneMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RetainerFee" id="cgen_RetainerFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RoyaltyContingentObligations" id="cgen_RoyaltyContingentObligations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="RoyaltyPercentage" id="cgen_RoyaltyPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RoyaltyPercentageBasedOnFutureRevenues" id="cgen_RoyaltyPercentageBasedOnFutureRevenues" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SalesAgreementWithSVBSecuritiesLLCMember" id="cgen_SalesAgreementWithSVBSecuritiesLLCMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock" id="cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfWeightedAverageAssumptionsForGrantedOptions" id="cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate" id="cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SegmentReportingGeograhicAreaLineItems" id="cgen_SegmentReportingGeograhicAreaLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SegmentReportingGeographicAreaAxis" id="cgen_SegmentReportingGeographicAreaAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="SegmentReportingGeographicAreaDomain" id="cgen_SegmentReportingGeographicAreaDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SegmentReportingGeographicAreaTable" id="cgen_SegmentReportingGeographicAreaTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="ServerancePayPolicyTextBlock" id="cgen_ServerancePayPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeverancePayFundNoncurrent" id="cgen_SeverancePayFundNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="SeverancePayNet" id="cgen_SeverancePayNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" id="cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" id="cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShortTermBankDepositsPolicyTextBlock" id="cgen_ShortTermBankDepositsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShortTermBankDepositsWeightedAverageRateForeign" id="cgen_ShortTermBankDepositsWeightedAverageRateForeign" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" id="cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" id="cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="StockIssuedDuringPeriodValueWarrantsExercised" id="cgen_StockIssuedDuringPeriodValueWarrantsExercised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="SupplementalRightOfUseAssetAndOperatingLeaseLiability" id="cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="SvbLeerinkLlcAndStifelNicolausAndCompanyMember" id="cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TaxExemptPeriod" id="cgen_TaxExemptPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TaxRateOnDistributions" id="cgen_TaxRateOnDistributions" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandAndTwoThousandTenOptionsPlanMember" id="cgen_TwoThousandAndTwoThousandTenOptionsPlanMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UnderwritersMember" id="cgen_UnderwritersMember" type="dtr-types:domainItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>cgen-20221231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#ConsolidatedBalanceSheets" roleURI="http://cgen.com/role/ConsolidatedBalanceSheets"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-csocl" roleURI="http://cgen.com/role/cgen-csocl"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://cgen.com/role/ConsolidatedStatementsOfCashFlows"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-oaraped" roleURI="http://cgen.com/role/cgen-oaraped"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#LeasesScheduleOfOperatingLeasesDetails" roleURI="http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-paend" roleURI="http://cgen.com/role/cgen-paend"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-oapaaed" roleURI="http://cgen.com/role/cgen-oapaaed"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#IncomeTaxesScheduleOfLossBeforeTaxesDetails" roleURI="http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails" roleURI="http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails"/>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/ConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermInvestments" xlink:label="loc_us-gaap_OtherShortTermInvestments_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_6"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_SeverancePayFundNoncurrent" xlink:label="loc_cgen_SeverancePayFundNoncurrent_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_13"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PostemploymentBenefitsLiabilityNoncurrent" xlink:label="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_17"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_23"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_AssetsCurrent_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_OtherShortTermInvestments_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_AssetsNoncurrent_6" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_6" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent_6" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_6" xlink:to="loc_cgen_SeverancePayFundNoncurrent_7" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_11" xlink:to="loc_us-gaap_LiabilitiesCurrent_12" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_12" xlink:to="loc_us-gaap_AccountsPayableCurrent_12" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_12" xlink:to="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_13" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_12" xlink:to="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_14" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_12" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_15" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_11" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_17" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_17" xlink:to="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_17" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_17" xlink:to="loc_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_18" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_17" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_19" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_11" xlink:to="loc_us-gaap_StockholdersEquity_21" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_21" xlink:to="loc_us-gaap_CommonStockValue_21" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_21" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_22" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_21" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_23" order="20" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-csocl">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDevelopment" xlink:label="loc_us-gaap_BusinessDevelopment_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_6"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_11"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_0" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xlink:to="loc_us-gaap_OperatingIncomeLoss_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1" xlink:to="loc_us-gaap_GrossProfit_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_1" xlink:to="loc_us-gaap_Revenues_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_1" xlink:to="loc_us-gaap_CostOfRevenue_2" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1" xlink:to="loc_us-gaap_OperatingExpenses_4" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_4" xlink:to="loc_us-gaap_BusinessDevelopment_5" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_6" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xlink:to="loc_cgen_FinancialIncomeExpenseNet_9" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_11" order="10" use="optional" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/ConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_SeverancePayNet" xlink:label="loc_cgen_SeverancePayNet_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" xlink:label="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_9"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_18"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities" xlink:label="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_23"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_ShareBasedCompensation_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_Depreciation_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_cgen_SeverancePayNet_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_5" order="40" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_6" order="50" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7" order="60" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8" order="70" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_9" order="80" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_10" order="90" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_11" order="100" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_12" order="110" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_13" order="120" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_15" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_15" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_15" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_15" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_16" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_15" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_17" order="20" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_15" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisposals_18" order="30" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_15" xlink:to="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_19" order="40" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_21" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_22" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_23" order="20" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-oaraped">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_GovernmentAuthorities" xlink:label="loc_cgen_GovernmentAuthorities_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_3"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0" xlink:to="loc_cgen_GovernmentAuthorities_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0" xlink:to="loc_us-gaap_OtherAssetsCurrent_3" order="20" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4" order="30" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-paend">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2" order="10" use="optional" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-oapaaed">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_0" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_0" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2" order="10" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2" order="10" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_DeferredIncomeTaxRightOfUseAssets" xlink:label="loc_cgen_DeferredIncomeTaxRightOfUseAssets_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_DeferredIncomeTaxLeaseLiabilities" xlink:label="loc_cgen_DeferredIncomeTaxLeaseLiabilities_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_8"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_0" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1" xlink:to="loc_cgen_DeferredIncomeTaxRightOfUseAssets_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1" xlink:to="loc_cgen_DeferredIncomeTaxLeaseLiabilities_5" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_1" xlink:to="loc_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_6" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_0" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_8" order="10" use="optional" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails">
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaap_InterestAndDebtExpense_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets_4"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cgen_FinancialIncomeExpenseNet_0" xlink:to="loc_us-gaap_InvestmentIncomeInterest_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cgen_FinancialIncomeExpenseNet_0" xlink:to="loc_us-gaap_InterestAndDebtExpense_2" order="10" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cgen_FinancialIncomeExpenseNet_0" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cgen_FinancialIncomeExpenseNet_0" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherAssets_4" order="30" use="optional" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>cgen-20221231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-daei1" roleURI="http://cgen.com/role/cgen-daei1"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#StatementsOfChangesInShareholdersEquity" roleURI="http://cgen.com/role/StatementsOfChangesInShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-sapnd" roleURI="http://cgen.com/role/cgen-sapnd"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-sapsodrfpaed" roleURI="http://cgen.com/role/cgen-sapsodrfpaed"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails" roleURI="http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-paend" roleURI="http://cgen.com/role/cgen-paend"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#CommitmentsAndContingenciesDetails" roleURI="http://cgen.com/role/CommitmentsAndContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-sesopnd" roleURI="http://cgen.com/role/cgen-sesopnd"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#ShareholdersEquityScheduleOfOptionActivityDetails" roleURI="http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-sesosced" roleURI="http://cgen.com/role/cgen-sesosced"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#IncomeTaxesNarrativeDetails" roleURI="http://cgen.com/role/IncomeTaxesNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#GeographicInformationAndMajorCustomersDetails" roleURI="http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#SubsequentEventsNarrativeDetails" roleURI="http://cgen.com/role/SubsequentEventsNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#PROPERTYANDEQUIPMENTNETNarrativeDetails" roleURI="http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-daei1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_dei_DocumentRegistrationStatement_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_dei_DocumentShellCompanyReport_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_dei_EntityAddressAddressLine3_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelFaxNumber" xlink:label="loc_dei_ContactPersonnelFaxNumber_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelEmailAddress" xlink:label="loc_dei_ContactPersonnelEmailAddress_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_dei_DocumentAccountingStandard_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_dei_OtherReportingStandardItemNumber_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_46"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_47"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_48"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_49"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityCentralIndexKey_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentFiscalYearFocus_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentType_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_AmendmentFlag_6" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_AmendmentDescription_7" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentRegistrationStatement_8" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentAnnualReport_9" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentTransitionReport_10" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_11" order="100" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_11" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_11" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_11" xlink:to="loc_dei_AddressTypeDomain_11" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_11" xlink:to="loc_dei_BusinessContactMember_11" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_11" xlink:to="loc_dei_AddressTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentShellCompanyReport_16" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentPeriodEndDate_17" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityFileNumber_18" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_ContactPersonnelName_19" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityRegistrantName_20" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_21" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityAddressAddressLine1_22" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityAddressAddressLine2_23" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityAddressAddressLine3_24" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityAddressCityOrTown_25" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityAddressCountry_26" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityAddressPostalZipCode_27" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_CityAreaCode_28" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_LocalPhoneNumber_29" order="240" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_ContactPersonnelFaxNumber_30" order="250" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_ContactPersonnelEmailAddress_31" order="260" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_Security12bTitle_32" order="270" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_TradingSymbol_33" order="280" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_SecurityExchangeName_34" order="290" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_35" order="300" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_36" order="310" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityVoluntaryFilers_37" order="320" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityCurrentReportingStatus_38" order="330" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityInteractiveDataCurrent_39" order="340" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityFilerCategory_40" order="350" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityEmergingGrowthCompany_41" order="360" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_IcfrAuditorAttestationFlag_42" order="370" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityExTransitionPeriod_43" order="380" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentAccountingStandard_44" order="390" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_OtherReportingStandardItemNumber_45" order="400" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityShellCompany_46" order="410" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_AuditorName_47" order="420" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_AuditorLocation_48" order="430" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_AuditorFirmId_49" order="440" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/StatementsOfChangesInShareholdersEquity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_11"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_IssuanceOfSharesAndWarrantsNetValue" xlink:label="loc_cgen_IssuanceOfSharesAndWarrantsNetValue_12"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_IssuanceOfSharesAndWarrantsNetShares" xlink:label="loc_cgen_IssuanceOfSharesAndWarrantsNetShares_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_15"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_16"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_NumberOfWarrantsExercised" xlink:label="loc_cgen_NumberOfWarrantsExercised_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_19"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" xlink:label="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_21"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_RetainedEarningsMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockholdersEquity_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_10" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_11" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_IssuanceOfSharesAndWarrantsNetValue_12" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_IssuanceOfSharesAndWarrantsNetShares_13" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_14" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_15" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_16" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_NumberOfWarrantsExercised_17" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_18" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_19" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_20" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetIncomeLoss_21" order="140" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sapnd">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_MasterClinicalAgreementOneMember" xlink:label="loc_cgen_MasterClinicalAgreementOneMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_MasterClinicalAgreementTwoMember" xlink:label="loc_cgen_MasterClinicalAgreementTwoMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ShortTermBankDepositsWeightedAverageRateForeign" xlink:label="loc_cgen_ShortTermBankDepositsWeightedAverageRateForeign_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="loc_us-gaap_ImpairmentOfInvestments_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_14"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues" xlink:label="loc_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting" xlink:label="loc_us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_21"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_DerivativeRelatedExpense" xlink:label="loc_cgen_DerivativeRelatedExpense_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNet_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount" xlink:label="loc_us-gaap_DerivativeNotionalAmount_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_27"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_28"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AccruedMilestonePayment" xlink:label="loc_cgen_AccruedMilestonePayment_29"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_DeferredParticipationOfBMSInRAndDExpenses" xlink:label="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_30"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_PercentageOfConsolidatedRevenuesOfCollaborator" xlink:label="loc_cgen_PercentageOfConsolidatedRevenuesOfCollaborator_31"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_srt_StatementScenarioAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_1" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_MasterClinicalAgreementOneMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_MasterClinicalAgreementTwoMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_1" xlink:to="loc_srt_ScenarioUnspecifiedDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6" xlink:to="loc_us-gaap_StockOptionMember_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_ShortTermBankDepositsWeightedAverageRateForeign_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AdjustmentForAmortization_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ImpairmentOfInvestments_13" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_DeferredRevenue_14" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues_15" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_16" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SeveranceCosts1_17" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_18" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_19" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting_20" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_21" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_DerivativeRelatedExpense_22" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeNet_23" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_24" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_25" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_DerivativeNotionalAmount_26" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_27" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_28" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_AccruedMilestonePayment_29" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_30" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_PercentageOfConsolidatedRevenuesOfCollaborator_31" order="210" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sapsodrfpaed">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AnnualDepreciationRate" xlink:label="loc_cgen_AnnualDepreciationRate_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AnnualDepreciationRateDescription" xlink:label="loc_cgen_AnnualDepreciationRateDescription_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_LaboratoryEquipmentAndOfficeFurnitureMember" xlink:label="loc_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_cgen_AnnualDepreciationRate_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_cgen_AnnualDepreciationRateDescription_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3" order="20" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_ComputerEquipmentMember_3" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_4" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_5" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3" xlink:to="loc_srt_RangeAxis_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9" xlink:to="loc_srt_RangeMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9" xlink:to="loc_srt_MinimumMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9" xlink:to="loc_srt_MaximumMember_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_EmployeeStockPurchasePlanMember" xlink:label="loc_cgen_EmployeeStockPurchasePlanMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5" order="40" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5" xlink:to="loc_us-gaap_AwardTypeAxis_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5" xlink:to="loc_cgen_EmployeeStockPurchasePlanMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5" xlink:to="loc_srt_RangeAxis_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_10" xlink:to="loc_srt_RangeMember_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_10" xlink:to="loc_srt_MinimumMember_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_10" xlink:to="loc_srt_MaximumMember_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_10" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-paend">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_LaboratoryEquipmentAndOfficeFurnitureMember" xlink:label="loc_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_10"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_ComputerEquipmentMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_10" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/CommitmentsAndContingenciesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaap_OtherCommitmentsTable_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_GovernmentAndOtherGrantsAxis" xlink:label="loc_cgen_GovernmentAndOtherGrantsAxis_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_GovernmentAndOtherGrantsDomain" xlink:label="loc_cgen_GovernmentAndOtherGrantsDomain_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ResearchAndDevelopmentGrantOneMember" xlink:label="loc_cgen_ResearchAndDevelopmentGrantOneMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_May2012AgreementMember" xlink:label="loc_cgen_May2012AgreementMember_2"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_GovernmentAndOtherGrantsDomain" xlink:label="loc_cgen_GovernmentAndOtherGrantsDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure_12"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_RoyaltyPercentageBasedOnFutureRevenues" xlink:label="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_13"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" xlink:label="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_15"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_RoyaltyContingentObligations" xlink:label="loc_cgen_RoyaltyContingentObligations_16"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ParticipationRights" xlink:label="loc_cgen_ParticipationRights_17"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_RetainerFee" xlink:label="loc_cgen_RetainerFee_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_19"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AgreementStartDate" xlink:label="loc_cgen_AgreementStartDate_20"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AgreementTerminationDescription" xlink:label="loc_cgen_AgreementTerminationDescription_21"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ExtendLease" xlink:label="loc_cgen_ExtendLease_22"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ContingentFees" xlink:label="loc_cgen_ContingentFees_23"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection" xlink:label="loc_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_24"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_RoyaltyPercentage" xlink:label="loc_cgen_RoyaltyPercentage_25"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ResearchAndDevelopmentExpensesMilestonePayment" xlink:label="loc_cgen_ResearchAndDevelopmentExpensesMilestonePayment_26"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_OtherCommitmentsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_cgen_GovernmentAndOtherGrantsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cgen_GovernmentAndOtherGrantsAxis_1" xlink:to="loc_cgen_GovernmentAndOtherGrantsDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsDomain_1" xlink:to="loc_cgen_ResearchAndDevelopmentGrantOneMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_GovernmentAndOtherGrantsDomain_1" xlink:to="loc_cgen_May2012AgreementMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cgen_GovernmentAndOtherGrantsAxis_1" xlink:to="loc_cgen_GovernmentAndOtherGrantsDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_srt_RangeAxis_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6" xlink:to="loc_srt_RangeMember_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6" xlink:to="loc_srt_MinimumMember_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6" xlink:to="loc_srt_MaximumMember_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_GuaranteeObligationsMaximumExposure_12" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_13" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_14" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_RoyaltyExpense_15" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cgen_RoyaltyContingentObligations_16" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cgen_ParticipationRights_17" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cgen_RetainerFee_18" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_19" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cgen_AgreementStartDate_20" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cgen_AgreementTerminationDescription_21" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cgen_ExtendLease_22" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cgen_ContingentFees_23" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_24" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cgen_RoyaltyPercentage_25" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_0" xlink:to="loc_cgen_ResearchAndDevelopmentExpensesMilestonePayment_26" order="150" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sesopnd">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AtMarketOfferingProgramMember" xlink:label="loc_cgen_AtMarketOfferingProgramMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AgreementMember" xlink:label="loc_cgen_AgreementMember_2"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_MasterClinicalAgreementMember" xlink:label="loc_cgen_MasterClinicalAgreementMember_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_CollaborativeArrangementsMember" xlink:label="loc_cgen_CollaborativeArrangementsMember_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_CollaborativeArrangementsTwoMember" xlink:label="loc_cgen_CollaborativeArrangementsTwoMember_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" xlink:label="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_RegisteredDirectOfferingMember" xlink:label="loc_cgen_RegisteredDirectOfferingMember_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_11"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_UnderwritersMember" xlink:label="loc_cgen_UnderwritersMember_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_16"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_TwoThousandAndTwoThousandTenOptionsPlanMember" xlink:label="loc_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_31"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" xlink:label="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_40"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_46"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable" xlink:label="loc_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_47"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_48"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AgreementOptionAdditionalNumberOfSharesIssuable" xlink:label="loc_cgen_AgreementOptionAdditionalNumberOfSharesIssuable_49"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_50"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_51"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_PercentageOfClosingPrice" xlink:label="loc_cgen_PercentageOfClosingPrice_52"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_DeferredParticipationOfBMSInRAndDExpenses" xlink:label="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_53"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_54"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InitialOfferingPeriod" xlink:label="loc_us-gaap_InitialOfferingPeriod_55"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares" xlink:label="loc_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares_56"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AggregateLimitOfOrdinarySharesPerCalendarYear" xlink:label="loc_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear_57"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering" xlink:label="loc_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering_58"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_59"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_StatementScenarioAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_1" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_AtMarketOfferingProgramMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_AgreementMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_MasterClinicalAgreementMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_CollaborativeArrangementsMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_CollaborativeArrangementsTwoMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_6" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_1" xlink:to="loc_srt_ScenarioUnspecifiedDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:to="loc_cgen_RegisteredDirectOfferingMember_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:to="loc_us-gaap_WarrantMember_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:to="loc_cgen_UnderwritersMember_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_16" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_16" xlink:to="loc_us-gaap_PlanNameDomain_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_16" xlink:to="loc_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_16" xlink:to="loc_us-gaap_PlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_20" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_20" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_20" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_20" xlink:to="loc_srt_DirectorMember_20" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_20" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_24" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_24" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_24" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_24" xlink:to="loc_us-gaap_EmployeeStockMember_24" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_24" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_29" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_30" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_31" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_32" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_33" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_34" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_35" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_36" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_37" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_38" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_39" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_40" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_41" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_42" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_43" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_44" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_45" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_46" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_47" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_48" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_cgen_AgreementOptionAdditionalNumberOfSharesIssuable_49" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_50" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_51" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_cgen_PercentageOfClosingPrice_52" order="240" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_53" order="250" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_54" order="260" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_InitialOfferingPeriod_55" order="270" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares_56" order="280" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear_57" order="290" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering_58" order="300" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_59" order="310" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_EmployeesAndDirectorsMember" xlink:label="loc_cgen_EmployeesAndDirectorsMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_20"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" xlink:label="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_26"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_cgen_EmployeesAndDirectorsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_9" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_10" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_11" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_12" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_14" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_15" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_16" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_17" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_18" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_19" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_20" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_22" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_22" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_22" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_22" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_23" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_25" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_25" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_25" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_26" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sesosced">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_Default"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2" order="10" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_3" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_Default" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/IncomeTaxesNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_12"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear" xlink:label="loc_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIncomeTaxRefunds" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_17"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_NetOperatingLossCarryforwardExpired" xlink:label="loc_cgen_NetOperatingLossCarryforwardExpired_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_19"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ReducedCorporateIncomeTaxRate" xlink:label="loc_cgen_ReducedCorporateIncomeTaxRate_20"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1" xlink:to="loc_us-gaap_DomesticCountryMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_srt_RangeAxis_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6" xlink:to="loc_srt_RangeMember_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6" xlink:to="loc_srt_MinimumMember_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6" xlink:to="loc_srt_MaximumMember_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_12" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_13" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_IncomeTaxesPaid_14" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIncomeTaxRefunds_15" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_16" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OperatingLossCarryforwards_17" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_NetOperatingLossCarryforwardExpired_18" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_19" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_cgen_ReducedCorporateIncomeTaxRate_20" order="90" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/GeographicInformationAndMajorCustomersDetails">
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_SegmentReportingGeograhicAreaLineItems" xlink:label="loc_cgen_SegmentReportingGeograhicAreaLineItems_0"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_SegmentReportingGeographicAreaTable" xlink:label="loc_cgen_SegmentReportingGeographicAreaTable_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_SegmentReportingGeographicAreaAxis" xlink:label="loc_cgen_SegmentReportingGeographicAreaAxis_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_SegmentReportingGeographicAreaDomain" xlink:label="loc_cgen_SegmentReportingGeographicAreaDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IL" xlink:label="loc_country_IL_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_SegmentReportingGeographicAreaDomain" xlink:label="loc_cgen_SegmentReportingGeographicAreaDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_15"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_CustomerOneMember" xlink:label="loc_cgen_CustomerOneMember_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_23"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cgen_SegmentReportingGeograhicAreaLineItems_0" xlink:to="loc_cgen_SegmentReportingGeographicAreaTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cgen_SegmentReportingGeographicAreaTable_1" xlink:to="loc_cgen_SegmentReportingGeographicAreaAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cgen_SegmentReportingGeographicAreaAxis_1" xlink:to="loc_cgen_SegmentReportingGeographicAreaDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_SegmentReportingGeographicAreaDomain_1" xlink:to="loc_srt_EuropeMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_SegmentReportingGeographicAreaDomain_1" xlink:to="loc_country_IL_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_SegmentReportingGeographicAreaDomain_1" xlink:to="loc_country_US_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cgen_SegmentReportingGeographicAreaAxis_1" xlink:to="loc_cgen_SegmentReportingGeographicAreaDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cgen_SegmentReportingGeographicAreaTable_1" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7" xlink:to="loc_us-gaap_SalesRevenueNetMember_7" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cgen_SegmentReportingGeographicAreaTable_1" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_11" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_11" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_11" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_11" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_11" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cgen_SegmentReportingGeographicAreaTable_1" xlink:to="loc_srt_MajorCustomersAxis_15" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_15" xlink:to="loc_srt_NameOfMajorCustomerDomain_15" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_15" xlink:to="loc_cgen_CustomerOneMember_15" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_15" xlink:to="loc_srt_NameOfMajorCustomerDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_SegmentReportingGeograhicAreaLineItems_0" xlink:to="loc_us-gaap_NumberOfOperatingSegments_20" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_SegmentReportingGeograhicAreaLineItems_0" xlink:to="loc_us-gaap_Revenues_21" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_SegmentReportingGeograhicAreaLineItems_0" xlink:to="loc_us-gaap_NoncurrentAssets_22" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cgen_SegmentReportingGeograhicAreaLineItems_0" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_23" order="40" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/SubsequentEventsNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_SalesAgreementWithSVBSecuritiesLLCMember" xlink:label="loc_cgen_SalesAgreementWithSVBSecuritiesLLCMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_10"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1" xlink:to="loc_us-gaap_SubsequentEventMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5" xlink:to="loc_cgen_SalesAgreementWithSVBSecuritiesLLCMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_10" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" xlink:label="loc_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_8"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_Depreciation_8" order="30" use="optional"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>cgen-20221231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AccruedMilestonePayment" xlink:label="loc_cgen_AccruedMilestonePayment_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AccruedMilestonePayment" xlink:label="loc_cgen_AccruedMilestonePayment_2"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AggregateLimitOfOrdinarySharesPerCalendarYear" xlink:label="loc_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AggregateLimitOfOrdinarySharesPerCalendarYear" xlink:label="loc_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AgreementMember" xlink:label="loc_cgen_AgreementMember_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AgreementMember" xlink:label="loc_cgen_AgreementMember_6"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AgreementOptionAdditionalNumberOfSharesIssuable" xlink:label="loc_cgen_AgreementOptionAdditionalNumberOfSharesIssuable_7"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AgreementOptionAdditionalNumberOfSharesIssuable" xlink:label="loc_cgen_AgreementOptionAdditionalNumberOfSharesIssuable_8"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AgreementOptionAdditionalNumberOfSharesIssuable" xlink:label="loc_cgen_AgreementOptionAdditionalNumberOfSharesIssuable_9"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AgreementStartDate" xlink:label="loc_cgen_AgreementStartDate_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AgreementStartDate" xlink:label="loc_cgen_AgreementStartDate_11"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AgreementStartDate" xlink:label="loc_cgen_AgreementStartDate_12"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AgreementTerminationDescription" xlink:label="loc_cgen_AgreementTerminationDescription_13"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AgreementTerminationDescription" xlink:label="loc_cgen_AgreementTerminationDescription_14"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AgreementTerminationDescription" xlink:label="loc_cgen_AgreementTerminationDescription_15"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" xlink:label="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_16"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" xlink:label="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_17"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" xlink:label="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_18"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" xlink:label="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_19"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AnnualDepreciationRate" xlink:label="loc_cgen_AnnualDepreciationRate_20"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AnnualDepreciationRate" xlink:label="loc_cgen_AnnualDepreciationRate_21"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AnnualDepreciationRateDescription" xlink:label="loc_cgen_AnnualDepreciationRateDescription_22"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AnnualDepreciationRateDescription" xlink:label="loc_cgen_AnnualDepreciationRateDescription_23"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AnnualDepreciationRateDescription" xlink:label="loc_cgen_AnnualDepreciationRateDescription_24"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AtMarketOfferingProgramMember" xlink:label="loc_cgen_AtMarketOfferingProgramMember_25"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AtMarketOfferingProgramMember" xlink:label="loc_cgen_AtMarketOfferingProgramMember_26"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AtMarketOfferingProgramMember" xlink:label="loc_cgen_AtMarketOfferingProgramMember_27"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:label="loc_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_28"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:label="loc_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_29"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable" xlink:label="loc_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_30"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable" xlink:label="loc_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_31"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable" xlink:label="loc_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_32"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_CollaborativeArrangementsMember" xlink:label="loc_cgen_CollaborativeArrangementsMember_33"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_CollaborativeArrangementsMember" xlink:label="loc_cgen_CollaborativeArrangementsMember_34"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_CollaborativeArrangementsTwoMember" xlink:label="loc_cgen_CollaborativeArrangementsTwoMember_35"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_CollaborativeArrangementsTwoMember" xlink:label="loc_cgen_CollaborativeArrangementsTwoMember_36"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ContingentFees" xlink:label="loc_cgen_ContingentFees_37"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ContingentFees" xlink:label="loc_cgen_ContingentFees_38"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ContingentFees" xlink:label="loc_cgen_ContingentFees_39"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_CostOfSalesContractWithCustomerPolicyTextBlock" xlink:label="loc_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_40"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_CostOfSalesContractWithCustomerPolicyTextBlock" xlink:label="loc_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_41"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_CostOfSalesContractWithCustomerPolicyTextBlock" xlink:label="loc_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_42"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_CustomerOneMember" xlink:label="loc_cgen_CustomerOneMember_43"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_CustomerOneMember" xlink:label="loc_cgen_CustomerOneMember_44"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_CustomerOneMember" xlink:label="loc_cgen_CustomerOneMember_45"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_DecreaseOperatingLeaseLiability" xlink:label="loc_cgen_DecreaseOperatingLeaseLiability_46"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_DecreaseOperatingLeaseLiability" xlink:label="loc_cgen_DecreaseOperatingLeaseLiability_47"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_DecreaseOperatingLeaseLiability" xlink:label="loc_cgen_DecreaseOperatingLeaseLiability_48"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_DeferredIncomeTaxLeaseLiabilities" xlink:label="loc_cgen_DeferredIncomeTaxLeaseLiabilities_49"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_DeferredIncomeTaxLeaseLiabilities" xlink:label="loc_cgen_DeferredIncomeTaxLeaseLiabilities_50"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_DeferredIncomeTaxLeaseLiabilities" xlink:label="loc_cgen_DeferredIncomeTaxLeaseLiabilities_51"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_DeferredIncomeTaxRightOfUseAssets" xlink:label="loc_cgen_DeferredIncomeTaxRightOfUseAssets_52"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_DeferredIncomeTaxRightOfUseAssets" xlink:label="loc_cgen_DeferredIncomeTaxRightOfUseAssets_53"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_DeferredIncomeTaxRightOfUseAssets" xlink:label="loc_cgen_DeferredIncomeTaxRightOfUseAssets_54"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_DeferredParticipationOfBMSInRAndDExpenses" xlink:label="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_55"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_DeferredParticipationOfBMSInRAndDExpenses" xlink:label="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_56"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_DeferredParticipationOfBMSInRAndDExpenses" xlink:label="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_57"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_58"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_59"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_60"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_DerivativeRelatedExpense" xlink:label="loc_cgen_DerivativeRelatedExpense_61"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_DerivativeRelatedExpense" xlink:label="loc_cgen_DerivativeRelatedExpense_62"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_DerivativeRelatedExpense" xlink:label="loc_cgen_DerivativeRelatedExpense_63"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear" xlink:label="loc_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_64"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear" xlink:label="loc_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_65"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear" xlink:label="loc_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_66"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_EmployeesAndDirectorsMember" xlink:label="loc_cgen_EmployeesAndDirectorsMember_67"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_EmployeesAndDirectorsMember" xlink:label="loc_cgen_EmployeesAndDirectorsMember_68"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_EmployeeStockPurchasePlanMember" xlink:label="loc_cgen_EmployeeStockPurchasePlanMember_69"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_EmployeeStockPurchasePlanMember" xlink:label="loc_cgen_EmployeeStockPurchasePlanMember_70"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_EmployeeStockPurchasePlanMember" xlink:label="loc_cgen_EmployeeStockPurchasePlanMember_71"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ExtendLease" xlink:label="loc_cgen_ExtendLease_72"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ExtendLease" xlink:label="loc_cgen_ExtendLease_73"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ExtendLease" xlink:label="loc_cgen_ExtendLease_74"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_75"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_76"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_77"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_78"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_GovernmentAndOtherGrantsAxis" xlink:label="loc_cgen_GovernmentAndOtherGrantsAxis_79"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_GovernmentAndOtherGrantsAxis" xlink:label="loc_cgen_GovernmentAndOtherGrantsAxis_80"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_GovernmentAuthorities" xlink:label="loc_cgen_GovernmentAuthorities_81"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_GovernmentAuthorities" xlink:label="loc_cgen_GovernmentAuthorities_82"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_83"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_84"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_85"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_86"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_87"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_88"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_IncreaseOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseOperatingLeaseRightOfUseAsset_89"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_IncreaseOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseOperatingLeaseRightOfUseAsset_90"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_IncreaseOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseOperatingLeaseRightOfUseAsset_91"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_InterestPaidReceivedNet" xlink:label="loc_cgen_InterestPaidReceivedNet_92"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_InterestPaidReceivedNet" xlink:label="loc_cgen_InterestPaidReceivedNet_93"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_InterestPaidReceivedNet" xlink:label="loc_cgen_InterestPaidReceivedNet_94"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_IssuanceOfSharesAndWarrantsNetShares" xlink:label="loc_cgen_IssuanceOfSharesAndWarrantsNetShares_95"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_IssuanceOfSharesAndWarrantsNetShares" xlink:label="loc_cgen_IssuanceOfSharesAndWarrantsNetShares_96"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_IssuanceOfSharesAndWarrantsNetValue" xlink:label="loc_cgen_IssuanceOfSharesAndWarrantsNetValue_97"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_IssuanceOfSharesAndWarrantsNetValue" xlink:label="loc_cgen_IssuanceOfSharesAndWarrantsNetValue_98"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_IssuanceOfSharesAndWarrantsNetValue" xlink:label="loc_cgen_IssuanceOfSharesAndWarrantsNetValue_99"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_LaboratoryEquipmentAndOfficeFurnitureMember" xlink:label="loc_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_100"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_LaboratoryEquipmentAndOfficeFurnitureMember" xlink:label="loc_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_101"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_102"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_103"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_104"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_MasterClinicalAgreementMember" xlink:label="loc_cgen_MasterClinicalAgreementMember_105"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_MasterClinicalAgreementMember" xlink:label="loc_cgen_MasterClinicalAgreementMember_106"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_MasterClinicalAgreementOneMember" xlink:label="loc_cgen_MasterClinicalAgreementOneMember_107"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_MasterClinicalAgreementOneMember" xlink:label="loc_cgen_MasterClinicalAgreementOneMember_108"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_MasterClinicalAgreementTwoMember" xlink:label="loc_cgen_MasterClinicalAgreementTwoMember_109"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_MasterClinicalAgreementTwoMember" xlink:label="loc_cgen_MasterClinicalAgreementTwoMember_110"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_111"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_112"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_113"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_114"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" xlink:label="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_115"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" xlink:label="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_116"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" xlink:label="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_117"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_May2012AgreementMember" xlink:label="loc_cgen_May2012AgreementMember_118"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_May2012AgreementMember" xlink:label="loc_cgen_May2012AgreementMember_119"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_May2012AgreementMember" xlink:label="loc_cgen_May2012AgreementMember_120"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_NetOperatingLossCarryforwardExpired" xlink:label="loc_cgen_NetOperatingLossCarryforwardExpired_121"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_NetOperatingLossCarryforwardExpired" xlink:label="loc_cgen_NetOperatingLossCarryforwardExpired_122"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues" xlink:label="loc_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues_123"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues" xlink:label="loc_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues_124"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_NumberOfWarrantsExercised" xlink:label="loc_cgen_NumberOfWarrantsExercised_125"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_NumberOfWarrantsExercised" xlink:label="loc_cgen_NumberOfWarrantsExercised_126"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_NumberOfWarrantsExercised" xlink:label="loc_cgen_NumberOfWarrantsExercised_127"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" xlink:label="loc_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_128"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" xlink:label="loc_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_129"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" xlink:label="loc_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_130"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:label="loc_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_131"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:label="loc_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_132"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:label="loc_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_133"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ParticipationRights" xlink:label="loc_cgen_ParticipationRights_134"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ParticipationRights" xlink:label="loc_cgen_ParticipationRights_135"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ParticipationRights" xlink:label="loc_cgen_ParticipationRights_136"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities" xlink:label="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_137"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities" xlink:label="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_138"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities" xlink:label="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_139"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities" xlink:label="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_140"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities" xlink:label="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_141"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_PercentageOfClosingPrice" xlink:label="loc_cgen_PercentageOfClosingPrice_142"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_PercentageOfClosingPrice" xlink:label="loc_cgen_PercentageOfClosingPrice_143"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_PercentageOfConsolidatedRevenuesOfCollaborator" xlink:label="loc_cgen_PercentageOfConsolidatedRevenuesOfCollaborator_144"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_PercentageOfConsolidatedRevenuesOfCollaborator" xlink:label="loc_cgen_PercentageOfConsolidatedRevenuesOfCollaborator_145"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering" xlink:label="loc_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering_146"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering" xlink:label="loc_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering_147"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares" xlink:label="loc_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares_148"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares" xlink:label="loc_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares_149"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_PeriodSinceApprovalWasGranted" xlink:label="loc_cgen_PeriodSinceApprovalWasGranted_150"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_PeriodSinceApprovalWasGranted" xlink:label="loc_cgen_PeriodSinceApprovalWasGranted_151"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_PeriodSinceEnterpriseBeganOperating" xlink:label="loc_cgen_PeriodSinceEnterpriseBeganOperating_152"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_PeriodSinceEnterpriseBeganOperating" xlink:label="loc_cgen_PeriodSinceEnterpriseBeganOperating_153"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ReceivablesOnAccountOfShares" xlink:label="loc_cgen_ReceivablesOnAccountOfShares_154"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ReceivablesOnAccountOfShares" xlink:label="loc_cgen_ReceivablesOnAccountOfShares_155"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ReducedCorporateIncomeTaxRate" xlink:label="loc_cgen_ReducedCorporateIncomeTaxRate_156"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ReducedCorporateIncomeTaxRate" xlink:label="loc_cgen_ReducedCorporateIncomeTaxRate_157"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ReducedTaxRate" xlink:label="loc_cgen_ReducedTaxRate_158"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ReducedTaxRate" xlink:label="loc_cgen_ReducedTaxRate_159"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_RegisteredDirectOfferingMember" xlink:label="loc_cgen_RegisteredDirectOfferingMember_160"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_RegisteredDirectOfferingMember" xlink:label="loc_cgen_RegisteredDirectOfferingMember_161"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_162"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_163"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_164"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_165"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_166"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_167"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_168"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_169"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_170"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ResearchAndDevelopmentExpensesMilestonePayment" xlink:label="loc_cgen_ResearchAndDevelopmentExpensesMilestonePayment_171"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ResearchAndDevelopmentExpensesMilestonePayment" xlink:label="loc_cgen_ResearchAndDevelopmentExpensesMilestonePayment_172"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ResearchAndDevelopmentExpensesMilestonePayment" xlink:label="loc_cgen_ResearchAndDevelopmentExpensesMilestonePayment_173"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection" xlink:label="loc_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_174"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection" xlink:label="loc_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_175"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection" xlink:label="loc_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_176"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ResearchAndDevelopmentGrantOneMember" xlink:label="loc_cgen_ResearchAndDevelopmentGrantOneMember_177"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ResearchAndDevelopmentGrantOneMember" xlink:label="loc_cgen_ResearchAndDevelopmentGrantOneMember_178"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ResearchAndDevelopmentGrantOneMember" xlink:label="loc_cgen_ResearchAndDevelopmentGrantOneMember_179"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_RetainerFee" xlink:label="loc_cgen_RetainerFee_180"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_RetainerFee" xlink:label="loc_cgen_RetainerFee_181"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_RetainerFee" xlink:label="loc_cgen_RetainerFee_182"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_RoyaltyContingentObligations" xlink:label="loc_cgen_RoyaltyContingentObligations_183"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_RoyaltyContingentObligations" xlink:label="loc_cgen_RoyaltyContingentObligations_184"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_RoyaltyContingentObligations" xlink:label="loc_cgen_RoyaltyContingentObligations_185"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_RoyaltyPercentage" xlink:label="loc_cgen_RoyaltyPercentage_186"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_RoyaltyPercentage" xlink:label="loc_cgen_RoyaltyPercentage_187"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_RoyaltyPercentage" xlink:label="loc_cgen_RoyaltyPercentage_188"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_RoyaltyPercentageBasedOnFutureRevenues" xlink:label="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_189"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_RoyaltyPercentageBasedOnFutureRevenues" xlink:label="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_190"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_RoyaltyPercentageBasedOnFutureRevenues" xlink:label="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_191"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_SalesAgreementWithSVBSecuritiesLLCMember" xlink:label="loc_cgen_SalesAgreementWithSVBSecuritiesLLCMember_192"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_SalesAgreementWithSVBSecuritiesLLCMember" xlink:label="loc_cgen_SalesAgreementWithSVBSecuritiesLLCMember_193"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_SalesAgreementWithSVBSecuritiesLLCMember" xlink:label="loc_cgen_SalesAgreementWithSVBSecuritiesLLCMember_194"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock" xlink:label="loc_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_195"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock" xlink:label="loc_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_196"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock" xlink:label="loc_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_197"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions" xlink:label="loc_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_198"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions" xlink:label="loc_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_199"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions" xlink:label="loc_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_200"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate" xlink:label="loc_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_201"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate" xlink:label="loc_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_202"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate" xlink:label="loc_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_203"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_SegmentReportingGeograhicAreaLineItems" xlink:label="loc_cgen_SegmentReportingGeograhicAreaLineItems_204"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_SegmentReportingGeograhicAreaLineItems" xlink:label="loc_cgen_SegmentReportingGeograhicAreaLineItems_205"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_SegmentReportingGeographicAreaAxis" xlink:label="loc_cgen_SegmentReportingGeographicAreaAxis_206"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_SegmentReportingGeographicAreaAxis" xlink:label="loc_cgen_SegmentReportingGeographicAreaAxis_207"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_SegmentReportingGeographicAreaTable" xlink:label="loc_cgen_SegmentReportingGeographicAreaTable_208"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_SegmentReportingGeographicAreaTable" xlink:label="loc_cgen_SegmentReportingGeographicAreaTable_209"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ServerancePayPolicyTextBlock" xlink:label="loc_cgen_ServerancePayPolicyTextBlock_210"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ServerancePayPolicyTextBlock" xlink:label="loc_cgen_ServerancePayPolicyTextBlock_211"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ServerancePayPolicyTextBlock" xlink:label="loc_cgen_ServerancePayPolicyTextBlock_212"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_SeverancePayFundNoncurrent" xlink:label="loc_cgen_SeverancePayFundNoncurrent_213"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_SeverancePayFundNoncurrent" xlink:label="loc_cgen_SeverancePayFundNoncurrent_214"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_SeverancePayFundNoncurrent" xlink:label="loc_cgen_SeverancePayFundNoncurrent_215"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_SeverancePayNet" xlink:label="loc_cgen_SeverancePayNet_216"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_SeverancePayNet" xlink:label="loc_cgen_SeverancePayNet_217"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_SeverancePayNet" xlink:label="loc_cgen_SeverancePayNet_218"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" xlink:label="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_219"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" xlink:label="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_220"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" xlink:label="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_221"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" xlink:label="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_222"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" xlink:label="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_223"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" xlink:label="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_224"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ShortTermBankDepositsPolicyTextBlock" xlink:label="loc_cgen_ShortTermBankDepositsPolicyTextBlock_225"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ShortTermBankDepositsPolicyTextBlock" xlink:label="loc_cgen_ShortTermBankDepositsPolicyTextBlock_226"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ShortTermBankDepositsPolicyTextBlock" xlink:label="loc_cgen_ShortTermBankDepositsPolicyTextBlock_227"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ShortTermBankDepositsWeightedAverageRateForeign" xlink:label="loc_cgen_ShortTermBankDepositsWeightedAverageRateForeign_228"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ShortTermBankDepositsWeightedAverageRateForeign" xlink:label="loc_cgen_ShortTermBankDepositsWeightedAverageRateForeign_229"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ShortTermBankDepositsWeightedAverageRateForeign" xlink:label="loc_cgen_ShortTermBankDepositsWeightedAverageRateForeign_230"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_231"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_232"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_233"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" xlink:label="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_234"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" xlink:label="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_235"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" xlink:label="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_236"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_237"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_238"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_239"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability" xlink:label="loc_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_240"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability" xlink:label="loc_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_241"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability" xlink:label="loc_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_242"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" xlink:label="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_243"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" xlink:label="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_244"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" xlink:label="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_245"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_TaxExemptPeriod" xlink:label="loc_cgen_TaxExemptPeriod_246"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_TaxExemptPeriod" xlink:label="loc_cgen_TaxExemptPeriod_247"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_TaxRateOnDistributions" xlink:label="loc_cgen_TaxRateOnDistributions_248"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_TaxRateOnDistributions" xlink:label="loc_cgen_TaxRateOnDistributions_249"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_TwoThousandAndTwoThousandTenOptionsPlanMember" xlink:label="loc_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember_250"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_TwoThousandAndTwoThousandTenOptionsPlanMember" xlink:label="loc_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember_251"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_TwoThousandAndTwoThousandTenOptionsPlanMember" xlink:label="loc_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember_252"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_UnderwritersMember" xlink:label="loc_cgen_UnderwritersMember_253"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_UnderwritersMember" xlink:label="loc_cgen_UnderwritersMember_254"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_255"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_256"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_257"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_258"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_259"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_260"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_261"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_262"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_263"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_264"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_265"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_266"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_267"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_268"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_269"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_270"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_271"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_272"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_273"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaap_InterestAndDebtExpense_274"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaap_InterestAndDebtExpense_275"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_276"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_277"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_278"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_279"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_280"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_281"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_282"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:label="loc_us-gaap_PaymentsForProceedsFromProductiveAssets_283"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromProductiveAssets" xlink:label="loc_us-gaap_PaymentsForProceedsFromProductiveAssets_284"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_285"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_286"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_287"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_288"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_289"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_290"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_291"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_292"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_293"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_294"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_295"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_296"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_297"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_298"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_299"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_300"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_301"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_302"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_303"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_304"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_305"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_306"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_307"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_308"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_309"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_310"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_311"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_312"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_313"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_314"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_315"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_316"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_317"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_318"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_319"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_320"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_321"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_322"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_323"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract" xlink:label="loc_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_324"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract" xlink:label="loc_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_325"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IL" xlink:label="loc_country_IL_326"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_327"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_328"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_329"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_330"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_331"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_332"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_333"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_334"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelEmailAddress" xlink:label="loc_dei_ContactPersonnelEmailAddress_335"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelFaxNumber" xlink:label="loc_dei_ContactPersonnelFaxNumber_336"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_337"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_338"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_dei_DocumentAccountingStandard_339"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_340"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_341"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_342"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_343"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_dei_DocumentRegistrationStatement_344"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_dei_DocumentShellCompanyReport_345"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_346"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_347"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_348"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_349"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_dei_EntityAddressAddressLine3_350"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_351"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_352"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_353"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_354"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_355"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_356"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_357"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_358"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_359"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_360"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_361"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_362"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_363"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_364"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_365"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_366"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_367"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_368"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_369"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_370"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_dei_OtherReportingStandardItemNumber_371"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_372"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_373"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_374"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_375"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_376"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_377"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_378"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_379"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_380"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_381"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_382"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_383"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_384"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_385"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_386"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_387"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_388"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_389"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_390"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_391"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_392"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_393"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_394"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_395"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_396"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_397"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_398"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_399"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_400"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_401"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_402"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_403"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_404"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_405"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDevelopment" xlink:label="loc_us-gaap_BusinessDevelopment_406"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_407"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_408"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_409"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_410"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_411"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_412"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_413"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_414"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_415"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_416"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_417"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_418"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_419"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_420"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_421"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_422"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_423"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_424"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_425"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_426"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_427"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_428"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_429"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_430"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_431"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_432"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_433"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_434"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_435"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_436"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaap_CostsAndExpensesRelatedParty_437"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_438"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_439"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_440"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_441"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_442"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_443"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_444"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_445"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_446"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_447"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_448"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNet_449"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_450"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting" xlink:label="loc_us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting_451"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount" xlink:label="loc_us-gaap_DerivativeNotionalAmount_452"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_453"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_454"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_455"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_456"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_457"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_458"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_459"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_460"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_461"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_462"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_463"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_464"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_465"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_466"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_467"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_468"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_469"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_470"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_471"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_472"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_473"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_474"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_475"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_476"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets_477"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_478"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_479"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_480"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_481"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure_482"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="loc_us-gaap_ImpairmentOfInvestments_483"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_484"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_485"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_486"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_487"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_488"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_489"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_490"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_491"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_492"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InitialOfferingPeriod" xlink:label="loc_us-gaap_InitialOfferingPeriod_493"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_494"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_495"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue" xlink:label="loc_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_496"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_497"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_498"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_499"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_500"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_501"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_502"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_503"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_504"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_505"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_506"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_507"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_508"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_509"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_510"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_511"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_512"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_513"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_514"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_515"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_516"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_517"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_518"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_519"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_520"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_521"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_522"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_523"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_524"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_525"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_526"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_527"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_528"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_529"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_530"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_531"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_532"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_533"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets_534"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_535"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_536"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_537"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_538"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_539"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_540"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_541"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_542"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_543"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_544"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_545"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_546"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_547"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_548"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_549"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_550"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_551"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_552"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_553"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_554"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_555"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_556"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_557"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_558"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_559"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_560"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaap_OtherCommitmentsTable_561"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_562"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_563"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_564"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_565"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_566"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermInvestments" xlink:label="loc_us-gaap_OtherShortTermInvestments_567"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermInvestments" xlink:label="loc_us-gaap_OtherShortTermInvestments_568"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_569"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_570"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_571"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_572"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PostemploymentBenefitsLiabilityNoncurrent" xlink:label="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_573"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_574"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_575"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_576"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_577"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIncomeTaxRefunds" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds_578"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_579"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_580"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_581"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_582"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_583"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_584"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_585"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_586"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_587"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_588"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_589"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_590"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_591"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentImpairment" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentImpairment_592"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_593"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_594"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_595"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_596"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_597"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_598"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_599"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_600"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_601"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_602"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_603"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_604"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_605"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_606"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_607"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_608"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_609"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_610"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_611"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_612"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_613"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_614"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_615"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_616"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_617"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_618"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_619"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_620"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_621"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_622"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_623"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_624"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_625"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_626"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_627"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_628"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_629"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_630"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_631"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_632"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_633"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_634"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_635"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_636"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_637"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_638"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_639"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_640"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_641"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_642"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_643"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_644"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_645"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_646"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_647"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_648"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_649"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_650"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_651"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_652"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_653"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_654"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_655"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_656"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_657"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_658"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_659"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_660"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_661"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_662"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_663"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_664"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_665"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_666"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_667"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_668"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_669"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_670"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_671"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_672"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_673"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_674"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_675"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_676"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_677"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_678"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_679"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_680"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_681"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_682"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_683"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_684"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_685"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_686"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_687"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_688"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_689"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_690"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_691"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_692"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_693"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_694"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaap_SubleaseIncome_695"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_696"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_697"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_698"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_699"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_700"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_701"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_702"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_703"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_704"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_705"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_706"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_707"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_708"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_709"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_710"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_711"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_712"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_713"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AccruedMilestonePayment_0" xml:lang="en-US">Accrued milestone payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AccruedMilestonePayment_1" xml:lang="en-US">Accrued milestone payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear_0" xml:lang="en-US">Aggregate limit of ordinary shares per calendar year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear_1" xml:lang="en-US">Aggregate limit of ordinary shares per calendar year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AgreementMember_0" xml:lang="en-US">Agreement Member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AgreementMember_1" xml:lang="en-US">Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AgreementOptionAdditionalNumberOfSharesIssuable_0" xml:lang="en-US">Agreement, additional shares issuable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AgreementOptionAdditionalNumberOfSharesIssuable_1" xml:lang="en-US">Agreement Option Additional Number Of Shares Issuable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_AgreementOptionAdditionalNumberOfSharesIssuable_2" xml:lang="en-US">Agreement, additional shares issuable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AgreementStartDate_0" xml:lang="en-US">Agreement start date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AgreementStartDate_1" xml:lang="en-US">Agreement Start Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_AgreementStartDate_2" xml:lang="en-US">Agreement, start date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AgreementTerminationDescription_0" xml:lang="en-US">Description of termination of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AgreementTerminationDescription_1" xml:lang="en-US">Agreement Termination Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_AgreementTerminationDescription_2" xml:lang="en-US">Agreement termination description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_0" xml:lang="en-US">Amortization Of Cash Consideration Of Research And Development Funding Arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_1" xml:lang="en-US">Decrease (increase) in interest receivables from short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_2" xml:lang="en-US">Amortization Of Cash Consideration Of Research And Development Funding Arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_3" xml:lang="en-US">Amortization research and development component</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AnnualDepreciationRate_0" xml:lang="en-US">Annual Depreciation Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AnnualDepreciationRate_1" xml:lang="en-US">Annual depreciation rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AnnualDepreciationRateDescription_0" xml:lang="en-US">Annual Depreciation Rates, Description.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AnnualDepreciationRateDescription_1" xml:lang="en-US">Annual Depreciation Rate, Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_AnnualDepreciationRateDescription_2" xml:lang="en-US">Annual depreciation rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_AtMarketOfferingProgramMember_0" xml:lang="en-US">At-the-Market Offering Program "ATM"</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_AtMarketOfferingProgramMember_1" xml:lang="en-US">At Market Offering Program [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_AtMarketOfferingProgramMember_2" xml:lang="en-US">At-the-Market Offering Program "ATM" [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_0" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_1" xml:lang="en-US">Cash paid for amounts included in measurement of lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_0" xml:lang="en-US">Expiration period of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_1" xml:lang="en-US">Class Of Warrant Or Rights Period From Which Warrants Or Rights Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_2" xml:lang="en-US">Expiration period of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_CollaborativeArrangementsMember_0" xml:lang="en-US">Collaborative Arrangements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_CollaborativeArrangementsMember_1" xml:lang="en-US">Collaborative Arrangements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_CollaborativeArrangementsTwoMember_0" xml:lang="en-US">Collaborative Arrangements Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_CollaborativeArrangementsTwoMember_1" xml:lang="en-US">Collaborative Arrangements Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ContingentFees_0" xml:lang="en-US">Contingent fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ContingentFees_1" xml:lang="en-US">Contingent Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ContingentFees_2" xml:lang="en-US">Contingent fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_0" xml:lang="en-US">Disclosure of accounting policy for recognition of costs in the period which correspond to the sales and revenue categories presented in the statement of operations. The accounting policy may include the amount and nature of costs incurred, provisions associated with inventories, purchase discounts, freight and other costs included in cost of sales incurred and recorded in the period. This disclosure also includes the nature of costs of sales incurred and recorded in the statement of operations for the period relating to transactions with related parties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_1" xml:lang="en-US">Cost Of Sales Contract With Customer Policy Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_2" xml:lang="en-US">Cost of revenues:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_CustomerOneMember_0" xml:lang="en-US">Customer One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_CustomerOneMember_1" xml:lang="en-US">Customer One Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_CustomerOneMember_2" xml:lang="en-US">Customer A [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_DecreaseOperatingLeaseLiability_0" xml:lang="en-US">Operating lease liability decreased.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_DecreaseOperatingLeaseLiability_1" xml:lang="en-US">Decrease Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_DecreaseOperatingLeaseLiability_2" xml:lang="en-US">Operating lease liability decreased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_DeferredIncomeTaxLeaseLiabilities_0" xml:lang="en-US">Amount of deferred tax lease liability attributable to taxable temporary differences.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_DeferredIncomeTaxLeaseLiabilities_1" xml:lang="en-US">Deferred Income Tax Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_DeferredIncomeTaxLeaseLiabilities_2" xml:lang="en-US">Lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_DeferredIncomeTaxRightOfUseAssets_0" xml:lang="en-US">Amount of deferred tax Right of use assets attributable to taxable temporary differences.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_DeferredIncomeTaxRightOfUseAssets_1" xml:lang="en-US">Deferred Income Tax Right Of Use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_DeferredIncomeTaxRightOfUseAssets_2" xml:lang="en-US">Right of use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_DeferredParticipationOfBMSInRAndDExpenses_0" xml:lang="en-US">Deferred participation of BMS in R and D expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_DeferredParticipationOfBMSInRAndDExpenses_1" xml:lang="en-US">Deferred Participation Of B M S In R And D Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_DeferredParticipationOfBMSInRAndDExpenses_2" xml:lang="en-US">Deferred participation of BMS in R&amp;D expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_0" xml:lang="en-US">Deferred tax asset (liabilities) for property, plant and equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_1" xml:lang="en-US">Deferred Tax Assets Liabilities Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_2" xml:lang="en-US">Property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_DerivativeRelatedExpense_0" xml:lang="en-US">Represents the derivative related expenses incurred during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_DerivativeRelatedExpense_1" xml:lang="en-US">Derivative Related Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_DerivativeRelatedExpense_2" xml:lang="en-US">Derivative related expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_0" xml:lang="en-US">Percentage of domestic federal statutory tax rate applicable to pretax income (loss) for next fiscal year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_1" xml:lang="en-US">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate For Next Fiscal Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_2" xml:lang="en-US">Israeli corporate tax rate for next fiscal year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_EmployeesAndDirectorsMember_0" xml:lang="en-US">Represents information pertaining to employees and directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_EmployeesAndDirectorsMember_1" xml:lang="en-US">Employees and Directors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_EmployeeStockPurchasePlanMember_0" xml:lang="en-US">Employee Stock Purchase Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_EmployeeStockPurchasePlanMember_1" xml:lang="en-US">Employee Stock Purchase Plan Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_EmployeeStockPurchasePlanMember_2" xml:lang="en-US">Employee Stock Purchase Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ExtendLease_0" xml:lang="en-US">Extend Lease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ExtendLease_1" xml:lang="en-US">Extend Lease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ExtendLease_2" xml:lang="en-US">Extend lease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_FinancialIncomeExpenseNet_0" xml:lang="en-US">Financial Income (Expense), Net.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_FinancialIncomeExpenseNet_1" xml:lang="en-US">Financial Income Expense Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_FinancialIncomeExpenseNet_2" xml:lang="en-US">Financial and other income, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_cgen_FinancialIncomeExpenseNet_3" xml:lang="en-US">Financial and other income, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_GovernmentAndOtherGrantsAxis_0" xml:lang="en-US">Government and Other Grants [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_GovernmentAndOtherGrantsAxis_1" xml:lang="en-US">Government and Other Grants [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_GovernmentAuthorities_0" xml:lang="en-US">Government Authorities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_GovernmentAuthorities_1" xml:lang="en-US">Government authorities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_0" xml:lang="en-US">Increase (decrease) in deferred participation in R and D expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_1" xml:lang="en-US">Increase Decrease In Deferred Participation In Research And Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_2" xml:lang="en-US">Increase (decrease) in deferred participation in R&amp;D expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_0" xml:lang="en-US">Increase (decrease) in operating lease right of use asset.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_1" xml:lang="en-US">Decrease in operating lease right of use asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_2" xml:lang="en-US">Increase Decrease In Operating Lease Right Of Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_IncreaseOperatingLeaseRightOfUseAsset_0" xml:lang="en-US">Operating lease right of use asset increased.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_IncreaseOperatingLeaseRightOfUseAsset_1" xml:lang="en-US">Increase Operating Lease Right Of Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_IncreaseOperatingLeaseRightOfUseAsset_2" xml:lang="en-US">Operating lease right of use asset increased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_InterestPaidReceivedNet_0" xml:lang="en-US">Interest payments paid (received) from bank short-term deposits and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_InterestPaidReceivedNet_1" xml:lang="en-US">Interest Paid Received Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_InterestPaidReceivedNet_2" xml:lang="en-US">Interest payments received from short-term bank deposits and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_IssuanceOfSharesAndWarrantsNetShares_0" xml:lang="en-US">Issuance of shares and warrants, net, shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_IssuanceOfSharesAndWarrantsNetShares_1" xml:lang="en-US">Issuance of shares and warrants, net, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_IssuanceOfSharesAndWarrantsNetValue_0" xml:lang="en-US">Issuance of shares and warrants, net.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_IssuanceOfSharesAndWarrantsNetValue_1" xml:lang="en-US">Issuance Of Shares And Warrants Net Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_IssuanceOfSharesAndWarrantsNetValue_2" xml:lang="en-US">Issuance of shares and warrants, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_0" xml:lang="en-US">Laboratory Equipment And Office Furniture [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_1" xml:lang="en-US">Laboratory equipment and office furniture [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_0" xml:lang="en-US">Long term deferred participation in R&amp;amp;D expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_1" xml:lang="en-US">Long Term Deferred Participation In Research And Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_2" xml:lang="en-US">Long-term deferred participation in R&amp;D expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_MasterClinicalAgreementMember_0" xml:lang="en-US">Master Clinical Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_MasterClinicalAgreementMember_1" xml:lang="en-US">Master Clinical Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_MasterClinicalAgreementOneMember_0" xml:lang="en-US">Master Clinical Agreement One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_MasterClinicalAgreementOneMember_1" xml:lang="en-US">Master Clinical Agreement One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_MasterClinicalAgreementTwoMember_0" xml:lang="en-US">Master Clinical Agreement Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_MasterClinicalAgreementTwoMember_1" xml:lang="en-US">Master Clinical Agreement Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_0" xml:lang="en-US">Maximum Authorized Proceeds From Issuance Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_1" xml:lang="en-US">Maximum Authorized Proceeds From Issuance Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_2" xml:lang="en-US">Aggregate offering price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_3" xml:lang="en-US">Proceeds from issuance of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_0" xml:lang="en-US">Maximum Royalty Repaid As Percentage Of Grant Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_1" xml:lang="en-US">Maximum Royalty Repaid As Percentage Of Grant Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_2" xml:lang="en-US">Maximum royalty repaid as percentage of grant received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_May2012AgreementMember_0" xml:lang="en-US">May 2012 Agreement Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_May2012AgreementMember_1" xml:lang="en-US">May 2012 Agreement Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_May2012AgreementMember_2" xml:lang="en-US">May 2012 Agreement With Advisor [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_NetOperatingLossCarryforwardExpired_0" xml:lang="en-US">Net operating loss carryforward, Expired.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_NetOperatingLossCarryforwardExpired_1" xml:lang="en-US">Net operating loss carryforward, Expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues_0" xml:lang="en-US">Represents the number of licensed programs to achieve substantive milestones revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues_1" xml:lang="en-US">Number of licensed programs to achieve substantive milestones revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_NumberOfWarrantsExercised_0" xml:lang="en-US">Number of warrants exercised.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_NumberOfWarrantsExercised_1" xml:lang="en-US">Number Of Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_NumberOfWarrantsExercised_2" xml:lang="en-US">Warrants exercised, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_0" xml:lang="en-US">Represents information pertaining to obsolete property and equipment and certain nonfunctional Lab equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_1" xml:lang="en-US">Obsolete property and equipment and nonfunctional Lab equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_2" xml:lang="en-US">Obsolete property and equipment and certain nonfunctional Lab equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_0" xml:lang="en-US">The entire disclosure for other accounts receivable and prepaid expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_1" xml:lang="en-US">Other Accounts Receivable And Prepaid Expenses Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_2" xml:lang="en-US">OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ParticipationRights_0" xml:lang="en-US">Percentage of the cash consideration received by the Company or its affiliates from third parties to be paid back to investors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ParticipationRights_1" xml:lang="en-US">Participation Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ParticipationRights_2" xml:lang="en-US">Participation Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_0" xml:lang="en-US">Amount of payments for Proceeds from Sales of equipment Investing Activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_1" xml:lang="en-US">Proceeds from sale of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_2" xml:lang="en-US">Payments For Proceeds From Sales Of Property And Equipment Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_3" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_4" xml:lang="en-US">Proceeds from sale of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_PercentageOfClosingPrice_0" xml:lang="en-US">Percentage of closing price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_PercentageOfClosingPrice_1" xml:lang="en-US">Percentage of closing price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_PercentageOfConsolidatedRevenuesOfCollaborator_0" xml:lang="en-US">Percentage of consolidated revenues of collaborator.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_PercentageOfConsolidatedRevenuesOfCollaborator_1" xml:lang="en-US">Percentage of consolidated revenues of collaborator</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering_0" xml:lang="en-US">Percentage of fair market value of ordinary shares at time of offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering_1" xml:lang="en-US">Percentage of fair market value of ordinary shares at time of offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares_0" xml:lang="en-US">Percentage of use of base salary to purchase ordinary shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares_1" xml:lang="en-US">Percentage of use of base salary to purchase ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_PeriodSinceApprovalWasGranted_0" xml:lang="en-US">Period since approval was granted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_PeriodSinceApprovalWasGranted_1" xml:lang="en-US">Period since approval was granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_PeriodSinceEnterpriseBeganOperating_0" xml:lang="en-US">Period since enterprise began operating.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_PeriodSinceEnterpriseBeganOperating_1" xml:lang="en-US">Period since enterprise began operating</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ReceivablesOnAccountOfShares_0" xml:lang="en-US">Receivables on account of shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ReceivablesOnAccountOfShares_1" xml:lang="en-US">Receivables on account of shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ReducedCorporateIncomeTaxRate_0" xml:lang="en-US">Reduced Corporate income tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ReducedCorporateIncomeTaxRate_1" xml:lang="en-US">Reduced Corporate income tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ReducedTaxRate_0" xml:lang="en-US">Reduced tax rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ReducedTaxRate_1" xml:lang="en-US">Reduced tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_RegisteredDirectOfferingMember_0" xml:lang="en-US">Registered direct offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_RegisteredDirectOfferingMember_1" xml:lang="en-US">Registered direct offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_0" xml:lang="en-US">Potential milestone revenue from arrangements for research and development, including collaboration and licenses agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_1" xml:lang="en-US">Research And Development Arrangement Payments Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_2" xml:lang="en-US">Potential milestone compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_0" xml:lang="en-US">Potential milestone compensation company is now eligible for.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_1" xml:lang="en-US">Research And Development Arrangement Payments Receivable On Remaining Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_2" xml:lang="en-US">Potential milestone compensation company is now eligible for</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_0" xml:lang="en-US">Potential milestone revenue for preclinical stages of research from arrangements for research and development, including collaboration and licenses agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_1" xml:lang="en-US">Research And Development Arrangement Preclinical Payments Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_2" xml:lang="en-US">Preclinical milestone compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ResearchAndDevelopmentExpensesMilestonePayment_0" xml:lang="en-US">Research and development expenses milestone payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ResearchAndDevelopmentExpensesMilestonePayment_1" xml:lang="en-US">Research And Development Expenses Milestone Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ResearchAndDevelopmentExpensesMilestonePayment_2" xml:lang="en-US">Research and development expenses milestone payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_0" xml:lang="en-US">Research and development expenses milestone payment with connection.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_1" xml:lang="en-US">Research And Development Expenses Milestone Payment With Connection</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_2" xml:lang="en-US">Research and development expenses milestone payment with connection</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ResearchAndDevelopmentGrantOneMember_0" xml:lang="en-US">Research and Development Grant One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ResearchAndDevelopmentGrantOneMember_1" xml:lang="en-US">Research And Development Grant One Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ResearchAndDevelopmentGrantOneMember_2" xml:lang="en-US">IIA [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_RetainerFee_0" xml:lang="en-US">Represents the retainer fee per month.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_RetainerFee_1" xml:lang="en-US">Retainer Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_RetainerFee_2" xml:lang="en-US">Retainer fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_RoyaltyContingentObligations_0" xml:lang="en-US">The contingent obligations for payments based on royalty-bearing participation received or accrued, net of royalties paid or accrued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_RoyaltyContingentObligations_1" xml:lang="en-US">Royalty Contingent Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_RoyaltyContingentObligations_2" xml:lang="en-US">Contingent royalty obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_RoyaltyPercentage_0" xml:lang="en-US">Royalty percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_RoyaltyPercentage_1" xml:lang="en-US">Royalty Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_RoyaltyPercentage_2" xml:lang="en-US">Royalty percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_RoyaltyPercentageBasedOnFutureRevenues_0" xml:lang="en-US">Royalty Percentage Based On Future Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_RoyaltyPercentageBasedOnFutureRevenues_1" xml:lang="en-US">Royalty Percentage Based On Future Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_RoyaltyPercentageBasedOnFutureRevenues_2" xml:lang="en-US">Royalty percentage based on future revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_SalesAgreementWithSVBSecuritiesLLCMember_0" xml:lang="en-US">Sales Agreement with SVB Securities LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_SalesAgreementWithSVBSecuritiesLLCMember_1" xml:lang="en-US">Sales Agreement With S V B Securities L L C [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_SalesAgreementWithSVBSecuritiesLLCMember_2" xml:lang="en-US">Sales Agreement with SVB Securities LLC. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_0" xml:lang="en-US">Tabular disclosure of the annual rates used to calculate depreciation for property, plant and equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_1" xml:lang="en-US">Schedule Of Property Plant And Equipment Depreciation Rates Table Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_2" xml:lang="en-US">Schedule of depreciation rates for property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_0" xml:lang="en-US">Tabular disclosure of the significant assumptions used during the year to estimate the fair value of granted stock options, including, but not limited to: (a) expected term of granted share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_1" xml:lang="en-US">Schedule Of Weighted Average Assumptions For Granted Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_2" xml:lang="en-US">Schedule of weighted average assumptions for granted options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_0" xml:lang="en-US">Tabular disclosure of weighted-average remaining lease term and discount rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_1" xml:lang="en-US">Schedule Of Weighted Average Remaining Lease Term And Discount Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_2" xml:lang="en-US">Schedule of weighted-average remaining lease term and discount rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_SegmentReportingGeograhicAreaLineItems_0" xml:lang="en-US">Segment Reporting Geograhic Area [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_SegmentReportingGeograhicAreaLineItems_1" xml:lang="en-US">Segment Reporting Geograhic Area [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_SegmentReportingGeographicAreaAxis_0" xml:lang="en-US">Segment Reporting Geographic Area [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_SegmentReportingGeographicAreaAxis_1" xml:lang="en-US">Segment Reporting Geographic Area [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_SegmentReportingGeographicAreaTable_0" xml:lang="en-US">Segment Reporting Geographic Area [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_SegmentReportingGeographicAreaTable_1" xml:lang="en-US">Segment Reporting Geographic Area [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ServerancePayPolicyTextBlock_0" xml:lang="en-US">Serverance Pay [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ServerancePayPolicyTextBlock_1" xml:lang="en-US">Serverance Pay Policy Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ServerancePayPolicyTextBlock_2" xml:lang="en-US">Severance pay:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_SeverancePayFundNoncurrent_0" xml:lang="en-US">Monthly deposits in externally managed funds which primarily cover Israeli law severance pay liability of one month's salary for each year of employment upon the retirement or death of an employee or termination of employment without a valid legal reason.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_SeverancePayFundNoncurrent_1" xml:lang="en-US">Severance Pay Fund Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_SeverancePayFundNoncurrent_2" xml:lang="en-US">Severance pay fund</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_SeverancePayNet_0" xml:lang="en-US">Severance pay, net.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_SeverancePayNet_1" xml:lang="en-US">Severance Pay Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_SeverancePayNet_2" xml:lang="en-US">Increase (decrease) in severance pay, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_0" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Award Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Award Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_2" xml:lang="en-US">Award expiration period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award Options, Remaining Contractual Term [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Remaining Contractual Term Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_2" xml:lang="en-US">Weighted average remaining contractual life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ShortTermBankDepositsPolicyTextBlock_0" xml:lang="en-US">The entire disclosure for short-term bank deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ShortTermBankDepositsPolicyTextBlock_1" xml:lang="en-US">Short Term Bank Deposits Policy Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cgen_ShortTermBankDepositsPolicyTextBlock_2" xml:lang="en-US">Short-term bank deposits:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ShortTermBankDepositsWeightedAverageRateForeign_0" xml:lang="en-US">The weighted average interest rate for short-term bank deposits outside of the domestic currency.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ShortTermBankDepositsWeightedAverageRateForeign_1" xml:lang="en-US">Short Term Bank Deposits Weighted Average Rate Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ShortTermBankDepositsWeightedAverageRateForeign_2" xml:lang="en-US">Average interest rate, short-term bank deposits in U.S. dollars</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_0" xml:lang="en-US">Short term deferred participation in R&amp;amp;D expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_1" xml:lang="en-US">Short Term Deferred Participation In Research And Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_2" xml:lang="en-US">Short-term deferred participation in R&amp;D expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_0" xml:lang="en-US">Stock-based compensation relating to options issued to employees and directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_1" xml:lang="en-US">Stock Based Compensation Relating To Options Issued To Employees, Directors And Non Employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_2" xml:lang="en-US">Stock-based compensation relating to options issued to employees, directors and non employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_StockIssuedDuringPeriodValueWarrantsExercised_0" xml:lang="en-US">Value of stock issued as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_StockIssuedDuringPeriodValueWarrantsExercised_1" xml:lang="en-US">Stock Issued During Period Value Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_StockIssuedDuringPeriodValueWarrantsExercised_2" xml:lang="en-US">Warrants exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_0" xml:lang="en-US">Change In right of use asset and operating lease liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_1" xml:lang="en-US">Supplemental Right Of Use Asset And Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_2" xml:lang="en-US">Right-of-use asset obtained in exchange for operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_0" xml:lang="en-US">SVB Leerink LLC and Stifel, Nicolaus &amp;amp; Company [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_1" xml:lang="en-US">Svb Leerink Llc And Stifel Nicolaus And Company Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_2" xml:lang="en-US">SVB Leerink LLC and Stifel, Nicolaus &amp; Company [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_TaxExemptPeriod_0" xml:lang="en-US">Tax exempt period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_TaxExemptPeriod_1" xml:lang="en-US">Tax exempt period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_TaxRateOnDistributions_0" xml:lang="en-US">Tax rate for dividends distributed to individuals or foreign residents from the preferred enterprise's earnings.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_TaxRateOnDistributions_1" xml:lang="en-US">Tax rate on distributions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember_0" xml:lang="en-US">Two Thousand and Two Thousand Ten Options Plan [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember_1" xml:lang="en-US">Two Thousand And Two Thousand Ten Options Plan Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember_2" xml:lang="en-US">2000 and 2010 Share Option Plans [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cgen_UnderwritersMember_0" xml:lang="en-US">Underwriters [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_UnderwritersMember_1" xml:lang="en-US">Underwriters [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0" xml:lang="en-US">Valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_0" xml:lang="en-US">Loss (gain) from property and equipment sales and disposals</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_0" xml:lang="en-US">Domestic (Israel)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_2" xml:lang="en-US">Domestic (Israel)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_0" xml:lang="en-US">Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_1" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2" xml:lang="en-US">Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_0" xml:lang="en-US">Taxes on income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_1" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_2" xml:lang="en-US">Taxes on income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_0" xml:lang="en-US">Decrease (increase) in trade receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_1" xml:lang="en-US">Increase (Decrease) in Accounts and Other Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0" xml:lang="en-US">Decrease (increase) in other accounts receivable and prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_1" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0" xml:lang="en-US">Decrease (increase) in long-term prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestAndDebtExpense_0" xml:lang="en-US">Bank fees and other finance expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestAndDebtExpense_1" xml:lang="en-US">Interest and Debt Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_NetIncomeLoss_0" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss_1" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss_2" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss_3" xml:lang="en-US">Net loss for basic and diluted loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsForProceedsFromProductiveAssets_0" xml:lang="en-US">Proceeds from sale of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForProceedsFromProductiveAssets_1" xml:lang="en-US">Payments for (Proceeds from) Productive Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments_0" xml:lang="en-US">Investment in short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments_1" xml:lang="en-US">Payments to Acquire Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisposals_0" xml:lang="en-US">Costs of disposal of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisposals_1" xml:lang="en-US">Property, Plant and Equipment, Disposals</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisposals_2" xml:lang="en-US">Costs of disposal of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0" xml:lang="en-US">Options forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0" xml:lang="en-US">Options expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0" xml:lang="en-US">Options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1" xml:lang="en-US">Options exercised, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0" xml:lang="en-US">Loss before taxes on income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2" xml:lang="en-US">Loss before taxes on income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xml:lang="en-US">Cash and cash equivalents and restricted cash at the end of the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" xml:lang="en-US">Cash, cash equivalents and restricted cash at the beginning of the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3" xml:lang="en-US">Total cash, cash equivalents and restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_0" xml:lang="en-US">Balance, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_1" xml:lang="en-US">Balance, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_2" xml:lang="en-US">Ordinary shares, shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents_0" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents_1" xml:lang="en-US">Restricted Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xml:lang="en-US">Options outstanding at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xml:lang="en-US">Options outstanding at beginning of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xml:lang="en-US">Options outstanding at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" xml:lang="en-US">Options outstanding at beginning of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity_0" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity_1" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity_2" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity_3" xml:lang="en-US">Total shareholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_0" xml:lang="en-US">Net Income Loss After Adjustment Of Change In Fair Value Of Research And Development Funding Arrangement Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_1" xml:lang="en-US">Numerator:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_IL_0" xml:lang="en-US">Israel [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_US_0" xml:lang="en-US">Unites States [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentDescription_0" xml:lang="en-US">Amendment Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag_0" xml:lang="en-US">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorFirmId_0" xml:lang="en-US">Auditor Firm Id</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorLocation_0" xml:lang="en-US">Auditor Location</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorName_0" xml:lang="en-US">Auditor Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_BusinessContactMember_0" xml:lang="en-US">Business Contact [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode_0" xml:lang="en-US">City Area Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ContactPersonnelEmailAddress_0" xml:lang="en-US">Contact Personnel Email Address</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ContactPersonnelFaxNumber_0" xml:lang="en-US">Contact Personnel Fax Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ContactPersonnelName_0" xml:lang="en-US">Contact Personnel Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate_0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentAccountingStandard_0" xml:lang="en-US">Document Accounting Standard</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentAnnualReport_0" xml:lang="en-US">Document Annual Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus_0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus_0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate_0" xml:lang="en-US">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentRegistrationStatement_0" xml:lang="en-US">Document Registration Statement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentShellCompanyReport_0" xml:lang="en-US">Document Shell Company Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentTransitionReport_0" xml:lang="en-US">Document Transition Report</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType_0" xml:lang="en-US">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1_0" xml:lang="en-US">Entity Address, Address Line One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine2_0" xml:lang="en-US">Entity Address, Address Line Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine3_0" xml:lang="en-US">Entity Address, Address Line Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown_0" xml:lang="en-US">Entity Address, City or Town</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCountry_0" xml:lang="en-US">Entity Address Country</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressesAddressTypeAxis_0" xml:lang="en-US">Entity Addresses Address Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityAddressesAddressTypeAxis_1" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode_0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey_0" xml:lang="en-US">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus_0" xml:lang="en-US">Entity Current Reporting Status</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany_0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityExTransitionPeriod_0" xml:lang="en-US">Entity Ex Transition Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFileNumber_0" xml:lang="en-US">Entity File Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory_0" xml:lang="en-US">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode_0" xml:lang="en-US">Entity Incorporation State Country Code</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent_0" xml:lang="en-US">Entity Interactive Data Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName_0" xml:lang="en-US">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityShellCompany_0" xml:lang="en-US">Entity Shell Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityVoluntaryFilers_0" xml:lang="en-US">Entity Voluntary Filers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_0" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_IcfrAuditorAttestationFlag_0" xml:lang="en-US">Auditor Attestation Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber_0" xml:lang="en-US">Local Phone Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_OtherReportingStandardItemNumber_0" xml:lang="en-US">Other Reporting Standard Item Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_Security12bTitle_0" xml:lang="en-US">Title of 12(b) Security</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_SecurityExchangeName_0" xml:lang="en-US">Name of Exchange on which Security is Registered</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol_0" xml:lang="en-US">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_DirectorMember_0" xml:lang="en-US">Director [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_EuropeMember_0" xml:lang="en-US">Europe [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MajorCustomersAxis_0" xml:lang="en-US">Customer [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember_0" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember_0" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis_0" xml:lang="en-US">Range [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_RangeAxis_1" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementScenarioAxis_0" xml:lang="en-US">Scenario [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualAxis_0" xml:lang="en-US">Title of Individual [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_0" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_0" xml:lang="en-US">OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent_0" xml:lang="en-US">Trade payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0" xml:lang="en-US">Accumulated depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_0" xml:lang="en-US">Additional paid-in capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_0" xml:lang="en-US">Additional paid-in capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentForAmortization_0" xml:lang="en-US">Amortization in R&amp;D expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">Adjustments required to reconcile net loss to net cash used in operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_0" xml:lang="en-US">Stock-based compensation expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0" xml:lang="en-US">Weighted average number of shares related to outstanding options excluded from the calculations of diluted net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets_0" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets_1" xml:lang="en-US">Total assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract_0" xml:lang="en-US">ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent_0" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent_1" xml:lang="en-US">Total current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract_0" xml:lang="en-US">CURRENT ASSETS:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsNoncurrent_0" xml:lang="en-US">Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsNoncurrent_1" xml:lang="en-US">Total non- current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract_0" xml:lang="en-US">NON-CURRENT ASSETS:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis_0" xml:lang="en-US">Award Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessDevelopment_0" xml:lang="en-US">Marketing and business development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0" xml:lang="en-US">Purchase of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0" xml:lang="en-US">Cash equivalents:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0" xml:lang="en-US">Restricted cash:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0" xml:lang="en-US">Reconciliation of cash, cash equivalents and restricted cash:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1" xml:lang="en-US">Increase (decrease) in cash, cash equivalents and restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0" xml:lang="en-US">Exercise price of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0" xml:lang="en-US">Warrants purchase to ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_0" xml:lang="en-US">Warrants purchase to ordinary shares remain outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies_0" xml:lang="en-US">COMMITMENTS AND CONTINGENT LIABILITIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember_0" xml:lang="en-US">Ordinary shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_1" xml:lang="en-US">Ordinary shares, par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_0" xml:lang="en-US">Ordinary shares, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued_0" xml:lang="en-US">Ordinary shares, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue_0" xml:lang="en-US">Share capital: Ordinary shares of NIS 0.01 par value: 200,000,000 shares authorized at December 31, 2021 and 2020; 86,433,432 and 83,675,856 shares issued and outstanding at December 31, 2021 and 2020, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue_1" xml:lang="en-US">Ordinary shares of NIS 0.01 par value: 200,000,000 shares authorized at December 31, 2022 and 2021; 86,624,643 and 86,433,432 shares issued and outstanding at December 31, 2022 and 2021, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_1" xml:lang="en-US">Total comprehensive loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_0" xml:lang="en-US">Comprehensive income (loss):</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComputerEquipmentMember_0" xml:lang="en-US">Computers, software and related equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_0" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_0" xml:lang="en-US">Concentration Risk Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_0" xml:lang="en-US">Concentration of credit risks:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_0" xml:lang="en-US">Sales to a single customer exceeding 10%</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_0" xml:lang="en-US">Basis of consolidation:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfRevenue_0" xml:lang="en-US">Cost of revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostsAndExpensesRelatedParty_0" xml:lang="en-US">Amounts charged to research and development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_0" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRevenue_0" xml:lang="en-US">Deferred revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_1" xml:lang="en-US">Deferred tax asset before valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_1" xml:lang="en-US">Net deferred tax asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0" xml:lang="en-US">Operating loss carryforward</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_0" xml:lang="en-US">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_0" xml:lang="en-US">Accrued social benefits and other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation_0" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeNet_0" xml:lang="en-US">Fair value of outstanding forward contracts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet_0" xml:lang="en-US">Net gain on derivative transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting_0" xml:lang="en-US">Net gain on derivative recorded as financial and other income, net for the ineffective portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeNotionalAmount_0" xml:lang="en-US">Derivative, notional amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock_0" xml:lang="en-US">Derivative instruments:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DomesticCountryMember_0" xml:lang="en-US">Domestic Tax Authority [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_0" xml:lang="en-US">Trade payables and accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract_0" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic_0" xml:lang="en-US">Basic net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic_1" xml:lang="en-US">Basic loss per ordinary share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted_0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted_1" xml:lang="en-US">Diluted net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_0" xml:lang="en-US">Basic and diluted loss per share:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_0" xml:lang="en-US">LOSSES PER SHARE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0" xml:lang="en-US">Israeli corporate tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_0" xml:lang="en-US">U.S. income state and local taxes rate (as a percent)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_0" xml:lang="en-US">Employees and related accruals</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0" xml:lang="en-US">Unrecognized share-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0" xml:lang="en-US">Unrecognized compensation cost, recognition period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockMember_0" xml:lang="en-US">Employee Stock Purchase Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember_0" xml:lang="en-US">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost_0" xml:lang="en-US">Investment amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost_1" xml:lang="en-US">Equity investment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_0" xml:lang="en-US">Fair value of financial instruments:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0" xml:lang="en-US">Foreign currency translation adjustments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_1" xml:lang="en-US">Foreign currency transaction adjustments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_0" xml:lang="en-US">Financial statements in U.S. dollars:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherAssets_0" xml:lang="en-US">Gain (loss) from sales and disposals of fixed assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_0" xml:lang="en-US">General and administrative expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_0" xml:lang="en-US">General and administrative expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GrossProfit_0" xml:lang="en-US">Gross Profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_GrossProfit_1" xml:lang="en-US">Gross profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GuaranteeObligationsMaximumExposure_0" xml:lang="en-US">Bank guarantees in favor of lessor, foreign currency derivative contracts and credit card security</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOfInvestments_0" xml:lang="en-US">Marketable securities impairment losses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract_0" xml:lang="en-US">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_0" xml:lang="en-US">Income Statement Location [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_0" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_0" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_0" xml:lang="en-US">INCOME TAXES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxesPaid_0" xml:lang="en-US">Tax payment withheld</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_0" xml:lang="en-US">Income taxes:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0" xml:lang="en-US">Increase (decrease) in trade payables and other accounts payable and accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0" xml:lang="en-US">Decrease in operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InitialOfferingPeriod_0" xml:lang="en-US">Offering period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember_0" xml:lang="en-US">United States [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeInterest_0" xml:lang="en-US">Interest income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_0" xml:lang="en-US">Amount of investment in Compugen</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_0" xml:lang="en-US">Leasehold improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeDisclosureAbstract_0" xml:lang="en-US">Lessee Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeDisclosureAbstract_1" xml:lang="en-US">Lessee Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_1" xml:lang="en-US">Leases:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0" xml:lang="en-US">Schedule of Operating Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1" xml:lang="en-US">Schedule of operating leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xml:lang="en-US">Total operating lease payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1" xml:lang="en-US">2023</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1" xml:lang="en-US">2026</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1" xml:lang="en-US">2025</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1" xml:lang="en-US">2024</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0" xml:lang="en-US">Less: imputed interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseOptionToExtend_0" xml:lang="en-US">Period of options to extend leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_0" xml:lang="en-US">LEASES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_0" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_1" xml:lang="en-US">Total liabilities and shareholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS' EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent_0" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent_1" xml:lang="en-US">Total current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_0" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrent_0" xml:lang="en-US">Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrent_1" xml:lang="en-US">Total non-current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract_0" xml:lang="en-US">NON- CURRENT LIABILITIES:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1" xml:lang="en-US">Net cash provided by financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0" xml:lang="en-US">Cash flows from financing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0" xml:lang="en-US">Cash flows from investing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">Cash flows from operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0" xml:lang="en-US">Recently issued and recently adopted Accounting Standards:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncurrentAssets_0" xml:lang="en-US">Long-lived assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NumberOfOperatingSegments_0" xml:lang="en-US">Number of operating segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses_0" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses_1" xml:lang="en-US">Total operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract_0" xml:lang="en-US">Operating expenses:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss_0" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss_1" xml:lang="en-US">Operating loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability_0" xml:lang="en-US">Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability_1" xml:lang="en-US">Present value of lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability_2" xml:lang="en-US">Present value of lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_0" xml:lang="en-US">Current maturity of operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_1" xml:lang="en-US">Lease liabilities, current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0" xml:lang="en-US">Long-term operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1" xml:lang="en-US">Lease liabilities, non- current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasePayments_0" xml:lang="en-US">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_0" xml:lang="en-US">Operating lease right of use asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0" xml:lang="en-US">Weighted average discount (annual) rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0" xml:lang="en-US">Weighted average remaining lease term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwards_0" xml:lang="en-US">Net operating loss carryforward</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwardsExpirationDate_0" xml:lang="en-US">Year of expiration of operating loss carryforward</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0" xml:lang="en-US">GENERAL</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccountsPayableAndAccruedLiabilities_0" xml:lang="en-US">Other accounts payable and accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherAccountsPayableAndAccruedLiabilities_1" xml:lang="en-US">Other accounts payable and accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_0" xml:lang="en-US">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsCurrent_0" xml:lang="en-US">Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentsLineItems_0" xml:lang="en-US">Other Commitments [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentsTable_0" xml:lang="en-US">Other Commitments [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_0" xml:lang="en-US">Foreign Currency Translation income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_0" xml:lang="en-US">Net gain on derivative classified to operating expenses as effective portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0" xml:lang="en-US">Unrealized gain (loss) arising from derivative contracts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract_0" xml:lang="en-US">Other Income and Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_0" xml:lang="en-US">FINANCIAL AND OTHER INCOME, NET</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherShortTermInvestments_0" xml:lang="en-US">Short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherShortTermInvestments_1" xml:lang="en-US">Short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract_0" xml:lang="en-US">Payables and Accruals [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_0" xml:lang="en-US">Issuance expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_1" xml:lang="en-US">Issuance expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis_0" xml:lang="en-US">Plan Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_0" xml:lang="en-US">Accrued severance pay</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0" xml:lang="en-US">Other accounts receivable and prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1" xml:lang="en-US">Other accounts receivable and prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_0" xml:lang="en-US">Prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseNoncurrent_0" xml:lang="en-US">Long-term prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIncomeTaxRefunds_0" xml:lang="en-US">Tax receivables refunded</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_0" xml:lang="en-US">Proceeds from ordinary shares in offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0" xml:lang="en-US">Proceeds from issuance of ordinary shares, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_0" xml:lang="en-US">Proceeds from maturity of short-term bank deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_0" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1" xml:lang="en-US">Proceeds from sale of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_0" xml:lang="en-US">Proceeds from exercise of stock-based awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_0" xml:lang="en-US">Proceeds from exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_1" xml:lang="en-US">Proceeds from warrant exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_0" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_0" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_0" xml:lang="en-US">Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentImpairment_0" xml:lang="en-US">Impairment of long-lived assets:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_0" xml:lang="en-US">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_1" xml:lang="en-US">Depreciated cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0" xml:lang="en-US">Property and equipment, net:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_0" xml:lang="en-US">Schedule of Property And Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_1" xml:lang="en-US">Schedule of property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_0" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0" xml:lang="en-US">RELATED PARTY BALANCES AND TRANSACTIONS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_0" xml:lang="en-US">Upfront payment received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_0" xml:lang="en-US">Research and development expenses, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0" xml:lang="en-US">Research and development expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_0" xml:lang="en-US">Research and development expenses, net:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_0" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember_0" xml:lang="en-US">Accumulated deficit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_0" xml:lang="en-US">Revenue recognition under milestone method</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_0" xml:lang="en-US">Revenue recognition:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Revenues_0" xml:lang="en-US">Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Revenues_1" xml:lang="en-US">Revenue from sales to customers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RoyaltyExpense_0" xml:lang="en-US">Royalty expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SalesRevenueNetMember_0" xml:lang="en-US">Revenue [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_0" xml:lang="en-US">Schedule of Other Accounts Payable and Accrued Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1" xml:lang="en-US">Schedule of other accounts payable and accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_0" xml:lang="en-US">Schedule of Stock-Based Compensation Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1" xml:lang="en-US">Schedule of stock-based compensation expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0" xml:lang="en-US">Summary Of Deferred Tax Assets And Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1" xml:lang="en-US">Schedule of deferred tax assets and liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0" xml:lang="en-US">Schedule of computation of basic and diluted losses per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_0" xml:lang="en-US">Schedule Of Loss Before Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1" xml:lang="en-US">Schedule of loss before taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_0" xml:lang="en-US">Schedule Of Other Accounts Receivable And Prepaid Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_1" xml:lang="en-US">Schedule of other accounts receivable and prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_0" xml:lang="en-US">Schedule of Financial and Other Income, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_1" xml:lang="en-US">Schedule of financial and other income, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_0" xml:lang="en-US">Schedule of Related Party Balances and Transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1" xml:lang="en-US">Schedule of related party balances and transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_0" xml:lang="en-US">Sales To A Single Customer Exceeding 10%:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_1" xml:lang="en-US">Schedule of sales to single customer xxceeding 10%:a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_0" xml:lang="en-US">Total Revenues And Long-Lived Assets By Geographic Area</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_1" xml:lang="en-US">Schedule of total revenues and long-lived assets by geographic area</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0" xml:lang="en-US">Schedule Of Option Activity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1" xml:lang="en-US">Schedule of option activity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingAbstract_0" xml:lang="en-US">Segment Reporting [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock_0" xml:lang="en-US">GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember_0" xml:lang="en-US">Marketing and business development expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeveranceCosts1_0" xml:lang="en-US">Severance expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation_0" xml:lang="en-US">Stock-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0" xml:lang="en-US">Vesting period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_0" xml:lang="en-US">Aggregate intrinsic value of exercised options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0" xml:lang="en-US">Dividend yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0" xml:lang="en-US">Expected life (years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0" xml:lang="en-US">Volatility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0" xml:lang="en-US">Risk-free interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0" xml:lang="en-US">Ordinary shares reserved for issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0" xml:lang="en-US">Ordinary shares available for issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0" xml:lang="en-US">Aggregate intrinsic value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1" xml:lang="en-US">Exercisable at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0" xml:lang="en-US">Exercisable at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0" xml:lang="en-US">Total intrinsic value of options exercised during the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_0" xml:lang="en-US">Options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1" xml:lang="en-US">Options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0" xml:lang="en-US">Weighted average fair value of stock options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" xml:lang="en-US">Options outstanding at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0" xml:lang="en-US">Number of options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0" xml:lang="en-US">Weighted average exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_1" xml:lang="en-US">Exercisable at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0" xml:lang="en-US">Options vested and expected to vest at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1" xml:lang="en-US">Options vested and expected to vest at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0" xml:lang="en-US">Options outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_0" xml:lang="en-US">Maximum percentage of total shares of common stock outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US">Options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Options forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Options expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US">Options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0" xml:lang="en-US">Stock-based compensation:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_0" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_1" xml:lang="en-US">Exercisable at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_0" xml:lang="en-US">SHAREHOLDERS' EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_0" xml:lang="en-US">Offering price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_0" xml:lang="en-US">Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems_0" xml:lang="en-US">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_0" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_0" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable_0" xml:lang="en-US">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract_0" xml:lang="en-US">SHAREHOLDERS' EQUITY:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract_0" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0" xml:lang="en-US">Exercise of options and ESPP shares, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0" xml:lang="en-US">Issuance of shares, net, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0" xml:lang="en-US">Exercise of options and ESPP shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0" xml:lang="en-US">Issuance of shares, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0" xml:lang="en-US">Options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockOptionMember_0" xml:lang="en-US">Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubleaseIncome_0" xml:lang="en-US">Sublease income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems_0" xml:lang="en-US">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember_0" xml:lang="en-US">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract_0" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_1" xml:lang="en-US">Subsequent Events</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable_0" xml:lang="en-US">Subsequent Event [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_0" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_0" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_0" xml:lang="en-US">Sale of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_0" xml:lang="en-US">Cash paid (received) during the year for:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis_0" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates_0" xml:lang="en-US">Use of estimates:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantMember_0" xml:lang="en-US">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1" xml:lang="en-US">Weighted average number of ordinary shares used in computing diluted net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0" xml:lang="en-US">Denominator:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1" xml:lang="en-US">Weighted average number of ordinary shares used in computing basic net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AccruedMilestonePayment_1" xlink:to="lab_cgen_AccruedMilestonePayment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AccruedMilestonePayment_2" xlink:to="lab_cgen_AccruedMilestonePayment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear_3" xlink:to="lab_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear_4" xlink:to="lab_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementMember_5" xlink:to="lab_cgen_AgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementMember_6" xlink:to="lab_cgen_AgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementOptionAdditionalNumberOfSharesIssuable_7" xlink:to="lab_cgen_AgreementOptionAdditionalNumberOfSharesIssuable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementOptionAdditionalNumberOfSharesIssuable_8" xlink:to="lab_cgen_AgreementOptionAdditionalNumberOfSharesIssuable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementOptionAdditionalNumberOfSharesIssuable_9" xlink:to="lab_cgen_AgreementOptionAdditionalNumberOfSharesIssuable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementStartDate_10" xlink:to="lab_cgen_AgreementStartDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementStartDate_11" xlink:to="lab_cgen_AgreementStartDate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementStartDate_12" xlink:to="lab_cgen_AgreementStartDate_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementTerminationDescription_13" xlink:to="lab_cgen_AgreementTerminationDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementTerminationDescription_14" xlink:to="lab_cgen_AgreementTerminationDescription_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AgreementTerminationDescription_15" xlink:to="lab_cgen_AgreementTerminationDescription_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_16" xlink:to="lab_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_17" xlink:to="lab_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_18" xlink:to="lab_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_19" xlink:to="lab_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AnnualDepreciationRate_20" xlink:to="lab_cgen_AnnualDepreciationRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AnnualDepreciationRate_21" xlink:to="lab_cgen_AnnualDepreciationRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AnnualDepreciationRateDescription_22" xlink:to="lab_cgen_AnnualDepreciationRateDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AnnualDepreciationRateDescription_23" xlink:to="lab_cgen_AnnualDepreciationRateDescription_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AnnualDepreciationRateDescription_24" xlink:to="lab_cgen_AnnualDepreciationRateDescription_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AtMarketOfferingProgramMember_25" xlink:to="lab_cgen_AtMarketOfferingProgramMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AtMarketOfferingProgramMember_26" xlink:to="lab_cgen_AtMarketOfferingProgramMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_AtMarketOfferingProgramMember_27" xlink:to="lab_cgen_AtMarketOfferingProgramMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_28" xlink:to="lab_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_29" xlink:to="lab_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_30" xlink:to="lab_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_31" xlink:to="lab_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_32" xlink:to="lab_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CollaborativeArrangementsMember_33" xlink:to="lab_cgen_CollaborativeArrangementsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CollaborativeArrangementsMember_34" xlink:to="lab_cgen_CollaborativeArrangementsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CollaborativeArrangementsTwoMember_35" xlink:to="lab_cgen_CollaborativeArrangementsTwoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CollaborativeArrangementsTwoMember_36" xlink:to="lab_cgen_CollaborativeArrangementsTwoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ContingentFees_37" xlink:to="lab_cgen_ContingentFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ContingentFees_38" xlink:to="lab_cgen_ContingentFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ContingentFees_39" xlink:to="lab_cgen_ContingentFees_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_40" xlink:to="lab_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_41" xlink:to="lab_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_42" xlink:to="lab_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CustomerOneMember_43" xlink:to="lab_cgen_CustomerOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CustomerOneMember_44" xlink:to="lab_cgen_CustomerOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_CustomerOneMember_45" xlink:to="lab_cgen_CustomerOneMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DecreaseOperatingLeaseLiability_46" xlink:to="lab_cgen_DecreaseOperatingLeaseLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DecreaseOperatingLeaseLiability_47" xlink:to="lab_cgen_DecreaseOperatingLeaseLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DecreaseOperatingLeaseLiability_48" xlink:to="lab_cgen_DecreaseOperatingLeaseLiability_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredIncomeTaxLeaseLiabilities_49" xlink:to="lab_cgen_DeferredIncomeTaxLeaseLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredIncomeTaxLeaseLiabilities_50" xlink:to="lab_cgen_DeferredIncomeTaxLeaseLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredIncomeTaxLeaseLiabilities_51" xlink:to="lab_cgen_DeferredIncomeTaxLeaseLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredIncomeTaxRightOfUseAssets_52" xlink:to="lab_cgen_DeferredIncomeTaxRightOfUseAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredIncomeTaxRightOfUseAssets_53" xlink:to="lab_cgen_DeferredIncomeTaxRightOfUseAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredIncomeTaxRightOfUseAssets_54" xlink:to="lab_cgen_DeferredIncomeTaxRightOfUseAssets_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_55" xlink:to="lab_cgen_DeferredParticipationOfBMSInRAndDExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_56" xlink:to="lab_cgen_DeferredParticipationOfBMSInRAndDExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_57" xlink:to="lab_cgen_DeferredParticipationOfBMSInRAndDExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_58" xlink:to="lab_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_59" xlink:to="lab_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_60" xlink:to="lab_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DerivativeRelatedExpense_61" xlink:to="lab_cgen_DerivativeRelatedExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DerivativeRelatedExpense_62" xlink:to="lab_cgen_DerivativeRelatedExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_DerivativeRelatedExpense_63" xlink:to="lab_cgen_DerivativeRelatedExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_64" xlink:to="lab_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_65" xlink:to="lab_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_66" xlink:to="lab_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_EmployeesAndDirectorsMember_67" xlink:to="lab_cgen_EmployeesAndDirectorsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_EmployeesAndDirectorsMember_68" xlink:to="lab_cgen_EmployeesAndDirectorsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_EmployeeStockPurchasePlanMember_69" xlink:to="lab_cgen_EmployeeStockPurchasePlanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_EmployeeStockPurchasePlanMember_70" xlink:to="lab_cgen_EmployeeStockPurchasePlanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_EmployeeStockPurchasePlanMember_71" xlink:to="lab_cgen_EmployeeStockPurchasePlanMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ExtendLease_72" xlink:to="lab_cgen_ExtendLease_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ExtendLease_73" xlink:to="lab_cgen_ExtendLease_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ExtendLease_74" xlink:to="lab_cgen_ExtendLease_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_FinancialIncomeExpenseNet_75" xlink:to="lab_cgen_FinancialIncomeExpenseNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_FinancialIncomeExpenseNet_76" xlink:to="lab_cgen_FinancialIncomeExpenseNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_FinancialIncomeExpenseNet_77" xlink:to="lab_cgen_FinancialIncomeExpenseNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_FinancialIncomeExpenseNet_78" xlink:to="lab_cgen_FinancialIncomeExpenseNet_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GovernmentAndOtherGrantsAxis_79" xlink:to="lab_cgen_GovernmentAndOtherGrantsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GovernmentAndOtherGrantsAxis_80" xlink:to="lab_cgen_GovernmentAndOtherGrantsAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GovernmentAuthorities_81" xlink:to="lab_cgen_GovernmentAuthorities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_GovernmentAuthorities_82" xlink:to="lab_cgen_GovernmentAuthorities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_83" xlink:to="lab_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_84" xlink:to="lab_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_85" xlink:to="lab_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_86" xlink:to="lab_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_87" xlink:to="lab_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_88" xlink:to="lab_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseOperatingLeaseRightOfUseAsset_89" xlink:to="lab_cgen_IncreaseOperatingLeaseRightOfUseAsset_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseOperatingLeaseRightOfUseAsset_90" xlink:to="lab_cgen_IncreaseOperatingLeaseRightOfUseAsset_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IncreaseOperatingLeaseRightOfUseAsset_91" xlink:to="lab_cgen_IncreaseOperatingLeaseRightOfUseAsset_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_InterestPaidReceivedNet_92" xlink:to="lab_cgen_InterestPaidReceivedNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_InterestPaidReceivedNet_93" xlink:to="lab_cgen_InterestPaidReceivedNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_InterestPaidReceivedNet_94" xlink:to="lab_cgen_InterestPaidReceivedNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IssuanceOfSharesAndWarrantsNetShares_95" xlink:to="lab_cgen_IssuanceOfSharesAndWarrantsNetShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IssuanceOfSharesAndWarrantsNetShares_96" xlink:to="lab_cgen_IssuanceOfSharesAndWarrantsNetShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IssuanceOfSharesAndWarrantsNetValue_97" xlink:to="lab_cgen_IssuanceOfSharesAndWarrantsNetValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IssuanceOfSharesAndWarrantsNetValue_98" xlink:to="lab_cgen_IssuanceOfSharesAndWarrantsNetValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_IssuanceOfSharesAndWarrantsNetValue_99" xlink:to="lab_cgen_IssuanceOfSharesAndWarrantsNetValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_100" xlink:to="lab_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_101" xlink:to="lab_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_102" xlink:to="lab_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_103" xlink:to="lab_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_104" xlink:to="lab_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MasterClinicalAgreementMember_105" xlink:to="lab_cgen_MasterClinicalAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MasterClinicalAgreementMember_106" xlink:to="lab_cgen_MasterClinicalAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MasterClinicalAgreementOneMember_107" xlink:to="lab_cgen_MasterClinicalAgreementOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MasterClinicalAgreementOneMember_108" xlink:to="lab_cgen_MasterClinicalAgreementOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MasterClinicalAgreementTwoMember_109" xlink:to="lab_cgen_MasterClinicalAgreementTwoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MasterClinicalAgreementTwoMember_110" xlink:to="lab_cgen_MasterClinicalAgreementTwoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_111" xlink:to="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_112" xlink:to="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_113" xlink:to="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_114" xlink:to="lab_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_115" xlink:to="lab_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_116" xlink:to="lab_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_117" xlink:to="lab_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_May2012AgreementMember_118" xlink:to="lab_cgen_May2012AgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_May2012AgreementMember_119" xlink:to="lab_cgen_May2012AgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_May2012AgreementMember_120" xlink:to="lab_cgen_May2012AgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NetOperatingLossCarryforwardExpired_121" xlink:to="lab_cgen_NetOperatingLossCarryforwardExpired_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NetOperatingLossCarryforwardExpired_122" xlink:to="lab_cgen_NetOperatingLossCarryforwardExpired_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues_123" xlink:to="lab_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues_124" xlink:to="lab_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NumberOfWarrantsExercised_125" xlink:to="lab_cgen_NumberOfWarrantsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NumberOfWarrantsExercised_126" xlink:to="lab_cgen_NumberOfWarrantsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NumberOfWarrantsExercised_127" xlink:to="lab_cgen_NumberOfWarrantsExercised_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_128" xlink:to="lab_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_129" xlink:to="lab_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_130" xlink:to="lab_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_131" xlink:to="lab_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_132" xlink:to="lab_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_133" xlink:to="lab_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ParticipationRights_134" xlink:to="lab_cgen_ParticipationRights_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ParticipationRights_135" xlink:to="lab_cgen_ParticipationRights_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ParticipationRights_136" xlink:to="lab_cgen_ParticipationRights_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_137" xlink:to="lab_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_138" xlink:to="lab_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_139" xlink:to="lab_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_140" xlink:to="lab_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_141" xlink:to="lab_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfClosingPrice_142" xlink:to="lab_cgen_PercentageOfClosingPrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfClosingPrice_143" xlink:to="lab_cgen_PercentageOfClosingPrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfConsolidatedRevenuesOfCollaborator_144" xlink:to="lab_cgen_PercentageOfConsolidatedRevenuesOfCollaborator_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfConsolidatedRevenuesOfCollaborator_145" xlink:to="lab_cgen_PercentageOfConsolidatedRevenuesOfCollaborator_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering_146" xlink:to="lab_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering_147" xlink:to="lab_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares_148" xlink:to="lab_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares_149" xlink:to="lab_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PeriodSinceApprovalWasGranted_150" xlink:to="lab_cgen_PeriodSinceApprovalWasGranted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PeriodSinceApprovalWasGranted_151" xlink:to="lab_cgen_PeriodSinceApprovalWasGranted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PeriodSinceEnterpriseBeganOperating_152" xlink:to="lab_cgen_PeriodSinceEnterpriseBeganOperating_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_PeriodSinceEnterpriseBeganOperating_153" xlink:to="lab_cgen_PeriodSinceEnterpriseBeganOperating_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ReceivablesOnAccountOfShares_154" xlink:to="lab_cgen_ReceivablesOnAccountOfShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ReceivablesOnAccountOfShares_155" xlink:to="lab_cgen_ReceivablesOnAccountOfShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ReducedCorporateIncomeTaxRate_156" xlink:to="lab_cgen_ReducedCorporateIncomeTaxRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ReducedCorporateIncomeTaxRate_157" xlink:to="lab_cgen_ReducedCorporateIncomeTaxRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ReducedTaxRate_158" xlink:to="lab_cgen_ReducedTaxRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ReducedTaxRate_159" xlink:to="lab_cgen_ReducedTaxRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RegisteredDirectOfferingMember_160" xlink:to="lab_cgen_RegisteredDirectOfferingMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RegisteredDirectOfferingMember_161" xlink:to="lab_cgen_RegisteredDirectOfferingMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_162" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_163" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_164" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_165" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_166" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_167" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_168" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_169" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_170" xlink:to="lab_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentExpensesMilestonePayment_171" xlink:to="lab_cgen_ResearchAndDevelopmentExpensesMilestonePayment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentExpensesMilestonePayment_172" xlink:to="lab_cgen_ResearchAndDevelopmentExpensesMilestonePayment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentExpensesMilestonePayment_173" xlink:to="lab_cgen_ResearchAndDevelopmentExpensesMilestonePayment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_174" xlink:to="lab_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_175" xlink:to="lab_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_176" xlink:to="lab_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentGrantOneMember_177" xlink:to="lab_cgen_ResearchAndDevelopmentGrantOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentGrantOneMember_178" xlink:to="lab_cgen_ResearchAndDevelopmentGrantOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ResearchAndDevelopmentGrantOneMember_179" xlink:to="lab_cgen_ResearchAndDevelopmentGrantOneMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RetainerFee_180" xlink:to="lab_cgen_RetainerFee_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RetainerFee_181" xlink:to="lab_cgen_RetainerFee_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RetainerFee_182" xlink:to="lab_cgen_RetainerFee_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyContingentObligations_183" xlink:to="lab_cgen_RoyaltyContingentObligations_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyContingentObligations_184" xlink:to="lab_cgen_RoyaltyContingentObligations_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyContingentObligations_185" xlink:to="lab_cgen_RoyaltyContingentObligations_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyPercentage_186" xlink:to="lab_cgen_RoyaltyPercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyPercentage_187" xlink:to="lab_cgen_RoyaltyPercentage_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyPercentage_188" xlink:to="lab_cgen_RoyaltyPercentage_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_189" xlink:to="lab_cgen_RoyaltyPercentageBasedOnFutureRevenues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_190" xlink:to="lab_cgen_RoyaltyPercentageBasedOnFutureRevenues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_191" xlink:to="lab_cgen_RoyaltyPercentageBasedOnFutureRevenues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SalesAgreementWithSVBSecuritiesLLCMember_192" xlink:to="lab_cgen_SalesAgreementWithSVBSecuritiesLLCMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SalesAgreementWithSVBSecuritiesLLCMember_193" xlink:to="lab_cgen_SalesAgreementWithSVBSecuritiesLLCMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SalesAgreementWithSVBSecuritiesLLCMember_194" xlink:to="lab_cgen_SalesAgreementWithSVBSecuritiesLLCMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_195" xlink:to="lab_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_196" xlink:to="lab_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_197" xlink:to="lab_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_198" xlink:to="lab_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_199" xlink:to="lab_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_200" xlink:to="lab_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_201" xlink:to="lab_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_202" xlink:to="lab_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_203" xlink:to="lab_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SegmentReportingGeograhicAreaLineItems_204" xlink:to="lab_cgen_SegmentReportingGeograhicAreaLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SegmentReportingGeograhicAreaLineItems_205" xlink:to="lab_cgen_SegmentReportingGeograhicAreaLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SegmentReportingGeographicAreaAxis_206" xlink:to="lab_cgen_SegmentReportingGeographicAreaAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SegmentReportingGeographicAreaAxis_207" xlink:to="lab_cgen_SegmentReportingGeographicAreaAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SegmentReportingGeographicAreaTable_208" xlink:to="lab_cgen_SegmentReportingGeographicAreaTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SegmentReportingGeographicAreaTable_209" xlink:to="lab_cgen_SegmentReportingGeographicAreaTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ServerancePayPolicyTextBlock_210" xlink:to="lab_cgen_ServerancePayPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ServerancePayPolicyTextBlock_211" xlink:to="lab_cgen_ServerancePayPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ServerancePayPolicyTextBlock_212" xlink:to="lab_cgen_ServerancePayPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SeverancePayFundNoncurrent_213" xlink:to="lab_cgen_SeverancePayFundNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SeverancePayFundNoncurrent_214" xlink:to="lab_cgen_SeverancePayFundNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SeverancePayFundNoncurrent_215" xlink:to="lab_cgen_SeverancePayFundNoncurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SeverancePayNet_216" xlink:to="lab_cgen_SeverancePayNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SeverancePayNet_217" xlink:to="lab_cgen_SeverancePayNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SeverancePayNet_218" xlink:to="lab_cgen_SeverancePayNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_219" xlink:to="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_220" xlink:to="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_221" xlink:to="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_222" xlink:to="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_223" xlink:to="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_224" xlink:to="lab_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShortTermBankDepositsPolicyTextBlock_225" xlink:to="lab_cgen_ShortTermBankDepositsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShortTermBankDepositsPolicyTextBlock_226" xlink:to="lab_cgen_ShortTermBankDepositsPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShortTermBankDepositsPolicyTextBlock_227" xlink:to="lab_cgen_ShortTermBankDepositsPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShortTermBankDepositsWeightedAverageRateForeign_228" xlink:to="lab_cgen_ShortTermBankDepositsWeightedAverageRateForeign_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShortTermBankDepositsWeightedAverageRateForeign_229" xlink:to="lab_cgen_ShortTermBankDepositsWeightedAverageRateForeign_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShortTermBankDepositsWeightedAverageRateForeign_230" xlink:to="lab_cgen_ShortTermBankDepositsWeightedAverageRateForeign_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_231" xlink:to="lab_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_232" xlink:to="lab_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_233" xlink:to="lab_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_234" xlink:to="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_235" xlink:to="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_236" xlink:to="lab_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_237" xlink:to="lab_cgen_StockIssuedDuringPeriodValueWarrantsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_238" xlink:to="lab_cgen_StockIssuedDuringPeriodValueWarrantsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_239" xlink:to="lab_cgen_StockIssuedDuringPeriodValueWarrantsExercised_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_240" xlink:to="lab_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_241" xlink:to="lab_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_242" xlink:to="lab_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_243" xlink:to="lab_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_244" xlink:to="lab_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_245" xlink:to="lab_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_TaxExemptPeriod_246" xlink:to="lab_cgen_TaxExemptPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_TaxExemptPeriod_247" xlink:to="lab_cgen_TaxExemptPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_TaxRateOnDistributions_248" xlink:to="lab_cgen_TaxRateOnDistributions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_TaxRateOnDistributions_249" xlink:to="lab_cgen_TaxRateOnDistributions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember_250" xlink:to="lab_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember_251" xlink:to="lab_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember_252" xlink:to="lab_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_UnderwritersMember_253" xlink:to="lab_cgen_UnderwritersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_UnderwritersMember_254" xlink:to="lab_cgen_UnderwritersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_255" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_256" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_257" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_258" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_259" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_260" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_261" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_262" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_263" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_264" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_265" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_266" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_267" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_268" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_269" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_270" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_271" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_272" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_273" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndDebtExpense_274" xlink:to="lab_us-gaap_InterestAndDebtExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndDebtExpense_275" xlink:to="lab_us-gaap_InterestAndDebtExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_276" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_277" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_278" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_279" xlink:to="lab_us-gaap_NetIncomeLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_280" xlink:to="lab_us-gaap_NetIncomeLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_281" xlink:to="lab_us-gaap_NetIncomeLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_282" xlink:to="lab_us-gaap_NetIncomeLoss_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromProductiveAssets_283" xlink:to="lab_us-gaap_PaymentsForProceedsFromProductiveAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromProductiveAssets_284" xlink:to="lab_us-gaap_PaymentsForProceedsFromProductiveAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments_285" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments_286" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_287" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_288" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisposals_289" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisposals_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisposals_290" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisposals_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisposals_291" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisposals_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_292" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_293" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_294" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_295" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_296" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_297" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_298" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_299" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_300" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_301" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_302" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_303" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_304" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_305" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_306" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_307" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_308" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_309" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_310" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_311" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents_312" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents_313" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_314" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_315" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_316" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_317" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_318" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_319" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_320" xlink:to="lab_us-gaap_StockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_321" xlink:to="lab_us-gaap_StockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_322" xlink:to="lab_us-gaap_StockholdersEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_323" xlink:to="lab_us-gaap_StockholdersEquity_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_324" xlink:to="lab_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_325" xlink:to="lab_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IL_326" xlink:to="lab_country_IL_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_327" xlink:to="lab_country_US_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentDescription_328" xlink:to="lab_dei_AmendmentDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_329" xlink:to="lab_dei_AmendmentFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId_330" xlink:to="lab_dei_AuditorFirmId_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation_331" xlink:to="lab_dei_AuditorLocation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName_332" xlink:to="lab_dei_AuditorName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_BusinessContactMember_333" xlink:to="lab_dei_BusinessContactMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_334" xlink:to="lab_dei_CityAreaCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelEmailAddress_335" xlink:to="lab_dei_ContactPersonnelEmailAddress_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelFaxNumber_336" xlink:to="lab_dei_ContactPersonnelFaxNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelName_337" xlink:to="lab_dei_ContactPersonnelName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_338" xlink:to="lab_dei_CurrentFiscalYearEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAccountingStandard_339" xlink:to="lab_dei_DocumentAccountingStandard_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport_340" xlink:to="lab_dei_DocumentAnnualReport_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_341" xlink:to="lab_dei_DocumentFiscalPeriodFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_342" xlink:to="lab_dei_DocumentFiscalYearFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_343" xlink:to="lab_dei_DocumentPeriodEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentRegistrationStatement_344" xlink:to="lab_dei_DocumentRegistrationStatement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentShellCompanyReport_345" xlink:to="lab_dei_DocumentShellCompanyReport_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_346" xlink:to="lab_dei_DocumentTransitionReport_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_347" xlink:to="lab_dei_DocumentType_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_348" xlink:to="lab_dei_EntityAddressAddressLine1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2_349" xlink:to="lab_dei_EntityAddressAddressLine2_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine3_350" xlink:to="lab_dei_EntityAddressAddressLine3_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_351" xlink:to="lab_dei_EntityAddressCityOrTown_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry_352" xlink:to="lab_dei_EntityAddressCountry_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_353" xlink:to="lab_dei_EntityAddressesAddressTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_354" xlink:to="lab_dei_EntityAddressesAddressTypeAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_355" xlink:to="lab_dei_EntityAddressPostalZipCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_356" xlink:to="lab_dei_EntityCentralIndexKey_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_357" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_358" xlink:to="lab_dei_EntityCurrentReportingStatus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_359" xlink:to="lab_dei_EntityEmergingGrowthCompany_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod_360" xlink:to="lab_dei_EntityExTransitionPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_361" xlink:to="lab_dei_EntityFileNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_362" xlink:to="lab_dei_EntityFilerCategory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_363" xlink:to="lab_dei_EntityIncorporationStateCountryCode_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_364" xlink:to="lab_dei_EntityInteractiveDataCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_365" xlink:to="lab_dei_EntityRegistrantName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_366" xlink:to="lab_dei_EntityShellCompany_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_367" xlink:to="lab_dei_EntityVoluntaryFilers_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_368" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag_369" xlink:to="lab_dei_IcfrAuditorAttestationFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_370" xlink:to="lab_dei_LocalPhoneNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_OtherReportingStandardItemNumber_371" xlink:to="lab_dei_OtherReportingStandardItemNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_372" xlink:to="lab_dei_Security12bTitle_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_373" xlink:to="lab_dei_SecurityExchangeName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_374" xlink:to="lab_dei_TradingSymbol_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember_375" xlink:to="lab_srt_DirectorMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember_376" xlink:to="lab_srt_EuropeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis_377" xlink:to="lab_srt_MajorCustomersAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_378" xlink:to="lab_srt_MaximumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_379" xlink:to="lab_srt_MinimumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_380" xlink:to="lab_srt_RangeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_381" xlink:to="lab_srt_RangeAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis_382" xlink:to="lab_srt_StatementScenarioAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis_383" xlink:to="lab_srt_TitleOfIndividualAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_384" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_385" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_386" xlink:to="lab_us-gaap_AccountsPayableCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_387" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_388" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_389" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization_390" xlink:to="lab_us-gaap_AdjustmentForAmortization_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_391" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_392" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_393" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_394" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_395" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_396" xlink:to="lab_us-gaap_Assets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_397" xlink:to="lab_us-gaap_Assets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_398" xlink:to="lab_us-gaap_AssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_399" xlink:to="lab_us-gaap_AssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_400" xlink:to="lab_us-gaap_AssetsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_401" xlink:to="lab_us-gaap_AssetsCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent_402" xlink:to="lab_us-gaap_AssetsNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent_403" xlink:to="lab_us-gaap_AssetsNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_404" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_405" xlink:to="lab_us-gaap_AwardTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDevelopment_406" xlink:to="lab_us-gaap_BusinessDevelopment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_407" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_408" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_409" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_410" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_411" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_412" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_413" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_414" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_415" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_416" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_417" xlink:to="lab_us-gaap_CommitmentsAndContingencies_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_418" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_419" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_420" xlink:to="lab_us-gaap_CommonStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_421" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_422" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_423" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_424" xlink:to="lab_us-gaap_CommonStockSharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_425" xlink:to="lab_us-gaap_CommonStockValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_426" xlink:to="lab_us-gaap_CommonStockValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_427" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_428" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_429" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember_430" xlink:to="lab_us-gaap_ComputerEquipmentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_431" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_432" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_433" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1_434" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_435" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue_436" xlink:to="lab_us-gaap_CostOfRevenue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesRelatedParty_437" xlink:to="lab_us-gaap_CostsAndExpensesRelatedParty_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember_438" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_439" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenue_440" xlink:to="lab_us-gaap_DeferredRevenue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_441" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_442" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_443" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_444" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_445" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_446" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_447" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_448" xlink:to="lab_us-gaap_Depreciation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeNet_449" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet_450" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting_451" xlink:to="lab_us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount_452" xlink:to="lab_us-gaap_DerivativeNotionalAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock_453" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember_454" xlink:to="lab_us-gaap_DomesticCountryMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_455" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_456" xlink:to="lab_us-gaap_EarningsPerShareAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_457" xlink:to="lab_us-gaap_EarningsPerShareBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_458" xlink:to="lab_us-gaap_EarningsPerShareBasic_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_459" xlink:to="lab_us-gaap_EarningsPerShareDiluted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_460" xlink:to="lab_us-gaap_EarningsPerShareDiluted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_461" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_462" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_463" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_464" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_465" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_466" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_467" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_468" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember_469" xlink:to="lab_us-gaap_EmployeeStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_470" xlink:to="lab_us-gaap_EmployeeStockOptionMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentAggregateCost_471" xlink:to="lab_us-gaap_EquityMethodInvestmentAggregateCost_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentAggregateCost_472" xlink:to="lab_us-gaap_EquityMethodInvestmentAggregateCost_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_473" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_474" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_475" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_476" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfOtherAssets_477" xlink:to="lab_us-gaap_GainLossOnSaleOfOtherAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_478" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_479" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit_480" xlink:to="lab_us-gaap_GrossProfit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit_481" xlink:to="lab_us-gaap_GrossProfit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsMaximumExposure_482" xlink:to="lab_us-gaap_GuaranteeObligationsMaximumExposure_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfInvestments_483" xlink:to="lab_us-gaap_ImpairmentOfInvestments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_484" xlink:to="lab_us-gaap_IncomeStatementAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_485" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_486" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_487" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_488" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid_489" xlink:to="lab_us-gaap_IncomeTaxesPaid_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_490" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_491" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_492" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InitialOfferingPeriod_493" xlink:to="lab_us-gaap_InitialOfferingPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember_494" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_495" xlink:to="lab_us-gaap_InvestmentIncomeInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_496" xlink:to="lab_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember_497" xlink:to="lab_us-gaap_LeaseholdImprovementsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_498" xlink:to="lab_us-gaap_LesseeDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_499" xlink:to="lab_us-gaap_LesseeDisclosureAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock_500" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock_501" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_502" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_503" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_504" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_505" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_506" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_507" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_508" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_509" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_510" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_511" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_512" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_513" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_514" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_515" xlink:to="lab_us-gaap_LesseeOperatingLeaseOptionToExtend_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock_516" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_517" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_518" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_519" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_520" xlink:to="lab_us-gaap_LiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_521" xlink:to="lab_us-gaap_LiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_522" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_523" xlink:to="lab_us-gaap_LiabilitiesNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_524" xlink:to="lab_us-gaap_LiabilitiesNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_525" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_526" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_527" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_528" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_529" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_530" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_531" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_532" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_533" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncurrentAssets_534" xlink:to="lab_us-gaap_NoncurrentAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_535" xlink:to="lab_us-gaap_NumberOfOperatingSegments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_536" xlink:to="lab_us-gaap_OperatingExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_537" xlink:to="lab_us-gaap_OperatingExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_538" xlink:to="lab_us-gaap_OperatingExpensesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_539" xlink:to="lab_us-gaap_OperatingIncomeLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_540" xlink:to="lab_us-gaap_OperatingIncomeLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_541" xlink:to="lab_us-gaap_OperatingLeaseLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_542" xlink:to="lab_us-gaap_OperatingLeaseLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_543" xlink:to="lab_us-gaap_OperatingLeaseLiability_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_544" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_545" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_546" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_547" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments_548" xlink:to="lab_us-gaap_OperatingLeasePayments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_549" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_550" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_551" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_552" xlink:to="lab_us-gaap_OperatingLossCarryforwards_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_553" xlink:to="lab_us-gaap_OperatingLossCarryforwardsExpirationDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_554" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_555" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_556" xlink:to="lab_us-gaap_OtherAccountsPayableAndAccruedLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_557" xlink:to="lab_us-gaap_OtherAccountsPayableAndAccruedLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_558" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_559" xlink:to="lab_us-gaap_OtherAssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_560" xlink:to="lab_us-gaap_OtherCommitmentsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable_561" xlink:to="lab_us-gaap_OtherCommitmentsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_562" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_563" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_564" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_565" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_566" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherShortTermInvestments_567" xlink:to="lab_us-gaap_OtherShortTermInvestments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherShortTermInvestments_568" xlink:to="lab_us-gaap_OtherShortTermInvestments_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_569" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_570" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_571" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_572" xlink:to="lab_us-gaap_PlanNameAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_573" xlink:to="lab_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_574" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_575" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_576" xlink:to="lab_us-gaap_PrepaidExpenseCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseNoncurrent_577" xlink:to="lab_us-gaap_PrepaidExpenseNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIncomeTaxRefunds_578" xlink:to="lab_us-gaap_ProceedsFromIncomeTaxRefunds_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_579" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_580" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_581" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_582" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_583" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_584" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_585" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_586" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_587" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_588" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_589" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_590" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_591" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentImpairment_592" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentImpairment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_593" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_594" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_595" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_596" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_597" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_598" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_599" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_600" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_601" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_602" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_603" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_604" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_605" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_606" xlink:to="lab_us-gaap_RetainedEarningsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_607" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_608" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_609" xlink:to="lab_us-gaap_Revenues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_610" xlink:to="lab_us-gaap_Revenues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense_611" xlink:to="lab_us-gaap_RoyaltyExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember_612" xlink:to="lab_us-gaap_SalesRevenueNetMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_613" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_614" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_615" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_616" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_617" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_618" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_619" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_620" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_621" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_622" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_623" xlink:to="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_624" xlink:to="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_625" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_626" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_627" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_628" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_629" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_630" xlink:to="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_631" xlink:to="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_632" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_633" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_634" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_635" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_636" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract_637" xlink:to="lab_us-gaap_SegmentReportingAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock_638" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpenseMember_639" xlink:to="lab_us-gaap_SellingAndMarketingExpenseMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1_640" xlink:to="lab_us-gaap_SeveranceCosts1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_641" xlink:to="lab_us-gaap_ShareBasedCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_642" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_643" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_644" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_645" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_646" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_647" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_648" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_649" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_650" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_651" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_652" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_653" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_654" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_655" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_656" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_657" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_658" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_659" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_660" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_661" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_662" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_663" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_664" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_665" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_666" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_667" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_668" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_669" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_670" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_671" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_672" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_673" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_674" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_675" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_676" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_677" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_678" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_679" xlink:to="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare_680" xlink:to="lab_us-gaap_SharesIssuedPricePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_681" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_682" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_683" xlink:to="lab_us-gaap_StatementLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_684" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_685" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_686" xlink:to="lab_us-gaap_StatementTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_687" xlink:to="lab_us-gaap_StockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_688" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_689" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_690" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_691" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_692" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_693" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember_694" xlink:to="lab_us-gaap_StockOptionMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome_695" xlink:to="lab_us-gaap_SubleaseIncome_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_696" xlink:to="lab_us-gaap_SubsequentEventLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_697" xlink:to="lab_us-gaap_SubsequentEventMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_698" xlink:to="lab_us-gaap_SubsequentEventsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_699" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_700" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_701" xlink:to="lab_us-gaap_SubsequentEventTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_702" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_703" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_704" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_705" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_706" xlink:to="lab_us-gaap_TypeOfArrangementAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_707" xlink:to="lab_us-gaap_UseOfEstimates_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_708" xlink:to="lab_us-gaap_WarrantMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_709" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_710" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_711" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_712" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_713" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>cgen-20221231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-daei1" roleURI="http://cgen.com/role/cgen-daei1"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#ConsolidatedBalanceSheets" roleURI="http://cgen.com/role/ConsolidatedBalanceSheets"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-cbsp" roleURI="http://cgen.com/role/cgen-cbsp"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-csocl" roleURI="http://cgen.com/role/cgen-csocl"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#StatementsOfChangesInShareholdersEquity" roleURI="http://cgen.com/role/StatementsOfChangesInShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://cgen.com/role/ConsolidatedStatementsOfCashFlows"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-g" roleURI="http://cgen.com/role/cgen-g"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-sap" roleURI="http://cgen.com/role/cgen-sap"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-oarape" roleURI="http://cgen.com/role/cgen-oarape"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#Leases" roleURI="http://cgen.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-paen" roleURI="http://cgen.com/role/cgen-paen"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-oapaae" roleURI="http://cgen.com/role/cgen-oapaae"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-cac1" roleURI="http://cgen.com/role/cgen-cac1"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-se12" roleURI="http://cgen.com/role/cgen-se12"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-it" roleURI="http://cgen.com/role/cgen-it"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-giamc" roleURI="http://cgen.com/role/cgen-giamc"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-faoin" roleURI="http://cgen.com/role/cgen-faoin"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-rpbat" roleURI="http://cgen.com/role/cgen-rpbat"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-lps" roleURI="http://cgen.com/role/cgen-lps"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-sapp" roleURI="http://cgen.com/role/cgen-sapp"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-sapt" roleURI="http://cgen.com/role/cgen-sapt"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-oarapet" roleURI="http://cgen.com/role/cgen-oarapet"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#LeasesTables" roleURI="http://cgen.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-paent" roleURI="http://cgen.com/role/cgen-paent"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-oapaaet" roleURI="http://cgen.com/role/cgen-oapaaet"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-set1" roleURI="http://cgen.com/role/cgen-set1"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-itt" roleURI="http://cgen.com/role/cgen-itt"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-giamct" roleURI="http://cgen.com/role/cgen-giamct"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-faoint" roleURI="http://cgen.com/role/cgen-faoint"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#RelatedPartyBalancesAndTransactionsTables" roleURI="http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-lpst" roleURI="http://cgen.com/role/cgen-lpst"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-gd" roleURI="http://cgen.com/role/cgen-gd"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-sapnd" roleURI="http://cgen.com/role/cgen-sapnd"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-sapsodrfpaed" roleURI="http://cgen.com/role/cgen-sapsodrfpaed"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails" roleURI="http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-oaraped" roleURI="http://cgen.com/role/cgen-oaraped"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#LeasesScheduleOfWeighted-averageRemainingLeaseTermAndDiscountRateDetails" roleURI="http://cgen.com/role/LeasesScheduleOfWeighted-averageRemainingLeaseTermAndDiscountRateDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#LeasesScheduleOfOperatingLeasesDetails" roleURI="http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-paend" roleURI="http://cgen.com/role/cgen-paend"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-oapaaed" roleURI="http://cgen.com/role/cgen-oapaaed"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#CommitmentsAndContingenciesDetails" roleURI="http://cgen.com/role/CommitmentsAndContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-sesopnd" roleURI="http://cgen.com/role/cgen-sesopnd"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#ShareholdersEquityScheduleOfOptionActivityDetails" roleURI="http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#cgen-sesosced" roleURI="http://cgen.com/role/cgen-sesosced"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#IncomeTaxesNarrativeDetails" roleURI="http://cgen.com/role/IncomeTaxesNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#IncomeTaxesEncouragementOfCapitalInvestmentsNarrativeDetails" roleURI="http://cgen.com/role/IncomeTaxesEncouragementOfCapitalInvestmentsNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#IncomeTaxesScheduleOfLossBeforeTaxesDetails" roleURI="http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#GeographicInformationAndMajorCustomersDetails" roleURI="http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails" roleURI="http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#RelatedPartyBalancesAndTransactionsDetails" roleURI="http://cgen.com/role/RelatedPartyBalancesAndTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails" roleURI="http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#SUBSEQUENTEVENTS" roleURI="http://cgen.com/role/SUBSEQUENTEVENTS"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#SubsequentEventsNarrativeDetails" roleURI="http://cgen.com/role/SubsequentEventsNarrativeDetails"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#LEASESNarrative" roleURI="http://cgen.com/role/LEASESNarrative"/>
  <roleRef xlink:type="simple" xlink:href="cgen-20221231.xsd#PROPERTYANDEQUIPMENTNETNarrativeDetails" roleURI="http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails"/>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-daei1">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_dei_DocumentRegistrationStatement_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_dei_DocumentShellCompanyReport_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_dei_EntityAddressAddressLine3_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_dei_EntityAddressCountry_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelFaxNumber" xlink:label="loc_dei_ContactPersonnelFaxNumber_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelEmailAddress" xlink:label="loc_dei_ContactPersonnelEmailAddress_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_40"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_dei_DocumentAccountingStandard_42"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_dei_OtherReportingStandardItemNumber_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_45"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_46"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_47"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1" xlink:to="loc_dei_AddressTypeDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_1" xlink:to="loc_dei_BusinessContactMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityCentralIndexKey_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_CurrentFiscalYearEndDate_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_DocumentFiscalYearFocus_6" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_DocumentFiscalPeriodFocus_7" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_DocumentType_8" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_AmendmentFlag_9" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_AmendmentDescription_10" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_DocumentRegistrationStatement_11" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_DocumentAnnualReport_12" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_DocumentTransitionReport_13" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_DocumentShellCompanyReport_14" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_DocumentPeriodEndDate_15" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityFileNumber_16" order="120" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_ContactPersonnelName_17" order="130" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityRegistrantName_18" order="140" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityIncorporationStateCountryCode_19" order="150" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityAddressAddressLine1_20" order="160" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityAddressAddressLine2_21" order="170" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityAddressAddressLine3_22" order="180" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityAddressCityOrTown_23" order="190" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityAddressCountry_24" order="200" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityAddressPostalZipCode_25" order="210" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_CityAreaCode_26" order="220" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_LocalPhoneNumber_27" order="230" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_ContactPersonnelFaxNumber_28" order="240" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_ContactPersonnelEmailAddress_29" order="250" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_Security12bTitle_30" order="260" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_TradingSymbol_31" order="270" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_SecurityExchangeName_32" order="280" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_33" order="290" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_34" order="300" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityVoluntaryFilers_35" order="310" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityCurrentReportingStatus_36" order="320" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityInteractiveDataCurrent_37" order="330" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityFilerCategory_38" order="340" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityEmergingGrowthCompany_39" order="350" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_IcfrAuditorAttestationFlag_40" order="360" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityExTransitionPeriod_41" order="370" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_DocumentAccountingStandard_42" order="380" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_OtherReportingStandardItemNumber_43" order="390" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_EntityShellCompany_44" order="400" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_AuditorName_45" order="410" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_AuditorLocation_46" order="420" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_dei_AuditorFirmId_47" order="430" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/ConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermInvestments" xlink:label="loc_us-gaap_OtherShortTermInvestments_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_7"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_SeverancePayFundNoncurrent" xlink:label="loc_cgen_SeverancePayFundNoncurrent_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_15"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_21"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PostemploymentBenefitsLiabilityNoncurrent" xlink:label="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_32"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_AssetsAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_OtherShortTermInvestments_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_AssetsCurrent_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_7" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent_7" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_7" xlink:to="loc_cgen_SeverancePayFundNoncurrent_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_7" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_10" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_7" xlink:to="loc_us-gaap_AssetsNoncurrent_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_Assets_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_15" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15" xlink:to="loc_us-gaap_AccountsPayableCurrent_15" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15" xlink:to="loc_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_17" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15" xlink:to="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_18" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15" xlink:to="loc_us-gaap_LiabilitiesCurrent_19" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_21" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_21" xlink:to="loc_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_21" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_22" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_21" xlink:to="loc_us-gaap_PostemploymentBenefitsLiabilityNoncurrent_23" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_21" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_24" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_CommitmentsAndContingencies_26" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_StockholdersEquityAbstract_27" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_27" xlink:to="loc_us-gaap_CommonStockValue_27" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_27" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_28" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_27" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_29" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_27" xlink:to="loc_us-gaap_StockholdersEquity_30" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_32" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-cbsp">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4" order="30" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-csocl">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDevelopment" xlink:label="loc_us-gaap_BusinessDevelopment_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_9"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_18"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_Revenues_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_CostOfRevenue_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_GrossProfit_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_BusinessDevelopment_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_6" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_OperatingExpenses_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingIncomeLoss_9" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_cgen_FinancialIncomeExpenseNet_10" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_11" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_12" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_13" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasic_14" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_15" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_16" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_17" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_18" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/StatementsOfChangesInShareholdersEquity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_IssuanceOfSharesAndWarrantsNetValue" xlink:label="loc_cgen_IssuanceOfSharesAndWarrantsNetValue_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_IssuanceOfSharesAndWarrantsNetShares" xlink:label="loc_cgen_IssuanceOfSharesAndWarrantsNetShares_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_13"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_14"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_NumberOfWarrantsExercised" xlink:label="loc_cgen_NumberOfWarrantsExercised_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_17"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees" xlink:label="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_21"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_RetainedEarningsMember_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_StockholdersEquity_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_8" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_cgen_IssuanceOfSharesAndWarrantsNetValue_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_cgen_IssuanceOfSharesAndWarrantsNetShares_11" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_12" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_13" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_cgen_StockIssuedDuringPeriodValueWarrantsExercised_14" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_cgen_NumberOfWarrantsExercised_15" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_16" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_17" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees_18" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_NetIncomeLoss_19" order="130" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_StockholdersEquity_20" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_21" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/ConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_SeverancePayNet" xlink:label="loc_cgen_SeverancePayNet_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement" xlink:label="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_11"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses" xlink:label="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_20"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities" xlink:label="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_32"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ReceivablesOnAccountOfShares" xlink:label="loc_cgen_ReceivablesOnAccountOfShares_33"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability" xlink:label="loc_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_34"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_36"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_InterestPaidReceivedNet" xlink:label="loc_cgen_InterestPaidReceivedNet_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_40"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_ShareBasedCompensation_2" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_Depreciation_3" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_cgen_SeverancePayNet_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_7" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8" order="60" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9" order="70" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_10" order="80" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_11" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses_12" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_13" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_17" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisposals_20" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17" xlink:to="loc_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities_21" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_22" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_24" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_25" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_26" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_27" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_24" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_28" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_30" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_31" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_32" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_32" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_32" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_32" xlink:to="loc_cgen_ReceivablesOnAccountOfShares_33" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_32" xlink:to="loc_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability_34" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_36" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_36" xlink:to="loc_cgen_InterestPaidReceivedNet_36" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_38" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_38" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_38" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_38" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_39" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_38" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_40" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-g">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sap">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-oarape">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:label="loc_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xlink:to="loc_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/Leases">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-paen">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-oapaae">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-cac1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-se12">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-it">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-giamc">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-faoin">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-rpbat">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-lps">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sapp">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ShortTermBankDepositsPolicyTextBlock" xlink:label="loc_cgen_ShortTermBankDepositsPolicyTextBlock_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentImpairment" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentImpairment_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_CostOfSalesContractWithCustomerPolicyTextBlock" xlink:label="loc_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_12"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ServerancePayPolicyTextBlock" xlink:label="loc_cgen_ServerancePayPolicyTextBlock_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_21"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_UseOfEstimates_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cgen_ShortTermBankDepositsPolicyTextBlock_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_7" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentImpairment_8" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_10" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cgen_CostOfSalesContractWithCustomerPolicyTextBlock_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_12" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cgen_ServerancePayPolicyTextBlock_13" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_14" order="130" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_15" order="140" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_16" order="150" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_17" order="160" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_18" order="170" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_19" order="180" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_20" order="190" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_21" order="200" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sapt">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock" xlink:label="loc_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions" xlink:label="loc_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-oarapet">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate" xlink:label="loc_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-paent">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-oapaaet">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-set1">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-itt">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-giamct">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-faoint">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-lpst">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-gd">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_2"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue" xlink:label="loc_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue_5" order="40" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sapnd">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_MasterClinicalAgreementOneMember" xlink:label="loc_cgen_MasterClinicalAgreementOneMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_MasterClinicalAgreementTwoMember" xlink:label="loc_cgen_MasterClinicalAgreementTwoMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_8"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ShortTermBankDepositsWeightedAverageRateForeign" xlink:label="loc_cgen_ShortTermBankDepositsWeightedAverageRateForeign_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfInvestments" xlink:label="loc_us-gaap_ImpairmentOfInvestments_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_11"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues" xlink:label="loc_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting" xlink:label="loc_us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_18"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_DerivativeRelatedExpense" xlink:label="loc_cgen_DerivativeRelatedExpense_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeNet" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNet_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_21"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount" xlink:label="loc_us-gaap_DerivativeNotionalAmount_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_24"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ResearchAndDevelopmentArrangementPaymentsReceivable" xlink:label="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_25"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AccruedMilestonePayment" xlink:label="loc_cgen_AccruedMilestonePayment_26"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_DeferredParticipationOfBMSInRAndDExpenses" xlink:label="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_27"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_PercentageOfConsolidatedRevenuesOfCollaborator" xlink:label="loc_cgen_PercentageOfConsolidatedRevenuesOfCollaborator_28"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_srt_StatementScenarioAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_1" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_MasterClinicalAgreementOneMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_MasterClinicalAgreementTwoMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5" xlink:to="loc_us-gaap_StockOptionMember_5" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_8" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_cgen_ShortTermBankDepositsWeightedAverageRateForeign_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_AdjustmentForAmortization_9" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_ImpairmentOfInvestments_10" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_DeferredRevenue_11" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues_12" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_13" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_SeveranceCosts1_14" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_15" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_16" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting_17" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_18" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_cgen_DerivativeRelatedExpense_19" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeNet_20" order="120" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_21" order="130" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_22" order="140" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_DerivativeNotionalAmount_23" order="150" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_24" order="160" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable_25" order="170" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_cgen_AccruedMilestonePayment_26" order="180" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_27" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_cgen_PercentageOfConsolidatedRevenuesOfCollaborator_28" order="200" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sapsodrfpaed">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_LaboratoryEquipmentAndOfficeFurnitureMember" xlink:label="loc_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AnnualDepreciationRate" xlink:label="loc_cgen_AnnualDepreciationRate_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AnnualDepreciationRateDescription" xlink:label="loc_cgen_AnnualDepreciationRateDescription_11"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_ComputerEquipmentMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_srt_RangeAxis_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6" xlink:to="loc_srt_RangeMember_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6" xlink:to="loc_srt_MinimumMember_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6" xlink:to="loc_srt_MaximumMember_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_10" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_10" xlink:to="loc_cgen_AnnualDepreciationRate_10" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_10" xlink:to="loc_cgen_AnnualDepreciationRateDescription_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_EmployeeStockPurchasePlanMember" xlink:label="loc_cgen_EmployeeStockPurchasePlanMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_12"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_cgen_EmployeeStockPurchasePlanMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_RangeAxis_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5" xlink:to="loc_srt_RangeMember_5" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5" xlink:to="loc_srt_MinimumMember_5" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5" xlink:to="loc_srt_MaximumMember_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_10" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_11" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_12" order="30" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-oaraped">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_GovernmentAuthorities" xlink:label="loc_cgen_GovernmentAuthorities_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xlink:to="loc_cgen_GovernmentAuthorities_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_OtherAssetsCurrent_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/LeasesScheduleOfWeighted-averageRemainingLeaseTermAndDiscountRateDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2" order="10" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_10"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeaseLiability_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeaseLiability_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-paend">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_LaboratoryEquipmentAndOfficeFurnitureMember" xlink:label="loc_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_ComputerEquipmentMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_cgen_LaboratoryEquipmentAndOfficeFurnitureMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-oapaaed">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/CommitmentsAndContingenciesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaap_OtherCommitmentsTable_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_GovernmentAndOtherGrantsAxis" xlink:label="loc_cgen_GovernmentAndOtherGrantsAxis_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_GovernmentAndOtherGrantsDomain" xlink:label="loc_cgen_GovernmentAndOtherGrantsDomain_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ResearchAndDevelopmentGrantOneMember" xlink:label="loc_cgen_ResearchAndDevelopmentGrantOneMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_May2012AgreementMember" xlink:label="loc_cgen_May2012AgreementMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure_9"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_RoyaltyPercentageBasedOnFutureRevenues" xlink:label="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived" xlink:label="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_12"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_RoyaltyContingentObligations" xlink:label="loc_cgen_RoyaltyContingentObligations_13"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ParticipationRights" xlink:label="loc_cgen_ParticipationRights_14"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_RetainerFee" xlink:label="loc_cgen_RetainerFee_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_16"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AgreementStartDate" xlink:label="loc_cgen_AgreementStartDate_17"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AgreementTerminationDescription" xlink:label="loc_cgen_AgreementTerminationDescription_18"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ExtendLease" xlink:label="loc_cgen_ExtendLease_19"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ContingentFees" xlink:label="loc_cgen_ContingentFees_20"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection" xlink:label="loc_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_21"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_RoyaltyPercentage" xlink:label="loc_cgen_RoyaltyPercentage_22"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ResearchAndDevelopmentExpensesMilestonePayment" xlink:label="loc_cgen_ResearchAndDevelopmentExpensesMilestonePayment_23"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_OtherCommitmentsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_cgen_GovernmentAndOtherGrantsAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsAxis_1" xlink:to="loc_cgen_GovernmentAndOtherGrantsDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsDomain_1" xlink:to="loc_cgen_ResearchAndDevelopmentGrantOneMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_GovernmentAndOtherGrantsDomain_1" xlink:to="loc_cgen_May2012AgreementMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_srt_RangeAxis_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5" xlink:to="loc_srt_RangeMember_5" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5" xlink:to="loc_srt_MinimumMember_5" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5" xlink:to="loc_srt_MaximumMember_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_1" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_9" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9" xlink:to="loc_us-gaap_GuaranteeObligationsMaximumExposure_9" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9" xlink:to="loc_cgen_RoyaltyPercentageBasedOnFutureRevenues_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9" xlink:to="loc_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9" xlink:to="loc_us-gaap_RoyaltyExpense_12" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9" xlink:to="loc_cgen_RoyaltyContingentObligations_13" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9" xlink:to="loc_cgen_ParticipationRights_14" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9" xlink:to="loc_cgen_RetainerFee_15" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_16" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9" xlink:to="loc_cgen_AgreementStartDate_17" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9" xlink:to="loc_cgen_AgreementTerminationDescription_18" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9" xlink:to="loc_cgen_ExtendLease_19" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9" xlink:to="loc_cgen_ContingentFees_20" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9" xlink:to="loc_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection_21" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9" xlink:to="loc_cgen_RoyaltyPercentage_22" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_9" xlink:to="loc_cgen_ResearchAndDevelopmentExpensesMilestonePayment_23" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sesopnd">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AtMarketOfferingProgramMember" xlink:label="loc_cgen_AtMarketOfferingProgramMember_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AgreementMember" xlink:label="loc_cgen_AgreementMember_2"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_MasterClinicalAgreementMember" xlink:label="loc_cgen_MasterClinicalAgreementMember_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_CollaborativeArrangementsMember" xlink:label="loc_cgen_CollaborativeArrangementsMember_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_CollaborativeArrangementsTwoMember" xlink:label="loc_cgen_CollaborativeArrangementsTwoMember_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember" xlink:label="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_RegisteredDirectOfferingMember" xlink:label="loc_cgen_RegisteredDirectOfferingMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_10"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_UnderwritersMember" xlink:label="loc_cgen_UnderwritersMember_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_14"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_TwoThousandAndTwoThousandTenOptionsPlanMember" xlink:label="loc_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_20"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_24"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_25"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" xlink:label="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_26"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_27"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_28"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_29"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_30"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_31"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_32"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_33"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_34"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_35"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_36"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_37"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_38"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_39"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_40"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable" xlink:label="loc_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_41"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_42"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AgreementOptionAdditionalNumberOfSharesIssuable" xlink:label="loc_cgen_AgreementOptionAdditionalNumberOfSharesIssuable_43"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_44"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_45"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_PercentageOfClosingPrice" xlink:label="loc_cgen_PercentageOfClosingPrice_46"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_DeferredParticipationOfBMSInRAndDExpenses" xlink:label="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_47"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_48"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InitialOfferingPeriod" xlink:label="loc_us-gaap_InitialOfferingPeriod_49"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares" xlink:label="loc_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares_50"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_AggregateLimitOfOrdinarySharesPerCalendarYear" xlink:label="loc_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear_51"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering" xlink:label="loc_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering_52"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_53"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_StatementScenarioAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_1" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_AtMarketOfferingProgramMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_AgreementMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_MasterClinicalAgreementMember_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_CollaborativeArrangementsMember_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_CollaborativeArrangementsTwoMember_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_1" xlink:to="loc_cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember_6" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_9" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9" xlink:to="loc_cgen_RegisteredDirectOfferingMember_9" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9" xlink:to="loc_us-gaap_WarrantMember_10" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9" xlink:to="loc_cgen_UnderwritersMember_11" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_14" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_14" xlink:to="loc_us-gaap_PlanNameDomain_14" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_14" xlink:to="loc_cgen_TwoThousandAndTwoThousandTenOptionsPlanMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_17" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_17" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_17" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_17" xlink:to="loc_srt_DirectorMember_17" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_20" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_20" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20" xlink:to="loc_us-gaap_EmployeeStockMember_20" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_23" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_24" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_25" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_26" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_27" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_28" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_29" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_30" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_31" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_32" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_33" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_34" order="110" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_35" order="120" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_36" order="130" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_37" order="140" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_38" order="150" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_39" order="160" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_40" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable_41" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_42" order="190" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_cgen_AgreementOptionAdditionalNumberOfSharesIssuable_43" order="200" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_44" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_45" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_cgen_PercentageOfClosingPrice_46" order="230" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_cgen_DeferredParticipationOfBMSInRAndDExpenses_47" order="240" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_48" order="250" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_InitialOfferingPeriod_49" order="260" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares_50" order="270" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear_51" order="280" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering_52" order="290" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_53" order="300" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_EmployeesAndDirectorsMember" xlink:label="loc_cgen_EmployeesAndDirectorsMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_18"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_20"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract" xlink:label="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_22"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_23"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_25"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_26"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_cgen_EmployeesAndDirectorsMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_10" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_11" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_16" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_17" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_18" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_19" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_20" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_22" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_22" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_22" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract_22" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_23" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_25" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_25" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_25" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_26" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/cgen-sesosced">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6" order="0" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/IncomeTaxesNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear" xlink:label="loc_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIncomeTaxRefunds" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_14"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_NetOperatingLossCarryforwardExpired" xlink:label="loc_cgen_NetOperatingLossCarryforwardExpired_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_16"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ReducedCorporateIncomeTaxRate" xlink:label="loc_cgen_ReducedCorporateIncomeTaxRate_17"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1" xlink:to="loc_us-gaap_DomesticCountryMember_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_srt_RangeAxis_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5" xlink:to="loc_srt_RangeMember_5" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5" xlink:to="loc_srt_MinimumMember_5" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5" xlink:to="loc_srt_MaximumMember_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_9" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_IncomeTaxesPaid_11" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_ProceedsFromIncomeTaxRefunds_12" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_13" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_OperatingLossCarryforwards_14" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_cgen_NetOperatingLossCarryforwardExpired_15" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_16" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_cgen_ReducedCorporateIncomeTaxRate_17" order="80" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/IncomeTaxesEncouragementOfCapitalInvestmentsNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_TaxExemptPeriod" xlink:label="loc_cgen_TaxExemptPeriod_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ReducedTaxRate" xlink:label="loc_cgen_ReducedTaxRate_2"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_TaxRateOnDistributions" xlink:label="loc_cgen_TaxRateOnDistributions_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_PeriodSinceApprovalWasGranted" xlink:label="loc_cgen_PeriodSinceApprovalWasGranted_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_PeriodSinceEnterpriseBeganOperating" xlink:label="loc_cgen_PeriodSinceEnterpriseBeganOperating_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_cgen_TaxExemptPeriod_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_cgen_ReducedTaxRate_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_cgen_TaxRateOnDistributions_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_cgen_PeriodSinceApprovalWasGranted_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_cgen_PeriodSinceEnterpriseBeganOperating_5" order="40" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_DeferredIncomeTaxRightOfUseAssets" xlink:label="loc_cgen_DeferredIncomeTaxRightOfUseAssets_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_DeferredIncomeTaxLeaseLiabilities" xlink:label="loc_cgen_DeferredIncomeTaxLeaseLiabilities_5"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_9"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_cgen_DeferredIncomeTaxRightOfUseAssets_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_cgen_DeferredIncomeTaxLeaseLiabilities_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/GeographicInformationAndMajorCustomersDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_SegmentReportingGeographicAreaTable" xlink:label="loc_cgen_SegmentReportingGeographicAreaTable_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_SegmentReportingGeographicAreaAxis" xlink:label="loc_cgen_SegmentReportingGeographicAreaAxis_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_SegmentReportingGeographicAreaDomain" xlink:label="loc_cgen_SegmentReportingGeographicAreaDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IL" xlink:label="loc_country_IL_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_12"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_CustomerOneMember" xlink:label="loc_cgen_CustomerOneMember_12"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_SegmentReportingGeograhicAreaLineItems" xlink:label="loc_cgen_SegmentReportingGeograhicAreaLineItems_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_18"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_cgen_SegmentReportingGeographicAreaTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_SegmentReportingGeographicAreaTable_1" xlink:to="loc_cgen_SegmentReportingGeographicAreaAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_SegmentReportingGeographicAreaAxis_1" xlink:to="loc_cgen_SegmentReportingGeographicAreaDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_SegmentReportingGeographicAreaDomain_1" xlink:to="loc_srt_EuropeMember_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_SegmentReportingGeographicAreaDomain_1" xlink:to="loc_country_IL_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_SegmentReportingGeographicAreaDomain_1" xlink:to="loc_country_US_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_SegmentReportingGeographicAreaTable_1" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_6" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6" xlink:to="loc_us-gaap_SalesRevenueNetMember_6" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_SegmentReportingGeographicAreaTable_1" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_9" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_9" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_9" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_9" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_9" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_SegmentReportingGeographicAreaTable_1" xlink:to="loc_srt_MajorCustomersAxis_12" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_12" xlink:to="loc_srt_NameOfMajorCustomerDomain_12" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_12" xlink:to="loc_cgen_CustomerOneMember_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_SegmentReportingGeographicAreaTable_1" xlink:to="loc_cgen_SegmentReportingGeograhicAreaLineItems_15" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_SegmentReportingGeograhicAreaLineItems_15" xlink:to="loc_us-gaap_NumberOfOperatingSegments_15" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_SegmentReportingGeograhicAreaLineItems_15" xlink:to="loc_us-gaap_Revenues_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_SegmentReportingGeograhicAreaLineItems_15" xlink:to="loc_us-gaap_NoncurrentAssets_17" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_SegmentReportingGeograhicAreaLineItems_15" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_18" order="30" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaap_InterestAndDebtExpense_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfOtherAssets" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_FinancialIncomeExpenseNet" xlink:label="loc_cgen_FinancialIncomeExpenseNet_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_us-gaap_InvestmentIncomeInterest_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_us-gaap_InterestAndDebtExpense_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherAssets_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_cgen_FinancialIncomeExpenseNet_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/RelatedPartyBalancesAndTransactionsDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaap_CostsAndExpensesRelatedParty_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_CostsAndExpensesRelatedParty_2" order="10" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract" xlink:label="loc_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3" xlink:to="loc_us-gaap_EarningsPerShareBasic_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3" xlink:to="loc_us-gaap_EarningsPerShareDiluted_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/SUBSEQUENTEVENTS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/SubsequentEventsNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_SalesAgreementWithSVBSecuritiesLLCMember" xlink:label="loc_cgen_SalesAgreementWithSVBSecuritiesLLCMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_7"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock" xlink:label="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_7"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1" xlink:to="loc_us-gaap_SubsequentEventMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4" xlink:to="loc_cgen_SalesAgreementWithSVBSecuritiesLLCMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventLineItems_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_7" xlink:to="loc_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/LEASESNarrative">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaap_LesseeDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_2"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_IncreaseOperatingLeaseRightOfUseAsset" xlink:label="loc_cgen_IncreaseOperatingLeaseRightOfUseAsset_3"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_DecreaseOperatingLeaseLiability" xlink:label="loc_cgen_DecreaseOperatingLeaseLiability_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaap_SubleaseIncome_6"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:label="loc_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_7"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeasePayments_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_cgen_IncreaseOperatingLeaseRightOfUseAsset_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_cgen_DecreaseOperatingLeaseLiability_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_us-gaap_SubleaseIncome_6" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeDisclosureAbstract_0" xlink:to="loc_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities_7" order="60" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="cgen-20221231.xsd#cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember" xlink:label="loc_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:to="loc_cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4" xlink:to="loc_us-gaap_Depreciation_6" order="20" use="optional"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>cgen_img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cgen_img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1H817AI9@  24DJ  @    % !H!!0 !
M    2@   !L!!0 !    4@   "@! P !     @   #$! @ -    6@   #(!
M @ 4    :    'P   !@     0   &     !    1TE-4" R+C$P+C$P   R
M,#$Y.C$R.C$W(#$V.C4V.C(S  @   $$  $   #>     0$$  $      0
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MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
M   ! @,$!08'" D*"__$ +41  (! @0$ P0'!00$  $"=P ! @,1! 4A,082
M05$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X
M.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3
ME)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+C
MY.7FY^CIZO+S]/7V]_CY^O_:  P# 0 "$0,1 #\ ]_HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BHY)1&,D''M6?-JRC(1
M#GW'_P!>N/%8_#X57K2L7"G*>R-/(J":[BB'WT)]-PK%DOYY"?FVC_9)']:K
M,S,<LQ/U-?-8OBNFE;#QN^[.J&#?VF:<^JODK&H'N"#_ $JFUU-*V6;]!5>G
MIWKYRKFV+Q-3WYNW;9?@=2HP@M$=31117ZH>0%%%% !1110 4444 %%%% !1
M110 4444 %%%% !136=5&68 >YJO+?P1#[P8^Q!_K6-7$4J*O4DD4HN6R+5-
M:14&6.*R)M6+#"(/^!#_ .O6?)*TK;B!^%?/8SB?#TM**YW]R.F&$D_BT-F;
M5(H^$^8_B/Z51FU2:3(7Y1^!_I5&BOF,5Q#CJ]TI<J\O\]SJAAJ<>@]Y7D.7
M.3]*9117BSG*;YI.[-TDM@HHHJ0"GIWIE/3O6M'XT)['4T445^RGB!1110 4
M444 %%%% !1110 449J.2:.,99U'U.*F4XQ5Y.PTKDE%9MQJ@3A K>X:L^6_
MGE&"V!Z8'^%>)B^(<'AFXW<GY?YF\,-.6NQN27,<6=S8Q[&J,VK)T1<^^2/Z
M5CDDG)HKYK%<4XFII1BHK[W_ )'5#"06^I/-=2RD_.X'IN-0$D]3FBBOG:U>
MK6ES5)79TJ*2L@HHHK$84444 %%* 3T!/TIX@E;I$_\ WR:TC2J3^%-B;2W(
MZ*MII\K@9#K_ , -6H](S]Z0_P#?/_UZ]*CDF.K?##[VC.5>G'=F53T[ULII
M,"_>^;\Q_6IUL+=1@)^IKU*'"V+YN:<HK[_\C&6+AT+-%%%?H!YP4444 %%%
M(6 &30 M%5)[^&'^+)],'_"J4VKL>(UQ[Y_^M7F8K.,%AKJ<U?LM6:PH3ELC
M4>:.,99U'U-5)=5A3(7+'VP?ZUD274TOWVS^ J&OF,9Q54D[8:-EW9UPPB7Q
M%Z75)G/RX4?B/ZU4>:20Y9V/U-,IRHS_ '1FOG:V-Q>*E:<F_(Z8TX0V0VBI
MULYW^['G\14Z:5.W7C\O\:=+*\95^"D_NM^8G5A'=E&BM5-'/\4G_CO_ ->I
MUTF$?>Y_/_&O1I<-8^>\5'U?^5S-XJFNIBA';[JD_04];:9ND3_]\FMY+&"/
MHGZFIEC1>@Q^->K1X2_Y^S^[_AC*6,_E1@KIUPQ^[CZ@_P"%3II$A^\RC\3_
M (5M45Z=+AG P^)-_,Q>*J/8S$TB,?>9OP/_ -:ITTVW7^'/U _PJY17HTLI
MP=+X::,W6F]V0K:0+TB3_OD5((T'10/PIU%=L*5.&D8I&;DWN&****T$%%%%
M !13&<+U.*@DN)"?W05OK652M"FM2E%LLD@=:ADNX8QEI%_ BJACNYOO[D'^
MR^/ZT+IB$_.TA^K UY\\7BIZ4*7SEI^!HH07Q,;+JR#B-23[C_Z]4)9YIS]P
M?@#6PNGVZ_P _4#_  J=;>%>D2?]\BO.K99F&+TKU4EV2-(U:</A1SBVTS=(
MG_[Y-3+IUPW\./J#_A70!5'10/H*7%9TN%,,OXDFQO&2Z(Q$TB0GYF7\"?\
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M?:+_ +X/_P 54MM\0Y)+F))8(U1G 8A,8&>?XJ /0:*S[B^<Z0;VS"R'RO,
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MGJ:YG_A*IDT"&]E$*W$V[8NUMIP^#W]/>H]-\3:C_:$=MJL4$ E(5-@)))(
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M>AK5\" #2">Y_P#BFK>ATJSM[1[6*"-8G!# (!NR,'/%26=A;V$7EV\81?0
M#^7UH Y2[4OXT1!U:P '_?RJ^BZS9Z+>WUM?/Y;M>2N#@GCIV!]#79'3K8W@
MNC&OG!=@;:,XSG&<9ZU5N?#VFW5P9Y+:/S#U(1>3Z]/>@#"\%3I<W>I31G*M
MY6/R85V-4[+3+33M_P!EA2/?C(50.F?0>]7* "BBB@ HHHH **** /_9_^("
ML$E#0U]04D]&24Q%  $!   "H&QC;7,$,   ;6YT<E)'0B!865H@!^, #  1
M  D #@ !86-S<$U31E0                                  /;6  $
M    TRUL8VUS
M               -9&5S8P   2    ! 8W!R=    6     V=W1P=    9@
M   48VAA9    :P    L<EA96@   =@    48EA96@   >P    49UA96@
M @     4<E120P   A0    @9U120P   A0    @8E120P   A0    @8VAR
M;0   C0    D9&UN9    E@    D9&UD9    GP    D;6QU8P         !
M    #&5N55,    D    ' !' $D 30!0 "  8@!U &D ; !T "T :0!N "
M<P!2 $< 0FUL=6,          0    QE;E53    &@   !P 4 !U &( ; !I
M &, ( !$ &\ ;0!A &D ;@  6%E:(        /;6  $     TRUS9C,R
M   !#$(   7>___S)0  !Y,  /V0___[H?___:(   /<  # ;EA96B
M  !OH   ./4   .06%E:(        "2?   /A   ML1865H@        8I<
M +>'   8V7!A<F$       ,    "9F8  /*G   -60  $]    I;8VAR;0
M     P    "CUP  5'P  $S-  "9F@  )F<   ]<;6QU8P         !
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MKY].LZ!]>G6>V.6^_:KH2A5#Z=:S0#K6P'>:UK6N?__$ "81  (! P,#! ,
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M-^%RE(BI<U2?O_R5\LP'M,<XXS9)8X!ZW5UT^)>6WU?C'\\_X7*7=A09=_!
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M.%-,L^M,:0&)Z>5%-[,RBZDW;0T0,5IM!P(; T04 9-FLI0!P>3_V@ , P$
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2X=''P0"*(X7OA(YX&![?)__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130165356464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001119774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Compugen Ltd<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">L3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Azrieli Center<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">26 Harokmim Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Building D<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Holon<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">5885849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary shares, par value NIS 0.01 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CGEN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of Exchange on which Security is Registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">86,624,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">U.S. GAAP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KOST FORER GABBAY & KASIERER<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tel-Aviv, Israel<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm Id</a></td>
<td class="text">1281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Alberto Sessa<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Azrieli Center<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">26 Harokmim Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Building D<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Holon<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">5885849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">3-765-8585<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelFaxNumber', window );">Contact Personnel Fax Number</a></td>
<td class="text">972-3-765-8555<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelFaxNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fax Number of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelFaxNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130169163632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 11,059<span></span>
</td>
<td class="nump">$ 7,801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">362<span></span>
</td>
<td class="nump">713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Short-term bank deposits</a></td>
<td class="nump">72,287<span></span>
</td>
<td class="nump">109,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other accounts receivable and prepaid expenses</a></td>
<td class="nump">2,417<span></span>
</td>
<td class="nump">5,460<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">86,125<span></span>
</td>
<td class="nump">123,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Long-term prepaid expenses</a></td>
<td class="nump">1,899<span></span>
</td>
<td class="nump">1,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_SeverancePayFundNoncurrent', window );">Severance pay fund</a></td>
<td class="nump">2,794<span></span>
</td>
<td class="nump">3,125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use asset</a></td>
<td class="nump">1,826<span></span>
</td>
<td class="nump">2,247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,532<span></span>
</td>
<td class="nump">1,658<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non- current assets</a></td>
<td class="nump">8,051<span></span>
</td>
<td class="nump">8,941<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">94,176<span></span>
</td>
<td class="nump">132,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Trade payables</a></td>
<td class="nump">1,773<span></span>
</td>
<td class="nump">4,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses', window );">Short-term deferred participation in R&amp;D expenses</a></td>
<td class="nump">325<span></span>
</td>
<td class="nump">3,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current maturity of operating lease liability</a></td>
<td class="nump">613<span></span>
</td>
<td class="nump">768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities', window );">Other accounts payable and accrued expenses</a></td>
<td class="nump">9,208<span></span>
</td>
<td class="nump">8,078<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">11,919<span></span>
</td>
<td class="nump">17,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>NON- CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses', window );">Long-term deferred participation in R&amp;D expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liability</a></td>
<td class="nump">1,312<span></span>
</td>
<td class="nump">1,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsLiabilityNoncurrent', window );">Accrued severance pay</a></td>
<td class="nump">3,265<span></span>
</td>
<td class="nump">3,677<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">4,577<span></span>
</td>
<td class="nump">8,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENT LIABILITIES</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares of NIS 0.01 par value: 200,000,000 shares authorized at December 31, 2022 and 2021; 86,624,643 and 86,433,432 shares issued and outstanding at December 31, 2022 and 2021, respectively</a></td>
<td class="nump">240<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">533,213<span></span>
</td>
<td class="nump">528,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(455,773)<span></span>
</td>
<td class="num">(422,079)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">77,680<span></span>
</td>
<td class="nump">106,693<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 94,176<span></span>
</td>
<td class="nump">$ 132,163<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long term deferred participation in R&amp;amp;D expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_SeverancePayFundNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Monthly deposits in externally managed funds which primarily cover Israeli law severance pay liability of one month's salary for each year of employment upon the retirement or death of an employee or termination of employment without a valid legal reason.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_SeverancePayFundNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short term deferred participation in R&amp;amp;D expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.5)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement that is payable after one year (or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=6410138&amp;loc=d3e79708-111665<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -SubTopic 10<br> -Section 25<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6410138&amp;loc=d3e79691-111665<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130165215744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - &#8362; / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value</a></td>
<td class="nump">&#8362; 0.01<span></span>
</td>
<td class="nump">&#8362; 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="nump">86,624,643<span></span>
</td>
<td class="nump">86,433,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding</a></td>
<td class="nump">86,624,643<span></span>
</td>
<td class="nump">86,433,432<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130165117648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">975<span></span>
</td>
<td class="nump">680<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">6,525<span></span>
</td>
<td class="nump">5,320<span></span>
</td>
<td class="nump">1,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses, net</a></td>
<td class="nump">30,648<span></span>
</td>
<td class="nump">28,694<span></span>
</td>
<td class="nump">22,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDevelopment', window );">Marketing and business development expenses</a></td>
<td class="nump">932<span></span>
</td>
<td class="nump">842<span></span>
</td>
<td class="nump">871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">10,319<span></span>
</td>
<td class="nump">10,858<span></span>
</td>
<td class="nump">9,805<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">41,899<span></span>
</td>
<td class="nump">40,394<span></span>
</td>
<td class="nump">33,436<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(35,374)<span></span>
</td>
<td class="num">(35,074)<span></span>
</td>
<td class="num">(31,496)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_FinancialIncomeExpenseNet', window );">Financial and other income, net</a></td>
<td class="nump">1,738<span></span>
</td>
<td class="nump">871<span></span>
</td>
<td class="nump">1,798<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxes on income</a></td>
<td class="num">(33,636)<span></span>
</td>
<td class="num">(34,203)<span></span>
</td>
<td class="num">(29,698)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Taxes on income</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (33,694)<span></span>
</td>
<td class="num">$ (34,203)<span></span>
</td>
<td class="num">$ (29,698)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share</a></td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (0.41)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share</a></td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (0.41)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (33,694)<span></span>
</td>
<td class="num">$ (34,203)<span></span>
</td>
<td class="num">$ (29,698)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of ordinary shares used in computing basic net loss per share</a></td>
<td class="nump">86,555,628<span></span>
</td>
<td class="nump">84,203,971<span></span>
</td>
<td class="nump">79,591,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of ordinary shares used in computing diluted net loss per share</a></td>
<td class="nump">86,555,628<span></span>
</td>
<td class="nump">84,203,971<span></span>
</td>
<td class="nump">79,591,187<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_FinancialIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Income (Expense), Net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_FinancialIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business development involves the development of products and services, their delivery, design and their implementation. Business development includes a number of techniques designed to grow an economic enterprise. Such techniques include, but are not limited to, assessments of marketing opportunities and target markets, intelligence gathering on customers and competitors, generating leads for possible sales, follow-up sales activity, formal proposal writing and business model design. Business development involves evaluating a business and then realizing its full potential, using such tools as marketing, sales, information management and customer service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130168898416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Ordinary shares [Member]</div></th>
<th class="th"><div>Additional paid-in capital [Member]</div></th>
<th class="th"><div>Accumulated deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 187<span></span>
</td>
<td class="nump">$ 396,312<span></span>
</td>
<td class="num">$ (358,178)<span></span>
</td>
<td class="nump">$ 38,321<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2019</a></td>
<td class="nump">67,922,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Options exercised</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">15,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,915<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised, shares</a></td>
<td class="nump">3,070,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_IssuanceOfSharesAndWarrantsNetValue', window );">Issuance of shares and warrants, net</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">74,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_IssuanceOfSharesAndWarrantsNetShares', window );">Issuance of shares and warrants, net, shares</a></td>
<td class="nump">8,816,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_StockIssuedDuringPeriodValueWarrantsExercised', window );">Warrants exercised</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">18,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,325<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_NumberOfWarrantsExercised', window );">Warrants exercised, shares</a></td>
<td class="nump">3,866,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees', window );">Stock-based compensation relating to options issued to employees, directors and non employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,698)<span></span>
</td>
<td class="num">(29,698)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 231<span></span>
</td>
<td class="nump">507,427<span></span>
</td>
<td class="num">(387,876)<span></span>
</td>
<td class="nump">119,782<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2020</a></td>
<td class="nump">83,675,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Exercise of options and ESPP shares</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Exercise of options and ESPP shares, shares</a></td>
<td class="nump">335,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_StockIssuedDuringPeriodValueWarrantsExercised', window );">Warrants exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_NumberOfWarrantsExercised', window );">Warrants exercised, shares</a></td>
<td class="nump">89,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of shares, net</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">14,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,958<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares, net, shares</a></td>
<td class="nump">2,332,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees', window );">Stock-based compensation relating to options issued to employees, directors and non employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34,203)<span></span>
</td>
<td class="num">(34,203)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 239<span></span>
</td>
<td class="nump">528,533<span></span>
</td>
<td class="num">(422,079)<span></span>
</td>
<td class="nump">$ 106,693<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="nump">86,433,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,433,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Exercise of options and ESPP shares</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Exercise of options and ESPP shares, shares</a></td>
<td class="nump">191,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees', window );">Stock-based compensation relating to options issued to employees, directors and non employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,694)<span></span>
</td>
<td class="num">(33,694)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 240<span></span>
</td>
<td class="nump">$ 533,213<span></span>
</td>
<td class="num">$ (455,773)<span></span>
</td>
<td class="nump">$ 77,680<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">86,624,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,624,643<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_IssuanceOfSharesAndWarrantsNetShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares and warrants, net, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_IssuanceOfSharesAndWarrantsNetShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_IssuanceOfSharesAndWarrantsNetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares and warrants, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_IssuanceOfSharesAndWarrantsNetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_NumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_NumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation relating to options issued to employees and directors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130169073312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (33,694)<span></span>
</td>
<td class="num">$ (34,203)<span></span>
</td>
<td class="num">$ (29,698)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">4,328<span></span>
</td>
<td class="nump">4,276<span></span>
</td>
<td class="nump">2,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">482<span></span>
</td>
<td class="nump">461<span></span>
</td>
<td class="nump">715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_SeverancePayNet', window );">Increase (decrease) in severance pay, net</a></td>
<td class="num">(81)<span></span>
</td>
<td class="num">(101)<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss (gain) from property and equipment sales and disposals</a></td>
<td class="nump">12<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement', window );">Decrease (increase) in interest receivables from short-term bank deposits</a></td>
<td class="num">(584)<span></span>
</td>
<td class="nump">469<span></span>
</td>
<td class="num">(532)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Decrease (increase) in trade receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Decrease (increase) in other accounts receivable and prepaid expenses</a></td>
<td class="nump">3,043<span></span>
</td>
<td class="num">(2,802)<span></span>
</td>
<td class="num">(1,613)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Decrease (increase) in long-term prepaid expenses</a></td>
<td class="nump">12<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="num">(1,187)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Decrease in operating lease right of use asset</a></td>
<td class="nump">658<span></span>
</td>
<td class="nump">525<span></span>
</td>
<td class="nump">475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase (decrease) in trade payables and other accounts payable and accrued expenses</a></td>
<td class="num">(1,601)<span></span>
</td>
<td class="nump">3,367<span></span>
</td>
<td class="nump">3,817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses', window );">Increase (decrease) in deferred participation in R&amp;D expenses</a></td>
<td class="num">(6,019)<span></span>
</td>
<td class="nump">3,708<span></span>
</td>
<td class="num">(829)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Decrease in operating lease liability</a></td>
<td class="num">(1,062)<span></span>
</td>
<td class="num">(416)<span></span>
</td>
<td class="num">(412)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(34,506)<span></span>
</td>
<td class="num">(22,750)<span></span>
</td>
<td class="num">(28,320)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from maturity of short-term bank deposits</a></td>
<td class="nump">114,445<span></span>
</td>
<td class="nump">136,850<span></span>
</td>
<td class="nump">70,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Investment in short-term bank deposits</a></td>
<td class="num">(76,900)<span></span>
</td>
<td class="num">(129,945)<span></span>
</td>
<td class="num">(152,350)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(477)<span></span>
</td>
<td class="num">(292)<span></span>
</td>
<td class="num">(166)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisposals', window );">Costs of disposal of property and equipment</a></td>
<td class="num">(10)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">37,060<span></span>
</td>
<td class="nump">6,616<span></span>
</td>
<td class="num">(82,172)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of ordinary shares, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,958<span></span>
</td>
<td class="nump">74,147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">425<span></span>
</td>
<td class="nump">18,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock-based awards</a></td>
<td class="nump">353<span></span>
</td>
<td class="nump">1,455<span></span>
</td>
<td class="nump">15,991<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">353<span></span>
</td>
<td class="nump">16,838<span></span>
</td>
<td class="nump">108,463<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">2,907<span></span>
</td>
<td class="nump">704<span></span>
</td>
<td class="num">(2,029)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the beginning of the year</a></td>
<td class="nump">8,514<span></span>
</td>
<td class="nump">7,810<span></span>
</td>
<td class="nump">9,839<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash at the end of the year</a></td>
<td class="nump">11,421<span></span>
</td>
<td class="nump">8,514<span></span>
</td>
<td class="nump">7,810<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchase of property and equipment</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange for operating lease liability</a></td>
<td class="nump">237<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(194)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Cash paid (received) during the year for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_InterestPaidReceivedNet', window );">Interest payments received from short-term bank deposits and cash equivalents</a></td>
<td class="nump">852<span></span>
</td>
<td class="nump">1,364<span></span>
</td>
<td class="nump">1,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">11,059<span></span>
</td>
<td class="nump">7,801<span></span>
</td>
<td class="nump">7,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">362<span></span>
</td>
<td class="nump">713<span></span>
</td>
<td class="nump">667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 11,421<span></span>
</td>
<td class="nump">$ 8,514<span></span>
</td>
<td class="nump">$ 7,810<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization Of Cash Consideration Of Research And Development Funding Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in deferred participation in R and D expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in operating lease right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_InterestPaidReceivedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest payments paid (received) from bank short-term deposits and cash equivalents</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_InterestPaidReceivedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payments for Proceeds from Sales of equipment Investing Activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_SeverancePayNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Severance pay, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_SeverancePayNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In right of use asset and operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisposals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisposals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130166791328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">GENERAL</a></td>
<td class="text">
    <div>
      <div>
        <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 1: -</span><span>&#160;<span style="font-weight:bold">GENERAL</span></span></span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>a.</span></span></span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Compugen Ltd. (the &#8220;Company&#8221;) is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Compugen&#8217;s innovative immuno-oncology pipeline consists of three clinical stage programs, targeting immune checkpoints Compugen discovered computationally by COM701, COM902 and rilvegostomig. The Company&#8217;s lead product candidates, COM701, a potential first-in-class anti-PVRIG antibody, and COM902, a potential best-in-class therapeutic anti-TIGIT antibody are in Phase 1 clinical trials and have been evaluated, for the treatment of solid tumors as a monotherapy and in combination of dual (PVRIG/PD-1, PVRIG/TIGIT) and triple (PVRIG/PD-1/TIGIT) blockade. As part of Phase 1 clinical trials for the Company&#8217;s lead product candidates, COM701, the Company evaluated COM701 as a monotherapy and under clinical collaboration with Bristol Myers Squibb Company in combination with nivolumab &#177; Bristol Myers Squibb investigational anti-TIGIT, BMS-986207. Following the termination of the Company&#8217;s collaboration with Bristol Myers Squibb Company, these combination studies are being wound down while the monitoring of patients on study treatment is ongoing. Rilvegostomig, a novel anti PD-1/TIGIT bispecific antibody with a TIGIT specific component that is derived from Compugen&#8217;s COM902 antibody, is being developed by AstraZeneca pursuant to an exclusive license agreement between Compugen and AstraZeneca and is in Phase 2 clinical trial in patients with advanced or metastatic non-small cell lung and locally advanced or metastatic gastric cancer. Compugen&#8217;s therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance. The Company&#8217;s most advanced early-stage program, COM503, is a potential first-in-class, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, thereby releasing the natural IL-18 into the tumor microenvironment to inhibit cancer growth. COM503 is &#160;being advanced into IND enabling studies. Compugen&#8217;s business model is to selectively enter into collaborations for its novel targets and drug product candidates at various stages of research and development under various revenue-sharing arrangements. Integrating cutting edge computational capabilities with ground-breaking immuno-oncology research and drug development expertise is the Company&#8217;s differentiator and has enabled the advancement of three drug targets from computer prediction through successful preclinical studies to the clinic.</span></span></span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">b.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company is headquartered in Holon, Israel. Its clinical development activities are headed from its United States subsidiary, Compugen USA, Inc, located in San Francisco, CA.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">c.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has incurred losses in the amount of $33,694 during the year ended December 31, 2022, has an accumulated deficit of $455,773 as of December 31, 2022 and has an accumulated negative cash flow from operating activities in the amount of $34,506 for the year ended December 31, 2022. <span style="color:rgb(0, 0, 0)">The Company believes that its existing capital resources will be adequate to satisfy its expected liquidity requirements at the current level of yearly expenditures at least </span>twelve months from the reporting date<span style="color:rgb(0, 0, 0)">.</span></span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div/>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">d.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On August 5, 2013, the Company entered into a Research and Development Collaboration and License Agreement (<span style="color:rgb(0, 0, 0)">&#8220;</span>Bayer Agreement<span style="color:rgb(0, 0, 0)">&#8220;</span>) with Bayer Pharma AG (<span style="color:rgb(0, 0, 0)">&#8220;</span>Bayer<span style="color:rgb(0, 0, 0)">&#8220;</span>) for the research, development, and commercialization of antibody-based therapeutics against two novel, Compugen-discovered immune checkpoint regulators.</span></span></div>
              </td>
            </tr>
            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">&#160;</td>
            </tr>

        </table>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under the terms of the Bayer Agreement, the Company received an upfront payment of $10,000, and,<span style="color:rgb(0, 0, 0)"> following the return of the CGEN 15022 program in 2017,</span> the Company is eligible to receive an aggregate amount of over $250,000 in potential milestone payments for <span style="color:rgb(0, 0, 0)">Bapotulimab (formerly known as BAY1905254)</span>, not including aggregate milestone payments of $23,200 received to date. Additionally, the Company is eligible to receive mid to high single digit royalties on global net sales of any approved products under the collaboration.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant to the terms of Bayer Agreement, <span style="color:rgb(0, 0, 0)">Bapotulimab</span> program was transferred to Bayer&#8217;s full control for further preclinical and clinical development activities, and worldwide commercialization under milestone and royalty bearing license from Compugen.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On November 29, 2022, Bayer notified the Company that it has resolved to terminate, effective as of February 27, 2023, the Bayer Agreement.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:54pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:31.5pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">e.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Effective March 30, 2018, the Company entered into an exclusive license agreement with MedImmune Limited, the global biologics research and development arm of AstraZeneca (&#8220;AstraZeneca&#8221;) to enable the development of bi-specific and multi-specific immuno-oncology antibody products. Under the terms of the agreement, Compugen provided an exclusive license to AstraZeneca for the development of bi-specific and multi-specific antibody products derived from COM902. AstraZeneca has the right to create multiple products under this license and will be solely responsible for all research, development, and commercial activities under the agreement. Compugen received a $10,000 upfront payment, and received $15,500 milestone payments out of up to $200,000 it is eligible to receive in development, regulatory and commercial milestones for the first product in addition to tiered royalties on future product sales. If additional products are developed, additional milestones and royalties would be due to Compugen for each product.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:54pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:31.5pt;vertical-align:top;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">f.</span></span></td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement (the &#8220;Agreement&#8221;) with Bristol-Myers Squibb Company (&#8220;Bristol-Myers Squibb&#8221;) to evaluate the safety and tolerability of Compugen&#8217;s COM701 in combination with Bristol-Myers Squibbs&#8217; PD-1 immune checkpoint inhibitor Opdivo&#174; (nivolumab), in patients with advanced solid tumors.</span></span></div>
              </td>
            </tr>

        </table>
        <div style="text-align:justify;margin-left:85.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div/>
        <div style="text-align:justify;text-indent:0pt;margin-left:85.5pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Pursuant to the Agreement, Compugen was responsible for and sponsored the ongoing two-part Phase 1 trial, which included the evaluation of the combination of COM701 and Opdivo&#174;. The collaboration was also designed to address potential future combinations, including trials sponsored by Bristol-Myers Squibb to investigate combined inhibition of checkpoint mechanisms, such as PVRIG and TIGIT. Bristol-Myers Squibb and Compugen each supplied the other company with its own compound for the other party&#8217;s study, and otherwise each party was responsible for all costs associated with the study that it is conducting.</span><br/><br/><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In conjunction with the signing of the Agreement in October 2018, Bristol-Myers Squibb made a $12,000 investment in Compugen, see Note 8b.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:85.5pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On February 14, 2020, the Agreement was amended to include a triple combination clinical trial to evaluate the safety, tolerability and antitumor activity of COM701 in combination with Opdivo&#174; (nivolumab), and Bristol-Myers Squibb&#8217;s investigational antibody targeting TIGIT known as BMS-986207, in patients with advanced solid tumors, instead of the planned expansion of the combined therapy study designed to evaluate the dual combination of COM701 and Opdivo&#174;.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:85.5pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Pursuant to the Agreement, as amended, the Company sponsored the two-part Phase 1/2 trial, which evaluates the triple combination of COM701, Opdivo&#174; and BMS-986207, in patients with advanced solid tumors where Bristol-Myers Squibb provided Opdivo&#174; and BMS-986207 at no cost to the Company.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;text-indent:-0.45pt;margin-left:85.5pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As part of the amended Agreement, it was agreed that the Company will complete the dose escalation arm of the dual combination of COM701 with Opdivo<sup style="vertical-align:text-top;line-height:1;font-size:smaller">&#174;</sup> under the ongoing Phase 1 study and will not continue the expansion cohorts of the dual combination. However, on February 19, 2021, the Agreement was further amended to include an expansion of the Phase 1 combination study designed to evaluate the dual combination of COM701 and Opdivo&#174; in patients with advanced solid tumors, where the Company is responsible for and sponsored the expansion cohort and Bristol Myers Squibb provided Opdivo&#174; at no cost to the Company for this study.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;text-indent:-0.45pt;margin-left:85.5pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On November 10, 2021, the Agreement was further amended to establish a joint steering committee (alongside the existing joint development committee which acts at an operational level) to facilitate strategic oversight and guidance for the programs run under the collaboration.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;text-indent:0pt;margin-left:85.5pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In conjunction with the signing of the amendment to the Agreement in November 2021, Bristol-Myers Squibb made a $20,000 investment in Compugen, see Note 8b.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;text-indent:-0.45pt;margin-left:85.5pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On August 3, 2022, the Company and Bristol-Myers Squibb entered into a letter agreement pursuant to which the Agreement, as amended thereafter, was terminated as of such date.</span></span></div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130166593632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-weight:bold">NOTE 2: -&#160;</span><span style="font-weight:bold">SIGNIFICANT ACCOUNTING POLICIES</span></span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:56.7pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;).</span></span></p>

      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">a.<span style="padding-left:22.06pt">Use of estimates:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company&#8217;s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</span></span></p>


      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">b.<span style="padding-left:22.5pt">Financial statements in U.S. dollars:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The reporting and functional currency of the Company is the U.S. dollar, as the Company&#8217;s management believes that the U.S. dollar is the primary currency of the economic environment in which the Company and Compugen USA, Inc. have operated and expect to continue to operate in the foreseeable future.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts denominated in currencies other than the dollar are re-measured into dollars in accordance with ASC No. 830, &#8220;Foreign Currency Matters&#8221;. All transaction gains and losses from the re-measurement of monetary balance sheet items are reflected in the consolidated statement of comprehensive loss as financial income or expenses, as appropriate.</span></span></p>


      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">c.<span style="padding-left:22.06pt">Basis of consolidation:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The consolidated financial statements include the accounts of the Company and Compugen USA, Inc. Intercompany transactions and balances have been eliminated upon consolidation.</span></span></p>


      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">d.<span style="padding-left:22.5pt">Cash equivalents:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition.</span></span></p>


      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">e.<span style="padding-left:22.06pt">Restricted cash:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Restricted cash is held in interest bearing saving accounts which are used as a security for the Company&#8217;s Israeli facility leasehold&#160;and leased cars fueling bank guarantees and credit card security for Compugen USA, Inc.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
      <div/>


      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">f.<span style="padding-left:22.17pt">Short-term bank deposits:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Bank deposits with maturities of more than three months but less than one year are included in short-term bank deposits. Such short-term bank deposits are stated at cost which approximates market values.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The short-term bank deposits as of December 31, 2022&#160;and 2021&#160;are in U.S. dollars and bear an annual weighted average interest rate of 4.84% and 0.77%, respectively.</span></span></p>


      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">g.<span style="padding-left:22.5pt">Property and equipment, net:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates:</span></span></p>
      <div style="margin-left:85.05pt">

          <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

              <tr>
                <td style="vertical-align:bottom;width:50%">&#160;</td>
                <td style="vertical-align:bottom;width:2%">&#160;</td>
                <td style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom;width:48%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">%</span></span></strong></p>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:50%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
                </td>
                <td style="vertical-align:bottom;width:2%">&#160;</td>
                <td style="vertical-align:bottom;width:48%">&#160;</td>
              </tr>


              <tr style="background-color:#cceeff">
                <td style="vertical-align:bottom;width:50%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Computers, software and related equipment</span></span></p>
                </td>
                <td style="vertical-align:bottom;width:2%">&#160;</td>
                <td style="vertical-align:bottom;width:48%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">33</span></span></p>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:50%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Laboratory equipment and office furniture</span></span></p>
                </td>
                <td style="vertical-align:bottom;width:2%">&#160;</td>
                <td style="vertical-align:bottom;width:48%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">6 - 20 (mainly 20)</span></span></p>
                </td>
              </tr>
              <tr style="background-color:#cceeff">
                <td style="vertical-align:bottom;width:50%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Leasehold improvements</span></span></p>
                </td>
                <td style="vertical-align:bottom;width:2%">&#160;</td>
                <td style="vertical-align:bottom;width:48%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Shorter of the term of the lease or useful life</span></span></p>
                </td>
              </tr>

          </table>

      </div>


      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">h.<span style="padding-left:22.5pt">Impairment of long-lived assets:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The long-lived assets of the Company and Compugen USA, Inc. are reviewed for impairment in accordance with ASC 360, &#8220;Property, Plant, and Equipment&#8221; whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset with the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the years 2022, 2021&#160;and 2020, no impairment losses have been identified.</span></span></p>

    <div>
      <div>
        <div>

            <div>
              <div>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">i.<span style="padding-left:22.72pt">Leases:</span></span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The Company accounts for its leases according to ASC 842 - Leases (&#8220;ASC 842&#8221;). The Company determines if an arrangement is a lease and the classification of that lease at inception based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of the asset. The Company elected to not recognize a lease liability and a right-of-use (&#8220;ROU&#8221;) asset for leases with a term of twelve months or less.</span></span></p>
                <p style="margin:0pt">&#160;</p>
                <div/>
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:85.05pt;text-align:justify">ROU assets and lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. ROU assets are initially measured at amounts, which represents the discounted present value of the lease payments over the lease, plus any initial direct costs incurred. The lease liability is initially measured based on the discounted present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. The implicit rate within the operating leases is generally not determinable, therefore the Company uses the Incremental Borrowing Rate (&#8220;IBR&#8221;) based on the information available at commencement date in determining the present value of lease payments. The Company&#8217;s IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located.</p>
                <p style="margin:0pt">&#160;</p>
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:85.05pt;text-align:justify">An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate the lease is considered unless it is reasonably certain that the Company will not exercise the option.</p>
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:85.05pt;text-align:justify">&#160;</p>
              </div>
            </div>

        </div>
      </div>
    </div>
    <div>
      <div>
        <div>
          <div>

              <div>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:76pt;text-indent:-20pt">j.<span style="padding-left:23.06pt">Revenue recognition:</span></p>
                <p style="margin:0pt">&#160;</p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:85.05pt;text-align:justify">The Company generates revenues mainly from its collaborative and license agreements. The revenues are derived mainly from upfront license payments, research and development services and contingent payments related to milestone achievements.</p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The Company recognizes revenue in accordance with ASC 606 &#8211; &#8220;Revenue from Contracts with Customers&#8221;.</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">As such, the Company analyzes its contracts to assess whether they are within the scope of ASC 606. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps:</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">&#8226;</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:-12pt;text-indent:114pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-style:italic">Identification of the contract, or contracts, with a customer</span></span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">&#8226;</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:-12pt;margin-left:114pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-style:italic">Identification of the performance obligations in the contract</span>&#160;</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">&#8226;</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:-12pt;margin-left:114pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-style:italic">Determination of the transaction price</span>&#160;</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">&#8226;</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:-12pt;margin-left:114pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-style:italic">Allocation of the transaction price to the performance obligations in the contract</span>&#160;</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">&#8226;</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:-12pt;margin-left:114pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-style:italic">Recognition of revenue when, or as, the Company satisfies a performance obligation</span>&#160;</span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
                <div/>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:85pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">At the contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></span></p>
                <p style="margin:0pt">&#160;</p>
                <div>
                  <div style="margin-left:85.05pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company entered into an exclusive license agreement with AstraZeneca. Under the terms of the agreement, Compugen provided AstraZeneca with an exclusive license to intellectual property ("IP&#8221;) rights of the Company for the development of bi-specific and multi-specific antibody products derived from COM902. Compugen received a $10,000 upfront nonrefundable payment and is eligible to receive up to $200,000 for development, regulatory and commercial milestones for the first product, of which $15,500 was received to date as well as tiered royalties on future product sales.</span></span></div>
                </div>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Under ASC 606, the Company determined the license to the IP to be a functional IP that has significant standalone functionality. The Company is not required to continue to support, develop or maintain the intellectual property transferred and will not undertake any activities to change the standalone functionality of the IP. Therefore, the license to the IP is a distinct performance obligation and as such revenue is recognized at the point in time that control of the license is transferred to the customer.</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Future milestone payments are considered variable consideration and are subject to the variable consideration constraint (i.e. will be recognized once concluded that it is &#8220;probable&#8221; that a significant reversal of the cumulative revenues recognized under the contract will not occur in future periods when the uncertainty related to the variable consideration is resolved). Therefore, as the milestone payments are not probable, revenue was not recognized in respect to such milestone payments prior to achievement of such milestone.</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Sales&#160;or usage-based royalties to be received in exchange for licenses of IP are recognized at the later of when (1) the subsequent sale or usage occurs or (2) the performance obligation to which some or all of the sales&#160;or usage-based royalty has been allocated is satisfied (in whole or in part). As royalties are payable based on future Commercial Sales, as defined in the agreement, which did not occur as of the financial statements date, the Company did not recognize any revenues from royalties.</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">On December 18, 2020 the first milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $&#160;2,000 in accordance with the criteria prescribed under ASC 606.</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">On September 29, 2021 the second milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $&#160;6,000 in accordance with the criteria prescribed under ASC 606.</span></span></p>
                <p style="margin:0pt">&#160;</p>
                <div/>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">On November 11, 2022, the third milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ 7,500 in accordance with the criteria prescribed under ASC 606.</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">For additional information regarding revenues, please refer to Note 10 below.</span></span></p>
              </div>

          </div>
        </div>
      </div>
    </div>

      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">k.<span style="padding-left:22.72pt">Cost of revenues:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Cost of revenues consist of certain royalties and milestones paid or accrued.</span></span></p>


      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">l.<span style="padding-left:24.5pt">Research and development expenses, net:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Research and development costs are charged to the statement of comprehensive loss as incurred and are presented net of the amount of any grants the Company receives for research and development in the period in which the grant was received.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">As part of the process of preparing the consolidated financial statements, the Company accrues costs for pre-clinical and clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the contract research organizations or other pre-clinical or clinical trial vendors that perform the activities. In certain circumstances, the Company is required to make nonrefundable advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the nonrefundable advance payments are deferred and capitalized, and amortized as the related goods or services are provided. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense.</span></span></p>
      <p style="margin:0pt">&#160;</p>
      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:85.05pt;text-align:justify">The portion of the Bristol-Myers Squibb $ 12,000 investment in 2018 over the fair market value of the shares issued in the amount of $ 4,121 and the portion of the $ 20,000 investment in 2021 over the fair market value of the shares issued in the amount of $ 5,000 were considered as deferred participation of Bristol-Myers Squibb in R&amp;D expenses which is amortized over the period of the clinical trial based on the progress in the R&amp;D, see Note 1f and Note 8b.</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Amortization of participation in R&amp;D expenses for the years ended December 31, 2022, 2021&#160;and 2020&#160;were $&#160;6,019, $&#160;1,291 and $&#160;829, respectively.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>

    <div/>

      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">m.<span style="padding-left:18.72pt">Severance pay:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The Company&#8217;s liability for severance pay for its Israeli employees is calculated pursuant to Israeli Severance Pay Law based on the most recent salary of the employees multiplied by the number of years of employment as of the balance sheet date, and is in large part covered by regular deposits with recognized pension funds, deposits with severance pay funds and purchases of insurance policies. The value of these deposits and policies is recorded as an asset in the Company&#8217;s balance sheet. Pursuant to Section 14 of the Israeli Severance Pay Law, for Israeli employees under this section, the Company&#8217;s contributions for severance pay have replaced its severance obligation. Upon contribution of the full amount of the employee&#8217;s monthly salary for each year of service, no additional calculations are conducted between the parties regarding the matter of severance pay and no additional payments are made by the Company to the employee.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Further, the related obligation and amounts deposited on behalf of the employee for such obligation are not stated on the balance sheet, as the Company is legally released from the obligation to employees once the deposit amounts have been paid.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Severance expenses for the years ended December 31, 2022, 2021&#160;and 2020&#160;amounted to approximately $&#160;468, $&#160;383 and $&#160;572, respectively.</span></span></p>


      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">n.<span style="padding-left:22.06pt">Stock-based compensation:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The Company accounts for stock-based compensation to employees and non-employees in accordance with ASC 718, &#8220;Compensation - Stock Compensation&#8221;, (&#8220;ASC 718&#8221;), which requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The Company accounts for forfeitures as they occur.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The Company recognizes compensation expenses for the value of its awards granted based on the straight-line method over the requisite service period of each of the awards.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The Company selected the Black-Scholes-Merton (&#8220;Black-Scholes&#8221;) option-pricing model as the most appropriate fair value method for its share-options awards and Employee Stock Purchase Plan (&#8220;ESPP&#8221;). The option-pricing model requires a number of assumptions, of which the most significant are the expected share price volatility and the expected option term. Expected volatility was calculated based on actual historical share price movements over a term that is equivalent to the expected term of granted options. The expected term of options granted is based on historical experience and represents the period of time that options granted are expected to be outstanding.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.</span></span></p>
      <p style="margin:0pt">&#160;</p>
      <div/>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The Company used the following assumptions for options granted to employees, directors and non-employees and ESPP:</span></span></p>
      <div style="margin-left:85.05pt">

          <table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%">

              <tr>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="10" rowspan="1" style="vertical-align:bottom;border-bottom:1.5pt solid black">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-weight:bold">Year ended December 31,</span></span></span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:1.5pt solid black">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-weight:bold">2022</span></span></span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:1.5pt solid black">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-weight:bold">2021</span></span></span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:1.5pt solid black">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-weight:bold">2020</span></span></span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:49%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:14%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:14%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:14%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
              </tr>


              <tr style="background-color:rgb(204, 238, 255)">
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>Employee stock options</span></span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              </tr>
              <tr style="background-color:rgb(255, 255, 255)">
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
              </tr>
              <tr style="background-color:rgb(204, 238, 255)">
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Volatility</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">69.44%-74.61%</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">66.02%-69.05%</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">55.12%-65.59%</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              </tr>
              <tr style="background-color:rgb(255, 255, 255)">
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Risk-free interest rate</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">1.54%-4.39%</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.51%-1.14%</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.26%-1.64%</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
              </tr>
              <tr style="background-color:rgb(204, 238, 255)">
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Dividend yield</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0%</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0%</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0%</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              </tr>
              <tr style="background-color:rgb(255, 255, 255)">
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Expected life (years)</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">5.05-5.4</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">5.04-5.31</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">5.02-5.31</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
              </tr>

          </table>

      </div>
      <div style="margin-left:85.05pt">
        <div style="margin-top:10pt">

            <div>
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%">

                  <tr>
                    <td style="vertical-align:bottom">&#160;</td>
                    <td style="vertical-align:bottom">&#160;</td>
                    <td colspan="10" rowspan="1" style="vertical-align:bottom;text-align:center;border-bottom:1.5pt solid black">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="line-height:110%">Year ended December 31,</span></span></span></strong></p>
                    </td>
                    <td style="vertical-align:bottom;text-align:center">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom">&#160;</td>
                    <td style="vertical-align:bottom">&#160;</td>
                    <td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center;border-bottom:1.5pt solid black">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span>2022</span></strong></span></span></p>
                    </td>
                    <td style="vertical-align:bottom;text-align:center">&#160;</td>
                    <td style="vertical-align:bottom;text-align:center">&#160;</td>
                    <td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center;border-bottom:1.5pt solid black">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span>2021</span></strong></span></span></p>
                    </td>
                    <td style="vertical-align:bottom;text-align:center">&#160;</td>
                    <td style="vertical-align:bottom;text-align:center">&#160;</td>
                    <td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center;border-bottom:1.5pt solid black">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span>2020</span></strong></span></span></p>
                    </td>
                    <td style="vertical-align:bottom;text-align:center">&#160;</td>
                  </tr>
                  <tr style="background-color:rgb(204, 238, 255)">
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>ESPP</span></span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                  </tr>
                  <tr style="background-color:rgb(255, 255, 255)">
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                  </tr>
                  <tr style="background-color:rgb(204, 238, 255)">
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Volatility</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="padding-left:0pt">69.74</span><span style="padding-left:0pt">%</span></span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">64.68%-69.68%</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">-</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                  </tr>
                  <tr style="background-color:rgb(255, 255, 255)">
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Risk-free interest rate</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">1.63%</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.04%-0.10%</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">-</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                  </tr>
                  <tr style="background-color:rgb(204, 238, 255)">
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Dividend yield</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0%</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0%</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">-</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                  </tr>
                  <tr style="background-color:rgb(255, 255, 255)">
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Expected life (years)</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.50</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.42-0.50</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">-</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                  </tr>

              </table>
            </div>

        </div>
      </div>


      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">o.<span style="padding-left:21.5pt">Concentration of credit risks:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Financial instruments that potentially subject the Company and Compugen USA, Inc. to concentration of credit risk consist principally of cash and cash equivalents, restricted cash and short-term bank deposits.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Cash, cash equivalents, restricted cash and short-term bank deposits are invested in major banks in Israel. Generally, these deposits may be redeemed upon demand and bear minimal risk.</span></span></p>


      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">p.<span style="padding-left:22.5pt">Basic and diluted loss per share:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Basic loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260, &#8220;Earnings per Share&#8220;.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">All outstanding share options and warrants for the years ended December 31, 2022, 2021 and 2020 have been excluded from the calculation of the diluted net loss per share, because all such securities are anti-dilutive for all periods presented. As of December 31, 2022, 2021 and 2020 the average number of shares related to outstanding options and warrants excluded from the calculations of diluted net loss per share were 8,405,615, 6,758,300 and 7,150,648, respectively.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
      <div/>


      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">q.<span style="padding-left:22.5pt">Income taxes:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The Company accounts for income taxes in accordance with ASC No. 740, &#8220;Income Taxes&#8220;, (&#8220;ASC 740&#8220;) which prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2022 and 2021, a full valuation allowance was provided by the Company.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been recorded pursuant to ASC 740-10.</span></span></p>


      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">r.<span style="padding-left:23.5pt">Fair value of financial instruments:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The Company applies ASC 820, &#8220;Fair Value Measurements and Disclosures&#8221; (&#8220;ASC 820&#8221;), pursuant to which fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &#8220;exit price&#8221;) in an orderly transaction between market participants at the measurement date.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputting that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company.</span></span></p>
      <p style="margin:0pt">&#160;</p>
      <div/>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:85.05pt;margin-bottom:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The hierarchy is broken down into three levels based on the inputs as follows:</span></span></p>
      <table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%">

          <tr>
            <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:85.5pt">&#160;</td>
            <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:56.7pt">
              <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt">Level 1&#160; &#160;&#160;</span><span style="font-size:10pt">-</span></p>
            </td>
            <td style="font-family:Times New Roman, Times, serif;vertical-align:top;text-align:justify;width:auto"><span style="font-size:10pt"><span>Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can </span>access at the measurement date.</span></td>
          </tr>

      </table>
      <div style="margin-top:10pt">
        <table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%">

            <tr>
              <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:85.5pt">&#160;</td>
              <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:56.7pt">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt">Level 2&#160; &#160; -</span></p>
              </td>
              <td style="font-family:Times New Roman, Times, serif;vertical-align:top;text-align:justify;width:auto"><span style="font-size:10pt"><span>Valuations based on one or more quoted prices in markets that are not active or for which all </span>significant inputs are observable, either directly or indirectly.</span></td>
            </tr>
            <tr>
              <td style="width:85.5pt">&#160;</td>
              <td style="width:56.7pt">&#160;</td>
              <td style="text-align:justify;width:auto">&#160;</td>
            </tr>
            <tr>
              <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:85.5pt">&#160;</td>
              <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:56.7pt">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt">Level 3&#160; &#160; -</span></p>
              </td>
              <td style="font-family:Times New Roman, Times, serif;vertical-align:top;text-align:justify;width:auto"><span style="font-size:10pt"><span>Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</span></span></td>
            </tr>

        </table>
      </div>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The carrying amounts of cash and cash equivalents, restricted cash, short-term bank deposits, other accounts receivable and prepaid expenses, trade payable and other accounts payable and accrued expenses approximate their fair values due to the short-term maturities of such instruments.</span></span></p>


      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">s.<span style="padding-left:22.06pt">Recently issued and recently adopted Accounting Standards:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Although there are several other new accounting standards issued or proposed by the FASB, which the Company has adopted or will adopt, as applicable, the Company does not believe any of these accounting pronouncements has had or will have a material impact on its consolidated financial statements.</span></span></p>

  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130166743936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock', window );">OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES</a></td>
<td class="text">
    <div>
      <div>
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:10pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 3: - OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES</span></span></span></p>
        <div>
          <div>
            <div>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;<div style="margin-left:63pt">

                    <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;float:left">

                        <tr>
                          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                          <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                            <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Prepaid expenses</span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,100</span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>5,272</span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
                            <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Government authorities</span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">85</span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">57</span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">
                            <div style="text-indent:-4.25pt;margin-left:7.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">232</span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">131</span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,417</span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>5,460</span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                        </tr>

                    </table>

                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other accounts receivable and prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130166739152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 4: - LEASES</span></span></span></p>
    <div>
      <div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company leases all its real estate, storage area and cars under various operating lease agreements that expire on various dates.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#8217;s operating leases have original lease periods expiring between 2021 and 2025. The offices in Israel lease include two options to renew, one of which was exercised in 2020. The Company does not assume renewals in its determination of the lease term unless the renewals are deemed to be reasonably certain.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In October 2020 the Company&#8217;s lease for its offices in Israel was amended. The amendment was not accounted for as a new lease. As a result of the amendment the operating lease right of use asset increased by $43, the operating lease liability decreased by $194 and the Company recorded foreign currency exchange rate of $237.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease payments included in the measurement of the lease liability comprise the following: the fixed non-cancelable lease payments and payments for optional renewal periods where it is reasonably certain the renewal period will be exercised.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under ASC 842, all leases, including non-cancelable operating leases, are now recognized on the balance sheet. The aggregated present value of lease payments is recorded as a long-term asset titled Operating lease right of use asset. The corresponding lease liabilities are split between current maturity of operating lease liability within current liabilities and long-term operating lease liability within long-term liabilities. The Company&#8217;s leases do not provide an implicit rate, therefore the Company uses its incremental borrowing rate based on information available on the commencement date in determining the present value of lease payments.</span></span></div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div/>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table represents the weighted-average remaining lease term and discount rate:</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="margin-left:56.7pt">

            <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:90%">

                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average remaining lease term</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.16</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%" valign="bottom">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average discount (annual) rate</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.52%</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25">&#160;</div>
                    </div>
                  </td>
                </tr>

            </table>

        </div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating lease expenses were approximately $884, $956 and $944 in the years ended December 31, 2022, 2021 and 2020, respectively.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Cash paid for amounts included in the measurement of lease liabilities was approximately $959, $914 and $927 in the years ended December 31, 2022, 2021 and 2020, respectively.</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Maturities of operating lease liabilities were as follows:</span></span></div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="margin-left:56.7pt">

            <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:90%">

                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December 31,</span><span>&#160;<span style="font-weight:bold">2022</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>699</span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%" valign="bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">669</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">609</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%;padding-bottom:2px" valign="bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2026</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">114</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%" valign="bottom">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total operating lease payments</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,091</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less: imputed interest</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">166</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Present value of lease liabilities</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,925</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%" valign="bottom">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease liabilities, current</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">613</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease liabilities, non- current</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,312</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Present value of lease liabilities</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>1,925</span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                </tr>

            </table>

        </div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
        <div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The above annual minimum future rental commitments include the period covered by the first exercised option with respect to the leased facility of Compugen Ltd. through March 2026 and exclude the second option to extend the lease of the Company facility for additional five-year period following expiration of the current lease period.</span></span></div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130166625984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:10pt"><span style="font-weight:bold">NOTE 5: -&#160;</span><span style="font-weight:bold">PROPERTY AND EQUIPMENT, NET</span></p>

      <div style="margin-left:56.7pt">
        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="6" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">December 31,</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2022</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2021</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Cost:</p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Computers, software and related equipment</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,617</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,506</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Laboratory equipment and office furniture</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">3,831</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">3,674</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Leasehold improvements</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">2,314</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">2,321</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:76%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">7,762</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">7,501</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Accumulated depreciation:</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Computers, software and related equipment</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,435</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,351</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Laboratory equipment and office furniture</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">3,190</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">3,114</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Leasehold improvements</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,605</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,378</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">6,230</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">5,843</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Depreciated cost</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,532</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,658</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>
      </div>

    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:56.7pt;margin-bottom:0pt">During 2022&#160;and 2021&#160;total cost of $&#160;99&#160;and $&#160;26, respectively and total accumulated depreciation of $&#160;95&#160;and $&#160;26, respectively were disposed from the consolidated balance sheets.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:56.7pt;margin-bottom:0pt">For the years ended December 31, 2022, 2021&#160;and 2020, depreciation expenses were approximately $&#160;482, $&#160;461&#160;and $&#160;715, respectively.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130166679664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES</a></td>
<td class="text">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:10pt"><span style="font-weight:bold">NOTE 6: - </span><strong>OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES</strong></p>
    <div>
      <div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
        <div style="margin-left:54pt">

            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;float:left">

                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold">December 31,</div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold">2022</div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold">2021</div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25">Employees and related accruals</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-family:'Times New Roman',Times,serif">$</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-family:'Times New Roman',Times,serif">2,812</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-family:'Times New Roman',Times,serif">$</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-family:'Times New Roman',Times,serif">3,299</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px" valign="bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25">Accrued expenses</div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                    <div style="line-height:1.25">6,396</div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                    <div style="line-height:1.25">4,779</div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-family:'Times New Roman',Times,serif">$</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-family:'Times New Roman',Times,serif">9,208</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-family:'Times New Roman',Times,serif">$</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-family:'Times New Roman',Times,serif">8,078</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>

            </table>

        </div>
        <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130166739152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0px;margin-bottom:0pt"><span style="font-weight:bold">NOTE 7: -&#160;</span><span style="font-weight:bold">COMMITMENTS AND CONTINGENCIES</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt">a.<span style="padding-left:21.5pt">The Company provided bank guarantees in the amount of $&#160;</span>318 related to its offices in Israel, leased cars fueling in Israel and credit card security for its U.S. subsidiary.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt">b.<span style="padding-left:21.5pt">Under the Office of the Israel Innovation Authority of the Israeli Ministry of Industry, Trade and Labor, formerly </span>known as the Office of the Chief Scientist, (the &#8220;IIA&#8221;), the Company is not obligated to repay any amounts received from the IIA if it does not generate any income from the results of the funded research program(s). If income is generated from a funded research program, the Company is committed to pay royalties at a rate of between 3% to 5% of future revenue arising from such research program(s), and up to a maximum of 100% of the amount received, linked to the U.S. dollar (for grants received under programs approved subsequent to January 1, 1999, the maximum to be repaid is 100% plus interest at LIBOR). For the years ended December 31, 2022, 2021&#160;and 2020, the Company had an aggregate of paid or accrued royalties to the IIA, recorded as cost of revenue in the consolidated statements of comprehensive loss in the amount of $&#160;225, $&#160;180 and $&#160;60, respectively.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt">As of December 31, 2022, the Company&#8217;s aggregate contingent obligations for payments to IIA, based on royalty-bearing participation received or accrued, net of royalties paid or accrued, totaled approximately to $&#160;9,631.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt">c.<span style="padding-left:21.06pt">On June 25, 2012 the Company entered into an Antibodies Discovery Collaboration Agreement (the &#8220;Antibodies </span>Discovery Agreement&#8221;) with a U.S. antibody technology company (&#8220;mAb Technology Company&#8221;), providing an established source for fully human mAbs. Under the Antibodies Discovery Agreement, the mAb Technology Company will be entitled to certain royalties that could be eliminated, upon payment of certain one-time fees (all payments referred together as &#8220;Contingent Fees&#8221;). For the years ended December 31, 2022, 2021&#160;and 2020, the Company incurred such Contingent Fees in the amounts of $&#160;750, $&#160;500 and $&#160;500.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt">d.<span style="padding-left:21.5pt">On </span>May 9, 2012, the Company entered into agreement (the &#8220;May 2012 Agreement&#8221;) with a U.S. Business Development Strategic Advisor (&#8220;Advisor&#8221;) for the purpose of entering into transactions with Pharma companies related to selected Pipeline Program Candidates.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt">Under the agreement the Advisor was entitled to 4% of the cash considerations that may be received under such transactions. In 2014, the May 2012 Agreement was terminated except for certain payments arising from the Bayer Agreement which survive termination until August 5, 2025.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt">The Bayer Agreement was terminated effective February 27, 2023 and no further payments are expected under the May 2012 Agreement</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt">For the years ended December 31, 2022, 2021 and 2020, the Company has not paid and did not accrue payments under this agreement.&#160;</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
    <div/>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt">e.<span style="padding-left:21.06pt">Effective as of January 5, 2018, the Company entered into a Commercial License Agreement (CLA) with a European </span>cell line development company. Under the agreement the Company is required to pay an annual maintenance fee, certain amounts upon the occurrence of specified milestones events, and 1% royalties on annual net sales with respect to each commercialized product manufactured using the company&#8217;s cell line. Royalties due under the CLA are creditable against the annual maintenance fee. In addition, the Company may at any time prior to the occurrence of a specific milestone event buy-out the royalty payment obligations in a single fixed amount. For the years ended December 31, 2022, 2021&#160;and 2020, the Company incurred in the research and development expenses in connection with such milestone payment in the amounts of $&#160;0, $&#160;0 and $&#160;52.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-27pt;margin-left:85pt;margin-bottom:0pt">f.<span style="padding-left:21.17pt">Effective as of October 28, 2020, the Company entered into a collaboration agreement with a U.S. antibody </span>discovery and optimization company for generation and optimization of therapeutic antibodies for the Company. Under the agreement the Company is required to pay service fees per services performed and certain amounts upon the occurrence of specified milestones events, and single-digit percent royalties on annual net sales with respect to each product sold that comprises or contains one or more antibodies so generated or optimized. The royalty rate is dependent upon the product type and any third-party contribution. For the years ended December 31, 2022, 2021&#160;and 2020, the Company incurred in the research and development expenses such milestone payment in the amounts of $&#160;0, $&#160;250 and $&#160;0.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130166661296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">SHAREHOLDERS' EQUITY</a></td>
<td class="text">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">NOTE 8: -&#160;</span><span style="font-weight:bold">SHAREHOLDERS&#8217; EQUITY</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt">a.<span style="padding-left:21.06pt">Ordinary shares:</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt">The ordinary shares confer upon their holders the right to attend and vote at general meetings of the shareholders. Subject to the rights of holders of shares with limited or preferred rights which may be issued in the future, the ordinary shares of the Company confer upon the holders thereof equal rights to receive dividends, and to participate in the distribution of the assets of the Company upon its winding-up, in proportion to the amount paid up or credited as paid up on account of the nominal value of the shares held by them respectively and in respect of which such dividends are being paid or such distribution is being made, without regard to any premium paid in excess of the nominal value, if any.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt">b.<span style="padding-left:21.5pt">Issuance of shares:</span></p>
    <p style="margin:0pt">&#160;</p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:85.05pt">On June 14, 2018, the Company entered into securities purchase agreement with certain institutional investors and a placement agency agreement with JMP Securities LLC in connection with a registered direct offering (the &#8220;Offering&#8221;) of an aggregate of 5,316,457 ordinary shares (the &#8220;RD Shares&#8221;) of the Company at a purchase price of $ 3.95 per RD Share. In connection with the issuance of the RD Shares, the Company also issued warrants to purchase an aggregate of up to 4,253,165 additional ordinary shares. The Warrants are exercisable at a price of $ 4.74 per ordinary share and have a term of five years from the date of issuance. The Offering was made pursuant to the Company&#8217;s Registration Statement. Proceeds from the Offering were $ 19,767 (net of $ 1,233 issuance expenses).</p>
    <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:80pt">&#160;</p>
    <div/>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">During the years ended December 31, 2021 and 2020, warrants to purchase an aggregate of 3,955,696 ordinary shares were exercised with proceeds of approximately $ 18,750 and as of December 31, 2022 and 2021, warrants to purchase up to 297,469 ordinary shares remain outstanding.&#160;</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt">On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement (the &#8220;Master Clinical Agreement&#8221;) with Bristol-Myers Squibb to evaluate the safety and tolerability of the Company&#8217;s COM701 in combination with Bristol-Myers Squibb&#8217;s PD-1 immune checkpoint inhibitor Opdivo&#174; (nivolumab), in patients with advanced solid tumors. In conjunction with the Master Clinical Agreement, Bristol-Myers Squibb made a $&#160;12,000 equity investment in the Company.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt">Under the terms of the securities purchase agreement, Bristol-Myers Squibb purchased 2,424,243 ordinary shares of the Company at a purchase price of $&#160;4.95 per share. The share price represented a 33% premium over the average closing price of Compugen&#8217;s ordinary shares for twenty (20) Nasdaq trading days prior to the execution of the securities purchase agreement. The investment closed on October 12, 2018.</p>
    <p style="margin:0pt">&#160;</p>
    <div>
      <div style="margin-left:85.05pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The premium over the fair market value in the amount of $4,121 represents the relative fair value of deferred participation of Bristol-Myers Squibb in R&amp;D expenses (which are amortized over the period of the clinical trial, based on the progress in the R&amp;D) and $7,788 (net of $91 issuance expenses) were considered equity investment.</span></span></div>
    </div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt">In conjunction with the signing of the amendment to the Master Clinical Agreement in November 2021, Bristol Myers Squibb made a $&#160;20,000 investment in the Company, purchasing 2,332,815 ordinary shares of the Company at a purchase price of $&#160;8.57333 per share. The share price represented a 33% premium over the closing price of Company&#8217;s ordinary shares on the last Nasdaq trading day immediately prior to the execution of the securities purchase agreement.</p>
    <p style="margin:0pt">&#160;</p>
    <div>
      <div style="margin-left:85.05pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The premium over the fair market value in the amount of $5,000 represents the relative fair value of deferred participation of Bristol-Myers Squibb in R&amp;D expenses (which are amortized over the period of the clinical trial, based on the progress in the R&amp;D) and $14,958 (net of $42 issuance expenses) were considered equity investment.</span></span></div>
      <div style="margin-left:85.05pt">&#160;</div>
    </div>
    <div/>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">In March 2020, the Company entered into an underwriting agreement with SVB Leerink LLC and Stifel, Nicolaus &amp; Company, Incorporated, as representatives of several underwriters relating to the issuance and sale in a public offering of 8,333,334 of the Company&#8217;s ordinary shares at a price to the public of $&#160;9.00 per share (and a price of $&#160;8.46 per share to the underwriters). Such shares were issued on March 16, 2020. In addition, the Company granted the underwriters a 30-day option to purchase additional ordinary shares at the price set forth above. On April 14, 2020, the Company issued and sold, pursuant to that underwriting agreement additional 483,005 ordinary shares pursuant to the underwriters&#8217; option specified above. The Company sold a total of 8,816,339 ordinary shares in the offering with proceeds of $74,147 (net of $&#160;5,200 issuance expenses).</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt">c.<span style="padding-left:21.06pt">Share option plan:</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt">Under the Company&#8217;s 2010 Share Option Plan as amended (the &#8220;Plan&#8220;), options may be granted to employees, directors and non-employees of the Company and Compugen USA, Inc.</p>
    <p style="margin:0pt">&#160;</p>
    <p style="margin:0pt 0pt 0pt 85.05pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Under the 2010 Share Option Plan the Company reserved for issuance up to an aggregate of 14,395,152 ordinary shares. <span style="color:rgb(0, 0, 0)">The Company</span>&#8217;<span style="color:rgb(0, 0, 0)">s Board of Directors last amended the Plan in March 2022, to increase the number of shares available under the 2010 Plan.</span> As of December 31, 2022, an aggregate of 1,918,297 options under the 2010 Share Option Plan of the Company were still available for future grants.</span></span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt">In general, options granted under the Plan vest over a four-year period and expire 10 years from the date of grant and are granted at an exercise price of not less than the fair market value of the Company&#8217;s ordinary shares on the date of grant, unless otherwise determined by the Company&#8217;s board of directors. The exercise price of the options granted under the Plan may not be less than the nominal value of the shares into which such options are exercised and the expiration date may not be later than 10 years from the date of grant. If a grantee leaves his or her employment or other relationship with the Company, or if his or her relationship with the Company is terminated without cause (and other than by reason of death or disability, as defined in the Plan), the term of his or her unexercised options will generally expire in 90 days, unless determined otherwise by the Company.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt">Any options that are cancelled, forfeited or expired become available for future grants.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:80pt;margin-bottom:0pt">&#160;</p>
    <div/>

      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:10pt">Transactions related to the grant of options to employees, directors and non-employees under the above Plan during the year ended December 31, 2022, were as follows:</p>
      <div style="margin-left:85.04pt">
        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Number of</span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">options</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Weighted</span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">average</span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">exercise </span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">price</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Weighted</span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">average</span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">remaining</span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">contractual </span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">life</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Aggregate</span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">intrinsic</span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">value</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">$</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Years</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">$</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:52%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Options outstanding at beginning of year</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">6,976,104</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">6.39</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">6.69</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">3,323</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:52%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Options granted</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">2,186,400</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">2.58</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:52%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Options exercised</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(33,186</p>
              </td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">)</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">3.14</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:52%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Options forfeited</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(778,069</p>
              </td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">)</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">6.42</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:baseline;width:52%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Options expired</p>
              </td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(193,500</p>
              </td>
              <td style="vertical-align:baseline;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:1pt">)</p>
              </td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">4.21</p>
              </td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;width:9%">&#160;</td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;width:9%">&#160;</td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:52%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:52%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Options outstanding at end of year</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">8,157,749</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">5.43</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">6.32</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">-</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:52%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:52%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Exercisable at end of year</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">4,635,040</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">5.68</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">4.52</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">-</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>
      </div>

    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt">Weighted average fair value of options granted to employees, directors and non-employees during the years 2022, 2021&#160;and 2020&#160;was $&#160;1.51, $&#160;3.81 and $&#160;7.15 per share, respectively.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt">Aggregate intrinsic value of exercised options by employees, directors and non-employees during the years 2022, 2021 and 2020&#160;was $&#160;19, $&#160;759&#160;and $&#160;21,610, respectively. The aggregate intrinsic value of the exercised options represents the total intrinsic value (the difference between the sale price of the Company&#8217;s share at the date of exercise, and the exercise price) multiplied by the number of options exercised.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt">The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the Company&#8217;s closing share price on the last trading day of calendar 2021 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on December 31, 2022. This amount is impacted by the changes in the fair market value of the Company&#8217;s shares.&#160;</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt">As of December 31, 2022, the total unrecognized estimated compensation cost related to non-vested share options granted prior to that date was $&#160;8,715 which is expected to be recognized over a weighted average period of approximately 2.47 years.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt">d.<span style="padding-left:21.5pt">Employee Stock Purchase Plan:</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt">The Company adopted an ESPP in November 2020, with the first offering period starting at January 1, 2021. In connection with its adoption, a total of 600,000 ordinary shares were reserved for issuance under this plan.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
    <div/>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">The ESPP is implemented through six-month offering periods (except for the first offering period that was five months). According to the ESPP, eligible employees and non-employees may use up to 15% of their base salaries to purchase ordinary shares up to an aggregate limit of $&#160;40 per participant for every calendar year. The price of an ordinary share purchased under the ESPP is equal to 85% of the lower of the fair market value of the ordinary share on the first day of each offering period or on the last day of such period.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt">Since its adoption and through December 31, 2022, 275,854 ordinary shares had been purchased under the ESPP and as of December 31, 2022, 324,146 ordinary shares were available for issuance under the ESPP.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt">In accordance with ASC No. 718, the ESPP is compensatory and, as such, results in recognition of compensation cost.</p>
    <p style="margin:0pt">&#160;</p>
    <div>

        <div>
          <div>
            <p style="text-indent:-28pt;margin-left:85pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">e.<span style="padding-left:21.5pt;font-size:10pt;font-family:Times New Roman, Times, serif">The stock-based compensation expenses related to stock options and ESPP are included as follows in the expense categories:</span></p>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
            <div style="margin-left:85.05pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;float:left">

                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="10" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2020</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development expenses</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>2,158</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>1,971</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>1,123</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Marketing and business development expenses</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">269</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">215</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">172</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General and administrative expenses</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,901</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,090</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,477</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>4,328</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>4,276</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>2,772</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>

              </table>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
            </div>
          </div>
        </div>

    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130166634160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">NOTE 9: - </span><span style="font-weight:bold">INCOME TAXES</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt">a. <span style="padding-left:18.73pt">Israeli taxation:</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-28pt;margin-left:113pt;margin-bottom:0pt">1.<span style="padding-left:20.5pt">Tax rates applicable to the income of the Company.</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt">Taxable income of the Company is subject to a corporate tax rate of 23% in 2020, 2021&#160;and 2022.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-28pt;margin-left:113pt;margin-bottom:0pt">2.<span style="padding-left:20.5pt">Measurement of taxable income in US dollars:</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt">The Company has elected to measure its taxable income and file its tax return under the Israeli Income Tax Regulations (Principles Regarding the Management of Books of Account of Foreign Invested Companies and Certain Partnerships and the Determination of Their Taxable Income), 1986. Accordingly, results for tax purposes are measured in terms of earnings in dollars.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:100pt;margin-bottom:0pt">&#160;</p>
    <div/>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;text-indent:-28pt;margin-left:113pt;margin-bottom:0pt;text-align:justify">3.<span style="padding-left:20.5pt">Tax benefits under the Israeli Law for the Encouragement of Capital Investments, 1959 (the &#8220;Investment Law&#8221;):</span>&#8201;&#8201;</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt">On April 1, 2005, an amendment to the Investment Law came into effect (the &#8220;Amendment 60&#8221;) that significantly changed the provisions of the Investment Law. The Amendment 60 limits the scope of enterprises that may be approved by the Investment Center by setting criteria for the approval of a facility as a &#8220;Beneficiary Enterprise&#8221; including a provision generally requiring that at least 25% of the Beneficiary Enterprise&#8217;s income will be derived from export.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt">Another condition for receiving the benefits under the alternative track in respect of expansion programs pursuant to Amendment 60 is a minimum qualifying investment. The Company was eligible under the terms of minimum qualifying investment and elected 2012 as its &#8220;year of election&#8221;.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt">Additionally, the Amendment 60 enacted major changes in the manner in which tax benefits are awarded under the Investment Law so that companies no longer require Investment Center approval in order to qualify for tax benefits. However, the Investment Law provides that terms and benefits included in any certificate of approval already granted will remain subject to the provisions of the Investment Law as they were on the date of such approval.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt">As of December 31, 2022, there was no taxable income attributable to the Beneficiary Enterprise.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt">In January 2011, another amendment to the Investment Law came into effect (&#8220;the 2011 Amendment&#8221;). According to the 2011 Amendment, the benefit tracks in the Investment Law were modified and a flat tax rate applies to the Company&#8217;s entire income subject to this amendment (the &#8220;Preferred Income&#8221;).</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt">Once an election is made, the Company&#8217;s income will be subject to the amended tax rate of 16% from 2015 and thereafter (or 9% for a preferred enterprise located in development area A).</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt">Commencing 2011 tax year, the Company can elect (without possibility of reversal) to apply the Amendment in a certain tax year and from that year and thereafter, it will be subject to the amended tax rates.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt">The Company does not currently intend to adopt the 2011 Amendment and intends to continue to comply with the Investment Law as in effect prior to enactment of the 2011 Amendment. Accordingly, the Company did not adjust its deferred tax balances as of December 31, 2022. The Company&#8217;s position may change in the future.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:113.4pt;margin-bottom:0pt">&#160;</p>
    <div/>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:113.4pt;margin-bottom:0pt">In December 2016, the Economic Efficiency Law (Legislative Amendments for Applying the Economic Policy for the 2016 and 2017 Budget Years), 2016, which includes Amendment 73 to the Law (the &#8220;Amendment 73&#8221;) was published. According to Amendment 73, a preferred enterprise located in development area A will be subject to a tax rate of 7.5% instead of 9% effective from January 1, 2016 and thereafter (the tax rate applicable to preferred enterprises located in other areas remains at 16%).</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt">Amendment 73 also prescribes special tax tracks for technological enterprises, which are subject to rules that were issued by the Minister of Finance in May 2017. The new tax tracks under the Amendment are as follows:</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt">Preferred Technological Enterprise (&#8220;PTE&#8221;) - an enterprise for which total consolidated revenues of its parent company and all subsidiaries are less than NIS 10 billion in a tax year. A PTE, as defined in the Law, which is located in the center of Israel will be subject to tax at a rate of 12% on profits deriving from intellectual property (in development area A - a tax rate of 7.5%).</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt">The above changes in the tax rates relating to PTE tax track were not taken into account in the computation of deferred taxes as of December 31, 2022 and 2021, since the Company estimates that it will not implement the PTE tax track.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-28pt;margin-left:113pt;margin-bottom:0pt">4.<span style="padding-left:20.5pt">Tax benefits under the law for the Encouragement of Industry (Taxes), 1969 (the &#8220;Encouragement Law&#8221;):</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt">The Encouragement Law provides several tax benefits for industrial companies. An industrial company is defined as a company resident in Israel, at least 90% of the income of which in a given tax year exclusive of income from specified Government loans, capital gains, interest and dividends, is derived from an industrial enterprise owned by it. An industrial enterprise is defined as an enterprise whose major activity in a given tax year is industrial production activity.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt">Management believes that the Company is currently qualified as an &#8220;industrial company&#8221; under the Encouragement Law and, as such, is entitled to tax benefits, including: (1) deduction of purchase of know-how and patents and/or right to use a patent over an eight-year period; (2) the right to elect, under specified conditions, to file a consolidated tax return with additional related Israeli industrial companies and an industrial holding company; (3) accelerated depreciation rates on equipment and buildings; and (4) expenses related to a public offering on the Tel-Aviv Stock exchange and on recognized stock markets outside of Israel, are deductible in equal amounts over three years.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;padding-left:100pt;margin-bottom:0pt">&#160;</p>
    <div/>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:113.4pt;margin-bottom:0pt">Eligibility for benefits under the Encouragement Law is not subject to receipt of prior approval from any Governmental authority. No assurance can be given that the Israeli tax authorities will agree that the Company qualifies, or, that the Company will continue to qualify as an industrial company or that the benefits described above will be available to the Company in the future.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-28pt;margin-left:113pt;margin-bottom:0pt">5.<span style="padding-left:20.5pt">Net operating losses carryforward and capital loss:</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt">As of December 31, 2022, Compugen Ltd. &#8217;s net operating losses carryforward for tax purposes in Israel amounted to approximately $&#160;398,100. These net operating losses may be carried forward indefinitely and may be offset against future taxable income.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt">b.<span style="padding-left:20.73pt">Non-Israeli subsidiary, Compugen USA, Inc.:</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:85.5pt;margin-bottom:0pt">On December 22, 2017, the United States enacted the Tax Cuts and Jobs Act (the &#8220;U.S. Tax Reform&#8221; or &#8220;TCJA&#8221;); a comprehensive tax legislation that includes significant changes to the taxation of business entities. These changes include several key tax provisions that might impact the Company, among others: (i) a permanent reduction to the statutory federal corporate income tax rate from 35% to 21% effective for tax years beginning after December 31, 2017; (ii) a shift of the U.S. taxation of multinational corporations from a tax on worldwide income to a territorial system (along with certain new rules designed to prevent erosion of the U.S. income tax base - &#8220;BEAT&#8221;); (iii) establishing immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits; and (iv) providing a permanent deduction to corporations generating revenues from non-US markets (known as a deduction for foreign derived intangible income - &#8220;FDII&#8221;).</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:85.5pt;margin-bottom:0pt">As of December 31, 2022, Compugen USA, Inc. has net operating loss carryforwards for federal income tax purposes of approximately $ 700. These losses may be carried forward indefinitely, but the deductibility of such federal NOLs may be limited. Utilization of the U.S. net operating losses may be subject to substantial annual limitation due to the &#8220;change in ownership&#8220; provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitation may result in the expiration of net operating losses before utilization.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:85.5pt;margin-bottom:0pt">Neither Israeli income taxes, foreign withholding taxes nor deferred income taxes were provided in relation to undistributed earnings of the Company&#8217;s foreign subsidiary. This is because the Company has the intent and ability to reinvest these earnings indefinitely in the foreign subsidiary and therefore those earnings are continually redeployed in those jurisdictions.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;padding-left:80pt;margin-bottom:0pt">&#160;</p>
    <div/>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:-28pt;margin-left:85pt;margin-bottom:11pt">c.<span style="padding-left:20.73pt">Loss (income) before taxes is comprised as follows:</span></p>
    <div style="margin-left:85.5pt">

        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="10" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Year ended December 31,</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2022</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2021</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2020</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:64%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Domestic (Israel)</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">34,096</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">34,619</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">30,010</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:baseline;width:64%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Foreign</p>
              </td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(460</p>
              </td>
              <td style="vertical-align:baseline;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:1.5pt">)</p>
              </td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(416</p>
              </td>
              <td style="vertical-align:baseline;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:1.5pt">)</p>
              </td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(312</p>
              </td>
              <td style="vertical-align:baseline;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:1.5pt">)</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:64%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:64%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">33,636</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">34,203</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">29,698</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>

    </div>
    <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
    <div>
      <div>
        <table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000">

            <tr>
              <td style="width:56.7pt;font-family:'Times New Roman',Times,serif">&#160;</td>
              <td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif">d.</td>
              <td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif">
                <div>Taxes on income for the year ended December 31, 2022, represent state income taxes in the United States.</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt">e.<span style="padding-left:20.73pt">Deferred taxes:</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.5pt;margin-bottom:11pt">Deferred taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company and Compugen USA, Inc.&#8217;s deferred tax assets are comprised of operating loss carryforward and other temporary differences. Significant components of the Company and Compugen USA, Inc. deferred tax assets are as follows:</p>
    <div>

        <div>
          <div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
            <div style="margin-left:85.5pt">
              <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;float:left;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%">

                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating loss carryforward</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>91,704</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>86,068</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12,083</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9,773</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrued social benefits and other</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,123</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,801</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Right of use assets</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(415</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(520</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease liabilities</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">444</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">636</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px" valign="bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property and equipment</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred tax asset before valuation allowance</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">106,941</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">98,760</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px" valign="bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Valuation allowance</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(106,941</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(98,760</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px" valign="bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net deferred tax asset</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>-</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>-</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>

              </table>
            </div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
          </div>
        </div>

    </div>
    <div>
      <div style="margin-left:85.5pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has provided full valuation allowances in respect of deferred tax assets resulting from operating loss carryforward and other temporary differences. Management currently believes that since the Company has a history of losses, it is more likely than not that the deferred tax regarding the operating loss carryforward and other temporary differences will not be realized in the foreseeable future.</span></span></div>
      <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
    </div>
    <div/>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt">f.<span style="padding-left:22.73pt">Reconciliation of the theoretical tax expense (benefit) to the actual tax expense (benefit):</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:85.5pt;margin-bottom:0pt">The main reconciling items between the statutory tax rate of the Company and the effective tax rate are the non-recognition of tax benefits from accumulated net operating loss carryforward among the Company and Compugen USA, Inc. due to the uncertainty of the realization of such tax benefits.</p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt">g.<span style="padding-left:20.73pt">Tax assessments:</span></p>
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11px;margin-left:85.5pt;margin-bottom:0px">The Company has tax assessments through 2017&#160;that are deemed to be final.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130166801104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS</a></td>
<td class="text">
    <div>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">NOTE 10: -&#160;</span><span style="font-weight:bold">GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS</span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:56.7pt;margin-bottom:0pt">The Company&#8217;s business is currently comprised of one operating segment, the research, development and commercialization of therapeutic and product candidates. The nature of the products and services provided by the Company and the type of customers for these products and services are similar. Operations in Israel and the United States include research and development, clinical operations, marketing and business development. The Company follows ASC 280, <span style="color:black">&#8220;</span>Segment Reporting<span style="color:black">&#8220;</span>. Total revenues are attributed to geographic areas based on the location of the end customer.</p>

        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:56.7pt;margin-bottom:11pt">The following represents the total revenue for the years ended December 31, 2022, 2021&#160;and 2020&#160;and long-lived assets as of December 31, 2022&#160;and 2021:</p>
        <div style="margin-left:56.7pt;margin-bottom:11pt">
          <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

              <tr>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="10" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Year ended December 31,</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2022</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2021</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2020</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>


              <tr style="background-color:#cceeff">
                <td style="vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Revenue from sales to customers:</p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>
              <tr style="background-color:#cceeff">
                <td style="vertical-align:bottom;width:64%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Europe</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
                </td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">7,500</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
                </td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">6,000</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
                </td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">2,000</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:9%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:9%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:9%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
              </tr>
              <tr style="background-color:#cceeff">
                <td style="vertical-align:bottom;width:64%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Total revenue</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
                </td>
                <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">7,500</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
                </td>
                <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">6,000</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
                </td>
                <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">2,000</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
              </tr>

          </table>
        </div>
        <div style="margin-left:60pt;margin-bottom:0pt">
          <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

              <tr>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="6" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">December 31,</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2022</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2021</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>


              <tr style="background-color:#cceeff">
                <td style="vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Long-lived assets:</p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>
              <tr style="background-color:#cceeff">
                <td style="vertical-align:bottom;width:76%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Israel</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
                </td>
                <td style="vertical-align:bottom;width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">3,239</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
                </td>
                <td style="vertical-align:bottom;width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">3,787</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">United States</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">119</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">118</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
              </tr>
              <tr style="background-color:#cceeff">
                <td style="vertical-align:bottom;width:76%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:9%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:9%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Total long-lived assets</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
                </td>
                <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">3,358</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
                </td>
                <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">3,905</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
              </tr>

          </table>
        </div>

      <p style="margin:0pt 0pt 0px">&#160;</p>
      <div/>

        <div style="margin-left:56.7pt;margin-top:0pt">
          <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

              <tr>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="8" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Year ended December 31,</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2022</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2021</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2020</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>


              <tr style="background-color:#cceeff">
                <td style="vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Sales to a single customer exceeding 10%:</p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>
              <tr style="background-color:#cceeff">
                <td style="vertical-align:bottom;width:62%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Customer A</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">100</p>
                </td>
                <td style="vertical-align:bottom;width:2%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">%</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">100</p>
                </td>
                <td style="vertical-align:bottom;width:2%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">%</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">100</p>
                </td>
                <td style="vertical-align:bottom;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td>
              </tr>

          </table>
        </div>

    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130166644352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL AND OTHER INCOME, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">FINANCIAL AND OTHER INCOME, NET</a></td>
<td class="text">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"><span style="font-weight:bold">NOTE 11: -&#160;</span><span style="font-weight:bold">FINANCIAL AND OTHER INCOME, NET</span></p>

      <div style="margin-left:56.7pt;margin-bottom:0pt">
        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="10" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Year ended December 31,</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2022</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2021</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2020</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:64%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Interest income</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,437</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">894</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,765</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:64%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Bank fees and other finance expenses</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(27</p>
              </td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">)</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(25</p>
              </td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">)</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(42</p>
              </td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">)</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:64%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Foreign currency transaction adjustments</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">340</p>
              </td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(1</p>
              </td>
              <td style="vertical-align:bottom;width:1%"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">63</p>
              </td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
            </tr>
            <tr>
              <td style="vertical-align:baseline;width:64%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gain (loss) from sales and disposals of fixed assets</span></span></p>
              </td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(12</span></span></p>
              </td>
              <td style="vertical-align:baseline;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3</span></span></p>
              </td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12</span></span></p>
              </td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:64%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:64%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Financial and other income, net</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,738</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">871</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,798</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>
      </div>

  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -URI https://asc.fasb.org/topic&amp;trid=2122503<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 610<br> -URI https://asc.fasb.org/topic&amp;trid=49130413<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130166584672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY BALANCES AND TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY BALANCES AND TRANSACTIONS</a></td>
<td class="text">
    <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"><span style="font-weight:bold">NOTE 12: - </span><span style="font-weight:bold">RELATED PARTY BALANCES AND TRANSACTION</span></p>

      <div>
        <div>
          <div style="margin-left:56.7pt">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt">

                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Trade payables and accrued expenses</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>83</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>94</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                </tr>

            </table>
          </div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <div style="margin-left:56.7pt">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt">

                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="10" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2020</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amounts charged to:</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development expenses</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>194</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>240</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>294</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                </tr>

            </table>
            <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
          </div>
        </div>
      </div>

    <div>
      <div style="margin-left:56.7pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">For the years ended December 31, 2022, 2021 and 2020 the Company received research and development services related with cancer studies in animal models, and breeding and maintenance of animals (mice) to support such studies. The transaction was at arm&#8217;s length.</span></span></div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130166743936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSSES PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">LOSSES PER SHARE</a></td>
<td class="text">
    <div>
      <div>
        <div>
          <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">NOTE 13: - LOSSES PER SHARE</span></span></span></p>
        </div>
      </div>
      <div>
        <div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>

            <div style="text-align:justify;text-indent:-28.35pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table sets forth the computation of basic and diluted losses per share:</span></span></div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
            <div style="margin-left:56.7pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt">

                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="10" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2020</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Numerator:</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss for basic and diluted loss per share</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(33,694</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(34,203</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(29,698</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Denominator:</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average number of ordinary shares used in computing basic and diluted net loss per share</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">86,555,628</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">84,203,971</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">79,591,187</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic and diluted loss per ordinary share</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(0.39</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(0.41</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(0.37</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></div>
                    </td>
                  </tr>

              </table>
            </div>

        </div>
      </div>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130168914704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">
    <div>
      <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong>NOTE 14: -&#160;<span>Subsequent Events</span></strong></span></span></p>
      <p style="margin-top:11pt;margin-bottom:0pt;font-family:Times New Roman, Times, serif;margin-left:56.7pt;text-align:justify"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span><span>On January 31, 2023, the Company entered into a </span>Sales Agreement with SVB Securities LLC (&#8220;SVB&#8221;), as sales agent, pursuant to which the Company may offer and sell, from time to time through SVB, our ordinary shares. The offer and sale of our ordinary shares, if any, will be made pursuant to our shelf registration statement on Form F-3, as supplemented by the prospectus supplement filed on January 31, 2023. Pursuant to the said prospectus supplement, the Company may offer and sell up to $50 million of its ordinary shares.</span></span></span></p>
    </div>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130169052912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates:</a></td>
<td class="text">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">a.<span style="padding-left:22.06pt">Use of estimates:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company&#8217;s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</span></span></p>
    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Financial statements in U.S. dollars:</a></td>
<td class="text">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">b.<span style="padding-left:22.5pt">Financial statements in U.S. dollars:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The reporting and functional currency of the Company is the U.S. dollar, as the Company&#8217;s management believes that the U.S. dollar is the primary currency of the economic environment in which the Company and Compugen USA, Inc. have operated and expect to continue to operate in the foreseeable future.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts denominated in currencies other than the dollar are re-measured into dollars in accordance with ASC No. 830, &#8220;Foreign Currency Matters&#8221;. All transaction gains and losses from the re-measurement of monetary balance sheet items are reflected in the consolidated statement of comprehensive loss as financial income or expenses, as appropriate.</span></span></p>
    <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of consolidation:</a></td>
<td class="text">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">c.<span style="padding-left:22.06pt">Basis of consolidation:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The consolidated financial statements include the accounts of the Company and Compugen USA, Inc. Intercompany transactions and balances have been eliminated upon consolidation.</span></span></p>
    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash equivalents:</a></td>
<td class="text">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">d.<span style="padding-left:22.5pt">Cash equivalents:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition.</span></span></p>
    <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted cash:</a></td>
<td class="text">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">e.<span style="padding-left:22.06pt">Restricted cash:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Restricted cash is held in interest bearing saving accounts which are used as a security for the Company&#8217;s Israeli facility leasehold&#160;and leased cars fueling bank guarantees and credit card security for Compugen USA, Inc.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
      <div/>
    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ShortTermBankDepositsPolicyTextBlock', window );">Short-term bank deposits:</a></td>
<td class="text">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">f.<span style="padding-left:22.17pt">Short-term bank deposits:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Bank deposits with maturities of more than three months but less than one year are included in short-term bank deposits. Such short-term bank deposits are stated at cost which approximates market values.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The short-term bank deposits as of December 31, 2022&#160;and 2021&#160;are in U.S. dollars and bear an annual weighted average interest rate of 4.84% and 0.77%, respectively.</span></span></p>
    <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment, net:</a></td>
<td class="text">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">g.<span style="padding-left:22.5pt">Property and equipment, net:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates:</span></span></p>
      <div style="margin-left:85.05pt">

          <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

              <tr>
                <td style="vertical-align:bottom;width:50%">&#160;</td>
                <td style="vertical-align:bottom;width:2%">&#160;</td>
                <td style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom;width:48%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">%</span></span></strong></p>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:50%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
                </td>
                <td style="vertical-align:bottom;width:2%">&#160;</td>
                <td style="vertical-align:bottom;width:48%">&#160;</td>
              </tr>


              <tr style="background-color:#cceeff">
                <td style="vertical-align:bottom;width:50%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Computers, software and related equipment</span></span></p>
                </td>
                <td style="vertical-align:bottom;width:2%">&#160;</td>
                <td style="vertical-align:bottom;width:48%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">33</span></span></p>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:50%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Laboratory equipment and office furniture</span></span></p>
                </td>
                <td style="vertical-align:bottom;width:2%">&#160;</td>
                <td style="vertical-align:bottom;width:48%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">6 - 20 (mainly 20)</span></span></p>
                </td>
              </tr>
              <tr style="background-color:#cceeff">
                <td style="vertical-align:bottom;width:50%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Leasehold improvements</span></span></p>
                </td>
                <td style="vertical-align:bottom;width:2%">&#160;</td>
                <td style="vertical-align:bottom;width:48%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Shorter of the term of the lease or useful life</span></span></p>
                </td>
              </tr>

          </table>

      </div>
    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentImpairment', window );">Impairment of long-lived assets:</a></td>
<td class="text">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">h.<span style="padding-left:22.5pt">Impairment of long-lived assets:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The long-lived assets of the Company and Compugen USA, Inc. are reviewed for impairment in accordance with ASC 360, &#8220;Property, Plant, and Equipment&#8221; whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset with the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the years 2022, 2021&#160;and 2020, no impairment losses have been identified.</span></span></p>
    <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases:</a></td>
<td class="text">
            <div>
              <div>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">i.<span style="padding-left:22.72pt">Leases:</span></span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The Company accounts for its leases according to ASC 842 - Leases (&#8220;ASC 842&#8221;). The Company determines if an arrangement is a lease and the classification of that lease at inception based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of the asset. The Company elected to not recognize a lease liability and a right-of-use (&#8220;ROU&#8221;) asset for leases with a term of twelve months or less.</span></span></p>
                <p style="margin:0pt">&#160;</p>
                <div/>
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:85.05pt;text-align:justify">ROU assets and lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. ROU assets are initially measured at amounts, which represents the discounted present value of the lease payments over the lease, plus any initial direct costs incurred. The lease liability is initially measured based on the discounted present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. The implicit rate within the operating leases is generally not determinable, therefore the Company uses the Incremental Borrowing Rate (&#8220;IBR&#8221;) based on the information available at commencement date in determining the present value of lease payments. The Company&#8217;s IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located.</p>
                <p style="margin:0pt">&#160;</p>
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:85.05pt;text-align:justify">An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate the lease is considered unless it is reasonably certain that the Company will not exercise the option.</p>
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:85.05pt;text-align:justify">&#160;</p>
              </div>
            </div>
          <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue recognition:</a></td>
<td class="text">
              <div>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:76pt;text-indent:-20pt">j.<span style="padding-left:23.06pt">Revenue recognition:</span></p>
                <p style="margin:0pt">&#160;</p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:85.05pt;text-align:justify">The Company generates revenues mainly from its collaborative and license agreements. The revenues are derived mainly from upfront license payments, research and development services and contingent payments related to milestone achievements.</p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The Company recognizes revenue in accordance with ASC 606 &#8211; &#8220;Revenue from Contracts with Customers&#8221;.</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">As such, the Company analyzes its contracts to assess whether they are within the scope of ASC 606. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps:</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">&#8226;</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:-12pt;text-indent:114pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-style:italic">Identification of the contract, or contracts, with a customer</span></span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">&#8226;</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:-12pt;margin-left:114pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-style:italic">Identification of the performance obligations in the contract</span>&#160;</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">&#8226;</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:-12pt;margin-left:114pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-style:italic">Determination of the transaction price</span>&#160;</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">&#8226;</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:-12pt;margin-left:114pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-style:italic">Allocation of the transaction price to the performance obligations in the contract</span>&#160;</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">&#8226;</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:-12pt;margin-left:114pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-style:italic">Recognition of revenue when, or as, the Company satisfies a performance obligation</span>&#160;</span></span></p>
                <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
                <div/>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:85pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">At the contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></span></p>
                <p style="margin:0pt">&#160;</p>
                <div>
                  <div style="margin-left:85.05pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company entered into an exclusive license agreement with AstraZeneca. Under the terms of the agreement, Compugen provided AstraZeneca with an exclusive license to intellectual property ("IP&#8221;) rights of the Company for the development of bi-specific and multi-specific antibody products derived from COM902. Compugen received a $10,000 upfront nonrefundable payment and is eligible to receive up to $200,000 for development, regulatory and commercial milestones for the first product, of which $15,500 was received to date as well as tiered royalties on future product sales.</span></span></div>
                </div>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Under ASC 606, the Company determined the license to the IP to be a functional IP that has significant standalone functionality. The Company is not required to continue to support, develop or maintain the intellectual property transferred and will not undertake any activities to change the standalone functionality of the IP. Therefore, the license to the IP is a distinct performance obligation and as such revenue is recognized at the point in time that control of the license is transferred to the customer.</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Future milestone payments are considered variable consideration and are subject to the variable consideration constraint (i.e. will be recognized once concluded that it is &#8220;probable&#8221; that a significant reversal of the cumulative revenues recognized under the contract will not occur in future periods when the uncertainty related to the variable consideration is resolved). Therefore, as the milestone payments are not probable, revenue was not recognized in respect to such milestone payments prior to achievement of such milestone.</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Sales&#160;or usage-based royalties to be received in exchange for licenses of IP are recognized at the later of when (1) the subsequent sale or usage occurs or (2) the performance obligation to which some or all of the sales&#160;or usage-based royalty has been allocated is satisfied (in whole or in part). As royalties are payable based on future Commercial Sales, as defined in the agreement, which did not occur as of the financial statements date, the Company did not recognize any revenues from royalties.</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">On December 18, 2020 the first milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $&#160;2,000 in accordance with the criteria prescribed under ASC 606.</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">On September 29, 2021 the second milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $&#160;6,000 in accordance with the criteria prescribed under ASC 606.</span></span></p>
                <p style="margin:0pt">&#160;</p>
                <div/>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">On November 11, 2022, the third milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ 7,500 in accordance with the criteria prescribed under ASC 606.</span></span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">For additional information regarding revenues, please refer to Note 10 below.</span></span></p>
              </div>
            <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_CostOfSalesContractWithCustomerPolicyTextBlock', window );">Cost of revenues:</a></td>
<td class="text">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">k.<span style="padding-left:22.72pt">Cost of revenues:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Cost of revenues consist of certain royalties and milestones paid or accrued.</span></span></p>
    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development expenses, net:</a></td>
<td class="text">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">l.<span style="padding-left:24.5pt">Research and development expenses, net:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Research and development costs are charged to the statement of comprehensive loss as incurred and are presented net of the amount of any grants the Company receives for research and development in the period in which the grant was received.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">As part of the process of preparing the consolidated financial statements, the Company accrues costs for pre-clinical and clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the contract research organizations or other pre-clinical or clinical trial vendors that perform the activities. In certain circumstances, the Company is required to make nonrefundable advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the nonrefundable advance payments are deferred and capitalized, and amortized as the related goods or services are provided. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense.</span></span></p>
      <p style="margin:0pt">&#160;</p>
      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:85.05pt;text-align:justify">The portion of the Bristol-Myers Squibb $ 12,000 investment in 2018 over the fair market value of the shares issued in the amount of $ 4,121 and the portion of the $ 20,000 investment in 2021 over the fair market value of the shares issued in the amount of $ 5,000 were considered as deferred participation of Bristol-Myers Squibb in R&amp;D expenses which is amortized over the period of the clinical trial based on the progress in the R&amp;D, see Note 1f and Note 8b.</p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Amortization of participation in R&amp;D expenses for the years ended December 31, 2022, 2021&#160;and 2020&#160;were $&#160;6,019, $&#160;1,291 and $&#160;829, respectively.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
    <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ServerancePayPolicyTextBlock', window );">Severance pay:</a></td>
<td class="text">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">m.<span style="padding-left:18.72pt">Severance pay:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The Company&#8217;s liability for severance pay for its Israeli employees is calculated pursuant to Israeli Severance Pay Law based on the most recent salary of the employees multiplied by the number of years of employment as of the balance sheet date, and is in large part covered by regular deposits with recognized pension funds, deposits with severance pay funds and purchases of insurance policies. The value of these deposits and policies is recorded as an asset in the Company&#8217;s balance sheet. Pursuant to Section 14 of the Israeli Severance Pay Law, for Israeli employees under this section, the Company&#8217;s contributions for severance pay have replaced its severance obligation. Upon contribution of the full amount of the employee&#8217;s monthly salary for each year of service, no additional calculations are conducted between the parties regarding the matter of severance pay and no additional payments are made by the Company to the employee.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Further, the related obligation and amounts deposited on behalf of the employee for such obligation are not stated on the balance sheet, as the Company is legally released from the obligation to employees once the deposit amounts have been paid.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Severance expenses for the years ended December 31, 2022, 2021&#160;and 2020&#160;amounted to approximately $&#160;468, $&#160;383 and $&#160;572, respectively.</span></span></p>
    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based compensation:</a></td>
<td class="text">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">n.<span style="padding-left:22.06pt">Stock-based compensation:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The Company accounts for stock-based compensation to employees and non-employees in accordance with ASC 718, &#8220;Compensation - Stock Compensation&#8221;, (&#8220;ASC 718&#8221;), which requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The Company accounts for forfeitures as they occur.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The Company recognizes compensation expenses for the value of its awards granted based on the straight-line method over the requisite service period of each of the awards.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The Company selected the Black-Scholes-Merton (&#8220;Black-Scholes&#8221;) option-pricing model as the most appropriate fair value method for its share-options awards and Employee Stock Purchase Plan (&#8220;ESPP&#8221;). The option-pricing model requires a number of assumptions, of which the most significant are the expected share price volatility and the expected option term. Expected volatility was calculated based on actual historical share price movements over a term that is equivalent to the expected term of granted options. The expected term of options granted is based on historical experience and represents the period of time that options granted are expected to be outstanding.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.</span></span></p>
      <p style="margin:0pt">&#160;</p>
      <div/>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The Company used the following assumptions for options granted to employees, directors and non-employees and ESPP:</span></span></p>
      <div style="margin-left:85.05pt">

          <table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%">

              <tr>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="10" rowspan="1" style="vertical-align:bottom;border-bottom:1.5pt solid black">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-weight:bold">Year ended December 31,</span></span></span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:1.5pt solid black">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-weight:bold">2022</span></span></span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:1.5pt solid black">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-weight:bold">2021</span></span></span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:1.5pt solid black">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-weight:bold">2020</span></span></span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:49%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:14%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:14%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:14%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
              </tr>


              <tr style="background-color:rgb(204, 238, 255)">
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>Employee stock options</span></span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              </tr>
              <tr style="background-color:rgb(255, 255, 255)">
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
              </tr>
              <tr style="background-color:rgb(204, 238, 255)">
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Volatility</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">69.44%-74.61%</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">66.02%-69.05%</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">55.12%-65.59%</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              </tr>
              <tr style="background-color:rgb(255, 255, 255)">
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Risk-free interest rate</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">1.54%-4.39%</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.51%-1.14%</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.26%-1.64%</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
              </tr>
              <tr style="background-color:rgb(204, 238, 255)">
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Dividend yield</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0%</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0%</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0%</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              </tr>
              <tr style="background-color:rgb(255, 255, 255)">
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Expected life (years)</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">5.05-5.4</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">5.04-5.31</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">5.02-5.31</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
              </tr>

          </table>

      </div>
      <div style="margin-left:85.05pt">
        <div style="margin-top:10pt">

            <div>
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%">

                  <tr>
                    <td style="vertical-align:bottom">&#160;</td>
                    <td style="vertical-align:bottom">&#160;</td>
                    <td colspan="10" rowspan="1" style="vertical-align:bottom;text-align:center;border-bottom:1.5pt solid black">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="line-height:110%">Year ended December 31,</span></span></span></strong></p>
                    </td>
                    <td style="vertical-align:bottom;text-align:center">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom">&#160;</td>
                    <td style="vertical-align:bottom">&#160;</td>
                    <td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center;border-bottom:1.5pt solid black">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span>2022</span></strong></span></span></p>
                    </td>
                    <td style="vertical-align:bottom;text-align:center">&#160;</td>
                    <td style="vertical-align:bottom;text-align:center">&#160;</td>
                    <td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center;border-bottom:1.5pt solid black">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span>2021</span></strong></span></span></p>
                    </td>
                    <td style="vertical-align:bottom;text-align:center">&#160;</td>
                    <td style="vertical-align:bottom;text-align:center">&#160;</td>
                    <td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center;border-bottom:1.5pt solid black">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span>2020</span></strong></span></span></p>
                    </td>
                    <td style="vertical-align:bottom;text-align:center">&#160;</td>
                  </tr>
                  <tr style="background-color:rgb(204, 238, 255)">
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>ESPP</span></span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                  </tr>
                  <tr style="background-color:rgb(255, 255, 255)">
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                  </tr>
                  <tr style="background-color:rgb(204, 238, 255)">
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Volatility</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="padding-left:0pt">69.74</span><span style="padding-left:0pt">%</span></span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">64.68%-69.68%</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">-</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                  </tr>
                  <tr style="background-color:rgb(255, 255, 255)">
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Risk-free interest rate</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">1.63%</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.04%-0.10%</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">-</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                  </tr>
                  <tr style="background-color:rgb(204, 238, 255)">
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Dividend yield</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0%</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0%</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">-</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                  </tr>
                  <tr style="background-color:rgb(255, 255, 255)">
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Expected life (years)</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.50</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.42-0.50</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">-</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                  </tr>

              </table>
            </div>

        </div>
      </div>
    <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of credit risks:</a></td>
<td class="text">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">o.<span style="padding-left:21.5pt">Concentration of credit risks:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Financial instruments that potentially subject the Company and Compugen USA, Inc. to concentration of credit risk consist principally of cash and cash equivalents, restricted cash and short-term bank deposits.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Cash, cash equivalents, restricted cash and short-term bank deposits are invested in major banks in Israel. Generally, these deposits may be redeemed upon demand and bear minimal risk.</span></span></p>
    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and diluted loss per share:</a></td>
<td class="text">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">p.<span style="padding-left:22.5pt">Basic and diluted loss per share:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Basic loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260, &#8220;Earnings per Share&#8220;.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">All outstanding share options and warrants for the years ended December 31, 2022, 2021 and 2020 have been excluded from the calculation of the diluted net loss per share, because all such securities are anti-dilutive for all periods presented. As of December 31, 2022, 2021 and 2020 the average number of shares related to outstanding options and warrants excluded from the calculations of diluted net loss per share were 8,405,615, 6,758,300 and 7,150,648, respectively.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt">&#160;</p>
      <div/>
    <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes:</a></td>
<td class="text">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">q.<span style="padding-left:22.5pt">Income taxes:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The Company accounts for income taxes in accordance with ASC No. 740, &#8220;Income Taxes&#8220;, (&#8220;ASC 740&#8220;) which prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2022 and 2021, a full valuation allowance was provided by the Company.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been recorded pursuant to ASC 740-10.</span></span></p>
    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value of financial instruments:</a></td>
<td class="text">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">r.<span style="padding-left:23.5pt">Fair value of financial instruments:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The Company applies ASC 820, &#8220;Fair Value Measurements and Disclosures&#8221; (&#8220;ASC 820&#8221;), pursuant to which fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &#8220;exit price&#8221;) in an orderly transaction between market participants at the measurement date.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputting that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company.</span></span></p>
      <p style="margin:0pt">&#160;</p>
      <div/>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:85.05pt;margin-bottom:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The hierarchy is broken down into three levels based on the inputs as follows:</span></span></p>
      <table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%">

          <tr>
            <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:85.5pt">&#160;</td>
            <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:56.7pt">
              <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt">Level 1&#160; &#160;&#160;</span><span style="font-size:10pt">-</span></p>
            </td>
            <td style="font-family:Times New Roman, Times, serif;vertical-align:top;text-align:justify;width:auto"><span style="font-size:10pt"><span>Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can </span>access at the measurement date.</span></td>
          </tr>

      </table>
      <div style="margin-top:10pt">
        <table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%">

            <tr>
              <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:85.5pt">&#160;</td>
              <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:56.7pt">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt">Level 2&#160; &#160; -</span></p>
              </td>
              <td style="font-family:Times New Roman, Times, serif;vertical-align:top;text-align:justify;width:auto"><span style="font-size:10pt"><span>Valuations based on one or more quoted prices in markets that are not active or for which all </span>significant inputs are observable, either directly or indirectly.</span></td>
            </tr>
            <tr>
              <td style="width:85.5pt">&#160;</td>
              <td style="width:56.7pt">&#160;</td>
              <td style="text-align:justify;width:auto">&#160;</td>
            </tr>
            <tr>
              <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:85.5pt">&#160;</td>
              <td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:56.7pt">
                <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt">Level 3&#160; &#160; -</span></p>
              </td>
              <td style="font-family:Times New Roman, Times, serif;vertical-align:top;text-align:justify;width:auto"><span style="font-size:10pt"><span>Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</span></span></td>
            </tr>

        </table>
      </div>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.</span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The carrying amounts of cash and cash equivalents, restricted cash, short-term bank deposits, other accounts receivable and prepaid expenses, trade payable and other accounts payable and accrued expenses approximate their fair values due to the short-term maturities of such instruments.</span></span></p>
    <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently issued and recently adopted Accounting Standards:</a></td>
<td class="text">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">s.<span style="padding-left:22.06pt">Recently issued and recently adopted Accounting Standards:</span></span></span></p>
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Although there are several other new accounting standards issued or proposed by the FASB, which the Company has adopted or will adopt, as applicable, the Company does not believe any of these accounting pronouncements has had or will have a material impact on its consolidated financial statements.</span></span></p>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_CostOfSalesContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognition of costs in the period which correspond to the sales and revenue categories presented in the statement of operations. The accounting policy may include the amount and nature of costs incurred, provisions associated with inventories, purchase discounts, freight and other costs included in cost of sales incurred and recorded in the period. This disclosure also includes the nature of costs of sales incurred and recorded in the statement of operations for the period relating to transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_CostOfSalesContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ServerancePayPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Serverance Pay [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ServerancePayPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ShortTermBankDepositsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for short-term bank deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ShortTermBankDepositsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130166654608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock', window );">Schedule of depreciation rates for property and equipment</a></td>
<td class="text">
          <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

              <tr>
                <td style="vertical-align:bottom;width:50%">&#160;</td>
                <td style="vertical-align:bottom;width:2%">&#160;</td>
                <td style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom;width:48%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">%</span></span></strong></p>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:50%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
                </td>
                <td style="vertical-align:bottom;width:2%">&#160;</td>
                <td style="vertical-align:bottom;width:48%">&#160;</td>
              </tr>


              <tr style="background-color:#cceeff">
                <td style="vertical-align:bottom;width:50%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Computers, software and related equipment</span></span></p>
                </td>
                <td style="vertical-align:bottom;width:2%">&#160;</td>
                <td style="vertical-align:bottom;width:48%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">33</span></span></p>
                </td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:50%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Laboratory equipment and office furniture</span></span></p>
                </td>
                <td style="vertical-align:bottom;width:2%">&#160;</td>
                <td style="vertical-align:bottom;width:48%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">6 - 20 (mainly 20)</span></span></p>
                </td>
              </tr>
              <tr style="background-color:#cceeff">
                <td style="vertical-align:bottom;width:50%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Leasehold improvements</span></span></p>
                </td>
                <td style="vertical-align:bottom;width:2%">&#160;</td>
                <td style="vertical-align:bottom;width:48%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Shorter of the term of the lease or useful life</span></span></p>
                </td>
              </tr>

          </table>
        <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions', window );">Schedule of weighted average assumptions for granted options</a></td>
<td class="text">
          <table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%">

              <tr>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="10" rowspan="1" style="vertical-align:bottom;border-bottom:1.5pt solid black">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-weight:bold">Year ended December 31,</span></span></span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:1.5pt solid black">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-weight:bold">2022</span></span></span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:1.5pt solid black">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-weight:bold">2021</span></span></span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:1.5pt solid black">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="font-weight:bold">2020</span></span></span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:49%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:14%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:14%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:14%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
              </tr>


              <tr style="background-color:rgb(204, 238, 255)">
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>Employee stock options</span></span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              </tr>
              <tr style="background-color:rgb(255, 255, 255)">
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
              </tr>
              <tr style="background-color:rgb(204, 238, 255)">
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Volatility</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">69.44%-74.61%</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">66.02%-69.05%</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">55.12%-65.59%</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              </tr>
              <tr style="background-color:rgb(255, 255, 255)">
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Risk-free interest rate</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">1.54%-4.39%</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.51%-1.14%</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.26%-1.64%</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
              </tr>
              <tr style="background-color:rgb(204, 238, 255)">
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Dividend yield</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0%</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0%</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0%</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
              </tr>
              <tr style="background-color:rgb(255, 255, 255)">
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Expected life (years)</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">5.05-5.4</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">5.04-5.31</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">5.02-5.31</span></span></p>
                </td>
                <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
              </tr>

          </table>

            <div>
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%">

                  <tr>
                    <td style="vertical-align:bottom">&#160;</td>
                    <td style="vertical-align:bottom">&#160;</td>
                    <td colspan="10" rowspan="1" style="vertical-align:bottom;text-align:center;border-bottom:1.5pt solid black">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><strong><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="line-height:110%">Year ended December 31,</span></span></span></strong></p>
                    </td>
                    <td style="vertical-align:bottom;text-align:center">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom">&#160;</td>
                    <td style="vertical-align:bottom">&#160;</td>
                    <td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center;border-bottom:1.5pt solid black">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span>2022</span></strong></span></span></p>
                    </td>
                    <td style="vertical-align:bottom;text-align:center">&#160;</td>
                    <td style="vertical-align:bottom;text-align:center">&#160;</td>
                    <td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center;border-bottom:1.5pt solid black">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span>2021</span></strong></span></span></p>
                    </td>
                    <td style="vertical-align:bottom;text-align:center">&#160;</td>
                    <td style="vertical-align:bottom;text-align:center">&#160;</td>
                    <td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center;border-bottom:1.5pt solid black">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><strong><span>2020</span></strong></span></span></p>
                    </td>
                    <td style="vertical-align:bottom;text-align:center">&#160;</td>
                  </tr>
                  <tr style="background-color:rgb(204, 238, 255)">
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span>ESPP</span></span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                  </tr>
                  <tr style="background-color:rgb(255, 255, 255)">
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                  </tr>
                  <tr style="background-color:rgb(204, 238, 255)">
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Volatility</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt"><span style="padding-left:0pt">69.74</span><span style="padding-left:0pt">%</span></span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">64.68%-69.68%</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">-</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                  </tr>
                  <tr style="background-color:rgb(255, 255, 255)">
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Risk-free interest rate</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">1.63%</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.04%-0.10%</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">-</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                  </tr>
                  <tr style="background-color:rgb(204, 238, 255)">
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Dividend yield</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0%</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0%</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">-</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%">&#160;</td>
                  </tr>
                  <tr style="background-color:rgb(255, 255, 255)">
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">Expected life (years)</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.50</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                      <p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">0.42-0.50</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%">
                      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">-</span></span></p>
                    </td>
                    <td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%">&#160;</td>
                  </tr>

              </table>
            </div>
          <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the annual rates used to calculate depreciation for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of granted stock options, including, but not limited to: (a) expected term of granted share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130166599120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of other accounts receivable and prepaid expenses</a></td>
<td class="text">
                    <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;float:left">

                        <tr>
                          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                          <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                            <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                          <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                            <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Prepaid expenses</span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,100</span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>5,272</span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
                            <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Government authorities</span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">85</span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">57</span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">
                            <div style="text-indent:-4.25pt;margin-left:7.1pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Other</span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">232</span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">131</span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                        </tr>
                        <tr>
                          <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,417</span></span></div>
                          </td>
                          <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                            <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>5,460</span></span></span></div>
                          </td>
                          <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                        </tr>

                    </table>
                  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130166766064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate', window );">Schedule of weighted-average remaining lease term and discount rate</a></td>
<td class="text">
            <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:90%">

                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average remaining lease term</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3.16</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%" valign="bottom">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average discount (annual) rate</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">5.52%</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25">&#160;</div>
                    </div>
                  </td>
                </tr>

            </table>
          <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of operating leases</a></td>
<td class="text">
            <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:90%">

                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-weight:bold">December 31,</span><span>&#160;<span style="font-weight:bold">2022</span></span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2023</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>699</span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%" valign="bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2024</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">669</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2025</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">609</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%;padding-bottom:2px" valign="bottom">
                    <div style="text-align:justify;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2026</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">114</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%" valign="bottom">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Total operating lease payments</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,091</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Less: imputed interest</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">166</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Present value of lease liabilities</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,925</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%" valign="bottom">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease liabilities, current</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">613</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease liabilities, non- current</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,312</span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Present value of lease liabilities</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>1,925</span></span></span></div>
                    </div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                </tr>

            </table>
          <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of weighted-average remaining lease term and discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130166709472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment, net</a></td>
<td class="text">
      <div style="margin-left:56.7pt">
        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="6" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">December 31,</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2022</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2021</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Cost:</p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Computers, software and related equipment</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,617</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,506</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Laboratory equipment and office furniture</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">3,831</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">3,674</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Leasehold improvements</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">2,314</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">2,321</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:76%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">7,762</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">7,501</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Accumulated depreciation:</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Computers, software and related equipment</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,435</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,351</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Laboratory equipment and office furniture</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">3,190</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">3,114</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Leasehold improvements</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,605</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,378</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">6,230</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">5,843</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:76%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Depreciated cost</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,532</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,658</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130166661296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of other accounts payable and accrued expenses</a></td>
<td class="text">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;float:left">

                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold">December 31,</div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold">2022</div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold">2021</div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25">Employees and related accruals</div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-family:'Times New Roman',Times,serif">$</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-family:'Times New Roman',Times,serif">2,812</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-family:'Times New Roman',Times,serif">$</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-family:'Times New Roman',Times,serif">3,299</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px" valign="bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25">Accrued expenses</div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                    <div style="line-height:1.25">6,396</div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                    <div style="line-height:1.25">4,779</div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-family:'Times New Roman',Times,serif">$</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-family:'Times New Roman',Times,serif">9,208</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-family:'Times New Roman',Times,serif">$</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-family:'Times New Roman',Times,serif">8,078</span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>

            </table>
          <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130166648608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of stock-based compensation expenses</a></td>
<td class="text">
      <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:10pt">Transactions related to the grant of options to employees, directors and non-employees under the above Plan during the year ended December 31, 2022, were as follows:</p>
      <div style="margin-left:85.04pt">
        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Number of</span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">options</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Weighted</span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">average</span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">exercise </span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">price</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Weighted</span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">average</span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">remaining</span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">contractual </span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">life</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Aggregate</span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">intrinsic</span></p>
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">value</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">$</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Years</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">$</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:52%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Options outstanding at beginning of year</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">6,976,104</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">6.39</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">6.69</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">3,323</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:52%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Options granted</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">2,186,400</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">2.58</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:52%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Options exercised</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(33,186</p>
              </td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">)</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">3.14</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:52%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Options forfeited</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(778,069</p>
              </td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">)</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">6.42</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:baseline;width:52%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Options expired</p>
              </td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(193,500</p>
              </td>
              <td style="vertical-align:baseline;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:1pt">)</p>
              </td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">4.21</p>
              </td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;width:9%">&#160;</td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;width:9%">&#160;</td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:52%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:52%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Options outstanding at end of year</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">8,157,749</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">5.43</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">6.32</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">-</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:52%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:52%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Exercisable at end of year</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">4,635,040</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">5.68</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">4.52</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%;border-bottom:4px double black">&#160;</td>
              <td style="vertical-align:bottom;width:9%;border-bottom:4px double black">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">-</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>
      </div>
    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of option activity</a></td>
<td class="text">
        <div>
          <div>
            <p style="text-indent:-28pt;margin-left:85pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">e.<span style="padding-left:21.5pt;font-size:10pt;font-family:Times New Roman, Times, serif">The stock-based compensation expenses related to stock options and ESPP are included as follows in the expense categories:</span></p>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
            <div style="margin-left:85.05pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;float:left">

                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="10" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2020</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development expenses</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>2,158</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>1,971</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>1,123</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Marketing and business development expenses</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">269</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">215</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">172</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">General and administrative expenses</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,901</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,090</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1,477</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>4,328</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>4,276</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>2,772</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>

              </table>
              <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
            </div>
          </div>
        </div>
      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130167903600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of loss before taxes</a></td>
<td class="text">
        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="10" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Year ended December 31,</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2022</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2021</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2020</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:64%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Domestic (Israel)</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">34,096</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">34,619</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">30,010</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:baseline;width:64%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Foreign</p>
              </td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(460</p>
              </td>
              <td style="vertical-align:baseline;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:1.5pt">)</p>
              </td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(416</p>
              </td>
              <td style="vertical-align:baseline;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:1.5pt">)</p>
              </td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(312</p>
              </td>
              <td style="vertical-align:baseline;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:1.5pt">)</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:64%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:64%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">33,636</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">34,203</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">29,698</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>
      <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text">
        <div>
          <div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
            <div style="margin-left:85.5pt">
              <table border="0" cellpadding="0" cellspacing="0" style="color:#000000;float:left;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%">

                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Operating loss carryforward</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>91,704</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>86,068</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12,083</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">9,773</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Accrued social benefits and other</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3,123</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2,801</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Right of use assets</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(415</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(520</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Lease liabilities</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">444</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">636</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px" valign="bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Property and equipment</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Deferred tax asset before valuation allowance</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">106,941</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">98,760</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px" valign="bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Valuation allowance</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(106,941</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(98,760</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px" valign="bottom">
                      <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net deferred tax asset</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>-</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>-</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>

              </table>
            </div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both">&#160;</div>
          </div>
        </div>
      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130167482800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock', window );">Schedule of total revenues and long-lived assets by geographic area</a></td>
<td class="text">
        <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:56.7pt;margin-bottom:11pt">The following represents the total revenue for the years ended December 31, 2022, 2021&#160;and 2020&#160;and long-lived assets as of December 31, 2022&#160;and 2021:</p>
        <div style="margin-left:56.7pt;margin-bottom:11pt">
          <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

              <tr>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="10" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Year ended December 31,</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2022</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2021</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2020</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>


              <tr style="background-color:#cceeff">
                <td style="vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Revenue from sales to customers:</p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>
              <tr style="background-color:#cceeff">
                <td style="vertical-align:bottom;width:64%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Europe</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
                </td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">7,500</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
                </td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">6,000</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
                </td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">2,000</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:64%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:9%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:9%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:9%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
              </tr>
              <tr style="background-color:#cceeff">
                <td style="vertical-align:bottom;width:64%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Total revenue</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
                </td>
                <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">7,500</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
                </td>
                <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">6,000</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
                </td>
                <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">2,000</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
              </tr>

          </table>
        </div>
        <div style="margin-left:60pt;margin-bottom:0pt">
          <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

              <tr>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="6" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">December 31,</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2022</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2021</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>


              <tr style="background-color:#cceeff">
                <td style="vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Long-lived assets:</p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>
              <tr style="background-color:#cceeff">
                <td style="vertical-align:bottom;width:76%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Israel</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
                </td>
                <td style="vertical-align:bottom;width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">3,239</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
                </td>
                <td style="vertical-align:bottom;width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">3,787</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">United States</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">119</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">118</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
              </tr>
              <tr style="background-color:#cceeff">
                <td style="vertical-align:bottom;width:76%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:9%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:9%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom;width:76%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Total long-lived assets</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
                </td>
                <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">3,358</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
                </td>
                <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">3,905</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
              </tr>

          </table>
        </div>
      <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Schedule of sales to single customer xxceeding 10%:a</a></td>
<td class="text">
        <div style="margin-left:56.7pt;margin-top:0pt">
          <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

              <tr>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="8" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Year ended December 31,</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2022</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2021</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2020</span></p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>


              <tr style="background-color:#cceeff">
                <td style="vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Sales to a single customer exceeding 10%:</p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align:bottom">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
                </td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
                <td colspan="2" style="vertical-align:bottom">&#160;</td>
                <td style="vertical-align:bottom">&#160;</td>
              </tr>
              <tr style="background-color:#cceeff">
                <td style="vertical-align:bottom;width:62%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Customer A</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">100</p>
                </td>
                <td style="vertical-align:bottom;width:2%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">%</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">100</p>
                </td>
                <td style="vertical-align:bottom;width:2%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">%</p>
                </td>
                <td style="vertical-align:bottom;width:1%">&#160;</td>
                <td style="vertical-align:bottom;width:9%">
                  <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">100</p>
                </td>
                <td style="vertical-align:bottom;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td>
              </tr>

          </table>
        </div>
      <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130166644352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL AND OTHER INCOME, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of financial and other income, net</a></td>
<td class="text">
      <div style="margin-left:56.7pt;margin-bottom:0pt">
        <table cellpadding="0" cellspacing="0" style="width:90%" width="100%">

            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="10" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">Year ended December 31,</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2022</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2021</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"><span style="font-weight:bold">2020</span></p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
              <td colspan="2" style="vertical-align:bottom">&#160;</td>
              <td style="vertical-align:bottom">&#160;</td>
            </tr>


            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:64%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Interest income</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,437</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">894</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,765</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:64%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Bank fees and other finance expenses</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(27</p>
              </td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">)</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(25</p>
              </td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">)</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(42</p>
              </td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">)</p>
              </td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:64%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Foreign currency transaction adjustments</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">340</p>
              </td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">(1</p>
              </td>
              <td style="vertical-align:bottom;width:1%"><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">)</span></span></td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">63</p>
              </td>
              <td style="vertical-align:bottom;width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
            </tr>
            <tr>
              <td style="vertical-align:baseline;width:64%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Gain (loss) from sales and disposals of fixed assets</span></span></p>
              </td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(12</span></span></p>
              </td>
              <td style="vertical-align:baseline;width:1%"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">3</span></span></p>
              </td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%">&#160;</td>
              <td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">12</span></span></p>
              </td>
              <td style="vertical-align:baseline;width:1%">&#160;</td>
            </tr>
            <tr style="background-color:#cceeff">
              <td style="vertical-align:bottom;width:64%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">&#160;</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:9%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>
            <tr>
              <td style="vertical-align:bottom;width:64%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt">Financial and other income, net</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,738</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">871</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt">$</p>
              </td>
              <td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%">
                <p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt">1,798</p>
              </td>
              <td style="vertical-align:bottom;width:1%">&#160;</td>
            </tr>

        </table>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130168914704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY BALANCES AND TRANSACTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of related party balances and transactions</a></td>
<td class="text">
      <div>
        <div>
          <div style="margin-left:56.7pt">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt">

                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Trade payables and accrued expenses</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>83</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>94</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                </tr>

            </table>
          </div>
          <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
          <div style="margin-left:56.7pt">
            <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt">

                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="10" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                    <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2020</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amounts charged to:</span></span></div>
                  </td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                  <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                  <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development expenses</span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>194</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>240</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                    <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>294</span></span></span></div>
                  </td>
                  <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                </tr>

            </table>
            <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif">&#160;</p>
          </div>
        </div>
      </div>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130170283296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSSES PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of computation of basic and diluted losses per share</a></td>
<td class="text">
            <div style="text-align:justify;text-indent:-28.35pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following table sets forth the computation of basic and diluted losses per share:</span></span></div>
            <div style="line-height:1.25;font-family:'Times New Roman',Times,serif">&#160;</div>
            <div style="margin-left:56.7pt">
              <table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt">

                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="10" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Year ended December 31,</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2022</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2021</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom">
                      <div style="text-align:center;line-height:1.25;font-weight:bold"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">2020</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="margin-left:2.85pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Numerator:</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom">&#160;</td>
                    <td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Net loss for basic and diluted loss per share</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(33,694</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(34,203</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">(29,698</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">)</span></span></div>
                    </td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Denominator:</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Weighted average number of ordinary shares used in computing basic and diluted net loss per share</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">86,555,628</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">84,203,971</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">79,591,187</span></span></div>
                    </td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom">&#160;</td>
                    <td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Basic and diluted loss per ordinary share</span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(0.39</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(0.41</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom">&#160;</td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>$</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>(0.37</span></span></span></div>
                    </td>
                    <td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom">
                      <div style="line-height:1.25"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>)</span></span></span></div>
                    </td>
                  </tr>

              </table>
            </div>
          <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130165363568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 05, 2013</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Upfront payment received</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable', window );">Potential milestone compensation</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable', window );">Preclinical milestone compensation</a></td>
<td class="nump">$ 23,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue', window );">Amount of investment in Compugen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential milestone revenue from arrangements for research and development, including collaboration and licenses agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ResearchAndDevelopmentArrangementPaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential milestone revenue for preclinical stages of research from arrangements for research and development, including collaboration and licenses agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount on the investment owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 10<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6438156&amp;loc=d3e57880-113973<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 10<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6431724&amp;loc=d3e32938-113948<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130169930480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 11, 2022</div></th>
<th class="th"><div>Aug. 05, 2013</div></th>
<th class="th"><div>Sep. 29, 2021</div></th>
<th class="th"><div>Dec. 18, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ShortTermBankDepositsWeightedAverageRateForeign', window );">Average interest rate, short-term bank deposits in U.S. dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.84%<span></span>
</td>
<td class="nump">0.77%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization in R&amp;D expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,019<span></span>
</td>
<td class="nump">$ 1,291<span></span>
</td>
<td class="nump">$ 829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue recognition under milestone method</a></td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">468<span></span>
</td>
<td class="nump">$ 383<span></span>
</td>
<td class="nump">$ 572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable', window );">Research And Development Arrangement Payments Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AccruedMilestonePayment', window );">Accrued milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Weighted average number of shares related to outstanding options excluded from the calculations of diluted net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,405,615<span></span>
</td>
<td class="nump">6,758,300<span></span>
</td>
<td class="nump">7,150,648<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=cgen_MasterClinicalAgreementOneMember', window );">Master Clinical Agreement One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_DeferredParticipationOfBMSInRAndDExpenses', window );">Deferred participation of BMS in R&amp;D expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=cgen_MasterClinicalAgreementTwoMember', window );">Master Clinical Agreement Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_DeferredParticipationOfBMSInRAndDExpenses', window );">Deferred participation of BMS in R&amp;D expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AccruedMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AccruedMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_DeferredParticipationOfBMSInRAndDExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred participation of BMS in R and D expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_DeferredParticipationOfBMSInRAndDExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ResearchAndDevelopmentArrangementPaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential milestone revenue from arrangements for research and development, including collaboration and licenses agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ResearchAndDevelopmentArrangementPaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ShortTermBankDepositsWeightedAverageRateForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average interest rate for short-term bank deposits outside of the domestic currency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ShortTermBankDepositsWeightedAverageRateForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=cgen_MasterClinicalAgreementOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=cgen_MasterClinicalAgreementOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=cgen_MasterClinicalAgreementTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=cgen_MasterClinicalAgreementTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130168971376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Schedule of Depreciation Rates for Property and Equipment) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers, software and related equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AnnualDepreciationRate', window );">Annual depreciation rate</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_LaboratoryEquipmentAndOfficeFurnitureMember', window );">Laboratory equipment and office furniture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AnnualDepreciationRate', window );">Annual depreciation rate</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_LaboratoryEquipmentAndOfficeFurnitureMember', window );">Laboratory equipment and office furniture [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AnnualDepreciationRate', window );">Annual depreciation rate</a></td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_LaboratoryEquipmentAndOfficeFurnitureMember', window );">Laboratory equipment and office furniture [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AnnualDepreciationRate', window );">Annual depreciation rate</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AnnualDepreciationRateDescription', window );">Annual depreciation rate</a></td>
<td class="text">Shorter of the term of the lease or useful life<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AnnualDepreciationRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual Depreciation Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AnnualDepreciationRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AnnualDepreciationRateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual Depreciation Rates, Description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AnnualDepreciationRateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_LaboratoryEquipmentAndOfficeFurnitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_LaboratoryEquipmentAndOfficeFurnitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130165028288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Schedule of Weighted-Average Assumptions for Granted Options) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">69.44%<span></span>
</td>
<td class="nump">66.02%<span></span>
</td>
<td class="nump">55.12%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.54%<span></span>
</td>
<td class="nump">0.51%<span></span>
</td>
<td class="nump">0.26%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">5 years 18 days<span></span>
</td>
<td class="text">5 years 14 days<span></span>
</td>
<td class="text">5 years 7 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">74.61%<span></span>
</td>
<td class="nump">69.05%<span></span>
</td>
<td class="nump">65.59%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.39%<span></span>
</td>
<td class="nump">1.14%<span></span>
</td>
<td class="nump">1.64%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">5 years 3 months 21 days<span></span>
</td>
<td class="text">5 years 3 months 21 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cgen_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">69.74%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.63%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cgen_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.68%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.04%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cgen_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.68%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cgen_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cgen_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130164156192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="nump">$ 5,272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_GovernmentAuthorities', window );">Government authorities</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">232<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other accounts receivable and prepaid expenses</a></td>
<td class="nump">$ 2,417<span></span>
</td>
<td class="nump">$ 5,460<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_GovernmentAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Government Authorities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_GovernmentAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130168964448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating Lease, Payments</a></td>
<td class="nump">$ 884<span></span>
</td>
<td class="nump">$ 956<span></span>
</td>
<td class="nump">$ 944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_IncreaseOperatingLeaseRightOfUseAsset', window );">Operating lease right of use asset increased</a></td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_DecreaseOperatingLeaseLiability', window );">Operating lease liability decreased</a></td>
<td class="nump">194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign Currency Translation income</a></td>
<td class="nump">237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities', window );">Cash paid for amounts included in measurement of lease liabilities</a></td>
<td class="nump">$ 959<span></span>
</td>
<td class="nump">$ 914<span></span>
</td>
<td class="nump">$ 927<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for amounts included in the measurement of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_DecreaseOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease liability decreased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_DecreaseOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_IncreaseOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease right of use asset increased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_IncreaseOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32262-110900<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30755-110894<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130165101392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES (Schedule of Weighted-Average Remaining Lease Term and Discount Rate) (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">3 years 1 month 28 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount (annual) rate</a></td>
<td class="nump">5.52%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130168846672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES (Schedule of Operating Leases) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease payments</a></td>
<td class="nump">2,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">1,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities, current</a></td>
<td class="nump">613<span></span>
</td>
<td class="nump">$ 768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, non- current</a></td>
<td class="nump">1,312<span></span>
</td>
<td class="nump">$ 1,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 1,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130164095728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">$ 7,762<span></span>
</td>
<td class="nump">$ 7,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">6,230<span></span>
</td>
<td class="nump">5,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">482<span></span>
</td>
<td class="nump">461<span></span>
</td>
<td class="nump">$ 715<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember', window );">Obsolete property and equipment and certain nonfunctional Lab equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">$ 95<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130161185632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">$ 7,762<span></span>
</td>
<td class="nump">$ 7,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">6,230<span></span>
</td>
<td class="nump">5,843<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Depreciated cost</a></td>
<td class="nump">1,532<span></span>
</td>
<td class="nump">1,658<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers, software and related equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">1,617<span></span>
</td>
<td class="nump">1,506<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">1,435<span></span>
</td>
<td class="nump">1,351<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_LaboratoryEquipmentAndOfficeFurnitureMember', window );">Laboratory equipment and office furniture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">3,831<span></span>
</td>
<td class="nump">3,674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">3,190<span></span>
</td>
<td class="nump">3,114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">2,314<span></span>
</td>
<td class="nump">2,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">$ 1,605<span></span>
</td>
<td class="nump">$ 1,378<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_LaboratoryEquipmentAndOfficeFurnitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cgen_LaboratoryEquipmentAndOfficeFurnitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130169002208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employees and related accruals</a></td>
<td class="nump">$ 2,812<span></span>
</td>
<td class="nump">$ 3,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">6,396<span></span>
</td>
<td class="nump">4,779<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities', window );">Other accounts payable and accrued expenses</a></td>
<td class="nump">$ 9,208<span></span>
</td>
<td class="nump">$ 8,078<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130165153792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsMaximumExposure', window );">Bank guarantees in favor of lessor, foreign currency derivative contracts and credit card security</a></td>
<td class="nump">$ 318,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ContingentFees', window );">Contingent fees</a></td>
<td class="nump">750,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection', window );">Research and development expenses milestone payment with connection</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_RoyaltyPercentage', window );">Royalty percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ResearchAndDevelopmentExpensesMilestonePayment', window );">Research and development expenses milestone payment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsAxis=cgen_ResearchAndDevelopmentGrantOneMember', window );">IIA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived', window );">Maximum royalty repaid as percentage of grant received</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="nump">$ 225,000<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_RoyaltyContingentObligations', window );">Contingent royalty obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,631,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsAxis=cgen_ResearchAndDevelopmentGrantOneMember', window );">IIA [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_RoyaltyPercentageBasedOnFutureRevenues', window );">Royalty percentage based on future revenues</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsAxis=cgen_ResearchAndDevelopmentGrantOneMember', window );">IIA [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_RoyaltyPercentageBasedOnFutureRevenues', window );">Royalty percentage based on future revenues</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsAxis=cgen_May2012AgreementMember', window );">May 2012 Agreement Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AgreementStartDate', window );">Agreement, start date</a></td>
<td class="text">May  09,  2012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AgreementTerminationDescription', window );">Agreement termination description</a></td>
<td class="text">In 2014, the May 2012 Agreement was terminated except for certain payments arising from the Bayer Agreement which survive termination until August 5, 2025.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_GovernmentAndOtherGrantsAxis=cgen_May2012AgreementMember', window );">May 2012 Agreement Member | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ParticipationRights', window );">Participation Rights</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AgreementStartDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement start date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AgreementStartDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AgreementTerminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of termination of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AgreementTerminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ContingentFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ContingentFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Royalty Repaid As Percentage Of Grant Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ParticipationRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the cash consideration received by the Company or its affiliates from third parties to be paid back to investors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ParticipationRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ResearchAndDevelopmentExpensesMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expenses milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ResearchAndDevelopmentExpensesMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expenses milestone payment with connection.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_RoyaltyContingentObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The contingent obligations for payments based on royalty-bearing participation received or accrued, net of royalties paid or accrued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_RoyaltyContingentObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_RoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_RoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_RoyaltyPercentageBasedOnFutureRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Percentage Based On Future Revenues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_RoyaltyPercentageBasedOnFutureRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12069-110248<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_GovernmentAndOtherGrantsAxis=cgen_ResearchAndDevelopmentGrantOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_GovernmentAndOtherGrantsAxis=cgen_ResearchAndDevelopmentGrantOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_GovernmentAndOtherGrantsAxis=cgen_May2012AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_GovernmentAndOtherGrantsAxis=cgen_May2012AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130159851312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Share Option Plans) (Narrative) (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 14, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 10, 2018 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 16, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>&#8362; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>&#8362; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of stock options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.51<span></span>
</td>
<td class="nump">$ 3.81<span></span>
</td>
<td class="nump">$ 7.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 5 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 425<span></span>
</td>
<td class="nump">$ 18,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Ordinary shares reserved for issuance | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Ordinary shares available for issuance | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">324,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InitialOfferingPeriod', window );">Offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">five months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares', window );">Percentage of use of base salary to purchase ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear', window );">Aggregate limit of ordinary shares per calendar year | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering', window );">Percentage of fair market value of ordinary shares at time of offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate intrinsic value of exercised options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 759<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cgen_TwoThousandAndTwoThousandTenOptionsPlanMember', window );">2000 and 2010 Share Option Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Ordinary shares reserved for issuance | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,395,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Ordinary shares available for issuance | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,918,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod', window );">Award expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,955,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,955,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants purchase to ordinary shares remain outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,750<span></span>
</td>
<td class="nump">$ 18,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=cgen_MasterClinicalAgreementMember', window );">Master Clinical Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.95<span></span>
</td>
<td class="nump">$ 8.57333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock', window );">Maximum Authorized Proceeds From Issuance Of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,424,243<span></span>
</td>
<td class="nump">$ 2,332,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_PercentageOfClosingPrice', window );">Percentage of closing price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=cgen_CollaborativeArrangementsMember', window );">Collaborative Arrangements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock', window );">Maximum Authorized Proceeds From Issuance Of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_DeferredParticipationOfBMSInRAndDExpenses', window );">Deferred Participation Of B M S In R And D Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=cgen_CollaborativeArrangementsTwoMember', window );">Collaborative Arrangements Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock', window );">Maximum Authorized Proceeds From Issuance Of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_DeferredParticipationOfBMSInRAndDExpenses', window );">Deferred Participation Of B M S In R And D Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember', window );">Svb Leerink Llc And Stifel Nicolaus And Company Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares, net, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,333,334<span></span>
</td>
<td class="nump">8,816,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from ordinary shares in offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember', window );">Svb Leerink Llc And Stifel Nicolaus And Company Member | Underwriters [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares, net, shares | shares</a></td>
<td class="nump">483,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_AggregateLimitOfOrdinarySharesPerCalendarYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate limit of ordinary shares per calendar year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_AggregateLimitOfOrdinarySharesPerCalendarYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_DeferredParticipationOfBMSInRAndDExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred participation of BMS in R and D expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_DeferredParticipationOfBMSInRAndDExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Authorized Proceeds From Issuance Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_PercentageOfClosingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of closing price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_PercentageOfClosingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of fair market value of ordinary shares at time of offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of use of base salary to purchase ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Award Expiration Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the time period when the company made its initial offering of a class of securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cgen_TwoThousandAndTwoThousandTenOptionsPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cgen_TwoThousandAndTwoThousandTenOptionsPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=cgen_MasterClinicalAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=cgen_MasterClinicalAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=cgen_CollaborativeArrangementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=cgen_CollaborativeArrangementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=cgen_CollaborativeArrangementsTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=cgen_CollaborativeArrangementsTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cgen_UnderwritersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cgen_UnderwritersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130165050976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Schedule Of Option Activity) (Details) - Employees and Directors [Member] - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at beginning of year</a></td>
<td class="nump">6,976,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="nump">2,186,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="num">(33,186)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options forfeited</a></td>
<td class="num">(778,069)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options expired</a></td>
<td class="num">(193,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at end of year</a></td>
<td class="nump">8,157,749<span></span>
</td>
<td class="nump">6,976,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of year</a></td>
<td class="nump">4,635,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at beginning of year</a></td>
<td class="nump">$ 6.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted</a></td>
<td class="nump">2.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised</a></td>
<td class="nump">3.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Options forfeited</a></td>
<td class="nump">6.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options expired</a></td>
<td class="nump">4.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at end of year</a></td>
<td class="nump">5.43<span></span>
</td>
<td class="nump">$ 6.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Exercisable at end of year</a></td>
<td class="nump">$ 5.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract', window );"><strong>Weighted average remaining contractual life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options outstanding</a></td>
<td class="text">6 years 3 months 25 days<span></span>
</td>
<td class="text">6 years 8 months 8 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Exercisable at end of year</a></td>
<td class="text">4 years 6 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Aggregate intrinsic value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding at end of year</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at end of year</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award Options, Remaining Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cgen_EmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cgen_EmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130168903264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Schedule Of Stock Compensation Expense) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses</a></td>
<td class="nump">$ 4,328<span></span>
</td>
<td class="nump">$ 4,276<span></span>
</td>
<td class="nump">$ 2,772<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses</a></td>
<td class="nump">2,158<span></span>
</td>
<td class="nump">1,971<span></span>
</td>
<td class="nump">1,123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Marketing and business development expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses</a></td>
<td class="nump">269<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses</a></td>
<td class="nump">$ 1,901<span></span>
</td>
<td class="nump">$ 2,090<span></span>
</td>
<td class="nump">$ 1,477<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130169141280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Israeli corporate tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_NetOperatingLossCarryforwardExpired', window );">Net operating loss carryforward, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 398,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_NetOperatingLossCarryforwardExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net operating loss carryforward, Expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_NetOperatingLossCarryforwardExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130167872704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Encouragement Of Capital Investments) (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_ReducedTaxRate', window );">Reduced tax rate</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_ReducedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduced tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_ReducedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130164153248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Schedule of Loss before Taxes) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic (Israel)</a></td>
<td class="nump">$ 34,096<span></span>
</td>
<td class="nump">$ 34,619<span></span>
</td>
<td class="nump">$ 30,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(460)<span></span>
</td>
<td class="num">(416)<span></span>
</td>
<td class="num">(312)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxes on income</a></td>
<td class="num">$ (33,636)<span></span>
</td>
<td class="num">$ (34,203)<span></span>
</td>
<td class="num">$ (29,698)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130164193888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES (Schedule of Deferred Tax Assets and Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Operating loss carryforward</a></td>
<td class="nump">$ 91,704<span></span>
</td>
<td class="nump">$ 86,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development</a></td>
<td class="nump">12,083<span></span>
</td>
<td class="nump">9,773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Accrued social benefits and other</a></td>
<td class="nump">3,123<span></span>
</td>
<td class="nump">2,801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_DeferredIncomeTaxRightOfUseAssets', window );">Right of use assets</a></td>
<td class="num">(415)<span></span>
</td>
<td class="num">(520)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_DeferredIncomeTaxLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">444<span></span>
</td>
<td class="nump">636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax asset before valuation allowance</a></td>
<td class="nump">106,941<span></span>
</td>
<td class="nump">98,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(106,941)<span></span>
</td>
<td class="num">(98,760)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_DeferredIncomeTaxLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax lease liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_DeferredIncomeTaxLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_DeferredIncomeTaxRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax Right of use assets attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_DeferredIncomeTaxRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax asset (liabilities) for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130161018672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Item</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_SegmentReportingGeograhicAreaLineItems', window );"><strong>Segment Reporting Geograhic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Item</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue from sales to customers</a></td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">$ 3,358<span></span>
</td>
<td class="nump">$ 3,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue [Member] | Customer Concentration Risk [Member] | Customer A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_SegmentReportingGeograhicAreaLineItems', window );"><strong>Segment Reporting Geograhic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Sales to a single customer exceeding 10%</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_SegmentReportingGeographicAreaAxis=srt_EuropeMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_SegmentReportingGeograhicAreaLineItems', window );"><strong>Segment Reporting Geograhic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue from sales to customers</a></td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_SegmentReportingGeographicAreaAxis=country_IL', window );">Israel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_SegmentReportingGeograhicAreaLineItems', window );"><strong>Segment Reporting Geograhic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">3,239<span></span>
</td>
<td class="nump">3,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_SegmentReportingGeographicAreaAxis=country_US', window );">Unites States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_SegmentReportingGeograhicAreaLineItems', window );"><strong>Segment Reporting Geograhic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">$ 119<span></span>
</td>
<td class="nump">$ 118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_SegmentReportingGeograhicAreaLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Segment Reporting Geograhic Area [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_SegmentReportingGeograhicAreaLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cgen_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cgen_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_SegmentReportingGeographicAreaAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_SegmentReportingGeographicAreaAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_SegmentReportingGeographicAreaAxis=country_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_SegmentReportingGeographicAreaAxis=country_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_SegmentReportingGeographicAreaAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_SegmentReportingGeographicAreaAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130161117632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL AND OTHER INCOME, NET (Schedule of Financial and Other Income, Net) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">$ 1,437<span></span>
</td>
<td class="nump">$ 894<span></span>
</td>
<td class="nump">$ 1,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Bank fees and other finance expenses</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency transaction adjustments</a></td>
<td class="nump">340<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherAssets', window );">Gain (loss) from sales and disposals of fixed assets</a></td>
<td class="num">(12)<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_FinancialIncomeExpenseNet', window );">Financial and other income, net</a></td>
<td class="nump">$ 1,738<span></span>
</td>
<td class="nump">$ 871<span></span>
</td>
<td class="nump">$ 1,798<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_FinancialIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Income (Expense), Net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_FinancialIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest and debt related expenses associated with nonoperating financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130169242304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY BALANCES AND TRANSACTIONS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Trade payables and accrued expenses</a></td>
<td class="nump">$ 83<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesRelatedParty', window );">Amounts charged to research and development expenses</a></td>
<td class="nump">$ 194<span></span>
</td>
<td class="nump">$ 240<span></span>
</td>
<td class="nump">$ 294<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs of sales and operating expenses for the period incurred from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130169939552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSSES PER SHARE (Schedule of Computation of Basic and Diluted Losses Per Share) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for basic and diluted loss per share</a></td>
<td class="num">$ (33,694)<span></span>
</td>
<td class="num">$ (34,203)<span></span>
</td>
<td class="num">$ (29,698)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of ordinary shares used in computing basic net loss per share</a></td>
<td class="nump">86,555,628<span></span>
</td>
<td class="nump">84,203,971<span></span>
</td>
<td class="nump">79,591,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of ordinary shares used in computing diluted net loss per share</a></td>
<td class="nump">86,555,628<span></span>
</td>
<td class="nump">84,203,971<span></span>
</td>
<td class="nump">79,591,187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per ordinary share</a></td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (0.41)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share</a></td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (0.41)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140130165242624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Narrative) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jan. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Sales Agreement with SVB Securities LLC. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Authorized Proceeds From Issuance Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cgen_SalesAgreementWithSVBSecuritiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cgen_SalesAgreementWithSVBSecuritiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>zk2329266_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cgen="http://cgen.com/20221231"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cgen-20221231.xsd" xlink:type="simple"/>
    <context id="C_20220101to20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20210101to20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20200101to20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_20130801to20130805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2013-08-01</startDate>
            <endDate>2013-08-05</endDate>
        </period>
    </context>
    <context id="C_20130805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2013-08-05</instant>
        </period>
    </context>
    <context id="C_20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapIncomeTaxAuthorityAxis_usgaapDomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20201231_usgaapIncomeTaxAuthorityAxis_usgaapInternalRevenueServiceIRSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cgen:LaboratoryEquipmentAndOfficeFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20201201to20201218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-18</endDate>
        </period>
    </context>
    <context id="C_20210901to20210929">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-29</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20200101to20201231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20200101to20201231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_20221101to20221111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-11</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20200101to20201231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_srtStatementScenarioAxis_cgenMasterClinicalAgreementOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_srtStatementScenarioAxis_cgenMasterClinicalAgreementOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_srtStatementScenarioAxis_cgenMasterClinicalAgreementTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_srtStatementScenarioAxis_cgenMasterClinicalAgreementTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20200101to20201231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_20200101to20201231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_20230101to20230131_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_usgaapTypeOfArrangementAxis_cgenSalesAgreementWithSVBSecuritiesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cgen:SalesAgreementWithSVBSecuritiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="C_20191231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_20191231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_20191231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_cgenSegmentReportingGeographicAreaAxis_srtEuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_cgenSegmentReportingGeographicAreaAxis_srtEuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_cgenSegmentReportingGeographicAreaAxis_countryIL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_cgenSegmentReportingGeographicAreaAxis_countryIL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_cgenSegmentReportingGeographicAreaAxis_countryUS">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_cgenSegmentReportingGeographicAreaAxis_countryUS">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_srtMajorCustomersAxis_cgenCustomerOneMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cgen:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_srtMajorCustomersAxis_cgenCustomerOneMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cgen:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20200101to20201231_cgenSegmentReportingGeographicAreaAxis_srtEuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:SegmentReportingGeographicAreaAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_20200101to20201231_srtMajorCustomersAxis_cgenCustomerOneMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cgen:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20181010_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-10</instant>
        </period>
    </context>
    <context id="C_20181001to20181010_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-10</endDate>
        </period>
    </context>
    <context id="C_20211130_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="C_20211102to20211130_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:MasterClinicalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-02</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="C_20200301to20200316_srtStatementScenarioAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-16</endDate>
        </period>
    </context>
    <context id="C_20200316_srtStatementScenarioAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-16</instant>
        </period>
    </context>
    <context id="C_20200316_srtStatementScenarioAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember_usgaapAwardTypeAxis_cgenUnderwritersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:UnderwritersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-16</instant>
        </period>
    </context>
    <context id="C_20200401to20200414_srtStatementScenarioAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember_usgaapAwardTypeAxis_cgenUnderwritersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:UnderwritersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-14</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_srtStatementScenarioAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:SvbLeerinkLlcAndStifelNicolausAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapPlanNameAxis_cgenTwoThousandAndTwoThousandTenOptionsPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgen:TwoThousandAndTwoThousandTenOptionsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapPlanNameAxis_cgenTwoThousandAndTwoThousandTenOptionsPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cgen:TwoThousandAndTwoThousandTenOptionsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20211231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cgen:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_srtTitleOfIndividualAxis_srtDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20211231_srtTitleOfIndividualAxis_srtDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20201231_srtTitleOfIndividualAxis_srtDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20221231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20200101to20201231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20200101to20201231_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20200101to20201231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_20211231_usgaapAwardTypeAxis_usgaapWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20201231_usgaapAwardTypeAxis_usgaapWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_20210101to20211231_usgaapAwardTypeAxis_usgaapWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_usgaapAwardTypeAxis_usgaapWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20221231_usgaapAwardTypeAxis_usgaapWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_srtStatementScenarioAxis_cgenCollaborativeArrangementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:CollaborativeArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_srtStatementScenarioAxis_cgenCollaborativeArrangementsTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">cgen:CollaborativeArrangementsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember_srtRangeAxis_srtMinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember_srtRangeAxis_srtMaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20210101to20211231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_20200101to20201231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_20211231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:ResearchAndDevelopmentGrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_20220101to20221231_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:May2012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_20220101to20221231_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember_srtRangeAxis_srtMinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001119774</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cgen:GovernmentAndOtherGrantsAxis">cgen:May2012AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="Item">
        <measure>cgen:Item</measure>
    </unit>
    <unit id="NIS_Per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:ILS</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USD_per_share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:AmendmentFlag contextRef="C_20220101to20221231" id="FFact_0000000000684">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="C_20220101to20221231" id="FFact_0000000000685">0001119774</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalPeriodFocus contextRef="C_20220101to20221231" id="FFact_0000000000686">FY</dei:DocumentFiscalPeriodFocus>
    <cgen:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      id="Fxbrl_20230214102832182"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="C_20220101to20221231" id="FFact_0000000000001">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="C_20220101to20221231" id="FFact_0000000000002">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="C_20220101to20221231" id="FFact_0000000000003">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="C_20220101to20221231" id="FFact_0000000000006">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="C_20220101to20221231" id="FFact_0000000000004">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="C_20220101to20221231" id="FFact_0000000000005">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="C_20220101to20221231" id="FFact_0000000000007">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="C_20220101to20221231" id="FFact_0000000000008">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="C_20220101to20221231" id="FFact_0000000000009">000-30902</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="C_20220101to20221231" id="FFact_0000000000010">Compugen Ltd</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230214183311741">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="C_20220101to20221231" id="FFact_0000000000012">Azrieli Center</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="C_20220101to20221231" id="FFact_0000000000013">26 Harokmim Street</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="C_20220101to20221231" id="FFact_0000000000014">Building D</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="C_20220101to20221231" id="FFact_0000000000015">Holon</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="C_20220101to20221231" id="FFact_0000000000016">5885849</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="C_20220101to20221231" id="FFact_0000000000017">IL</dei:EntityAddressCountry>
    <dei:ContactPersonnelName
      contextRef="C_20220101to20221231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="FFact_0000000000018">Alberto Sessa</dei:ContactPersonnelName>
    <dei:CityAreaCode
      contextRef="C_20220101to20221231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="FFact_0000000000019">972</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_20220101to20221231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="FFact_0000000000020">3-765-8585</dei:LocalPhoneNumber>
    <dei:ContactPersonnelFaxNumber
      contextRef="C_20220101to20221231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="FFact_0000000000021">972-3-765-8555</dei:ContactPersonnelFaxNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_20220101to20221231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="FFact_0000000000022">Azrieli Center</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_20220101to20221231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="FFact_0000000000023">26 Harokmim Street</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3
      contextRef="C_20220101to20221231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="FFact_0000000000024">Building D</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown
      contextRef="C_20220101to20221231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="FFact_0000000000025">Holon</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="C_20220101to20221231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="FFact_0000000000026">5885849</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry
      contextRef="C_20220101to20221231_deiEntityAddressesAddressTypeAxis_deiBusinessContactMember"
      id="FFact_0000000000027">IL</dei:EntityAddressCountry>
    <dei:Security12bTitle contextRef="C_20220101to20221231" id="FFact_0000000000028">Ordinary shares, par value NIS 0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_20220101to20221231" id="FFact_0000000000029">CGEN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_20220101to20221231" id="FFact_0000000000030">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_20221231"
      decimals="INF"
      id="FFact_0000000000031"
      unitRef="Shares">86624643</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="C_20220101to20221231" id="FFact_0000000000032">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="C_20220101to20221231" id="FFact_0000000000033">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="C_20220101to20221231" id="FFact_0000000000034">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="C_20220101to20221231" id="FFact_0000000000035">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="C_20220101to20221231" id="FFact_0000000000036">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="C_20220101to20221231" id="FFact_0000000000037">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="C_20220101to20221231" id="FFact_0000000000038">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentAccountingStandard contextRef="C_20220101to20221231" id="FFact_0000000000039">U.S. GAAP</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany contextRef="C_20220101to20221231" id="FFact_0000000000040">false</dei:EntityShellCompany>
    <dei:AuditorFirmId contextRef="C_20220101to20221231" id="FFact_0000000000042">1281</dei:AuditorFirmId>
    <dei:AuditorName contextRef="C_20220101to20221231" id="FFact_0000000000043">KOST FORER GABBAY &amp; KASIERER</dei:AuditorName>
    <dei:AuditorLocation contextRef="C_20220101to20221231" id="FFact_0000000000044">Tel-Aviv, Israel</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000045"
      unitRef="usd">11059000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000046"
      unitRef="usd">7801000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000047"
      unitRef="usd">362000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000048"
      unitRef="usd">713000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherShortTermInvestments
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000049"
      unitRef="usd">72287000</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000050"
      unitRef="usd">109248000</us-gaap:OtherShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000053"
      unitRef="usd">2417000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000054"
      unitRef="usd">5460000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000055"
      unitRef="usd">86125000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000056"
      unitRef="usd">123222000</us-gaap:AssetsCurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000057"
      unitRef="usd">1899000</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000058"
      unitRef="usd">1911000</us-gaap:PrepaidExpenseNoncurrent>
    <cgen:SeverancePayFundNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000059"
      unitRef="usd">2794000</cgen:SeverancePayFundNoncurrent>
    <cgen:SeverancePayFundNoncurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000060"
      unitRef="usd">3125000</cgen:SeverancePayFundNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000061"
      unitRef="usd">1826000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000062"
      unitRef="usd">2247000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000063"
      unitRef="usd">1532000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000064"
      unitRef="usd">1658000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000065"
      unitRef="usd">8051000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000066"
      unitRef="usd">8941000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000067"
      unitRef="usd">94176000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000068"
      unitRef="usd">132163000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000069"
      unitRef="usd">1773000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000070"
      unitRef="usd">4621000</us-gaap:AccountsPayableCurrent>
    <cgen:ShortTermDeferredParticipationInResearchAndDevelopmentExpenses
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000071"
      unitRef="usd">325000</cgen:ShortTermDeferredParticipationInResearchAndDevelopmentExpenses>
    <cgen:ShortTermDeferredParticipationInResearchAndDevelopmentExpenses
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000072"
      unitRef="usd">3629000</cgen:ShortTermDeferredParticipationInResearchAndDevelopmentExpenses>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000073"
      unitRef="usd">613000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000074"
      unitRef="usd">768000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000075"
      unitRef="usd">9208000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000076"
      unitRef="usd">8078000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000077"
      unitRef="usd">11919000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000078"
      unitRef="usd">17096000</us-gaap:LiabilitiesCurrent>
    <cgen:LongTermDeferredParticipationInResearchAndDevelopmentExpenses
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000079"
      unitRef="usd">0</cgen:LongTermDeferredParticipationInResearchAndDevelopmentExpenses>
    <cgen:LongTermDeferredParticipationInResearchAndDevelopmentExpenses
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000080"
      unitRef="usd">2715000</cgen:LongTermDeferredParticipationInResearchAndDevelopmentExpenses>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000081"
      unitRef="usd">1312000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000082"
      unitRef="usd">1982000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:PostemploymentBenefitsLiabilityNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000083"
      unitRef="usd">3265000</us-gaap:PostemploymentBenefitsLiabilityNoncurrent>
    <us-gaap:PostemploymentBenefitsLiabilityNoncurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000084"
      unitRef="usd">3677000</us-gaap:PostemploymentBenefitsLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000085"
      unitRef="usd">4577000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000086"
      unitRef="usd">8374000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_20221231"
      id="Fxbrl_20230221100858646"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_20211231"
      id="Fxbrl_20230221100903927"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_20211231"
      decimals="INF"
      id="Fxbrl_20230214011115128"
      unitRef="NIS_Per_Share">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_20221231"
      decimals="INF"
      id="Fxbrl_20230214011053357"
      unitRef="NIS_Per_Share">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_20211231"
      decimals="INF"
      id="Fxbrl_s_20230214011030882"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_20221231"
      decimals="INF"
      id="Fxbrl_20230214011030883"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20221231"
      decimals="INF"
      id="Fxbrl_20230214101530012"
      unitRef="Shares">86624643</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_20221231"
      decimals="INF"
      id="FFact_0000000000092"
      unitRef="Shares">86624643</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20211231"
      decimals="INF"
      id="Fxbrl_20230214011437479"
      unitRef="Shares">86433432</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_20211231"
      decimals="INF"
      id="FFact_0000000000094"
      unitRef="Shares">86433432</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000095"
      unitRef="usd">240000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000096"
      unitRef="usd">239000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000097"
      unitRef="usd">533213000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000098"
      unitRef="usd">528533000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000099"
      unitRef="usd">-455773000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000100"
      unitRef="usd">-422079000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000101"
      unitRef="usd">77680000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000102"
      unitRef="usd">106693000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000103"
      unitRef="usd">94176000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000104"
      unitRef="usd">132163000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000105"
      unitRef="usd">7500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000106"
      unitRef="usd">6000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="Fxbrl_20230214012425376"
      unitRef="usd">2000000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000108"
      unitRef="usd">975000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000109"
      unitRef="usd">680000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="Fxbrl_20230214012430928"
      unitRef="usd">60000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000111"
      unitRef="usd">6525000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000112"
      unitRef="usd">5320000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="Fxbrl_20230214012436309"
      unitRef="usd">1940000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230222115443735_Fact_0000000000117"
      unitRef="usd">30648000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230222115443735_Fact_0000000000118"
      unitRef="usd">28694000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="Fxbrl_20230222115443735_Fact_0000000000119"
      unitRef="usd">22760000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:BusinessDevelopment
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000117"
      unitRef="usd">932000</us-gaap:BusinessDevelopment>
    <us-gaap:BusinessDevelopment
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000118"
      unitRef="usd">842000</us-gaap:BusinessDevelopment>
    <us-gaap:BusinessDevelopment
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000119"
      unitRef="usd">871000</us-gaap:BusinessDevelopment>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230222115622478_Fact_0000000000117"
      unitRef="usd">10319000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230222115622478_Fact_0000000000118"
      unitRef="usd">10858000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="Fxbrl_20230222115622478_Fact_0000000000119"
      unitRef="usd">9805000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230222115529913"
      unitRef="usd">41899000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000124"
      unitRef="usd">40394000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000125"
      unitRef="usd">33436000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000126"
      unitRef="usd">-35374000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000127"
      unitRef="usd">-35074000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000128"
      unitRef="usd">-31496000</us-gaap:OperatingIncomeLoss>
    <cgen:FinancialIncomeExpenseNet
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000129"
      unitRef="usd">1738000</cgen:FinancialIncomeExpenseNet>
    <cgen:FinancialIncomeExpenseNet
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000130"
      unitRef="usd">871000</cgen:FinancialIncomeExpenseNet>
    <cgen:FinancialIncomeExpenseNet
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000131"
      unitRef="usd">1798000</cgen:FinancialIncomeExpenseNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000132"
      unitRef="usd">-33636000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000133"
      unitRef="usd">-34203000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000134"
      unitRef="usd">-29698000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230214012403897"
      unitRef="usd">58000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230214012406780"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000137"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000138"
      unitRef="usd">-33694000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000139"
      unitRef="usd">-34203000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000140"
      unitRef="usd">-29698000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000141"
      unitRef="USD_per_share">-0.39</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="FFact_0000000000142"
      unitRef="USD_per_share">-0.41</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20200101to20201231"
      decimals="INF"
      id="FFact_0000000000143"
      unitRef="USD_per_share">-0.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000144"
      unitRef="USD_per_share">-0.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="FFact_0000000000145"
      unitRef="USD_per_share">-0.41</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20200101to20201231"
      decimals="INF"
      id="FFact_0000000000146"
      unitRef="USD_per_share">-0.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000147"
      unitRef="usd">-33694000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000148"
      unitRef="usd">-34203000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000149"
      unitRef="usd">-29698000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000150"
      unitRef="Shares">86555628</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="FFact_0000000000151"
      unitRef="Shares">84203971</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20200101to20201231"
      decimals="INF"
      id="FFact_0000000000152"
      unitRef="Shares">79591187</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000153"
      unitRef="Shares">86555628</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="FFact_0000000000154"
      unitRef="Shares">84203971</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_20200101to20201231"
      decimals="INF"
      id="FFact_0000000000155"
      unitRef="Shares">79591187</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20191231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="FFact_0000000000156"
      unitRef="Shares">67922836</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20191231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="FFact_0000000000157"
      unitRef="usd">187000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20191231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="FFact_0000000000158"
      unitRef="usd">396312000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20191231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="FFact_0000000000159"
      unitRef="usd">-358178000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20191231"
      decimals="-3"
      id="FFact_0000000000160"
      unitRef="usd">38321000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="FFact_0000000000161"
      unitRef="Shares">3070542</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="FFact_0000000000162"
      unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="FFact_0000000000163"
      unitRef="usd">15906000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000164"
      unitRef="usd">15915000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <cgen:NumberOfWarrantsExercised
      contextRef="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230214013524660"
      unitRef="Shares">3866139</cgen:NumberOfWarrantsExercised>
    <cgen:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230214013608017"
      unitRef="usd">11000</cgen:StockIssuedDuringPeriodValueWarrantsExercised>
    <cgen:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230214013559422"
      unitRef="usd">18314000</cgen:StockIssuedDuringPeriodValueWarrantsExercised>
    <cgen:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="Fxbrl_20230214013636006"
      unitRef="usd">18325000</cgen:StockIssuedDuringPeriodValueWarrantsExercised>
    <cgen:IssuanceOfSharesAndWarrantsNetShares
      contextRef="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="FFact_0000000000165"
      unitRef="Shares">8816339</cgen:IssuanceOfSharesAndWarrantsNetShares>
    <cgen:IssuanceOfSharesAndWarrantsNetValue
      contextRef="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="FFact_0000000000166"
      unitRef="usd">24000</cgen:IssuanceOfSharesAndWarrantsNetValue>
    <cgen:IssuanceOfSharesAndWarrantsNetValue
      contextRef="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="FFact_0000000000167"
      unitRef="usd">74123000</cgen:IssuanceOfSharesAndWarrantsNetValue>
    <cgen:IssuanceOfSharesAndWarrantsNetValue
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000168"
      unitRef="usd">74147000</cgen:IssuanceOfSharesAndWarrantsNetValue>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees
      contextRef="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="FFact_0000000000169"
      unitRef="usd">2772000</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000170"
      unitRef="usd">2772000</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees>
    <us-gaap:NetIncomeLoss
      contextRef="C_20200101to20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="FFact_0000000000171"
      unitRef="usd">-29698000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000172"
      unitRef="usd">-29698000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="FFact_0000000000173"
      unitRef="Shares">83675856</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="FFact_0000000000174"
      unitRef="usd">231000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="FFact_0000000000175"
      unitRef="usd">507427000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20201231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="FFact_0000000000176"
      unitRef="usd">-387876000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20201231"
      decimals="-3"
      id="FFact_0000000000177"
      unitRef="usd">119782000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="Fxbrl_20230214013709298"
      unitRef="Shares">335204</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="Fxbrl_20230214013718917"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fxbrl_20230214013728837"
      unitRef="usd">1454000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230214013739149"
      unitRef="usd">1455000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <cgen:NumberOfWarrantsExercised
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="FFact_0000000000182"
      unitRef="Shares">89557</cgen:NumberOfWarrantsExercised>
    <cgen:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="FFact_0000000000184"
      unitRef="usd">425000</cgen:StockIssuedDuringPeriodValueWarrantsExercised>
    <cgen:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230221102251303"
      unitRef="usd">425000</cgen:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="FFact_0000000000186"
      unitRef="Shares">2332815</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="FFact_0000000000187"
      unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="FFact_0000000000188"
      unitRef="usd">14951000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000189"
      unitRef="usd">14958000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="FFact_0000000000190"
      unitRef="usd">4276000</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000191"
      unitRef="usd">4276000</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="FFact_0000000000192"
      unitRef="usd">-34203000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000193"
      unitRef="usd">-34203000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="FFact_0000000000194"
      unitRef="Shares">86433432</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="FFact_0000000000195"
      unitRef="usd">239000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="FFact_0000000000196"
      unitRef="usd">528533000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="FFact_0000000000197"
      unitRef="usd">-422079000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000198"
      unitRef="usd">106693000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="FFact_0000000000199"
      unitRef="Shares">191211</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="FFact_0000000000200"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="FFact_0000000000201"
      unitRef="usd">352000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000202"
      unitRef="usd">353000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="FFact_0000000000211"
      unitRef="usd">4328000</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees>
    <cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000212"
      unitRef="usd">4328000</cgen:StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="FFact_0000000000213"
      unitRef="usd">-33694000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000214"
      unitRef="usd">-33694000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="INF"
      id="FFact_0000000000215"
      unitRef="Shares">86624643</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember"
      decimals="-3"
      id="FFact_0000000000216"
      unitRef="usd">240000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember"
      decimals="-3"
      id="FFact_0000000000217"
      unitRef="usd">533213000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember"
      decimals="-3"
      id="FFact_0000000000218"
      unitRef="usd">-455773000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000219"
      unitRef="usd">77680000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000220"
      unitRef="usd">-33694000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000221"
      unitRef="usd">-34203000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000222"
      unitRef="usd">-29698000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000223"
      unitRef="usd">4328000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000224"
      unitRef="usd">4276000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000225"
      unitRef="usd">2772000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000226"
      unitRef="usd">482000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000227"
      unitRef="usd">461000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000228"
      unitRef="usd">715000</us-gaap:Depreciation>
    <cgen:SeverancePayNet
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000229"
      unitRef="usd">-81000</cgen:SeverancePayNet>
    <cgen:SeverancePayNet
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230214015430934"
      unitRef="usd">-101000</cgen:SeverancePayNet>
    <cgen:SeverancePayNet
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000231"
      unitRef="usd">184000</cgen:SeverancePayNet>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000232"
      unitRef="usd">-12000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000233"
      unitRef="usd">3000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000234"
      unitRef="usd">12000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230214015508662"
      unitRef="usd">584000</cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement>
    <cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000236"
      unitRef="usd">-469000</cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement>
    <cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="Fxbrl_20230214015458380"
      unitRef="usd">532000</cgen:AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000238"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000239"
      unitRef="usd">-2000000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="Fxbrl_20230214015520285"
      unitRef="usd">2000000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000241"
      unitRef="usd">-3043000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000242"
      unitRef="usd">2802000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000243"
      unitRef="usd">1613000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000244"
      unitRef="usd">-12000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000245"
      unitRef="usd">31000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="Fxbrl_20230214015551570"
      unitRef="usd">1187000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000247"
      unitRef="usd">-658000</cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000248"
      unitRef="usd">-525000</cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000249"
      unitRef="usd">-475000</cgen:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230214015610319"
      unitRef="usd">-1601000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000251"
      unitRef="usd">3367000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000252"
      unitRef="usd">3817000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230214015629815"
      unitRef="usd">-6019000</cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses>
    <cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000254"
      unitRef="usd">3708000</cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses>
    <cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000255"
      unitRef="usd">-829000</cgen:IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000256"
      unitRef="usd">-1062000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000257"
      unitRef="usd">-416000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000258"
      unitRef="usd">-412000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000259"
      unitRef="usd">-34506000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000260"
      unitRef="usd">-22750000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000261"
      unitRef="usd">-28320000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000262"
      unitRef="usd">114445000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000263"
      unitRef="usd">136850000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000264"
      unitRef="usd">70300000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000265"
      unitRef="usd">76900000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000266"
      unitRef="usd">129945000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000267"
      unitRef="usd">152350000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000268"
      unitRef="usd">477000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000269"
      unitRef="usd">292000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000270"
      unitRef="usd">166000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentDisposals
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230222115924752_Fact_0000000000268"
      unitRef="usd">10000</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:PropertyPlantAndEquipmentDisposals
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230222115924752_Fact_0000000000269"
      unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:PropertyPlantAndEquipmentDisposals
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="Fxbrl_20230222115924752_Fact_0000000000270"
      unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentDisposals>
    <cgen:PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230222112447073"
      unitRef="usd">-2000</cgen:PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities>
    <cgen:PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000272"
      unitRef="usd">-3000</cgen:PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities>
    <cgen:PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000273"
      unitRef="usd">-44000</cgen:PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000274"
      unitRef="usd">37060000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000275"
      unitRef="usd">6616000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="Fxbrl_20230214015724492"
      unitRef="usd">-82172000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000277"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000278"
      unitRef="usd">14958000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000279"
      unitRef="usd">74147000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000280"
      unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000281"
      unitRef="usd">425000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="Fxbrl_20230214015741861"
      unitRef="usd">18325000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000283"
      unitRef="usd">353000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000284"
      unitRef="usd">1455000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000285"
      unitRef="usd">15991000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000286"
      unitRef="usd">353000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000287"
      unitRef="usd">16838000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000288"
      unitRef="usd">108463000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000289"
      unitRef="usd">2907000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000290"
      unitRef="usd">704000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="Fxbrl_20230214015801453"
      unitRef="usd">-2029000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000292"
      unitRef="usd">8514000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20201231"
      decimals="-3"
      id="FFact_0000000000293"
      unitRef="usd">7810000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20191231"
      decimals="-3"
      id="FFact_0000000000294"
      unitRef="usd">9839000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000295"
      unitRef="usd">11421000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000296"
      unitRef="usd">8514000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20201231"
      decimals="-3"
      id="FFact_0000000000297"
      unitRef="usd">7810000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000298"
      unitRef="usd">117000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000299"
      unitRef="usd">116000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000300"
      unitRef="usd">16000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230214015821971"
      unitRef="usd">237000</cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability>
    <cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000305"
      unitRef="usd">0</cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability>
    <cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="Fxbrl_20230214015838501"
      unitRef="usd">-194000</cgen:SupplementalRightOfUseAssetAndOperatingLeaseLiability>
    <cgen:InterestPaidReceivedNet
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000307"
      unitRef="usd">852000</cgen:InterestPaidReceivedNet>
    <cgen:InterestPaidReceivedNet
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000308"
      unitRef="usd">1364000</cgen:InterestPaidReceivedNet>
    <cgen:InterestPaidReceivedNet
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000309"
      unitRef="usd">1232000</cgen:InterestPaidReceivedNet>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000310"
      unitRef="usd">11059000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000311"
      unitRef="usd">7801000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_20201231"
      decimals="-3"
      id="FFact_0000000000312"
      unitRef="usd">7143000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000313"
      unitRef="usd">362000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000314"
      unitRef="usd">713000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="C_20201231"
      decimals="-3"
      id="FFact_0000000000315"
      unitRef="usd">667000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000316"
      unitRef="usd">11421000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000317"
      unitRef="usd">8514000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_20201231"
      decimals="-3"
      id="FFact_0000000000318"
      unitRef="usd">7810000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000331">
    &lt;div&gt;
      &lt;div&gt;
        &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;NOTE 1: -&lt;/span&gt;&lt;span&gt;&#160;&lt;span style="font-weight:bold"&gt;GENERAL&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;a.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Compugen Ltd. (the &#x201c;Company&#x201d;) is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Compugen&#x2019;s innovative immuno-oncology pipeline consists of three clinical stage programs, targeting immune checkpoints Compugen discovered computationally by COM701, COM902 and rilvegostomig. The Company&#x2019;s lead product candidates, COM701, a potential first-in-class anti-PVRIG antibody, and COM902, a potential best-in-class therapeutic anti-TIGIT antibody are in Phase 1 clinical trials and have been evaluated, for the treatment of solid tumors as a monotherapy and in combination of dual (PVRIG/PD-1, PVRIG/TIGIT) and triple (PVRIG/PD-1/TIGIT) blockade. As part of Phase 1 clinical trials for the Company&#x2019;s lead product candidates, COM701, the Company evaluated COM701 as a monotherapy and under clinical collaboration with Bristol Myers Squibb Company in combination with nivolumab &#xb1; Bristol Myers Squibb investigational anti-TIGIT, BMS-986207. Following the termination of the Company&#x2019;s collaboration with Bristol Myers Squibb Company, these combination studies are being wound down while the monitoring of patients on study treatment is ongoing. Rilvegostomig, a novel anti PD-1/TIGIT bispecific antibody with a TIGIT specific component that is derived from Compugen&#x2019;s COM902 antibody, is being developed by AstraZeneca pursuant to an exclusive license agreement between Compugen and AstraZeneca and is in Phase 2 clinical trial in patients with advanced or metastatic non-small cell lung and locally advanced or metastatic gastric cancer. Compugen&#x2019;s therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance. The Company&#x2019;s most advanced early-stage program, COM503, is a potential first-in-class, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, thereby releasing the natural IL-18 into the tumor microenvironment to inhibit cancer growth. COM503 is &#160;being advanced into IND enabling studies. Compugen&#x2019;s business model is to selectively enter into collaborations for its novel targets and drug product candidates at various stages of research and development under various revenue-sharing arrangements. Integrating cutting edge computational capabilities with ground-breaking immuno-oncology research and drug development expertise is the Company&#x2019;s differentiator and has enabled the advancement of three drug targets from computer prediction through successful preclinical studies to the clinic.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;b.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company is headquartered in Holon, Israel. Its clinical development activities are headed from its United States subsidiary, Compugen USA, Inc, located in San Francisco, CA.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;c.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company has incurred losses in the amount of $33,694 during the year ended December 31, 2022, has an accumulated deficit of $455,773 as of December 31, 2022 and has an accumulated negative cash flow from operating activities in the amount of $34,506 for the year ended December 31, 2022. &lt;span style="color:rgb(0, 0, 0)"&gt;The Company believes that its existing capital resources will be adequate to satisfy its expected liquidity requirements at the current level of yearly expenditures at least &lt;/span&gt;twelve months from the reporting date&lt;span style="color:rgb(0, 0, 0)"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div/&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;d.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On August 5, 2013, the Company entered into a Research and Development Collaboration and License Agreement (&lt;span style="color:rgb(0, 0, 0)"&gt;&#x201c;&lt;/span&gt;Bayer Agreement&lt;span style="color:rgb(0, 0, 0)"&gt;&#x201c;&lt;/span&gt;) with Bayer Pharma AG (&lt;span style="color:rgb(0, 0, 0)"&gt;&#x201c;&lt;/span&gt;Bayer&lt;span style="color:rgb(0, 0, 0)"&gt;&#x201c;&lt;/span&gt;) for the research, development, and commercialization of antibody-based therapeutics against two novel, Compugen-discovered immune checkpoint regulators.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="width:56.7pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Under the terms of the Bayer Agreement, the Company received an upfront payment of $10,000, and,&lt;span style="color:rgb(0, 0, 0)"&gt; following the return of the CGEN 15022 program in 2017,&lt;/span&gt; the Company is eligible to receive an aggregate amount of over $250,000 in potential milestone payments for &lt;span style="color:rgb(0, 0, 0)"&gt;Bapotulimab (formerly known as BAY1905254)&lt;/span&gt;, not including aggregate milestone payments of $23,200 received to date. Additionally, the Company is eligible to receive mid to high single digit royalties on global net sales of any approved products under the collaboration.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Pursuant to the terms of Bayer Agreement, &lt;span style="color:rgb(0, 0, 0)"&gt;Bapotulimab&lt;/span&gt; program was transferred to Bayer&#x2019;s full control for further preclinical and clinical development activities, and worldwide commercialization under milestone and royalty bearing license from Compugen.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On November 29, 2022, Bayer notified the Company that it has resolved to terminate, effective as of February 27, 2023, the Bayer Agreement.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:54pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:31.5pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;e.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Effective March 30, 2018, the Company entered into an exclusive license agreement with MedImmune Limited, the global biologics research and development arm of AstraZeneca (&#x201c;AstraZeneca&#x201d;) to enable the development of bi-specific and multi-specific immuno-oncology antibody products. Under the terms of the agreement, Compugen provided an exclusive license to AstraZeneca for the development of bi-specific and multi-specific antibody products derived from COM902. AstraZeneca has the right to create multiple products under this license and will be solely responsible for all research, development, and commercial activities under the agreement. Compugen received a $10,000 upfront payment, and received $15,500 milestone payments out of up to $200,000 it is eligible to receive in development, regulatory and commercial milestones for the first product in addition to tiered royalties on future product sales. If additional products are developed, additional milestones and royalties would be due to Compugen for each product.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:54pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:31.5pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;f.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                &lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement (the &#x201c;Agreement&#x201d;) with Bristol-Myers Squibb Company (&#x201c;Bristol-Myers Squibb&#x201d;) to evaluate the safety and tolerability of Compugen&#x2019;s COM701 in combination with Bristol-Myers Squibbs&#x2019; PD-1 immune checkpoint inhibitor Opdivo&#xae; (nivolumab), in patients with advanced solid tumors.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
        &lt;div style="text-align:justify;margin-left:85.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div/&gt;
        &lt;div style="text-align:justify;text-indent:0pt;margin-left:85.5pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Pursuant to the Agreement, Compugen was responsible for and sponsored the ongoing two-part Phase 1 trial, which included the evaluation of the combination of COM701 and Opdivo&#xae;. The collaboration was also designed to address potential future combinations, including trials sponsored by Bristol-Myers Squibb to investigate combined inhibition of checkpoint mechanisms, such as PVRIG and TIGIT. Bristol-Myers Squibb and Compugen each supplied the other company with its own compound for the other party&#x2019;s study, and otherwise each party was responsible for all costs associated with the study that it is conducting.&lt;/span&gt;&lt;br/&gt;&lt;br/&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In conjunction with the signing of the Agreement in October 2018, Bristol-Myers Squibb made a $12,000 investment in Compugen, see Note 8b.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.5pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On February 14, 2020, the Agreement was amended to include a triple combination clinical trial to evaluate the safety, tolerability and antitumor activity of COM701 in combination with Opdivo&#xae; (nivolumab), and Bristol-Myers Squibb&#x2019;s investigational antibody targeting TIGIT known as BMS-986207, in patients with advanced solid tumors, instead of the planned expansion of the combined therapy study designed to evaluate the dual combination of COM701 and Opdivo&#xae;.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:85.5pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Pursuant to the Agreement, as amended, the Company sponsored the two-part Phase 1/2 trial, which evaluates the triple combination of COM701, Opdivo&#xae; and BMS-986207, in patients with advanced solid tumors where Bristol-Myers Squibb provided Opdivo&#xae; and BMS-986207 at no cost to the Company.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;text-indent:-0.45pt;margin-left:85.5pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As part of the amended Agreement, it was agreed that the Company will complete the dose escalation arm of the dual combination of COM701 with Opdivo&lt;sup style="vertical-align:text-top;line-height:1;font-size:smaller"&gt;&#xae;&lt;/sup&gt; under the ongoing Phase 1 study and will not continue the expansion cohorts of the dual combination. However, on February 19, 2021, the Agreement was further amended to include an expansion of the Phase 1 combination study designed to evaluate the dual combination of COM701 and Opdivo&#xae; in patients with advanced solid tumors, where the Company is responsible for and sponsored the expansion cohort and Bristol Myers Squibb provided Opdivo&#xae; at no cost to the Company for this study.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;text-indent:-0.45pt;margin-left:85.5pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On November 10, 2021, the Agreement was further amended to establish a joint steering committee (alongside the existing joint development committee which acts at an operational level) to facilitate strategic oversight and guidance for the programs run under the collaboration.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;text-indent:0pt;margin-left:85.5pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In conjunction with the signing of the amendment to the Agreement in November 2021, Bristol-Myers Squibb made a $20,000 investment in Compugen, see Note 8b.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;text-indent:-0.45pt;margin-left:85.5pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On August 3, 2022, the Company and Bristol-Myers Squibb entered into a letter agreement pursuant to which the Agreement, as amended thereafter, was terminated as of such date.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000319"
      unitRef="usd">-33694000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000320"
      unitRef="usd">-455773000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000321"
      unitRef="usd">-34506000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="C_20130801to20130805"
      decimals="-3"
      id="FFact_0000000000323"
      unitRef="usd">10000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <cgen:ResearchAndDevelopmentArrangementPaymentsReceivable
      contextRef="C_20130805"
      decimals="-3"
      id="FFact_0000000000324"
      unitRef="usd">250000000</cgen:ResearchAndDevelopmentArrangementPaymentsReceivable>
    <cgen:ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable
      contextRef="C_20130805"
      decimals="-3"
      id="FFact_0000000000325"
      unitRef="usd">23200000</cgen:ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000326"
      unitRef="usd">10000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <cgen:AccruedMilestonePayment
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000327"
      unitRef="usd">15500000</cgen:AccruedMilestonePayment>
    <cgen:ResearchAndDevelopmentArrangementPaymentsReceivable
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000328"
      unitRef="usd">200000000</cgen:ResearchAndDevelopmentArrangementPaymentsReceivable>
    <us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000329"
      unitRef="usd">12000000</us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue>
    <us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue
      contextRef="C_20211130"
      decimals="-3"
      id="FFact_0000000000330"
      unitRef="usd">20000000</us-gaap:InvestmentOwnedUnderlyingFaceAmountAtMarketValue>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000405">
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-weight:bold"&gt;NOTE 2: -&#160;&lt;/span&gt;&lt;span style="font-weight:bold"&gt;SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:56.7pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;a.&lt;span style="padding-left:22.06pt"&gt;Use of estimates:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company&#x2019;s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;b.&lt;span style="padding-left:22.5pt"&gt;Financial statements in U.S. dollars:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The reporting and functional currency of the Company is the U.S. dollar, as the Company&#x2019;s management believes that the U.S. dollar is the primary currency of the economic environment in which the Company and Compugen USA, Inc. have operated and expect to continue to operate in the foreseeable future.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts denominated in currencies other than the dollar are re-measured into dollars in accordance with ASC No. 830, &#x201c;Foreign Currency Matters&#x201d;. All transaction gains and losses from the re-measurement of monetary balance sheet items are reflected in the consolidated statement of comprehensive loss as financial income or expenses, as appropriate.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;c.&lt;span style="padding-left:22.06pt"&gt;Basis of consolidation:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The consolidated financial statements include the accounts of the Company and Compugen USA, Inc. Intercompany transactions and balances have been eliminated upon consolidation.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;d.&lt;span style="padding-left:22.5pt"&gt;Cash equivalents:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;e.&lt;span style="padding-left:22.06pt"&gt;Restricted cash:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Restricted cash is held in interest bearing saving accounts which are used as a security for the Company&#x2019;s Israeli facility leasehold&#160;and leased cars fueling bank guarantees and credit card security for Compugen USA, Inc.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
      &lt;div/&gt;


      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;f.&lt;span style="padding-left:22.17pt"&gt;Short-term bank deposits:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Bank deposits with maturities of more than three months but less than one year are included in short-term bank deposits. Such short-term bank deposits are stated at cost which approximates market values.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The short-term bank deposits as of December 31, 2022&#160;and 2021&#160;are in U.S. dollars and bear an annual weighted average interest rate of 4.84% and 0.77%, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;g.&lt;span style="padding-left:22.5pt"&gt;Property and equipment, net:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;div style="margin-left:85.05pt"&gt;

          &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:50%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom;width:48%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:50%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:48%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;


              &lt;tr style="background-color:#cceeff"&gt;
                &lt;td style="vertical-align:bottom;width:50%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Computers, software and related equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:48%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:50%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Laboratory equipment and office furniture&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:48%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;6 - 20 (mainly 20)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="background-color:#cceeff"&gt;
                &lt;td style="vertical-align:bottom;width:50%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Leasehold improvements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:48%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Shorter of the term of the lease or useful life&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;

      &lt;/div&gt;


      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;h.&lt;span style="padding-left:22.5pt"&gt;Impairment of long-lived assets:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The long-lived assets of the Company and Compugen USA, Inc. are reviewed for impairment in accordance with ASC 360, &#x201c;Property, Plant, and Equipment&#x201d; whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset with the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the years 2022, 2021&#160;and 2020, no impairment losses have been identified.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

    &lt;div&gt;
      &lt;div&gt;
        &lt;div&gt;

            &lt;div&gt;
              &lt;div&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;i.&lt;span style="padding-left:22.72pt"&gt;Leases:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The Company accounts for its leases according to ASC 842 - Leases (&#x201c;ASC 842&#x201d;). The Company determines if an arrangement is a lease and the classification of that lease at inception based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of the asset. The Company elected to not recognize a lease liability and a right-of-use (&#x201c;ROU&#x201d;) asset for leases with a term of twelve months or less.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
                &lt;div/&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:85.05pt;text-align:justify"&gt;ROU assets and lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. ROU assets are initially measured at amounts, which represents the discounted present value of the lease payments over the lease, plus any initial direct costs incurred. The lease liability is initially measured based on the discounted present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. The implicit rate within the operating leases is generally not determinable, therefore the Company uses the Incremental Borrowing Rate (&#x201c;IBR&#x201d;) based on the information available at commencement date in determining the present value of lease payments. The Company&#x2019;s IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located.&lt;/p&gt;
                &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:85.05pt;text-align:justify"&gt;An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate the lease is considered unless it is reasonably certain that the Company will not exercise the option.&lt;/p&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:85.05pt;text-align:justify"&gt;&#160;&lt;/p&gt;
              &lt;/div&gt;
            &lt;/div&gt;

        &lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
    &lt;div&gt;
      &lt;div&gt;
        &lt;div&gt;
          &lt;div&gt;

              &lt;div&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:76pt;text-indent:-20pt"&gt;j.&lt;span style="padding-left:23.06pt"&gt;Revenue recognition:&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:85.05pt;text-align:justify"&gt;The Company generates revenues mainly from its collaborative and license agreements. The revenues are derived mainly from upfront license payments, research and development services and contingent payments related to milestone achievements.&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The Company recognizes revenue in accordance with ASC 606 &#x2013; &#x201c;Revenue from Contracts with Customers&#x201d;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;As such, the Company analyzes its contracts to assess whether they are within the scope of ASC 606. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:-12pt;text-indent:114pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-style:italic"&gt;Identification of the contract, or contracts, with a customer&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:-12pt;margin-left:114pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-style:italic"&gt;Identification of the performance obligations in the contract&lt;/span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:-12pt;margin-left:114pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-style:italic"&gt;Determination of the transaction price&lt;/span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:-12pt;margin-left:114pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-style:italic"&gt;Allocation of the transaction price to the performance obligations in the contract&lt;/span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:-12pt;margin-left:114pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-style:italic"&gt;Recognition of revenue when, or as, the Company satisfies a performance obligation&lt;/span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif"&gt;&#160;&lt;/p&gt;
                &lt;div/&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:85pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;At the contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
                &lt;div&gt;
                  &lt;div style="margin-left:85.05pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company entered into an exclusive license agreement with AstraZeneca. Under the terms of the agreement, Compugen provided AstraZeneca with an exclusive license to intellectual property ("IP&#x201d;) rights of the Company for the development of bi-specific and multi-specific antibody products derived from COM902. Compugen received a $10,000 upfront nonrefundable payment and is eligible to receive up to $200,000 for development, regulatory and commercial milestones for the first product, of which $15,500 was received to date as well as tiered royalties on future product sales.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/div&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Under ASC 606, the Company determined the license to the IP to be a functional IP that has significant standalone functionality. The Company is not required to continue to support, develop or maintain the intellectual property transferred and will not undertake any activities to change the standalone functionality of the IP. Therefore, the license to the IP is a distinct performance obligation and as such revenue is recognized at the point in time that control of the license is transferred to the customer.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Future milestone payments are considered variable consideration and are subject to the variable consideration constraint (i.e. will be recognized once concluded that it is &#x201c;probable&#x201d; that a significant reversal of the cumulative revenues recognized under the contract will not occur in future periods when the uncertainty related to the variable consideration is resolved). Therefore, as the milestone payments are not probable, revenue was not recognized in respect to such milestone payments prior to achievement of such milestone.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Sales&#160;or usage-based royalties to be received in exchange for licenses of IP are recognized at the later of when (1) the subsequent sale or usage occurs or (2) the performance obligation to which some or all of the sales&#160;or usage-based royalty has been allocated is satisfied (in whole or in part). As royalties are payable based on future Commercial Sales, as defined in the agreement, which did not occur as of the financial statements date, the Company did not recognize any revenues from royalties.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;On December 18, 2020 the first milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $&#160;2,000 in accordance with the criteria prescribed under ASC 606.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;On September 29, 2021 the second milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $&#160;6,000 in accordance with the criteria prescribed under ASC 606.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
                &lt;div/&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;On November 11, 2022, the third milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ 7,500 in accordance with the criteria prescribed under ASC 606.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;For additional information regarding revenues, please refer to Note 10 below.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/div&gt;

          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;

      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;k.&lt;span style="padding-left:22.72pt"&gt;Cost of revenues:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Cost of revenues consist of certain royalties and milestones paid or accrued.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;l.&lt;span style="padding-left:24.5pt"&gt;Research and development expenses, net:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Research and development costs are charged to the statement of comprehensive loss as incurred and are presented net of the amount of any grants the Company receives for research and development in the period in which the grant was received.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;As part of the process of preparing the consolidated financial statements, the Company accrues costs for pre-clinical and clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the contract research organizations or other pre-clinical or clinical trial vendors that perform the activities. In certain circumstances, the Company is required to make nonrefundable advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the nonrefundable advance payments are deferred and capitalized, and amortized as the related goods or services are provided. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:85.05pt;text-align:justify"&gt;The portion of the Bristol-Myers Squibb $ 12,000 investment in 2018 over the fair market value of the shares issued in the amount of $ 4,121 and the portion of the $ 20,000 investment in 2021 over the fair market value of the shares issued in the amount of $ 5,000 were considered as deferred participation of Bristol-Myers Squibb in R&amp;amp;D expenses which is amortized over the period of the clinical trial based on the progress in the R&amp;amp;D, see Note 1f and Note 8b.&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Amortization of participation in R&amp;amp;D expenses for the years ended December 31, 2022, 2021&#160;and 2020&#160;were $&#160;6,019, $&#160;1,291 and $&#160;829, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;

    &lt;div/&gt;

      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;m.&lt;span style="padding-left:18.72pt"&gt;Severance pay:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The Company&#x2019;s liability for severance pay for its Israeli employees is calculated pursuant to Israeli Severance Pay Law based on the most recent salary of the employees multiplied by the number of years of employment as of the balance sheet date, and is in large part covered by regular deposits with recognized pension funds, deposits with severance pay funds and purchases of insurance policies. The value of these deposits and policies is recorded as an asset in the Company&#x2019;s balance sheet. Pursuant to Section 14 of the Israeli Severance Pay Law, for Israeli employees under this section, the Company&#x2019;s contributions for severance pay have replaced its severance obligation. Upon contribution of the full amount of the employee&#x2019;s monthly salary for each year of service, no additional calculations are conducted between the parties regarding the matter of severance pay and no additional payments are made by the Company to the employee.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Further, the related obligation and amounts deposited on behalf of the employee for such obligation are not stated on the balance sheet, as the Company is legally released from the obligation to employees once the deposit amounts have been paid.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Severance expenses for the years ended December 31, 2022, 2021&#160;and 2020&#160;amounted to approximately $&#160;468, $&#160;383 and $&#160;572, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;n.&lt;span style="padding-left:22.06pt"&gt;Stock-based compensation:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The Company accounts for stock-based compensation to employees and non-employees in accordance with ASC 718, &#x201c;Compensation - Stock Compensation&#x201d;, (&#x201c;ASC 718&#x201d;), which requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The Company recognizes compensation expenses for the value of its awards granted based on the straight-line method over the requisite service period of each of the awards.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The Company selected the Black-Scholes-Merton (&#x201c;Black-Scholes&#x201d;) option-pricing model as the most appropriate fair value method for its share-options awards and Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;). The option-pricing model requires a number of assumptions, of which the most significant are the expected share price volatility and the expected option term. Expected volatility was calculated based on actual historical share price movements over a term that is equivalent to the expected term of granted options. The expected term of options granted is based on historical experience and represents the period of time that options granted are expected to be outstanding.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
      &lt;div/&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The Company used the following assumptions for options granted to employees, directors and non-employees and ESPP:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;div style="margin-left:85.05pt"&gt;

          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" rowspan="1" style="vertical-align:bottom;border-bottom:1.5pt solid black"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-weight:bold"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:1.5pt solid black"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:1.5pt solid black"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:1.5pt solid black"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-weight:bold"&gt;2020&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:49%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:14%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:14%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:14%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;


              &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;Employee stock options&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Volatility&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;69.44%-74.61%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;66.02%-69.05%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;55.12%-65.59%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;1.54%-4.39%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.51%-1.14%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.26%-1.64%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Expected life (years)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;5.05-5.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;5.04-5.31&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;5.02-5.31&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;

      &lt;/div&gt;
      &lt;div style="margin-left:85.05pt"&gt;
        &lt;div style="margin-top:10pt"&gt;

            &lt;div&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="10" rowspan="1" style="vertical-align:bottom;text-align:center;border-bottom:1.5pt solid black"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="line-height:110%"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center;border-bottom:1.5pt solid black"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center;border-bottom:1.5pt solid black"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;&lt;span&gt;2021&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center;border-bottom:1.5pt solid black"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;&lt;span&gt;2020&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;ESPP&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Volatility&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="padding-left:0pt"&gt;69.74&lt;/span&gt;&lt;span style="padding-left:0pt"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;64.68%-69.68%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;1.63%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.04%-0.10%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Expected life (years)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.50&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.42-0.50&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;

        &lt;/div&gt;
      &lt;/div&gt;


      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;o.&lt;span style="padding-left:21.5pt"&gt;Concentration of credit risks:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Financial instruments that potentially subject the Company and Compugen USA, Inc. to concentration of credit risk consist principally of cash and cash equivalents, restricted cash and short-term bank deposits.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Cash, cash equivalents, restricted cash and short-term bank deposits are invested in major banks in Israel. Generally, these deposits may be redeemed upon demand and bear minimal risk.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;p.&lt;span style="padding-left:22.5pt"&gt;Basic and diluted loss per share:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Basic loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260, &#x201c;Earnings per Share&#x201c;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;All outstanding share options and warrants for the years ended December 31, 2022, 2021 and 2020 have been excluded from the calculation of the diluted net loss per share, because all such securities are anti-dilutive for all periods presented. As of December 31, 2022, 2021 and 2020 the average number of shares related to outstanding options and warrants excluded from the calculations of diluted net loss per share were 8,405,615, 6,758,300 and 7,150,648, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
      &lt;div/&gt;


      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;q.&lt;span style="padding-left:22.5pt"&gt;Income taxes:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The Company accounts for income taxes in accordance with ASC No. 740, &#x201c;Income Taxes&#x201c;, (&#x201c;ASC 740&#x201c;) which prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2022 and 2021, a full valuation allowance was provided by the Company.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been recorded pursuant to ASC 740-10.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;r.&lt;span style="padding-left:23.5pt"&gt;Fair value of financial instruments:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The Company applies ASC 820, &#x201c;Fair Value Measurements and Disclosures&#x201d; (&#x201c;ASC 820&#x201d;), pursuant to which fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &#x201c;exit price&#x201d;) in an orderly transaction between market participants at the measurement date.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputting that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
      &lt;div/&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:85.05pt;margin-bottom:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The hierarchy is broken down into three levels based on the inputs as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%"&gt;

          &lt;tr&gt;
            &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:85.5pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:56.7pt"&gt;
              &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;Level 1&#160; &#160;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;-&lt;/span&gt;&lt;/p&gt;
            &lt;/td&gt;
            &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;text-align:justify;width:auto"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can &lt;/span&gt;access at the measurement date.&lt;/span&gt;&lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="margin-top:10pt"&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%"&gt;

            &lt;tr&gt;
              &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:85.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:56.7pt"&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;Level 2&#160; &#160; -&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;text-align:justify;width:auto"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;Valuations based on one or more quoted prices in markets that are not active or for which all &lt;/span&gt;significant inputs are observable, either directly or indirectly.&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="width:85.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:justify;width:auto"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:85.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:56.7pt"&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;Level 3&#160; &#160; -&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;text-align:justify;width:auto"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;Valuations based on inputs that are unobservable and significant to the overall fair value measurement.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      &lt;/div&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The carrying amounts of cash and cash equivalents, restricted cash, short-term bank deposits, other accounts receivable and prepaid expenses, trade payable and other accounts payable and accrued expenses approximate their fair values due to the short-term maturities of such instruments.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;s.&lt;span style="padding-left:22.06pt"&gt;Recently issued and recently adopted Accounting Standards:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Although there are several other new accounting standards issued or proposed by the FASB, which the Company has adopted or will adopt, as applicable, the Company does not believe any of these accounting pronouncements has had or will have a material impact on its consolidated financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

  </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="C_20220101to20221231" id="FFact_0000000000332">
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;a.&lt;span style="padding-left:22.06pt"&gt;Use of estimates:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company&#x2019;s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    </us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000333">
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;b.&lt;span style="padding-left:22.5pt"&gt;Financial statements in U.S. dollars:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The reporting and functional currency of the Company is the U.S. dollar, as the Company&#x2019;s management believes that the U.S. dollar is the primary currency of the economic environment in which the Company and Compugen USA, Inc. have operated and expect to continue to operate in the foreseeable future.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Transactions and balances denominated in U.S. dollars are presented at their original amounts. Monetary accounts denominated in currencies other than the dollar are re-measured into dollars in accordance with ASC No. 830, &#x201c;Foreign Currency Matters&#x201d;. All transaction gains and losses from the re-measurement of monetary balance sheet items are reflected in the consolidated statement of comprehensive loss as financial income or expenses, as appropriate.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    </us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000334">
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;c.&lt;span style="padding-left:22.06pt"&gt;Basis of consolidation:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The consolidated financial statements include the accounts of the Company and Compugen USA, Inc. Intercompany transactions and balances have been eliminated upon consolidation.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    </us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000335">
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;d.&lt;span style="padding-left:22.5pt"&gt;Cash equivalents:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less at acquisition.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    </us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="C_20220101to20221231" id="FFact_0000000000336">
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;e.&lt;span style="padding-left:22.06pt"&gt;Restricted cash:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Restricted cash is held in interest bearing saving accounts which are used as a security for the Company&#x2019;s Israeli facility leasehold&#160;and leased cars fueling bank guarantees and credit card security for Compugen USA, Inc.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
      &lt;div/&gt;
    </us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <cgen:ShortTermBankDepositsPolicyTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000339">
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;f.&lt;span style="padding-left:22.17pt"&gt;Short-term bank deposits:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Bank deposits with maturities of more than three months but less than one year are included in short-term bank deposits. Such short-term bank deposits are stated at cost which approximates market values.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The short-term bank deposits as of December 31, 2022&#160;and 2021&#160;are in U.S. dollars and bear an annual weighted average interest rate of 4.84% and 0.77%, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    </cgen:ShortTermBankDepositsPolicyTextBlock>
    <cgen:ShortTermBankDepositsWeightedAverageRateForeign
      contextRef="C_20220101to20221231"
      decimals="4"
      id="FFact_0000000000337"
      unitRef="Pure">0.0484</cgen:ShortTermBankDepositsWeightedAverageRateForeign>
    <cgen:ShortTermBankDepositsWeightedAverageRateForeign
      contextRef="C_20210101to20211231"
      decimals="4"
      id="FFact_0000000000338"
      unitRef="Pure">0.0077</cgen:ShortTermBankDepositsWeightedAverageRateForeign>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000346">
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;g.&lt;span style="padding-left:22.5pt"&gt;Property and equipment, net:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;div style="margin-left:85.05pt"&gt;

          &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:50%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom;width:48%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:50%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:48%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;


              &lt;tr style="background-color:#cceeff"&gt;
                &lt;td style="vertical-align:bottom;width:50%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Computers, software and related equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:48%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:50%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Laboratory equipment and office furniture&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:48%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;6 - 20 (mainly 20)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="background-color:#cceeff"&gt;
                &lt;td style="vertical-align:bottom;width:50%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Leasehold improvements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:48%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Shorter of the term of the lease or useful life&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;

      &lt;/div&gt;
    </us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <cgen:ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230214021114712">
          &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:50%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
                &lt;td style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom;width:48%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:50%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:48%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;


              &lt;tr style="background-color:#cceeff"&gt;
                &lt;td style="vertical-align:bottom;width:50%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Computers, software and related equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:48%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:50%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Laboratory equipment and office furniture&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:48%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;6 - 20 (mainly 20)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="background-color:#cceeff"&gt;
                &lt;td style="vertical-align:bottom;width:50%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Leasehold improvements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:48%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Shorter of the term of the lease or useful life&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        </cgen:ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock>
    <cgen:AnnualDepreciationRate
      contextRef="C_20220101to20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"
      decimals="2"
      id="FFact_0000000000340"
      unitRef="Pure">0.33</cgen:AnnualDepreciationRate>
    <cgen:AnnualDepreciationRate
      contextRef="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember"
      decimals="2"
      id="FFact_0000000000341"
      unitRef="Pure">0.06</cgen:AnnualDepreciationRate>
    <cgen:AnnualDepreciationRate
      contextRef="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember"
      decimals="2"
      id="FFact_0000000000342"
      unitRef="Pure">0.20</cgen:AnnualDepreciationRate>
    <cgen:AnnualDepreciationRate
      contextRef="C_20220101to20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember"
      decimals="2"
      id="FFact_0000000000343"
      unitRef="Pure">0.20</cgen:AnnualDepreciationRate>
    <cgen:AnnualDepreciationRateDescription
      contextRef="C_20220101to20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"
      id="FFact_0000000000344">Shorter of the term of the lease or useful life</cgen:AnnualDepreciationRateDescription>
    <us-gaap:PropertyPlantAndEquipmentImpairment contextRef="C_20220101to20221231" id="FFact_0000000000347">
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;h.&lt;span style="padding-left:22.5pt"&gt;Impairment of long-lived assets:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The long-lived assets of the Company and Compugen USA, Inc. are reviewed for impairment in accordance with ASC 360, &#x201c;Property, Plant, and Equipment&#x201d; whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset with the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the years 2022, 2021&#160;and 2020, no impairment losses have been identified.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    </us-gaap:PropertyPlantAndEquipmentImpairment>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230222132032545">
            &lt;div&gt;
              &lt;div&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;i.&lt;span style="padding-left:22.72pt"&gt;Leases:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The Company accounts for its leases according to ASC 842 - Leases (&#x201c;ASC 842&#x201d;). The Company determines if an arrangement is a lease and the classification of that lease at inception based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of the asset. The Company elected to not recognize a lease liability and a right-of-use (&#x201c;ROU&#x201d;) asset for leases with a term of twelve months or less.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
                &lt;div/&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:85.05pt;text-align:justify"&gt;ROU assets and lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. ROU assets are initially measured at amounts, which represents the discounted present value of the lease payments over the lease, plus any initial direct costs incurred. The lease liability is initially measured based on the discounted present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. The implicit rate within the operating leases is generally not determinable, therefore the Company uses the Incremental Borrowing Rate (&#x201c;IBR&#x201d;) based on the information available at commencement date in determining the present value of lease payments. The Company&#x2019;s IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located.&lt;/p&gt;
                &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:85.05pt;text-align:justify"&gt;An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate the lease is considered unless it is reasonably certain that the Company will not exercise the option.&lt;/p&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:85.05pt;text-align:justify"&gt;&#160;&lt;/p&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          </us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230222132059448">
              &lt;div&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:76pt;text-indent:-20pt"&gt;j.&lt;span style="padding-left:23.06pt"&gt;Revenue recognition:&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-left:85.05pt;text-align:justify"&gt;The Company generates revenues mainly from its collaborative and license agreements. The revenues are derived mainly from upfront license payments, research and development services and contingent payments related to milestone achievements.&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The Company recognizes revenue in accordance with ASC 606 &#x2013; &#x201c;Revenue from Contracts with Customers&#x201d;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;As such, the Company analyzes its contracts to assess whether they are within the scope of ASC 606. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:-12pt;text-indent:114pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-style:italic"&gt;Identification of the contract, or contracts, with a customer&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:-12pt;margin-left:114pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-style:italic"&gt;Identification of the performance obligations in the contract&lt;/span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:-12pt;margin-left:114pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-style:italic"&gt;Determination of the transaction price&lt;/span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:-12pt;margin-left:114pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-style:italic"&gt;Allocation of the transaction price to the performance obligations in the contract&lt;/span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&#x2022;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:-12pt;margin-left:114pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-style:italic"&gt;Recognition of revenue when, or as, the Company satisfies a performance obligation&lt;/span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif"&gt;&#160;&lt;/p&gt;
                &lt;div/&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:85pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;At the contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
                &lt;div&gt;
                  &lt;div style="margin-left:85.05pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company entered into an exclusive license agreement with AstraZeneca. Under the terms of the agreement, Compugen provided AstraZeneca with an exclusive license to intellectual property ("IP&#x201d;) rights of the Company for the development of bi-specific and multi-specific antibody products derived from COM902. Compugen received a $10,000 upfront nonrefundable payment and is eligible to receive up to $200,000 for development, regulatory and commercial milestones for the first product, of which $15,500 was received to date as well as tiered royalties on future product sales.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                &lt;/div&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Under ASC 606, the Company determined the license to the IP to be a functional IP that has significant standalone functionality. The Company is not required to continue to support, develop or maintain the intellectual property transferred and will not undertake any activities to change the standalone functionality of the IP. Therefore, the license to the IP is a distinct performance obligation and as such revenue is recognized at the point in time that control of the license is transferred to the customer.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Future milestone payments are considered variable consideration and are subject to the variable consideration constraint (i.e. will be recognized once concluded that it is &#x201c;probable&#x201d; that a significant reversal of the cumulative revenues recognized under the contract will not occur in future periods when the uncertainty related to the variable consideration is resolved). Therefore, as the milestone payments are not probable, revenue was not recognized in respect to such milestone payments prior to achievement of such milestone.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Sales&#160;or usage-based royalties to be received in exchange for licenses of IP are recognized at the later of when (1) the subsequent sale or usage occurs or (2) the performance obligation to which some or all of the sales&#160;or usage-based royalty has been allocated is satisfied (in whole or in part). As royalties are payable based on future Commercial Sales, as defined in the agreement, which did not occur as of the financial statements date, the Company did not recognize any revenues from royalties.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;On December 18, 2020 the first milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $&#160;2,000 in accordance with the criteria prescribed under ASC 606.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;On September 29, 2021 the second milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $&#160;6,000 in accordance with the criteria prescribed under ASC 606.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
                &lt;div/&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;On November 11, 2022, the third milestone with respect to the first licensed product, under the AstraZeneca License Agreement was achieved and the Company recognized revenues in total amount of $ 7,500 in accordance with the criteria prescribed under ASC 606.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;For additional information regarding revenues, please refer to Note 10 below.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/div&gt;
            </us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000348"
      unitRef="usd">10000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <cgen:ResearchAndDevelopmentArrangementPaymentsReceivable
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000349"
      unitRef="usd">200000000</cgen:ResearchAndDevelopmentArrangementPaymentsReceivable>
    <cgen:AccruedMilestonePayment
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000350"
      unitRef="usd">15500000</cgen:AccruedMilestonePayment>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_20201201to20201218"
      decimals="-3"
      id="FFact_0000000000351"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_20210901to20210929"
      decimals="-3"
      id="FFact_0000000000352"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_20221101to20221111"
      decimals="-3"
      id="Fxbrl_20230214012742011"
      unitRef="usd">7500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <cgen:CostOfSalesContractWithCustomerPolicyTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000354">
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;k.&lt;span style="padding-left:22.72pt"&gt;Cost of revenues:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Cost of revenues consist of certain royalties and milestones paid or accrued.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    </cgen:CostOfSalesContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="C_20220101to20221231" id="FFact_0000000000363">
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;l.&lt;span style="padding-left:24.5pt"&gt;Research and development expenses, net:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Research and development costs are charged to the statement of comprehensive loss as incurred and are presented net of the amount of any grants the Company receives for research and development in the period in which the grant was received.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;As part of the process of preparing the consolidated financial statements, the Company accrues costs for pre-clinical and clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the contract research organizations or other pre-clinical or clinical trial vendors that perform the activities. In certain circumstances, the Company is required to make nonrefundable advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the nonrefundable advance payments are deferred and capitalized, and amortized as the related goods or services are provided. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:85.05pt;text-align:justify"&gt;The portion of the Bristol-Myers Squibb $ 12,000 investment in 2018 over the fair market value of the shares issued in the amount of $ 4,121 and the portion of the $ 20,000 investment in 2021 over the fair market value of the shares issued in the amount of $ 5,000 were considered as deferred participation of Bristol-Myers Squibb in R&amp;amp;D expenses which is amortized over the period of the clinical trial based on the progress in the R&amp;amp;D, see Note 1f and Note 8b.&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Amortization of participation in R&amp;amp;D expenses for the years ended December 31, 2022, 2021&#160;and 2020&#160;were $&#160;6,019, $&#160;1,291 and $&#160;829, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
    </us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="C_20221231_srtStatementScenarioAxis_cgenMasterClinicalAgreementOneMember"
      decimals="-3"
      id="Fxbrl_20230221140432370"
      unitRef="usd">12000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <cgen:DeferredParticipationOfBMSInRAndDExpenses
      contextRef="C_20220101to20221231_srtStatementScenarioAxis_cgenMasterClinicalAgreementOneMember"
      decimals="-3"
      id="Fxbrl_20230221140440887"
      unitRef="usd">4121000</cgen:DeferredParticipationOfBMSInRAndDExpenses>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="C_20221231_srtStatementScenarioAxis_cgenMasterClinicalAgreementTwoMember"
      decimals="-3"
      id="Fxbrl_20230221140447657"
      unitRef="usd">20000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <cgen:DeferredParticipationOfBMSInRAndDExpenses
      contextRef="C_20220101to20221231_srtStatementScenarioAxis_cgenMasterClinicalAgreementTwoMember"
      decimals="-3"
      id="Fxbrl_20230221140456655"
      unitRef="usd">5000000</cgen:DeferredParticipationOfBMSInRAndDExpenses>
    <us-gaap:AdjustmentForAmortization
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000360"
      unitRef="usd">6019000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000361"
      unitRef="usd">1291000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000362"
      unitRef="usd">829000</us-gaap:AdjustmentForAmortization>
    <cgen:ServerancePayPolicyTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000367">
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;m.&lt;span style="padding-left:18.72pt"&gt;Severance pay:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The Company&#x2019;s liability for severance pay for its Israeli employees is calculated pursuant to Israeli Severance Pay Law based on the most recent salary of the employees multiplied by the number of years of employment as of the balance sheet date, and is in large part covered by regular deposits with recognized pension funds, deposits with severance pay funds and purchases of insurance policies. The value of these deposits and policies is recorded as an asset in the Company&#x2019;s balance sheet. Pursuant to Section 14 of the Israeli Severance Pay Law, for Israeli employees under this section, the Company&#x2019;s contributions for severance pay have replaced its severance obligation. Upon contribution of the full amount of the employee&#x2019;s monthly salary for each year of service, no additional calculations are conducted between the parties regarding the matter of severance pay and no additional payments are made by the Company to the employee.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Further, the related obligation and amounts deposited on behalf of the employee for such obligation are not stated on the balance sheet, as the Company is legally released from the obligation to employees once the deposit amounts have been paid.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Severance expenses for the years ended December 31, 2022, 2021&#160;and 2020&#160;amounted to approximately $&#160;468, $&#160;383 and $&#160;572, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    </cgen:ServerancePayPolicyTextBlock>
    <us-gaap:SeveranceCosts1
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000364"
      unitRef="usd">468000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000365"
      unitRef="usd">383000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000366"
      unitRef="usd">572000</us-gaap:SeveranceCosts1>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="C_20220101to20221231" id="FFact_0000000000394">
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;n.&lt;span style="padding-left:22.06pt"&gt;Stock-based compensation:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The Company accounts for stock-based compensation to employees and non-employees in accordance with ASC 718, &#x201c;Compensation - Stock Compensation&#x201d;, (&#x201c;ASC 718&#x201d;), which requires companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The Company recognizes compensation expenses for the value of its awards granted based on the straight-line method over the requisite service period of each of the awards.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The Company selected the Black-Scholes-Merton (&#x201c;Black-Scholes&#x201d;) option-pricing model as the most appropriate fair value method for its share-options awards and Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;). The option-pricing model requires a number of assumptions, of which the most significant are the expected share price volatility and the expected option term. Expected volatility was calculated based on actual historical share price movements over a term that is equivalent to the expected term of granted options. The expected term of options granted is based on historical experience and represents the period of time that options granted are expected to be outstanding.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
      &lt;div/&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The Company used the following assumptions for options granted to employees, directors and non-employees and ESPP:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;div style="margin-left:85.05pt"&gt;

          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" rowspan="1" style="vertical-align:bottom;border-bottom:1.5pt solid black"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-weight:bold"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:1.5pt solid black"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:1.5pt solid black"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:1.5pt solid black"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-weight:bold"&gt;2020&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:49%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:14%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:14%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:14%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;


              &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;Employee stock options&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Volatility&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;69.44%-74.61%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;66.02%-69.05%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;55.12%-65.59%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;1.54%-4.39%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.51%-1.14%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.26%-1.64%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Expected life (years)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;5.05-5.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;5.04-5.31&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;5.02-5.31&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;

      &lt;/div&gt;
      &lt;div style="margin-left:85.05pt"&gt;
        &lt;div style="margin-top:10pt"&gt;

            &lt;div&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="10" rowspan="1" style="vertical-align:bottom;text-align:center;border-bottom:1.5pt solid black"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="line-height:110%"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center;border-bottom:1.5pt solid black"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center;border-bottom:1.5pt solid black"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;&lt;span&gt;2021&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center;border-bottom:1.5pt solid black"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;&lt;span&gt;2020&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;ESPP&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Volatility&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="padding-left:0pt"&gt;69.74&lt;/span&gt;&lt;span style="padding-left:0pt"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;64.68%-69.68%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;1.63%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.04%-0.10%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Expected life (years)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.50&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.42-0.50&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;

        &lt;/div&gt;
      &lt;/div&gt;
    </us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <cgen:ScheduleOfWeightedAverageAssumptionsForGrantedOptions
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230214021045368">
          &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" rowspan="1" style="vertical-align:bottom;border-bottom:1.5pt solid black"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-weight:bold"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:1.5pt solid black"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:1.5pt solid black"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;border-bottom:1.5pt solid black"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-weight:bold"&gt;2020&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:49%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:14%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:14%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:14%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;


              &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;Employee stock options&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Volatility&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;69.44%-74.61%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;66.02%-69.05%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;55.12%-65.59%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;1.54%-4.39%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.51%-1.14%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.26%-1.64%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Expected life (years)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;5.05-5.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;5.04-5.31&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;5.02-5.31&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;

            &lt;div&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="10" rowspan="1" style="vertical-align:bottom;text-align:center;border-bottom:1.5pt solid black"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;strong&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="line-height:110%"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center;border-bottom:1.5pt solid black"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center;border-bottom:1.5pt solid black"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;&lt;span&gt;2021&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" rowspan="1" style="vertical-align:bottom;text-align:center;border-bottom:1.5pt solid black"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;&lt;span&gt;2020&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;text-align:center"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;ESPP&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Volatility&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="padding-left:0pt"&gt;69.74&lt;/span&gt;&lt;span style="padding-left:0pt"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;64.68%-69.68%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;1.63%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.04%-0.10%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="background-color:rgb(204, 238, 255)"&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:49%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:14%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(204, 238, 255);width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr style="background-color:rgb(255, 255, 255)"&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:49%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Expected life (years)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.50&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;
                      &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:center"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;0.42-0.50&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:14%"&gt;
                      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
                    &lt;/td&gt;
                    &lt;td style="vertical-align:bottom;background-color:rgb(255, 255, 255);width:1%"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          </cgen:ScheduleOfWeightedAverageAssumptionsForGrantedOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="4"
      id="Fxbrl_20230222111557515"
      unitRef="Pure">0.6944</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="4"
      id="Fxbrl_20230222111657770"
      unitRef="Pure">0.7461</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20210101to20211231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="4"
      id="Fxbrl_20230222111705802"
      unitRef="Pure">0.6602</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20210101to20211231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="4"
      id="Fxbrl_20230222111709770"
      unitRef="Pure">0.6905</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20200101to20201231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="4"
      id="Fxbrl_20230222111716009"
      unitRef="Pure">0.5512</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20200101to20201231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="4"
      id="Fxbrl_20230222111720906"
      unitRef="Pure">0.6559</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="4"
      id="Fxbrl_20230222111846385"
      unitRef="Pure">0.0154</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="4"
      id="Fxbrl_20230222111850185"
      unitRef="Pure">0.0439</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20210101to20211231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="4"
      id="Fxbrl_20230222111857816"
      unitRef="Pure">0.0051</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20210101to20211231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="4"
      id="Fxbrl_20230222111901472"
      unitRef="Pure">0.0114</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20200101to20201231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="4"
      id="Fxbrl_20230222111908255"
      unitRef="Pure">0.0026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20200101to20201231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="4"
      id="Fxbrl_20230222111911818"
      unitRef="Pure">0.0164</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20220101to20221231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="2"
      id="FFact_0000000000374"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20210101to20211231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="2"
      id="FFact_0000000000375"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20200101to20201231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      decimals="2"
      id="FFact_0000000000376"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20220101to20221231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      id="Fxbrl_20230222111920863">P5Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20220101to20221231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      id="Fxbrl_20230222111935802">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20210101to20211231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      id="Fxbrl_20230222111942937">P5Y14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20210101to20211231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      id="Fxbrl_20230222111945746">P5Y3M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20200101to20201231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      id="Fxbrl_20230222111951712">P5Y7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20200101to20201231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember"
      id="Fxbrl_20230222111955217">P5Y3M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"
      decimals="4"
      id="FFact_0000000000380"
      unitRef="Pure">0.6974</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20210101to20211231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"
      decimals="4"
      id="Fxbrl_20230214015505042"
      unitRef="Pure">0.6468</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20210101to20211231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"
      decimals="4"
      id="Fxbrl_20230214015511155"
      unitRef="Pure">0.6968</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_20200101to20201231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"
      decimals="2"
      id="Fxbrl_20230214015610374"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"
      decimals="4"
      id="FFact_0000000000384"
      unitRef="Pure">0.0163</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20210101to20211231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"
      decimals="4"
      id="Fxbrl_20230214015516923"
      unitRef="Pure">0.0004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20210101to20211231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"
      decimals="4"
      id="Fxbrl_20230214015523604"
      unitRef="Pure">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_20200101to20201231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"
      decimals="2"
      id="Fxbrl_20230214015615908"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"
      decimals="2"
      id="FFact_0000000000388"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20210101to20211231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"
      decimals="2"
      id="Fxbrl_20230214015529421"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_20200101to20201231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"
      decimals="2"
      id="Fxbrl_20230214015623237"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"
      id="FFact_0000000000391">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20210101to20211231_srtRangeAxis_srtMinimumMember_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"
      id="Fxbrl_20230214015535420">P0Y5M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_20210101to20211231_srtRangeAxis_srtMaximumMember_usgaapAwardTypeAxis_cgenEmployeeStockPurchasePlanMember"
      id="Fxbrl_20230214015542343">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="C_20220101to20221231" id="FFact_0000000000395">
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;o.&lt;span style="padding-left:21.5pt"&gt;Concentration of credit risks:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Financial instruments that potentially subject the Company and Compugen USA, Inc. to concentration of credit risk consist principally of cash and cash equivalents, restricted cash and short-term bank deposits.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Cash, cash equivalents, restricted cash and short-term bank deposits are invested in major banks in Israel. Generally, these deposits may be redeemed upon demand and bear minimal risk.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    </us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000399">
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;p.&lt;span style="padding-left:22.5pt"&gt;Basic and diluted loss per share:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Basic loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260, &#x201c;Earnings per Share&#x201c;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;All outstanding share options and warrants for the years ended December 31, 2022, 2021 and 2020 have been excluded from the calculation of the diluted net loss per share, because all such securities are anti-dilutive for all periods presented. As of December 31, 2022, 2021 and 2020 the average number of shares related to outstanding options and warrants excluded from the calculations of diluted net loss per share were 8,405,615, 6,758,300 and 7,150,648, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
      &lt;div/&gt;
    </us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20220101to20221231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapStockOptionMember"
      decimals="INF"
      id="FFact_0000000000396"
      unitRef="Shares">8405615</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20210101to20211231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapStockOptionMember"
      decimals="INF"
      id="FFact_0000000000397"
      unitRef="Shares">6758300</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_20200101to20201231_usgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_usgaapStockOptionMember"
      decimals="INF"
      id="FFact_0000000000398"
      unitRef="Shares">7150648</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000400">
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;q.&lt;span style="padding-left:22.5pt"&gt;Income taxes:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The Company accounts for income taxes in accordance with ASC No. 740, &#x201c;Income Taxes&#x201c;, (&#x201c;ASC 740&#x201c;) which prescribes the use of the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2022 and 2021, a full valuation allowance was provided by the Company.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;ASC 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position. Therefore, no reserves for uncertain income tax positions have been recorded pursuant to ASC 740-10.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    </us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="C_20220101to20221231" id="FFact_0000000000401">
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;r.&lt;span style="padding-left:23.5pt"&gt;Fair value of financial instruments:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The Company applies ASC 820, &#x201c;Fair Value Measurements and Disclosures&#x201d; (&#x201c;ASC 820&#x201d;), pursuant to which fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the &#x201c;exit price&#x201d;) in an orderly transaction between market participants at the measurement date.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;In determining fair value, the Company uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputting that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
      &lt;div/&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:85.05pt;margin-bottom:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The hierarchy is broken down into three levels based on the inputs as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%"&gt;

          &lt;tr&gt;
            &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:85.5pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:56.7pt"&gt;
              &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;Level 1&#160; &#160;&#160;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;-&lt;/span&gt;&lt;/p&gt;
            &lt;/td&gt;
            &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;text-align:justify;width:auto"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can &lt;/span&gt;access at the measurement date.&lt;/span&gt;&lt;/td&gt;
          &lt;/tr&gt;

      &lt;/table&gt;
      &lt;div style="margin-top:10pt"&gt;
        &lt;table border="0" cellpadding="0" cellspacing="0" style="font-size:10pt;font-family:Times New Roman, Times, serif;width:100%"&gt;

            &lt;tr&gt;
              &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:85.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:56.7pt"&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;Level 2&#160; &#160; -&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;text-align:justify;width:auto"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;Valuations based on one or more quoted prices in markets that are not active or for which all &lt;/span&gt;significant inputs are observable, either directly or indirectly.&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="width:85.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:56.7pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="text-align:justify;width:auto"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:85.5pt"&gt;&#160;&lt;/td&gt;
              &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;width:56.7pt"&gt;
                &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;Level 3&#160; &#160; -&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="font-family:Times New Roman, Times, serif;vertical-align:top;text-align:justify;width:auto"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;Valuations based on inputs that are unobservable and significant to the overall fair value measurement.&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      &lt;/div&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The carrying amounts of cash and cash equivalents, restricted cash, short-term bank deposits, other accounts receivable and prepaid expenses, trade payable and other accounts payable and accrued expenses approximate their fair values due to the short-term maturities of such instruments.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    </us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000404">
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:76pt;text-indent:-20pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;s.&lt;span style="padding-left:22.06pt"&gt;Recently issued and recently adopted Accounting Standards:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;Although there are several other new accounting standards issued or proposed by the FASB, which the Company has adopted or will adopt, as applicable, the Company does not believe any of these accounting pronouncements has had or will have a material impact on its consolidated financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    </us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <cgen:OtherAccountsReceivableAndPrepaidExpensesTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230222132226340">
    &lt;div&gt;
      &lt;div&gt;
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:10pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;NOTE 3: - OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;div&gt;
          &lt;div&gt;
            &lt;div&gt;
              &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;div style="margin-left:63pt"&gt;

                    &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;float:left"&gt;

                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                            &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Prepaid expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;5,272&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom"&gt;
                            &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Government authorities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;57&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom"&gt;
                            &lt;div style="text-indent:-4.25pt;margin-left:7.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;232&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;131&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,417&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;5,460&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;

                    &lt;/table&gt;

                &lt;/div&gt;
              &lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
      &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both"&gt;&#160;&lt;/div&gt;
    &lt;/div&gt;
  </cgen:OtherAccountsReceivableAndPrepaidExpensesTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230222132243765">
                    &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;float:left"&gt;

                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                            &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                            &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Prepaid expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;5,272&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom"&gt;
                            &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Government authorities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;57&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom"&gt;
                            &lt;div style="text-indent:-4.25pt;margin-left:7.1pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Other&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;232&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;131&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;
                        &lt;tr&gt;
                          &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,417&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                            &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;5,460&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                          &lt;/td&gt;
                          &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                        &lt;/tr&gt;

                    &lt;/table&gt;
                  </us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000406"
      unitRef="usd">2100000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000407"
      unitRef="usd">5272000</us-gaap:PrepaidExpenseCurrent>
    <cgen:GovernmentAuthorities
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000408"
      unitRef="usd">85000</cgen:GovernmentAuthorities>
    <cgen:GovernmentAuthorities
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000409"
      unitRef="usd">57000</cgen:GovernmentAuthorities>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000410"
      unitRef="usd">232000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000411"
      unitRef="usd">131000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000412"
      unitRef="usd">2417000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000413"
      unitRef="usd">5460000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000441">
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;NOTE 4: - LEASES&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;div&gt;
      &lt;div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company leases all its real estate, storage area and cars under various operating lease agreements that expire on various dates.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company&#x2019;s operating leases have original lease periods expiring between 2021 and 2025. The offices in Israel lease include two options to renew, one of which was exercised in 2020. The Company does not assume renewals in its determination of the lease term unless the renewals are deemed to be reasonably certain.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In October 2020 the Company&#x2019;s lease for its offices in Israel was amended. The amendment was not accounted for as a new lease. As a result of the amendment the operating lease right of use asset increased by $43, the operating lease liability decreased by $194 and the Company recorded foreign currency exchange rate of $237.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Lease payments included in the measurement of the lease liability comprise the following: the fixed non-cancelable lease payments and payments for optional renewal periods where it is reasonably certain the renewal period will be exercised.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Under ASC 842, all leases, including non-cancelable operating leases, are now recognized on the balance sheet. The aggregated present value of lease payments is recorded as a long-term asset titled Operating lease right of use asset. The corresponding lease liabilities are split between current maturity of operating lease liability within current liabilities and long-term operating lease liability within long-term liabilities. The Company&#x2019;s leases do not provide an implicit rate, therefore the Company uses its incremental borrowing rate based on information available on the commencement date in determining the present value of lease payments.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div/&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The following table represents the weighted-average remaining lease term and discount rate:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="margin-left:56.7pt"&gt;

            &lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:90%"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3.16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%" valign="bottom"&gt;
                    &lt;div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average discount (annual) rate&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5.52%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;

        &lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Operating lease expenses were approximately $884, $956 and $944 in the years ended December 31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Cash paid for amounts included in the measurement of lease liabilities was approximately $959, $914 and $927 in the years ended December 31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Maturities of operating lease liabilities were as follows:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="margin-left:56.7pt"&gt;

            &lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:90%"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;December 31,&lt;/span&gt;&lt;span&gt;&#160;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;699&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%" valign="bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;669&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;609&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%;padding-bottom:2px" valign="bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%" valign="bottom"&gt;
                    &lt;div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total operating lease payments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,091&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Less: imputed interest&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;166&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,925&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%" valign="bottom"&gt;
                    &lt;div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Lease liabilities, current&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;613&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom"&gt;
                    &lt;div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Lease liabilities, non- current&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,312&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;1,925&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;

        &lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both"&gt;&#160;&lt;/div&gt;
        &lt;div style="text-align:justify;margin-left:56.7pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The above annual minimum future rental commitments include the period covered by the first exercised option with respect to the leased facility of Compugen Ltd. through March 2026 and exclude the second option to extend the lease of the Company facility for additional five-year period following expiration of the current lease period.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:LesseeOperatingLeasesTextBlock>
    <cgen:IncreaseOperatingLeaseRightOfUseAsset
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000416"
      unitRef="usd">43000</cgen:IncreaseOperatingLeaseRightOfUseAsset>
    <cgen:DecreaseOperatingLeaseLiability
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000417"
      unitRef="usd">194000</cgen:DecreaseOperatingLeaseLiability>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000418"
      unitRef="usd">237000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <cgen:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230222013426728">
            &lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:90%"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman',Times,serif;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3.16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%" valign="bottom"&gt;
                    &lt;div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average discount (annual) rate&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;5.52%&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&#160;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          </cgen:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_20221231" id="FFact_0000000000421">P3Y1M28D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_20221231"
      decimals="4"
      id="FFact_0000000000422"
      unitRef="Pure">0.0552</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000424"
      unitRef="usd">884000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000425"
      unitRef="usd">956000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000426"
      unitRef="usd">944000</us-gaap:OperatingLeasePayments>
    <cgen:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000427"
      unitRef="usd">959000</cgen:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities>
    <cgen:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000428"
      unitRef="usd">914000</cgen:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities>
    <cgen:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000429"
      unitRef="usd">927000</cgen:CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230222013609784">
            &lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;font-family:'Times New Roman',Times,serif;font-size:10pt;text-align:left;width:90%"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-family:'Times New Roman', serif;font-size:11pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;December 31,&lt;/span&gt;&lt;span&gt;&#160;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:top;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;699&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%" valign="bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;669&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;609&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:88%;padding-bottom:2px" valign="bottom"&gt;
                    &lt;div style="text-align:justify;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%" valign="bottom"&gt;
                    &lt;div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Total operating lease payments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,091&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Less: imputed interest&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;166&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,925&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%" valign="bottom"&gt;
                    &lt;div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Lease liabilities, current&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;613&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom"&gt;
                    &lt;div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Lease liabilities, non- current&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,312&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:88%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="text-align:justify;text-indent:-25.95pt;margin-left:25.95pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;1,925&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          </us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000430"
      unitRef="usd">699000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000431"
      unitRef="usd">669000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000432"
      unitRef="usd">609000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000433"
      unitRef="usd">114000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000435"
      unitRef="usd">2091000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000436"
      unitRef="usd">166000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000437"
      unitRef="usd">1925000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000438"
      unitRef="usd">613000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000439"
      unitRef="usd">1312000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230214024012785"
      unitRef="usd">1925000</us-gaap:OperatingLeaseLiability>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000468">
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:10pt"&gt;&lt;span style="font-weight:bold"&gt;NOTE 5: -&#160;&lt;/span&gt;&lt;span style="font-weight:bold"&gt;PROPERTY AND EQUIPMENT, NET&lt;/span&gt;&lt;/p&gt;

      &lt;div style="margin-left:56.7pt"&gt;
        &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="6" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;December 31,&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;


            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Cost:&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Computers, software and related equipment&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,617&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,506&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Laboratory equipment and office furniture&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;3,831&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;3,674&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Leasehold improvements&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;2,314&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;2,321&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;7,762&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;7,501&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Accumulated depreciation:&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Computers, software and related equipment&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,435&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,351&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Laboratory equipment and office furniture&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;3,190&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;3,114&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Leasehold improvements&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,605&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,378&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;6,230&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;5,843&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Depreciated cost&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,532&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,658&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      &lt;/div&gt;

    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:56.7pt;margin-bottom:0pt"&gt;During 2022&#160;and 2021&#160;total cost of $&#160;99&#160;and $&#160;26, respectively and total accumulated depreciation of $&#160;95&#160;and $&#160;26, respectively were disposed from the consolidated balance sheets.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:56.7pt;margin-bottom:0pt"&gt;For the years ended December 31, 2022, 2021&#160;and 2020, depreciation expenses were approximately $&#160;482, $&#160;461&#160;and $&#160;715, respectively.&lt;/p&gt;
  </us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000460">
      &lt;div style="margin-left:56.7pt"&gt;
        &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="6" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;December 31,&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;


            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Cost:&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Computers, software and related equipment&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,617&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,506&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Laboratory equipment and office furniture&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;3,831&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;3,674&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Leasehold improvements&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;2,314&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;2,321&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;7,762&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;7,501&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Accumulated depreciation:&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Computers, software and related equipment&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,435&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,351&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Laboratory equipment and office furniture&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;3,190&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;3,114&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Leasehold improvements&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,605&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,378&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;6,230&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;5,843&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:76%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Depreciated cost&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,532&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,658&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      &lt;/div&gt;
    </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"
      decimals="-3"
      id="FFact_0000000000442"
      unitRef="usd">1617000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"
      decimals="-3"
      id="FFact_0000000000443"
      unitRef="usd">1506000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember"
      decimals="-3"
      id="FFact_0000000000444"
      unitRef="usd">3831000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember"
      decimals="-3"
      id="FFact_0000000000445"
      unitRef="usd">3674000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"
      decimals="-3"
      id="FFact_0000000000446"
      unitRef="usd">2314000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"
      decimals="-3"
      id="FFact_0000000000447"
      unitRef="usd">2321000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000448"
      unitRef="usd">7762000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000449"
      unitRef="usd">7501000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"
      decimals="-3"
      id="FFact_0000000000450"
      unitRef="usd">1435000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember"
      decimals="-3"
      id="FFact_0000000000451"
      unitRef="usd">1351000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember"
      decimals="-3"
      id="FFact_0000000000452"
      unitRef="usd">3190000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenLaboratoryEquipmentAndOfficeFurnitureMember"
      decimals="-3"
      id="FFact_0000000000453"
      unitRef="usd">3114000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"
      decimals="-3"
      id="FFact_0000000000454"
      unitRef="usd">1605000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapLeaseholdImprovementsMember"
      decimals="-3"
      id="FFact_0000000000455"
      unitRef="usd">1378000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000456"
      unitRef="usd">6230000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000457"
      unitRef="usd">5843000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000458"
      unitRef="usd">1532000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000459"
      unitRef="usd">1658000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember"
      decimals="-3"
      id="FFact_0000000000461"
      unitRef="usd">99000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember"
      decimals="-3"
      id="FFact_0000000000462"
      unitRef="usd">26000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember"
      decimals="-3"
      id="FFact_0000000000463"
      unitRef="usd">95000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_20211231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember"
      decimals="-3"
      id="FFact_0000000000464"
      unitRef="usd">26000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:Depreciation
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000465"
      unitRef="usd">482000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000466"
      unitRef="usd">461000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000467"
      unitRef="usd">715000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000476">
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:10pt"&gt;&lt;span style="font-weight:bold"&gt;NOTE 6: - &lt;/span&gt;&lt;strong&gt;OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES&lt;/strong&gt;&lt;/p&gt;
    &lt;div&gt;
      &lt;div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
        &lt;div style="margin-left:54pt"&gt;

            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;float:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;December 31,&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;2022&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;2021&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;Employees and related accruals&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:'Times New Roman',Times,serif"&gt;$&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:'Times New Roman',Times,serif"&gt;2,812&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:'Times New Roman',Times,serif"&gt;$&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:'Times New Roman',Times,serif"&gt;3,299&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px" valign="bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;Accrued expenses&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;6,396&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;4,779&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:'Times New Roman',Times,serif"&gt;$&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:'Times New Roman',Times,serif"&gt;9,208&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:'Times New Roman',Times,serif"&gt;$&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:'Times New Roman',Times,serif"&gt;8,078&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;

        &lt;/div&gt;
        &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both"&gt;&#160;&lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230222132609363">
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;float:left"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;December 31,&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;2022&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;2021&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;Employees and related accruals&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:'Times New Roman',Times,serif"&gt;$&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:'Times New Roman',Times,serif"&gt;2,812&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:'Times New Roman',Times,serif"&gt;$&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:'Times New Roman',Times,serif"&gt;3,299&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px" valign="bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;Accrued expenses&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;6,396&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;4,779&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:'Times New Roman',Times,serif"&gt;$&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:'Times New Roman',Times,serif"&gt;9,208&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:'Times New Roman',Times,serif"&gt;$&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-family:'Times New Roman',Times,serif"&gt;8,078&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          </us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000469"
      unitRef="usd">2812000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000470"
      unitRef="usd">3299000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000471"
      unitRef="usd">6396000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000472"
      unitRef="usd">4779000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000473"
      unitRef="usd">9208000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000474"
      unitRef="usd">8078000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000498">
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0px;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;NOTE 7: -&#160;&lt;/span&gt;&lt;span style="font-weight:bold"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt"&gt;a.&lt;span style="padding-left:21.5pt"&gt;The Company provided bank guarantees in the amount of $&#160;&lt;/span&gt;318 related to its offices in Israel, leased cars fueling in Israel and credit card security for its U.S. subsidiary.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt"&gt;b.&lt;span style="padding-left:21.5pt"&gt;Under the Office of the Israel Innovation Authority of the Israeli Ministry of Industry, Trade and Labor, formerly &lt;/span&gt;known as the Office of the Chief Scientist, (the &#x201c;IIA&#x201d;), the Company is not obligated to repay any amounts received from the IIA if it does not generate any income from the results of the funded research program(s). If income is generated from a funded research program, the Company is committed to pay royalties at a rate of between 3% to 5% of future revenue arising from such research program(s), and up to a maximum of 100% of the amount received, linked to the U.S. dollar (for grants received under programs approved subsequent to January 1, 1999, the maximum to be repaid is 100% plus interest at LIBOR). For the years ended December 31, 2022, 2021&#160;and 2020, the Company had an aggregate of paid or accrued royalties to the IIA, recorded as cost of revenue in the consolidated statements of comprehensive loss in the amount of $&#160;225, $&#160;180 and $&#160;60, respectively.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;As of December 31, 2022, the Company&#x2019;s aggregate contingent obligations for payments to IIA, based on royalty-bearing participation received or accrued, net of royalties paid or accrued, totaled approximately to $&#160;9,631.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt"&gt;c.&lt;span style="padding-left:21.06pt"&gt;On June 25, 2012 the Company entered into an Antibodies Discovery Collaboration Agreement (the &#x201c;Antibodies &lt;/span&gt;Discovery Agreement&#x201d;) with a U.S. antibody technology company (&#x201c;mAb Technology Company&#x201d;), providing an established source for fully human mAbs. Under the Antibodies Discovery Agreement, the mAb Technology Company will be entitled to certain royalties that could be eliminated, upon payment of certain one-time fees (all payments referred together as &#x201c;Contingent Fees&#x201d;). For the years ended December 31, 2022, 2021&#160;and 2020, the Company incurred such Contingent Fees in the amounts of $&#160;750, $&#160;500 and $&#160;500.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt"&gt;d.&lt;span style="padding-left:21.5pt"&gt;On &lt;/span&gt;May 9, 2012, the Company entered into agreement (the &#x201c;May 2012 Agreement&#x201d;) with a U.S. Business Development Strategic Advisor (&#x201c;Advisor&#x201d;) for the purpose of entering into transactions with Pharma companies related to selected Pipeline Program Candidates.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;Under the agreement the Advisor was entitled to 4% of the cash considerations that may be received under such transactions. In 2014, the May 2012 Agreement was terminated except for certain payments arising from the Bayer Agreement which survive termination until August 5, 2025.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;The Bayer Agreement was terminated effective February 27, 2023 and no further payments are expected under the May 2012 Agreement&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;For the years ended December 31, 2022, 2021 and 2020, the Company has not paid and did not accrue payments under this agreement.&#160;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
    &lt;div/&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt"&gt;e.&lt;span style="padding-left:21.06pt"&gt;Effective as of January 5, 2018, the Company entered into a Commercial License Agreement (CLA) with a European &lt;/span&gt;cell line development company. Under the agreement the Company is required to pay an annual maintenance fee, certain amounts upon the occurrence of specified milestones events, and 1% royalties on annual net sales with respect to each commercialized product manufactured using the company&#x2019;s cell line. Royalties due under the CLA are creditable against the annual maintenance fee. In addition, the Company may at any time prior to the occurrence of a specific milestone event buy-out the royalty payment obligations in a single fixed amount. For the years ended December 31, 2022, 2021&#160;and 2020, the Company incurred in the research and development expenses in connection with such milestone payment in the amounts of $&#160;0, $&#160;0 and $&#160;52.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;text-indent:-27pt;margin-left:85pt;margin-bottom:0pt"&gt;f.&lt;span style="padding-left:21.17pt"&gt;Effective as of October 28, 2020, the Company entered into a collaboration agreement with a U.S. antibody &lt;/span&gt;discovery and optimization company for generation and optimization of therapeutic antibodies for the Company. Under the agreement the Company is required to pay service fees per services performed and certain amounts upon the occurrence of specified milestones events, and single-digit percent royalties on annual net sales with respect to each product sold that comprises or contains one or more antibodies so generated or optimized. The royalty rate is dependent upon the product type and any third-party contribution. For the years ended December 31, 2022, 2021&#160;and 2020, the Company incurred in the research and development expenses such milestone payment in the amounts of $&#160;0, $&#160;250 and $&#160;0.&lt;/p&gt;
  </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:GuaranteeObligationsMaximumExposure
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000477"
      unitRef="usd">318000</us-gaap:GuaranteeObligationsMaximumExposure>
    <cgen:RoyaltyPercentageBasedOnFutureRevenues
      contextRef="C_20220101to20221231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember_srtRangeAxis_srtMinimumMember"
      decimals="2"
      id="FFact_0000000000478"
      unitRef="Pure">0.03</cgen:RoyaltyPercentageBasedOnFutureRevenues>
    <cgen:RoyaltyPercentageBasedOnFutureRevenues
      contextRef="C_20220101to20221231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember_srtRangeAxis_srtMaximumMember"
      decimals="2"
      id="FFact_0000000000479"
      unitRef="Pure">0.05</cgen:RoyaltyPercentageBasedOnFutureRevenues>
    <cgen:MaximumRoyaltyRepaidAsPercentageOfGrantReceived
      contextRef="C_20220101to20221231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember"
      decimals="2"
      id="FFact_0000000000480"
      unitRef="Pure">1</cgen:MaximumRoyaltyRepaidAsPercentageOfGrantReceived>
    <us-gaap:RoyaltyExpense
      contextRef="C_20220101to20221231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember"
      decimals="-3"
      id="FFact_0000000000481"
      unitRef="usd">225000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="C_20210101to20211231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember"
      decimals="-3"
      id="FFact_0000000000482"
      unitRef="usd">180000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="C_20200101to20201231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember"
      decimals="0"
      id="FFact_0000000000483"
      unitRef="usd">60</us-gaap:RoyaltyExpense>
    <cgen:RoyaltyContingentObligations
      contextRef="C_20211231_cgenGovernmentAndOtherGrantsAxis_cgenResearchAndDevelopmentGrantOneMember"
      decimals="-3"
      id="FFact_0000000000484"
      unitRef="usd">9631000</cgen:RoyaltyContingentObligations>
    <cgen:ContingentFees
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000485"
      unitRef="usd">750000</cgen:ContingentFees>
    <cgen:ContingentFees
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000486"
      unitRef="usd">500000</cgen:ContingentFees>
    <cgen:ContingentFees
      contextRef="C_20201231"
      decimals="0"
      id="FFact_0000000000487"
      unitRef="usd">500</cgen:ContingentFees>
    <cgen:AgreementStartDate
      contextRef="C_20220101to20221231_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember"
      id="FFact_0000000000488">2012-05-09</cgen:AgreementStartDate>
    <cgen:ParticipationRights
      contextRef="C_20220101to20221231_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember_srtRangeAxis_srtMinimumMember"
      decimals="2"
      id="FFact_0000000000489"
      unitRef="Pure">0.04</cgen:ParticipationRights>
    <cgen:AgreementTerminationDescription
      contextRef="C_20220101to20221231_cgenGovernmentAndOtherGrantsAxis_cgenMay2012AgreementMember"
      id="FFact_0000000000490">In 2014, the May 2012 Agreement was terminated except for certain payments arising from the Bayer Agreement which survive termination until August 5, 2025.</cgen:AgreementTerminationDescription>
    <cgen:RoyaltyPercentage
      contextRef="C_20220101to20221231"
      decimals="2"
      id="FFact_0000000000491"
      unitRef="Pure">0.01</cgen:RoyaltyPercentage>
    <cgen:ResearchAndDevelopmentExpensesMilestonePaymentWithConnection
      contextRef="C_20220101to20221231"
      decimals="0"
      id="FFact_0000000000492"
      unitRef="usd">0</cgen:ResearchAndDevelopmentExpensesMilestonePaymentWithConnection>
    <cgen:ResearchAndDevelopmentExpensesMilestonePaymentWithConnection
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000493"
      unitRef="usd">0</cgen:ResearchAndDevelopmentExpensesMilestonePaymentWithConnection>
    <cgen:ResearchAndDevelopmentExpensesMilestonePaymentWithConnection
      contextRef="C_20200101to20201231"
      decimals="0"
      id="FFact_0000000000494"
      unitRef="usd">52</cgen:ResearchAndDevelopmentExpensesMilestonePaymentWithConnection>
    <cgen:ResearchAndDevelopmentExpensesMilestonePayment
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000495"
      unitRef="usd">0</cgen:ResearchAndDevelopmentExpensesMilestonePayment>
    <cgen:ResearchAndDevelopmentExpensesMilestonePayment
      contextRef="C_20210101to20211231"
      decimals="0"
      id="FFact_0000000000496"
      unitRef="usd">250</cgen:ResearchAndDevelopmentExpensesMilestonePayment>
    <cgen:ResearchAndDevelopmentExpensesMilestonePayment
      contextRef="C_20200101to20201231"
      decimals="0"
      id="FFact_0000000000497"
      unitRef="usd">0</cgen:ResearchAndDevelopmentExpensesMilestonePayment>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000590">
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;NOTE 8: -&#160;&lt;/span&gt;&lt;span style="font-weight:bold"&gt;SHAREHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt"&gt;a.&lt;span style="padding-left:21.06pt"&gt;Ordinary shares:&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;The ordinary shares confer upon their holders the right to attend and vote at general meetings of the shareholders. Subject to the rights of holders of shares with limited or preferred rights which may be issued in the future, the ordinary shares of the Company confer upon the holders thereof equal rights to receive dividends, and to participate in the distribution of the assets of the Company upon its winding-up, in proportion to the amount paid up or credited as paid up on account of the nominal value of the shares held by them respectively and in respect of which such dividends are being paid or such distribution is being made, without regard to any premium paid in excess of the nominal value, if any.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt"&gt;b.&lt;span style="padding-left:21.5pt"&gt;Issuance of shares:&lt;/span&gt;&lt;/p&gt;
    &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:85.05pt"&gt;On June 14, 2018, the Company entered into securities purchase agreement with certain institutional investors and a placement agency agreement with JMP Securities LLC in connection with a registered direct offering (the &#x201c;Offering&#x201d;) of an aggregate of 5,316,457 ordinary shares (the &#x201c;RD Shares&#x201d;) of the Company at a purchase price of $ 3.95 per RD Share. In connection with the issuance of the RD Shares, the Company also issued warrants to purchase an aggregate of up to 4,253,165 additional ordinary shares. The Warrants are exercisable at a price of $ 4.74 per ordinary share and have a term of five years from the date of issuance. The Offering was made pursuant to the Company&#x2019;s Registration Statement. Proceeds from the Offering were $ 19,767 (net of $ 1,233 issuance expenses).&lt;/p&gt;
    &lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;margin-left:80pt"&gt;&#160;&lt;/p&gt;
    &lt;div/&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;During the years ended December 31, 2021 and 2020, warrants to purchase an aggregate of 3,955,696 ordinary shares were exercised with proceeds of approximately $ 18,750 and as of December 31, 2022 and 2021, warrants to purchase up to 297,469 ordinary shares remain outstanding.&#160;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;On October 10, 2018, the Company entered into a Master Clinical Trial Collaboration Agreement (the &#x201c;Master Clinical Agreement&#x201d;) with Bristol-Myers Squibb to evaluate the safety and tolerability of the Company&#x2019;s COM701 in combination with Bristol-Myers Squibb&#x2019;s PD-1 immune checkpoint inhibitor Opdivo&#xae; (nivolumab), in patients with advanced solid tumors. In conjunction with the Master Clinical Agreement, Bristol-Myers Squibb made a $&#160;12,000 equity investment in the Company.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;Under the terms of the securities purchase agreement, Bristol-Myers Squibb purchased 2,424,243 ordinary shares of the Company at a purchase price of $&#160;4.95 per share. The share price represented a 33% premium over the average closing price of Compugen&#x2019;s ordinary shares for twenty (20) Nasdaq trading days prior to the execution of the securities purchase agreement. The investment closed on October 12, 2018.&lt;/p&gt;
    &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
    &lt;div&gt;
      &lt;div style="margin-left:85.05pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The premium over the fair market value in the amount of $4,121 represents the relative fair value of deferred participation of Bristol-Myers Squibb in R&amp;amp;D expenses (which are amortized over the period of the clinical trial, based on the progress in the R&amp;amp;D) and $7,788 (net of $91 issuance expenses) were considered equity investment.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
    &lt;/div&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;In conjunction with the signing of the amendment to the Master Clinical Agreement in November 2021, Bristol Myers Squibb made a $&#160;20,000 investment in the Company, purchasing 2,332,815 ordinary shares of the Company at a purchase price of $&#160;8.57333 per share. The share price represented a 33% premium over the closing price of Company&#x2019;s ordinary shares on the last Nasdaq trading day immediately prior to the execution of the securities purchase agreement.&lt;/p&gt;
    &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
    &lt;div&gt;
      &lt;div style="margin-left:85.05pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The premium over the fair market value in the amount of $5,000 represents the relative fair value of deferred participation of Bristol-Myers Squibb in R&amp;amp;D expenses (which are amortized over the period of the clinical trial, based on the progress in the R&amp;amp;D) and $14,958 (net of $42 issuance expenses) were considered equity investment.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;div style="margin-left:85.05pt"&gt;&#160;&lt;/div&gt;
    &lt;/div&gt;
    &lt;div/&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;In March 2020, the Company entered into an underwriting agreement with SVB Leerink LLC and Stifel, Nicolaus &amp;amp; Company, Incorporated, as representatives of several underwriters relating to the issuance and sale in a public offering of 8,333,334 of the Company&#x2019;s ordinary shares at a price to the public of $&#160;9.00 per share (and a price of $&#160;8.46 per share to the underwriters). Such shares were issued on March 16, 2020. In addition, the Company granted the underwriters a 30-day option to purchase additional ordinary shares at the price set forth above. On April 14, 2020, the Company issued and sold, pursuant to that underwriting agreement additional 483,005 ordinary shares pursuant to the underwriters&#x2019; option specified above. The Company sold a total of 8,816,339 ordinary shares in the offering with proceeds of $74,147 (net of $&#160;5,200 issuance expenses).&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt"&gt;c.&lt;span style="padding-left:21.06pt"&gt;Share option plan:&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;Under the Company&#x2019;s 2010 Share Option Plan as amended (the &#x201c;Plan&#x201c;), options may be granted to employees, directors and non-employees of the Company and Compugen USA, Inc.&lt;/p&gt;
    &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
    &lt;p style="margin:0pt 0pt 0pt 85.05pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Under the 2010 Share Option Plan the Company reserved for issuance up to an aggregate of 14,395,152 ordinary shares. &lt;span style="color:rgb(0, 0, 0)"&gt;The Company&lt;/span&gt;&#x2019;&lt;span style="color:rgb(0, 0, 0)"&gt;s Board of Directors last amended the Plan in March 2022, to increase the number of shares available under the 2010 Plan.&lt;/span&gt; As of December 31, 2022, an aggregate of 1,918,297 options under the 2010 Share Option Plan of the Company were still available for future grants.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;In general, options granted under the Plan vest over a four-year period and expire 10 years from the date of grant and are granted at an exercise price of not less than the fair market value of the Company&#x2019;s ordinary shares on the date of grant, unless otherwise determined by the Company&#x2019;s board of directors. The exercise price of the options granted under the Plan may not be less than the nominal value of the shares into which such options are exercised and the expiration date may not be later than 10 years from the date of grant. If a grantee leaves his or her employment or other relationship with the Company, or if his or her relationship with the Company is terminated without cause (and other than by reason of death or disability, as defined in the Plan), the term of his or her unexercised options will generally expire in 90 days, unless determined otherwise by the Company.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:85.05pt;margin-bottom:0pt"&gt;Any options that are cancelled, forfeited or expired become available for future grants.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:80pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
    &lt;div/&gt;

      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:10pt"&gt;Transactions related to the grant of options to employees, directors and non-employees under the above Plan during the year ended December 31, 2022, were as follows:&lt;/p&gt;
      &lt;div style="margin-left:85.04pt"&gt;
        &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Number of&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;options&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Weighted&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;average&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;exercise &lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;price&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Weighted&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;average&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;remaining&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;contractual &lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;life&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Aggregate&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;intrinsic&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;value&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;$&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Years&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;$&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;


            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td style="vertical-align:bottom;width:52%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Options outstanding at beginning of year&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;6,976,104&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;6.39&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;6.69&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;3,323&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:52%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Options granted&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;2,186,400&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;2.58&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td style="vertical-align:bottom;width:52%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Options exercised&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;(33,186&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;)&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;3.14&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:52%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Options forfeited&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;(778,069&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;)&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;6.42&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td style="vertical-align:baseline;width:52%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Options expired&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;(193,500&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:1pt"&gt;)&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;4.21&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:52%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td style="vertical-align:bottom;width:52%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Options outstanding at end of year&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;8,157,749&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;5.43&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;6.32&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;-&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:52%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td style="vertical-align:bottom;width:52%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Exercisable at end of year&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;4,635,040&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;5.68&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;4.52&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;-&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      &lt;/div&gt;

    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;Weighted average fair value of options granted to employees, directors and non-employees during the years 2022, 2021&#160;and 2020&#160;was $&#160;1.51, $&#160;3.81 and $&#160;7.15 per share, respectively.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;Aggregate intrinsic value of exercised options by employees, directors and non-employees during the years 2022, 2021 and 2020&#160;was $&#160;19, $&#160;759&#160;and $&#160;21,610, respectively. The aggregate intrinsic value of the exercised options represents the total intrinsic value (the difference between the sale price of the Company&#x2019;s share at the date of exercise, and the exercise price) multiplied by the number of options exercised.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the Company&#x2019;s closing share price on the last trading day of calendar 2021 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on December 31, 2022. This amount is impacted by the changes in the fair market value of the Company&#x2019;s shares.&#160;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;As of December 31, 2022, the total unrecognized estimated compensation cost related to non-vested share options granted prior to that date was $&#160;8,715 which is expected to be recognized over a weighted average period of approximately 2.47 years.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt"&gt;d.&lt;span style="padding-left:21.5pt"&gt;Employee Stock Purchase Plan:&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;The Company adopted an ESPP in November 2020, with the first offering period starting at January 1, 2021. In connection with its adoption, a total of 600,000 ordinary shares were reserved for issuance under this plan.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
    &lt;div/&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:0pt"&gt;The ESPP is implemented through six-month offering periods (except for the first offering period that was five months). According to the ESPP, eligible employees and non-employees may use up to 15% of their base salaries to purchase ordinary shares up to an aggregate limit of $&#160;40 per participant for every calendar year. The price of an ordinary share purchased under the ESPP is equal to 85% of the lower of the fair market value of the ordinary share on the first day of each offering period or on the last day of such period.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;Since its adoption and through December 31, 2022, 275,854 ordinary shares had been purchased under the ESPP and as of December 31, 2022, 324,146 ordinary shares were available for issuance under the ESPP.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.05pt;margin-bottom:0pt"&gt;In accordance with ASC No. 718, the ESPP is compensatory and, as such, results in recognition of compensation cost.&lt;/p&gt;
    &lt;p style="margin:0pt"&gt;&#160;&lt;/p&gt;
    &lt;div&gt;

        &lt;div&gt;
          &lt;div&gt;
            &lt;p style="text-indent:-28pt;margin-left:85pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;e.&lt;span style="padding-left:21.5pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;The stock-based compensation expenses related to stock options and ESPP are included as follows in the expense categories:&lt;/span&gt;&lt;/p&gt;
            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
            &lt;div style="margin-left:85.05pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;float:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="10" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2020&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;2,158&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;1,971&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;1,123&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Marketing and business development expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;269&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;215&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;172&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;General and administrative expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,901&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,090&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,477&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;4,328&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;4,276&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;2,772&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
              &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both"&gt;&#160;&lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;

    &lt;/div&gt;
  </us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_20201231_usgaapAwardTypeAxis_usgaapWarrantMember"
      decimals="INF"
      id="Fxbrl_20230214033051318"
      unitRef="Shares">3955696</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_20211231_usgaapAwardTypeAxis_usgaapWarrantMember"
      decimals="INF"
      id="Fxbrl_20230214032847386"
      unitRef="Shares">3955696</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_20220101to20221231_usgaapAwardTypeAxis_usgaapWarrantMember"
      decimals="-3"
      id="Fxbrl_20230214033059280"
      unitRef="usd">18750000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_20210101to20211231_usgaapAwardTypeAxis_usgaapWarrantMember"
      decimals="-3"
      id="Fxbrl_20230214032855904"
      unitRef="usd">18750000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_20221231_usgaapAwardTypeAxis_usgaapWarrantMember"
      decimals="INF"
      id="Fxbrl_20230214032904124"
      unitRef="Shares">297469</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="C_20181010_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember"
      decimals="-3"
      id="FFact_0000000000516"
      unitRef="usd">12000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock
      contextRef="C_20181001to20181010_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember"
      decimals="-3"
      id="FFact_0000000000517"
      unitRef="usd">2424243000</cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_20181010_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember"
      decimals="INF"
      id="FFact_0000000000518"
      unitRef="USD_per_share">4.95</us-gaap:SharesIssuedPricePerShare>
    <cgen:PercentageOfClosingPrice
      contextRef="C_20181001to20181010_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember"
      decimals="2"
      id="FFact_0000000000519"
      unitRef="Pure">0.33</cgen:PercentageOfClosingPrice>
    <cgen:DeferredParticipationOfBMSInRAndDExpenses
      contextRef="C_20220101to20221231_srtStatementScenarioAxis_cgenCollaborativeArrangementsMember"
      decimals="-3"
      id="Fxbrl_20230221120705140"
      unitRef="usd">4121000</cgen:DeferredParticipationOfBMSInRAndDExpenses>
    <cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock
      contextRef="C_20220101to20221231_srtStatementScenarioAxis_cgenCollaborativeArrangementsMember"
      decimals="-3"
      id="Fxbrl_20230221120728895"
      unitRef="usd">7788000</cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20220101to20221231_srtStatementScenarioAxis_cgenCollaborativeArrangementsMember"
      decimals="-3"
      id="Fxbrl_20230221120826639"
      unitRef="usd">91000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="C_20211130_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember"
      decimals="-3"
      id="FFact_0000000000523"
      unitRef="usd">20000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock
      contextRef="C_20211102to20211130_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember"
      decimals="-3"
      id="FFact_0000000000524"
      unitRef="usd">2332815000</cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_20211130_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember"
      decimals="INF"
      id="FFact_0000000000525"
      unitRef="USD_per_share">8.57333</us-gaap:SharesIssuedPricePerShare>
    <cgen:PercentageOfClosingPrice
      contextRef="C_20211102to20211130_srtStatementScenarioAxis_cgenMasterClinicalAgreementMember"
      decimals="2"
      id="FFact_0000000000526"
      unitRef="Pure">0.33</cgen:PercentageOfClosingPrice>
    <cgen:DeferredParticipationOfBMSInRAndDExpenses
      contextRef="C_20220101to20221231_srtStatementScenarioAxis_cgenCollaborativeArrangementsTwoMember"
      decimals="-3"
      id="Fxbrl_20230221122449076"
      unitRef="usd">5000000</cgen:DeferredParticipationOfBMSInRAndDExpenses>
    <cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock
      contextRef="C_20220101to20221231_srtStatementScenarioAxis_cgenCollaborativeArrangementsTwoMember"
      decimals="-3"
      id="Fxbrl_20230221122456788"
      unitRef="usd">14958000</cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20220101to20221231_srtStatementScenarioAxis_cgenCollaborativeArrangementsTwoMember"
      decimals="-3"
      id="Fxbrl_20230221122504540"
      unitRef="usd">42000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20200301to20200316_srtStatementScenarioAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"
      decimals="INF"
      id="FFact_0000000000530"
      unitRef="Shares">8333334</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_20200316_srtStatementScenarioAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"
      decimals="INF"
      id="FFact_0000000000531"
      unitRef="USD_per_share">9</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_20200316_srtStatementScenarioAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember_usgaapAwardTypeAxis_cgenUnderwritersMember"
      decimals="INF"
      id="FFact_0000000000532"
      unitRef="USD_per_share">8.46</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20200401to20200414_srtStatementScenarioAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember_usgaapAwardTypeAxis_cgenUnderwritersMember"
      decimals="INF"
      id="FFact_0000000000533"
      unitRef="Shares">483005</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_20220101to20221231_srtStatementScenarioAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"
      decimals="INF"
      id="FFact_0000000000534"
      unitRef="Shares">8816339</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_20220101to20221231_srtStatementScenarioAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"
      decimals="-3"
      id="FFact_0000000000535"
      unitRef="usd">74147000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_20220101to20221231_srtStatementScenarioAxis_cgenSvbLeerinkLlcAndStifelNicolausAndCompanyMember"
      decimals="-3"
      id="FFact_0000000000536"
      unitRef="usd">5200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_20221231_usgaapPlanNameAxis_cgenTwoThousandAndTwoThousandTenOptionsPlanMember"
      decimals="INF"
      id="FFact_0000000000537"
      unitRef="Shares">14395152</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_20221231_usgaapPlanNameAxis_cgenTwoThousandAndTwoThousandTenOptionsPlanMember"
      decimals="INF"
      id="FFact_0000000000538"
      unitRef="Shares">1918297</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cgenTwoThousandAndTwoThousandTenOptionsPlanMember"
      id="FFact_0000000000539">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <cgen:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod
      contextRef="C_20220101to20221231_usgaapPlanNameAxis_cgenTwoThousandAndTwoThousandTenOptionsPlanMember"
      id="FFact_0000000000540">P10Y</cgen:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000561">
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:85.05pt;margin-bottom:10pt"&gt;Transactions related to the grant of options to employees, directors and non-employees under the above Plan during the year ended December 31, 2022, were as follows:&lt;/p&gt;
      &lt;div style="margin-left:85.04pt"&gt;
        &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Number of&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;options&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Weighted&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;average&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;exercise &lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;price&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Weighted&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;average&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;remaining&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;contractual &lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;life&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Aggregate&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;intrinsic&lt;/span&gt;&lt;/p&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;value&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;$&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Years&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;$&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;


            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td style="vertical-align:bottom;width:52%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Options outstanding at beginning of year&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;6,976,104&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;6.39&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;6.69&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;3,323&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:52%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Options granted&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;2,186,400&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;2.58&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td style="vertical-align:bottom;width:52%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Options exercised&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;(33,186&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;)&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;3.14&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:52%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Options forfeited&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;(778,069&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;)&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;6.42&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td style="vertical-align:baseline;width:52%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Options expired&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;(193,500&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:1pt"&gt;)&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;4.21&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:52%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td style="vertical-align:bottom;width:52%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Options outstanding at end of year&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;8,157,749&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;5.43&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;6.32&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;-&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:52%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td style="vertical-align:bottom;width:52%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Exercisable at end of year&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;4,635,040&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;5.68&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;4.52&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%;border-bottom:4px double black"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%;border-bottom:4px double black"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;-&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      &lt;/div&gt;
    </us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20211231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember"
      decimals="INF"
      id="FFact_0000000000541"
      unitRef="Shares">6976104</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20211231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember"
      decimals="INF"
      id="FFact_0000000000542"
      unitRef="USD_per_share">6.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_20210101to20211231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember"
      id="FFact_0000000000543">P6Y8M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_20211231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember"
      decimals="-3"
      id="FFact_0000000000544"
      unitRef="usd">3323000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember"
      decimals="INF"
      id="FFact_0000000000545"
      unitRef="Shares">2186400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember"
      decimals="INF"
      id="FFact_0000000000546"
      unitRef="USD_per_share">2.58</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember"
      decimals="INF"
      id="FFact_0000000000547"
      unitRef="Shares">33186</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember"
      decimals="INF"
      id="FFact_0000000000548"
      unitRef="USD_per_share">3.14</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember"
      decimals="INF"
      id="FFact_0000000000549"
      unitRef="Shares">778069</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember"
      decimals="INF"
      id="FFact_0000000000550"
      unitRef="USD_per_share">6.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember"
      decimals="INF"
      id="FFact_0000000000551"
      unitRef="Shares">193500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember"
      decimals="INF"
      id="FFact_0000000000552"
      unitRef="USD_per_share">4.21</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_20221231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember"
      decimals="INF"
      id="FFact_0000000000553"
      unitRef="Shares">8157749</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_20221231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember"
      decimals="INF"
      id="FFact_0000000000554"
      unitRef="USD_per_share">5.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember"
      id="FFact_0000000000555">P6Y3M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_20221231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember"
      decimals="-3"
      id="FFact_0000000000556"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_20221231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember"
      decimals="INF"
      id="FFact_0000000000557"
      unitRef="Shares">4635040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="C_20221231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember"
      decimals="INF"
      id="FFact_0000000000558"
      unitRef="USD_per_share">5.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember"
      id="FFact_0000000000559">P4Y6M7D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_20221231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember"
      decimals="-3"
      id="FFact_0000000000560"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000562"
      unitRef="USD_per_share">1.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="FFact_0000000000563"
      unitRef="USD_per_share">3.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_20200101to20201231"
      decimals="INF"
      id="FFact_0000000000564"
      unitRef="USD_per_share">7.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="C_20221231_srtTitleOfIndividualAxis_srtDirectorMember"
      decimals="-3"
      id="FFact_0000000000565"
      unitRef="usd">19000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="C_20211231_srtTitleOfIndividualAxis_srtDirectorMember"
      decimals="-3"
      id="FFact_0000000000566"
      unitRef="usd">759000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="C_20201231_srtTitleOfIndividualAxis_srtDirectorMember"
      decimals="-3"
      id="FFact_0000000000567"
      unitRef="usd">21610000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000568"
      unitRef="usd">8715000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="C_20220101to20221231" id="FFact_0000000000569">P2Y5M19D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_20221231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="INF"
      id="FFact_0000000000570"
      unitRef="Shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:InitialOfferingPeriod
      contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      id="FFact_0000000000571">five months</us-gaap:InitialOfferingPeriod>
    <cgen:PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares
      contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="2"
      id="FFact_0000000000572"
      unitRef="Pure">0.15</cgen:PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares>
    <cgen:AggregateLimitOfOrdinarySharesPerCalendarYear
      contextRef="C_20221231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="INF"
      id="FFact_0000000000573"
      unitRef="USD_per_share">40</cgen:AggregateLimitOfOrdinarySharesPerCalendarYear>
    <cgen:PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering
      contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="2"
      id="FFact_0000000000574"
      unitRef="Pure">0.85</cgen:PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="C_20220101to20221231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="INF"
      id="FFact_0000000000575"
      unitRef="Shares">275854</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_20221231_usgaapSubsidiarySaleOfStockAxis_usgaapEmployeeStockMember"
      decimals="INF"
      id="FFact_0000000000576"
      unitRef="Shares">324146</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000589">
        &lt;div&gt;
          &lt;div&gt;
            &lt;p style="text-indent:-28pt;margin-left:85pt;font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;e.&lt;span style="padding-left:21.5pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;The stock-based compensation expenses related to stock options and ESPP are included as follows in the expense categories:&lt;/span&gt;&lt;/p&gt;
            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
            &lt;div style="margin-left:85.05pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt;text-align:left;float:left"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="10" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2020&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;2,158&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;1,971&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;1,123&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Marketing and business development expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;269&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;215&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;172&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;General and administrative expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,901&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,090&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255);border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1,477&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;4,328&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;4,276&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;2,772&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
              &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both"&gt;&#160;&lt;/div&gt;
            &lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="FFact_0000000000577"
      unitRef="usd">2158000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="FFact_0000000000578"
      unitRef="usd">1971000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20200101to20201231_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="FFact_0000000000579"
      unitRef="usd">1123000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember"
      decimals="-3"
      id="FFact_0000000000580"
      unitRef="usd">269000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember"
      decimals="-3"
      id="FFact_0000000000581"
      unitRef="usd">215000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20200101to20201231_usgaapIncomeStatementLocationAxis_usgaapSellingAndMarketingExpenseMember"
      decimals="-3"
      id="FFact_0000000000582"
      unitRef="usd">172000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20220101to20221231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="FFact_0000000000583"
      unitRef="usd">1901000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20210101to20211231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="FFact_0000000000584"
      unitRef="usd">2090000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20200101to20201231_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="FFact_0000000000585"
      unitRef="usd">1477000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000586"
      unitRef="usd">4328000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000587"
      unitRef="usd">4276000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000588"
      unitRef="usd">2772000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000629">
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;NOTE 9: - &lt;/span&gt;&lt;span style="font-weight:bold"&gt;INCOME TAXES&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt"&gt;a. &lt;span style="padding-left:18.73pt"&gt;Israeli taxation:&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-28pt;margin-left:113pt;margin-bottom:0pt"&gt;1.&lt;span style="padding-left:20.5pt"&gt;Tax rates applicable to the income of the Company.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt"&gt;Taxable income of the Company is subject to a corporate tax rate of 23% in 2020, 2021&#160;and 2022.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-28pt;margin-left:113pt;margin-bottom:0pt"&gt;2.&lt;span style="padding-left:20.5pt"&gt;Measurement of taxable income in US dollars:&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt"&gt;The Company has elected to measure its taxable income and file its tax return under the Israeli Income Tax Regulations (Principles Regarding the Management of Books of Account of Foreign Invested Companies and Certain Partnerships and the Determination of Their Taxable Income), 1986. Accordingly, results for tax purposes are measured in terms of earnings in dollars.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:100pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
    &lt;div/&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;margin-top:0pt;text-indent:-28pt;margin-left:113pt;margin-bottom:0pt;text-align:justify"&gt;3.&lt;span style="padding-left:20.5pt"&gt;Tax benefits under the Israeli Law for the Encouragement of Capital Investments, 1959 (the &#x201c;Investment Law&#x201d;):&lt;/span&gt;&#x2009;&#x2009;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt"&gt;On April 1, 2005, an amendment to the Investment Law came into effect (the &#x201c;Amendment 60&#x201d;) that significantly changed the provisions of the Investment Law. The Amendment 60 limits the scope of enterprises that may be approved by the Investment Center by setting criteria for the approval of a facility as a &#x201c;Beneficiary Enterprise&#x201d; including a provision generally requiring that at least 25% of the Beneficiary Enterprise&#x2019;s income will be derived from export.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt"&gt;Another condition for receiving the benefits under the alternative track in respect of expansion programs pursuant to Amendment 60 is a minimum qualifying investment. The Company was eligible under the terms of minimum qualifying investment and elected 2012 as its &#x201c;year of election&#x201d;.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt"&gt;Additionally, the Amendment 60 enacted major changes in the manner in which tax benefits are awarded under the Investment Law so that companies no longer require Investment Center approval in order to qualify for tax benefits. However, the Investment Law provides that terms and benefits included in any certificate of approval already granted will remain subject to the provisions of the Investment Law as they were on the date of such approval.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt"&gt;As of December 31, 2022, there was no taxable income attributable to the Beneficiary Enterprise.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt"&gt;In January 2011, another amendment to the Investment Law came into effect (&#x201c;the 2011 Amendment&#x201d;). According to the 2011 Amendment, the benefit tracks in the Investment Law were modified and a flat tax rate applies to the Company&#x2019;s entire income subject to this amendment (the &#x201c;Preferred Income&#x201d;).&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt"&gt;Once an election is made, the Company&#x2019;s income will be subject to the amended tax rate of 16% from 2015 and thereafter (or 9% for a preferred enterprise located in development area A).&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt"&gt;Commencing 2011 tax year, the Company can elect (without possibility of reversal) to apply the Amendment in a certain tax year and from that year and thereafter, it will be subject to the amended tax rates.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt"&gt;The Company does not currently intend to adopt the 2011 Amendment and intends to continue to comply with the Investment Law as in effect prior to enactment of the 2011 Amendment. Accordingly, the Company did not adjust its deferred tax balances as of December 31, 2022. The Company&#x2019;s position may change in the future.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:113.4pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
    &lt;div/&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:113.4pt;margin-bottom:0pt"&gt;In December 2016, the Economic Efficiency Law (Legislative Amendments for Applying the Economic Policy for the 2016 and 2017 Budget Years), 2016, which includes Amendment 73 to the Law (the &#x201c;Amendment 73&#x201d;) was published. According to Amendment 73, a preferred enterprise located in development area A will be subject to a tax rate of 7.5% instead of 9% effective from January 1, 2016 and thereafter (the tax rate applicable to preferred enterprises located in other areas remains at 16%).&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt"&gt;Amendment 73 also prescribes special tax tracks for technological enterprises, which are subject to rules that were issued by the Minister of Finance in May 2017. The new tax tracks under the Amendment are as follows:&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt"&gt;Preferred Technological Enterprise (&#x201c;PTE&#x201d;) - an enterprise for which total consolidated revenues of its parent company and all subsidiaries are less than NIS 10 billion in a tax year. A PTE, as defined in the Law, which is located in the center of Israel will be subject to tax at a rate of 12% on profits deriving from intellectual property (in development area A - a tax rate of 7.5%).&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt"&gt;The above changes in the tax rates relating to PTE tax track were not taken into account in the computation of deferred taxes as of December 31, 2022 and 2021, since the Company estimates that it will not implement the PTE tax track.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-28pt;margin-left:113pt;margin-bottom:0pt"&gt;4.&lt;span style="padding-left:20.5pt"&gt;Tax benefits under the law for the Encouragement of Industry (Taxes), 1969 (the &#x201c;Encouragement Law&#x201d;):&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt"&gt;The Encouragement Law provides several tax benefits for industrial companies. An industrial company is defined as a company resident in Israel, at least 90% of the income of which in a given tax year exclusive of income from specified Government loans, capital gains, interest and dividends, is derived from an industrial enterprise owned by it. An industrial enterprise is defined as an enterprise whose major activity in a given tax year is industrial production activity.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt"&gt;Management believes that the Company is currently qualified as an &#x201c;industrial company&#x201d; under the Encouragement Law and, as such, is entitled to tax benefits, including: (1) deduction of purchase of know-how and patents and/or right to use a patent over an eight-year period; (2) the right to elect, under specified conditions, to file a consolidated tax return with additional related Israeli industrial companies and an industrial holding company; (3) accelerated depreciation rates on equipment and buildings; and (4) expenses related to a public offering on the Tel-Aviv Stock exchange and on recognized stock markets outside of Israel, are deductible in equal amounts over three years.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;padding-left:100pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
    &lt;div/&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;margin-left:113.4pt;margin-bottom:0pt"&gt;Eligibility for benefits under the Encouragement Law is not subject to receipt of prior approval from any Governmental authority. No assurance can be given that the Israeli tax authorities will agree that the Company qualifies, or, that the Company will continue to qualify as an industrial company or that the benefits described above will be available to the Company in the future.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-28pt;margin-left:113pt;margin-bottom:0pt"&gt;5.&lt;span style="padding-left:20.5pt"&gt;Net operating losses carryforward and capital loss:&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:113.4pt;margin-bottom:0pt"&gt;As of December 31, 2022, Compugen Ltd. &#x2019;s net operating losses carryforward for tax purposes in Israel amounted to approximately $&#160;398,100. These net operating losses may be carried forward indefinitely and may be offset against future taxable income.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt"&gt;b.&lt;span style="padding-left:20.73pt"&gt;Non-Israeli subsidiary, Compugen USA, Inc.:&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:85.5pt;margin-bottom:0pt"&gt;On December 22, 2017, the United States enacted the Tax Cuts and Jobs Act (the &#x201c;U.S. Tax Reform&#x201d; or &#x201c;TCJA&#x201d;); a comprehensive tax legislation that includes significant changes to the taxation of business entities. These changes include several key tax provisions that might impact the Company, among others: (i) a permanent reduction to the statutory federal corporate income tax rate from 35% to 21% effective for tax years beginning after December 31, 2017; (ii) a shift of the U.S. taxation of multinational corporations from a tax on worldwide income to a territorial system (along with certain new rules designed to prevent erosion of the U.S. income tax base - &#x201c;BEAT&#x201d;); (iii) establishing immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits; and (iv) providing a permanent deduction to corporations generating revenues from non-US markets (known as a deduction for foreign derived intangible income - &#x201c;FDII&#x201d;).&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:85.5pt;margin-bottom:0pt"&gt;As of December 31, 2022, Compugen USA, Inc. has net operating loss carryforwards for federal income tax purposes of approximately $ 700. These losses may be carried forward indefinitely, but the deductibility of such federal NOLs may be limited. Utilization of the U.S. net operating losses may be subject to substantial annual limitation due to the &#x201c;change in ownership&#x201c; provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitation may result in the expiration of net operating losses before utilization.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:85.5pt;margin-bottom:0pt"&gt;Neither Israeli income taxes, foreign withholding taxes nor deferred income taxes were provided in relation to undistributed earnings of the Company&#x2019;s foreign subsidiary. This is because the Company has the intent and ability to reinvest these earnings indefinitely in the foreign subsidiary and therefore those earnings are continually redeployed in those jurisdictions.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:0pt;padding-left:80pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
    &lt;div/&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:-28pt;margin-left:85pt;margin-bottom:11pt"&gt;c.&lt;span style="padding-left:20.73pt"&gt;Loss (income) before taxes is comprised as follows:&lt;/span&gt;&lt;/p&gt;
    &lt;div style="margin-left:85.5pt"&gt;

        &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="10" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2020&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;


            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td style="vertical-align:bottom;width:64%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Domestic (Israel)&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;34,096&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;34,619&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;30,010&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:baseline;width:64%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Foreign&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;(460&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:1.5pt"&gt;)&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;(416&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:1.5pt"&gt;)&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;(312&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:1.5pt"&gt;)&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td style="vertical-align:bottom;width:64%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:64%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;33,636&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;34,203&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;29,698&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;

    &lt;/div&gt;
    &lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif"&gt;&#160;&lt;/p&gt;
    &lt;div&gt;
      &lt;div&gt;
        &lt;table cellpadding="0" cellspacing="0" style="font-family:'Times New Roman', Times, serif;font-size:10pt;width:100%;text-align:left;color:#000000"&gt;

            &lt;tr&gt;
              &lt;td style="width:56.7pt;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/td&gt;
              &lt;td style="width:28.35pt;vertical-align:top;font-family:'Times New Roman',Times,serif"&gt;d.&lt;/td&gt;
              &lt;td style="width:auto;vertical-align:top;text-align:justify;font-family:'Times New Roman',Times,serif"&gt;
                &lt;div&gt;Taxes on income for the year ended December 31, 2022, represent state income taxes in the United States.&lt;/div&gt;
              &lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      &lt;/div&gt;
    &lt;/div&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt"&gt;e.&lt;span style="padding-left:20.73pt"&gt;Deferred taxes:&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:85.5pt;margin-bottom:11pt"&gt;Deferred taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company and Compugen USA, Inc.&#x2019;s deferred tax assets are comprised of operating loss carryforward and other temporary differences. Significant components of the Company and Compugen USA, Inc. deferred tax assets are as follows:&lt;/p&gt;
    &lt;div&gt;

        &lt;div&gt;
          &lt;div&gt;
            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
            &lt;div style="margin-left:85.5pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;float:left;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Operating loss carryforward&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;91,704&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;86,068&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;12,083&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;9,773&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Accrued social benefits and other&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,123&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,801&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Right of use assets&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(415&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(520&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;444&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;636&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px" valign="bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Property and equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deferred tax asset before valuation allowance&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;106,941&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;98,760&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px" valign="bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Valuation allowance&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(106,941&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(98,760&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px" valign="bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net deferred tax asset&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both"&gt;&#160;&lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;

    &lt;/div&gt;
    &lt;div&gt;
      &lt;div style="margin-left:85.5pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company has provided full valuation allowances in respect of deferred tax assets resulting from operating loss carryforward and other temporary differences. Management currently believes that since the Company has a history of losses, it is more likely than not that the deferred tax regarding the operating loss carryforward and other temporary differences will not be realized in the foreseeable future.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
      &lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif"&gt;&#160;&lt;/p&gt;
    &lt;/div&gt;
    &lt;div/&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt"&gt;f.&lt;span style="padding-left:22.73pt"&gt;Reconciliation of the theoretical tax expense (benefit) to the actual tax expense (benefit):&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;padding-left:85.5pt;margin-bottom:0pt"&gt;The main reconciling items between the statutory tax rate of the Company and the effective tax rate are the non-recognition of tax benefits from accumulated net operating loss carryforward among the Company and Compugen USA, Inc. due to the uncertainty of the realization of such tax benefits.&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11pt;text-indent:-28pt;margin-left:85pt;margin-bottom:0pt"&gt;g.&lt;span style="padding-left:20.73pt"&gt;Tax assessments:&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:11px;margin-left:85.5pt;margin-bottom:0px"&gt;The Company has tax assessments through 2017&#160;that are deemed to be final.&lt;/p&gt;
  </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_20200101to20201231"
      decimals="2"
      id="Fxbrl_20230214114856319"
      unitRef="Pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_20210101to20211231"
      decimals="2"
      id="Fxbrl_20230214114847978"
      unitRef="Pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_20220101to20221231"
      decimals="2"
      id="Fxbrl_20230214114839776"
      unitRef="Pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <cgen:ReducedTaxRate
      contextRef="C_20220101to20221231"
      decimals="2"
      id="FFact_0000000000594"
      unitRef="Pure">0.25</cgen:ReducedTaxRate>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_20221231_usgaapIncomeTaxAuthorityAxis_usgaapDomesticCountryMember"
      decimals="-3"
      id="FFact_0000000000595"
      unitRef="usd">398100000</us-gaap:OperatingLossCarryforwards>
    <cgen:NetOperatingLossCarryforwardExpired
      contextRef="C_20201231_usgaapIncomeTaxAuthorityAxis_usgaapInternalRevenueServiceIRSMember"
      decimals="-3"
      id="FFact_0000000000597"
      unitRef="usd">700000</cgen:NetOperatingLossCarryforwardExpired>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230214044607742">
        &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="10" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2020&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;


            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td style="vertical-align:bottom;width:64%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Domestic (Israel)&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;34,096&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;34,619&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;30,010&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:baseline;width:64%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Foreign&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;(460&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:1.5pt"&gt;)&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;(416&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:1.5pt"&gt;)&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;(312&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-bottom:1.5pt"&gt;)&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td style="vertical-align:bottom;width:64%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:64%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;33,636&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;34,203&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;29,698&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      </us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000600"
      unitRef="usd">-34096000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000601"
      unitRef="usd">-34619000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000602"
      unitRef="usd">-30010000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000603"
      unitRef="usd">460000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000604"
      unitRef="usd">416000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000605"
      unitRef="usd">312000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000606"
      unitRef="usd">-33636000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000607"
      unitRef="usd">-34203000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000608"
      unitRef="usd">-29698000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230214044633836">
        &lt;div&gt;
          &lt;div&gt;
            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
            &lt;div style="margin-left:85.5pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="color:#000000;float:left;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:left;width:90%"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Operating loss carryforward&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;91,704&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;86,068&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;12,083&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;9,773&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Accrued social benefits and other&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3,123&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2,801&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%" valign="bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Right of use assets&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(415&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(520&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;444&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;636&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px" valign="bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Property and equipment&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Deferred tax asset before valuation allowance&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;106,941&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;98,760&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:2px" valign="bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Valuation allowance&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(106,941&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:2px solid rgb(0, 0, 0)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(98,760&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px" valign="bottom"&gt;
                      &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net deferred tax asset&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif;clear:both"&gt;&#160;&lt;/div&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      </us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000610"
      unitRef="usd">91704000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000611"
      unitRef="usd">86068000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000612"
      unitRef="usd">12083000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000613"
      unitRef="usd">9773000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000614"
      unitRef="usd">3123000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000615"
      unitRef="usd">2801000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <cgen:DeferredIncomeTaxRightOfUseAssets
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000616"
      unitRef="usd">-415000</cgen:DeferredIncomeTaxRightOfUseAssets>
    <cgen:DeferredIncomeTaxRightOfUseAssets
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000617"
      unitRef="usd">-520000</cgen:DeferredIncomeTaxRightOfUseAssets>
    <cgen:DeferredIncomeTaxLeaseLiabilities
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000618"
      unitRef="usd">444000</cgen:DeferredIncomeTaxLeaseLiabilities>
    <cgen:DeferredIncomeTaxLeaseLiabilities
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000619"
      unitRef="usd">636000</cgen:DeferredIncomeTaxLeaseLiabilities>
    <cgen:DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000620"
      unitRef="usd">2000</cgen:DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment>
    <cgen:DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000621"
      unitRef="usd">2000</cgen:DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000622"
      unitRef="usd">106941000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000623"
      unitRef="usd">98760000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000624"
      unitRef="usd">106941000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000625"
      unitRef="usd">98760000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_20221231"
      decimals="-3"
      id="Fxbrl_20230214114648154"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_20211231"
      decimals="-3"
      id="Fxbrl_20230214114719209"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230222123726446">
    &lt;div&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;NOTE 10: -&#160;&lt;/span&gt;&lt;span style="font-weight:bold"&gt;GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS&lt;/span&gt;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:56.7pt;margin-bottom:0pt"&gt;The Company&#x2019;s business is currently comprised of one operating segment, the research, development and commercialization of therapeutic and product candidates. The nature of the products and services provided by the Company and the type of customers for these products and services are similar. Operations in Israel and the United States include research and development, clinical operations, marketing and business development. The Company follows ASC 280, &lt;span style="color:black"&gt;&#x201c;&lt;/span&gt;Segment Reporting&lt;span style="color:black"&gt;&#x201c;&lt;/span&gt;. Total revenues are attributed to geographic areas based on the location of the end customer.&lt;/p&gt;

        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:56.7pt;margin-bottom:11pt"&gt;The following represents the total revenue for the years ended December 31, 2022, 2021&#160;and 2020&#160;and long-lived assets as of December 31, 2022&#160;and 2021:&lt;/p&gt;
        &lt;div style="margin-left:56.7pt;margin-bottom:11pt"&gt;
          &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2020&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;


              &lt;tr style="background-color:#cceeff"&gt;
                &lt;td style="vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Revenue from sales to customers:&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="background-color:#cceeff"&gt;
                &lt;td style="vertical-align:bottom;width:64%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Europe&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;7,500&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;6,000&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;2,000&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="background-color:#cceeff"&gt;
                &lt;td style="vertical-align:bottom;width:64%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Total revenue&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;7,500&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;6,000&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;2,000&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
        &lt;div style="margin-left:60pt;margin-bottom:0pt"&gt;
          &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;December 31,&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;


              &lt;tr style="background-color:#cceeff"&gt;
                &lt;td style="vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Long-lived assets:&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="background-color:#cceeff"&gt;
                &lt;td style="vertical-align:bottom;width:76%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Israel&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:9%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;3,239&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:9%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;3,787&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;United States&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;119&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;118&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="background-color:#cceeff"&gt;
                &lt;td style="vertical-align:bottom;width:76%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Total long-lived assets&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;3,358&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;3,905&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;

      &lt;p style="margin:0pt 0pt 0px"&gt;&#160;&lt;/p&gt;
      &lt;div/&gt;

        &lt;div style="margin-left:56.7pt;margin-top:0pt"&gt;
          &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="8" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2020&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;


              &lt;tr style="background-color:#cceeff"&gt;
                &lt;td style="vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Sales to a single customer exceeding 10%:&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="background-color:#cceeff"&gt;
                &lt;td style="vertical-align:bottom;width:62%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Customer A&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:9%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;100&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;%&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:9%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;100&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;%&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:9%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;100&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;

    &lt;/div&gt;
  </us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000630"
      unitRef="Item">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000643">
        &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:justify;margin-top:11pt;margin-left:56.7pt;margin-bottom:11pt"&gt;The following represents the total revenue for the years ended December 31, 2022, 2021&#160;and 2020&#160;and long-lived assets as of December 31, 2022&#160;and 2021:&lt;/p&gt;
        &lt;div style="margin-left:56.7pt;margin-bottom:11pt"&gt;
          &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="10" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2020&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;


              &lt;tr style="background-color:#cceeff"&gt;
                &lt;td style="vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Revenue from sales to customers:&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="background-color:#cceeff"&gt;
                &lt;td style="vertical-align:bottom;width:64%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Europe&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;7,500&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;6,000&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;2,000&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:64%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="background-color:#cceeff"&gt;
                &lt;td style="vertical-align:bottom;width:64%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Total revenue&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;7,500&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;6,000&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;2,000&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
        &lt;div style="margin-left:60pt;margin-bottom:0pt"&gt;
          &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="6" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;December 31,&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;


              &lt;tr style="background-color:#cceeff"&gt;
                &lt;td style="vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Long-lived assets:&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="background-color:#cceeff"&gt;
                &lt;td style="vertical-align:bottom;width:76%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Israel&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:9%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;3,239&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:9%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;3,787&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;United States&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;119&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;118&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="background-color:#cceeff"&gt;
                &lt;td style="vertical-align:bottom;width:76%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom;width:76%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Total long-lived assets&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;3,358&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;3,905&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
      </us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:Revenues
      contextRef="C_20220101to20221231_cgenSegmentReportingGeographicAreaAxis_srtEuropeMember"
      decimals="-3"
      id="FFact_0000000000631"
      unitRef="usd">7500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20210101to20211231_cgenSegmentReportingGeographicAreaAxis_srtEuropeMember"
      decimals="-3"
      id="FFact_0000000000632"
      unitRef="usd">6000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20200101to20201231_cgenSegmentReportingGeographicAreaAxis_srtEuropeMember"
      decimals="-3"
      id="Fxbrl_20230214023238881"
      unitRef="usd">2000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000634"
      unitRef="usd">7500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000635"
      unitRef="usd">6000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="Fxbrl_20230214023305010"
      unitRef="usd">2000000</us-gaap:Revenues>
    <us-gaap:NoncurrentAssets
      contextRef="C_20221231_cgenSegmentReportingGeographicAreaAxis_countryIL"
      decimals="-3"
      id="FFact_0000000000637"
      unitRef="usd">3239000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="C_20211231_cgenSegmentReportingGeographicAreaAxis_countryIL"
      decimals="-3"
      id="FFact_0000000000638"
      unitRef="usd">3787000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="C_20221231_cgenSegmentReportingGeographicAreaAxis_countryUS"
      decimals="-3"
      id="FFact_0000000000639"
      unitRef="usd">119000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="C_20211231_cgenSegmentReportingGeographicAreaAxis_countryUS"
      decimals="-3"
      id="FFact_0000000000640"
      unitRef="usd">118000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000641"
      unitRef="usd">3358000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000642"
      unitRef="usd">3905000</us-gaap:NoncurrentAssets>
    <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000647">
        &lt;div style="margin-left:56.7pt;margin-top:0pt"&gt;
          &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

              &lt;tr&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="8" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2020&lt;/span&gt;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;


              &lt;tr style="background-color:#cceeff"&gt;
                &lt;td style="vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Sales to a single customer exceeding 10%:&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr&gt;
                &lt;td style="vertical-align:bottom"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;/tr&gt;
              &lt;tr style="background-color:#cceeff"&gt;
                &lt;td style="vertical-align:bottom;width:62%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Customer A&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:9%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;100&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;%&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:9%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;100&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:2%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;%&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:9%"&gt;
                  &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;100&lt;/p&gt;
                &lt;/td&gt;
                &lt;td style="vertical-align:bottom;width:1%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;/tr&gt;

          &lt;/table&gt;
        &lt;/div&gt;
      </us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_20220101to20221231_srtMajorCustomersAxis_cgenCustomerOneMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember"
      decimals="2"
      id="FFact_0000000000644"
      unitRef="Pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_20210101to20211231_srtMajorCustomersAxis_cgenCustomerOneMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember"
      decimals="2"
      id="FFact_0000000000645"
      unitRef="Pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_20200101to20201231_srtMajorCustomersAxis_cgenCustomerOneMember_usgaapConcentrationRiskByBenchmarkAxis_usgaapSalesRevenueNetMember_usgaapConcentrationRiskByTypeAxis_usgaapCustomerConcentrationRiskMember"
      decimals="2"
      id="Fxbrl_20230214023433284"
      unitRef="Pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000665">
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"&gt;&lt;span style="font-weight:bold"&gt;NOTE 11: -&#160;&lt;/span&gt;&lt;span style="font-weight:bold"&gt;FINANCIAL AND OTHER INCOME, NET&lt;/span&gt;&lt;/p&gt;

      &lt;div style="margin-left:56.7pt;margin-bottom:0pt"&gt;
        &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="10" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2020&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;


            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td style="vertical-align:bottom;width:64%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Interest income&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,437&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;894&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,765&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:64%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Bank fees and other finance expenses&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;(27&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;)&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;(25&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;)&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;(42&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;)&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td style="vertical-align:bottom;width:64%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Foreign currency transaction adjustments&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;340&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;(1&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;63&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:baseline;width:64%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Gain (loss) from sales and disposals of fixed assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(12&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td style="vertical-align:bottom;width:64%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:64%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Financial and other income, net&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,738&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;871&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,798&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      &lt;/div&gt;

  </us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000664">
      &lt;div style="margin-left:56.7pt;margin-bottom:0pt"&gt;
        &lt;table cellpadding="0" cellspacing="0" style="width:90%" width="100%"&gt;

            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="10" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2022&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2021&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="border-bottom:1.5pt solid rgb(0, 0, 0);vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:center;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-weight:bold"&gt;2020&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td colspan="2" style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;


            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td style="vertical-align:bottom;width:64%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Interest income&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,437&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;894&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,765&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:64%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Bank fees and other finance expenses&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;(27&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;)&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;(25&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;)&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;(42&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;)&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td style="vertical-align:bottom;width:64%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Foreign currency transaction adjustments&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;340&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;(1&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;63&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:baseline;width:64%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Gain (loss) from sales and disposals of fixed assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(12&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:baseline;border-bottom:1.5pt solid rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:baseline;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr style="background-color:#cceeff"&gt;
              &lt;td style="vertical-align:bottom;width:64%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:9%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;
            &lt;tr&gt;
              &lt;td style="vertical-align:bottom;width:64%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:4pt"&gt;Financial and other income, net&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,738&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;871&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:1%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;$&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;border-bottom:4px double rgb(0, 0, 0);width:9%"&gt;
                &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:right;margin-top:0pt;margin-bottom:0pt"&gt;1,798&lt;/p&gt;
              &lt;/td&gt;
              &lt;td style="vertical-align:bottom;width:1%"&gt;&#160;&lt;/td&gt;
            &lt;/tr&gt;

        &lt;/table&gt;
      &lt;/div&gt;
    </us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000649"
      unitRef="usd">1437000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000650"
      unitRef="usd">894000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000651"
      unitRef="usd">1765000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestAndDebtExpense
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000652"
      unitRef="usd">27000</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000653"
      unitRef="usd">25000</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000654"
      unitRef="usd">42000</us-gaap:InterestAndDebtExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000655"
      unitRef="usd">340000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="Fxbrl_20230214022140608"
      unitRef="usd">-1000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000657"
      unitRef="usd">63000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="Fxbrl_20230214022153855"
      unitRef="usd">-12000</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000659"
      unitRef="usd">3000</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:GainLossOnSaleOfOtherAssets
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000660"
      unitRef="usd">12000</us-gaap:GainLossOnSaleOfOtherAssets>
    <cgen:FinancialIncomeExpenseNet
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000661"
      unitRef="usd">1738000</cgen:FinancialIncomeExpenseNet>
    <cgen:FinancialIncomeExpenseNet
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000662"
      unitRef="usd">871000</cgen:FinancialIncomeExpenseNet>
    <cgen:FinancialIncomeExpenseNet
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000663"
      unitRef="usd">1798000</cgen:FinancialIncomeExpenseNet>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000672">
    &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:11pt"&gt;&lt;span style="font-weight:bold"&gt;NOTE 12: - &lt;/span&gt;&lt;span style="font-weight:bold"&gt;RELATED PARTY BALANCES AND TRANSACTION&lt;/span&gt;&lt;/p&gt;

      &lt;div&gt;
        &lt;div&gt;
          &lt;div style="margin-left:56.7pt"&gt;
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Trade payables and accrued expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;83&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;94&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;
          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
          &lt;div style="margin-left:56.7pt"&gt;
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="10" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2020&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="margin-left:2.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Amounts charged to:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;194&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;240&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;294&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif"&gt;&#160;&lt;/p&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;

    &lt;div&gt;
      &lt;div style="margin-left:56.7pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;For the years ended December 31, 2022, 2021 and 2020 the Company received research and development services related with cancer studies in animal models, and breeding and maintenance of animals (mice) to support such studies. The transaction was at arm&#x2019;s length.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="C_20220101to20221231" id="FFact_0000000000671">
      &lt;div&gt;
        &lt;div&gt;
          &lt;div style="margin-left:56.7pt"&gt;
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="6" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:top;font-family:'Times New Roman',Times,serif;width:76%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="text-indent:-8.5pt;margin-left:11.35pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Trade payables and accrued expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;83&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;94&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
          &lt;/div&gt;
          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
          &lt;div style="margin-left:56.7pt"&gt;
            &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt"&gt;

                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="10" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                    &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2020&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="margin-left:2.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Amounts charged to:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;
                &lt;tr&gt;
                  &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development expenses&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;194&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;240&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                    &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;294&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;
                  &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                &lt;/tr&gt;

            &lt;/table&gt;
            &lt;p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman,Times,serif"&gt;&#160;&lt;/p&gt;
          &lt;/div&gt;
        &lt;/div&gt;
      &lt;/div&gt;
    </us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="C_20221231"
      decimals="-3"
      id="FFact_0000000000666"
      unitRef="usd">83000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="C_20211231"
      decimals="-3"
      id="FFact_0000000000667"
      unitRef="usd">94000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000668"
      unitRef="usd">194000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000669"
      unitRef="usd">240000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000670"
      unitRef="usd">294000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230222124735774">
    &lt;div&gt;
      &lt;div&gt;
        &lt;div&gt;
          &lt;p style="font-family:Times New Roman, Times, serif;font-size:10pt;text-align:left;margin-top:0pt;margin-bottom:0pt"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-weight:bold"&gt;NOTE 13: - LOSSES PER SHARE&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
        &lt;/div&gt;
      &lt;/div&gt;
      &lt;div&gt;
        &lt;div&gt;
          &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;

            &lt;div style="text-align:justify;text-indent:-28.35pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The following table sets forth the computation of basic and diluted losses per share:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
            &lt;div style="margin-left:56.7pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="10" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2020&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="margin-left:2.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Numerator:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net loss for basic and diluted loss per share&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(33,694&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(34,203&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(29,698&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Denominator:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average number of ordinary shares used in computing basic and diluted net loss per share&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;86,555,628&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;84,203,971&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;79,591,187&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Basic and diluted loss per ordinary share&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;(0.39&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;(0.41&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;(0.37&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;

        &lt;/div&gt;
      &lt;/div&gt;
    &lt;/div&gt;
  </us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230222124750140">
            &lt;div style="text-align:justify;text-indent:-28.35pt;margin-left:85.05pt;line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The following table sets forth the computation of basic and diluted losses per share:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
            &lt;div style="line-height:1.25;font-family:'Times New Roman',Times,serif"&gt;&#160;&lt;/div&gt;
            &lt;div style="margin-left:56.7pt"&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" style="width:90%;color:#000000;font-family:'Times New Roman', Times, serif;font-size:10pt"&gt;

                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="10" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Year ended December 31,&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;border-bottom:#000000 solid 2px" valign="bottom"&gt;
                      &lt;div style="text-align:center;line-height:1.25;font-weight:bold"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;2020&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;padding-bottom:2px;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="margin-left:2.85pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Numerator:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="2" style="vertical-align:bottom;font-family:'Times New Roman',Times,serif" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Net loss for basic and diluted loss per share&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(33,694&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(34,203&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;(29,698&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Denominator:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Weighted average number of ordinary shares used in computing basic and diluted net loss per share&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;86,555,628&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;84,203,971&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;79,591,187&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;text-align:right;width:9%" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="font-family:'Times New Roman',Times,serif;vertical-align:bottom;width:1%;white-space:nowrap" valign="bottom"&gt;&#160;&lt;/td&gt;
                  &lt;/tr&gt;
                  &lt;tr&gt;
                    &lt;td style="vertical-align:bottom;font-family:'Times New Roman',Times,serif;width:64%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="text-indent:-11.35pt;margin-left:14.2pt;line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Basic and diluted loss per ordinary share&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;(0.39&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;(0.41&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255)" valign="bottom"&gt;&#160;&lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;text-align:right;width:9%;border-bottom:4px double rgb(0, 0, 0);background-color:rgb(204, 238, 255)" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;(0.37&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                    &lt;td colspan="1" style="vertical-align:bottom;width:1%;padding-bottom:4px;background-color:rgb(204, 238, 255);white-space:nowrap" valign="bottom"&gt;
                      &lt;div style="line-height:1.25"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
                    &lt;/td&gt;
                  &lt;/tr&gt;

              &lt;/table&gt;
            &lt;/div&gt;
          </us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_20220101to20221231"
      decimals="-3"
      id="FFact_0000000000673"
      unitRef="usd">-33694000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20210101to20211231"
      decimals="-3"
      id="FFact_0000000000674"
      unitRef="usd">-34203000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_20200101to20201231"
      decimals="-3"
      id="FFact_0000000000675"
      unitRef="usd">-29698000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000676"
      unitRef="Shares">86555628</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="FFact_0000000000677"
      unitRef="Shares">84203971</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_20200101to20201231"
      decimals="INF"
      id="FFact_0000000000678"
      unitRef="Shares">79591187</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="Fxbrl_20230214135651704"
      unitRef="USD_per_share">-0.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20220101to20221231"
      decimals="INF"
      id="FFact_0000000000679"
      unitRef="USD_per_share">-0.39</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="Fxbrl_20230214135713278"
      unitRef="USD_per_share">-0.41</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20210101to20211231"
      decimals="INF"
      id="FFact_0000000000680"
      unitRef="USD_per_share">-0.41</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_20200101to20201231"
      decimals="INF"
      id="Fxbrl_20230214135731057"
      unitRef="USD_per_share">-0.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_20200101to20201231"
      decimals="INF"
      id="FFact_0000000000681"
      unitRef="USD_per_share">-0.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_20220101to20221231"
      id="Fxbrl_20230214053733944">
    &lt;div&gt;
      &lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;strong&gt;NOTE 14: -&#160;&lt;span&gt;Subsequent Events&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
      &lt;p style="margin-top:11pt;margin-bottom:0pt;font-family:Times New Roman, Times, serif;margin-left:56.7pt;text-align:justify"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span&gt;&lt;span&gt;On January 31, 2023, the Company entered into a &lt;/span&gt;Sales Agreement with SVB Securities LLC (&#x201c;SVB&#x201d;), as sales agent, pursuant to which the Company may offer and sell, from time to time through SVB, our ordinary shares. The offer and sale of our ordinary shares, if any, will be made pursuant to our shelf registration statement on Form F-3, as supplemented by the prospectus supplement filed on January 31, 2023. Pursuant to the said prospectus supplement, the Company may offer and sell up to $50 million of its ordinary shares.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;/div&gt;
  </us-gaap:SubsequentEventsTextBlock>
    <cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock
      contextRef="C_20230101to20230131_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_usgaapTypeOfArrangementAxis_cgenSalesAgreementWithSVBSecuritiesLLCMember"
      decimals="-6"
      id="Fxbrl_20230222014139521"
      unitRef="usd">50000000</cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>71
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MFEE!XE)7#'OD2^V-I??0!;BB^=Z( M9)QFEZ6J)V47*?TPJD@@BP1?:+3<8
ML5RK<KV(U< EP,9($18,KZGP34/'^*7DLQ!2P% A%M;4MX%J0(.^/K$C6!GA
M$#L!'N=T^?U+-2I'S7;6=9).,-@GU(^\ZAPA'6 ;+$T)60+,V-1,^155X !1
ME&6I+"XNMRGE^4[ZTYO!E\'BXH8@&&!L1:V\=(1R.?S6C%T-K!,YF)VH.EA
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M\C!PL+(-_ZN_B!RR!RXF!QZ8R0,SXILG(B[?Z$Z__+YU#ZK%T4 -_Z"ETM/
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M>6W(4U6J7\/B;<.^FYS@O;8U#9 )@+S!/S9$8*4K0USZKYRZU$!SL0 72]1
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MODGU0^ M[U5.-RUX'>F>+I>68[M.-$2^KF]H3,CTTU'&\ H^3C8/]9U'WE]
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M.F>XLYAP70P+IQ?^BC;5#A<^_YCCABT,;<#WF=9NLR %S9W]ZE]02P,$%
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M 3)UTDH1M'O1M \F.4A4.\YL4]I_/]L)&9,HTK0OL<^^Y[GG?+D;'[AXE#F
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MT(O!?6;T1$-E!>@\D=+L%]9!\^@;_0=02P,$%     @ '3A<5F:I(VWU#@
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MI^,S]XE3?6/-AC\T7!AK3<:7:R5A?+0 [Y?&V/J&$#1?GK[Z+U!+ P04
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M[3.ZM77UJ%83JPK_D"V4)1O]<$W_(:B= .TOE;+UQ"EH_FQ&_P)02P,$%
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M4@W)NI'5$RU*VSR60E,KLF9*O1^E<:#]E1!Z-S$)]G^3\1]02P,$%     @
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MP\H8W^%D\@/?.!'/R^OQ#ACV\] QI>9/QF#1O0:?I>7$!XI1V.U<TV*0QBE
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M$2BK@.=+*<U^81W4KUOZ%U!+ P04    "  =.%Q6G:C20.@"  !I!@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6R556UOVC 0_IY?8673M$E1\PZ,
M020H3*O4=HS23=.T#R:YD*A)G-I.:?_]S@ZD3 *D?CF_W?/XN8OO,MHR_B R
M $F>RZ(28S.3LA[:MH@S**FX8#54>)(R7E*)2[ZQ1<V!)AI4%K;G.#V[I'EE
M1B.]M^#1B#6RR"M8<"*:LJ3\90H%VXY-U]QO+/--)M6&'8UJNH$[D/?U@N/*
M[EB2O(1*Y*PB'-*Q.7&'TT#Y:X>?.6S%P9RH2-:,/:C%53(V'24("HBE8J X
M/,$E%(4B0AF/.TZSNU(!#^=[]J\Z=HQE305<LN)7GLAL; Y,DD!*FT(NV?8;
M[.()%5_,"J$MV;:^ =X8-T*R<@?&=9E7[4B?=WDX  R<$P!O!_"T[O8BK7)&
M)8U&G&T)5][(IB8Z5(U&<7FE/LJ=Y'B:(TY&B^7WQ7RY^DTFMS,R_W%_M;B9
MWZXL<CM?D8\KNBY ?!K9$F]2_G:\8YVVK-X)5M<C-ZR2F2#S*H'D?P(;)78Z
MO;W.J7>6<0;Q!?%=BWB.YYWA\[NX?<T7GHJ;X[OF\L4BBX)6DM J(?/')J_Q
MP4GR9[(6DN.+^7LL]I;9/\ZLJF@H:AK#V,0R$<"?P(P^O'-[SI<SNH-.=W".
M/;K#JDR: @A+2;V+08N'O7B+5""/R3Y+?%PV9AW*-7"5>4-E7AG7N&1"#M&6
M=2.!"XL(ELHMY:"5<"BHA -%QGO#M7IN7X^ATS.NZ9IQ*AE_>7724):F>0PD
M;7B5RX:#X5L#WT7;ZP?&-6#U9:Q(2%YBZ$^@8,+P+-\-E$5A?:O?\]"&CFM,
MXK@IFU9* AA3G%/5"-XBW+4"/T3KA^Z;1+N?'67=DZ(Q'XXF[@^,GN7YCA%:
M@\ W9GNA*"/&++<I\[TVA>& ''M"]D'YE\ WNLD)Q#>5;#M!M]OUT4G;/E[=
MVR9\0_DFKP0I($6H<]''^N%M8VL7DM6ZF:R9Q-:DIQG^"X K!SQ/&9/[A;J@
M^[M$_P!02P,$%     @ '3A<5AF0-]>. @  8@4  !D   !X;"]W;W)K<VAE
M971S+W-H965T,C8N>&UL?53;;MLP#'WW5PC>,&R 45^2YM(E!IS$0P>L;9"T
MNV#8@V(SL5'9\B2Y:?]^E.QXV9#F11(E\O <2M1DS\6CS  4>2Y8*:=VIE1U
MY;HRR:"@\H)74.+)EHN"*C3%SI65 )J:H(*Y@><-W(+FI1U.S-Y2A!->*Y:7
ML!1$UD5!Q<L,&-]/;=\^;*SR7:;TAAM.*KJ#-:B':BG0<CN4-"^@E#DOB8#M
MU([\JUE?^QN'KSGLY=&::"4;SA^U\3F=VIXF! P2I1$H3D\P!\8T$-+XW6+:
M74H=>+P^H'\RVE'+ADJ8<_8M3U4VM4<V26%+:Z96?'\-K9Y+C9=P)LU(]HWO
MY< F22T5+]I@9%#D93/3Y[8.1P$C[Y6 H T(#.\FD6&YH(J&$\'W1&AO1-,+
M(]5$([F\U)>R5@)/<XQ3X=W]=;PBT7Q^]W![OR;+Z$<T^Q*3Z':A-U</\8+$
MWY?Q[3I>D_?W=,- ?IBX"C/K>#=IL\R:+,$K6?R W/!299+$90KIOP N4NYX
M!P?>L^ LX@*2"]+S'1)X07 &K]?5H6?P+E_!6](7(X[0,B51DHB:,DE^1ANI
M!+Z<7Z<T-XB]TXBZFZYD11.8VM@N$L03V.&[-_[ ^WB&;[_CVS^''JZQ.].:
M >%;PE4& M]WPNM225(U4HP2JI5 2N 9NUB"/"7C;*+3,K#Z4&PP*=Z I6]
M#[X5%Q7C+]!640"C"EH.6$WKK14X(S_ N><$X[$5_4?.&CB]\<#J.\/A&)W&
M3N"-<!XYWG!$3M7,/7KW!8B=Z6Y)3!V:%NAVNP\D:OKFKWOS^]Q0L<M+21AL
M,=2[&.)#$4U'-X;BE>FB#5?8DV:9X2<(0CO@^99S=3!T@NY;#?\ 4$L#!!0
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M_B!#'<BN17<?6C2V+2Z%QB9KAQO\JP%I#'!]); I[#],@/X_:?H74$L#!!0
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MVQQ'*$CC@/<;(?3!, 3M4([^ E!+ P04    "  =.%Q6J9T.^>X"  !S!@
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M83$M:H/'9"I! =?%@%B02\8ICQA-R P' 0M1*_)S-%=:8BG]JA%T7@30K@_
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M???=?2<=.=XI_<.D )8\2I&9B9=:FU_ZOHE2D,R<JQPR?)(H+9G%J=[X)M?
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MARG>TT"[#?@\4<KN)\Y!<_.;_@M02P,$%     @ '3A<5NOECI:7!0  D"8
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M$81^E'WCEYR( P=D'W% N0-JZF#F#F93!RMWL%)FLE12'ES,\>B*T1U@B;5
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MQ!DY)(4%+;FYE>M/L,EG8/D2R77U2]:U;3AT2%)J(_,-&"/(F:C_Z=U&ARV
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M45#6 -<74IJ'@770M+?1?U!+ P04    "  =.%Q62$$F4TH"   !!0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6R55-&.VC 0_)55*E4@M20$N%XI
M1(+CJE:Z2@C:WD/5!Y,LQ#K'3FT'CK_OV@D1E0"I+XG7]HQG=M>>')1^,3FB
MA=="2#,-<FO+<1B:-,>"F9XJ4=+*5NF"60KU+C2E1I9Y4"'".(KNPH)Q&203
M/[?4R4155G")2PVF*@JFCW,4ZC -^L%I8L5WN74383(IV0[7:'^42TU1V+)D
MO$!IN)*@<3L-9OWQ?.CV^PT_.1[,V1B<DXU2+R[XFDV#R E"@:EU#(Q^>WQ
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MG.NN8N%5GZL"R0K3*A9,JL9CAJGZ-0#7"6I]R9A\"73W:7XVP3]02P,$%
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MQ\MF+SRO][_+OP^P-8MHHVFX.?&.:37_#?MQW++@<&B.^I.2N>CV>:CFHUJ
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MEWE>/7W1#'"?%]^6=__L?P%02P,$%     @ '3A<5F DG^G*!   TA8  !D
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M5R8URPY0LQM!E^D9Y)0*0:/T<D&P3UC20/X^HU1L;Y(!BF/LX?]02P,$%
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M($R WI]SKC83<T#[#R'Y"U!+ P04    "  =.%Q670@(/&L#  !J"@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6RMEEN/VCH0Q[^*E59'6^ET<R6$
M/1")0H].I5Y6R_8B57TPR4"L.C&U'=C]]L=VLBD0$^U#7\!.9O[YS=@>S_3
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M$ZI&K]'GU1)=O7R%7B)2H?N"U4*9BZDK%:;^F)NU2&\:I. "TA*R:Q3Z?Z/
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M-Y3&@-XG0NBWA?E /0R&_P%02P,$%     @ '3A<5N>G\T;- @  MP<  !D
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MSA6583.,J;.BT &TO^!<;2?Z@+I7>W\ 4$L#!!0    ( !TX7%8,X-]/=0,
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M,(<FG' 5 /LKQN1NHA[0M_71?U!+ P04    "  =.%Q6 'O,P&L"  "<!0
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M?UE^[QS=XQ>< _QO\?@%4$L#!!0    ( !TX7%:/X;=ITP$  #8A   3
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M:X8B:X8B:X8B:X8B:_:?LKX;L_SK-_GM-:UUV1SR6?>YQ.034$L! A0#%
M  @ '3A<5@=!36*!    L0   !               ( !     &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    "  =.%Q69N5Y"NX    K @  $0
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M=#(N>&UL4$L! A0#%     @ '3A<5H*M(J>8 @  /0<  !@
M ("!GA4  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( !TX
M7%9O3Z\;+@4  $H5   8              " @6P8  !X;"]W;W)K<VAE971S
M+W-H965T-"YX;6Q02P$"% ,4    "  =.%Q683HJQ6H&  !=*   &
M        @('0'0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%
M  @ '3A<5B?(U+;*"   J2L  !@              ("!<"0  'AL+W=O<FMS
M:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( !TX7%9H[@S$% T   4C   8
M              " @7 M  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"
M% ,4    "  =.%Q6:=]F?&L<  #>50  &               @(&Z.@  >&PO
M=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ '3A<5IKLBCN: @
MN 4  !@              ("!6U<  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM
M;%!+ 0(4 Q0    ( !TX7%:*0JIT<@8  +\/   9              " @2M:
M  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ '3A<5GL[
MQ4-B P  G@<  !D              ("!U&   'AL+W=O<FMS:&5E=',O<VAE
M970Q,2YX;6Q02P$"% ,4    "  =.%Q6Z]DM4'L"  "#!0  &0
M    @(%M9   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (
M !TX7%;$1O9V@@0    *   9              " @1]G  !X;"]W;W)K<VAE
M971S+W-H965T,3,N>&UL4$L! A0#%     @ '3A<5F:I(VWU#@  A2H  !D
M             ("!V&L  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"
M% ,4    "  =.%Q6T>&0'R01  # +0  &0              @($$>P  >&PO
M=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( !TX7%;=%IBGX0,
M .4(   9              " @5^,  !X;"]W;W)K<VAE971S+W-H965T,38N
M>&UL4$L! A0#%     @ '3A<5N>HJ^'? @  ( 8  !D              ("!
M=Y   'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    "  =.%Q6
M99=#V@\#  "T!@  &0              @(&-DP  >&PO=V]R:W-H965T<R]S
M:&5E=#$X+GAM;%!+ 0(4 Q0    ( !TX7%9RI;A(Z (  %D&   9
M      " @=.6  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%
M  @ '3A<5A2-[.TC @  [P0  !D              ("!\ID  'AL+W=O<FMS
M:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    "  =.%Q6LJ14[H0=  "@7P
M&0              @(%,G   >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+
M 0(4 Q0    ( !TX7%8IPH_<HP,  /D'   9              " @0>Z  !X
M;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ '3A<5MD3ZM.P
M @  E 4  !D              ("!X;T  'AL+W=O<FMS:&5E=',O<VAE970R
M,RYX;6Q02P$"% ,4    "  =.%Q6_7YOD^,"  #I!@  &0
M@('(P   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( !TX
M7%:=J-) Z (  &D&   9              " @>+#  !X;"]W;W)K<VAE971S
M+W-H965T,C4N>&UL4$L! A0#%     @ '3A<5AF0-]>. @  8@4  !D
M         ("! <<  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
M    "  =.%Q6GJ>8-BX$   S"0  &0              @('&R0  >&PO=V]R
M:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( !TX7%:;5X:#70,  ' '
M   9              " @2O.  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL
M4$L! A0#%     @ '3A<5LOD(T@V P  L <  !D              ("!O]$
M 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    "  =.%Q61T C
M<]X"   *!@  &0              @($LU0  >&PO=V]R:W-H965T<R]S:&5E
M=#,P+GAM;%!+ 0(4 Q0    ( !TX7%96ZHU5H0(  * %   9
M  " @4'8  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @
M'3A<5JF=#OGN @  <P8  !D              ("!&=L  'AL+W=O<FMS:&5E
M=',O<VAE970S,BYX;6Q02P$"% ,4    "  =.%Q6/8XLY!X#  #L"0  &0
M            @($^W@  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4
M Q0    ( !TX7%8[[=@Q)P8  $XI   9              " @9/A  !X;"]W
M;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ '3A<5I@K1/AX P
M!0X  !D              ("!\><  'AL+W=O<FMS:&5E=',O<VAE970S-2YX
M;6Q02P$"% ,4    "  =.%Q6Z^6.EI<%  "0)@  &0              @(&@
MZP  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( !TX7%8X
M48$ORP(  "X'   9              " @6[Q  !X;"]W;W)K<VAE971S+W-H
M965T,S<N>&UL4$L! A0#%     @ '3A<5I*%L2U# P  Z@H  !D
M     ("!</0  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !TX7%9'Q=&XE (  '@&   9              "
M@6$% 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ '3A<
M5DL#NLKC!0  ?"$  !D              ("!+ @! 'AL+W=O<FMS:&5E=',O
M<VAE970T-"YX;6Q02P$"% ,4    "  =.%Q6X"YP%I,/  #-U@  &0
M        @(%&#@$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0
M   ( !TX7%9@))_IR@0  -(6   9              " @1 > 0!X;"]W;W)K
M<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ '3A<5J74)GW/ P  Z!$
M !D              ("!$2,! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q0
M2P$"% ,4    "  =.%Q6N*;M,_("   A"@  &0              @($7)P$
M>&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( !TX7%:V7!3A
M0P(  +P$   9              " @4 J 0!X;"]W;W)K<VAE971S+W-H965T
M-#DN>&UL4$L! A0#%     @ '3A<5L2WYD[? @  +0@  !D
M ("!NBP! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    "  =
M.%Q670@(/&L#  !J"@  &0              @('0+P$ >&PO=V]R:W-H965T
M<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( !TX7%8[:Z_;3P0   ,7   9
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M970U-BYX;6Q02P$"% ,4    "  =.%Q6W92U TT#  #V$P  #0
M    @ 'J1 $ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( !TX7%:7BKL<P
M !,"   +              "  6)( 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M !TX7%:_.&76OP0  ' E   /              "  4M) 0!X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    "  =.%Q6##^0_.4!  !_(0  &@
M@ $W3@$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  =
M.%Q6C^&W:=,!   V(0  $P              @ %44 $ 6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     0 !  '<1  !84@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>126</ContextCount>
  <ElementCount>286</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>40</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-daei1</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-cbsp</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-csocl</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0005 - Statement - STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/StatementsOfChangesInShareholdersEquity</Role>
      <ShortName>STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0007 - Disclosure - GENERAL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-g</Role>
      <ShortName>GENERAL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-sap</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0009 - Disclosure - OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-oarape</Role>
      <ShortName>OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0010 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/Leases</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0011 - Disclosure - PROPERTY AND EQUIPMENT, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-paen</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0012 - Disclosure - OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-oapaae</Role>
      <ShortName>OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0013 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-cac1</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0014 - Disclosure - SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-se12</Role>
      <ShortName>SHAREHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0015 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-it</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0016 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-giamc</Role>
      <ShortName>GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0017 - Disclosure - FINANCIAL AND OTHER INCOME, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-faoin</Role>
      <ShortName>FINANCIAL AND OTHER INCOME, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0018 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-rpbat</Role>
      <ShortName>RELATED PARTY BALANCES AND TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0019 - Disclosure - LOSSES PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-lps</Role>
      <ShortName>LOSSES PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0020 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0021 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-sapp</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0022 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-sapt</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-sap</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0023 - Disclosure - OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-oarapet</Role>
      <ShortName>OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-oarape</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0024 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/LeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/Leases</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0025 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-paent</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-paen</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0026 - Disclosure - OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-oapaaet</Role>
      <ShortName>OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-oapaae</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0027 - Disclosure - SHAREHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-set1</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-se12</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0028 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-itt</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-it</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0029 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-giamct</Role>
      <ShortName>GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-giamc</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0030 - Disclosure - FINANCIAL AND OTHER INCOME, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-faoint</Role>
      <ShortName>FINANCIAL AND OTHER INCOME, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-faoin</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0031 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables</Role>
      <ShortName>RELATED PARTY BALANCES AND TRANSACTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-rpbat</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0032 - Disclosure - LOSSES PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-lpst</Role>
      <ShortName>LOSSES PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-lps</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0033 - Disclosure - GENERAL (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-gd</Role>
      <ShortName>GENERAL (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-g</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0034 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-sapnd</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-sapt</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0035 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Depreciation Rates for Property and Equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-sapsodrfpaed</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Schedule of Depreciation Rates for Property and Equipment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-sapt</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0036 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Weighted-Average Assumptions for Granted Options) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Schedule of Weighted-Average Assumptions for Granted Options) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-sapt</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0037 - Disclosure - OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-oaraped</Role>
      <ShortName>OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-oarapet</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0038 - Disclosure - LEASES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/LEASESNarrative</Role>
      <ShortName>LEASES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/LeasesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0039 - Disclosure - LEASES (Schedule of Weighted-Average Remaining Lease Term and Discount Rate) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/LeasesScheduleOfWeighted-averageRemainingLeaseTermAndDiscountRateDetails</Role>
      <ShortName>LEASES (Schedule of Weighted-Average Remaining Lease Term and Discount Rate) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/LeasesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0040 - Disclosure - LEASES (Schedule of Operating Leases) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails</Role>
      <ShortName>LEASES (Schedule of Operating Leases) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/LeasesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0041 - Disclosure - PROPERTY AND EQUIPMENT, NET (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-paent</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0042 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-paend</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-paent</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0043 - Disclosure - OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-oapaaed</Role>
      <ShortName>OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-oapaaet</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0044 - Disclosure - COMMITMENTS AND CONTINGENCIES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-cac1</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0045 - Disclosure - SHAREHOLDERS' EQUITY (Share Option Plans) (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-sesopnd</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Share Option Plans) (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-set1</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0046 - Disclosure - SHAREHOLDERS' EQUITY (Schedule Of Option Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Schedule Of Option Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-set1</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0047 - Disclosure - SHAREHOLDERS' EQUITY (Schedule Of Stock Compensation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/cgen-sesosced</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Schedule Of Stock Compensation Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-set1</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0048 - Disclosure - INCOME TAXES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>INCOME TAXES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-itt</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0049 - Disclosure - INCOME TAXES (Encouragement Of Capital Investments) (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/IncomeTaxesEncouragementOfCapitalInvestmentsNarrativeDetails</Role>
      <ShortName>INCOME TAXES (Encouragement Of Capital Investments) (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-itt</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0050 - Disclosure - INCOME TAXES (Schedule of Loss before Taxes) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails</Role>
      <ShortName>INCOME TAXES (Schedule of Loss before Taxes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-itt</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0051 - Disclosure - INCOME TAXES (Schedule of Deferred Tax Assets and Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>INCOME TAXES (Schedule of Deferred Tax Assets and Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-itt</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0052 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/GeographicInformationAndMajorCustomersDetails</Role>
      <ShortName>GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-giamct</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0053 - Disclosure - FINANCIAL AND OTHER INCOME, NET (Schedule of Financial and Other Income, Net) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails</Role>
      <ShortName>FINANCIAL AND OTHER INCOME, NET (Schedule of Financial and Other Income, Net) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-faoint</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0054 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/RelatedPartyBalancesAndTransactionsDetails</Role>
      <ShortName>RELATED PARTY BALANCES AND TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0055 - Disclosure - LOSSES PER SHARE (Schedule of Computation of Basic and Diluted Losses Per Share) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails</Role>
      <ShortName>LOSSES PER SHARE (Schedule of Computation of Basic and Diluted Losses Per Share) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/cgen-lpst</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="zk2329266.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0056 - Disclosure - Subsequent Events (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cgen.com/role/SubsequentEventsNarrativeDetails</Role>
      <ShortName>Subsequent Events (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cgen.com/role/SUBSEQUENTEVENTS</ParentRole>
      <Position>56</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="20-F" original="zk2329266.htm">zk2329266.htm</File>
    <File>cgen-20221231.xsd</File>
    <File>cgen-20221231_cal.xml</File>
    <File>cgen-20221231_def.xml</File>
    <File>cgen-20221231_lab.xml</File>
    <File>cgen-20221231_pre.xml</File>
    <File>exhibit_12-1.htm</File>
    <File>exhibit_12-2.htm</File>
    <File>exhibit_13-1.htm</File>
    <File>exhibit_15-1.htm</File>
    <File>exhibit_8-1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cgen_img01.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="513">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="46">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>76
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "zk2329266.htm": {
   "axisCustom": 2,
   "axisStandard": 17,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 513,
    "http://xbrl.sec.gov/dei/2022": 46
   },
   "contextCount": 126,
   "dts": {
    "calculationLink": {
     "local": [
      "cgen-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cgen-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "zk2329266.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cgen-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cgen-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cgen-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 462,
   "entityCount": 1,
   "hidden": {
    "http://cgen.com/20221231": 1,
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 4
   },
   "keyCustom": 55,
   "keyStandard": 231,
   "memberCustom": 16,
   "memberStandard": 24,
   "nsprefix": "cgen",
   "nsuri": "http://cgen.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "dei:DocumentPeriodEndDate",
       "span",
       "span",
       "span",
       "p",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:CurrentFiscalYearEndDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://cgen.com/role/cgen-daei1",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "dei:DocumentPeriodEndDate",
       "span",
       "span",
       "span",
       "p",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:CurrentFiscalYearEndDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0010 - Disclosure - LEASES",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://cgen.com/role/Leases",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0011 - Disclosure - PROPERTY AND EQUIPMENT, NET",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://cgen.com/role/cgen-paen",
     "shortName": "PROPERTY AND EQUIPMENT, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0012 - Disclosure - OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://cgen.com/role/cgen-oapaae",
     "shortName": "OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0013 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://cgen.com/role/cgen-cac1",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0014 - Disclosure - SHAREHOLDERS' EQUITY",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://cgen.com/role/cgen-se12",
     "shortName": "SHAREHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0015 - Disclosure - INCOME TAXES",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://cgen.com/role/cgen-it",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0016 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://cgen.com/role/cgen-giamc",
     "shortName": "GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0017 - Disclosure - FINANCIAL AND OTHER INCOME, NET",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://cgen.com/role/cgen-faoin",
     "shortName": "FINANCIAL AND OTHER INCOME, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0018 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://cgen.com/role/cgen-rpbat",
     "shortName": "RELATED PARTY BALANCES AND TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0019 - Disclosure - LOSSES PER SHARE",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://cgen.com/role/cgen-lps",
     "shortName": "LOSSES PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://cgen.com/role/ConsolidatedBalanceSheets",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0020 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://cgen.com/role/SUBSEQUENTEVENTS",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0021 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "menuCat": "Policies",
     "order": "21",
     "role": "http://cgen.com/role/cgen-sapp",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cgen:ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0022 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://cgen.com/role/cgen-sapt",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cgen:ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "cgen:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0023 - Disclosure - OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://cgen.com/role/cgen-oarapet",
     "shortName": "OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "cgen:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cgen:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0024 - Disclosure - LEASES (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://cgen.com/role/LeasesTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cgen:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0025 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://cgen.com/role/cgen-paent",
     "shortName": "PROPERTY AND EQUIPMENT, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0026 - Disclosure - OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://cgen.com/role/cgen-oapaaet",
     "shortName": "OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0027 - Disclosure - SHAREHOLDERS' EQUITY (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://cgen.com/role/cgen-set1",
     "shortName": "SHAREHOLDERS' EQUITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0028 - Disclosure - INCOME TAXES (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://cgen.com/role/cgen-itt",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0029 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://cgen.com/role/cgen-giamct",
     "shortName": "GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20221231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "NIS_Per_Share",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://cgen.com/role/cgen-cbsp",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20221231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0030 - Disclosure - FINANCIAL AND OTHER INCOME, NET (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://cgen.com/role/cgen-faoint",
     "shortName": "FINANCIAL AND OTHER INCOME, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0031 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables",
     "shortName": "RELATED PARTY BALANCES AND TRANSACTIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0032 - Disclosure - LOSSES PER SHARE (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://cgen.com/role/cgen-lpst",
     "shortName": "LOSSES PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20130801to20130805",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0033 - Disclosure - GENERAL (Narrative) (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://cgen.com/role/cgen-gd",
     "shortName": "GENERAL (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20130805",
      "decimals": "-3",
      "lang": null,
      "name": "cgen:ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "cgen:ShortTermBankDepositsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "cgen:ShortTermBankDepositsWeightedAverageRateForeign",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0034 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://cgen.com/role/cgen-sapnd",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "cgen:ShortTermBankDepositsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "cgen:ShortTermBankDepositsWeightedAverageRateForeign",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "cgen:ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "cgen:AnnualDepreciationRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0035 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Depreciation Rates for Property and Equipment) (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://cgen.com/role/cgen-sapsodrfpaed",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Schedule of Depreciation Rates for Property and Equipment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "cgen:ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "cgen:AnnualDepreciationRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "cgen:ScheduleOfWeightedAverageAssumptionsForGrantedOptions",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0036 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Schedule of Weighted-Average Assumptions for Granted Options) (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Schedule of Weighted-Average Assumptions for Granted Options) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "cgen:ScheduleOfWeightedAverageAssumptionsForGrantedOptions",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "cgen:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0037 - Disclosure - OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://cgen.com/role/cgen-oaraped",
     "shortName": "OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "cgen:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0038 - Disclosure - LEASES (Narrative) (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://cgen.com/role/LEASESNarrative",
     "shortName": "LEASES (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "cgen:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate",
       "div",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0039 - Disclosure - LEASES (Schedule of Weighted-Average Remaining Lease Term and Discount Rate) (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://cgen.com/role/LeasesScheduleOfWeighted-averageRemainingLeaseTermAndDiscountRateDetails",
     "shortName": "LEASES (Schedule of Weighted-Average Remaining Lease Term and Discount Rate) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "cgen:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate",
       "div",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://cgen.com/role/cgen-csocl",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0040 - Disclosure - LEASES (Schedule of Operating Leases) (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails",
     "shortName": "LEASES (Schedule of Operating Leases) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0041 - Disclosure - PROPERTY AND EQUIPMENT, NET (Narrative) (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails",
     "shortName": "PROPERTY AND EQUIPMENT, NET (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_cgenObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0042 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://cgen.com/role/cgen-paend",
     "shortName": "PROPERTY AND EQUIPMENT, NET (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20221231_usgaapPropertyPlantAndEquipmentByTypeAxis_usgaapComputerEquipmentMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0043 - Disclosure - OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://cgen.com/role/cgen-oapaaed",
     "shortName": "OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "div",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:GuaranteeObligationsMaximumExposure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0044 - Disclosure - COMMITMENTS AND CONTINGENCIES (Narrative) (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://cgen.com/role/CommitmentsAndContingenciesDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:GuaranteeObligationsMaximumExposure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD_per_share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0045 - Disclosure - SHAREHOLDERS' EQUITY (Share Option Plans) (Narrative) (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://cgen.com/role/cgen-sesopnd",
     "shortName": "SHAREHOLDERS' EQUITY (Share Option Plans) (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD_per_share",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20211231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0046 - Disclosure - SHAREHOLDERS' EQUITY (Schedule Of Option Activity) (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails",
     "shortName": "SHAREHOLDERS' EQUITY (Schedule Of Option Activity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231_usgaapAwardTypeAxis_cgenEmployeesAndDirectorsMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0047 - Disclosure - SHAREHOLDERS' EQUITY (Schedule Of Stock Compensation Expense) (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://cgen.com/role/cgen-sesosced",
     "shortName": "SHAREHOLDERS' EQUITY (Schedule Of Stock Compensation Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0048 - Disclosure - INCOME TAXES (Narrative) (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://cgen.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "INCOME TAXES (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "cgen:ReducedTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0049 - Disclosure - INCOME TAXES (Encouragement Of Capital Investments) (Narrative) (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://cgen.com/role/IncomeTaxesEncouragementOfCapitalInvestmentsNarrativeDetails",
     "shortName": "INCOME TAXES (Encouragement Of Capital Investments) (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "cgen:ReducedTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20191231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0005 - Statement - STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://cgen.com/role/StatementsOfChangesInShareholdersEquity",
     "shortName": "STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20191231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0050 - Disclosure - INCOME TAXES (Schedule of Loss before Taxes) (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails",
     "shortName": "INCOME TAXES (Schedule of Loss before Taxes) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0051 - Disclosure - INCOME TAXES (Schedule of Deferred Tax Assets and Liabilities) (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "INCOME TAXES (Schedule of Deferred Tax Assets and Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Item",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0052 - Disclosure - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails",
     "shortName": "GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Item",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0053 - Disclosure - FINANCIAL AND OTHER INCOME, NET (Schedule of Financial and Other Income, Net) (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails",
     "shortName": "FINANCIAL AND OTHER INCOME, NET (Schedule of Financial and Other Income, Net) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueToRelatedPartiesCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0054 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://cgen.com/role/RelatedPartyBalancesAndTransactionsDetails",
     "shortName": "RELATED PARTY BALANCES AND TRANSACTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueToRelatedPartiesCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0055 - Disclosure - LOSSES PER SHARE (Schedule of Computation of Basic and Diluted Losses Per Share) (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails",
     "shortName": "LOSSES PER SHARE (Schedule of Computation of Basic and Diluted Losses Per Share) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20230101to20230131_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_usgaapTypeOfArrangementAxis_cgenSalesAgreementWithSVBSecuritiesLLCMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0056 - Disclosure - Subsequent Events (Narrative) (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://cgen.com/role/SubsequentEventsNarrativeDetails",
     "shortName": "Subsequent Events (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20230101to20230131_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_usgaapTypeOfArrangementAxis_cgenSalesAgreementWithSVBSecuritiesLLCMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "cgen:MaximumAuthorizedProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://cgen.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0007 - Disclosure - GENERAL",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://cgen.com/role/cgen-g",
     "shortName": "GENERAL",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://cgen.com/role/cgen-sap",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cgen:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0009 - Disclosure - OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://cgen.com/role/cgen-oarape",
     "shortName": "OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "zk2329266.htm",
      "contextRef": "C_20220101to20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cgen:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 40,
   "tag": {
    "cgen_AccruedMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued milestone payment.",
        "label": "Accrued milestone payment"
       }
      }
     },
     "localname": "AccruedMilestonePayment",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_AggregateLimitOfOrdinarySharesPerCalendarYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate limit of ordinary shares per calendar year.",
        "label": "Aggregate limit of ordinary shares per calendar year"
       }
      }
     },
     "localname": "AggregateLimitOfOrdinarySharesPerCalendarYear",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "perShareItemType"
    },
    "cgen_AgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement Member.",
        "label": "Agreement [Member]"
       }
      }
     },
     "localname": "AgreementMember",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "domainItemType"
    },
    "cgen_AgreementOptionAdditionalNumberOfSharesIssuable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement, additional shares issuable.",
        "label": "Agreement Option Additional Number Of Shares Issuable",
        "terseLabel": "Agreement, additional shares issuable"
       }
      }
     },
     "localname": "AgreementOptionAdditionalNumberOfSharesIssuable",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "sharesItemType"
    },
    "cgen_AgreementStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement start date.",
        "label": "Agreement Start Date",
        "verboseLabel": "Agreement, start date"
       }
      }
     },
     "localname": "AgreementStartDate",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "cgen_AgreementTerminationDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of termination of agreement.",
        "label": "Agreement Termination Description",
        "verboseLabel": "Agreement termination description"
       }
      }
     },
     "localname": "AgreementTerminationDescription",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cgen_AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement": {
     "auth_ref": [],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 50.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization Of Cash Consideration Of Research And Development Funding Arrangement",
        "label": "Amortization Of Cash Consideration Of Research And Development Funding Arrangement",
        "negatedLabel": "Decrease (increase) in interest receivables from short-term bank deposits",
        "terseLabel": "Amortization research and development component"
       }
      }
     },
     "localname": "AmortizationOfCashConsiderationOfResearchAndDevelopmentFundingArrangement",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_AnnualDepreciationRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Depreciation Rate",
        "label": "Annual depreciation rate"
       }
      }
     },
     "localname": "AnnualDepreciationRate",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "xbrltype": "percentItemType"
    },
    "cgen_AnnualDepreciationRateDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Depreciation Rates, Description.",
        "label": "Annual Depreciation Rate, Description",
        "verboseLabel": "Annual depreciation rate"
       }
      }
     },
     "localname": "AnnualDepreciationRateDescription",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "xbrltype": "stringItemType"
    },
    "cgen_AtMarketOfferingProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-the-Market Offering Program \"ATM\"",
        "label": "At Market Offering Program [Member]",
        "terseLabel": "At-the-Market Offering Program \"ATM\" [Member]"
       }
      }
     },
     "localname": "AtMarketOfferingProgramMember",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "domainItemType"
    },
    "cgen_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for amounts included in the measurement of lease liabilities.",
        "label": "Cash paid for amounts included in measurement of lease liabilities"
       }
      }
     },
     "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/LEASESNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration period of warrants.",
        "label": "Class Of Warrant Or Rights Period From Which Warrants Or Rights Exercisable",
        "terseLabel": "Expiration period of warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightsPeriodFromWhichWarrantsOrRightsExercisable",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "durationItemType"
    },
    "cgen_CollaborativeArrangementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangements [Member]",
        "label": "Collaborative Arrangements [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementsMember",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "domainItemType"
    },
    "cgen_CollaborativeArrangementsTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangements Two [Member]",
        "label": "Collaborative Arrangements Two [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementsTwoMember",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "domainItemType"
    },
    "cgen_ContingentFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent fees.",
        "label": "Contingent Fees",
        "verboseLabel": "Contingent fees"
       }
      }
     },
     "localname": "ContingentFees",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_CostOfSalesContractWithCustomerPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognition of costs in the period which correspond to the sales and revenue categories presented in the statement of operations. The accounting policy may include the amount and nature of costs incurred, provisions associated with inventories, purchase discounts, freight and other costs included in cost of sales incurred and recorded in the period. This disclosure also includes the nature of costs of sales incurred and recorded in the statement of operations for the period relating to transactions with related parties.",
        "label": "Cost Of Sales Contract With Customer Policy Text Block",
        "terseLabel": "Cost of revenues:"
       }
      }
     },
     "localname": "CostOfSalesContractWithCustomerPolicyTextBlock",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cgen_CustomerOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer One [Member]",
        "label": "Customer One Member",
        "terseLabel": "Customer A [Member]"
       }
      }
     },
     "localname": "CustomerOneMember",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cgen_DecreaseOperatingLeaseLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease liability decreased.",
        "label": "Decrease Operating Lease Liability",
        "terseLabel": "Operating lease liability decreased"
       }
      }
     },
     "localname": "DecreaseOperatingLeaseLiability",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/LEASESNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_DeferredIncomeTaxLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 40.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax lease liability attributable to taxable temporary differences.",
        "label": "Deferred Income Tax Lease Liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLeaseLiabilities",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_DeferredIncomeTaxRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 30.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax Right of use assets attributable to taxable temporary differences.",
        "label": "Deferred Income Tax Right Of Use Assets",
        "terseLabel": "Right of use assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxRightOfUseAssets",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_DeferredParticipationOfBMSInRAndDExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred participation of BMS in R and D expenses.",
        "label": "Deferred Participation Of B M S In R And D Expenses",
        "terseLabel": "Deferred participation of BMS in R&amp;D expenses"
       }
      }
     },
     "localname": "DeferredParticipationOfBMSInRAndDExpenses",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 50.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax asset (liabilities) for property, plant and equipment.",
        "label": "Deferred Tax Assets Liabilities Property Plant And Equipment",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_DerivativeRelatedExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the derivative related expenses incurred during the reporting period.",
        "label": "Derivative Related Expense",
        "terseLabel": "Derivative related expenses"
       }
      }
     },
     "localname": "DerivativeRelatedExpense",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss) for next fiscal year.",
        "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate For Next Fiscal Year",
        "terseLabel": "Israeli corporate tax rate for next fiscal year"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRateForNextFiscalYear",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cgen_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan [Member]",
        "label": "Employee Stock Purchase Plan Member",
        "verboseLabel": "Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cgen_EmployeesAndDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to employees and directors.",
        "label": "Employees and Directors [Member]"
       }
      }
     },
     "localname": "EmployeesAndDirectorsMember",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cgen_ExtendLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extend Lease",
        "label": "Extend Lease",
        "verboseLabel": "Extend lease"
       }
      }
     },
     "localname": "ExtendLease",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cgen_FinancialIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://cgen.com/role/cgen-csocl": {
       "order": 10.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Income (Expense), Net.",
        "label": "Financial Income Expense Net",
        "terseLabel": "Financial and other income, net",
        "totalLabel": "Financial and other income, net"
       }
      }
     },
     "localname": "FinancialIncomeExpenseNet",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails",
      "http://cgen.com/role/cgen-csocl"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_GovernmentAndOtherGrantsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government and Other Grants [Axis]",
        "label": "Government and Other Grants [Axis]"
       }
      }
     },
     "localname": "GovernmentAndOtherGrantsAxis",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cgen_GovernmentAndOtherGrantsDomain": {
     "auth_ref": [],
     "localname": "GovernmentAndOtherGrantsDomain",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cgen_GovernmentAuthorities": {
     "auth_ref": [],
     "calculation": {
      "http://cgen.com/role/cgen-oaraped": {
       "order": 10.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Authorities",
        "label": "Government authorities"
       }
      }
     },
     "localname": "GovernmentAuthorities",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/cgen-oaraped"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 90.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in deferred participation in R and D expenses.",
        "label": "Increase Decrease In Deferred Participation In Research And Development Expenses",
        "terseLabel": "Increase (decrease) in deferred participation in R&amp;D expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredParticipationInResearchAndDevelopmentExpenses",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 100.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in operating lease right of use asset.",
        "label": "Increase Decrease In Operating Lease Right Of Use Asset",
        "negatedLabel": "Decrease in operating lease right of use asset"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_IncreaseOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease right of use asset increased.",
        "label": "Increase Operating Lease Right Of Use Asset",
        "terseLabel": "Operating lease right of use asset increased"
       }
      }
     },
     "localname": "IncreaseOperatingLeaseRightOfUseAsset",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/LEASESNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_InterestPaidReceivedNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest payments paid (received) from bank short-term deposits and cash equivalents",
        "label": "Interest Paid Received Net",
        "terseLabel": "Interest payments received from short-term bank deposits and cash equivalents"
       }
      }
     },
     "localname": "InterestPaidReceivedNet",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_IssuanceOfSharesAndWarrantsNetShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of shares and warrants, net, shares.",
        "label": "Issuance of shares and warrants, net, shares"
       }
      }
     },
     "localname": "IssuanceOfSharesAndWarrantsNetShares",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "cgen_IssuanceOfSharesAndWarrantsNetValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of shares and warrants, net.",
        "label": "Issuance Of Shares And Warrants Net Value",
        "terseLabel": "Issuance of shares and warrants, net"
       }
      }
     },
     "localname": "IssuanceOfSharesAndWarrantsNetValue",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_LaboratoryEquipmentAndOfficeFurnitureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment And Office Furniture [Member]",
        "label": "Laboratory equipment and office furniture [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentAndOfficeFurnitureMember",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/cgen-paend",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "xbrltype": "domainItemType"
    },
    "cgen_LongTermDeferredParticipationInResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term deferred participation in R&amp;amp;D expenses.",
        "label": "Long Term Deferred Participation In Research And Development Expenses",
        "terseLabel": "Long-term deferred participation in R&amp;D expenses"
       }
      }
     },
     "localname": "LongTermDeferredParticipationInResearchAndDevelopmentExpenses",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_MasterClinicalAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Master Clinical Agreement [Member]",
        "label": "Master Clinical Agreement [Member]"
       }
      }
     },
     "localname": "MasterClinicalAgreementMember",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "domainItemType"
    },
    "cgen_MasterClinicalAgreementOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Master Clinical Agreement One [Member]",
        "label": "Master Clinical Agreement One [Member]"
       }
      }
     },
     "localname": "MasterClinicalAgreementOneMember",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "domainItemType"
    },
    "cgen_MasterClinicalAgreementTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Master Clinical Agreement Two [Member]",
        "label": "Master Clinical Agreement Two [Member]"
       }
      }
     },
     "localname": "MasterClinicalAgreementTwoMember",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "domainItemType"
    },
    "cgen_MaximumAuthorizedProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Authorized Proceeds From Issuance Of Common Stock",
        "label": "Maximum Authorized Proceeds From Issuance Of Common Stock",
        "terseLabel": "Aggregate offering price",
        "verboseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "MaximumAuthorizedProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/SubsequentEventsNarrativeDetails",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_MaximumRoyaltyRepaidAsPercentageOfGrantReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Royalty Repaid As Percentage Of Grant Received",
        "label": "Maximum Royalty Repaid As Percentage Of Grant Received",
        "verboseLabel": "Maximum royalty repaid as percentage of grant received"
       }
      }
     },
     "localname": "MaximumRoyaltyRepaidAsPercentageOfGrantReceived",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cgen_May2012AgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "May 2012 Agreement Member",
        "label": "May 2012 Agreement Member",
        "terseLabel": "May 2012 Agreement With Advisor [Member]"
       }
      }
     },
     "localname": "May2012AgreementMember",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cgen_NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income Loss After Adjustment Of Change In Fair Value Of Research And Development Funding Arrangement Abstract",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAfterAdjustmentOfChangeInFairValueOfResearchAndDevelopmentFundingArrangementAbstract",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cgen_NetOperatingLossCarryforwardExpired": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net operating loss carryforward, Expired.",
        "label": "Net operating loss carryforward, Expired"
       }
      }
     },
     "localname": "NetOperatingLossCarryforwardExpired",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of licensed programs to achieve substantive milestones revenues.",
        "label": "Number of licensed programs to achieve substantive milestones revenues"
       }
      }
     },
     "localname": "NumberOfLicensedProgramsToAchieveSubstantiveMilestonesRevenues",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "integerItemType"
    },
    "cgen_NumberOfWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants exercised.",
        "label": "Number Of Warrants Exercised",
        "terseLabel": "Warrants exercised, shares"
       }
      }
     },
     "localname": "NumberOfWarrantsExercised",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "cgen_ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to obsolete property and equipment and certain nonfunctional Lab equipment.",
        "label": "Obsolete property and equipment and nonfunctional Lab equipment [Member]",
        "terseLabel": "Obsolete property and equipment and certain nonfunctional Lab equipment [Member]"
       }
      }
     },
     "localname": "ObsoletePropertyAndEquipmentAndNonfunctionalLabEquipmentMember",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cgen_OtherAccountsReceivableAndPrepaidExpensesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other accounts receivable and prepaid expenses.",
        "label": "Other Accounts Receivable And Prepaid Expenses Text Block",
        "terseLabel": "OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES"
       }
      }
     },
     "localname": "OtherAccountsReceivableAndPrepaidExpensesTextBlock",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/cgen-oarape"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cgen_ParticipationRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the cash consideration received by the Company or its affiliates from third parties to be paid back to investors.",
        "label": "Participation Rights",
        "verboseLabel": "Participation Rights"
       }
      }
     },
     "localname": "ParticipationRights",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cgen_PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 40.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payments for Proceeds from Sales of equipment Investing Activities.",
        "label": "Payments For Proceeds From Sales Of Property And Equipment Investing Activities",
        "negatedLabel": "Proceeds from sale of property and equipment",
        "totalLabel": "Proceeds from Sale of Property, Plant, and Equipment, Total",
        "verboseLabel": "Proceeds from sale of property and equipment"
       }
      }
     },
     "localname": "PaymentsForProceedsFromSalesOfPropertyAndEquipmentInvestingActivities",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_PercentageOfClosingPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of closing price.",
        "label": "Percentage of closing price"
       }
      }
     },
     "localname": "PercentageOfClosingPrice",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "percentItemType"
    },
    "cgen_PercentageOfConsolidatedRevenuesOfCollaborator": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of consolidated revenues of collaborator.",
        "label": "Percentage of consolidated revenues of collaborator"
       }
      }
     },
     "localname": "PercentageOfConsolidatedRevenuesOfCollaborator",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "percentItemType"
    },
    "cgen_PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of fair market value of ordinary shares at time of offering.",
        "label": "Percentage of fair market value of ordinary shares at time of offering"
       }
      }
     },
     "localname": "PercentageOfFairMarketValueOfOrdinarySharesAtTimeOfOffering",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "percentItemType"
    },
    "cgen_PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of use of base salary to purchase ordinary shares.",
        "label": "Percentage of use of base salary to purchase ordinary shares"
       }
      }
     },
     "localname": "PercentageOfUseOfBaseSalaryToPurchaseOrdinaryShares",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "percentItemType"
    },
    "cgen_PeriodSinceApprovalWasGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period since approval was granted.",
        "label": "Period since approval was granted"
       }
      }
     },
     "localname": "PeriodSinceApprovalWasGranted",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesEncouragementOfCapitalInvestmentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cgen_PeriodSinceEnterpriseBeganOperating": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period since enterprise began operating.",
        "label": "Period since enterprise began operating"
       }
      }
     },
     "localname": "PeriodSinceEnterpriseBeganOperating",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesEncouragementOfCapitalInvestmentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cgen_ReceivablesOnAccountOfShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivables on account of shares.",
        "label": "Receivables on account of shares"
       }
      }
     },
     "localname": "ReceivablesOnAccountOfShares",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_ReducedCorporateIncomeTaxRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduced Corporate income tax rate",
        "label": "Reduced Corporate income tax rate"
       }
      }
     },
     "localname": "ReducedCorporateIncomeTaxRate",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cgen_ReducedTaxRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduced tax rate.",
        "label": "Reduced tax rate"
       }
      }
     },
     "localname": "ReducedTaxRate",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesEncouragementOfCapitalInvestmentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cgen_RegisteredDirectOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Registered direct offering [Member]",
        "label": "Registered direct offering [Member]"
       }
      }
     },
     "localname": "RegisteredDirectOfferingMember",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "domainItemType"
    },
    "cgen_ResearchAndDevelopmentArrangementPaymentsReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential milestone revenue from arrangements for research and development, including collaboration and licenses agreements.",
        "label": "Research And Development Arrangement Payments Receivable",
        "terseLabel": "Potential milestone compensation"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementPaymentsReceivable",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/cgen-gd",
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential milestone compensation company is now eligible for.",
        "label": "Research And Development Arrangement Payments Receivable On Remaining Program",
        "terseLabel": "Potential milestone compensation company is now eligible for"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementPaymentsReceivableOnRemainingProgram",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/cgen-gd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential milestone revenue for preclinical stages of research from arrangements for research and development, including collaboration and licenses agreements.",
        "label": "Research And Development Arrangement Preclinical Payments Receivable",
        "terseLabel": "Preclinical milestone compensation"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementPreclinicalPaymentsReceivable",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/cgen-gd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_ResearchAndDevelopmentExpensesMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expenses milestone payment.",
        "label": "Research And Development Expenses Milestone Payment",
        "verboseLabel": "Research and development expenses milestone payment"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensesMilestonePayment",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_ResearchAndDevelopmentExpensesMilestonePaymentWithConnection": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expenses milestone payment with connection.",
        "label": "Research And Development Expenses Milestone Payment With Connection",
        "verboseLabel": "Research and development expenses milestone payment with connection"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensesMilestonePaymentWithConnection",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_ResearchAndDevelopmentGrantOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Grant One [Member]",
        "label": "Research And Development Grant One Member",
        "terseLabel": "IIA [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentGrantOneMember",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cgen_RetainerFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the retainer fee per month.",
        "label": "Retainer Fee",
        "verboseLabel": "Retainer fee"
       }
      }
     },
     "localname": "RetainerFee",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_RoyaltyContingentObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The contingent obligations for payments based on royalty-bearing participation received or accrued, net of royalties paid or accrued.",
        "label": "Royalty Contingent Obligations",
        "verboseLabel": "Contingent royalty obligations"
       }
      }
     },
     "localname": "RoyaltyContingentObligations",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_RoyaltyPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty percentage.",
        "label": "Royalty Percentage",
        "verboseLabel": "Royalty percentage"
       }
      }
     },
     "localname": "RoyaltyPercentage",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cgen_RoyaltyPercentageBasedOnFutureRevenues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Percentage Based On Future Revenues",
        "label": "Royalty Percentage Based On Future Revenues",
        "verboseLabel": "Royalty percentage based on future revenues"
       }
      }
     },
     "localname": "RoyaltyPercentageBasedOnFutureRevenues",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cgen_SalesAgreementWithSVBSecuritiesLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Agreement with SVB Securities LLC.",
        "label": "Sales Agreement With S V B Securities L L C [Member]",
        "terseLabel": "Sales Agreement with SVB Securities LLC. [Member]"
       }
      }
     },
     "localname": "SalesAgreementWithSVBSecuritiesLLCMember",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cgen_ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the annual rates used to calculate depreciation for property, plant and equipment.",
        "label": "Schedule Of Property Plant And Equipment Depreciation Rates Table Text Block",
        "verboseLabel": "Schedule of depreciation rates for property and equipment"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentDepreciationRatesTableTextBlock",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/cgen-sapt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cgen_ScheduleOfWeightedAverageAssumptionsForGrantedOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of granted stock options, including, but not limited to: (a) expected term of granted share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Weighted Average Assumptions For Granted Options",
        "verboseLabel": "Schedule of weighted average assumptions for granted options"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageAssumptionsForGrantedOptions",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/cgen-sapt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cgen_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of weighted-average remaining lease term and discount rate.",
        "label": "Schedule Of Weighted Average Remaining Lease Term And Discount Rate",
        "terseLabel": "Schedule of weighted-average remaining lease term and discount rate"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRate",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cgen_SegmentReportingGeograhicAreaLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Segment Reporting Geograhic Area [Line Items]",
        "label": "Segment Reporting Geograhic Area [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingGeograhicAreaLineItems",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cgen_SegmentReportingGeographicAreaAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Segment Reporting Geographic Area [Axis]",
        "label": "Segment Reporting Geographic Area [Axis]"
       }
      }
     },
     "localname": "SegmentReportingGeographicAreaAxis",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cgen_SegmentReportingGeographicAreaDomain": {
     "auth_ref": [],
     "localname": "SegmentReportingGeographicAreaDomain",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cgen_SegmentReportingGeographicAreaTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Segment Reporting Geographic Area [Table]",
        "label": "Segment Reporting Geographic Area [Table]"
       }
      }
     },
     "localname": "SegmentReportingGeographicAreaTable",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cgen_ServerancePayPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Serverance Pay [Policy Text Block]",
        "label": "Serverance Pay Policy Text Block",
        "terseLabel": "Severance pay:"
       }
      }
     },
     "localname": "ServerancePayPolicyTextBlock",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cgen_SeverancePayFundNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monthly deposits in externally managed funds which primarily cover Israeli law severance pay liability of one month's salary for each year of employment upon the retirement or death of an employee or termination of employment without a valid legal reason.",
        "label": "Severance Pay Fund Noncurrent",
        "verboseLabel": "Severance pay fund"
       }
      }
     },
     "localname": "SeverancePayFundNoncurrent",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_SeverancePayNet": {
     "auth_ref": [],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 30.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Severance pay, net.",
        "label": "Severance Pay Net",
        "terseLabel": "Increase (decrease) in severance pay, net"
       }
      }
     },
     "localname": "SeverancePayNet",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Award Expiration Period",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Expiration Period",
        "verboseLabel": "Award expiration period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "durationItemType"
    },
    "cgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award Options, Remaining Contractual Term [Abstract]",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Remaining Contractual Term Abstract",
        "verboseLabel": "Weighted average remaining contractual life"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemainingContractualTermAbstract",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cgen_ShortTermBankDepositsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for short-term bank deposits.",
        "label": "Short Term Bank Deposits Policy Text Block",
        "verboseLabel": "Short-term bank deposits:"
       }
      }
     },
     "localname": "ShortTermBankDepositsPolicyTextBlock",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cgen_ShortTermBankDepositsWeightedAverageRateForeign": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average interest rate for short-term bank deposits outside of the domestic currency.",
        "label": "Short Term Bank Deposits Weighted Average Rate Foreign",
        "terseLabel": "Average interest rate, short-term bank deposits in U.S. dollars"
       }
      }
     },
     "localname": "ShortTermBankDepositsWeightedAverageRateForeign",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "percentItemType"
    },
    "cgen_ShortTermDeferredParticipationInResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short term deferred participation in R&amp;amp;D expenses.",
        "label": "Short Term Deferred Participation In Research And Development Expenses",
        "terseLabel": "Short-term deferred participation in R&amp;D expenses"
       }
      }
     },
     "localname": "ShortTermDeferredParticipationInResearchAndDevelopmentExpenses",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock-based compensation relating to options issued to employees and directors.",
        "label": "Stock Based Compensation Relating To Options Issued To Employees, Directors And Non Employees",
        "terseLabel": "Stock-based compensation relating to options issued to employees, directors and non employees"
       }
      }
     },
     "localname": "StockBasedCompensationRelatingToOptionsIssuedToEmployeesDirectorsAndNonEmployees",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_StockIssuedDuringPeriodValueWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period Value Warrants Exercised",
        "terseLabel": "Warrants exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_SupplementalRightOfUseAssetAndOperatingLeaseLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In right of use asset and operating lease liability.",
        "label": "Supplemental Right Of Use Asset And Operating Lease Liability",
        "terseLabel": "Right-of-use asset obtained in exchange for operating lease liability"
       }
      }
     },
     "localname": "SupplementalRightOfUseAssetAndOperatingLeaseLiability",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cgen_SvbLeerinkLlcAndStifelNicolausAndCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SVB Leerink LLC and Stifel, Nicolaus &amp;amp; Company [Member]",
        "label": "Svb Leerink Llc And Stifel Nicolaus And Company Member",
        "terseLabel": "SVB Leerink LLC and Stifel, Nicolaus &amp; Company [Member]"
       }
      }
     },
     "localname": "SvbLeerinkLlcAndStifelNicolausAndCompanyMember",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "domainItemType"
    },
    "cgen_TaxExemptPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax exempt period.",
        "label": "Tax exempt period"
       }
      }
     },
     "localname": "TaxExemptPeriod",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesEncouragementOfCapitalInvestmentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cgen_TaxRateOnDistributions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax rate for dividends distributed to individuals or foreign residents from the preferred enterprise's earnings.",
        "label": "Tax rate on distributions"
       }
      }
     },
     "localname": "TaxRateOnDistributions",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesEncouragementOfCapitalInvestmentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cgen_TwoThousandAndTwoThousandTenOptionsPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand and Two Thousand Ten Options Plan [Member].",
        "label": "Two Thousand And Two Thousand Ten Options Plan Member",
        "terseLabel": "2000 and 2010 Share Option Plans [Member]"
       }
      }
     },
     "localname": "TwoThousandAndTwoThousandTenOptionsPlanMember",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "domainItemType"
    },
    "cgen_UnderwritersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriters [Member]",
        "label": "Underwriters [Member]"
       }
      }
     },
     "localname": "UnderwritersMember",
     "nsuri": "http://cgen.com/20221231",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "domainItemType"
    },
    "country_IL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Israel [Member]"
       }
      }
     },
     "localname": "IL",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unites States [Member]"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r407",
      "r408",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm Id"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r407",
      "r408",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r407",
      "r408",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_BusinessContactMember": {
     "auth_ref": [
      "r408",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business contact for the entity",
        "label": "Business Contact [Member]"
       }
      }
     },
     "localname": "BusinessContactMember",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelEmailAddress": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Email address of contact personnel.",
        "label": "Contact Personnel Email Address"
       }
      }
     },
     "localname": "ContactPersonnelEmailAddress",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelFaxNumber": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fax Number of contact personnel.",
        "label": "Contact Personnel Fax Number"
       }
      }
     },
     "localname": "ContactPersonnelFaxNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of contact personnel",
        "label": "Contact Personnel Name"
       }
      }
     },
     "localname": "ContactPersonnelName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r407",
      "r408",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses Address Type [Axis]",
        "verboseLabel": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r407",
      "r408",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Name of Exchange on which Security is Registered"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cgen.com/role/cgen-daei1"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r219",
      "r396",
      "r439",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r259",
      "r366",
      "r375",
      "r387",
      "r388",
      "r395",
      "r397",
      "r402",
      "r438",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails",
      "http://cgen.com/role/IncomeTaxesNarrativeDetails",
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r259",
      "r366",
      "r375",
      "r387",
      "r388",
      "r395",
      "r397",
      "r402",
      "r438",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails",
      "http://cgen.com/role/IncomeTaxesNarrativeDetails",
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r219",
      "r396",
      "r439",
      "r489"
     ],
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r258",
      "r259",
      "r288",
      "r289",
      "r290",
      "r365",
      "r366",
      "r375",
      "r387",
      "r388",
      "r395",
      "r397",
      "r402",
      "r434",
      "r438",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "verboseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails",
      "http://cgen.com/role/IncomeTaxesNarrativeDetails",
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r233",
      "r258",
      "r259",
      "r288",
      "r289",
      "r290",
      "r365",
      "r366",
      "r375",
      "r387",
      "r388",
      "r395",
      "r397",
      "r402",
      "r434",
      "r438",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails",
      "http://cgen.com/role/IncomeTaxesNarrativeDetails",
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r176",
      "r260",
      "r414",
      "r428"
     ],
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r176",
      "r260",
      "r414",
      "r415",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r432",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-oapaae"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r14",
      "r401"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Trade payables"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r66",
      "r138"
     ],
     "calculation": {
      "http://cgen.com/role/cgen-paend": {
       "order": 10.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails",
      "http://cgen.com/role/cgen-paend"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r8"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r294",
      "r295",
      "r296",
      "r425",
      "r426",
      "r427",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional paid-in capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r43",
      "r63"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization in R&amp;D expenses"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments required to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r292"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Stock-based compensation expenses"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sesosced"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Weighted average number of shares related to outstanding options excluded from the calculations of diluted net loss per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r113",
      "r121",
      "r139",
      "r158",
      "r202",
      "r206",
      "r211",
      "r222",
      "r234",
      "r235",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r243",
      "r244",
      "r322",
      "r324",
      "r330",
      "r401",
      "r436",
      "r437",
      "r480"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r134",
      "r142",
      "r158",
      "r222",
      "r234",
      "r235",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r243",
      "r244",
      "r322",
      "r324",
      "r330",
      "r401",
      "r436",
      "r437",
      "r480"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r158",
      "r222",
      "r234",
      "r235",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r243",
      "r244",
      "r322",
      "r324",
      "r330",
      "r436",
      "r437",
      "r480"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non- current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NON-CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r263",
      "r264",
      "r265",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails",
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessDevelopment": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "order": 10.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business development involves the development of products and services, their delivery, design and their implementation. Business development includes a number of techniques designed to grow an economic enterprise. Such techniques include, but are not limited to, assessments of marketing opportunities and target markets, intelligence gathering on customers and competitors, generating leads for possible sales, follow-up sales activity, formal proposal writing and business model design. Business development involves evaluating a business and then realizing its full potential, using such tools as marketing, sales, information management and customer service.",
        "label": "Marketing and business development expenses"
       }
      }
     },
     "localname": "BusinessDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r48",
      "r49",
      "r50"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Purchase of property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r45",
      "r136",
      "r389"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents",
        "periodEndLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets",
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash equivalents:"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r46",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Restricted cash:"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r39",
      "r45",
      "r51"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents and restricted cash at the end of the year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at the beginning of the year",
        "verboseLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of cash, cash equivalents and restricted cash:"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r39",
      "r109"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Exercise price of warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Warrants purchase to ordinary shares"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Warrants purchase to ordinary shares remain outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r17",
      "r116",
      "r126"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "COMMITMENTS AND CONTINGENT LIABILITIES"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r70",
      "r228",
      "r229",
      "r383",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-cac1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r425",
      "r426",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Ordinary shares [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Ordinary shares, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-cbsp",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Ordinary shares, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-cbsp",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Ordinary shares, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-cbsp"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r7",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Ordinary shares, shares outstanding",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity",
      "http://cgen.com/role/cgen-cbsp"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r7",
      "r401"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Share capital: Ordinary shares of NIS 0.01 par value: 200,000,000 shares authorized at December 31, 2021 and 2020; 86,433,432 and 83,675,856 shares issued and outstanding at December 31, 2021 and 2020, respectively",
        "terseLabel": "Ordinary shares of NIS 0.01 par value: 200,000,000 shares authorized at December 31, 2022 and 2021; 86,624,643 and 86,433,432 shares issued and outstanding at December 31, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r23",
      "r146",
      "r148",
      "r154",
      "r368",
      "r372"
     ],
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive income (loss):"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computers, software and related equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-paend",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r56",
      "r57",
      "r107",
      "r108",
      "r219",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r56",
      "r57",
      "r107",
      "r108",
      "r219",
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r56",
      "r57",
      "r107",
      "r108",
      "r219",
      "r382",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r120",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration of credit risks:"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r56",
      "r57",
      "r107",
      "r108",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Sales to a single customer exceeding 10%"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r56",
      "r57",
      "r107",
      "r108",
      "r219",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r93",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Basis of consolidation:"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r30",
      "r158",
      "r222",
      "r234",
      "r235",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r243",
      "r244",
      "r330",
      "r436"
     ],
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "order": 10.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesRelatedParty": {
     "auth_ref": [
      "r30"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs of sales and operating expenses for the period incurred from transactions with related parties.",
        "label": "Amounts charged to research and development expenses"
       }
      }
     },
     "localname": "CostsAndExpensesRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/RelatedPartyBalancesAndTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r55",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [
      "r417"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred revenues"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r306"
     ],
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred tax asset before valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r469"
     ],
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r92",
      "r470"
     ],
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 20.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Operating loss carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r91",
      "r92",
      "r470"
     ],
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Research and development"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "auth_ref": [
      "r92",
      "r470"
     ],
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.",
        "label": "Accrued social benefits and other"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r307"
     ],
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r43",
      "r64"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows",
      "http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeNet": {
     "auth_ref": [
      "r329"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives.",
        "label": "Fair value of outstanding forward contracts"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r475"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Net gain on derivative transactions"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting": {
     "auth_ref": [
      "r100",
      "r103"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of gains on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness.",
        "label": "Net gain on derivative recorded as financial and other income, net for the ineffective portion"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTesting",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r473",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r99",
      "r101",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivative instruments:"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r115",
      "r128",
      "r236",
      "r237",
      "r238",
      "r242",
      "r243",
      "r244",
      "r359",
      "r424"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Trade payables and accrued expenses"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/RelatedPartyBalancesAndTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r155",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r177",
      "r179",
      "r181",
      "r182",
      "r183",
      "r187",
      "r327",
      "r328",
      "r369",
      "r373",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Basic net loss per share",
        "terseLabel": "Basic loss per ordinary share"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails",
      "http://cgen.com/role/cgen-csocl"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r155",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r179",
      "r181",
      "r182",
      "r183",
      "r187",
      "r327",
      "r328",
      "r369",
      "r373",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails",
      "http://cgen.com/role/cgen-csocl"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r53",
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Basic and diluted loss per share:"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "LOSSES PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-lps"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r160",
      "r302",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Israeli corporate tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r468",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "U.S. income state and local taxes rate (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://cgen.com/role/cgen-oapaaed": {
       "order": 0.0,
       "parentTag": "us-gaap_OtherAccountsPayableAndAccruedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employees and related accruals"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-oapaaed"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sesosced"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Unrecognized share-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Unrecognized compensation cost, recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r72",
      "r132",
      "r150",
      "r151",
      "r152",
      "r163",
      "r164",
      "r165",
      "r167",
      "r173",
      "r175",
      "r189",
      "r223",
      "r246",
      "r294",
      "r295",
      "r296",
      "r311",
      "r312",
      "r326",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r342",
      "r356",
      "r376",
      "r377",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "auth_ref": [
      "r13"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting.",
        "label": "Investment amount",
        "verboseLabel": "Equity investment"
       }
      }
     },
     "localname": "EquityMethodInvestmentAggregateCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r105",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair value of financial instruments:"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r335"
     ],
     "calculation": {
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails": {
       "order": 20.0,
       "parentTag": "cgen_FinancialIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign currency translation adjustments",
        "terseLabel": "Foreign currency transaction adjustments"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Financial statements in U.S. dollars:"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainLossOnSaleOfOtherAssets": {
     "auth_ref": [
      "r421"
     ],
     "calculation": {
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails": {
       "order": 30.0,
       "parentTag": "cgen_FinancialIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of other assets.",
        "label": "Gain (loss) from sales and disposals of fixed assets"
       }
      }
     },
     "localname": "GainLossOnSaleOfOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 40.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss (gain) from property and equipment sales and disposals"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "order": 20.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and administrative expenses [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sesosced"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r29",
      "r158",
      "r202",
      "r205",
      "r210",
      "r213",
      "r222",
      "r234",
      "r235",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r243",
      "r244",
      "r330",
      "r394",
      "r436"
     ],
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GuaranteeObligationsMaximumExposure": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.",
        "label": "Bank guarantees in favor of lessor, foreign currency derivative contracts and credit card security"
       }
      }
     },
     "localname": "GuaranteeObligationsMaximumExposure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfInvestments": {
     "auth_ref": [
      "r221"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.",
        "label": "Marketable securities impairment losses"
       }
      }
     },
     "localname": "ImpairmentOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r159",
      "r315"
     ],
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "negatedLabel": "Domestic (Israel)",
        "verboseLabel": "Domestic (Israel)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r24",
      "r111",
      "r118",
      "r130",
      "r202",
      "r205",
      "r210",
      "r213",
      "r370",
      "r394"
     ],
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://cgen.com/role/cgen-csocl": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "negatedTotalLabel": "Loss before taxes on income",
        "totalLabel": "Loss before taxes on income"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails",
      "http://cgen.com/role/cgen-csocl"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r159",
      "r315"
     ],
     "calculation": {
      "http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "negatedLabel": "Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesScheduleOfLossBeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r226",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sesosced"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sesosced"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r160",
      "r303",
      "r304",
      "r309",
      "r313",
      "r317",
      "r319",
      "r320",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-it"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r161",
      "r174",
      "r175",
      "r201",
      "r301",
      "r314",
      "r318",
      "r374"
     ],
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "order": 10.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Taxes on income",
        "terseLabel": "Taxes on income"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r149",
      "r299",
      "r300",
      "r304",
      "r305",
      "r308",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income taxes:"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r40",
      "r47"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Tax payment withheld"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 120.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.",
        "label": "Increase (Decrease) in Accounts and Other Receivables",
        "negatedLabel": "Decrease (increase) in trade receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsAndOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 80.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (decrease) in trade payables and other accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 60.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Decrease (increase) in other accounts receivable and prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 110.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Decrease in operating lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 70.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Decrease (increase) in long-term prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InitialOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of the time period when the company made its initial offering of a class of securities.",
        "label": "Offering period"
       }
      }
     },
     "localname": "InitialOfferingPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestAndDebtExpense": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails": {
       "order": 10.0,
       "parentTag": "cgen_FinancialIncomeExpenseNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest and debt related expenses associated with nonoperating financing activities of the entity.",
        "label": "Interest and Debt Expense",
        "negatedLabel": "Bank fees and other finance expenses"
       }
      }
     },
     "localname": "InterestAndDebtExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "United States [Member]"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r33",
      "r200"
     ],
     "calculation": {
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails": {
       "order": 0.0,
       "parentTag": "cgen_FinancialIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/FinancialAndOtherIncomeNetScheduleOfFinancialAndOtherIncomeNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedUnderlyingFaceAmountAtMarketValue": {
     "auth_ref": [
      "r95",
      "r102"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount on the investment owned.",
        "label": "Amount of investment in Compugen"
       }
      }
     },
     "localname": "InvestmentOwnedUnderlyingFaceAmountAtMarketValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-gd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-paend",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Disclosure [Abstract]",
        "verboseLabel": "Lessee Disclosure [Abstract]"
       }
      }
     },
     "localname": "LesseeDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "verboseLabel": "Leases:"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Schedule of Operating Leases",
        "terseLabel": "Schedule of operating leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r354"
     ],
     "calculation": {
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r354"
     ],
     "calculation": {
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r354"
     ],
     "calculation": {
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails": {
       "order": 30.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r354"
     ],
     "calculation": {
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails": {
       "order": 20.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r354"
     ],
     "calculation": {
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r354"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Period of options to extend leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/LEASESNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r12",
      "r114",
      "r124",
      "r401",
      "r422",
      "r433",
      "r477"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r16",
      "r135",
      "r158",
      "r222",
      "r234",
      "r235",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r243",
      "r244",
      "r323",
      "r324",
      "r325",
      "r330",
      "r401",
      "r436",
      "r480",
      "r481"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r158",
      "r222",
      "r234",
      "r235",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r243",
      "r244",
      "r323",
      "r324",
      "r325",
      "r330",
      "r436",
      "r480",
      "r481"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NON- CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r156"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r156"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r39",
      "r41",
      "r44"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedLabel": "Net cash used in operating activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r25",
      "r44",
      "r119",
      "r129",
      "r133",
      "r145",
      "r147",
      "r152",
      "r158",
      "r166",
      "r168",
      "r169",
      "r170",
      "r171",
      "r174",
      "r175",
      "r180",
      "r202",
      "r205",
      "r210",
      "r213",
      "r222",
      "r234",
      "r235",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r243",
      "r244",
      "r328",
      "r330",
      "r394",
      "r436"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://cgen.com/role/cgen-csocl": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "negatedLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss for basic and diluted loss per share"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows",
      "http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails",
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity",
      "http://cgen.com/role/cgen-csocl"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recently issued and recently adopted Accounting Standards:"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncurrentAssets": {
     "auth_ref": [
      "r217"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.",
        "label": "Long-lived assets"
       }
      }
     },
     "localname": "NoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "order": 10.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r202",
      "r205",
      "r210",
      "r213",
      "r394"
     ],
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r346"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease Liability",
        "terseLabel": "Present value of lease liabilities",
        "verboseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r346"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 30.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Current maturity of operating lease liability",
        "verboseLabel": "Lease liabilities, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets",
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r346"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Long-term operating lease liability",
        "verboseLabel": "Lease liabilities, non- current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets",
      "http://cgen.com/role/LeasesScheduleOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r347",
      "r351"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/LEASESNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r345"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 30.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating lease right of use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r353",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Weighted average discount (annual) rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/LeasesScheduleOfWeighted-averageRemainingLeaseTermAndDiscountRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r352",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/LeasesScheduleOfWeighted-averageRemainingLeaseTermAndDiscountRateDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r91"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Net operating loss carryforward"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsExpirationDate": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of each operating loss carryforward included in operating loss carryforward, in YYYY-MM-DD format.",
        "label": "Year of expiration of operating loss carryforward"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "GENERAL"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-g"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://cgen.com/role/cgen-oapaaed": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.",
        "label": "Other accounts payable and accrued expenses",
        "totalLabel": "Other accounts payable and accrued expenses"
       }
      }
     },
     "localname": "OtherAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets",
      "http://cgen.com/role/cgen-oapaaed"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://cgen.com/role/cgen-oapaaed": {
       "order": 10.0,
       "parentTag": "us-gaap_OtherAccountsPayableAndAccruedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-oapaaed"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r141",
      "r401"
     ],
     "calculation": {
      "http://cgen.com/role/cgen-oaraped": {
       "order": 20.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-oaraped"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "auth_ref": [
      "r19",
      "r22",
      "r334",
      "r341"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Foreign Currency Translation income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/LEASESNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r20",
      "r21",
      "r104"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).",
        "label": "Net gain on derivative classified to operating expenses as effective portion"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r143",
      "r144"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Unrealized gain (loss) arising from derivative contracts"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "auth_ref": [
      "r75",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.",
        "label": "FINANCIAL AND OTHER INCOME, NET"
       }
      }
     },
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-faoin"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherShortTermInvestments": {
     "auth_ref": [
      "r117",
      "r127",
      "r418"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term investments classified as other.",
        "label": "Short-term bank deposits",
        "verboseLabel": "Short-term bank deposits"
       }
      }
     },
     "localname": "OtherShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Issuance expense",
        "verboseLabel": "Issuance expenses"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Investment in short-term bank deposits"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PostemploymentBenefitsLiabilityNoncurrent": {
     "auth_ref": [
      "r440",
      "r441"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For a classified balance sheet, the carrying amount as of the balance sheet date of the portion of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement that is payable after one year (or beyond the operating cycle if longer).",
        "label": "Accrued severance pay"
       }
      }
     },
     "localname": "PostemploymentBenefitsLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r419"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 30.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://cgen.com/role/cgen-oaraped": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Other accounts receivable and prepaid expenses",
        "totalLabel": "Other accounts receivable and prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets",
      "http://cgen.com/role/cgen-oaraped"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r140",
      "r224",
      "r225",
      "r390"
     ],
     "calculation": {
      "http://cgen.com/role/cgen-oaraped": {
       "order": 0.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-oaraped"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "auth_ref": [
      "r416"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.",
        "label": "Long-term prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIncomeTaxRefunds": {
     "auth_ref": [
      "r41",
      "r47"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash received during the period as refunds for the overpayment of taxes.",
        "label": "Tax receivables refunded"
       }
      }
     },
     "localname": "ProceedsFromIncomeTaxRefunds",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from ordinary shares in offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from issuance of ordinary shares, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from maturity of short-term bank deposits"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r37",
      "r82"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from exercise of stock-based awards"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r420"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from exercise of warrants",
        "verboseLabel": "Proceeds from warrant exercised"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "verboseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails",
      "http://cgen.com/role/cgen-paend",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r69",
      "r384",
      "r385",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "PROPERTY AND EQUIPMENT, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-paen"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisposals": {
     "auth_ref": [],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 30.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Disposals",
        "negatedLabel": "Costs of disposal of property and equipment",
        "verboseLabel": "Costs of disposal of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisposals",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r65",
      "r137"
     ],
     "calculation": {
      "http://cgen.com/role/cgen-paend": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails",
      "http://cgen.com/role/cgen-paend"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentImpairment": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment.",
        "label": "Impairment of long-lived assets:"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentImpairment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails",
      "http://cgen.com/role/cgen-paend",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r67",
      "r125",
      "r371",
      "r401"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://cgen.com/role/cgen-paend": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net",
        "totalLabel": "Depreciated cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets",
      "http://cgen.com/role/cgen-paend"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r67",
      "r384",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property and equipment, net:"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule of Property And Equipment, Net",
        "terseLabel": "Schedule of property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-paent"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails",
      "http://cgen.com/role/cgen-paend",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r357",
      "r358",
      "r359",
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "RELATED PARTY BALANCES AND TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-rpbat"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "auth_ref": [
      "r87",
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Upfront payment received"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-gd",
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r86",
      "r131",
      "r488"
     ],
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development expenses, net"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-csocl"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and development expenses [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sesosced"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and development expenses, net:"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r45",
      "r51",
      "r112",
      "r122",
      "r136"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "periodEndLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r45",
      "r51",
      "r136"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r9",
      "r73",
      "r123",
      "r379",
      "r380",
      "r401"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r132",
      "r163",
      "r164",
      "r165",
      "r167",
      "r173",
      "r175",
      "r223",
      "r294",
      "r295",
      "r296",
      "r311",
      "r312",
      "r326",
      "r376",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r198",
      "r199",
      "r204",
      "r208",
      "r209",
      "r215",
      "r216",
      "r219",
      "r255",
      "r256",
      "r367"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue recognition under milestone method"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r257",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue recognition:"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r153",
      "r158",
      "r198",
      "r199",
      "r204",
      "r208",
      "r209",
      "r215",
      "r216",
      "r219",
      "r222",
      "r234",
      "r235",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r243",
      "r244",
      "r330",
      "r370",
      "r436"
     ],
     "calculation": {
      "http://cgen.com/role/cgen-csocl": {
       "order": 0.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenue",
        "verboseLabel": "Revenue from sales to customers"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails",
      "http://cgen.com/role/cgen-csocl"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r31"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty expense"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r219",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue [Member]"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/GeographicInformationAndMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Other Accounts Payable and Accrued Expenses",
        "terseLabel": "Schedule of other accounts payable and accrued expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-oapaaet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Schedule of Stock-Based Compensation Expenses",
        "terseLabel": "Schedule of stock-based compensation expenses"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-set1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Summary Of Deferred Tax Assets And Liabilities",
        "terseLabel": "Schedule of deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-itt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of computation of basic and diluted losses per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-lpst"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r80",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sesosced"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule Of Loss Before Taxes",
        "terseLabel": "Schedule of loss before taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-itt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other current assets.",
        "label": "Schedule Of Other Accounts Receivable And Prepaid Expenses",
        "terseLabel": "Schedule of other accounts receivable and prepaid expenses"
       }
      }
     },
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-oarapet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Financial and Other Income, Net",
        "terseLabel": "Schedule of financial and other income, net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-faoint"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails",
      "http://cgen.com/role/cgen-paend",
      "http://cgen.com/role/cgen-sapsodrfpaed"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.",
        "label": "Schedule of Related Party Balances and Transactions",
        "terseLabel": "Schedule of related party balances and transactions"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/RelatedPartyBalancesAndTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.",
        "label": "Sales To A Single Customer Exceeding 10%:",
        "terseLabel": "Schedule of sales to single customer xxceeding 10%:a"
       }
      }
     },
     "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-giamct"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": {
     "auth_ref": [
      "r28",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Total Revenues And Long-Lived Assets By Geographic Area",
        "terseLabel": "Schedule of total revenues and long-lived assets by geographic area"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-giamct"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails",
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r76",
      "r77",
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Option Activity",
        "terseLabel": "Schedule of option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-set1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r202",
      "r203",
      "r207",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r218",
      "r219",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "GEOGRAPHIC INFORMATION AND MAJOR CUSTOMERS"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-giamc"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling and marketing expense.",
        "label": "Marketing and business development expenses [Member]"
       }
      }
     },
     "localname": "SellingAndMarketingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sesosced"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r43"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance expenses"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails",
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Ordinary shares reserved for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Ordinary shares available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Exercisable at end of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r282"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Total intrinsic value of options exercised during the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Options forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Weighted average fair value of stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r81"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Options outstanding at end of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r267",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding at end of year",
        "periodStartLabel": "Options outstanding at beginning of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Number of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r267",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding at end of year",
        "periodStartLabel": "Options outstanding at beginning of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Exercisable at end of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Options vested and expected to vest at end of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "verboseLabel": "Options vested and expected to vest at end of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Maximum percentage of total shares of common stock outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r263",
      "r264",
      "r265",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails",
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Options forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Options expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r266",
      "r285",
      "r286",
      "r287",
      "r288",
      "r291",
      "r297",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Stock-based compensation:"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Aggregate intrinsic value of exercised options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/SignificantAccountingPoliciesScheduleOfWeighted-averageAssumptionsForGrantedOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r81"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Exercisable at end of year"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Exercisable at end of year"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r74",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).",
        "label": "SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-se12"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Offering price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r52",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sap"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r18",
      "r72",
      "r132",
      "r150",
      "r151",
      "r152",
      "r163",
      "r164",
      "r165",
      "r167",
      "r173",
      "r175",
      "r189",
      "r223",
      "r246",
      "r294",
      "r295",
      "r296",
      "r311",
      "r312",
      "r326",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r342",
      "r356",
      "r376",
      "r377",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails",
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity",
      "http://cgen.com/role/cgen-daei1",
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r189",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/IncomeTaxesNarrativeDetails",
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity",
      "http://cgen.com/role/cgen-daei1",
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r6",
      "r7",
      "r72",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Exercise of options and ESPP shares, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r6",
      "r7",
      "r72",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Issuance of shares, net, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity",
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r6",
      "r7",
      "r72",
      "r73",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Options exercised, shares",
        "negatedLabel": "Options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ShareholdersEquityScheduleOfOptionActivityDetails",
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r6",
      "r7",
      "r72",
      "r73"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Exercise of options and ESPP shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r6",
      "r7",
      "r72",
      "r73"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Issuance of shares, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r18",
      "r72",
      "r73"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Options [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sapnd"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r7",
      "r10",
      "r11",
      "r62",
      "r401",
      "r422",
      "r433",
      "r477"
     ],
     "calculation": {
      "http://cgen.com/role/ConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets",
      "http://cgen.com/role/StatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHAREHOLDERS' EQUITY:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r350",
      "r400"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/LEASESNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r343",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r343",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r343",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r343",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r362",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/SUBSEQUENTEVENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid (received) during the year for:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/SubsequentEventsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r58",
      "r59",
      "r60",
      "r190",
      "r191",
      "r193",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of estimates:"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sapp"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/cgen-sesopnd"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r178",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average number of ordinary shares used in computing diluted net loss per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails",
      "http://cgen.com/role/cgen-csocl"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r177",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of ordinary shares used in computing basic net loss per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cgen.com/role/LossesPerShareScheduleOfComputationOfBasicAndDilutedLossesPerShareDetails",
      "http://cgen.com/role/cgen-csocl"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "10",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=6438156&loc=d3e57880-113973",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121558989&loc=d3e80720-113993",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.5)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(6))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30755-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r403": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r404": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r405": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r406": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r407": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r408": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r409": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r411": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r412": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r413": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410138&loc=d3e79691-111665",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410138&loc=d3e79708-111665",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "610",
   "URI": "https://asc.fasb.org/topic&trid=49130413",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "720",
   "URI": "https://asc.fasb.org/topic&trid=2122503",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "10",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=6431724&loc=d3e32938-113948",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>77
<FILENAME>0001178913-23-000772-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001178913-23-000772-xbrl.zip
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MIL1\Q]&:%'$;10:;Z21EU46!&P>)_[H!Q@HLXWD$4X/K<_J5=Z[M"W@OT$]
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MU'RI3U#F\)6\8!IR%SB,HPFATK*%TL;M/#FG.OXEP]W^CJ^:4@H-1KDVV.!
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MWN OM(7FM'8N#,+X & 0^_)0UMH[ET;@G.$1!:"1)LZ'3J$9X7G\C RANV"
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M^Y#R$=K&TMEY8U+@I!QJY?"[_NP0PJJ9C=;OK9]3;EB@<=50RNK$!E<"-7'
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M-?<>C8BO.)9W@#^+R2>3=[DL",J%?7LG;NU-M',J'LQE80UB>::^YV2_X[I
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M=5W,QG+/D.VJJ;(R?R;&JZ]D3R,@,E_0I?OJ<5X0/'R.4QBO^2^?]2:M8$+
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M2J_3^;.FM%W'SQK24RQBO:J2,;F+HWL:QZ'VZ&GZ #!#.L@\,$,ZQ#PP0SJ
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MH0"XZK2A)Z)J!SAM6Q@'XNR:I\L93MM6P*$X;>ML12$F^'NXQG5#&I5TRQ&
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M48?*!]MVYU#Y8-L:A;/#,DVHI<B,QLFZR L_">4%J]MT RIL6YB]4-$U_^9
MJ;#O1=P1]_:+IZDK4&/?@]@G-2_->UB3K.NUXF58;]\"?KTTSZ%K?KTTKZ%K
M?KTTCV&-AIU,6L+?<P,[D.[<8@D!\-:Z9_%?B+?6?9C_0KRU;<M20^XAC4.2
MY6@M2'.EJ!O/WW?-YSL Q+9MU.,1V[9#CT=L)CG 5H3@:%&0;!3^?<VBG2:+
MLP=<?N/DTH\RZO&:+.3I]##U.P;#5NNU*4]M[Q\&%IE)9?.'9M$Q%F5.@A_N
MT\<?Z;.8;,/$GO^CDGC^@_GX2D9G^4O <HRUU@W+UUL-EJ^W@.48ZT9@"4G$
M<,!?*@SPC_D(9B&DX4$D#[*(JC )(E53P'>,A= !WV7LRUP5>VT T3%ZM06B
M=1C!&)=1MAS++E#WVLS?=\TW>QBB*QQ*,WW;K0#5,;JQ-:IK?RFSMG9: )IC
M]%XSFM-U'B4DS_&6#/8;9?8995M >(Q/I1GA&2A3+!YTEH8JAM6; )YC?!8M
M\##J;T#3ITE"XHNE'\6C,,R(--"_J0O@-;'#M\=[Z3\K3_K:]H#4Q/[?'JEF
MB<B: KY^=<(9*YMS&>6!'_\&>OP"M+B\*IZN.>#L5S><I\&:&A'L.2Q8%K=X
M\(*CF *IN@-@[5=KE)].DK4?L[IA32AK3>?ONV8'/1 ?FT46ZW,)/U,M=65[
M0-JO7MG^,LI;>YQE:T#9K[X1WV6<T2\@:5M V*^^$5^=DGM,44B- E@.!5$\
M;VCL XC[U4CBZ[</)(YYOLU6*VF_ V#M5QN)3\_@J)-'+"UV"Z2[S0%GO[JH
M_#",V(0-F@">?G7/!6S+8.0PFX'_<076V%L%.&5[0-JO]E%]^5U'I.\ :;^Z
M1_7E]QV1OI^_[YH#]!BD:.U.LEGZI#K1*%H#RGXUT/9WV5F]%41^K'_?-:?G
M,?B(F$%<OHKZL,V= '._VJ@?S/WJHZW/WZ1YX<?_)UIISF_J#H"U7WW$/GU&
ML))6/$Y"\OR?1"^T.VT!8;^:B'^U6Z1*NXZ W8;6X@>ALB@P6D9*PU37!?#:
MT%T72Y+=8_'B+'TJ'KA]I(4K[0%H;>BOB^?*.%(^8=$UG[\_*KME6YR744RT
MCH?=9H#+AK["#V9G8*O?IPWJ:JLEH+.AK?!Z(8-%4!TIN+9LW$ZU/0&]#;U%
MP^9]FBD!SF[^F;)2<5,7P&M#9XGS6U)H?$^RIH#/AIZJ']BTZ.H- 9L-#?5K
M&H-X^1E;)OKM?:<M(+2AA[X!3_XS 4OXEOAYFI"0/N/2;T>*/H"X7TTT#A89
MOP<8%04!C8W+6'/9H^X 6/O50WAU$M\\ '>T^_MNL_G[HS(.-N/BB1LK$X*Z
M-/%UCQ9G4S? W:]>NB7!.@/9>_ON;A85TAR(LF: JU^-)#YX\1S0FVW-'BEK
M"OCZU3E@V*!5>[M9WJ6Q MA6&T!D)+XUSXI:1 G\J\(%_YB+LF[*R[7]1H#,
M2"1I [*+-6;%T.*J-P%41N(U&U!]\?^>9F?KO$C!K,X5YUQY0T!H).JQ$>%S
MM%POM8S;:@.XC$0,-N&*DF9<]3: RTBT70.N*>X!FHDL?S]_;R:CG$$\1B+E
M&O"4=P6W 4E\.)1IL$G; DXC\7$-.*F>F2S&21@]1N':CS4XI6T!I^T7&-6E
M)BV6'9%<$]75W DHL/TF0J0UOO$WF-,8_IFM22AJ\2$VGO^V]J/S* _B-%]G
MA)^@=/7%^_D0<,KV:X@= M3G37T'0&[[7<)6JJ,5F (1M=_A[S&A<=9).%JB
M1?I/^O-#\J^9^@1PQ_;+@E$84H<5G!_\*!PG9_XJ*ORXYMO4T=W8&2BR'<^O
M *74W*WZ 1VV8^>K>-=+.'C6Q$=+@Z+/_+WUG'(5EGR63DF0)@$Z(.MQO;.T
M97KA-GJEA\\!UVQ'\V-5LP W$OFCD.8LXNT& ,IL1_V/0.F'4;Q&_R,_Q$:8
M'B2(US ;+)_(<K5FWI7)0F2JNR$9I02D>:W?A$V,#WRQ;D4=A_MT(Q] 83]:
M^"KPT+H=5\7W\PKO?O43>BN#?N\T4=> /' DH-6Z)=:46IEG3GYO/6=<>V36
MK1SZX39:9*LA(+5NO5  +<SK>CO :=TZ.0CG!^NYQK:^WUH =MH#;NMV ,6!
MJ;):LKAJ"FBMZ_:CT%K7N#L06HO%?A= ;UW7X<M?39B2M!W@M*VGQ)N6VFL\
M#5I):\!L/Z,4/?-1(SD4^43IE(>GZ^(Z+7XC!9X.-82T'0*H<Y$G:C]U"W7#
M;=HXL5KU![JLYWV2XFI*6<-P=R:WW;# !>MYHX[)UM5B"S0R_OR#_4Q4Q^!F
M<5R[U=+8,0G.0^(2=@H'[HO%@O3'P,Y @-.V;99_74Z[R%QZ&:=/:)# 7UF1
M%G1A)>%EE/A)L.7.JBX26B[S8X8&;EC/=QK[>3Y9?*,G]6*233$'RE;JD_*7
M.?]M+GO=<=1X0+?U?*@RG"R29K*H?#)G?ARCNW,7<E<.M!\9>&$])ZH,<<N<
M@PU=@1KK=FBZ7$:%<$*Q/,OW) GTY?HTO8 &Z]:F&DVW#:G+.$"GBZRCC?A:
MF=>=!@)*'68F;?2C[K6=?[">RZF&X<;/)AF-[PAIOACAQVY'@:HWT&3=QK)
MDW5K9O<AS6A=/*19]$]MN0A-+Z#!N@VRBX85LNB"G_4 [-;MB I)8VKXG::
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M6U,JD#1[B_0=@1+;6K0_2ISITVU K;PRC7V!'F?ZMB=ZG.ECBDE<U+4F0G0
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M]DV6!H2$.99AJK+HD\4ZT?J1==V "NN:NPZ'[_H\'\_-^BZ. I&5IRU)NC&
M/NM:78)MLL"C/A8XT%N]C7WG'ZWGIJQCPIRK(BD"[$5G:1P3EEZV;?[$ T8#
MFJU; SLH)POXR8IDQ08- "ST5%:*[T"K9A2@T;HMX8!&^_9$#5V5.SZ_>"99
M$.7:B@R-?8$>^[9$A>F;GV%&50&G[:+;[094V+<>^J#"OBVAD/,VY]"FOD"/
M ^M"CNET,X//-AV,FGL#30YLC=YI<F!?R%%U<[!U&6;^T7J^3B6\I@KD^HY
MB0-;0@ZH2B5]"#E5;Z#)@>T@1]7FVJZY,U#DP%*0@](7'=9U RH<V <]4.'
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MMK&N0P&UMO5\6XBG6/'! *ET'*#3MDW@BLZ:[8"#;5$*/=)U5H4O9&E,&*E
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M=R)R23J9-&IQ(<)MV"I=1 E]5^1V_J0DR.>'QR*R3,YW97B9PQFX)L69GS_
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M^J.8]W6CN]$+Y\>3Q0*LC.1>4UY+-''HL*.UCQ(L4$UC<;F#<SR]U=CC7X%
M$!ZJZMQ:WI5I)*)ZL)R&TL7%?LFO6]SBG3PE)/R:@"$:;T "+OV YTL=%<R>
M4S]&Y5<$8-]6GBY<!/1AU3UQ$BQTA<ON(8U#,%RS])%Y!C0B5+9'.[7LX%26
MKK"^)FEI;[#&]FR-EIY3)0VR$Y]M&MI- )6,5LXHUO[$8SV\O[$^'G;R:"_W
M,R$G1CX9V-*)<<*@5GH7D0CEN_GB%_00/$/;03\?M\$#"=>LTD05$,X(<^;;
M/80X:9&2&G$[UH83ZTE+%[]SSL\5&D2LG)U9@J4D1CC!%V1WQ,-S@#.756L:
MU6^]=PU#?G09])1=@R#.GDC\2+ZD2?$@MWZ[3>&)]QOQL[ZJU!^_$'74RR;W
MW9MW[X<\A<CM2_BZN:G#T08_=R79BCG[-/0YFSUDQ,26R2>-#O<B9HT1KIBV
MCX.?MJ?4X*0]I2]CRH!HQ81]&-R$P4D7CAEX;L47:P$TU3PFP9'^C =#&HT;
M\6/[4&AB03ZS].*Y((DBJ33+*4M-15:0!*2,T/8#,QGSAB/6Q<A1B;'M<FHT
MO K=!;"(6)2/'&[5B;HY65-W]FL3#6J[-=ZAA 9%\LY_HBERW/@VFTC2.TVJ
M!)PTJR.-5?_+Y.K\8GK[)^_B?W\=SWYS3)0NEKG6S'T]#PGFYJ(>-:D:!I];
ME?>HB8T;_T@%N^$-VY:$#*#:AQRYON3'\&2E0^T/;R@R<TT*664\29IQY6MB
MFJI>#.#=;;Q77UG!N^^]<ABO&L>9D'4@594$@R9)7]5(E:5('_8TZG<RI&\1
MIT\Y"S8<3 9X!7U59ORCQ+0<9L!B*B.UM9B^6@M2:QG^ARBP$BH[":R,O"$)
M;->*H[OT#::$Z#5YJM7'SM($_AJ0VLN!-A=C4X*O!.--/7MM)G[FAW FA1_6
MZFK?8D82?++DAN1*O:OCM:_2Y/YU'#TZ#<86)21*:;LE]^JPS.NRI&DE73GO
MX )]B5HD%6S(Y'318VQ0JQU['W";>QZ7(4U[B+6;T&0/LY/U5\*HRCHWP-U*
M$.U>/&JXI7G$MW*3.>7PMD^T@<NT<>6I=N:35J&7\?H&DX["X;%\Q;8=CM>3
M4=0R)$-%R+O!$'*@(.F<5OQWWI*'.DCB%_J-ECQN<G2^K:O=*3GQ>G2X'#@W
M31XCM&M@&2Y?TJ0T^)(D\U*O)>M^<L1%6IL-^$0D<!C @F>UO19PY*&6<E,F
M3CH-&?;!10]'57?Y1;?I^$80% E'((;^/0U7Q*,(9E+A6='E5<MX-\]G_3QQ
MI>B]\I-D[<??.TL+HZ5O2@NIB5_.8+'+,SSLT9>)CGPN<9]P2UVK9+ T)>^P
M$L*J*0!+/6()Q<]5&8AH5 "L(%(VW5&B@Z PN_>3Z)\\T4@MR?XH";DQP_/9
ME&^XRZ=J#<>4VL@GWM;8U+-0'QT94[T1KS[@.++X*.:T?;WU^>+Z8CJZ<D(?
M?>U^Z(NBB=MW0NT.>ZTIE!X!A_T22A"W0XK.K!\-!C;UQNF@3EQEE*8?KA6C
MO-+F[&(R4B^QZ3H'URY^&J7>%CMM[!3V;G4K5+VR;"0L_<BH3)/2E$9&=/9J
MO1T^Z5*1B_FZ6%(W66+M?)1%6-;G?%T]$=1GT5$DF ZP_F^TB%C-EWTW*":>
M'D0ZZ68^_26-,2]Z+95+F<U PBUM0;MJ4,8SGNG%9\.P.Q]9#@AGC&&\J%7\
MT9MD=+US-RP-="O3H+BUL[9(H?_BR-H:49?CZ]'UV7AT10/$)K._7$P]]BS^
MQ+N^F#DCZO8!5@X>W9J2<="&S*-SAYE)0K)*\Z@?R6KKQ5$2('WH9)& )M9S
M0R\7EIX?Z]?%3?WYN^CA>$T(]]%D0:,EL38N5J>A6405"6]9BS[S7;:4'"UV
MF?#L8G<C-0#IVE^JZQO2))/8PF&"DQO@(:'9(Y'#HEQ+6[=Q6<&%H*L(&0YG
M&B=DL))D?)??+GG6>"BH3F08G0#*6!S*5FQ4]\?.-N2U.' Z(*_;Q.FFZF9P
M:%O?J0R#T2E6Z\RQFDR5-)PLUHG"?8H9=BJ!0>'!MFZ*HV^!YWL[3V]RL[Z+
MHT!D,%%(#NO-8ZQVZGGC48;W'@IIDT6M,GD+DB*A[M ?O%O9/G%SU5*G"W-A
MBC?NL'F=I7%,6.[/YJQRVY36KX_S(5F(.]1.%O 3. 07&U3R6':F+$G=@DH<
M 2D48YS0?-3%2?F8J+<*<&T-L@[DRN,SZN3FG-P5'X.22?HDL]-T5AFX\XMG
MD@51KD@?OTT5X6VIJ.(8/)>\3^][7%/US<<Z (4@J,W:JQ/TQ+J[/$YJJ6D6
M.DY!294KO29?-?KCY?:VL+TKN#YFJBAJJ/6NI>FD[[KO[46ND3AI) I:@E<T
M:G@&/X_0 *?&N\N#GXJ6MBZRF^GDYF(Z^XUZR/#1Y,V7B^N9,_>8DAYU067T
M'PP*:I5M5^Z1J5+I8B3@;BBZDZA=)2WZ6ZZ&+<SQC9>2*%4=TANIY=*;[=W2
M9Z A0EZAFQ>VI85=!K8TVKPWT<S"L-9&^_QE)4FC;7UXW9-@M0G$;D%64^8R
MN:7O[*Q:*Q6Z79E"9X7Q3A[MY=6[.3;!5-2T5>S3BZO1[.+<NQFA=C\=78VN
MSWBFA-ET='T[.IN-)]=.LG%,>3%TD+KSJA1ZK:39&;]!G:4W)%NDV?(RS:@3
M-*]7P,*JAJH28"LX'8 *$KFEF0?,S>E 3JVNY,9442R^]#PZ7&(:6C0)6ALI
M<IJK54N5IL12NWERHK0 6I%% 6P@^#@5O77P!V[QCWY,8S0+&K<:)??JS,#5
M&/2MLALR"A^,R% 4,-6(V"@(ULLUV\Q#LHB"J' L5#0%-OHUQ';V+2H>SM9Y
MD2YI7$.\Q@ 5/$'"_T)5\ D?9ZLB'WKP,V\9Q3!#*=C82UK<;(!4MGM?O$>@
MHR5#<<A/.OR7#KT6)3R9529X6"L^5:1>P&?!B9MRFF[\N-AH]1QKXK(4)[J]
M<\X]L,:U*HRQV.6>(HSOR:)-\'+7),OTEED,[-W4PII%@$"OC[C;'%J.8D!C
M(N9AQW57M.^6@07KN*HARZ-L:M9T7J\_+"\V2V-P3NE9L*/4T'N5UW1 KS[B
MD&3%)K^:A*Q^AR2K1^Q8M,[)@F09M4987 I6'N^VI:R72[RXGBP\,1BK T6'
MHQZ0JW[?/7>4CFXD-\UO*&C&NO+,H\MJL+M]ZUV1*TSI&U(N@BC DT\48X+4
MCLL?17A=O=:ZP\%XW4LZ'*\6AR5I6"B#8^*-E&M7/YTP4*K=W5.+BDTLLHB]
M(*CJCL$?>4%EA3^>Z"(KL!U@&+['!O5H6; !+/[#*&W:!.@;SCM&:=$7I>VG
MDSV6J&=%ZCAS.Z;AM I '+$GFS0N;D :OY'BCK;@ $,N=XB]3I/RN0X39#X=
M'3?TZKTM$EI_&N+VNN) <IOF>;%%+IOUB)/KR,=:4:J^HE$JH(8;V2$H%]7%
M1D=!W;ZX.?5C#)UDME9]U $(;$N"FT0UXP2O*,%W=8*+G@GN,KG42W*Z^>+_
M/<V$&Q".2E-"7PM66>[:3#=U9,U2;^3=0D]@@QC0PZS_!-VGWMLW_Z,7=V'G
M23Z0\,8#H_#FY8P%PJGG/6^QP!_$O-,P/BQE@$4@2R;@@2K%$IR/)&3:^'3S
MF:3WF;]ZB (_'F'ES1;RP)+SB4^QHV05D\4/F*<;KQK;PZ&'(QWFV-,D-32V
M!+8,SBIZ MV--,*<L_<5J_R>6-5>B!3'L9IGYG2S[[C!0%S-B:SNJZJ=SK9\
M5?5/(%>DQSC\SC TJ)Q/]0AGGKBV4YT]M/-7C!V\]P 6SL&D-E?=8REG>B2U
M<4*90B@5A#9.A3?VRM:.PU-VP;?/:S/Y/!W=_&5\YHVO+R?3+R,,0Z%A*5]&
M_]]DZIU]O9U-OEQ,G42FW)(XQIE(0E8VMTJ^JKD9*IO2;?9N#8J:P/E_<&$.
MM^)Y)W5BR;.&E6W<GFVEJUX.6.%/'P[LFG)1J2_ZGU]93G3F9Y3/#F_BL, W
MQ7_73.+=+HFLH,\X@2UKS5Z!XUE[]N G8A^_O\_(/9QPQDF114D>!30R9;(N
M<DPHKGH56';#REZL7Y5FM7P5(BIGO2BIN/2CC/( C,+U4CQ=6A&,R#F/,&-]
M$DY5:>9$ V\3D?AEB8J.;G6^0]'"BZ,%\5YMB)_UDT[:R7S_FF)J(GS+KYSQ
MJLF+IWH:Y;]?9@2W EJL3TDS-GR]@)9E73]G23L/9L"5]HE%FS-+PY'ERNTS
MC(,9(PHDT-_FHW7QD&9X5Z;(*[G]'ASS,&9XUEVD6?FR^B63_^A',1YQ+M/L
M,SYY;,4%7_1ZN6P0YD$8TM! /ZY.&OK(?J5E\**4X?:399S*;?M(8<8?NVN<
M<%] CE?6Y:=/O/+CWJ]]L;)E/&2/')7Y#FK-/1\.= DMR(I6QDM<335JV#:C
M,*G^@#23?)RP,Q9U)V_/O<;M+#E>B'*\U3$CI"D%/3C:N#ZC'<$HJEY*+BGR
MPC/*[[&IFV<U9JE4/R\VN96R;V*N&O95_$E/562Z[**&N2@OF_,'$YB=K/ST
MEYCSO3S.M$O*OX#FU89"@T/+;>4%\ZKFM6FQP0KA2*M>?P!]4^/!-(WC2Y;-
MO[&XV\OS4^W3N[,XA.:]R:* ("\6&E[L+9$R8<T*N[]$SJ#;%IC!TO%2+U:*
M/ZJ95SJ&]:Z5&+PR\R]UHA4I_?&.]5_.#<<I?DN\F[[FQI(>.W**_O@G!@6#
M:HM><Y 0&_QC)6FD)FGXXW\)%@UWF== _@LN\[93I+-L7X!L'^$MZ<RXLDR5
M>!:\]F/UY8W$ GQ1.P O- 9T3Q8UGM#+Z2_^<[1<+Q6A _1WZ"S@_:O@+>["
M98]LEK#F^>E@X"Q2QFBIW#"];(KZ,*Y][R;9.I6_X W0+/MU&Y[3E(L&^"#*
MKQTNB((3<)Q9D&BH1_4F3EPR]'B?<C0G:%&[%\H'K7_'\JZT[RC\ V])'1C_
MHER+#!C83.,$E7OT2/!-3JY)**0*9G.2#T5N,NY>QG_%5#2U>%Q*XK;#!^6@
M=ACF\]727GQWV#M;]I&3G57B42Q-3HT2BE?#XLUZ*I=ZU'6G_=EX(9Z.AS0&
M3N0LZA"6X-X&E#=$Q?]E-+WXR^3J_&)Z^R>:%W?VFS-B<JPH ,AQ_L2S?;D:
MYA40F*O4\:/[Z#Z)%E& 3Q?9,UH,;L6]#Y,JZ)D__GP]OAR?C:YGWNCL;/+U
M>C:^_NS=3*[&9^,+-X'AHH KDRA<@VE"<X6H4F&SAE[5TF&6Z!)]0ZR9:.8^
M9DP@F2PP<=UEG#[I@WTJZ+#S8!>/]G']2*(BHWQ7?8/5+= N:$U.]21;]!T*
M69IG5Y4H.7PQA8IP6Q-HF2[9\]U87GNXK]."- A,U>5/'M][L)=S4>&5WDA8
M+[?)U%J9C04;W<"G'T!!4Y-%%XZT%7I#O=FW-S=EG1SVY^!(O29/]%<-1?IH
M/9RRX,\ J:&7^,IY.W3:AD;@0;,U-"+:5[P9AD>O@JMY:R>@.GU'MP:%!A+/
M\HXHDJ"Q)@XK20.$G/QCC2;K8[/E5S;V:&OW!N V>HU$[$-W*QIUV TVZPYR
MY];J#OBF/'][Z+&#1WOT@K_=TW$E$=(7X;M$#(#O&J-Z3]0=VM8[H'55H?9P
M]UP'Z@#LYRDZO+J@9SV<X8_"R,\VK&H?59UJ[ONU3*U.N;Y:Q?1,Z,?B4#].
ML+J#WW@>IB=ZFG+ME2CE\'T]V!Y]C7@-Y^2XAO(P6=3<S\JIP)*9_EV*]XZ/
M9"N&AV99KOV;)5XK'OS$V^[D;OZ^YIA ,R\BF"^%9?R56?E$-'(R';R*H,9D
MX"V<6@H[#G?QV(]G866'QJ:W[WLW%U4<,1M@.ZR+C^U,-7<E6::P]Z*#DRIT
M>N?MXQHOAZ*$IZC%G4+DI(7#&DO1Z=1!KF#''A^T&^,Y2=(ED%TXVOO:$D&S
M#)L08CK0T$180:YQ 6;IE5N)[R@+MECB9X&@"_[:P!#>XL<@30*R*EYO20'6
MF "NI,$\N"?)G*?=_R**D?#[-4H\^W[*>*AM_>:['P>%_ETG]&]=H1=/G*^B
M951,%N+Y-Y/'&Y*=8;6?T,]^ _MH_EY.4Z<QG,U3)Y0?#%#J;DXS0FU ;L!\
M5-"RW<K=O&SC^-0*K7/>\M"<,J? ]D9.';QX"/])3TW+49S/34N</QNA]J7,
M[2]&J'WGFMK;PL_HP]/YVS=ZBJJ6S@6R!EIA)DA:#@BTPCK8;^E</#!H"X\'
M(,/G) ^RB(KU_*W*%M!W<RXX*G)4"K^AVU#):=#YBF[.A&V)*4#_R2NFH*ON
M+$WR*"19641%5E_S<LV.MY77:_Y683X8^X S 3;'(H5-8NX#+Y]%"D/&V ?^
M  M-8?T8^\![5RQ*DK4?GY-51H*(@J:Y ]\I;"-Y:V>[A *\PD:2MW:V?J5P
MMO23PFQJ[#BL^=@B26%'-78<\"PI;*GFCJY(*E@";A'\?I-A28,E=S6\4]A2
MVD[.!$Y/BL(ZTG9R)FAZ4A16C+Z3(U)0#][X$=:"8T7Z<E:\FX3CY OQ,1,E
MB_&^PI"O6NG(^3NY)7+X@*X$\P@6R"V-PP=T)=!GL9_GDP6_.YYD4[S'R5F\
M)99U^?80!0_\M[GX=>UEU/R]W 8Y>EQG,G$T0^1VS='COEP)D1M(1X_K;..L
M1Z[4'P3S#?V]W'IJZN9,X)O(D5M.3=V<B:L*U^PI%13)C:<6/0<W1S6BY&94
MBY[N9HH^GL23-@$-^%YN/.VT<C<#VV 5)M!VJZ%P5F&L;+=RMYWF8!#1HHCB
M6?:WJ'@0=>187H$JWOF#PM[H-HH[,>I&K,*6Z#:*.S'L1JS"3N@VBC,QYG@F
MB2BJ]4%A!^PU=":,^Y 5NGZOH3.1VH>L4.9[#5T)QCD)L-(EF8C"SEMGO\W\
M@UQQ-W5S)32-Y,C5>%,W5P+52(Y<T3=U<R=L"Y)EZ&[ !WHS_WG/T?!!;@PT
M=W0G<$W(/LI-@N:.[H2ND22YXF_N.!C!H^?UR>)K3ECQW_E'N7IO[C@8P=LG
M2:[AFSL.1O#V29); ,T=70L>UJ&/@FC%KW1/O]R.DRE>Z/)*IT":W%)H/X!K
M06Q!HLJ6:#N :\%L0:+*OF@[@&M!A<7#EDQMV[[)4C DB@UFFR@P'?$_UA&-
M09A_5-D?APSF6H [DJZW5+H-YEJPNZ']I+=HN@WF3N"SZ)'Z':<D]@L2\B4X
M_Z0R;A3MW8FMB@"5*:-H[T[X5 2H#!=%>U<B=+%8$"QE3RJ[ V!-"?8%N6<O
MK(M+@J%<,2;G6A=IMMEJ?)EFU^2YN(SRP(_I$YA/<A.GEV^Y$MU^&"<WH'KY
MEJLETP_CY&99+]]RME1Y]JP<C:TH \+23-P%?I+;;+HNSA:.C@RY+:;KXDR,
M5;G,!"ERVZJIF^M94>'Z26XO-74;ZNS\)#>0FKHY6_K/!4E"ZHJ:_R0WC>I-
MG E1':;< *HW<28<=9@*4Z76Q-6DE^E;F3[BEN(U*>8_R<T$=0=7 J$A0:ZP
MU1U<"8N&!+G.57<8H"#)]:VZ@ZOG&9_31Y(E-$=2$M(<1ZSX \V8])-<U6K[
MN%H16E _RY6LMH^K=5$#Q:H(T,N1G^5Z5=YX '-0AR[7J_+&KK@."Y+>BHK;
MT7$B=<N.$_F#J])%^[-<.YL:WM7,&F./W"HP-?R+EQZY_6%J>%=Z<A__=O#!
MSHW<_&>Y#=-UF.$LE@9RY?9.UV&&(_P-Y,IMHZ[#N!;F!B+EIE.[SJX%5X_N
M%[DQU:ZS:R%M($UN9;7K[$X@"Y*1O,#76U.>BQ6/%+_([2Y5<W="IX"OLJ3D
MS=T)E@*^RM*1-W<F/+QT@LBC!):#>+@$L-C/YK\HS)(V?9V)52O"%(9&F[[.
M!$X+CA::F/^BL"A:=!WF?'&R%)9#BZZ#GBV%K="BJZMMXXH]S$JS31FL@2Z4
MQ2(*R.4Z2VCU6G%5\49N,'09PY54=J-3;CUT&L,5G6ERCTFL#CQVOY&;&L>-
MZFS.C^2%W&XY<M07R@NY$73<J*[VO"]^#K;;&?PJ"OQX+X/J&[F1I._E2L:;
M:)';10V]AD5+[<77&[DYU-AQ8+-3ITAN"35W'!9%M9?<;^1&4&/'@<U1C2)%
M^M?FCLXH>HZ6ZV55N_HF2P-"PAQ36E3&Z%FZ7*8)#>0 &N4FSP%#N9O' ZB6
MFSN'#/62J)8;-@<,Y4Z#'T"UW(0Y8"A75_P<ZC3=^'&QF1*LVC3";#4!5GZZ
M!Y3TUEMXHX!DE273;1S'*[H#O2IKI^,X+X9>E3G4;1QWJWCS[LW;=WOFIR++
MK**Y.^E4H%?9/_+F T.O2.>J:.Y*<JY)45WAI'E^YF?99I%F3WZ&[T6B#%>'
M(KEKF[ZN9*H=77*CI55?5W3Q$@]748!'_Y!GG\QGZ2AXB,@CP;J+!>Q)L!^5
M)8#R*?PBP5+1;Q7)8(\<UMDL'\L-N25S[+".N2%<XE5![;>*#+/J'JYG5$:#
MW";1]!@@#7([0]W#E5Z8W.70M"#B(6K]#2K\_3I-%NLD8&5GKOR[\G>E]I-;
M'D<.ZTHJC^:&W)(Y=M@7R@U%DMDCAW6V4C!(>A0$-$$P.PE@0E- ?)/1 X/P
MTM=2N"FRRAXPE+,5<0C5<G/KD*%>$M5RB^N H5Q)^-9=%,O<"V3)32=96U<R
M*L<MMX2D;0>%6V[]R-JZDQ-::32_3+.ZZX\F>YPL9-OZ.'G$.MS)_0A?3O/G
M#HK4L69&=R>+9G@C-ZL,C?[">2,WLLR,_L+7E"+/KIG177GQ3?%&;HR9&?V#
M*][4?-1G<9K30B510(!<N16F[.!LQU13(+>HU!V&0$&:P.DF"C$/CW 4X4]%
M/O<4SD6*?+T=AQG$?+6A5F&(=1QF -1>^E'&:@+1"-3=HMVC8A8M\:>\8!"0
MKK#ECAAS"+/>G0\*2^^8,0? AZ\Y_.?4SPGH"D Z2T5VCVWL0+_"FCM@K"',
M?WNZ%9;:(6.YHSM*P]L(6HY6JRQ]].-O?DYO@]'/JTABK._E< ZUM"CL(WTO
M][1<X+NB51;E_W][U]H;-ZYDO^]_62P2Q\Z7Q07\ZJQQ';=A.Q/,?C&4%KNM
MB5KJJX>3OK]^JTB]NLFB'JUV49X%!I/$9I7J\"$>4N0I<2%67GUU$A"1%*C5
MUH$VLN BB5&[+1.N>N<KG4?%=EAYNP, F1F1U8BKA5J0F-F.W8@-B9\OA'\9
M)QMD6;N"=@#%S%[L5GRM8L=B9B M5KQ8ZN#-]&&O&'/-U]&:)_W]8FS1K@(\
MA"P*T;^24);?K @-WQ8SOKIO06.>TMO,V-"8+K\TTI^56S7UVQ0@FN?X(;[X
M6G$(;C,'&.1K4K@IJM#?%]=>[X!8Y]&#6'M!5.<AAIJ@J,88WB<T%HQU0W&7
M4;Q/O&XH+C2&=W?'%$QTH;IX9'RM4!SK(+?NCJ*6VJ XW&%N)UH;A$[Q@6[=
M&BGE*93JF&L1,:"G.&0O-VZ-! O:/G22=C,5M'U().EF&CU9IA^-HTC(HX6
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MH&M_^/CC*<A">%_JFK;&<LSQ7O]>R(,TZAVO:]"299GB!IZ(BXW'[?I''$+
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M7AA[:O<H&]V7Y! #O+G7SG4.DF8[D[RBAY>)8*7%<7MX<:]/&Z*L^S2MH#O
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M__P5?KJ21WYQ&85R5$4ND.=36O*VMR]7<3^(M1=$Y2^?1++^ +@[DHH.OIS
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MFK_M8!#!O,!GY61P\)"8W:FV5F<I('OZ.]76:@_E?1BXBN+J>$JG6E;=>>8
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M'#_V,KY'=K#A"/!OY[34%THX/J' ]9VRPP@G31AE9RPG$G'\Z#;X:#E1A2/
MMS?7[13#!E48Z,A)S(D''!%:S?[D K?.JF1J9LV#U>@^N,A=7="H<^Y,$XUZ
MC@F]PL<_]+T5J:97B0\%T<N-'WZ/!HL&+2!0"P(]FF8\]A,+" +$ PI?/?P1
M+O??L/R]#8JLM)D;>Z]I15DQ9NJ+&8]G;/FZ9CSJ\M])UFIT&3Y"-PQ<SX<5
MF):AON_6QW;&8SSS=)NJ^L [AXT3C,-]#;%X=#T1M.5AJG&HK#?Y4O='3E6F
MVC#CX:1?@!<0%EP$3\"'BW6E2V'1HI!#.KD%5,NC,8@ZVX8H]GZGWRD5\.36
MPH<&9;]JSN$GW3?).2(FWP8R$-*[@?&X52Q-$.GH<@W3_[\-\BY2>>M@+'N@
M]TI>5WBR66D=XY&M;.@.4+5"[C#=>/SJ,5!9;]R\VU%C"V@E+&46U!7'>K0Y
MM\<K,UA4;9E!:M@Q6(G7M:T5;_+;P"FJ3]*?K56O+?G/V;(SHFD%HH$/R9$Y
M,&/+;\M<Q7RA.WG#0HMU8KXD'@.VV^ 51KK,,,YBYLNS8>!<"%>T> 71RKZ"
M.$$D9(UTL_)]Z%)?WV*= DU-$P[&+58; &6PSTRLF8N53E*:0PHWSC3ST:E'
MT#![AJN@Q%S$?%PK$Y1K+]J%$? %?"B8K!SWRK@,<Q+>A*C._-'!PBF#T'#\
M65>AEL7+P;&V"5$MPI-TH;0"P:Q6DIY;@K,8:<<XW"UQB)4H^;@E[X3&N<.B
MD[WNYH^[LK=;?9IS;CJ?IB(1%%,7A7-)\TI;SY26LT0ZW1G.>R >(OP_(JM?
ML02GG@1\H#TWABOR!RS'J[\HC4S?F^NVP?S-]9,5K>7GTM(<CR"&\_4:<@6.
M64!(]\<1$;HONI%FB>]DP&0P7N8C>]HC)?;PCP?](5@UB 6L'[I^&"4(2MS<
M79<F;2!-$X/F;% ?R<K#MADIYD.;/*\ND_@^C/\%8Y+=P45:;@EEY!@*=LF%
MO,C=7'F8)DMOYLUQ+C0]VB2[G4_]]\"O>1B)L[2Y=3KS::?-8LZ%\8(B)3!S
MYK\-UB':@G++,=Y;G]P*SH6B^L%T5::5- E#IDP!5YP7-L9P96B&E=V2DJOS
M^L[%$#<[<275X,$Z'T)[?#Y8I2^4YIM'ZXCT\I>Q:*IS8=IO8Z?:\?F@?0T=
M/-8<;92#<1PWJ![)8VOB:3MDF(2IQ 6= LX]A0=9FQ'9%[[-U&6&(=G*6F;)
M4XM[.G&F801DZ>L!8TV4NUDNDPX1Z]ZRXN>4T@'<D##F$Z*U]NBU[IFC)_LM
MVH;2=>^\\4YRN0"_[@TXWBG=-LBP>W>/DZ5]V\C([@F_)TOR[M&9UO8F&91G
M6X=_3K$+RM"LS U&M3?YV2S9U")<->9&6].(1JNW4Q P:ZTKHB4ZS;1I&5IK
MJ_-*+VT$H;G=RWY9J-3T2T%N)'!W-]?DZ2D5@#Q))Y86.NH-?YZD@THKOZI%
M6^OK^SI-A440NVUM,<66Z(@5%F;<]\C4D^Z4:(H;'YL"VYT*S)CSTS@::F'J
M$^S.KI6:YN/9)]@5OMW]USDD7AMO6UN0V20]=6BZ=E=>4Z9FU_A\:RO^:D&.
M13?Y$'];%;@>R".56F"M+M<705JG+DPP5JJ=F%+(B;"W K<"#HV/?LS$"UU=
M+<;.)=I2-JRM8JX/0S8%I;(_]#92L46'ZIN\,JDHFONOG II.^>^:+MK7R%Z
M#BMRM.=2PS2Q;V.VGO ";4"0Q<8>2AT3E@I6#R6\%NM,<P+^H0JR1/:=EO6-
M5RCN!/5!GUSBCW_I\TN&Z-[*&;P]I*Y/SA 0/1",;]B9./41V)D]]YDY1]H[
M8 *ZDC6;F9.,G] G;Q-X:\\E3\Y'4,F<.[D%AC]-7)JSK"Q9W(9G_! @L(-F
M>3\/LKP*HSC*'$#>[W"516I70[.5JF1T7%GU%#$J :1[' 7XI_*1P)$'CO+.
M2<N5AC\PW;]!D]7>BA)]V?,]'TSJOS+<U^(.XN\!E0X;:XKQNR@%I.K^D[J#
M^!.'/TH<"C-N'B%&P]\X.P #L[S-#)"38'+A7./<S@OW4[![5)89_B3(? 9V
M+(@*HL,?D!#L #"LDF790E&>+@1\&7N$,\OXL:CG/1TE/>6*1^E7!PZX(B^.
M02QS</1N9,'1XGY$QJ'23H3ACYT+W#.SAX[$)WIIY@#-K*!F(@Q<Y=J *NL8
M/YA2T,D</+6%AC]8JI^%Y9!717OXHQ3!LW/3;?GJS2'OPUCF[/ GFG>KD>".
M"CCXFQ^J!16I,S(.-L6EAC\PPF_!<K>I8SK\&?%BLR<D33Y=@C>EJX4SR_C9
M:(!%YASPI@W/\WP",QA>@-+PS+WQP-8U? / #3GECW!'B@T%&QG9SYAB7NK7
M %%C<(G9P_,YA]8LJ2Z%UO"\O@:A9]BA12VK5 @0AT;F^9:)!N!.-/_,7P&'
M_BN#2?$-7V6=X<^"\"NP7MX5T1S^;*#=,S"LYSQ"GZ3-D@(N^R4"0032:@42
MIT,TU?CY8 &D=CH45AG^;$A\ \;I4$-S^+/A[PP_\<T!"O ]2M+0J'$D<2)8
M4XR?A#H@,GS/G#,\EW/HRN!N'C+#\W($=N_Q4TKP?XO@8CV/8F^+A1:O%GUU
MH&.ZI<U-B*"W"5*/O5L5R<&*_M.G/!11DNYE#F;K-1WC/6S*\8WR"/*F.:;[
MZ#9'R"L@(S/?,=T>IADJ45Y "K4RLG++.HI=^5C-?EZPO;N$:'L)@M^NL?4;
M>3*?2WJN8[K!#/,!7IX'99=P!FAIW S8[78'/"3JB2N>[9AN$)-&$*6!0_(?
MB#/+,=T5YA&^PB"!I/8'>2TCU_NO7OQRE40QMIR1/%)J"Y&*MCK./XF;7*QI
MX:EVX+=8A12$-=Z'B%U152BF)6:3HJQ:Q#%$A\X+LF*8,X?4+AW@3?&HV4A:
M$0<3\!:#B77B5TBDD/B&;+$:*3QJ7&\C8*3]!1Z]Z+<K!%=>3'[BJVVL6<Z9
MZ9:[=8-/7FP)9CIGIA6 XKE*'@?6%%)6SK !A"]BFJU;RF>Z#; ^F&RE-$JI
M^:1PJ%FTKB'"VBLYJ JW/'L2J=1I/*QHA^ +%D 8G)1=4IA4S#2Y)4CY3-,-
MJK^7?!4H#/"/+BPQC#R2JDN1&I8C3+DZ<I/86BRF#7)='";6%HEI0PB!8\7:
MBGZM<)7TN[#+FDT&:6G_"[LDV8AHH>+)T58=][C8PCB(U<)#9&UA(ZUX5UQ(
MUM;A:8,RW]?4O:G01$Z$NO?*WI9 JM)3W?LUR?X]K;A&RK-F<?<=Y9M6X*S3
MV#)GU)S1TO%7D&\:^BG?15@@.VH%5,&16"!L7<W:-@CSO(X%II-0&Z6]D@7:
MDU =^0[, M=CW7&$N*IX-PO,1ZWZ=7%Y'EQ'@T;1&0Z6'CB*CO7DZK[ 57+4
MDKU2NP%BRF.A1:]AXO%=DC1T\<-LYY55 _"$*/X*22%KN)H1)71#BEDGV[19
MR4V(OI#^+7"5=2\18Z6P6"F6;@1'6]_7TU43:JSN@4X<HZVF[C"U7=-B=X9E
M[&2JW74/1"FXCL*550%)P1/*;_5%A@_SUUX*KQ411ET%CV)S.K7P5-6%1[@%
M7I!7>B/O1<1QA\$@]P&Y )5U!N&*QE,0FFK:%=T]\M;$TO*CQ6K#JTKRA0"[
M?]SI-<'04T91S"3:M"/#DK8HRVA8,SJ1NHR=$APLTF;ZJ,$X 3VE5+/1]/D9
M?='&PT55+RB8 5>I*=C"1E!?UH)SUJ8@8T>4QWSVL-%CN'#C9*K-%4Q3?M(E
MUNI-B(X*J,U(-^E-UB;$IQ"1!^!U\\,PM7DOJ<1O<6X-PF/<GCE@V0QIN6%U
MUB51WKSIOOCPUD[K.H #L<_T+*;N7Z #]XW:C/+B][J.K>5A"M4E7(<('B#$
M_Q?%GDN:QZ9Y$"V$8:N5![P9<L\QAC+UZF(8NVG"2BL.?P>TJHO9_7M/3Y1W
M)*0JVXQ:>-.RI8;E]ZCKEA9LD@6;1R3:?(ZICO 7SZ.M*<N$P>:.=%I.F>AR
M_P6&&P1V+YX+_!F"H(U(T[WI@/(^0^5R_Q7\.T0%$I?[XB-G'[T#G907'_X6
M:%$UMD_NF-[MH(' ;=AJU+<$+?AK^):82L7?6N#"?1B$^2-;"F0&8=MP$,D%
MAW?RMJT!W!K?D7IXRU5=+X%/TG2*G/<L!7Z($)$I51DN2_1FT%KI'#)+#7\.
MV]<;;H'K2,]@7J[8\)TWYGK%!^:H@W0)(NJ!N/;\)"9VM?+14EIQ^!.F7NNX
M/:K#5T+>K PKAF@# N_W[(VB5!TE[8Q<(%;*\WK"O\F>/23T1QWK#U XORF+
MN?3BDV>%+T/,6NL0;6]"1!6JJ/Q<0=CO\.FEZQ"VW$=3:HD0IKP?UJ&+-BM(
MM,52JB6:]2&Q"(KHQ@=$+/FM1K2.%U>MX]P:401=O QQ2NC\<+Q5C1=SO@U>
M841;'"Z^XX/P#0M<Y.\QK6^ "V=;$LXRB[\"]!N,:=(J]V%+;:E2T>:A+$%-
M$I9QF>H64;;65>N)C!WD8&].KG<B\Z0RNPC<.]E;D5UP5;#KS[W3NUDDM[BC
M!(7M#&6G!X:-F[$W>2F88LE0UIH'ZGF'C%!<@A'_ZP ?_L=ARR<7!@!YX>S-
M:\HP9XXU V6VX;<@VD'76WMP=1T2D<^"E#5>DW'U%4183%UE\G"V09#291'
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M]%_AUS"(7WBA4&V7-"XH90']%P1H^3W4@'*VT@"E!!3@PWOR(F.4US)NCZI
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M^4DR14U)$)3O;'(E_/436?@91/#O_Q]02P,$%     @ '3A<5O]]$R93)P
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M[%4:(;\HLBN0R_S^J.Y79A*%<Z#0 N,!VMT8Y1&D<DB^E;,[>P)6;T*;\VY
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M!0^/B(*(F)2,G)P<G_ J)049)0D9.=GO+!X:- 8= P<# X>, (^ [/^YH)H
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M8,6WM4X'U>GH+A>Q0%1T#SJ#PPJ1N3OD^\6W=?K+L\ZO1_W'N?JN$.VPN('
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M"C)B;6A#)/IZ<5>OK:Q,B5BV7DPDB3:I=\!K1-Q2H$:0"&GLX27=*S0$I7"
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MZOWH8GS=N?SEX_@_WN2HZ1VRFD^]1OY;N5(EBUVGOW=R'M!(A]*6AJZE<R*
M82T/364JROZSGNDNP.ONURK\?__/*14S25;.E)QSR$Z5(Y'GE= H+(PMR>1T
M9FP&O'3.R"2(OUE1365.'\MX?_ 9H/_ES=O;R;SO!>=!L&"VH)O<S+5$@A+4
M5F[,&QN(SPW2(:@E5 [K+ZC*2UM)*(P$R>=*L+M Y -1*'@F$1&*+)D,\0Z
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MC"UVGRX<->VG5RO11.QCY21\K#;?GVV-ZD'*.'43:EYPCWJKL]WT88@EPGV
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MS54+_HKLMGU:($EF[A)RDF^\2@U@X8_=+.A+U5G$\:3KST20_/9L?'Q4K)4
MF.YX4;JC+GGV9MAO]-O=1K_;T1J"7O8M_8F.T://5*./-2A L# )3M"]E'#@
M<-%GQ^=3CO,46V*?US((=CZ'T35L5(H$.)&G4*J!B.+)J1]R!NYI!MRAV^QI
M?+$8,W/3QV:CJ@#&^4LF0 ZM4>\U_=-]K:IS;Z>55D3._@08_1U!=*8@-"8
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M3MD#M+V%S.5(JP'P)NDE3W 2>26P_@0=Y4$G'F\,8!7+U)E%%J>]W:KV +$
ME ?2E50FWFDUG':SW::$BDN!_3/1H9#-,D943V)R&C4ZH_9/7U2'7N=OW5YO
M=^C *P/=*A-OI[.()3HY4GT6R_=V.KN#[2U]+YP&+Z%\57>W[10OXE&)I>O:
MH]U!Z;IF@Z-DV'H<P\6.QWUCV%>:3U+ H:21B_JSM[U%V;/VH!=3"F-UF3&=
M-'2#.#V-%/Y0";J<TPL:]3A/2&D44=;N9</HF\-K>ZNHNJBEDVZ1YW*H?LKY
M8"G$#="99@*GPEG[<LRVP#@V7=1)<S$?3,DGS9W"S$'L_XX1<LICHY@C02^6
M,B^Y4:W.=[C%ET[:O_3G=JL"[!@?YYUHB:K+D (R3R/T6XD9#KLBY]JHF1]J
M T&B&H# M7_KM'>;UH%K4;7K['/J,P[X4*]2B3DRW^R*I@J(+]S,WC0?4O-K
M)U+WP=[>4D/\N*.(VH:==&20@;=-'87R5T0Z-4<]8$4_E#A&;P>#3[L[[.;T
M>*#;6X"<&IN^H[5:PRRF/!/;?GT#TU!)^--Z]23?/&45EZ%V3)Y(9K-+T^2K
MTA37E\?>@?!:A\'E5%*S#@/+X7:DG%6#RC< (WY4ZKY%B(+@#0N5]O, .V=?
MHS$;$-V8N=@&P*Y(6/K0'W@&5W >H6+\R644ISN860AG%GY&_V>4^&EBVASF
MA(KH@4=LH0)HF"D6@B2I:1A.B,&SB$&(=KD!.#:50@T="T7UK UX3T+N6>*!
M\U3GNR^C*&-NPC,/087E_'.S0<31I:1-%2AY&=F-S8G3&KE"_(L>E7O*=IW?
MHVO4]QJ*DO3T)#7. R%HR_Z)7$0JKJ*.9'N+SJ21WS 1 0Y=MLP; U$:H\AG
M(*D^QX\(<I@V0W+4S#\GSJR'/:+'#;=!G2)9KJ38WT2&M"=DIR#NI@TC)=04
M].(\9,-VH[B:[9*?0G=ZQ_P?B;9=SBZ6^)&ME1B8 LZ6,B7&6K^ZMN0X*B_F
M@)?5O4'72&LZ,J$J?^#2*>-4A5;7*=X$ZAE)IE17)Q)GD5\PVS:19F&MXL)
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M>7T*"%:KK8%N19#7IMME:7$I#Y #WGD7:N5QX68CN;>!$V,H=T9U;F &0VP
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M*H<RDC'M7C<3,*D(VUNP>@!1K]G1#6NX*93=K:0<"+;R$S8-I5>]S9H[4:$
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MMC'$5B"O98+*)SE-G5A<Y[.WN-& HC<:9*,7-/6#8&>*M6B7&*MW/XL+W>4
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M&X1 R;8(RT-IUFR7H3<)[K:"E>#C4N]\OW,C#(<-KEN*4YPHC2R)3&&QB?Z
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MR &:!B$U5$<1<RE[ EU7HPA'N;J*MN;5=O B3>!![D%A.XI^Q)>4TG#O_.'
M;[2.&IT-WI&/))VW!-PPV1I,!X%;H*<^VZT//H+_::J8P+7TL"4PNM$1<:6W
M#?W2$2_9+GK0>H*&U#KJ#%>RZ5OGKDK@/ R'IQ*/D@^I1BYT_JB.<L5UKCLX
M5; &'Y[Q?^Z_&N06Q::30T2L$;:*AG#,0A%!E9TVWRE2A4P?#D0-7?$"E[42
MP9&&.?MQ=J@\JBBQU'#:/I@-_==GI> GO04WTD!0(&#9-I<Y(2#@"DXK)M-N
M3" <*I4MI]+@TDR].IXNXG<+".J.O*2MKU46AO]XQQU'_Q1M>$!I0TP"AN?7
MVVG4/QU-$TR/P5(]DUW#/^U.,JT0FCNI[_Z"A5)KMKQTWB!89,@/<N@YTCSF
MTKOP5:I1;3/J=:%*F@Y#O1%?ZC TD@UIP++LJ(=34MS6<O@&R7=&.$?5N7JA
MR@99QW:C,L+RHDEB4FH"3T<#4TIY<3?9WX6O Q98WF>8<L?6'H&V :.":R4N
MH,N%! 8(Q>LP"AH\[!26KWB?W9"'!Q$'P^K#)6$)LAM!HV?,"8*WL*U-A)OB
MQ]^!PNOFUJS\NB\U,62Y7?& V<3O%#P:E HJ"@0I7;(Z/E4?>BW>UGQNJ!A1
M,9MGJU51%<LH+I9)OLZ7T6)=INM5E)MH^:*Z7^?7T9?6_SH>#=G$#N60)-MU
M-$.NA.)>]=,B4W, Z+=^GTC;MTFS>&ZB^7PVG\?1<I4NUE6\2M9YM$@7U?QE
M#2]]N8+O=7GY1"AEW7?[NT$[DM2,'> JG_W@4M8G,ZJ] &&>S1:+:#&+XGQ5
MY$6\SI;E/ $CGU7QRQI-?7%B'4+EC2(NVC#H, .ML3]6R"BRXJF)8QZ4>S+?
M<PW&F,2//17EJ:)TE2=$:%_%ZXI\H<ADJT5LHBI/T[/R?!'*HZFB#B(<9!88
M^CF87X1H>*0$>RJ"O$JR#'R9U7PVJV(0Z#R:KU*3@ B7<0FGPUF0OPA!QJD=
MH6PD^JE\6^^H.!4F%SVB5BK/8SKR\%-<J)_:N/PP315(_RD %"PRD^7Y<EE4
MZR)>1,FZ+"-PC-)RF<35/'U9\]Y?KAILN"$+*X%V@$E+=4%/]*F8[SPVZ=+,
M$S./%G&R2-(T6<_C99$OTK@PL_59;K\(N<U#DL."4)$@,F5L:1)B,M?8+4L8
MX%@>0I3C;%?<FGY8C3ZEH?MDMB[*R%3S+"[C9%GE29K/DW*]3E?S*%N=/>T3
MEW"LR&VIH6-ZI"&#:["NKE@:N&;9#]V/GJJH[)[8?N@_;O;^7S>@_=Q:A12!
M'F[;+37\V^[(K-[T3Q0R?,YP^'O!-B=HB?,;@*3"R4D"+1[#OO0&Z>>FW#MH
MV\X..F^)$D(V/1A#<F.+ >X*&3JIE3+3@VL0DH(0_GL\*Q'TN793UPTWW@<D
MB8JV&P5\GX1X[V1W<6I>2-^IH,S9P??U9J/3X)@WP2JO;\\/NX79H;94ZD0)
MK77GKKZIL=4LV'>OGXG6S:NP:QZGL_1N]H%LAX217 XVLUSM[_C\X*8J<U3
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M9S<?>GGAST)3 T?=" XVXP!Z#WF[[\J-]HXI;8=42\A=IE$LBF/'T7W*5GO
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M+)[$"E=M,)8VA'&^GKSU6%G]-T?9138 8U%UI&12@9BT#_!T__9[',F,>5Q
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M/V2E(.&C:VJ;_2V1A(QMH_L6(CV$I*>$R>\QJ=HQFQ!#U_=>F_&MFQ[?NXP
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M4%1:TF#U#6CR#L&9[+@"ZN!MMM_HG)RO,/TCN&I;XA,S.-AZ@,.F1/>&K_^
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MI99KR>SIG12)S[\5NG1[D@"T.:XRC;4A3;038#I7X$? 7:XGK_5-2E-(8*'
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M#5@4-(#P5UJ!![R%Y\1E>R0F<P17AT>#5O +7(HA.\8'!(=ZF/S#[/15]54
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MF/@6>2&@W(MZV9W#22-S#<SI!>+;;F[P*=ED,E<'HQ^H:6:U,LB'Z,9QI+W
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M7"&[%<LZ=[L5N+8<FQ39VAO.8"4?[89+4:+])E_M%ZY^ 1CD_#T49M9@J4H
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M-?:%U[A:_/#'EY.O1@-HG5UQW7SR;\2QMH$8[GI5+?"P08:'5DN@ +_AC9@
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ML5WYFZ/ Z70$(';!LSO,:W9^9G#EG=9.[Y5A$2W*I)A,AS"A:Q:WA0I7K&R
MC8(A7D-H%@ZCA5N5WOX3',T 4=$\^^GPCU<K.%@!'M3XS'+L#?22$>P>7.[
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MMII/%\5DDBV*;.S\_BIFLV(Q'@_FH],V.^9MUE]"AOV!%+V/.&>HQ9.1(AA
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M/Q1P7D;S2ZAO#+FA_!T">W%_$.C%,A]F3^ !"R\GI.A@$M,'MD+:LQ>P_@K
M7NSY"K3J+0JYK+TO[+9 S:;VMCAJNQ9;*6E%H@9HCDNQ'PD:61%S[/Q.@Q8=
MA1R"]R-1JQ'TAHT9ND)2FZQNY[$M*(1:>$-KD7]_6VAB[BV?(Q<-YU(1#X&M
MHM0=)3@X'1TV1Q&+(,?SE'$272!J7X)XOPM_$0P@C\GYQ<--=^1SH>D@A)P6
ME<E^LQ02;Q]LAV\:-LC,SW:(Y@5AB@]?-.JG++UK6M]"4Z=#-Q$S6C5F:91
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M38+4,6M8$0.7-UMTD7>4QP:O?^4M+&N[!;SNT<\Z)AJ1CL7;A_JV(L,1K"(
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MW"K;0_$*$T3$W_K>X1'7E)0+A"V8^PB"24UA*1$-P(.%,<1T-LRHZ ^/+\#
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M%M5A M4!M7^#?\0%)$>.GG=\<NY1CBZHW)U^;3BA]_&!>4E$  )=91 ]_#K
M\-D_2GAHMN<<OHLSMF%>$5JR'?!I6+V]6]+OQAK];MD]3#G/NE#V0%(B_L(M
M_5-3?9%ZLW(NL8&8A+\^+A&]<I"8-8VX2BL1N[Q-4S9"J(HV6X,FN)M_[5K-
MXUL)AK]<8Z; )HH;=/"DB"(6U915&&Q:$L.:8V8[?R7PQ@PDTQH93/=QWA?M
MZ*9[2*AWA80H^UO(D:-,WYK2,=7FT%ELC>X?'K\X/.$7?QU7ZY?[O;&/^YUW
M^)ODNZ"V 3O@6^F^>T?][T_!G?R=4W/,C"7&#;P I0LBML859SO1RJ'Y];:
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ML]GL,KT<3=++R?BCFB7E[ES?;2RFYP^O:3$9G;*U3]7^_-D2#6WPA1MFUN!
M^M.3:D!4+8<=-QKXB!$SNMYI%/COVU465;?1+N$G^2^<'D01S==\BO)5W@JT
MG3X*:D'OWK[%JYGM>WX6]N]PD$X&@W0X'W7WOQ1:&#MG?&&+MS/V%"BR:D@E
MP4'$!'* <D&7IO78,$)R*&"(Q"45^?4(R.^WHF$DJ7PBYVJL1NO-C@)L!=VE
M?< HK6#[H2RAQY7D&^"*=]5JMW944LNLLA%F2H:3B8'7&A&1E_FV71W]@.T<
MS:_2R>5<3R/ ^87IY6(]*_SX!Y*/=PCYWHB&DRVN]<4TWOC28;=D:G\\6)@+
MBDZ2?9##IH\?/,Z23SC-CG[/1^\WD@OI6V6TS,F9#ZN,* .E!8;VM> 5#JS4
M "#%M)%^&8P$ZU:MD06-"O'42! 6[?G9<+"8OACVM?H$%KS;78TE6O^A$/H_
MY*!R("*?,+XJ\2\T$4JA":IDQI_A=5=U/9@VC-)AVPCN!*'LZ7WNU')X'I1\
M1GZ@QZ[B)[%N?Z=(Y<T2LWTPQ7VNKK"%2D0)4!OKAS,]IK\E!H<EO"\4+RG*
MU6[+6$\Z]51UM!6I<!1#%N0+\!O>&+;>.BMCNZV(H7NN=MI<-LDM/&#E13#\
M4-R(N^>QP2/VP99$9RQ,IUQ[)98W(/9J3%D3N\T/78U1?3&8Z/OPW9#*V0;"
M95QUX7G!@$1733\B1N9G;WT_+.$(:L6I6NB.)S#3BN!)FNYMCQJ?G9^Q-R*5
M!"DZ*!\1ZO</NSV5G$0S.\VLDD_<:@]'<7T&I!79?0D[-?;F;J&!8;>AMP1I
M%8:8K?U"O4.- T[Z8FQ([\Z0RP9V/O3XKJ7T&ZN=QL>>NM'(0;W8VG52=;<9
M9B(K1JQ!TX!9![]@HUPD/[#R$^A[5]NPDNWUU6YD""F$-$E*$I?V*;I#A@R+
M4)1&G\0[=MMMB2JR$F56S>:H^6-D*W 8<F#4,1WPFE*3S>S;+Z*N<4"XII=^
MFX7-,>72WET0"VIF!=9<Z-@SZ1I,+M,3H%B-M_E.JG300E""HABDKK#I YL0
MV6UK#TA%K\R8U%R'O-@#Z9^O6RM.FT8@84Q)\#NWR10PH1S740+9S^ERY:VB
M:,[6@@9<>5O5H%O([\U2(S(&D/J>XD=II;4>F\UZ"@;I=V^@X-FRE5>.>-%C
M7C@'>&L@Q>"^>#X+]7<M+=P-!X_T9HAY7M>U@'1-#0+.=.IHL_:"VOS-#J(+
MM>H7WO&'>B-0:^_9=UKZ,.>)M*S^HKM]O5/*+4@2A#(PZ ?10<V0A?@]AN9A
M/%&$'P$<%BR4#2ZF,T(L@S.#OYI<7$[ZWO^]/^+D+9-OIN\\VF'TWBBXU>8^
M_6CKHE8((=9 ,,W,%=BY0KCQ09=>,"2E?(XP#[Q^[-)!" "N'?*4B6U:FD'P
MVCXLU(.@4?:'QE!9 W(>@&&.6CFI[8K-'5723-:]U]QH^OK)TOI=+B;+Y>7<
M[\?I=.*N!MDXF\RR23X=7\ZSV?1$Z7+4E"[7A$7 9.PUG;GK+*\K)Q(Z1KC@
M>/BX9N.KV7P\&"W&L\ED/AW-)_/)93&<#9?S13:Z<J<U>\QK%M,(WO)G12KM
M=/YP$,(@].V!S_[;_W[S]8OA/+CW/6O]QF4K'_GXL+-P?K5C+.!N2_KA>)9[
M/KF<%9=C-QLL)K-\-IO-G0_Z)FZQ6%Z.B\O3<C_FY0Y!"-P",+*9\@"(I 3G
MS7(6!?/NQ]$LV_'P,AL,9E>+\1#-]")?NL%P<GDU&5Z.\]'@M&R/>=FNH7WP
M3DH D4 R"$DD*Q_11I6>HUFWWK".9K/!?#A;3B>+69X5PZO!;#(8NB+WOQV=
MUNTQKUM<IY0P2)Y!"C_+WU/';+5$S41,TA+'(?;N"%(14^4@R!58_K/\IG2H
MU"*56JL*9GUK\+M]&.P#VXTET-VJ5,C1[([1?#&:3+-Q?N7&D]%HO/"!XO1J
M/%UFDV$V<./3[CCVW;%Q!)4Y5(54R)%L(T#WL!Z7WP(B3WDT*WJ^'$^'PW&6
MC:8^D+PLYGY%C[S?,IID@^%XEIU6]+&O:,D5=^V]8=Y*WKL]%:CNH%I*%&TF
M.Y(403D1]7GO$"#O+3^AW63;8%V$JCP &5X!*?0.JM0RK-L:2B!^.")F_M61
M;!1WY:Z6@^GH<NZ#SRLWF&>3O"B&H\5B-)Q.BNEIHQSS1B%G1EM2"K<I"<'-
M*@>@@1CTR8\^.G57PV613^?3Z96;Y,O!8GF9Y8O)*!\L(6 ]Y;V/>S%O-M7.
MV^:@9ZMZM3D2\8NB'9MND/A>KP%::U0!!;GS9);W'[/98?P':W;HW0GXRW(#
MA+#_)WE!&Y9?)=@1/XK+ Z !OGU]O7@V2!/XW_./VUAJ07[UNN5'V.R3,3Y>
M8QS_>'#E_.D_M[7;%$2_:;$,RT"<*:PZR]*M"N[0\^.K]\8P_R+[+%;WM#1/
M2].N"NM0T(H4.F"+$$Z%T)&R@_^S*RG"LU(G 8W-J$\D!D!G0Y>YE3\YL-Y/
MR_VTW'^[Y2[<U:TT=F-Z@#Z+&6Y?S?SG8P.^P31;NND @[O)<#B;#2;98.;<
M8#R<SXOI2;_TJ%=VM$@Y+0>K5!N](.L&2#[   N,.F#JP\=(%/UXTAB+Z7@^
M<</<#4>3\7BY&!?#T<#-1^-I,9J[$Q3JBUS543^1)C!,I?)X%O#\:C"938OB
MZNHRGRR7D_EB-)V.E\/A9#P=75V>%O!1+V"3.X[6<I^X3,H$V(9'GN2WO$-\
M/,OY<GA9#*Z*R^FBF.3+V2P;7HT&\VFQN+QT5Y/\M)R/>3F+6\S+UWN\NUQ8
MT@EKFE/;YQ[CQ&;?;-VZ.9;ZWG POKQ<#(I9,9]/1L/Y+/>^_F1VN9AER\OY
MX.JT=H]Y[19NE>TM5B,JX0%U[X:U;X@)<XO2&TA"Y\3/R#;9:O\S$2,X!:Y6
MT(3$_]Z"%]T(?^X.-:D::IS9AP$5K@'I(^*( 3D[9(H _@;Z_M&8^^GL<C2?
M3JZ&H]EX4N3@=U_-+L?Y[&H^FTRRD_=RU%N&64^A68S^M5R!O>?"(:?FS H.
MW(A'LX 7;E'X6#'+)\5@<ID/%J/1;.FR43Z^G%\-LU-6Y*@7L/%70%MOC41#
MBZAK'DUZ<T09CWPX+R;#T64QGLPFBTF>#6:3>3$=7@TRE[F3A_W%K%BF,O#?
MR*X5E@1>Q:+*:B2<#P18X(*T?//R9R2QB'QT(S!V-.M],IX-W.5@-BIRO^Z'
MHVQP.1CGXV+D!J-Y?O+*CWN]/QZ>RFM70$K &0Y.1TJZ9M4UTOEB+P'S AQG
M/O!R/"C<;#Z[NAIZC_KJ:NXM?#89%L,LOYKEHY-'_64O]^:FNN?JN7=1O+^R
MVBL+!(KW[2 9"!\XDO5<N/EL?#F^&LRO\LED.9G-O04O+F?3\;AP@^&I>?>H
MUW-$#]>6@SQ >%=N0-B=G!80U"RW.VZP4>Z3B]]U=?^FC#8_.%5K%.4$5@L%
M3V]OY"29;D7%/A9N!0!UXA6B@/S%MGK!H3FZ=779L"0EH1.08XWTFS%&5]UZ
M42CQXR6U!>1Y)X95^B[Q&+$"+I+!/ 4RH5^7)ZK%94<I[2I_#QR3R&D#,L(D
M$9L:.2#\$W#U+,I*<=7[&*1G)8R)G59)" O_[RUH7_Q_]MZVN6TK:1O\KBK]
M!VQV<I==0RDD18I4<C]3)<MVXAD[]EK.G7IV:S^ P"&%,4AP %(*\V%_^_;5
MW><%("A;\4LD15-3L202P,$Y??KTR]57!YQ32@M4BZ](3R'EF5HO2FV!B-J$
MK$(ZORAYWZRDSS-:MDC\!>%)OVX1=]!-;:M[WX-;>Y1.RB).[5M)IV3!LH1\
M/_M[F+!B7>7HMES./TC\XS@9T1:D3'-3>;[<ME'>2^EZOBYQML\+$!CZ&5.>
M3)Z0%AJ_$.[)>UTY>Q$RYL9ABY6R+"9<<*A90T="AYXLC%(2$@6VF^$;<EFB
M/(<>F*F<N<;3K[*4EBEZAH9>S&'E)!C-&NUCN/>!9\H4/F,_W@:QK=)?X8'R
ME*R4':8<JGC0=RS02H'%V#_4$<?2D#NHOO2,D:Z1'8F]XK&XHZ0(EFRH64EV
ME#S0]AT3D5\#I+@M[ #!U_>?,GD5Z+V;0 $XSB"F?\-;0<[1*2IS ='&1';H
MX2M9%9OQ/9>%:K:D^2#ILF72:MM1,5?8_84V5B"#-JSA1<U1. 8@:F:7%PJ]
M2:V-5;#QL-#2>;E.J^C9,,-^)TE1K2P-.0RM($YC.Y^C0Y[MF1)K/S$<\71#
M&A[$GUGI,%0KH[=BM;X&\^(3PT258<\\;C"36F9*:11?741\<C$N7JDO=[26
M04/#RBAYLY+&UDFWT:RT9$6QX$H^HSWL282DJ[JCV&OMT,GY/ZP>W7NA'2YJ
M1'R.%U)ZO7$/ ;Z$V1@CRSUK>=GE\OM/JLXV+Y]A"_3+LZN;,L,I,T1_W#KS
M7A-1P1Y,LB4SIO/=-#^[C#?2/W'3O.=.(3G<W]LR FUL21>/+6%F&0[X+[#.
MG 1>T[FQUJVLSW>/;9R65V(&)K:)[2+?U 21-=>'J%NYPR -S#+Z^YZ6*IEH
M*^]()&T;@Y87K[?EF,B&E&Z%W+7V2VS(K(4?^$H[L-H=([M%R$26TI1@QT1P
M9P[>ULS"T[JA>/BDYXNOO;.^$G]M6T\3Z:DE;7A@? I#>[$PH>7#G2XAQ?Y\
M$[$#XZ>80+="&7TN_PZ",#&L>-WD[&REW6G70&#VA3'G[P!!?T?6]^DEO8:T
MV[9]1#@R_>[T_!F9G6K99>T;1NY3V>5!:P%PPR[S6"Q\F,>@NUZA<REHKV&N
M/$H1X"ZK@.L6R_KSBW,W+GKV8^407P4W6?&,/?*\@JR[ZI]'OX.II^.[LTD;
M:5C$TO.&=F_&?VN#,O(7Q6%X+)RY-=MV=V\_.Q&KJ\).AKB?,CK+0:&-?1Q.
M4CU5:;U"RJHTZ']DF_1<QX-=U/9%2 D>;]WHX_K$Z>3+P.2^#PW;!G^Q&N8_
M746V+M6NIT<W.W6V6V!\9&=*MO99B9*E)/1Y,!( A0NL:'636'V^>?[B3'3Q
M+X?GA]M-=.K.G&UFQ-^=FA2!.Q2Y%*3/5O%OTHW\/VN$)BKNF7-K&G)\]LA3
M4;;- @Z6WVQ+*^G!KO'-?!,T.,?:3#/2YMP5!6O@O!^ZG@TZ\*]#+VJ3==Z@
M87]QUT]=B>'RHGA_L+J@W32[B,IU;BIIQM',%\#%SM(,I.-H'L:M]KZ/'F6/
MH]'P6T@$VS.J>FES5I5=8#1N4Z'2O]"W'V5TI>M3/^Q^:\,%Y(Z4:%W!+M_^
MWB/;A-J?ZI.XRL0)B$3\Z:/_K..2O@>S7:Y_;(<B_3ZE*X,SNFN3):P:/"IL
M@0M4#KHF8\*X85V ^GL<1EA-NV@N04!>2L6],.HO+35=F+QX7L KTH[LTH7*
MV>X=MN[164(,!+374"=&VACEW!S$]4"1*++;HX[#*6S35AIM-U(6FYAC>=$C
MNEY+S$I'&^@_=CT5U?97GGX?[.8@I,8$:?<N#$^2[RS-=<7,0X7YD]5BXPS#
ML$&5QW##>&$D=?)1"Q%MK8,8(CJ_[ IUN'893@W?A';+55&^9SY$I8K#9(!&
M+F56?6L[<<<JAA>+?<!"XB-1G<"RB8.!B\O)@R<;I"$C/]I]S-V;K#AC+%?:
MHR:FXWAQP%K!5F]S[UR[QSN[OL$/%ZQ1OK%M@>4WDI&K1>5W6)\VZ613ZU7@
M[")XK;:LI?;X%9WQ*]$VT.WBP:<J$^)/Z[.S5175,Q\2XT, 1V=*@KJR_Q53
M'3SN5G@TGT'91S;K_,>.8F[2RLW^.'S,$,C,6>46*FDGLA/\Q?:="0KZ)>HE
M]K.(??:[#:,VLI9H&V_X_'>'BK2 #A4EMWG=;A!Z&/U47"& )#$:*^'NI+G:
M:L44^R>QD,-+.."@!N^<^AWFI#1X1F+\?X%XNIP >#T;' D.. PWCZ]PY\ "
M(=]YH]RIIER61ENE2O@9' HK'Z^ATY1F<UURDDZ"^EK;N+_'@Z[HZG7EZ"9U
M7Z[)AN&>9B7G-.AEHV)).]VJQ<:!&MZI[1"W'=@XO%,_^748K4=_*HU9)$X>
M;UEGO)&K]J@-?[?9XZG=D&L:;?M[]>2'77,.[B_(EQ7WD([IG'::-U^:[<-8
MXU@J"SGZZ"\DM_[XYWZ[.UR\N H:9]D]0@KFPC;#HP?;$P!W%XG-B\J>WJZ!
M%:<2)&GEQ8I1;S;&YD[&]F#;_AXC*FQZETZ@BX+7DF?9FLJ/:$"IF;)Y0Z<#
M0TBZ/[Q8F3GY070Z^BS;BP4GCGA+<!ZC]T.$  :M?>UO9WKFO]+"\?T]?N!S
M-3=?B :FRZ*S0O >-JM=R-!^DJ'Q4'H_/)8I<K$:MC;$/D'RLIR)8VTM#9(+
M4SLW4DPGQY3Y(PUZ^-<J#9\9/GG(05STM]F27+8A6/"]:<SM>B0]9%Q7X6M]
MC?V]4&YQ)LYCM@QB._LBI-AK)E=*"40^=4+TCX6TK?Z_GCW'OWRT5WA"DI7)
M>HYD5,)O:V\*/8PI%GVL]]K?LS<[C'XUUHQ@)<2]]((EM[B0#>_ZF@SQ7=\;
MC,4-KH+M8Y5ZL!SM3L/^GG1M0IT@_(".(-^@0DF)>5WHC@HX)!*[10SI0]_D
M% -B5[1@[Q?%56[2F>_.I+K4J[5:PRZ2A"3AK36#!55[<8? L)N3IR&VCPKG
MXV,@4(?WR^W\1$OD.;HR3@4GP5C?-9U OLD@KQ2[BPY_<Q,GWRXR4PSM..6L
M[0N'E!NK5K[OM!-S9W\#7'$99[F5A5!2,!?F,RC7_;VF=HW^F')U#WFCSL)S
MC;:\\)[<F2:ET1';:N/;)*)?L9NSV(N*QLM-ZH)3@0-A=9:S6BQS2KZYF60"
M]Z>K'"[9KF37?7%<:@-X%I/QJ/OE'3G2;Z2EZ/[>N3^/[7D8FC#D4Q17C\6E
MWNVQTF'1W.H?6EN<5W9 9\_/]-D=TE#M\;0H#*<%]D)6U4!*-F; M<5\W=;]
M:C=BKS68D*@Q'P(NH3,<IF/L?&!6=3IL?,6^R?EZ@CA*]%R?OGM*._82[25%
M-AB 8^SK $]%MI5S"IUQ(1ZW4R@ M<5,T\+JE]_2AHN:X*7 ?I=#=<$4Y*LR
MFZPE QDU!Q_.LH:Z@J@6XC,VK,4!IXZ/-G7:@EP<) BK 5WT@+_F#,X6G',M
M0E7/IM.D[%H_VQ&6O8U*VMHV1E2/NOFD>HS%M:=0*%\JYF@[HZ$1&_O8W^,'
MQ'Z.[.N%[DKHJR"'%N)%[5;:_4)-FT>&&<25H2H%48#3,T?3\#0TY4D(->@F
MO11T9[+*1.F#C7]=69UK[\$/NW:>>>!-]7"XO_?K!]SQFF&)R:V"]JV[ FQ7
M$E,4$'< HG8J*@QNVSQ]8#-CVO#^:]H]U06_'=TKL#"VS/6:$("I8.-#H][E
M8<LI_NU T2G%)%><6V4M+CA.\:2X1*Q9V1&V[UB%]PQO HFTSOLUZU'4$*SS
M8B%D9$NST&@PC5/PSLM2##8!9)/AON*=P,UOX_9:@X]1F3LUN )G;! 87HJH
M? EO^+=&+UBDH'G#TLCXKP_9W>%#=O<.65VGK383G10?S 1"07V4)91-=^W%
M"LWB.SNR"1W.[@&+2<*JR3I) 4K4CG-L]+0)FRR7A6"=Z2B0J T-FD<LR0;!
MF;?D -#A*EOEHC7I)JRUU7J21VA2T.8O=MT(X:-MZ[6I>6!IR3%40\B0/531
M6&HVF(#U7V#+PEU\*_5^Y X6*2O WLGXN,-+,><@N<2$V.JC;SSFV!_G8QZU
MS^]CVA>U).K-9I5G1&:C;0IWWMME@SYVA>ZEL_.N)6E!2_O<1>?AKS#;T&_6
M#!7K-EXY>UA"(9VV1+L<51P@6_'R,-)9K:P&UM-2!6C94/" _3T)MK!UR]'R
MHCW;$HR[O9<YHT8UI\[&4'!%>QY"(>&2 (%F7H9SH E&@+7JMM0F>H08QIK4
M5_3+^6D'X9%#CB>C:GSWJVI8":-7P-=BTVZJL4)B<Q"6%]MX"=M=]1BB  S#
M,.CU[N:]\>D_,02(*("F#]14;*0K/F>>XB,C:;3D[7D*%&@S1I"^Q*C9%9]H
M?/S%Z656P3]H&J><\2E6FNZIA8FVXD*TMR:&1L6&^_[>+FO:NH.[TW>PA_3,
MYF2(Q%+#J66+_W$;"DA]-2_*<&CY^NU7*ZI&LDEBI<:L5'-,F4]-U,9N]T 3
MBCQ54M%JT44^E8OW_7-"DU\C"AG.AJ37JSF\5'*=S2S6&C<M%[MU-4-_5(U\
MJO)X@2/+L#3A%*EJ-3]V&FF/<G*(-Q:T]F617XIN6:SGAHZ:RD)S@O+8EO58
MV70U@U JH[46N!M7$,TK0S^ZM,,,K?10M8A2I!72O#-ZA%ACMBC,<Z;)_E#T
M(V?J2".  -; PV<;R8G%L@0UD":8^MW>R&(6="-KM>"%5U[D /.F9-C1U07M
MPJL =A7ST<:)4E)$=,ZRAQO7(D'TS$L'N9$[=SQ@!YW1?F.0"$EI[_#((NU@
MO?(;.2]<+4PA(<?)S@H#V;2.Y/Y3=UK3VZ2Q-29U]!:GM>0NX?3<(ENXR"-P
MXR"#MLQ(V#]IEC*][OX>JT2VE>CE.&>IE5J@E6'4">=I;1T?LHZ9 HXJF@!X
M_Z7Y=ZVRMH9(C5?A0 ]E$[5MZX[%D8FI;4\&3"%7E"JT3RL+L<;;U84"3-FB
M@K)K72\]O*;DL(-4-61ZA@Q1F8E4+Z&B6330]8//4(G15%;J;%U439J;%9,A
M[L&_IWTT"3\B*^M%)B _01*))<EN1,V<A.T6)RM]'S[5?0Y=W*F%R=FXM)TE
M>2?RJ@<L6KSK%@&35@YF9HF2:==7I"2Y?(L.5]3\+@Q>/;V,N7P?_;U5'S36
MGX;,.4,ITU?9%"^)IWR;N(O/TSC">8K(F(I\AV< <,.M0N&00:91_\QO($GI
M#'Z$; I.?EO=L\QC";)RO17'H&E]%K,#6.KJJ#D)$:P7F5UY570X0]82>R8Y
MQA."R!Y*W!8<!7 BGM,!1BMCK&>AL=N6240^C<9"3]7B^4ZSE->*:Z..-QA
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M]"[/42F?54G1B<Y.HY-!KSNP28$K\:B\0J)!/C5Y?"4Q/W"LT[=(AXQ$[*H
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MD=E/2WM;"-%SY"G-*L[R*EKF[*:@P5RVF"(=(QSUW/<M:,:'9*XI SHI#.V
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MEB- W+P.0U6[^<VB*@.(AKLN%E"FS[_5P'<8&D/PQ&=VX*D:T%3Q=CP<_X1
M8':A(L6*M@_FE!/J[JN.P]!8P!R#8R1K!\O,,5"&=UY7$A"7VY)A'K;4OB^2
M^8DNU"^(N0L)4>-DL*=!9UN>L>HD<9>0">B)T,D2G1^X5[T@&>$<K2T!^)?9
MK,IU&G?8?ZKS!3JQ(#T'^2W-:ETNQ"]#?,@?E"1_$Q/Z:IPJ<7H4TO/FZ<O>
M%L5C.!S/W?KQ^(O[#409/ !1;K<.J W@]2(@P3KI6"IKV9>D_K)I1CME73D_
M6;945>27BD6P6;R.JFP^?QC'ZAWP44>=<$3@8!XV[,T@FE;3*V(G;IF<A]=-
MV]U>#[(6XB0A06<(ITV$DLHUBJ6OXBP-U>T6P:1:6$M@BBN^I)BL8C(:$7@B
M*R]&$T\,3KG29*GA!.1<N<>6+-A'LL7:-(.=LB"D ,E 24@[9[^[A'N@][E8
M?IVG&%QR4102@4WIW"]NQ4'ZN:%;3RPY;?14R&FMGW,77_83381?25C)(RAF
MB^QWQ3D7"P=&YD:T$2 1*P4<@X%!9+?633FTYW FX^*<E#3?J"AR\;=,OH1I
M0<:>1XSZDI;]O7<*N,+5:VD*(\6JTNM6%TT9A<57G''-B^N-BRL7]*;T[;R8
ML>/E0-%7OOA ]F$VYP!B"FS7=..?4"E\':4G/.9UY88MQ04N[HN]S+UW\^R]
MR3DRH"72[#*N2PT$>%Q5] ZTF'FQF!U 2;AY4TO;F/<2UIPS(DN,-_IQ$L#8
MJG7B= 4]H5D"=)OBQ)^*T\+\KBM?AAY*V8+?WJW:_IY*Q$:P'Z6IEXWD&Z&Y
M^9V!<N3+5EH)%(C -J2?GB)+KI4\$"4[\1K+@0F:D\6YDMJ2C'%\RJ>3:5$
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MMN9Y]I]U%O8YQT7,#X02G&6NIP:$A(Q9/I5JS[ 0+SFJ+@ T(]TQIW]+X/_
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M)FKAHHZ/M%J'+[E ( J2R4EP>:&P0\&+G\Y(>],F0/3WN380 W0M9IA<<(I
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M&R&D*+@XKNC[B"*9"C @V!> 2I8+Q1&SYU1SBM6G#$-PNAA<<S7ZH0J&@5
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M23*WJC046DCFB2+AU6^ [D*9QJH W=^">UI,R#1>RO%"^HB<Q3RKYIUZ%8>
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M7*\O_9>59%?E0H=Y5E<(6Z07B0TU]_ F5_9E@E2"K\+["<79)+\UM@. HWW
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MF;<Q;BRCFROL<%K,GS,4HC.9Q;9>7W.3JGTS6QC%&O)^6 F+\K#_)'UG&#N
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MC<_5? X')[U3*!]P<B 2<KHD[*:" \<UWIJP" PEB"N0=X7JS?/Q0@2494)
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MU@L-"[7QV"?V2T3V740$-@+51@T-#NMV0Q;#\J6FEC]LAO;N,PL.'L)KF!]
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MUXT!=]4>VGRDQ_&MR?^;Q("[&@/VXKP+,>"MA\> -Y?$@%WH-PECRHN1X*=
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M62CN;#[D/' C]C26R&FWD'\AJO[V)K'8[EVDUW L SB\)6]Q!.?1(V_-I[]
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M"BVO]V"2D#?]7]A;BJMQW68$NY;(9" <$N959G*2?G"=YR4Y1L,<;L%F4.Q
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M'B'>[?K:$4/V,=:][5)"D#?# \00I&R4#-()HU4B_-B(9EA7\.>-N4X'$\3
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M\PUMN4&12_8"7V^:!_Y;EN+[+RM;CVF#@P5U9'(?B4L.I/CWT21A3=#+. .
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M7R.13@U\B5N*A>0U-QT2O8W<"=TSO?LV"GX/<^/<ARQ<0C%-]!5O](9"TOM
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M&NQ<HEJ#B@JS.3;(& EA43J&*,NZF$=_&3 JP!Z9T?/*6H%S$^G@I>/'$[?
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M$1N\=A12U"6[-4HIQ:]728,(H33J&E$A5$7@!EL8B'+>V>F(7Q,5!<,_4<Q
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MMWI]V9?L1**=%*^PBNH[BK<6-W;+B0CS%R6VV ,)TIEHQ3 GY?#4JA. K:@
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MU: 5I)2Y'K@16 /$\4*[O1BC !5"^6OM;I,D1UO 1/AX7Q()5MW4DD!5FD/
M2I1=_-H<)$.@H!?/F4E$'0+QCM+V#&V%_TE6211V@I>+%"QW@AH2YP%K7P5J
MCP)5\_D-=0]_.FFWK.N/N&4DH;I*BK&9\.9KJTU'U9EX^KIA<2\QZIG8.7F'
MQG0$I*Z-I&/=JT]<5930.]C+:##=7R] *F1IH;.ZJE"K_E'8811>9)W@68:^
M *-T<<VY^$84@R3;C>X('G<6_[M<@4-Y5A2@$S&E?9YG<_@H'()6_!)PJ4L
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MMEL?D/5!3)1D7&+3:U+[1O=DK+Z!2':P0ZQOM<X2EB'@P<&:(30[DNTC:]*
M0>*7BA2>%8*3FZR2>8IE ;-RTVXEG^3EJ(A7!;::FB9<714!AA&89U1(@5$N
M5O5.W418%%G$QE\0EQ+G5<\\AK6DRUF9R^&A<-5B5QH?J3T4+!!X;Z(728A!
MV8H$K'X QMB0JF8W;F&S3CKM'V\]R&=3W(BP*D1\B#044JQ)SOH6+O+R'WQW
M0Q6!P;1[VAEUNX0LB-R*9%=B/UJ!U!BS:5J 1<LU\PD&2]1G44O"3>=16A J
M8X@QA2!$&KW0?Z$NW8BLY;_T3\:G*!?X@1T5H\<,]H**^E/D-U/ZC:DQY#\*
M%Y!OA[(646,+"JW121 ^)D90U3B9@0"-DNQ"JYTTNMGRL#/H]3OC_A K4Y0%
MLLL!L#MPS6[<@F@4+N!6.\YS X?D*2=/)]U#\O012:K;+)_7VM)U#!XRWI]+
MU)8S2(0I!@; _GAS3^YYI.3F! Q+.TL6V35*%?Q4H3MB]*S;BN2F$4T4!\+L
MYN+&?!@;?]R##(Y"1@$&^9@O,8P0@Q)=*5]#51G1G*CP.G@*2D>MAQO2,43<
M[_YT1A7PZ*K\GD@++3KRE9=]2#!7BEVBR_4BNT$I1M_O_70L0#PBCY5?A@(;
MK22LW1$YS/>DA#&VU2S$*,*8 4:?S.+Y^/)DOJ!GTKD5^N$:I8*ZF:/L8I7^
M*;@.?(RJG0<;;,3#5,57.RSL7_3F)%>OHVNQG3I\%AB(2XIY+3)"XL7ICVR>
M83D64#Z&( M:CYRTGR'D&$_^URP'81&H_]0&^.TP+G3P)& A1W]*XW\\^3,9
M)J/9;#0*^_/QL#\834^3;C@8#?J3^'04]P9ZP&@TWVQVG2WJ2(7&8:+YQ>RH
MVPGP?\>.,-TR7E1DM-)7]B-0\G(_0'TL*'_>78M25SM.A_6(M_K>4."9U/CO
MX 'EL:DO;!9W0674*9P0*KE_/.G9YW]1;F#%>*/Z$IHV*E>N#XJTDF_W2C8V
MO'[XY-N??,4.]OP]J-@$][W0)S\[@\9I^!^/92G^5U&NFPZ=]D:39]V7. .J
M"C!?%KAK&K(-3ZNO=A<:F*]VNO]K!!]]2C4S:#M=Y^&Z^6X\Q.(A#%EBOL?,
M^982Y1BV!@<)9T5@])NS)I_Q?GL/N=\OP>-:9?C?WW\$/.X/#:)']3Y<H#]U
M])?CNXC*"IMXV:&^W(>RR&,2W8_W5E4P!QGQX1+[/,EYY@3&JH!(/A\?#SZC
MG#X0X.,AP/>;+/KX]!F%;C^SQ?!Y"7!X(,#OD@ _4%SQ81KM41E^3<^OT3^2
MOCAZH_Y??7$QO)L^=A3U!Q/X?Z/1\1W\!-\TRCMQ.*@376,D>)=^6+TOY+8U
MWJHXQSL?V1T8$R'6'^WB5N7R06NS63?'>];+G7Y^\AN>3CO=T\&WYNHO>1\'
M6OY!:'G0.^T,A^,#+1]H>>]I>30^[70'HP,M'VAY[VFYUQF,!YW1:+C_U/S%
M_(H[>@P./MP=W05OSY4,3O  P7TKM^$;,>NC8<.[&/'];F<R>#Q&_#=3 P>:
MV5TH3X:=X6ARH)D#S>SN8'7'G<GD\:CQ \T\?IJ9]OJ=WNGC<62<,]RC&#%C
M)5K0<9\Q:3-J2MK<PY#L!+=#*!XBT0<OL:Y<)GVLT7\T@N(0\7A4B]LK6AZ-
M#W1\H./]I^/^>-#I3P^T?*#E_:?E\7#<&8R^ UJF-3^"&+3"-,'_?T?/H>HR
M6-@XC\%/.+CWNVN([J@S'/8>#5<=0D+[0#/3SG@T/=#,@69V3U=T)YWI\)&&
M$0\T\RAI9M0?=KJ/E6;V*/1,HS($B?^>(>+SAJD77ZJ7]."J[;.KAD;E8/)X
MC,I#V.%1+6ZO:+DW['8&O4-1\H&6OP-:/IUTNM/3 RT?:'GO:7G4'W1.IX^G
MENDSA8/_1H W/]\*&54'@OJ\<%4[(/LH.)]A&,\&H_XI_+X[G,['DV$R[$?#
MV229)-$XZNHK>/'^_-5O:;'YL"NF#_]"H DKV&>-$#\*Y:S9-U//F2 :W>YG
MY(>T\#W3Z^3M_B($\]CRCK#<9 WO\(*!W05;S&:^GQ$+RX\@Y" (*V L@AR<
MEXO%TPT\U$ 9"P"QX&,%,>.V,F BP83!!PJ&O.&9)?W^2<U-K;C<N[+)U^*!
M7A3-3V?SX7C6.QU&W?%D/N@/)W%O.ADGT6B2''C@CCS0?R0\\#PL+EUX/(4.
M%]/8KE4H?(":/5E%"&W'.+*;RY"Y(\X6B'I+[!%E*UPT?663R9\*P21-/D67
MB#X>4/$=<,7;U^_-<@8G@]%T_(_@+[V3;E>-K10P.D;Q4YBF_!*:!49/0DPI
MAAH5N+G?DS7BX:]DQ-/O\*$36Y$^8D:;3KO36?>TUQM.^\-D%D][_>E\/I[%
MO>YLT!V/#HQV1T8;/!)&._."+N+8D6Q1+E<*HMK@,M.</@/$TPD,:/3F,BL2
M'+4=$W?.;M2T/"2S17A]$KQ'C,JF1YF5+<,;]>*.!O?':7H;^XGR!PO\UZLU
M.V TKLH"E[H.":T2_H4C[_)T5@I6\2K^&Z)K+Q:9&NT'S&O64X17-!]J#D8F
M/L8#N7T51C+8-@*A P_#_^ #K_GO2^D.2U=%25\I9**7PN3.T^*C^6MPE)Q<
MG'1 X<_ARS%B*..8)!S<JA851A&5 1S#@BXS' V" BA<)$5$8V]@LV;')(P(
MIWL!JXXP,HVS6<)/. 2J*)Z6:_-1 DDG6=IT4_@F'']'0R?5>@CYTS?2>)W!
MC>'@E#V1=;UD-I@,Y_'H-)D,1TE_%@WB03@<XO_&D][X(.ON*.N&>R+K<J6?
M1> 0A#V!RN8Q?_H^B+(&<KS"*Q9*KA=?O,QK&.,5C&"_EX"8YT6Y7&O9%GQ,
M;FAZ&])I$92%=B',BN#DHY(GF9!C@():F5P(Y8[HMF4AWWR;@7G37ZIEX.9(
M)&0TWAM1@WUGA),,X)Q@Y\FB2'CBE;H!OI*]\S^B4YS5G?0'DVD\',R2<!KV
MQ]%XE$S[TVX4_QAFD>RB=QLZ\&TBY<G/HT<B*+R-0S)5(S;#'LV@]U7P*IGE
M-!^^UR5N'WQ3;?=CS@OH'>8%W(.EJ^#B7WMN@(.J>(ZVXLV>CT=X\O,?A*I?
M1]Z7\66YH.NW6S@.*0;M'X1NM(-LYAL5;B@2-C$VES+WIF)<XY <&W]\HQ#Z
M.1C($WDT6+_UATNV&#H(EZ^\.'L=G0!7B@, K^'QA>7Q>+R$#DYU8;.#9>0B
M%:^%)V?"F2Q7>ABO.(.>7;=;Q656+G#&[\>$ S;@ZZ ITI'Y:BK2@TX9#Z$B
MN/U"C!?X84T3,U'LT)PAC/DX<UA4E+2#[JH:Q8*#[<$+*]!S)>,H4K,%\!7R
M%7WRM@M)8ZVBRQ1K?? $52=G-OLWNZ:%'(&>?HOSE.C,U/C?.8X5EPU8KPO0
M#U5KW\L)1\[;WH&YZ"7TS+"+F1QR+G^D@18XG)E-WUFX(!*<)9OK).%H7[I$
M Y)^#0>HKC[]DZ;W.,2.3X!; -KC(61@I%:&20>KA%\$>J/$^6$TVH<NY8K&
M$;E;6";X76MLH":1!1#K4XJURW35-,*7TM@ Q4/&5#;$0L.4 H]@;+=DK@2_
MSUD&#LQ*-YM$6!/^/,N :?$X#.V3XQ'&P-5(GDL@QC(7XIPODD^I\"N&5L(4
MM%% !R7S%)US=*=TF_L$=8;!T!EB[KK\N@PQ1XQ#P5?!18*C9->7%(0 ENOP
M&'*90ZU$1A2N18*<!&^R/,'C[]3H1)]-BL/ -NQ]P0Z6&1PF<6%U[87A5_CK
MZB(CP4E$ %^% RD7&QHLIF8_XN=Q#,O3!799F-EG]F5*4@;O'"@&+IU'7F?E
M!AQ"$%]Y>(&O23Y%.$<-7DP1'Y!Q\%MSX92JR<-K<-/6&/4&!LEH,-4F7+!G
M"J0(&Y6A, 7.UMW(,"P06PL:/DOROD!#,RTN4<U<++*9&3XKXX<Y )5F&U-A
MJ*>J.=/U<)05W: UJA>,+[QFC$_QU/ HL6:RL=I"*8SGCR81G44JXX%QM!9-
MM)M[ T:*.(!;0I27[NG,D@7>FPS<2C<\R(NF\2U+&IN,XUH<HB1]V.%UP$V"
MW,7Q=_84.OFUQ2GT]#"7(3V;E *,.L;E/)[&A*%^Y"\!&Q4;10[6F>!W:5(,
MK)D?BC%/"LS1Z!ZZX&+_93S.3(TP9D)L40D+BB6$>J_=XKE]:; N@5*CFFWC
M410\LABH( 0BC#FN0/>/_(ZW/TMXF.(5!Z#QQ74QV!&&H3!FG/ (/8XEHQ1-
M,(!-P1,A4+^<9=V-46Z<VDTB?!G^FZ672$P*VR@CBP8X!N_EHV_DH_7!?PPS
M@?[TDY\[:/N34R.6(%M&*BI_A#,M-P%X'@6:D/;K<=WVZVF*)8^NW;#MDBT6
M*)"<#^&.\(-Q1I^[#*]P.IY2E&@FPKDEAKQ9IN-X2 Z<X?>O,AK*>Q3.*$*L
MIP'&:<%F:A(?TV$<I;!\TK<X@GW;DJH; 9/(N\# OS[:$B4"*^O$P=X78;HJ
M-O:G\44T3WZ-)4T\1'.!XEZ.53:XSN"1--[,,/HMUZE&^Y% \Y&WHF$<@YY<
MJV #)?91)^-_':K&?>!WVBWZTE--^TAK2U:%C6R@[1WG>%<9;Y82J6CNX]?S
MA&.;((M?>WA"5I^"/,-;J7*@RP;-'*47Y%DKYH2 3A+X,RU/WL'6O]B)\PP3
M+L3-\S)GE<5Q2\NPEDLFDR=#G8:6#JG]$$?2[K_\?2>6:,4^HMVZ9E"[A>-J
M062 94)3-NV+J\HO9*GWR7K#0>U^MS?H&.%.@^K@JHBWE&AFUQ9YC-FKW^UW
M@[/5"D<$_L*3/8,W8#S3A>$L7NMM^WX-_N'0WOEZM6E^G@%[^W@:#QQM^P$]
M<'*>9&:><THR*@_-TZVS#LV(92U+1 (1:&=M!'Q'_J!-?(X/Y*"(XV1=@FYM
M_")54C7^E6;"DTAB984E6_.4]1T*:TS9I.[L>+1IV3=1D>9"N13M%JM2&DA=
M:E]6FTY@KR[$0,$'RB9(#Z;*RD7WH9QQBDF22EL.!@2_ZP^A9PC^*&_&5YCF
MC):4X;9F(''',PL7E\LTG\"-/0W.3FX;8"QD +>#^IK/UY[.2/;!#(,$%1X+
M_6.!&V;O[@6_5=Y&QZY%R3L3":R-[6RWEDFX*G8-'9;5B:!V#8@) >(W\P1-
M4^WH.5^KQ@A)$LYR%7# ! M<->GPDDW:"*W(VMC/%1,:.]+DQTF@\:;^S@YR
MTB:8A]&F7%8CDO@Z78#Q$WJJ-YQPU644.%E]6:+BDE(/)U2*ZM4.B.H9H%2G
MEJU6"0?X6&G".2/?J7RK%&(JAI5'=/B)P&;AC1KG7MFMF@./WU*?PAGT*#R*
M,(T?JR+UIGF^B"IQLT4I^-EIY*8=V NO2 B?;&P8$:.EQOTT'7D#Q'AD!C5R
M7G7HKU7P6+?I&\3XL4H^<.FB&"0^1Y<">[?:Y1U#Y7H ,;M[J3\,L(.3?V);
M@L"':I$@$4"F9SI]$J0>5T05+ZCX>5J0H^A9#>M->>.OX,Q1=!$^J+SY*,VC
M<EE05+G@ ,%VOV5U5^>EJ*5 8!$KW%?]+VBJPT[4>31Y5]H' HO'XP0UN#T8
M@SR,G><T<O^01GY$5LVW$/TJ5&:,3_A,@^PO/H?P_Z"%O]=.JTA<K]S'-:,5
MD:#V;Q#^NM(5/PR64$&RR(D&J@ :#5 /E;0.Y#MX*%B(FV.LS;S[J*E&][BS
ML[JQXZIU"<IY R<<P8'7% XIT8%/2EM@!@;_*V'VA0Z^-X2M3H)_5<OQP,1=
M.R,>*@>*5R5^G;A4I)AL'Q-/K/)8/,B&FU&/H>B9?DKSP>KZO7FY*7,\9R7K
MJV=</3/\734&'5!U$RM5K0K_'AR='8L3%Z'%B5:LK1$[*G%""Y$EZE0I)N$S
MK!?<[H(H4X%OJFXJU!+%AB91J<X2\3C8F\ (5'I%\21KW^9,JC>R4;S7O#[X
M [P2?DFEC;K0T]1^S1OO]$B91E8&V3RI=MO'%,[7YI3YRC:+R;5!?#%>92V@
M1<$!%64DPO.-S0;7'1[K!,$2TVGLA!"EZ*X:[1]*@&*)U-$4\\"X!DJ, F/N
M*448B23#94+RA9O1DOD<UOI3<#0[5M2 2F(K'?Q$6SB*^!NSG-.@E$OSW;N<
MY J(-+B0R./2BCS:3"*/?G9L2.V^1X\)!_3S-N)"*+//0W+M5I7FC"A1:61J
M,%JQ:5?915#91*="1Q7;/%LM;ISK=9QJ.)+<^[4&/N4/F/)>B0*I[)X)R/V>
M7$B-,>B,W\L%_TH*EYR0-3$A%V"S7GRIM([6R<<8L<&6+$_IB/VFD^!#@Q#M
M^'09$>R*XF=T9Y6[8D5DRR_/SIN60NJI*&$!%+PR)OPM1W6V6"17*3\.:?R<
M\J7MEOGX-;7>2)4X;N%#'N+E9[P@FH,,9RB-;N],_IW?7#U+^X7.45HQP(ZU
M\G;K/3>5X%K.2B!74BO4QU,49>)+8Y7P#B!=LJU H\SG1J9:1>-Y@N^F4(>_
M^LMU6=?AC>H-JM\M^)4I%0CY:V/ ):*@C-37@TY!IA-1)^J1KAP?CNU_1*44
M8:R_B^D$%Z<V%<&1@,D7JB>&9<P6BB5$&N1+V5!.N"[SH@Q76I7E6!H!LN,*
M7#L3@F7/M>%*B22UGZB<0E663U';60(.I1O-?4:G=YZ'T2:-*%1;YT_:T&OX
MUAK3D-@I9/[44!^IHKFJ3A(U45%2690.=.]&-X\\CONM@U__E&80%B&.U)7\
M'#7@/N/&N7KLZ6$NCUW/(S>/^0QB,%5XLUCHCI5:?,<-=C7Z.C.I0@NH1@\K
MW?AIPH=6]A)KLM8L0$CU8CT"T!W:N6BV!%A:*.\NUTB) S"05ALJP H7L$PT
MAIT"#5.ZJFI,I!*)O2!EQ==26K7*4BH1MJS NK/2X+LB[\2V_]IT3AV/8*'&
M1;D*##[ AUF*^._$/FD\.\]IGP1-:6EYUYRJ8VX]^7[WK[KD@OHZ[1K;N2I8
MI#8LK!2]?6'&4NH$ERH(2!NO.@MHG=>3'^V6_\17F XHMQG'VPLX&Z*(4D*L
MZA[TZ4@):[MUVWZ#<*;*)E2_.YQI1XYW!'=--4 >C_@>.V$M>+^MW'IS=-V\
M;"Y0.1H<:[[$+VOF/&FW7K&*8V(/6<9%*..$B.9.I:N'I^K.>>J8#!Q=EJ0,
MK6T).E;7:]H=LTY)7(T=E&L&:N-C8=&Y2NX44<9I,.M(\$O_@2VE BU@\81E
M0$D!9+WBDM*X3E6R"!W[UV"JTA&1%G8S>9*N0WK!;5)"#X\=S45V>CD'Z$L=
MNJ@-[59S EUER+5CS.?"W@><+Z[4]F0J)^M<?4UT4'@)! ]H(;HCY[2E?LU<
MMICM=V)?TA"+I+;R^79!T6Z)J[>X<6-I8H:C=ZO<7$_5SDGP2@G%>5I@U2_*
MQLZM-G AM5*?TF6Y%)8$X4+KUF+VUFSPEGT=T@V2;A@<T@V/*-UPMVZU,$51
M"08)T/E;T%(F.V!\'3M-^P;G/X3E(GB??+S,T^-]/*$'EG6] Y/VK+S .M<Q
M1AUZDTZ]U% %+>UTYAIK8K.2U$RV$.2.91@G2NQ5'>HCRLB":TCJ+RPJ/796
M?OMX:X*;'7.EOMDTROS&+*&5Z)<DCI1$*\9(02M0<'V9$(4PE!&692'2 ,O4
MC(*86;JRJJLXY(_!*P.\@J4)88J:6H47V$4_HA6$RF_WKT'<[F.PU@HY\.+O
MW\:!?CB[5CQ=ATJ)_F/$<Z!+^SL'-?"=3PAQ"LS$)/ER&W=:;G?B3=%FV.3_
M]^#TI(<:[D%+H(:!E;*"YDE"GMU?AJ,.B74@]<>W[^EGV+5LV[*9Z 2 X@GC
M0GS%-<OS)E;E_(*JU +A0[6#!;HHBM$]QK612!)LTPSV%0[Z#E@6X7@X#*?1
M?#(;]8>3\#0<#OO3WNEH.)K,3L>SP6/%LNCW3T:/%/CF*'PD@!9GI!J?:]7X
M-/@+30V5J L3,D7__T*20*<Y(]0J7./[TPZ %G<@MV04CR?C[G RFI\.I]W)
M='PZ&(Q[HTET&HZ[@]Z!W.Y.;K-'0FZ.952ANJZ7ZH:-5&=TTN>BO&$X&D2#
MV6P03V8@Z :S7K\?=7NGDW#2"Z?=Z8'R[DYYT2.AO+>9KJI&L_T7[!A?4?C*
M(<-> QD.FLCP:Z+YW-U<>M#KWF:V7>0V-E]B'D8,(ZZ4P^:Y%1?18II&.4RY
MY7=)2<)C+3S?_6W_//M I5UQ;"K .7KNG!)UM5=JBRO EWM^% ]TK5X2ALSC
MSLC>K;W=:H.2^':E6%METH$RD& Z["#X_0JD,;OB)*00[4*:3RA\X($']'D:
M%;A 4$29)"!6G+Z;IWFQX>R8W73B=L=M6ZJ6".Z",SA/JNK02QZP'2DK)^GZ
M>I5B3J_=>L<-0K]P;PW(Z8Z-M='QGT&O:S\0OV#[7"9,1%W*UNY,30O[O,[+
M*>*AJQZHT&'?>94:)^788DGPT4G)\3L'0)@I>#CJDQ)LHM1'Q=NUZM$D8)7R
M$[EO6&)4DAEYIM2"_'Q;N9HDQ0B-.\FCM, "4GPQ(M7H^K1HD0EX4AHUHH=4
M,3,EZ_XV+.+P/^JG!0(F;/*0PF=Q>(./1#K)F$_4<7"!HNS3.9R-JK:6!]*&
MN;#!<_8>VC.L1 DU+@E=F?1UNX4]'U138 Y4XJ*%G<IBCN"WDHA0:#NZK;+:
M-U0O,?5<,U4AI*L2Z^_D4\3A:DOTOF,IHO@:]\8WTWAQ?(SV,86+_>?E9RIC
MJ[A7!:H]%(47E2>Z8,K..Y"4*Z(\G<&M(UQ*NCI6EV,J@N'&X]0!/NEW>]W@
M?!%R=Z-I8694N*><H=<X:\%ZH;*X"JP'\_P,<.<$KQE0VJI>TX1>)"[D7'!-
M]32S1&'?GF E&U^VD/P5XGV@H4]I]S)_2OH-[/8TBYV0=K"YAH7>@!:\2C2V
MQU%_]-=C#;HFVD7A[/*C9>6D.Y'DY,- X3DB28#R0_A<-(MSUJWI$N&^@:,7
M-S8FA?VEU&9N]5J"*)%W_R2]H+9Q/@;J^>O6M1)KJG?@5264'^QHGP9+H-NM
MP9@+)?8>9@'=EPV*(,)@JN$?2E%D<D6Z;DV$C%*W>G9;8KXSA 3B 2LW=,9(
M\=;]$DR7*@; RD0N8D&B@".G.OJJC=)N89??IC":%+3D-1-6: $IDS&T3/(+
M@@&$C63Y1;A*_]2%<)88U=W'UR"#I98?ZU]8J^.6\\ JK%I0W1554E7E,!7L
M2J\-(K"AN2\(!0DK&",'-$ BF8.(-\]P .188WYX37B,]$LV K'(GY17Q&#R
MO)-VBPZ*9-6H^]<F%2&2 1YC0_!0)]#JQJG\AX_HUU?*(50AT*I..*H]HD(Y
M03/AJ*(_4>5"'Z%^A+("$.5O46WZ5HV^A12^6>U%6@M7;MGTO)"RC056C<B-
M1(\QA'7M?NV-U8KX17+!%*'KADGTF#KY=HM;:I682GFW%O>0:&G@H,TEM6?
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M:FS-=@N,S>..,M2:0#@K9GMQF=3KK2_R#"=]V)!.Y#B^??T^Z V&G5Y_!!O
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MC6*_^^'!6NYA,/^QEJH:N>&&>A"?Z:L2^:I@18;E8 *V*+(H#75@SWK^=V&
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MPC@9Q.-Y.#\=1,/1=#KICN?3*)[,>\/)..X?6GGWVO_5RL$?>':(N=(DWR'
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M*2:.R5IVPACU@U>$)YHG6<1]^5&RERDHYVT&#Z6)J35QMEM1N,*P338CMK%
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M>'9!TQ]TJ.XD.%-O#LR+T\*,=2#<=\]"[8_/.4S($QTYQ</AW1G"I^FV&Z]
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MW<-F5EH4TNQWU<6WXW@_1*;17=9JZFUEO!Y9][",M>K'TEK]EJ^>P"7B2/J
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M0F(ZL?7I+<Q9S"A..,5MVC[RTE,9^OP^=R]19^ZY7.=\;9C;&;1HT..SYH4
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M44JMVK':B;[.!?&ULIP/EFJ\O$G,G[EA7"KGE<\7C^."Z67C^F?S!",'F ]
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MWVU7O;8]$LQ%[/H'AZODYDS&+^HHE,=4? A.BVAU@>-X2O/'IO#&BPJJB?4
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M"L7L^%ZBA#A.M,7?L4N#?)/8:'(T'_<C'Y8TH'Z9H7Y&30O1&KA<PPG4E*T
M._@DP8A;T5,!+%L3W,L26V%ZLP18TU-=+NQ2>$Y)BXB]TOD4\604$HMJN(IY
M8_1:NU1>FL!*70L9F#0_%>94V<KHSDJMT"@VY4@Y49V,-IH9$JS4ZU/\!YW
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MPAOZ4:+0F9FU56,'>EV%5"U6(/77UW$<<!D*3)H \52K$/F-)1Q0?_/!5N,
MLM/03/*-LH,7^D0%HDW\1[<Q^J]&L ?O39H(C*3&Q1FI!&W?>/YM)9G"0ZS%
M^I1A N>& ?.9@!8H<5>D66YN< F)_;J)2M(B1*AE0'M]!@%1U+2%H7_<@VV<
M&WH,*,X<*_*J>K_+BNZX=Q+8S3C_K'[-PI..1_RXRGT8C[.YB];BLK_ SYPC
MD=5OB=8N)V%.FH"CECMJ3D>7#2X^:DYJ_QQRK @]FA&Z>+#N=P0</$?8!EW+
M@RMFAV.?^\<@O4:2ECCT\><C/5,^KS&*&BXS(-><,D%HOX0![ U]L/7+7>@
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ML"O^Q^92J;/)E&*Z=9=Y^:8+!5$ B >=^U=F)9YRY]@00/H*PCLU"8O\:25
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M*1JR7$6R0@U(+%&VDCYI\JRKJV]N2)I2QO9D^T?MT8-+$R!)[V$<26?W%!H
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MO;Y;;<#P6[LP"VZALW58K15-P*/QT:BU)X"<SK]#I 1)@:W7?BK:J>)IL%.
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M6%E@=ENE*)TG3:@OB/<\F4F],);D6T!C@L:^H_=7[SM"" ^2J(];&8[BNZK
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MPOL<(;Q?@.C6N;KL --[[Q%%%T$C6RN^-8Q[4PBY)!!.9+#[DPCM?C+BTW
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M>-,5;2U<;PFM+4VKSGY]&\;@->2VT-+,?N F_GC*78_X7494E2#_R3[$_XU
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MS@ H/)Q2VV_3J&":1+#:Z2A,<U+R1;*]/TICA_>9'F!#DH"8G#8.]QLH:!+
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M-B%<S6"E.X\,K?QP^C>WV.F74O>"39Z5OT/S,1):MN?+125D//L@3!?H==R
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MA%.9?VO4M74S J(5Q<9]E,( 6#WG/U'WF,7%9NG'L)PU,?,3#K+-I['@(-7
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MLMRO%B0#;EM2X1'2"&7>MGS)@JG!C!$&^EFIR+051> 6VUI"[66.AS[2B2-
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MVFD5IRMU.CT5S@S=3*(L *E%?-J/3]IPI&5[J+=,1-\*3T=#IS>XPA&=1%D
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M1@,MOLB,1^*<)Y.LF+C?SK[Z9$QE?>R8M[%0?Z8R_3D6Z6.-[^@(;IQ7&;]
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M0VM5>0)=6=%G8 ];P4N"(X#'C2>.66P_F!<L]A+')WS]^50; I\Z5"^F7QT
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M$B(&(D9%B)&^S)J&&%29L!PC]"A:V*[ODZ431Y^#9L-4BG_D2W88;48%;D@
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M&G4PUPASC3#7"'.-,-<(<XT$R#5B]^W^ 9_=5F]3+9Y0-7UF&:"GC V#:L$
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M\_43.VQW\^2\[9@47(Z*NC\&%?LBT_A\\@%T_;7FEVM6 FN!Z:TYDW0^=8B
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M 8#="+<'5#!QTP&"\. D<@C^<3G,^)LVC(N'@U$*S%?P&(%,TY'((ND2- Z
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MJ2!NDW!DG7'_@E;5OZ#J7U#U+ZCZ%U3]"ZK^!:L1Z2#]"Y8'B_8FW==5PL_
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M<$-F6$\V_-L[<)+]TE; )K4V2G, ; ?R,GT]TGSFC-, NU4:8)4&6*4!5FF
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MF&\N1"[$/1]6&HBE)(Y25N4K+'JAO&\V/BBWFJMK?^+%?RI6I&L+-YX6#X;
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MK77:G"2XDU?H6G6UBM%L1P-E64N91CF:0G?.^EI0G>><Z;),4B6GOE9<];Q
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M6;3(67FVMI/;=,N]GIBD2S6F.+AU+?@ 2+I!C OL)8S46!]&.B,F<Q(:=L5
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MISC,\QTKTD9*RC>.N0J*@P?V[)L:[X[S_MZ!H8RY"7N&YYIHBPD__*Y9VG,
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M$G(,63<Q;F3&<A8>RT&8$^L/'H6 KX%8SWN(!PUP;!OGTFT2L"!N?< @,C^
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M!"P>I4*H,0AM'@5<,T5%-:%B7O!.;CXW)I>4Z@NMU*K44T*:>R*637BN4+M
MB2<EGHX KMG$D]"38#OQE%\Q5KM9JC33,BY.1#Q)8@@?OI'[B%VL.Z,IC56.
M\2LV;3J2768O2Y@-),_13KH5+97>,DOF3#)9:'4AR&3XQPT=$Q63QP&E%VHV
M:M52I9V6LBH_-\GL39*0P>1;T?&RO-#'8GN6S\\4NRBU6J?+\9(88J?AD>R,
M1HZ/ 7HV3:D+!S^'Z6H'074[=1&<YJJ/]NR>25T(O572U$7PV1V;34K2-.$W
M+;SH6.-KSEJ%&HNU$CSJ,#7'OKV0I\G6A[GJTQ9&0C>97(51?F9LM=2N:$H8
MR6_J'KX9^TBGP]L34O#!ZQ\.@<[DD:CRK>@0?0_9VH%IS=C0\4!2AU6YE)C[
MD^\N9M*\2(MQ47%;UQJ'*:NSR&%I*$28+RDC2.41 O*MZ(C%4FMKL51 QXY&
M-:U]K_P\='IB21)C]C3\M@]8!TLW4AM]$#QQ4$Z&PUSU:;M&VJM5&.6:2&5Z
MH;[8>GU]LN>A<JGRQ*I5*W&C76PM;O+SMJ8WH%3B)K)#*<S3+)6^AV:-?G-(
MZQN/M:?!__:-@TGXE+JYP8)%8A78L,:4Z0CR+'N%3OC0/@Y+*50KJ4HAC,U%
M]$' -M],W?(ZUO@NX)Q"[=*TP0X'R:B'880J :,$3+X"1BM$P.08]U<")K8A
M*<S.D_"*W@IM$-$3[7A,=N;3Y!>DDW:(NC7"!T&4!^4,.,Q5G[0+H[J^]NEW
MQW:+]91JE6;IHJY2Q133'OFJ3UO4K*^Y6B9J<BRM:I=:J0.!E:2)[% *B_48
M':7_/% S5#DQE!,CWVRSZOJ2JI!9.@&O*"LT9^>%-$1S$'FQ2@PJ,9BW&%Q?
MS)5)#"H+64G!\ LIS/>#.I@?ICOA,%>=LQ/D$("O'(!JU8KVC\XE53\&EU0/
M>RGCX_;8[S,+D(MJ[YME7K#$]J/$#7Z/ K*I1[K8M$1-JS?K;:VQWKL%?)>G
M.VMBO./Q^7^P8Y]=G4O8Q5?DZGWV%%<R1LD822&;2<:TM(MJY>*#,N;#OJ+3
ME#%+C,_D)\E)U<&G14VH_3(RL>X0&$R7#ZM-?A+_.\/4^N1$^6#=:7-O"V")
MZ(3FJ>ZBF6._&F1 ^<0WS;2D/CJ*W,'NC(RDMB>I@Y'A:]^D4W@FCOVRW=3F
MK[JE/V.24HM&/KS(\LPY>L*F@5]A+=Y4]Y!KP*6Q(<YD)SJ:&JYGP_-@E>3%
ML&ED>,APT0M)6#2-'Q@>!4^PD&5[[%'D(;$=.?@9EDG63K[:8B?HS0" DA<]
M@;S$P"'_@5?PL>XD@]+%F$XQGOB>[^#R*BY?3"N/3!BOI(U'SSK(>$'@LV5$
M2L0F?A^9_ABG+"1.C2M?&Y^B'IV1GKX%89#A5N)_)?OPG_?H'-4:2\0M_S6[
MBG+K#&CT_ G0^N-<G\ 2+W7S39^[\-BI$URS.,I?1O5E(%TKE5#!$F LPC%/
M)MP8A5--G!M/MH!^Y62R9 HD5>9G*[]=/R+RRSJ**P@YGF-;SS$D"3]3);Y&
M9F_?]+]^^_[[70\]#&_+J-.[1=WA  V^7P^ZM]W.XY^K,1W\XDN(?YS@1 :!
M!2]QA(1H$6Y8 L@Z?,*(@:@/'"C>R\HH9I_]RW<]8S)/CB'/S'V%<](&2 IP
MW.L/[P9HV$<W_=Z@_]"][0SO;M%]M]?IW70[#V@PA ^^WO4 @\N0DN77+,J:
M?"$DG#6*C807W&_!%^)TU:C"UGW/#CZ@C,4^B6)4E&J$?].HH[Y.*AXC%62Z
M^'MY4(8CB&GJCLM4J>V[H(==] DT%9Z!:3#50=43U0R:F_\UUCU=B -N14B_
M;L#96RGEC51_A$((4>9*'K&AP81CT<4E*,T **NO[_9 (-^A8>?_@-$_W<#W
MY<\1<.YUJZ(9%#%[8C;1+ N_Q&V=Q+*2JTYL,^;#KK83+NQV(UW[3LHQZ <G
M-GI/M5INU<A%CQC.K"/#-)AQ#P8RL4+A?[!#Z?F/VKZ8=;9%GWC3^L_(L^F%
M<![UEUUS*6 R7T@%PBYJ-VIP26RC[,"4!AYRWGG1Z1&&@P",>3C!OKA@EWMO
M&#.#W/5TSZ>'!WH(T#T< "DX8A"90O[&8.'#\?P5+ZXD0H9\!7+^G+SFV3)"
M,,,UX0@ >CC21R/_Q3?AOC&RL+?ZB/%B\X-(=!7DW_XS+/S[H%-"76L$,M''
M :Y\.'PX'NS8FP=;8*>/$/6N/YK&%E8N"G=)*J>(^QB9/Z\B\PHG\R$_DKHN
M.3^Z19-FRO;>OXCG>&$[[^(QW(NO'- &1LCS%%4K6HN)*'I<I>H,P^EX3- -
M!\N)8>EFB+\T]\,ZB_6__XM>%;M1<)%1+WJKVJS7FTD7V0 _DR4_8C@"$S*^
M-=P14#(<:8< J6O3'OU(\\I7M(KFV0O_/'9'^HR<4!P?GZ7Z2@J7OYF.-J(B
MU"J@"0-X9E&'O]_U?W_L?/M']P9U>_?]QZ^=8;??H\>4KYT_^H_HYOM@" KS
M<;!2218I7*-$W&B66\ME*R?BO__4KFJM+R!4?1?,-A!DAAOQWXS@*L=P@6Q!
M_F1*XZL)4V>!-I^PTY^$TQPYY:56TB7)*W3-=D'T1SVR@(&82_;<Q2.2PO<&
MIKN+K;,KL-T%QVQ$:+ML$24N:-DLHU)T2A^5V0  X"PR$28BB(GS"(C>!PW,
M3%;''OLC#W2 -3; :B7N, )C2R<>HD":\ZO81!E \*M!O$VA'^]IGJJVO/F,
M/F$$&+=A*2[9-/G&7?9$(FM< \A+=\J( ]VVJ-W==1T=F^&SOP-PX<T#CRP9
MOJ?&4PB,Y-3"$AJ!$J9&AQT^M01*VOF!*4C)]2$916YDP @V-K&)A])%G<$-
MJK8K)13C.G9XHYX4(NS:0!$!=W*R0:'$RGHCO-_V8-4.+,GR.81TSW.,)]]C
M$OD9V\^ TBE!*&A=8 >=$CTS,D 6QNPO3 B#XZ,<8_(4:9QDD+I0_#483?'8
M-W%_\LA7> \&Q]T[G#5!2=P$B.]8XP<P*Q[ A!FSH,;U_/=PW;K9(0L?$M?D
MU@)<(H%%KF(2BQ$.(30'SPB1,GU+#*@(=@/V0'-,#IN *L#C+1YA(H1032LA
MLG7Z4V/"GY M_%59_&7:Q$(A< X<Y4 1@'OA,;$':)=14E@>)%BQS5C @@91
MT B;)C>:?CL#V4K^)D&<X&_^ A[Z@\,VHO_\[8SX*9,A/2%2DQK/69<PM"9.
ME,/MBX#78H?QF*9&#+24-/CT-*WTT&:^%![W+GW<-OD3Z#:%;%-,BLA."L!$
M:K!/>H*IGAR]$#FT<^)02-L::9I"VN$AK2*#&%ZKT\5 9A 4&8TPGDS2@+Y^
MD<4C*M/A/F8RUIF3E%M^Q$WGZB9)-[ 7!Z;+77-8"HOLB5G51N392*[VE"2\
MF!;XBNWXB/&I-B+;1I9Q6!'JD"<#->O"&9O?+X-BO/-)U\M<F7,QAVH[1'[)
M:#0N7B<)E,](PG>> -T($!<[ 01+,<M@+V<*"&A)?V?@Y5SOG?R+]'5-!JH6
M/D_B\>R\&^Y?KN,Q6O]*_26Y5/^W2HU*6O&_C,RDF%(QY69,*32[7,&46LB4
MVKZ9LEFJ**943'D<3!DK98)?U5J[W=Y$6U9"QJSLFS&KLC!FCL=L"6W\0@[<
MTDF\!0?+M![9GJ/@(P5\E-<AX76()=O(*:@RU4>?G$6U&@X'8% )IQRA]T1V
MUX/R(2C>4KRU@K>$=IW9/0C*%:!X2_'6<D= K=*H:$(>?79'P-&?Z*-_B=U&
MA%8?2Q)QFTMP%'NZRL+][:QY<JE>*O-6Y0.JS-LC1=KN,V]5$N=:K]%#LN9&
MI6T>\D94MN-QX?-H-K('=WVK*<]17!2\K"98=K^)).#+W9-Q,#X*P?_7$NK\
M;8LW#F#5R<MZ.F=-4Q@!$WK.O/N0BSNC5JK6+F1P9RCV4>P#[-/^ /MLE'Z7
M-_NTVBT9V"?__!ZYU7.L1X><XFKC!,4=ONX018/0S;P@S?I]D,^T4.W4]*HB
M^%P)OBZVC"I&%^9&\&T9"/[$3[(J%?;P]W5@\#DUVY-E<@K=L.3D.)4;<Y2Y
M,8*Q(!3(9+6.<SH'UQI2:'_%68JS<N8LH28TJQF>$V==5!HR<-:6^6;IHZ2B
MF%_T<T;L__?4 0++9OD(1'14TWR::IJ/FN:CIOFH:3YJFH^:YB/--)\]&;"9
MQQAD'.BS^02#@I7*<B)C.$@.'5I"+WM'5(KYMFP>$<K6)5Y(KQ"ZQ%_/O^K_
MLIVP/_SU/'2!!Q,6<NP&GZF9.8>0*J$(;@\SWMHGEVBM^IBKQ/P#J:8X;:CO
MJQ'Y:4-==1(O$E$?#'@-@N;A.IE5_DRL%FY=(7*RP72^.)BG)UR;HE:2P+@J
M<SDB?*J52)%GU*S*$T84M41PXD:=XX[['FXD4^C[=&-;Q'9C0PL?#??'-^R0
M#_1GK&5H0^TZ7MS7PK(*G[$5?-*W>#?-OWR7O%%XX?7\&ENC*6SI![V9748-
M#N[/Z6%OW2.&\QF.W!V\7+A2:.SYS7=P&)<]KT8#L]5UV8X[Z@(B$<N?7?TL
M,V<?(D<*W:(VY,AD#VK%D8HC%4=NT6.J7JM5V]OJR60#:L65N\E>6A\"WCAF
M]W,RIK:KS*C%-6G?%QW>I>_($(]K"@JL3Z: =ZT1$%;'&M._[MYGV'+QK>&.
M3-L%4MHZ]+9K4<O&$&<*.VN7Z#R 9);8\R*5A(2;^\-_W#VB;N^F__6NA'IW
M0\$=F@DK@@!;1$DI1GJV%8Y\9[CB.,HK,KK1D.=$:#3_P&B<-]/\4-MY K:]
M>1=SG>7T^&\>#<T; RG"6V("*2XF)"=]K(E^%@-MA:H"0J8*55*A:E6<55H1
M6S1\MXX#[8Q.]\ M:@O[W8+ 12LMW,VC4%EC4.E#5J2(0'6)>,2NAPQZILF-
M0S,62&W3=TJ>0L!M]I;N\)/(W2<XX(6F,EWK%2B(I FS@W% 4SL:C:*5ZK5L
M#:7DH&3%#T?%#PVAY\P&_%#$.)/V15UQ@^*&/7&#T%1A VXH8OB(5FHULQ6#
M%T;).1WF#L":O-:M'VB"X96D8L\F?G,T,2S=&F&$F;L\M>>+'$)D^Z?(Q*Z?
MLO&KT*HAX,^.-;[%3QZ/<NS(EJONQI"3@GW.KCXK7I"*%VH?YH4B[+CJ;M26
MX@7%"RF\(,3#,_-"$59<O:IX(:MA>9)^S'O;P7 [8EVF1G/D.;KE<@K7QZ3#
M!JUC5U)&IL.BD K%T7C#L3A<(/%WW; >;->]QB H\%!_WY%%6JMG2\8[$M&3
M<Z!.<<D'='$BP9;\:%:$*0_;L4H!!BMR83EPV=F5MA..*:"CC-!5:-_$>GPD
MGTTQ"#UKMJ/V(DS29DWIA24;W-[AJ;N8-'(Z ,.S@ 1Z0M'HDPDT_1E-'/L%
MN;29 '&IC@UW9L.?+K(G:&*\1SII+^]C]3%"C*/@XX(H>$Z>HR[R?IU4 C)_
M@LIH9C1J;=$B#\1KWR*5,SP9?GE[[/PM\(A9D>8$*)[L"T#(EG:&8LVC8<UL
MYI"0<K,95Q;AG4ZS?F1708I?3H-?FD)*SF;\4D@>PGZ4UX9)"2?@.SX5'Y<L
M:Y'I*0HN>X/+Z21!W=.$)T,W(TE0++N^A"SLR29WMI_)<^BIEMM/XY'8E=H,
M$S))\XS+D#AC->P]O+MD_58MV]2K_4M%Q5F*LU9Q5O7#G%5(VG]K-V$WQ5>*
MKXKEJ]J'^:J@ H*+/6NL%76LR4Y)T3Y)J5V0).Z,U!)RT1^QJ7MX_$UWO&C(
MUSV-ODC5[.-X'N\>Z)2M;YW'X9_HNO/0Z=W<#6A_I.%CIS?HW)#Q/!_JC-02
M*GJB\V/2\9-G3Z0(X2?^1&MZ)B7E'N^2Q(1GV"!IDX9)B>%B48KY)4$ROZRD
M&5$DIXCHU.;?&23*ZF5%V#282A?09G7V?H9>Z;-(7X^UI?G!:A;-F,[2F&GU
M&M+WD/?*FJL[$&P L[CNY:3 _?&IRTQ;6YQTQ7XE:\<X%N)<3^TGQ7\E62_<
MQ]X)X\O;U/#P.>%;#-+LS=%G&])*BF]*,6#.*UO3 D0Q(&' 6.^N$V \1;U'
M1KW:*5'OWM2&)%PF"4M) @UYI:'"4[YXRHWO/7NV@>9@I]!6\^>D,*N#,!,2
M-H@GL%JIEU"UUH8?C<;G#ZL6PQJ#6KD\;Y/,HUB\4]/*-?)94M\4HEZ&CC[&
M:*;/R2F>I4/KHY'CXW&DMT0QVF>UYRXW?'R,']8L+INON"#ZV0EAL%'C?ULR
MWKM8&A"<X('3_63@GLVGWTPZ$6]]/+0C_D,#NZRXAQ28]VR+%?*FAJ7S"YFM
M3V(]!$%2H.6A!)_\#*@$G\R"3ZAD_+C@RR]7(+5#X"D*OE137@B^)F;1Q*.L
MZVEP@R-2N%H5Z4+*T?ZQE564KW*]"%\W146Y+Q4SJKB!BGJIJ)>B7A7U4M1[
MQ-1;.27JW9_14Y##(WH8K);;.XO&=%Y@*YZ+1E-8 %C1GGTI*QT5[I+,4=+L
MSGNZ ZA*K&P432B:4#0A"50/6*U+ F5)Z%(2:,@K8Q2>%)Y.$4_[.W:%_4+V
ME347Y,C%\N;JY>JN#FJ/V,6Z,YJR_J'X%9OVC+3"5TES*G=$Y8Y(G3LB]'R_
ML5W/[5AC7@3O1NMO=]7 1>6.[&6]2O IP7<$<,\F^(1^MQL*OD+&L:4.@E&"
M3PF^@V) )?@D%GPMH7'QAH*OB 9(567Q+;;QD6QA5'B'I>C[$RUS8G^OZPZ%
MXBUVUB4=%\ L][:#O"E&<ZP[;DJ")B*'&?I3HPX-0NGTAAO[!=XW1PY<;+S"
M7<XROP>\Z=48P1(<QDOHS?"F:$2&5)/^U_[8@.\,"^XC](]>[#$VW1)]S).#
M,:$\^L>+;@#WL>'6]H1?[J)/+_#PS\BSD>O/9K8#+_1A%?S!932$Q4:'$[[I
M+M(]I#LO?_^I7=5:7UQD8NO9FY:7<]?BW_OHYY5*&(N'+NFLM>B7E;W15F3]
M6OH&A#R:0N:"<1%.?]ZC<U1K+1& _-?L*@JAF?Z,SX%T]!_G^@26>*F;;_K<
MA<=.4QJN7Z9U,:Q40DU)@%$%-<G2CYY,N#$*IYK8<8QL ?W*"6A)$A+5RF<K
MOUV?H?2AD0 Y(,=S;.LYAB3A9ZK&URH_GUW=]+]^^_[[70\]#&_+M&-:=SA
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M     &-G96XM,C R,C$R,S$N>'-D4$L! A0#%     @ '3A<5M>.KBUX#
M&*\  !4              ( !WA,  &-G96XM,C R,C$R,S%?8V%L+GAM;%!+
M 0(4 Q0    ( !TX7%;ETNUE'"8  )1B @ 5              "  8D@  !C
M9V5N+3(P,C(Q,C,Q7V1E9BYX;6Q02P$"% ,4    "  =.%Q61DS?ET66   M
M. < %0              @ '81@  8V=E;BTR,#(R,3(S,5]L86(N>&UL4$L!
M A0#%     @ '3A<5F?;F-""0@  VD0$ !4              ( !4-T  &-G
M96XM,C R,C$R,S%?<')E+GAM;%!+ 0(4 Q0    ( !TX7%;_?1,F4R<   0L
M   .              "  04@ 0!C9V5N7VEM9S Q+FIP9U!+ 0(4 Q0    (
M !TX7%;FPW^Y=0<  -XD   0              "  81' 0!E>&AI8FET7S$R
M+3$N:'1M4$L! A0#%     @ '3A<5CU3?N)9!P  NB,  !
M ( !)T\! &5X:&EB:71?,3(M,BYH=&U02P$"% ,4    "  =.%Q661"-1XX$
M   Q%   $               @ &N5@$ 97AH:6)I=%\Q,RTQ+FAT;5!+ 0(4
M Q0    ( !TX7%;/F8YFX ,  %X-   0              "  6I; 0!E>&AI
M8FET7S$U+3$N:'1M4$L! A0#%     @ '3A<5IS, 9_) @  W0L   \
M         ( !>%\! &5X:&EB:71?."TQ+FAT;5!+ 0(4 Q0    ( !TX7%90
M &GX,"P$   .)0 -              "  6YB 0!Z:S(S,CDR-C8N:'1M4$L%
3!@     ,  P ]P(  ,F.!0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
